Clustering O 0 1.7854744100986863e-06
of O 0 3.899812099916744e-07
missense O 0 2.5953318072424736e-06
mutations O 0 1.718693987129427e-08
in O 0 9.934826294966115e-09
the O 0 7.626349542988464e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.3025003681832459e-05
in O 0 3.2092475521494634e-07
a O 0 4.9873310814518845e-08
sporadic B-Disease 0 0.0002195552660850808
T I-Disease 1 0.9945205450057983
- I-Disease 0 0.0005848243017680943
cell I-Disease 0 0.00011207101488253102
leukaemia I-Disease 1 0.9962170720100403
. O 0 2.612540868085489e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999990463256836
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.27624227536694e-09
is O 0 3.2270996985772626e-10
a O 0 7.201281793101089e-10
recessive B-Disease 0 3.548375843820395e-06
multi I-Disease 1 0.8221454620361328
- I-Disease 0 0.4608190059661865
system I-Disease 0 0.20558853447437286
disorder I-Disease 0 0.0239205714315176
caused O 0 7.252047296013586e-10
by O 0 3.727942867598477e-12
mutations O 0 2.5029620737138103e-11
in O 0 3.693350139610807e-11
the O 0 3.4060723685946925e-10
ATM O 0 3.7107469097463763e-08
gene O 0 3.6049769835955203e-09
at O 0 1.3796908149288356e-07
11q22 O 0 1.6886360754142515e-07
- O 0 3.2721317211326095e-08
q23 O 0 9.39013631295893e-08
( O 0 8.766931069992268e-10
ref O 0 7.239601984565525e-08
. O 0 7.973753324286292e-10
3 O 0 2.5487956634151487e-08
) O 0 1.546688777054328e-09
. O 0 4.041267587240327e-08

The O 0 3.5899594763577625e-07
risk O 0 1.289933152293088e-06
of O 0 2.1030828634138743e-07
cancer B-Disease 0 3.413488229853101e-06
, O 0 3.0329576627963206e-09
especially O 0 8.357000425007755e-09
lymphoid B-Disease 0 1.2597671457115212e-06
neoplasias I-Disease 0 8.17962281871587e-05
, O 0 1.0084038049029687e-09
is O 0 2.04416778643024e-11
substantially O 0 6.025118737262858e-10
elevated O 0 1.5515713869262981e-07
in O 0 2.595826131823742e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.3663236586580751e-06
and O 0 4.087616467529642e-09
has O 0 2.0074471251962933e-10
long O 0 1.6399805125022482e-11
been O 0 3.5678823177148766e-12
associated O 0 4.131128425455266e-11
with O 0 1.654058001676617e-10
chromosomal O 1 1.0
instability O 1 1.0
. O 0 9.792854143597651e-06

By O 0 1.526744064506147e-08
analysing O 0 2.6648413040675223e-06
tumour B-Disease 1 0.9999897480010986
DNA O 0 3.401861903284953e-08
from O 0 1.1957630441372658e-09
patients O 0 7.553441899732505e-11
with O 0 6.916645641646957e-12
sporadic B-Disease 0 5.491915544553194e-07
T I-Disease 0 1.9042967323912308e-05
- I-Disease 0 4.247079630204098e-07
cell I-Disease 0 7.951759357638366e-07
prolymphocytic I-Disease 0 5.246977161732502e-05
leukaemia I-Disease 1 0.7980315685272217
( O 0 9.444937276725796e-09
T B-Disease 0 1.9218068700865842e-06
- I-Disease 0 1.1443167124980391e-07
PLL I-Disease 0 8.140391969391203e-07
) O 0 9.958436159029915e-11
, O 0 1.9229349015881247e-11
a O 0 3.7137085073801757e-11
rare O 0 2.686097178017377e-10
clonal B-Disease 0 7.611413721519966e-09
malignancy I-Disease 0 1.05508703995838e-07
with O 0 1.6073350983525359e-10
similarities O 0 5.726186191878924e-09
to O 0 9.54100354277898e-10
a O 0 8.410521168400464e-09
mature B-Disease 0 4.651541729572273e-08
T I-Disease 0 4.167177394265309e-06
- I-Disease 0 1.5113367624053353e-07
cell I-Disease 0 5.941927838648553e-08
leukaemia I-Disease 0 1.466438448005647e-06
seen O 0 6.140781660946004e-09
in O 0 6.5788801073551895e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9995230436325073
T I-Disease 1 1.0
, O 0 8.58083326615855e-10
we O 0 9.218027036128618e-11
demonstrate O 0 1.4168241579959329e-10
a O 0 1.6952113324197882e-11
high O 0 3.850605598265666e-11
frequency O 0 3.3261618459512476e-10
of O 0 6.145653430600362e-10
ATM O 0 3.9164007148428936e-08
mutations O 0 1.004493377365634e-09
in O 0 1.0805009331704696e-08
T B-Disease 0 1.4268852282839362e-05
- I-Disease 0 1.9856229300785344e-06
PLL I-Disease 0 3.03691194858402e-05
. O 0 2.4609772708572564e-07

In O 0 5.1074042772825123e-08
marked O 0 2.7006585412436834e-08
contrast O 0 7.308869620636926e-10
to O 0 2.1810922512521813e-10
the O 0 6.773008820459836e-10
ATM O 0 9.129938405294524e-08
mutation O 0 5.150167514678117e-10
pattern O 0 9.808562850821545e-09
in O 0 3.202642773203479e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999973773956299
T I-Disease 1 1.0
, O 0 7.057457951376023e-10
the O 0 5.2321556809342695e-11
most O 0 1.4685632267544269e-12
frequent O 0 8.893671389620383e-13
nucleotide O 0 2.151749438350503e-11
changes O 0 1.5815730669554995e-11
in O 0 2.359154364917071e-11
this O 0 8.196290868234257e-11
leukaemia B-Disease 0 2.0821360067202477e-06
were O 0 9.71048219611248e-09
missense O 0 9.220639185514301e-07
mutations O 0 1.0554574458865318e-07
. O 0 1.9018662555936316e-07

These O 0 1.081657607926445e-08
clustered O 0 8.225808301176585e-08
in O 0 2.2795489940108382e-09
the O 0 1.5765238003950799e-09
region O 0 3.0791806882035644e-09
corresponding O 0 2.3463313514326956e-09
to O 0 1.3129682896462214e-09
the O 0 6.736487367930977e-09
kinase O 0 1.3768537421299243e-08
domain O 0 5.903249089556084e-08
, O 0 6.717955636226236e-10
which O 0 5.4708310798234905e-11
is O 0 4.006249845756038e-11
highly O 0 1.1954706669037307e-10
conserved O 0 8.188731914771097e-10
in O 0 1.0128701211087332e-09
ATM O 0 2.2568812596546195e-07
- O 0 1.2038142926940054e-08
related O 0 2.045659641680686e-09
proteins O 0 1.7563818455190727e-10
in O 0 3.53126583529928e-10
mouse O 0 1.2969120222194874e-09
, O 0 2.3212780309034287e-10
yeast O 0 6.065478341810149e-09
and O 0 1.8567134496549897e-09
Drosophila O 0 1.0673674211147954e-07
. O 0 3.6438713379993715e-08

The O 0 1.2143328831371036e-07
resulting O 0 2.717068170454695e-08
amino O 0 4.096758132732248e-08
- O 0 9.772577413968975e-09
acid O 0 5.453688167733617e-09
substitutions O 0 8.881145596717488e-09
are O 0 4.7786750251299637e-11
predicted O 0 5.177274164935852e-09
to O 0 1.0349572310275335e-09
interfere O 0 2.6794023710863257e-07
with O 0 3.0799323091912356e-09
ATP O 0 5.182175755180651e-06
binding O 0 1.1601111538084297e-07
or O 0 2.723386183234311e-09
substrate O 0 5.328918639690983e-09
recognition O 0 4.0501340947685094e-08
. O 0 1.0127454430630678e-07

Two O 0 7.603262730526694e-08
of O 0 3.0687638741255796e-07
seventeen O 0 3.873041123370058e-07
mutated O 0 3.437907736270063e-08
T B-Disease 0 9.73436726781074e-07
- I-Disease 0 3.290099215291775e-08
PLL I-Disease 0 4.504879029809672e-07
samples O 0 1.8765728970748796e-09
had O 0 1.5129794084245418e-09
a O 0 1.4057394137623191e-10
previously O 0 1.861855669638146e-09
reported O 0 1.4577103968349547e-08
A B-Disease 1 0.9999920129776001
- I-Disease 1 0.9561454057693481
T I-Disease 1 0.999998927116394
allele O 0 3.032502604582987e-07
. O 0 9.36656050498641e-08

In O 0 1.1716387859905808e-07
contrast O 0 4.51718271676782e-08
, O 0 5.872438646470357e-10
no O 0 5.616617171355642e-10
mutations O 0 7.598742468584163e-11
were O 0 9.418769930658044e-11
detected O 0 1.3647007968131675e-09
in O 0 1.2597410614656468e-10
the O 0 1.0780980552738129e-09
p53 O 0 1.7838547305970565e-09
gene O 0 9.803288847365366e-09
, O 0 1.6372910804918206e-09
suggesting O 0 4.1306362774662375e-09
that O 0 6.939165908548262e-11
this O 0 1.0997259353162647e-10
tumour B-Disease 1 0.9999996423721313
suppressor O 0 7.120376267266693e-06
is O 0 1.789948522734619e-09
not O 0 5.033625599670799e-11
frequently O 0 2.838689873441158e-11
altered O 0 9.263058375896804e-11
in O 0 5.936266062045448e-11
this O 0 1.283661371642708e-10
leukaemia B-Disease 0 3.257161552028265e-06
. O 0 6.993306556069001e-08

Occasional O 0 1.9008376739293453e-06
missense O 0 2.5784547688090242e-06
mutations O 0 9.964165492704069e-09
in O 0 3.3448424030524393e-09
ATM O 0 4.312464341182931e-07
were O 0 1.0607445588561859e-08
also O 0 1.1255216897376741e-10
found O 0 3.565360506829762e-11
in O 0 9.337241396734086e-11
tumour B-Disease 1 0.9999979734420776
DNA O 0 6.43801323363391e-09
from O 0 2.1397100757880594e-10
patients O 0 1.5559694158118198e-11
with O 0 4.8771451287288325e-12
B B-Disease 0 1.585110993573835e-07
- I-Disease 0 2.466681436885665e-08
cell I-Disease 0 6.219904662430054e-07
non I-Disease 0 0.22600717842578888
- I-Disease 1 0.982254683971405
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 0.0003984921786468476
( O 0 2.8439226529286543e-09
B B-Disease 0 2.1769930924619985e-07
- I-Disease 0 4.163803524193099e-09
NHL I-Disease 0 1.242238880649893e-07
) O 0 1.0341003747749156e-10
and O 0 8.033101267512777e-11
a O 0 1.8464999529399506e-09
B B-Disease 0 7.068160243761668e-07
- I-Disease 0 5.653747692235811e-08
NHL I-Disease 0 1.5698833522037603e-06
cell O 0 1.5970846334312228e-06
line O 0 1.0217476074103615e-06
. O 0 1.0928896898576568e-07

The O 0 6.814818220846064e-08
evidence O 0 4.6230788086631946e-08
of O 0 5.147881676492716e-09
a O 0 9.589345983940234e-11
significant O 0 8.17072312586653e-11
proportion O 0 4.5794829039991214e-10
of O 0 5.990995699534096e-09
loss O 0 1.109987657343936e-08
- O 0 6.565404664371499e-09
of O 0 6.277446829017208e-08
- O 0 3.807447690462595e-09
function O 0 8.394350103912984e-09
mutations O 0 9.626937025331017e-10
and O 0 3.345274612875926e-10
a O 0 6.591134860123304e-10
complete O 0 4.1266439154696855e-09
absence O 0 1.4516015767185309e-07
of O 0 1.742166766405262e-08
the O 0 1.1890470830167033e-09
normal O 0 3.2584719367179105e-09
copy O 0 3.1850422299584125e-09
of O 0 9.095793007674047e-10
ATM O 0 1.4775429768576487e-08
in O 0 1.6332418750764077e-10
the O 0 2.2080653971912056e-10
majority O 0 1.0422645385643747e-10
of O 0 2.7437883076686376e-09
mutated O 0 6.492656723366963e-08
tumours B-Disease 1 0.9999997615814209
establishes O 0 2.196821696998086e-06
somatic O 0 2.0653936871894985e-07
inactivation O 0 9.72071120486362e-07
of O 0 2.643941066082789e-08
this O 0 6.709935385096344e-11
gene O 0 2.9443442128851416e-10
in O 0 2.0368906561429867e-10
the O 0 4.758885507882837e-10
pathogenesis O 0 1.8280388758284971e-06
of O 0 1.0072359657442576e-07
sporadic B-Disease 0 5.905764191993512e-05
T I-Disease 0 0.003382675349712372
- I-Disease 0 4.499285751080606e-06
PLL I-Disease 0 2.1805781216244213e-05
and O 0 1.4958376759466319e-09
suggests O 0 1.844176922283225e-09
that O 0 2.2041469344147302e-11
ATM O 0 3.5963459765753214e-08
acts O 0 5.552518889118119e-09
as O 0 3.2392621918120312e-09
a O 0 2.486777184174116e-08
tumour B-Disease 1 1.0
suppressor O 0 0.00019736916874535382
. O 0 2.08429946724209e-06

As O 0 7.596304385515396e-08
constitutional O 0 5.558094358093513e-07
DNA O 0 1.2046618813599252e-08
was O 0 8.477891277891558e-09
not O 0 1.530923304793319e-11
available O 0 1.7447781067159163e-11
, O 0 1.3841453157248385e-11
a O 0 1.4965473305039723e-10
putative O 0 5.6172446250002395e-08
hereditary O 1 0.8013368248939514
predisposition O 0 0.005153297446668148
to O 0 5.3151838983467314e-06
T B-Disease 1 0.9997654557228088
- I-Disease 0 0.017301585525274277
PLL I-Disease 0 0.0003070534730795771
will O 0 3.856048369499376e-09
require O 0 6.42512931747774e-10
further O 0 1.3310694213508611e-10
investigation O 0 1.259179538415367e-09
. O 0 1.640726027263284e-10
. O 0 4.37669811503838e-09

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0003233612806070596
kinase O 0 6.70287272441783e-06
is O 0 1.3210291749388148e-09
involved O 0 7.001241808524128e-10
in O 0 3.2723140169776954e-11
the O 0 2.739596743905892e-11
modulation O 0 1.2873766497278893e-09
of O 0 6.533409369069432e-10
the O 0 2.013505889797429e-10
Ca2 O 0 6.270898023075233e-09
+ O 0 9.916125520703645e-08
homeostasis O 0 9.0230860223528e-06
in O 0 2.1412724038327724e-07
skeletal O 0 0.02600787580013275
muscle O 0 1.7245791241293773e-05
cells O 0 2.713107107865653e-07
. O 0 2.2795073562065227e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9988835453987122
DM B-Disease 1 1.0
) O 0 2.359373851845703e-08
, O 0 1.337602667517146e-10
the O 0 5.5255307274126864e-11
most O 0 6.190390561267023e-11
prevalent O 0 1.0846090845006984e-05
muscular B-Disease 1 0.742654025554657
disorder I-Disease 0 0.15493759512901306
in O 0 7.106414123825289e-09
adults O 0 5.109620504484269e-10
, O 0 1.376765021432469e-11
is O 0 4.733144431945391e-12
caused O 0 1.226954648991807e-10
by O 0 1.4601410358583422e-10
( O 0 1.9399185036128586e-10
CTG O 0 8.070092150092023e-08
) O 0 7.874285945508319e-11
n O 0 3.754601074490438e-09
- O 0 2.6595214919211685e-10
repeat O 0 2.0981041903844755e-10
expansion O 0 1.860076259685428e-10
in O 0 6.667274371485732e-11
a O 0 4.6828249611330364e-11
gene O 0 1.9564828923623878e-11
encoding O 0 9.425998870327135e-10
a O 0 7.438159421724322e-09
protein O 0 5.286352333655486e-08
kinase O 0 6.476503813246381e-07
( O 0 6.951376008146326e-08
DM B-Disease 1 0.9999972581863403
protein O 0 4.2467290768399835e-06
kinase O 0 5.903823421249399e-07
; O 0 1.8826531444915418e-09
DMPK O 0 6.848226803413127e-07
) O 0 2.642370766636759e-10
and O 0 4.3155347351220286e-11
involves O 0 2.591544201457907e-10
changes O 0 3.422711558620506e-10
in O 0 1.19612797444546e-09
cytoarchitecture O 0 5.570958023781714e-07
and O 0 1.495632950820891e-08
ion O 0 0.00016471859999001026
homeostasis O 0 0.0008688601083122194
. O 0 3.1417939680977724e-06

To O 0 2.0174873327505338e-07
obtain O 0 1.7054465217825054e-07
clues O 0 3.7283240317265154e-07
to O 0 5.510336076319788e-10
the O 0 8.73926708777617e-10
normal O 0 1.2177001629254391e-08
biological O 0 3.763247491406219e-09
role O 0 2.1245221137888848e-09
of O 0 5.76727821055556e-09
DMPK O 0 3.339771410537651e-06
in O 0 2.7954307313393656e-08
cellular O 0 1.1148208614031319e-06
ion O 0 1.970524317584932e-05
homeostasis O 0 3.895127520081587e-05
, O 0 1.3384359398571632e-08
we O 0 2.934573251067718e-09
have O 0 2.940083246305569e-11
compared O 0 3.1706573477841005e-10
the O 0 1.1843249991816407e-10
resting O 0 1.1808794830869829e-08
[ O 0 9.307870585395506e-10
Ca2 O 0 1.203731003762698e-09
+ O 0 8.97923690956759e-09
] O 0 2.2852965742004017e-08
i O 0 1.1842358205171877e-08
, O 0 1.598429305582627e-10
the O 0 9.980703069567554e-11
amplitude O 0 1.189727538708496e-09
and O 0 1.4165377204555796e-10
shape O 0 4.428019284574702e-09
of O 0 3.6698790673028725e-09
depolarization O 0 4.1517806970148285e-09
- O 0 7.220609443692183e-09
induced O 0 4.847012569086928e-09
Ca2 O 0 3.6955170035213314e-09
+ O 0 3.118992353279282e-08
transients O 0 3.2986733344841923e-07
, O 0 1.0413946371912175e-09
and O 0 1.906516333693986e-10
the O 0 1.9777272874943463e-10
content O 0 1.0527422267259112e-09
of O 0 2.201565152404328e-09
ATP O 0 2.870141599942144e-07
- O 0 4.62921150301554e-08
driven O 0 2.5193079622454206e-08
ion O 0 6.616193104491686e-07
pumps O 0 2.8275420049794775e-07
in O 0 1.7349711001202195e-08
cultured O 0 1.0706211241995334e-06
skeletal O 0 0.00017472734907642007
muscle O 0 3.939574071409879e-07
cells O 0 7.584314509756496e-09
of O 0 1.191574980907717e-07
wild O 0 3.865892606036425e-10
- O 0 1.2852341413349677e-10
type O 0 3.5154734678854993e-10
and O 0 3.509769905263305e-11
DMPK O 0 4.2251429022144293e-08
[ O 0 2.324003656184459e-09
- O 0 7.193913464931256e-09
/ O 0 2.2843117619686382e-08
- O 0 1.4757320698777221e-08
] O 0 1.7691364817551403e-08
knockout O 0 9.985807992052287e-06
mice O 0 4.299905924654013e-07
. O 0 6.50831637472038e-08

In O 0 4.3005701400034013e-07
vitro O 0 1.4680573485748027e-06
- O 0 1.051344540314858e-07
differentiated O 0 7.414818981033022e-08
DMPK O 0 1.2062770110787824e-05
[ O 0 1.2471697630189738e-07
- O 0 7.767744136799593e-08
/ O 0 1.3204861204485496e-07
- O 0 2.855806613411005e-08
] O 0 5.544718906236312e-09
myotubes O 0 2.081103644968607e-08
exhibit O 0 1.0420145857281682e-09
a O 0 2.0578685977490352e-10
higher O 0 6.265419294493313e-10
resting O 0 4.559248090174606e-09
[ O 0 3.042353868831782e-10
Ca2 O 0 6.635005322941367e-10
+ O 0 1.5573018430359298e-08
] O 0 5.0063256651355914e-08
i O 0 4.4547824984420004e-08
than O 0 8.272246776463987e-10
do O 0 3.186559904833075e-10
wild O 0 9.144966034435598e-11
- O 0 1.2999129550550492e-10
type O 0 1.2592972220559773e-09
myotubes O 0 4.130433239879494e-08
because O 0 1.5665772845618875e-10
of O 0 9.044153759241169e-10
an O 0 1.0303551414847512e-11
altered O 0 2.0759954866278463e-10
open O 0 6.900445215229922e-10
probability O 0 8.469773771224709e-10
of O 0 2.4171253887317334e-09
voltage O 0 1.095945734164161e-07
- O 0 2.6397777297404446e-09
dependent O 0 2.1698693952743042e-09
l O 0 1.3547426291893316e-08
- O 0 5.695846017061967e-10
type O 0 2.4740626214381223e-10
Ca2 O 0 6.06944494663253e-10
+ O 0 2.7710578276440856e-09
and O 0 1.810806060653647e-09
Na O 0 2.611487275316904e-07
+ O 0 4.581287171845361e-08
channels O 0 2.679277315564832e-07
. O 0 1.220204666196878e-07

The O 0 4.158766273576475e-07
mutant O 0 1.9301552356409957e-07
myotubes O 0 8.886239015737374e-07
exhibit O 0 5.3597131177696156e-09
smaller O 0 4.299548772568329e-10
and O 0 1.0817906292981405e-10
slower O 0 2.1761983326484824e-09
Ca2 O 0 2.1933323213207956e-10
+ O 0 3.2835947849640945e-10
responses O 0 3.0714816107169085e-11
upon O 0 3.4974889651095964e-10
triggering O 0 2.4912466534132705e-10
by O 0 1.463863058548398e-11
acetylcholine O 0 9.656734079044327e-09
or O 0 1.8336090423787255e-09
high O 0 1.3728024050863041e-08
external O 0 1.1034569524781546e-07
K O 0 5.437912022898672e-07
+ O 0 1.9175726606590615e-07
. O 0 6.310747835414077e-08

In O 0 2.7585619477576984e-07
addition O 0 2.1829174912113558e-08
, O 0 1.3502841067492e-09
we O 0 3.143128257665495e-10
observed O 0 1.943577659924145e-10
that O 0 1.1742737858477792e-12
these O 0 5.238351527721286e-13
Ca2 O 0 8.26218191085637e-11
+ O 0 1.118701353775009e-09
transients O 0 8.593940670209577e-09
partially O 0 1.5465678737669464e-09
result O 0 1.9535678630333564e-10
from O 0 2.4253016261965854e-11
an O 0 2.0936848175306944e-12
influx O 0 1.882970862565614e-11
of O 0 3.588175312430053e-10
extracellular O 0 3.497457656820302e-09
Ca2 O 0 5.211087117373836e-09
+ O 0 4.322335378503794e-09
through O 0 2.7960839199536736e-10
the O 0 9.883621698847378e-10
l O 0 3.5819547328230783e-09
- O 0 2.99740954279315e-10
type O 0 3.798378833685945e-10
Ca2 O 0 2.2448327641200194e-09
+ O 0 2.7244267286619106e-08
channel O 0 4.703061620148219e-07
. O 0 1.2600695242781512e-07

Neither O 0 6.2274348238133825e-06
the O 0 4.963767352705872e-08
content O 0 3.53002871378294e-09
nor O 0 1.0637588587769642e-09
the O 0 2.4927761244075697e-11
activity O 0 5.6825395083892616e-11
of O 0 3.0089059022131437e-10
Na O 0 2.9500865750264893e-08
+ O 0 2.737019277887498e-09
/ O 0 9.882626272883499e-09
K O 0 2.174689051059886e-08
+ O 0 7.249368216832863e-09
ATPase O 0 1.0955716334137833e-07
and O 0 4.82449813432595e-09
sarcoplasmic O 0 3.1035401093504333e-07
reticulum O 0 2.2742656824448204e-07
Ca2 O 0 2.405725467724551e-07
+ O 0 4.2161428837061976e-07
- O 0 2.4011595201045566e-07
ATPase O 0 4.4347413563627924e-07
are O 0 1.1488003603954411e-10
affected O 0 1.5588604018734742e-10
by O 0 1.9592770461596132e-10
DMPK O 0 2.978992779389955e-05
absence O 0 4.895463462162297e-06
. O 0 1.5811009745902993e-07

In O 0 1.8367784093697992e-07
conclusion O 0 2.536047816192877e-07
, O 0 2.383794495131042e-09
our O 0 5.389654278431522e-10
data O 0 5.447114981294021e-10
suggest O 0 1.4550145810421355e-10
that O 0 1.1978688006786253e-11
DMPK O 0 1.0029876307271479e-07
is O 0 1.272554839282236e-10
involved O 0 3.5226818684286343e-10
in O 0 6.30395458056654e-11
modulating O 0 9.298790182299399e-09
the O 0 3.1039806835941874e-10
initial O 0 1.143699787653496e-10
events O 0 1.782921726922737e-10
of O 0 8.051451172441659e-10
excitation O 0 1.2240076330272132e-07
- O 0 4.125614694316937e-08
contraction O 0 1.3480718763503319e-08
coupling O 0 3.660345626599337e-08
in O 0 1.5778744977268389e-09
skeletal O 0 6.242359177122125e-06
muscle O 0 5.612445761471463e-07
. O 0 1.4167850892476963e-08
. O 0 6.279746145310128e-08

Constitutional O 0 0.0006924895569682121
RB1 O 0 0.0014830734580755234
- O 0 2.259268057969166e-06
gene O 0 1.3222599015705327e-08
mutations O 0 4.055326741081444e-09
in O 0 5.671844105492596e-10
patients O 0 2.9941124579657696e-10
with O 0 8.571603149487572e-11
isolated O 0 4.834670619402459e-08
unilateral B-Disease 0 1.4325667052617064e-06
retinoblastoma I-Disease 1 0.9860385060310364
. O 0 3.5225625651946757e-06

In O 0 5.852139395301492e-08
most O 0 1.4293378702845416e-09
patients O 0 8.785830396540462e-10
with O 0 8.496012920966578e-11
isolated O 0 1.9381458571388066e-07
unilateral B-Disease 0 2.2042065666028066e-06
retinoblastoma I-Disease 1 0.5808393955230713
, O 0 3.4147387140137653e-09
tumor B-Disease 0 1.1702335989127732e-08
development O 0 4.1436325481925e-09
is O 0 5.3038063524413204e-11
initiated O 0 4.5151365979378966e-10
by O 0 1.0426676883001917e-11
somatic O 0 2.1769497315915487e-09
inactivation O 0 6.551022124767769e-08
of O 0 4.442654688574521e-09
both O 0 2.064087512021473e-10
alleles O 0 4.3042092112699493e-10
of O 0 6.0962257464325376e-09
the O 0 1.0819588780464073e-08
RB1 O 0 5.566334039031062e-06
gene O 0 3.507647932110558e-07
. O 0 4.3791683879135235e-07

However O 0 2.213123764249758e-07
, O 0 1.882107358852636e-09
some O 0 3.428315964448814e-11
of O 0 6.005557162680475e-10
these O 0 2.9023297654084956e-11
patients O 0 2.508062368899999e-10
can O 0 1.0254816440458114e-10
transmit O 0 3.472645460078638e-08
retinoblastoma B-Disease 0 9.428185876458883e-06
predisposition O 0 3.4114535196749785e-07
to O 0 2.225303941116863e-09
their O 0 1.8169366011733246e-09
offspring O 0 1.4495451949869675e-08
. O 0 1.973512553377077e-08

To O 0 1.839838859041265e-08
determine O 0 1.1280158140891672e-08
the O 0 5.84852888341203e-10
frequency O 0 7.271303115174987e-09
and O 0 2.4024150724333282e-11
nature O 0 2.584933933569289e-10
of O 0 6.163872745545973e-10
constitutional O 0 3.471010359135107e-07
RB1 O 0 5.571969268203247e-06
- O 0 3.031582451740178e-08
gene O 0 1.0651963755492488e-09
mutations O 0 8.367952997190287e-10
in O 0 2.0003455836192785e-10
patients O 0 1.7896267801020826e-10
with O 0 2.081967237499427e-10
isolated O 0 4.59248532536094e-08
unilateral B-Disease 0 2.5666565761639504e-07
retinoblastoma I-Disease 0 0.00012243421224411577
, O 0 2.520517794479815e-09
we O 0 2.0339906148247877e-10
analyzed O 0 1.2542818172978087e-10
DNA O 0 2.3236434998352706e-10
from O 0 7.83331663423148e-11
peripheral O 0 2.700514301068324e-08
blood O 0 5.197180463767381e-09
and O 0 2.902908358137779e-09
from O 0 6.419583531425133e-09
tumor B-Disease 0 3.0044989784983045e-07
tissue O 0 4.401900355333055e-07
. O 0 5.358550652090344e-07

The O 0 1.5681903775544015e-08
analysis O 0 8.478958868352038e-09
of O 0 7.628305809248559e-08
tumors B-Disease 1 0.9999998807907104
from O 0 9.692370639413639e-08
54 O 0 6.306103728093149e-08
( O 0 1.1949370659625203e-10
71 O 0 4.45483072653019e-09
% O 0 1.2758211154206833e-10
) O 0 1.818193165470383e-11
of O 0 1.986165898415493e-09
76 O 0 1.5190863678071764e-07
informative O 0 2.87117583042118e-08
patients O 0 3.305974605183337e-09
showed O 0 7.155692038907091e-09
loss O 0 2.754994676834599e-09
of O 0 1.1430292268244102e-08
constitutional O 0 1.9442006760073127e-06
heterozygosity O 0 4.320426523918286e-05
( O 0 3.640883861066868e-08
LOH O 0 0.0014564270386472344
) O 0 3.5996177150110498e-09
at O 0 3.521168139286601e-07
intragenic O 0 3.7356132907007122e-06
loci O 0 3.027930972621107e-07
. O 0 4.6517058649442333e-07

Three O 0 1.258253945479737e-07
of O 0 1.6882512454685639e-07
13 O 0 2.2921597064851085e-07
uninformative O 0 4.998440635972656e-05
patients O 0 5.213406240045515e-08
had O 0 1.9733844780489562e-08
constitutional O 0 8.668286568536132e-07
deletions O 0 2.0444092285742954e-07
. O 0 8.749015023568063e-08

For O 0 2.342697484891687e-07
39 O 0 2.2985035741385218e-07
randomly O 0 1.802330373834593e-08
selected O 0 8.485806546332242e-08
tumors B-Disease 1 1.0
, O 0 2.5478820830926452e-08
SSCP O 0 3.3605570934014395e-05
, O 0 2.489149864004503e-08
hetero O 0 4.769121915160213e-06
- O 0 3.392880998376313e-08
duplex O 0 5.917825660617382e-07
analysis O 0 4.733221592445602e-10
, O 0 5.163558816634328e-12
sequencing O 0 1.492051968088326e-11
, O 0 1.6675738914728733e-11
and O 0 2.4470895795825065e-11
Southern O 0 1.7006926977813919e-09
blot O 0 9.962493052739774e-09
analysis O 0 5.460388252664927e-10
were O 0 7.07214287132274e-11
used O 0 4.954631496745243e-11
to O 0 3.671058249055115e-11
identify O 0 3.6439875561455892e-09
mutations O 0 1.5141874598612048e-07
. O 0 2.6686817022891773e-07

Mutations O 0 7.795246403929923e-08
were O 0 5.2346265100311484e-09
detected O 0 1.018591611057218e-08
in O 0 4.1924744231813804e-10
21 O 0 3.0864719668954876e-09
( O 0 3.6239181794295305e-11
91 O 0 1.3680366839352587e-09
% O 0 7.311082989014395e-11
) O 0 4.070798906297135e-11
of O 0 2.50547813607227e-08
23 O 0 9.035152470460162e-05
tumors B-Disease 1 1.0
with O 0 0.004592021461576223
LOH O 1 1.0
. O 0 7.74443251430057e-05

In O 0 7.535219879173383e-07
6 O 0 6.520841679957812e-07
( O 0 1.1627595553065362e-09
38 O 0 1.3098673257161408e-08
% O 0 1.5914476680922718e-10
) O 0 8.03474023425288e-11
of O 0 1.8062502604720976e-08
16 O 0 9.52214304561494e-06
tumors B-Disease 1 1.0
without O 0 0.3109060227870941
LOH O 1 0.9999953508377075
, O 0 4.194708136395775e-09
one O 0 2.3194236808965485e-10
mutation O 0 1.9486322277995072e-11
was O 0 3.2639937974643374e-10
detected O 0 3.3617067463076467e-10
, O 0 5.2843354692022615e-12
and O 0 5.2173148613887665e-12
in O 0 1.2724625519933142e-10
9 O 0 1.1316362069635488e-08
( O 0 5.683515116872151e-11
56 O 0 2.650847541474377e-09
% O 0 1.2885995048783627e-10
) O 0 1.0088765239890662e-10
of O 0 1.9100305337360624e-08
the O 0 1.0313348184354254e-06
tumors B-Disease 1 1.0
without O 0 0.07187779247760773
LOH O 1 0.9999992847442627
, O 0 6.316068557055132e-09
both O 0 2.435256218902282e-09
mutations O 0 3.949329752117592e-09
were O 0 7.85936471459081e-09
found O 0 5.912271561214766e-09
. O 0 2.962372924741885e-08

Thus O 0 2.8042430244568095e-07
, O 0 2.8673978746951434e-09
a O 0 4.313841506231597e-10
total O 0 1.0594858323997869e-10
of O 0 2.7510826949850298e-09
45 O 0 1.5870288416763856e-09
mutations O 0 2.4851909419254525e-10
were O 0 2.3614560307194665e-10
identified O 0 1.2920036152053171e-09
in O 0 3.109528412537088e-09
tumors B-Disease 1 1.0
of O 0 7.751308658043854e-06
36 O 0 3.5829348234983627e-06
patients O 0 3.70398055338228e-07
. O 0 3.778086750116927e-07

Thirty O 0 1.1513785466377158e-05
- O 0 1.8163075310440036e-07
nine O 0 1.0850174092524867e-08
of O 0 3.1927060994974e-09
the O 0 5.531965996397048e-10
mutations O 0 1.4435704021042994e-10
- O 0 3.048493402157959e-10
including O 0 6.06488193000132e-11
34 O 0 3.339627685505775e-09
small O 0 5.019783477777651e-10
mutations O 0 9.232231090727794e-10
, O 0 1.1944433220278938e-09
2 O 0 3.091717104553027e-08
large O 0 5.788073131895999e-09
structural O 0 2.1441266653710045e-05
alterations O 0 5.296068593452219e-06
, O 0 2.1299997321477804e-09
and O 0 1.5218268867300822e-09
hypermethylation O 0 0.023942293599247932
in O 0 3.436496399444877e-06
3 O 0 0.09166164696216583
tumors O 1 1.0
- O 0 1.7876484434964368e-06
were O 0 1.5976507228288028e-08
not O 0 3.406194076793767e-11
detected O 0 4.0913894494565284e-10
in O 0 9.826186739281262e-12
the O 0 5.272970948766442e-11
corresponding O 0 1.3505494500520854e-09
peripheral O 0 5.013731652070419e-07
blood O 0 3.94082846355559e-08
DNA O 0 5.7285593157985204e-08
. O 0 2.2593960480321584e-08

In O 0 7.429547963511141e-07
6 O 0 1.0138234074474894e-06
( O 0 1.5247323403855262e-09
17 O 0 4.178569934509824e-09
% O 0 7.843692362285992e-11
) O 0 2.3348113373233836e-11
of O 0 1.1387700782350407e-09
the O 0 3.587568242480188e-09
36 O 0 3.9882021241055554e-08
patients O 0 1.386228687394464e-09
, O 0 7.85018786086944e-11
a O 0 1.1258437931926935e-10
mutation O 0 2.087724264299151e-11
was O 0 1.0360198254844022e-09
detected O 0 1.2114447223154912e-09
in O 0 8.16248318935564e-11
constitutional O 0 6.6073759796836384e-09
DNA O 0 6.450153189341279e-10
, O 0 4.670087927483024e-11
and O 0 4.834663225317115e-11
1 O 0 4.285632293488106e-09
of O 0 1.3003152998791734e-09
these O 0 6.318230660884439e-11
mutations O 0 5.840536387857753e-10
is O 0 6.663002788398487e-11
known O 0 1.1506885722045723e-10
to O 0 6.080797670948712e-11
be O 0 2.939339049934375e-10
associated O 0 3.1751370421773117e-09
with O 0 6.333025215354837e-10
reduced O 0 3.2263093885376293e-07
expressivity O 0 3.403014125069603e-05
. O 0 5.124167614667385e-07

The O 0 2.1718047094054782e-07
presence O 0 4.610688719708378e-08
of O 0 4.356279248440842e-08
a O 0 2.6761468596703253e-09
constitutional O 0 4.478457782397527e-08
mutation O 0 1.5784425155818127e-10
was O 0 2.7627509169292352e-09
not O 0 1.8363336892757154e-11
associated O 0 9.054246935535915e-11
with O 0 6.16149145593603e-12
an O 0 1.748215981700607e-11
early O 0 4.06603062330646e-09
age O 0 1.7745707125982335e-08
at O 0 1.5090496674474707e-07
treatment O 0 1.913068246039984e-07
. O 0 5.9269751773172175e-08

In O 0 4.4357565798236465e-07
1 O 0 3.016974005731754e-06
patient O 0 2.12034180435694e-07
, O 0 2.9130193812676453e-09
somatic O 0 2.5240439072149456e-07
mosaicism O 0 1.0752587513707113e-05
was O 0 8.467294776437484e-08
demonstrated O 0 1.184745745952398e-09
by O 0 4.0553667195186716e-12
molecular O 0 1.4643664059121875e-10
analysis O 0 3.6481147963618454e-11
of O 0 7.50617623612726e-11
DNA O 0 7.179458416661788e-11
and O 0 3.1277033046839264e-11
RNA O 0 1.4841119444497508e-09
from O 0 1.1491778639793893e-09
peripheral O 0 1.0116186786035541e-06
blood O 0 3.276466600254935e-07
. O 0 2.111106880420266e-07

In O 0 4.225651082379045e-07
2 O 0 1.1449600378909963e-06
patients O 0 3.806213122459212e-09
without O 0 1.7081307479571706e-09
a O 0 4.859646574040255e-10
detectable O 0 2.0843222614530532e-07
mutation O 0 2.89412360743313e-09
in O 0 1.53102996947041e-09
peripheral O 0 3.798353873207816e-06
blood O 0 9.015740829454444e-07
, O 0 1.2916446578969953e-08
mosaicism O 0 2.3987066015251912e-05
was O 0 5.018261504119437e-07
suggested O 0 3.39841186303147e-08
because O 0 3.1001817779596763e-10
1 O 0 1.7521901707340248e-09
of O 0 2.1080762135916586e-10
the O 0 2.1121815407809663e-10
patients O 0 6.532653085145057e-09
showed O 0 3.0450974008999765e-07
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 3.751024166831485e-07
the O 0 3.367581768998207e-08
other O 0 2.691682154942754e-10
later O 0 4.672907838454421e-09
developed O 0 1.3240315510643086e-08
bilateral B-Disease 0 0.0006277667125687003
retinoblastoma I-Disease 0 0.0018631145358085632
. O 0 3.7155425047785684e-07

In O 0 1.1065357057304936e-06
conclusion O 0 1.2311353430050076e-06
, O 0 4.953918164574134e-09
our O 0 1.6513164169396077e-09
results O 0 4.0956057989482986e-10
emphasize O 0 2.6679924935990584e-09
that O 0 9.80433963182481e-12
the O 0 1.0209928041904348e-10
manifestation O 0 1.132601479270079e-08
and O 0 3.873605325388496e-10
transmissibility O 0 1.2488425227275002e-06
of O 0 3.196972997443481e-08
retinoblastoma B-Disease 0 7.158082553360146e-07
depend O 0 1.8003445845238275e-08
on O 0 1.6901966048976647e-08
the O 0 5.521635926264423e-10
nature O 0 1.216492462319252e-09
of O 0 5.723223561737711e-10
the O 0 8.235592763305988e-11
first O 0 5.98334992663041e-11
mutation O 0 9.118000625363276e-12
, O 0 4.6336185756390424e-12
its O 0 3.605246526663941e-12
time O 0 2.0075963114152273e-10
in O 0 1.5127274433091031e-10
development O 0 5.007600445416927e-10
, O 0 4.777153325696837e-11
and O 0 6.192618900308089e-12
the O 0 5.268095681909557e-11
number O 0 3.304754386812547e-11
and O 0 8.511811394606994e-11
types O 0 7.823021341835101e-09
of O 0 2.401914755978396e-08
cells O 0 1.16047685350118e-10
that O 0 1.521137729665334e-11
are O 0 2.8327067254363403e-12
affected O 0 1.580707439940987e-11
. O 0 4.829115232696246e-11
. O 0 2.7475115516040205e-09

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9998854398727417
the I-Disease 0 2.3366928871837445e-05
fifth I-Disease 0 2.7897108338947874e-06
component I-Disease 0 8.454027238258277e-07
of I-Disease 0 1.8693866365993017e-07
complement I-Disease 0 6.40365129811471e-08
in O 0 7.712736049825253e-08
man O 0 3.857032425003126e-06
. O 0 3.00637935879422e-07

I O 0 0.011706771329045296
. O 0 1.7046095308614895e-05

Clinical O 0 6.563866190845147e-05
, O 0 6.376848915579103e-08
immunochemical O 0 4.0449649532092735e-06
, O 0 1.7111861927432415e-09
and O 0 1.3168128809581958e-09
family O 0 1.5760397431563433e-09
studies O 0 1.047499154083198e-08
. O 0 1.623782175386168e-08

The O 0 1.4934100533992023e-07
first O 0 9.890810837021036e-09
recognized O 0 2.8334202539781472e-08
human O 0 1.2562205142785388e-07
kindred O 0 3.6950215871911496e-05
with O 0 6.288447451652246e-08
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999929666519165
the I-Disease 0 0.005437557119876146
fifth I-Disease 0 1.2066060662618838e-05
component I-Disease 0 4.2038677747768816e-06
of I-Disease 0 1.736552621878218e-05
complement I-Disease 0 5.448561296361731e-06
( O 0 6.870508428846733e-08
C5 O 0 9.21802711673081e-06
) O 0 6.422972709252406e-10
is O 0 4.4267081666937713e-10
described O 0 2.4472475601555743e-08
. O 0 4.737706404966957e-08

The O 0 1.6209032764891163e-06
proband O 0 1.5736333807581104e-05
, O 0 7.35629956949424e-09
a O 0 4.363520211825289e-09
20 O 0 8.484006386311194e-09
- O 0 1.4893466460108584e-09
year O 0 8.014785501941901e-10
- O 0 8.372140314349963e-09
old O 0 3.786165692076793e-08
black O 0 7.505435162258323e-10
female O 0 8.533207473959692e-10
with O 0 6.259726603730087e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.8496368527412415
age O 0 0.0007265982567332685
11 O 0 1.463991452510527e-07
, O 0 9.553349222812813e-10
lacked O 0 4.412656267049897e-07
serum O 0 3.4198503584548234e-08
hemolytic O 0 5.0229687076353e-07
complement O 0 4.167897671436549e-08
activity O 0 1.046165678530997e-07
, O 0 7.519951328305297e-10
even O 0 2.8631827464487003e-10
during O 0 1.666581006531942e-08
remission O 0 9.998875327710266e-08
. O 0 1.8685376801386155e-08

C5 O 0 0.00480752345174551
was O 0 1.3763250535703264e-05
undetectable O 0 2.1536889107665047e-05
in O 0 1.0564196628592981e-08
her O 0 5.070978637000678e-10
serum O 0 1.5890637417026454e-10
by O 0 8.288489686258949e-12
both O 0 3.344521604109474e-10
immunodiffusion O 0 2.776291978534573e-07
and O 0 6.09192474243514e-09
hemolytic O 0 0.00026481819804757833
assays O 0 2.912637910412741e-06
. O 0 9.130266107604257e-07

Other O 0 9.113162668938912e-09
complement O 0 1.2187109099670579e-08
components O 0 1.9596797073972994e-07
were O 0 1.3180089242226245e-09
normal O 0 1.0380932558007316e-08
during O 0 2.74847589132321e-09
remission O 0 1.0546641782127608e-08
of O 0 5.791529922305472e-09
lupus O 0 8.408326834796753e-08
, O 0 2.021607325985997e-09
but O 0 2.433668155887858e-09
C1 O 0 2.3089105525286868e-05
, O 0 1.6797452317973693e-08
C4 O 0 0.0002587059570942074
, O 0 8.277584839788688e-09
C2 O 0 2.1472283151524607e-06
, O 0 2.7758717546788603e-09
and O 0 3.6476035525367934e-09
C3 O 0 0.0003127726085949689
levels O 0 2.753467924776487e-06
fell O 0 5.955174856353551e-05
during O 0 6.654616413470649e-07
exacerbations O 0 8.038135274546221e-05
. O 0 1.1627449936213452e-07

A O 0 3.6437999369809404e-05
younger O 0 1.0056136261482607e-06
half O 0 2.655237096860219e-07
- O 0 2.139165928838338e-07
sister O 0 3.1885576845525065e-07
, O 0 9.745718010378823e-09
who O 0 6.197709456756684e-09
had O 0 1.0462893840212928e-07
no O 0 9.087442265354184e-08
underlying O 1 0.9327600598335266
disease O 0 0.0015309433219954371
, O 0 3.731802367124004e-10
was O 0 1.5322225266345413e-08
also O 0 2.496955142650137e-10
found O 0 2.5388127711245545e-10
to O 0 2.204412902218067e-10
lack O 0 2.2929906151603063e-07
immunochemically O 0 3.7539379263762385e-05
detectable O 0 0.00038338627200573683
C5 O 0 0.00078055530320853
. O 0 8.882943234311824e-07

By O 0 1.4531140379858698e-07
hemolytic O 0 0.0002820106747094542
assay O 0 1.9285503185528796e-06
, O 0 1.3361020734237172e-08
she O 0 2.338481408514781e-09
exhibited O 0 3.7517178697044073e-08
1 O 0 8.413621088720902e-08
- O 0 1.6367665001126852e-09
2 O 0 3.742060883382692e-09
% O 0 4.269962161629337e-11
of O 0 6.041540046020089e-10
the O 0 1.0589853438602859e-09
normal O 0 1.247812235760648e-07
serum O 0 9.466578632100209e-09
C5 O 0 6.706822830437886e-08
level O 0 5.44722178474899e-09
and O 0 6.919314426978573e-11
normal O 0 1.4180847607292435e-09
concentrations O 0 4.6200943071283973e-10
of O 0 2.346876304404333e-10
other O 0 8.035211385148955e-12
complement O 0 6.03929350972976e-10
components O 0 6.269895891364285e-08
. O 0 2.6840307754127934e-08

C5 O 0 0.0004206279118079692
levels O 0 7.121042813196254e-07
of O 0 9.978966630797004e-08
other O 0 3.468180187482517e-10
family O 0 7.32723534624391e-11
members O 0 2.8877627719636756e-11
were O 0 4.843434542323166e-10
either O 0 1.1443811454014963e-09
normal O 0 4.7687031212717557e-08
or O 0 2.6356961058127126e-10
approximately O 0 1.4731180164595514e-10
half O 0 2.1051552168138699e-10
- O 0 9.869769584947008e-11
normal O 0 1.0618412815688316e-09
, O 0 2.426707055788735e-12
consistent O 0 4.00028656033502e-11
with O 0 8.906118897922255e-12
autosomal O 0 5.0875598844868364e-08
codominant O 0 2.2351150619215332e-07
inheritance O 0 2.1372851932710546e-08
of O 0 4.431821576389439e-09
the O 0 1.8914856347862496e-09
gene O 0 1.0351654822216005e-07
determining O 0 5.624430923489854e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 5.602527835435467e-06

Normal O 0 0.00014431061572395265
hemolytic O 0 0.0006078560254536569
titers O 0 2.6884456019615754e-05
were O 0 4.829638555747806e-08
restored O 0 1.551139376942956e-07
to O 0 1.1441192437899872e-09
both O 0 1.0151857132711939e-08
homozygous O 0 3.869972351822071e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 4.143953447055537e-06
C5D B-Disease 1 1.0
) O 0 1.4116835478361622e-09
sera O 0 1.4756869504140013e-08
by O 0 4.8450553465084756e-12
addition O 0 7.606486274180924e-11
of O 0 2.123408116005976e-09
highly O 0 3.797223868673427e-08
purified O 0 5.86090784793214e-08
human O 0 7.034094551272574e-08
C5 O 0 3.719713640748523e-05
. O 0 1.5557705523860932e-07

In O 0 1.5114088114387414e-07
specific O 0 1.3311233715285198e-07
C5 O 0 4.643045394914225e-05
titrations O 0 3.17794319926179e-06
, O 0 5.248142809222145e-09
however O 0 3.6489744559276005e-09
, O 0 1.5842971379242954e-10
it O 0 1.7772710386720902e-11
was O 0 1.8547985369821163e-09
noted O 0 3.4099398305009743e-10
that O 0 5.29280872602067e-12
when O 0 1.072375088034816e-11
limited O 0 2.9844071658402527e-11
amounts O 0 7.335009682973848e-11
of O 0 1.5313045276243997e-09
C5 O 0 7.085682085516964e-08
were O 0 4.953547572128514e-10
assayed O 0 6.6838592438500655e-09
in O 0 1.1584798398356355e-10
the O 0 3.594941705431509e-11
presence O 0 9.563664443712483e-11
of O 0 1.5429879596240426e-09
low O 0 2.5232898437366202e-08
dilutions O 0 3.2085009138427267e-07
of O 0 2.1559801055559547e-08
either O 0 1.8462425543930294e-07
C5D B-Disease 1 1.0
serum O 0 4.2415021539454756e-07
, O 0 7.37064964617673e-10
curving O 0 5.905532507455291e-09
rather O 0 4.721931734508189e-10
than O 0 5.760060831083713e-11
linear O 0 3.716312590995585e-09
dose O 0 2.2476916328173502e-08
- O 0 1.1635022112432836e-10
response O 0 1.6562133609010488e-11
plots O 0 7.892811404452971e-11
were O 0 2.3576878296904802e-11
consistently O 0 2.6268317382394102e-11
obtained O 0 2.4030197970370537e-11
, O 0 1.753845983373803e-12
suggesting O 0 1.55232927206983e-11
some O 0 3.030553238914102e-12
inhibitory O 0 1.0001027561656883e-08
effect O 0 1.3785177088720957e-07
. O 0 7.220557307618947e-08

Further O 0 5.623344279115372e-08
studies O 0 9.679046897304033e-09
suggested O 0 3.6760929855716995e-09
that O 0 6.510455369257429e-11
low O 0 1.930213500145328e-08
dilutions O 0 1.875863631539687e-06
of O 0 3.000908179728867e-07
C5D B-Disease 1 1.0
serum O 0 8.66143068378733e-08
contain O 0 4.83510842474999e-10
a O 0 2.882410143900671e-10
factor O 0 1.4356157929107383e-10
( O 0 7.512689255417815e-12
or O 0 2.7749687964151448e-11
factors O 0 6.230751470326368e-10
) O 0 7.16372794418163e-11
interfering O 0 1.4396783321046769e-08
at O 0 5.8676526748513425e-08
some O 0 2.3031433704634452e-10
step O 0 1.0039729936295316e-08
in O 0 5.104671685352002e-10
the O 0 2.5260813441008168e-09
hemolytic O 0 2.8720303362206323e-06
assay O 0 7.026263801890309e-07
of O 0 1.250733566848794e-05
C5 O 0 0.0003426718176342547
, O 0 3.948094295935789e-09
rather O 0 1.2564446150165054e-09
than O 0 1.5459269975259815e-10
a O 0 9.116808974418689e-10
true O 0 1.3163012901884485e-08
C5 O 0 2.3435115963366115e-06
inhibitor O 0 1.0730747845855149e-07
or O 0 2.6414801457264048e-09
inactivator O 0 5.526054565052618e-07
. O 0 9.308730852808367e-08

Of O 0 3.100066578554106e-06
clinical O 0 1.5500465451623313e-05
interest O 0 9.172177328764519e-08
are O 0 2.309403085432038e-10
( O 0 1.3990435546173963e-11
a O 0 2.570536838941706e-11
) O 0 1.1520489423544333e-12
the O 0 1.6836495739247503e-11
documentation O 0 1.965518592328408e-08
of O 0 9.473735218534785e-08
membranous O 1 0.9999864101409912
glomerulonephritis B-Disease 1 1.0
, O 0 0.0003046481579076499
vasculitis B-Disease 1 1.0
, O 0 3.8254518130997894e-07
and O 0 6.923402793290734e-07
arthritis B-Disease 1 1.0
in O 0 2.6283025817974703e-06
an O 0 4.1409462525621166e-09
individual O 0 1.662958126757985e-08
lacking O 1 0.8995124101638794
C5 O 0 0.002814036328345537
( O 0 1.2914906644123647e-10
and O 0 2.006519603248158e-11
its O 0 1.1518122393361363e-11
biologic O 0 2.2465387772285794e-08
functions O 0 2.0565511515968637e-09
) O 0 1.8846344623790756e-11
, O 0 2.0439649972558982e-11
and O 0 7.535095464250574e-11
( O 0 4.318169433137342e-11
b O 0 3.411496640737255e-09
) O 0 2.81931353263154e-11
a O 0 6.815267239446143e-10
remarkable O 0 2.1568429264817723e-09
propensity O 0 5.182651463542243e-08
to O 0 2.6714550571682594e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.7059423590714005e-09
the O 0 1.1448374470646172e-09
proband O 0 3.6352496124436584e-08
, O 0 3.133220419226923e-11
even O 0 1.0543709134946955e-11
during O 0 1.3167895940302543e-10
periods O 0 2.2705493041286218e-09
of O 0 1.0604729316909811e-09
low O 0 8.20252310518299e-09
- O 0 8.772969573023204e-10
dose O 0 1.6818858528111491e-09
or O 0 2.3764738441012234e-11
alternate O 0 4.1246900339686476e-10
- O 0 1.1954049972118241e-09
day O 0 1.8659083167449353e-09
corticosteroid O 0 1.1191370958840707e-06
therapy O 0 1.5496564174100058e-06
. O 0 2.8324800283030527e-08

Other O 0 4.0626140673794e-08
observations O 0 5.1735948858322445e-08
indicate O 0 6.071532165918825e-09
that O 0 6.653732426142867e-11
the O 0 1.515009451225069e-09
C5D B-Disease 1 0.9999998807907104
state O 0 9.256245769861948e-10
is O 0 1.8328694464941897e-11
compatible O 0 7.735742046932614e-10
with O 0 7.166911508704743e-11
normal O 0 7.768455390078088e-08
coagulation O 0 1.896587598082533e-08
function O 0 4.58916709078494e-08
and O 0 1.0828006269392176e-09
the O 0 7.990180739270158e-10
capacity O 0 1.5926631125040558e-09
to O 0 1.7061761725667424e-10
mount O 0 1.0308210107723426e-07
a O 0 1.3049547220589375e-08
neutrophilic O 0 0.00020244208280928433
leukocytosis O 0 9.810033952817321e-05
during O 0 4.493106644076761e-06
pyogenic B-Disease 0 0.00012979100574739277
infection I-Disease 0 2.860544725535874e-07
. O 0 3.834105477551475e-09
. O 0 3.176326046627764e-08

Susceptibility O 0 0.00033545916085131466
to O 0 7.5830748755834065e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9918094277381897
twins O 0 3.643257059593452e-06
: O 0 6.09944109108973e-11
the O 0 7.210693153680836e-11
role O 0 6.472842262184031e-10
of O 0 6.451215117664333e-09
genes O 0 6.218783821232421e-10
, O 0 3.3874716920401227e-10
HLA O 0 2.787003339221883e-08
, O 0 7.3060957284099e-10
and O 0 2.0028118052906052e-10
the O 0 2.3310311458857313e-09
environment O 0 2.452488843118772e-07
. O 0 8.590929923002477e-08

OBJECTIVE O 0 5.640846211463213e-05
To O 0 1.1879005334947124e-08
determine O 0 8.481578994690153e-09
the O 0 4.6092596406310804e-10
relative O 0 1.1151016110488854e-08
effects O 0 1.7044222033746337e-07
of O 0 2.6384840978721513e-09
genetic O 0 1.030529106493816e-09
and O 0 9.70681954953756e-12
environmental O 0 1.4735226927520273e-10
factors O 0 6.710997729753032e-11
in O 0 3.928821851184594e-11
susceptibility O 0 3.4347483079955055e-08
to O 0 6.713478484243751e-08
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00022343467571772635
AS B-Disease 1 0.9999998807907104
) O 0 4.647238149857458e-09
. O 0 1.7098820137562143e-08

METHODS O 0 0.000333191710524261
Twins O 0 3.742516582860844e-06
with O 0 8.134236395562766e-09
AS B-Disease 1 0.9999984502792358
were O 0 1.6542324177137857e-09
identified O 0 1.848493441647392e-10
from O 0 3.233666112656408e-11
the O 0 7.459605849691187e-11
Royal O 0 6.618427761395651e-08
National O 0 1.2861698373001218e-08
Hospital O 0 1.4980760170146823e-06
for O 0 1.3947905941336103e-08
Rheumatic B-Disease 1 0.9999986886978149
Diseases I-Disease 1 0.999847412109375
database O 0 8.836152005642361e-07
. O 0 1.0699851600293186e-06

Clinical O 0 4.13049929193221e-06
and O 0 5.587322160494068e-09
radiographic O 0 5.503728743860847e-07
examinations O 0 3.7015300335951906e-07
were O 0 1.1085504736385587e-09
performed O 0 7.442200189444748e-10
to O 0 1.6669356173171224e-10
establish O 0 2.1080461820588425e-08
diagnoses O 0 3.777622339384834e-07
, O 0 8.042456700607659e-10
and O 0 1.0042348064231987e-09
disease O 0 1.9991048816336843e-07
severity O 0 4.1675011175357213e-07
was O 0 2.1917736514609487e-09
assessed O 0 1.197481780401688e-09
using O 0 1.1037458447216153e-10
a O 0 7.197831219940554e-11
combination O 0 9.378327975317902e-11
of O 0 6.587176359929003e-10
validated O 0 8.52429771214247e-09
scoring O 0 1.4140072224222422e-08
systems O 0 6.998149615355942e-07
. O 0 2.0206336159844795e-07

HLA O 0 1.5638506738469005e-05
typing O 0 1.3462611150316661e-06
for O 0 2.2855580539271614e-08
HLA O 0 1.0480624723641085e-06
- O 0 1.5692890542595705e-07
B27 O 0 2.294758019161236e-07
, O 0 7.01348423781667e-10
HLA O 0 1.9310384402615455e-08
- O 0 7.796700174367288e-09
B60 O 0 2.1592764909428297e-08
, O 0 9.287524915801981e-11
and O 0 2.2462282034396708e-10
HLA O 0 2.7021224013878964e-07
- O 0 2.50900342280147e-07
DR1 O 0 0.00050456722965464
was O 0 2.422730283058172e-08
performed O 0 9.718389426538465e-10
by O 0 2.5766581576713854e-11
polymerase O 0 7.856052697263749e-09
chain O 0 8.421785491208311e-10
reaction O 0 2.6798832250540805e-11
with O 0 7.05049560401072e-12
sequence O 0 2.470125215481289e-10
- O 0 1.1087274848220474e-10
specific O 0 1.8723699674039196e-11
primers O 0 1.216504008638708e-09
, O 0 1.6601794591841745e-11
and O 0 3.261478240257354e-11
zygosity O 0 1.229070889507966e-08
was O 0 5.2414206308526445e-09
assessed O 0 5.225130106367715e-09
using O 0 1.930779758296808e-09
microsatellite O 0 2.1813531247971696e-07
markers O 0 7.70368018265799e-08
. O 0 1.1431594515443066e-07

Genetic O 0 4.196550662527443e-07
and O 0 3.891885036466647e-09
environmental O 0 7.851063799080293e-09
variance O 0 1.2379588465449842e-09
components O 0 5.119039059309216e-08
were O 0 1.3777778917756223e-09
assessed O 0 9.222502761474516e-09
with O 0 7.02401678487341e-11
the O 0 5.689830828714548e-10
program O 0 9.376723841825196e-10
Mx O 0 6.958470688545049e-09
, O 0 7.49821645745774e-12
using O 0 1.041516786010055e-11
data O 0 5.889125992419864e-11
from O 0 1.247674186188874e-11
this O 0 1.411713736361453e-12
and O 0 3.913458099247258e-12
previous O 0 4.4281078803720675e-11
studies O 0 1.1997947080288895e-10
of O 0 6.196996804597177e-10
twins O 0 1.2196381682372248e-09
with O 0 1.7073414904089645e-10
AS B-Disease 1 0.9999991655349731
. O 0 3.416258778088377e-07

RESULTS O 0 5.192378011997789e-07
Six O 0 1.0367659797339002e-07
of O 0 7.439453497681825e-08
8 O 0 3.5544277920962486e-07
monozygotic O 0 8.866422263054119e-07
( O 0 3.6713772022523017e-09
MZ O 0 2.0249096905899933e-06
) O 0 1.9701078546319195e-09
twin O 0 4.845277956633254e-08
pairs O 0 8.481190860720744e-09
were O 0 6.567045574001895e-09
disease O 0 5.640639244575141e-08
concordant O 0 5.2439229847323077e-08
, O 0 5.910055778102219e-11
compared O 0 3.248702418190419e-10
with O 0 5.388068810563418e-11
4 O 0 1.6861651630506458e-08
of O 0 1.1830934454337694e-08
15 O 0 7.256118372822584e-09
B27 O 0 1.2388784220718208e-08
- O 0 1.170201713307506e-09
positive O 0 5.3535162414242166e-11
dizygotic O 0 1.4825056737777231e-08
( O 0 9.238267789646315e-11
DZ O 0 4.065202929837142e-08
) O 0 3.2900893121023955e-10
twin O 0 1.795204518373339e-08
pairs O 0 1.4539416337555622e-09
( O 0 2.1686186180147615e-10
27 O 0 4.093632099966271e-09
% O 0 8.037805837579626e-11
) O 0 1.882608131886787e-11
and O 0 1.1506753883061549e-10
4 O 0 6.046777301094153e-09
of O 0 1.7085811876427215e-08
32 O 0 4.188202922250639e-07
DZ O 0 1.2176175914646592e-05
twin O 0 5.240054292698915e-07
pairs O 0 8.14583422936721e-09
overall O 0 2.7231124022364384e-08
( O 0 2.28477126107407e-10
12 O 0 1.4152314875559568e-09
. O 0 5.8128717117522655e-11
5 O 0 7.334202134501311e-10
% O 0 4.8930897528220996e-11
) O 0 7.568468074481416e-11
. O 0 8.99499053019781e-09

Nonsignificant O 0 7.099017693690257e-06
increases O 0 2.039551993959776e-08
in O 0 3.9163522425056385e-10
similarity O 0 7.963873449590153e-10
with O 0 3.3682064082274366e-11
regard O 0 2.8123665618551286e-09
to O 0 2.0744200801559032e-10
age O 0 8.864661893426273e-09
at O 0 1.578143837832613e-07
disease O 0 7.087520259574376e-08
onset O 0 2.417541722365968e-08
and O 0 6.197916485595201e-11
all O 0 1.682302075423081e-10
of O 0 2.374659358039821e-09
the O 0 1.151848505465125e-09
disease O 0 6.718638090319473e-09
severity O 0 1.973206931182858e-09
scores O 0 9.063507583340069e-11
assessed O 0 3.902229650520894e-10
were O 0 6.67842378621053e-11
noted O 0 1.421488066144505e-10
in O 0 1.3102631479799953e-10
disease O 0 1.2851158714966004e-07
- O 0 3.529990166839525e-08
concordant O 0 8.372222168873122e-07
MZ O 0 4.9035905249184e-05
twins O 0 1.0975376341093579e-07
compared O 0 7.729565432157415e-09
with O 0 3.5098739470385e-09
concordant O 0 5.819351281388663e-05
DZ O 0 0.001943629002198577
twins O 0 1.226086442329688e-05
. O 0 8.308954306812666e-07

HLA O 0 0.00014297272718977183
- O 0 5.305804279487347e-06
B27 O 0 1.3865090977560612e-06
and O 0 1.6752393916519281e-09
B60 O 0 3.366997347598044e-08
were O 0 6.701190713442884e-10
associated O 0 5.855951834554673e-10
with O 0 3.1852697562895216e-11
the O 0 3.005053095250787e-09
disease O 0 1.6810697900382365e-07
in O 0 5.958105120384971e-10
probands O 0 1.6929381274621846e-07
, O 0 8.539390722317464e-11
and O 0 2.4146760979615323e-11
the O 0 2.4971980039367736e-10
rate O 0 2.67706590229011e-09
of O 0 1.6718463280440687e-09
disease O 0 6.317128597999044e-09
concordance O 0 6.656274420535624e-10
was O 0 2.4263901998722304e-10
significantly O 0 1.4492727851145304e-10
increased O 0 3.4675654014826307e-10
among O 0 1.528484838697608e-10
DZ O 0 3.926566023437772e-07
twin O 0 7.399997770107802e-08
pairs O 0 6.358434223585618e-09
in O 0 2.4231492368187446e-09
which O 0 9.236576781201933e-11
the O 0 4.067085335179854e-09
co O 0 5.317519580216867e-08
- O 0 7.651427935684296e-09
twin O 0 1.7899596471693258e-08
was O 0 1.3068352622269686e-08
positive O 0 1.0204866118801448e-10
for O 0 1.2880464750342213e-10
both O 0 7.735299067945789e-10
B27 O 0 1.0997840149684635e-07
and O 0 1.0603400824038545e-08
DR1 O 0 0.0007365229539573193
. O 0 1.7593416146155505e-07

Additive O 0 2.4013334609662706e-07
genetic O 0 6.177306488552858e-08
effects O 0 1.9707709952854202e-07
were O 0 9.776525144999937e-10
estimated O 0 5.502256983369591e-11
to O 0 9.010723590885394e-12
contribute O 0 3.974095358350027e-11
97 O 0 2.4831452449802782e-09
% O 0 3.739003551217479e-11
of O 0 7.787136213632806e-11
the O 0 2.1675465242121383e-11
population O 0 2.672805282221552e-13
variance O 0 3.237759227392445e-10
. O 0 4.8656030315896714e-09

CONCLUSION O 0 2.1388537788880058e-05
Susceptibility O 0 9.68615131569095e-06
to O 0 5.8148874160224295e-08
AS B-Disease 1 0.9999990463256836
is O 0 4.7787618306927016e-09
largely O 0 2.9309876747873886e-09
genetically O 0 1.3901202411403801e-10
determined O 0 6.828265730618455e-10
, O 0 4.49877565755763e-11
and O 0 1.3614859240007604e-11
the O 0 1.5929478569542965e-10
environmental O 0 3.007283533307259e-09
trigger O 0 9.38586763865601e-10
for O 0 1.3328478598584326e-10
the O 0 1.8842625237880384e-09
disease O 0 1.695230622544841e-07
is O 0 2.046864622240463e-10
probably O 0 4.224407490482918e-09
ubiquitous O 0 5.4774488944531186e-08
. O 0 2.1837504249333506e-08

HLA O 0 0.00010979591752402484
- O 0 2.373683855694253e-06
B27 O 0 7.263390671141678e-07
accounts O 0 8.342662116689326e-10
for O 0 6.902363403060718e-11
a O 0 8.472451906715861e-11
minority O 0 3.647920160387841e-11
of O 0 1.2858085707279088e-09
the O 0 8.642609961029279e-10
overall O 0 4.519058904861595e-09
genetic O 0 3.970795692254114e-09
susceptibility O 0 4.947902976226715e-09
to O 0 1.2604458587972545e-09
AS B-Disease 1 0.9999934434890747
. O 0 5.866678520760615e-07

Cell O 0 7.0254186539386865e-06
cycle O 0 2.9712808213844255e-07
- O 0 1.0846843423450991e-08
dependent O 0 6.6793095498951516e-09
colocalization O 0 2.2651268238860212e-07
of O 0 5.4096709334316984e-08
BARD1 O 0 1.998438165173866e-05
and O 0 4.433275968551698e-09
BRCA1 O 0 2.6169477695958676e-09
proteins O 0 2.725011050142001e-10
in O 0 4.054350188908984e-10
discrete O 0 9.651122212517294e-08
nuclear O 0 3.835230586446414e-07
domains O 0 2.6893530957750045e-07
. O 0 4.880691051312169e-08

Germ O 0 0.02492823265492916
- O 0 2.7847427190863527e-06
line O 0 1.7159203480332508e-07
mutations O 0 1.0059275634688447e-09
of O 0 4.726187441406182e-09
the O 0 6.721919021401845e-09
BRCA1 O 0 8.444130727980337e-09
gene O 0 2.9885569574616966e-09
predispose O 0 1.542450078773072e-08
women O 0 1.2978196295421185e-10
to O 0 3.374868440264578e-11
early O 0 5.05203331613302e-07
- O 0 0.00019492220599204302
onset O 1 0.9999949932098389
breast B-Disease 1 0.9999997615814209
and I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.5073381121055718e-07
compromising O 0 5.424206392490305e-05
the O 0 2.7567464755406945e-08
genes O 0 7.98124411005574e-09
presumptive O 0 2.5058611186068447e-07
function O 0 4.714980406106406e-08
as O 0 6.301339894321245e-09
a O 0 4.121027519232712e-09
tumor B-Disease 0 1.2572942864608194e-07
suppressor O 0 9.22408617043402e-06
. O 0 1.4660497527074767e-06

Although O 0 2.1359450386171375e-07
the O 0 2.6645153639037744e-08
biochemical O 0 4.2072059613929014e-07
properties O 0 1.2129040669606184e-06
of O 0 5.836449417984113e-06
BRCA1 O 0 1.8712309213242406e-07
polypeptides O 0 7.423634684755598e-08
are O 0 1.852753922504391e-10
not O 0 5.7666343922235797e-11
understood O 0 1.5978570688801597e-09
, O 0 8.746528674941079e-12
their O 0 2.682249387875313e-12
expression O 0 1.9162063602529145e-10
pattern O 0 1.5959655819131058e-09
and O 0 8.685255986629059e-11
subcellular O 0 1.070478532483321e-07
localization O 0 4.3702942775780684e-07
suggest O 0 4.4735126714101625e-09
a O 0 1.4127198022517717e-10
role O 0 1.0904089853269738e-09
in O 0 1.076474687167206e-09
cell O 0 5.396458391260239e-07
- O 0 1.0735926991856104e-07
cycle O 0 2.9733490336525392e-08
regulation O 0 2.2552610801085393e-07
. O 0 3.0390800986879185e-08

When O 0 5.582009521276632e-07
resting O 0 1.4544503756042104e-05
cells O 0 2.9570761395092404e-09
are O 0 2.2797089216375355e-10
induced O 0 3.3955400713381323e-09
to O 0 5.006967410126073e-11
proliferate O 0 5.60962665208109e-10
, O 0 1.9944774998226222e-11
the O 0 7.648136984839127e-11
steady O 0 6.590660905914092e-09
- O 0 9.112283844148195e-11
state O 0 1.6457836829464334e-11
levels O 0 2.374001550897731e-10
of O 0 1.7190036893932614e-10
BRCA1 O 0 3.04998665212608e-11
increase O 0 4.5305849349919214e-11
in O 0 1.1454156373380542e-10
late O 0 2.840991086827671e-08
G1 O 0 2.9198130135910105e-08
and O 0 3.9889819225535916e-10
reach O 0 1.52971935118984e-09
a O 0 5.830785854143983e-10
maximum O 0 3.331331877021171e-09
during O 0 9.065487027726249e-09
S O 0 3.8211274500099535e-07
phase O 0 7.816311722308456e-07
. O 0 2.3405938520681957e-07

Moreover O 0 5.588144631474279e-07
, O 0 3.326284359062015e-09
in O 0 1.8826926684312184e-09
S O 0 3.931931757961138e-08
phase O 0 1.059539940229115e-07
cells O 0 6.641627248171744e-10
, O 0 3.102571810575938e-10
BRCA1 O 0 1.623162160235836e-09
polypeptides O 0 1.98684024788065e-09
are O 0 4.2789386617281266e-11
hyperphosphorylated O 0 2.1672439842745916e-08
and O 0 3.106752355375164e-10
accumulate O 0 1.087714807113116e-09
into O 0 5.4749441091850315e-11
discrete O 0 2.0565719793808057e-08
subnuclear O 0 5.580635615842766e-07
foci O 0 1.6541943068659748e-06
termed O 0 8.218171387852635e-08
" O 0 3.614156085518516e-08
BRCA1 O 0 9.483824214839842e-08
nuclear O 0 7.836747499823105e-07
dots O 0 2.6303109734726604e-07
. O 0 9.73026814676814e-08

" O 0 2.4501910047547426e-06
BRCA1 O 0 1.361612248729216e-06
associates O 0 1.563133764648228e-06
in O 0 8.128699491294356e-09
vivo O 0 1.9956036112489528e-07
with O 0 2.4714836843742205e-09
a O 0 3.306606899400322e-08
structurally O 0 0.00010927471157629043
related O 0 9.815247722144704e-06
protein O 0 1.2822201824747026e-05
termed O 0 7.723268936388195e-06
BARD1 O 0 0.0004964096588082612
. O 0 1.4901279428158887e-06

Here O 0 3.893523626175011e-06
we O 0 3.4136334647882904e-08
show O 0 3.0567979258933065e-09
that O 0 2.6424347085440836e-11
the O 0 1.0117670590226169e-10
steady O 0 3.8762091314481495e-09
- O 0 5.6314713309246756e-11
state O 0 1.2411043547044809e-11
levels O 0 2.1273838246571586e-10
of O 0 5.188976470726914e-10
BARD1 O 0 7.112993216651375e-08
, O 0 4.519382090784063e-11
unlike O 0 2.032497503634545e-10
those O 0 1.419477729802665e-10
of O 0 3.1547937595632902e-09
BRCA1 O 0 1.1113089337655424e-09
, O 0 7.544687097293945e-11
remain O 0 4.225267635771246e-10
relatively O 0 4.248669124851112e-11
constant O 0 7.297711879239444e-10
during O 0 1.8469084039907102e-09
cell O 0 5.1479428719858333e-08
cycle O 0 1.3875521176487382e-08
progression O 0 1.5832118549496954e-07
. O 0 8.030340126197189e-08

However O 0 1.0927578841801733e-06
, O 0 5.347737896954641e-08
immunostaining O 0 2.3037446226226166e-06
revealed O 0 2.2191217396994034e-07
that O 0 2.272689814120099e-09
BARD1 O 0 1.3084524653095286e-05
resides O 0 1.3043235185250524e-06
within O 0 1.2782294334101607e-07
BRCA1 O 0 2.797068816562387e-07
nuclear O 0 1.1090098723798292e-06
dots O 0 2.0056655003486412e-08
during O 0 1.2233758894808489e-08
S O 0 4.1628048563779885e-08
phase O 0 8.585589483800504e-08
of O 0 4.390594998682218e-09
the O 0 8.535747109128522e-10
cell O 0 4.669558073544522e-09
cycle O 0 3.8391234635781757e-10
, O 0 1.1143834119375917e-11
but O 0 5.90556856888691e-12
not O 0 1.0063814365190993e-11
during O 0 3.8401634649964933e-10
the O 0 8.427602504745835e-10
G1 O 0 5.9187737377897065e-08
phase O 0 3.921095412806608e-07
. O 0 6.108891881240197e-08

Nevertheless O 0 6.028853476891527e-06
, O 0 3.327523145912892e-08
BARD1 O 0 6.000478151690913e-06
polypeptides O 0 8.851706922996527e-08
are O 0 9.302204839745087e-11
found O 0 5.871204217244852e-11
exclusively O 0 2.4942800602723025e-10
in O 0 1.33806452029539e-10
the O 0 4.5238859880392113e-10
nuclear O 0 1.0054888477384338e-08
fractions O 0 4.814255660789968e-10
of O 0 2.1909114800156004e-10
both O 0 9.336226236555945e-11
G1 O 0 1.742140298688355e-08
- O 0 4.3890207024332994e-09
and O 0 5.242317691056542e-10
S O 0 5.2757453516960595e-08
- O 0 1.979977737320837e-09
phase O 0 1.4306232642979921e-08
cells O 0 8.030592302255002e-10
. O 0 1.2980486907565592e-08

Therefore O 0 2.4899393338273512e-06
, O 0 1.9783366056458362e-08
progression O 0 1.6316374740199535e-07
to O 0 7.307228599984228e-09
S O 0 2.0949818235749262e-07
phase O 0 4.174915488874831e-07
is O 0 2.5732704855840893e-10
accompanied O 0 3.4824651495846126e-10
by O 0 1.2694898951504108e-11
the O 0 1.0228425051383994e-10
aggregation O 0 2.4157749134445794e-09
of O 0 7.258305512181096e-09
nuclear O 0 2.6805679453900666e-07
BARD1 O 0 6.307294597718283e-07
polypeptides O 0 3.1013914991717684e-08
into O 0 3.1656391286105645e-08
BRCA1 O 0 2.1572147090864746e-07
nuclear O 0 6.899134632476489e-07
dots O 0 1.6128591084907384e-07
. O 0 4.080529691918855e-08

This O 0 2.3867983145464677e-08
cell O 0 3.6698531857837224e-07
cycle O 0 3.4389959324698793e-08
- O 0 4.7453911911077284e-09
dependent O 0 3.590313379930876e-09
colocalization O 0 1.5586634560804669e-07
of O 0 4.117635654665719e-08
BARD1 O 0 2.53308880928671e-05
and O 0 6.292788512496372e-09
BRCA1 O 0 2.609441329681772e-09
indicates O 0 5.655402812720922e-10
a O 0 3.0027252906350554e-10
role O 0 1.0823959506467418e-09
for O 0 1.0139912243189997e-09
BARD1 O 0 4.918951617582934e-06
in O 0 5.0585512667566945e-08
BRCA1 O 0 2.581931823897321e-07
- O 0 4.677195022395608e-07
mediated O 0 7.504650056944229e-06
tumor B-Disease 0 7.67545589042129e-06
suppression O 0 8.485391299473122e-05
. O 0 2.1185530840739375e-07

Ethnic O 0 1.4826561312020203e-07
differences O 0 6.594460728592821e-07
in O 0 5.707659234133189e-09
the O 0 5.477080566862469e-09
HFE O 0 1.542237669127644e-06
codon O 0 7.128110013354672e-08
282 O 0 1.9631700354239e-07
( O 0 1.7232927973509504e-08
Cys O 0 0.0002613163669593632
/ O 0 4.289955086278496e-06
Tyr O 0 1.6101994333439507e-05
) O 0 1.2684316708089227e-08
polymorphism O 0 1.2054155149598955e-06
. O 0 4.818220418201236e-07

Recent O 0 2.6487311899359156e-08
studies O 0 9.542646672855426e-09
have O 0 5.464021596290891e-11
shown O 0 2.036720792020219e-09
that O 0 5.017191995193571e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 6.884596132294973e-06
HH B-Disease 1 0.8570805191993713
) O 0 4.367067152344362e-09
is O 0 6.103854643946249e-10
likely O 0 1.9486703917159787e-10
to O 0 4.377771062324953e-11
be O 0 8.502157311518488e-11
caused O 0 2.1224431934196986e-10
by O 0 3.903880343991695e-11
homozygosity O 0 7.184715400399e-08
for O 0 9.220932906117696e-10
a O 0 7.590634232279569e-10
Cys282Tyr O 0 1.307867592004186e-08
mutation O 0 1.31759866905945e-10
in O 0 2.3757362743737076e-10
the O 0 2.015105193819977e-09
HFE O 0 7.803307653375668e-07
gene O 0 1.16937233229919e-08
located O 0 6.239355343495845e-08
4 O 0 6.281877631408861e-07
. O 0 3.4313964647481043e-07

5 O 0 1.2241084732522722e-05
Mb O 0 5.399872316047549e-05
telomeric O 0 1.0097563972522039e-05
to O 0 1.7277201891374716e-07
HLA O 0 3.309812018414959e-05
- O 0 2.7417734145274153e-06
A O 0 1.0264120646752417e-06
. O 0 7.413333946715284e-08

Population O 0 1.0812028355955405e-10
studies O 0 1.2180201292011361e-09
of O 0 4.1402573036641854e-10
this O 0 8.413701159393216e-12
polymorphism O 0 1.4143516358089414e-09
are O 0 3.3825355710837e-12
facilitated O 0 1.9237979265174232e-10
by O 0 1.875790842098546e-11
the O 0 1.9845590448763772e-10
fact O 0 1.604914950936731e-10
that O 0 4.634821172688763e-12
the O 0 1.0482575224513013e-10
Cys282Tyr O 0 2.7766143162466506e-08
mutation O 0 3.0191152355918405e-10
creates O 0 1.2836668394911044e-09
a O 0 9.188278471405908e-10
Rsal O 0 1.0871847422322389e-07
restriction O 0 3.711999951860889e-08
site O 0 4.27840625150111e-08
. O 0 4.3816456241074775e-08

We O 0 3.880598171690508e-07
have O 0 1.4811313286955397e-09
studied O 0 2.4857953917489795e-08
the O 0 1.5662973140706526e-09
codon O 0 8.526119366081275e-09
282 O 0 5.183491680327279e-08
( O 0 7.631605569713429e-09
Cys O 0 9.382916323374957e-05
/ O 0 1.0529174687690102e-06
Tyr O 0 1.086344809664297e-06
) O 0 1.4734327646870327e-10
polymorphism O 0 1.893413204001604e-09
in O 0 5.1652550292491384e-11
different O 0 5.0440724513878266e-11
ethnic O 0 2.711205426830787e-10
groups O 0 8.71404615132576e-11
. O 0 5.7716360579718184e-09

In O 0 1.5304941314298048e-07
agreement O 0 3.1012913837003e-07
with O 0 1.993931686428141e-09
previous O 0 1.5626218541342496e-08
observations O 0 4.380074614118712e-08
the O 0 5.027384286648839e-09
Tyr O 0 1.617791696162385e-07
allele O 0 5.047185780426844e-09
appeared O 0 7.257436607233103e-08
to O 0 2.66755839639643e-10
be O 0 3.5486050209421194e-10
rare O 0 8.312610599858772e-10
or O 0 3.400587311741532e-10
absent O 0 1.1090374840705408e-08
in O 0 1.346303291072104e-09
Asiatic O 0 1.4195956410389954e-08
( O 0 7.58970056941033e-12
Indian O 0 1.2792782458359575e-11
, O 0 5.933376186206818e-12
Chinese O 0 5.2139154105290686e-11
) O 0 3.5052926273398954e-12
populations O 0 8.495733630486946e-12
. O 0 2.4962802935846184e-09

The O 0 1.3806965171170305e-07
highest O 0 9.403560596865645e-08
allele O 0 1.196988508311847e-09
frequency O 0 1.3520115693665957e-08
( O 0 1.4320003516310464e-10
7 O 0 1.9612935719948155e-09
. O 0 3.896322153806864e-11
5 O 0 6.035700828022073e-10
% O 0 1.9863456365842858e-11
) O 0 8.045962333891321e-12
was O 0 1.1423225698692363e-09
found O 0 1.2343533140057872e-10
in O 0 1.044119027349133e-10
Swedes O 0 1.697055296290273e-07
. O 0 1.3504012486009742e-07

Saamis O 0 5.4454612836707383e-05
( O 0 3.6897858990414534e-08
2 O 0 1.0885894852208367e-07
% O 0 2.0117170429490017e-10
) O 0 1.6156577811732298e-11
and O 0 1.6503236277554123e-10
Mordvinians O 0 1.4379045865098306e-07
( O 0 1.1275286260215012e-10
1 O 0 1.2278026373380158e-09
. O 0 3.689695771136314e-11
8 O 0 1.3472588600293989e-09
% O 0 6.27229101990423e-11
) O 0 1.6408815278756705e-11
had O 0 2.951530131412028e-10
significantly O 0 4.2198150529415557e-10
lower O 0 3.511253288124294e-09
frequencies O 0 8.081086910749491e-09
of O 0 2.113198060982313e-09
the O 0 1.138824368140945e-09
Tyr O 0 2.0381330045893264e-07
allele O 0 1.7287280940081473e-08
. O 0 6.97373963021164e-08

Comparisons O 0 4.4274475641259414e-08
with O 0 8.191231026799528e-10
allele O 0 2.8519184791520047e-09
frequencies O 0 1.4257525826621986e-08
based O 0 4.0706843451587815e-10
on O 0 2.3973547591538136e-09
prevalence O 0 4.906851813757385e-09
estimates O 0 2.446148283929972e-10
of O 0 1.137552163577027e-09
HH B-Disease 0 3.566217128536664e-05
showed O 0 1.8964183823300118e-07
some O 0 8.266127227152253e-10
disagreements O 0 1.5705661837728258e-07
with O 0 1.2083010980656894e-10
the O 0 3.634032519350683e-10
RFLP O 0 3.522381497589322e-09
data O 0 3.548693006116821e-10
, O 0 4.3737898719475865e-11
particularly O 0 1.693076234765556e-10
in O 0 4.6475021053815624e-10
Finns O 0 1.735296137894693e-07
. O 0 5.066739561243594e-08

The O 0 8.321619020534854e-07
newly O 0 3.9838196244090796e-06
described O 0 1.3678334198630182e-06
HFE O 0 2.6435978725203313e-05
marker O 0 4.269471958195936e-07
provides O 0 4.078504645121939e-09
a O 0 9.106746468034999e-10
new O 0 4.779178719438448e-10
approach O 0 3.1350708695754292e-09
to O 0 8.249034094687246e-11
the O 0 1.7243333150229745e-10
screening O 0 3.421682048809771e-09
of O 0 8.532984985265557e-09
HH B-Disease 0 8.510893167112954e-06
as O 0 6.642137062584652e-09
well O 0 4.21424950491911e-10
as O 0 3.3070938348922496e-11
studies O 0 9.474301204681623e-11
of O 0 1.619898243321316e-10
the O 0 5.365223265663133e-10
relationship O 0 1.4572017370539925e-08
between O 0 3.8162760063187307e-08
the O 0 5.599388508414904e-09
HFE O 0 8.059168976615183e-07
Tyr O 0 8.134348661315016e-08
allele O 0 1.388401060786748e-09
and O 0 1.707530505878907e-10
different O 0 1.913683433940605e-09
disorders O 1 0.5559894442558289
including O 0 7.07064202742913e-08
cancer B-Disease 1 0.9802636504173279

Autosomal B-Disease 1 0.9999992847442627
dominant I-Disease 1 0.9999996423721313
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9085254669189453
associated O 0 2.4962250222415605e-07
with O 0 2.618715244651071e-09
a O 0 3.5425355093821054e-08
missense O 0 1.292949178832714e-07
mutation O 0 7.197533125058442e-10
encoding O 0 1.069366017958373e-08
Gly23 O 0 5.7040879255509935e-06
- O 0 3.80277612066493e-07
- O 0 3.5087185779048014e-07
> O 0 2.536135070840828e-07
Val O 0 2.8433879606382106e-07
in O 0 4.9003894275756466e-09
neurophysin O 0 1.3952576409792528e-05
II O 1 0.9999650716781616
. O 0 4.460914624360157e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.6721427300581126e-06
ADNDI B-Disease 1 0.7776904702186584
) O 0 7.238618593419233e-09
is O 0 1.0224802116098886e-09
an O 0 4.8706172428580885e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.00010812273831106722
by O 0 1.3670298226742261e-09
progressive O 1 0.9776115417480469
degeneration O 1 0.9999983310699463
of O 0 6.97816903993953e-06
the O 0 1.8584333361104655e-07
magnocellular O 0 5.691057594958693e-06
neurons O 0 1.1085556650414219e-07
of O 0 1.310852439928567e-07
the O 0 2.0282937995830252e-08
hypothalamus O 0 8.943125351379422e-08
leading O 0 1.2389255843459068e-08
to O 0 2.705006774128549e-10
decreased O 0 1.0107727987929138e-08
ability O 0 7.121675471566391e-10
to O 0 4.2902509322928495e-10
produce O 0 4.812997778103068e-10
the O 0 1.240636926524985e-09
hormone O 0 3.4224914013947227e-09
arginine O 0 3.85811027570071e-08
vasopressin O 0 1.9595900369040464e-07
( O 0 3.176596985454694e-09
AVP O 0 1.2251923635631101e-06
) O 0 6.967687316006277e-09
. O 0 8.414904328901684e-08

Affected O 0 2.478510054970684e-07
individuals O 0 1.6378751688250759e-09
are O 0 1.3718587377198332e-10
not O 0 1.3837184176246353e-10
symptomatic O 0 1.6910735922692766e-08
at O 0 5.512819978292782e-09
birth O 0 1.4411775106637492e-09
, O 0 1.6407751893265932e-11
but O 0 1.2641282985670355e-11
usually O 0 1.6338648489711005e-10
develop O 0 7.047242434055079e-08
diabetes B-Disease 1 0.619618833065033
insipidus I-Disease 0 5.71418195249862e-06
at O 0 6.627739367104368e-06
1 O 0 5.631245130643947e-06
- O 0 4.662942956201732e-07
6 O 0 5.960491762380116e-07
yr O 0 4.583198006002931e-06
of O 0 7.54576348072078e-08
age O 0 8.710558745406161e-07
. O 0 3.485113779788662e-07

The O 0 1.851152688914226e-07
genetic O 0 5.441544104201057e-08
locus O 0 2.7739201158283322e-08
of O 0 7.352556963269308e-08
the O 0 4.03272863991333e-08
disease O 0 1.1577761824810295e-06
is O 0 4.0989034388871914e-10
the O 0 1.2991880460333505e-08
AVP O 0 3.495375131024048e-05
- O 0 7.434704912157031e-06
neurophysin O 0 8.215409616241232e-05
II O 1 0.9999983310699463
( O 0 1.194462040388089e-08
NPII O 0 2.646878328960156e-06
) O 0 2.0707120740315332e-10
gene O 0 9.695505509554891e-10
, O 0 1.5899034866428963e-10
and O 0 1.71775815793751e-10
mutations O 0 6.56371446083881e-09
that O 0 2.898264961359587e-10
cause O 0 1.1439277969316208e-08
ADNDI B-Disease 0 3.2168084089789772e-06
have O 0 7.369647253563372e-11
been O 0 2.3164780857398704e-11
found O 0 3.593054890074776e-12
in O 0 3.844835474303698e-12
both O 0 8.118089533937223e-12
the O 0 2.425705469821793e-10
signal O 0 6.445213251993209e-09
peptide O 0 1.2064479415485607e-09
of O 0 5.971863448195336e-09
the O 0 1.0340441392031607e-08
prepro O 0 7.793136319378391e-06
- O 0 3.3533706300659105e-06
AVP O 0 3.635903340182267e-05
- O 0 6.167547894619929e-07
NPII O 0 1.940376023412682e-05
precursor O 0 1.7539974805913516e-07
and O 0 2.396289611183988e-09
within O 0 1.6682445647120403e-08
NPII O 0 1.662663635215722e-05
itself O 0 2.9066441697978007e-08
. O 0 5.99947185264682e-08

An O 0 1.8768171017313762e-08
affected O 0 5.612907116869792e-08
girl O 0 1.2133466498198686e-07
who O 0 1.638612578958032e-09
presented O 0 8.117977401411736e-09
at O 0 8.892981639974096e-08
9 O 0 1.2379381963967262e-08
months O 0 1.5228228678054734e-09
of O 0 4.046024848491925e-09
age O 0 1.096514079534927e-08
and O 0 6.532113183688182e-10
her O 0 2.397861076364194e-10
similarly O 0 2.8326069267947673e-10
affected O 0 1.9080551028061166e-10
younger O 0 2.6158997190606215e-09
brother O 0 3.7669476427026893e-08
and O 0 3.2703395547173386e-09
father O 0 8.530661688155305e-08
were O 0 1.0151643969891211e-08
all O 0 6.454313195014549e-10
found O 0 2.8178526179090113e-10
to O 0 2.5017163687857114e-11
have O 0 1.0574099755522592e-11
a O 0 4.554541119250466e-11
novel O 0 4.5541157650541564e-11
missense O 0 1.5633394578884463e-09
mutation O 0 1.0029307939696253e-10
( O 0 4.61832135034701e-11
G1758 O 0 2.1913734826739528e-08
- O 0 2.7461245721838168e-08
- O 0 3.9258019057797355e-08
> O 0 8.156780140211595e-09
T O 0 2.3199115961602956e-09
) O 0 2.9118818901247012e-12
encoding O 0 1.2627672518750188e-10
the O 0 3.900019751590378e-10
amino O 0 1.2372246560587996e-09
acid O 0 9.825672497854043e-10
substitution O 0 2.222674044816131e-09
Gly23 O 0 2.7687775627782685e-07
- O 0 2.1598077992734943e-08
- O 0 2.4357499128768723e-08
> O 0 5.875817166156594e-08
Val O 0 4.931008561470662e-07
within O 0 6.946392261397705e-08
NPII O 0 4.997401629225351e-05
. O 0 5.76388288209273e-07

The O 0 1.110939038539982e-07
mutation O 0 3.7176171030495198e-09
was O 0 1.0106089298744791e-08
confirmed O 0 3.5478331383842487e-10
by O 0 2.3175430324817725e-11
restriction O 0 2.7047657447099027e-09
endonuclease O 0 3.5864410108388256e-08
analysis O 0 2.3806423499195262e-08
. O 0 4.34891589407016e-08

A O 0 5.116218017064966e-05
T1 O 0 0.00026175525272265077
- O 0 3.775284085349995e-08
weighted O 0 2.5387172364332855e-09
magnetic O 0 7.986908912016588e-09
resonance O 0 7.72418662364771e-09
imaging O 0 3.177865721681883e-07
of O 0 3.309414609020678e-08
the O 0 9.072063988924128e-08
fathers O 0 1.7610504698950535e-07
pituitary O 0 1.5260561667673755e-06
gland O 0 6.18173885413853e-07
demonstrates O 0 1.467133472488058e-07
an O 0 3.5574301282537135e-09
attenuated O 0 6.310748403848265e-07
posterior O 0 3.2131415537151042e-06
pituitary O 0 0.00021122214093338698
bright O 0 1.7224901966983452e-05
spot O 0 4.370371243567206e-06
. O 0 2.6582063128444133e-07

This O 0 2.0828588631616185e-08
mutation O 0 5.126689828216513e-08
may O 0 5.45735101553646e-09
be O 0 5.950325787651423e-10
valuable O 0 4.431162103912811e-09
for O 0 1.222084794472167e-10
developing O 0 2.534580545443532e-09
models O 0 1.2125318527012041e-08
of O 0 9.431690983774388e-08
dominantly B-Disease 1 0.9962471127510071
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 6.917265693573427e-08
as O 0 1.0137688466471673e-09
the O 0 2.520680053574864e-10
early O 0 2.662781550810678e-09
age O 0 2.2415511669038324e-09
of O 0 4.180737978032312e-09
onset O 0 8.875525963958353e-06
of O 0 7.583288947898836e-07
symptoms O 0 2.8363992896629497e-05
suggests O 0 1.5195268376899662e-09
that O 0 1.3260261812197971e-11
this O 0 1.8042883159763434e-11
mutation O 0 1.3840774359952235e-10
may O 0 4.5816495042316774e-10
be O 0 1.5639202433082033e-10
particularly O 0 5.846332307157809e-10
deleterious O 0 1.689268458449078e-08
to O 0 8.426332409605664e-10
the O 0 5.575356620823868e-09
magnocellular O 0 4.19699489384584e-07
neuron O 0 1.0825249319168506e-07
. O 0 8.798965112077894e-09
. O 0 7.403583879295184e-08

Frequent O 0 6.922558100086462e-07
inactivation O 0 1.9619135855464265e-05
of O 0 1.3918076547270175e-05
PTEN O 0 0.00935741513967514
/ O 0 6.468960054917261e-05
MMAC1 O 0 0.004962932784110308
in O 0 4.560781405871239e-07
primary O 1 0.9999690055847168
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.2703602910041809

Sporadic B-Disease 1 0.9999991655349731
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.0017567436443641782
the O 0 9.569513395035756e-07
most O 0 3.7586422863000735e-09
common O 0 1.809826422061178e-08
male B-Disease 0 1.2225920720254635e-08
cancer I-Disease 0 2.556620160021339e-08
in O 0 5.048572226939996e-09
the O 0 6.296344423617484e-08
Western O 0 2.532712528591219e-07
world O 0 1.0631442393105317e-09
, O 0 9.363255830396877e-12
yet O 0 1.0077451893797384e-11
many O 0 8.712391702178635e-13
of O 0 3.242906290723546e-11
the O 0 1.490032749962289e-11
major O 0 2.551648337068002e-10
genetic O 0 3.0491156821632615e-10
events O 0 1.0931717336903901e-10
involved O 0 3.7126265950426784e-10
in O 0 6.836289173639543e-11
the O 0 6.293865428830259e-10
progression O 0 7.559520298627831e-08
of O 0 1.513978808986849e-08
this O 0 1.4618806165600517e-09
often O 0 2.5968661887532107e-08
fatal O 0 5.412103746493813e-06
cancer B-Disease 0 6.128375957814569e-07
remain O 0 1.9668392781113653e-07
to O 0 1.9141617180196135e-09
be O 0 5.8246971690323335e-09
elucidated O 0 3.0017379685887136e-05
. O 0 2.717255540574115e-07

Numerous O 0 4.098228316706809e-07
cytogenetic O 0 5.7015466154552996e-05
and O 0 4.640243744802319e-08
allelotype O 0 6.747111456206767e-06
studies O 0 1.2882148681114813e-08
have O 0 4.8221936860270986e-11
reported O 0 1.3429787837360152e-10
frequent O 0 1.4625603506068785e-10
loss O 0 7.287822012536083e-10
of O 0 1.2737897847614477e-08
heterozygosity O 0 2.8490212571341544e-05
on O 0 1.4044676390767563e-05
chromosomal O 0 0.0023313818965107203
arm O 0 4.4046690163668245e-05
10q O 0 4.016672392026521e-06
in O 0 8.462482981030917e-08
sporadic B-Disease 1 0.999743640422821
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00015698085189796984

Deletion O 0 1.1574173868211801e-06
mapping O 0 3.247755557822529e-07
studies O 0 1.5651453466603016e-08
have O 0 7.696090292830249e-11
unambiguously O 0 1.741750854655777e-09
identified O 0 5.609187558874851e-10
a O 0 7.515047473205527e-10
region O 0 5.477540199194664e-09
of O 0 9.434062420154987e-09
chromosome O 0 1.3319728964233946e-07
10q23 O 0 4.8680192321626237e-08
to O 0 1.5883636073077412e-10
be O 0 3.298274847685079e-11
the O 0 5.4754038109061653e-11
minimal O 0 8.66373905950013e-09
area O 0 2.4594313252634947e-09
of O 0 5.242930090076925e-09
loss O 0 1.1827395240970873e-07
. O 0 2.396570266682829e-07

A O 0 8.919445235733292e-07
new O 0 2.9891115360669573e-08
tumor B-Disease 0 1.0048334786461055e-07
suppressor O 0 7.292402983694046e-07
gene O 0 9.762167252347353e-08
, O 0 3.263642511797116e-08
PTEN O 0 2.864708767447155e-05
/ O 0 3.857264346152078e-06
MMAC1 O 0 0.00046268670121207833
, O 0 1.547684114200365e-08
was O 0 2.608139766380191e-07
isolated O 0 3.581751428782809e-08
recently O 0 5.112020584618904e-09
at O 0 1.0143186734978826e-08
this O 0 1.9909351944846776e-11
region O 0 6.601930668814759e-10
of O 0 1.53980395101172e-09
chromosome O 0 2.113384489632608e-08
10q23 O 0 7.794368883651259e-08
and O 0 1.5073166048651387e-09
found O 0 3.826279293406287e-10
to O 0 9.62334725795877e-12
be O 0 8.040209123483244e-12
inactivated O 0 1.5917542284249464e-10
by O 0 1.4593154159039945e-12
mutation O 0 9.452406218857234e-11
in O 0 3.71551706068729e-10
three O 0 3.5245271590156335e-08
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.041481178253889084
lines O 0 3.453171984801884e-06
. O 0 2.295187186973635e-07

We O 0 6.371050176312565e-07
screened O 0 2.3918491933727637e-06
80 O 0 1.3001568959225551e-06
prostate B-Disease 0 0.00023777579190209508
tumors I-Disease 1 0.9999992847442627
by O 0 4.3375232294806665e-09
microsatellite O 0 2.595505179669999e-07
analysis O 0 7.490237763363439e-09
and O 0 2.5069099574004383e-10
found O 0 4.935666320093901e-10
chromosome O 0 7.308371685610382e-09
10q23 O 0 4.805985298617088e-08
to O 0 2.700872303584845e-10
be O 0 1.0163627578441137e-10
deleted O 0 8.741884438556724e-10
in O 0 2.4726282132903066e-10
23 O 0 9.029627712209276e-09
cases O 0 1.4207541809696522e-09
. O 0 7.151011782724481e-09

We O 0 8.906201856007101e-07
then O 0 2.753152195111852e-08
proceeded O 0 2.1372120073692713e-08
with O 0 2.8685765568470245e-11
sequence O 0 2.93554042185562e-10
analysis O 0 6.619924053374859e-10
of O 0 8.203332457767942e-10
the O 0 1.2740587473913934e-09
entire O 0 1.0092706048681066e-07
PTEN O 0 2.69620682047389e-06
/ O 0 1.6662768587138999e-07
MMAC1 O 0 1.9719677766261157e-06
coding O 0 5.561848865909269e-07
region O 0 1.0025247831890738e-07
and O 0 6.030165811132804e-10
tested O 0 9.194484063002051e-10
for O 0 5.132082606107424e-11
homozygous O 0 2.2825759338207519e-10
deletion O 0 2.502773543966441e-09
with O 0 1.203567384644444e-10
new O 0 1.855375297843409e-09
intragenic O 0 1.606087067784756e-07
markers O 0 1.2466008669775874e-08
in O 0 6.320294843042973e-10
these O 0 1.0479576928457135e-10
23 O 0 3.180452790019217e-09
cases O 0 7.176281791032579e-11
with O 0 2.5064783581996153e-11
10q23 O 0 5.3319613613211914e-08
loss O 0 2.184658498549652e-08
of O 0 2.448737461691053e-07
heterozygosity O 0 0.00019464566139504313
. O 0 1.6117318182296003e-06

The O 0 1.5234338235359246e-08
identification O 0 4.167609368721514e-09
of O 0 5.513681955449101e-09
the O 0 1.1765690643983362e-09
second O 0 2.82803047646496e-09
mutational O 0 3.192098674276167e-08
event O 0 7.08926117809483e-09
in O 0 3.352967237191251e-09
10 O 0 9.03503671878525e-09
( O 0 2.8513186256517997e-10
43 O 0 3.278097437942051e-08
% O 0 8.528786565875635e-09
) O 0 9.176271476007969e-08
tumors B-Disease 1 1.0
establishes O 0 0.0013589736772701144
PTEN O 0 0.05734189599752426
/ O 0 4.72646024718415e-05
MMAC1 O 0 0.0002697380259633064
as O 0 3.4571215223877516e-08
a O 0 2.3632145129681703e-09
main O 0 6.591541090728015e-09
inactivation O 0 9.548858770358493e-08
target O 0 2.9162883219413516e-09
of O 0 5.160090577049914e-09
10q O 0 2.247092396601147e-07
loss O 0 3.502646350739269e-08
in O 0 2.6623462545671828e-08
sporadic B-Disease 1 0.9997850060462952
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.810086918245361e-07
. O 0 3.183131411788054e-07

Risk O 0 3.955830720769882e-07
reversals O 0 1.7772066485122195e-07
in O 0 1.6842029160191174e-10
predictive O 0 8.456929379008216e-09
testing O 0 6.797096219202103e-09
for O 0 5.825197213482625e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.7730602621668368e-06

The O 0 1.445255115584132e-08
first O 0 1.1496755769613287e-09
predictive O 0 2.448391533960148e-08
testing O 0 1.0137731543125028e-08
for O 0 4.8446771927501686e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.172490853880049e-09
HD B-Disease 0 3.5196774206269765e-07
) O 0 9.927694083478045e-11
was O 0 1.7087889991884708e-09
based O 0 6.596665574898353e-11
on O 0 4.3673734073657045e-10
analysis O 0 3.8820965886365855e-10
of O 0 5.547646231285341e-10
linked O 0 2.4392357023117484e-09
polymorphic O 0 5.564775307220771e-09
DNA O 0 2.937345477960207e-09
markers O 0 1.6343207898117385e-09
to O 0 8.516146815518155e-11
estimate O 0 3.8777156485814146e-10
the O 0 1.6795577428840858e-10
likelihood O 0 5.358629540097581e-09
of O 0 1.5672036113301147e-08
inheriting O 0 1.0131917349553987e-07
the O 0 9.885756213634522e-09
mutation O 0 4.450200763450596e-10
for O 0 1.0067625622056653e-09
HD B-Disease 0 7.585613730043406e-06
. O 0 5.175006663193926e-07

Limits O 0 7.37252605631511e-08
to O 0 7.706464355550224e-10
accuracy O 0 1.0100866809636955e-08
included O 0 3.3936928267586097e-10
recombination O 0 1.5449699297676034e-09
between O 0 1.04456376881501e-09
the O 0 3.535066683824084e-10
DNA O 0 5.889174148343557e-10
markers O 0 1.0069277633917295e-09
and O 0 6.57274026871768e-11
the O 0 2.073008015246458e-10
mutation O 0 1.0516740950317072e-10
, O 0 1.0165333158562717e-10
pedigree O 0 7.445891681001626e-10
structure O 0 6.490636472733513e-09
, O 0 3.595259090438674e-10
and O 0 5.0732206630099697e-11
whether O 0 7.630637094413473e-11
DNA O 0 5.078138604064364e-11
samples O 0 1.1511028241706356e-11
were O 0 7.971859283806282e-12
available O 0 3.040890456107448e-11
from O 0 1.912806579795756e-10
family O 0 2.3920052050208085e-10
members O 0 8.615830826563808e-10
. O 0 2.8830783094235812e-08

With O 0 8.082968072642416e-09
direct O 0 1.293330864626796e-08
tests O 0 8.220624736487991e-10
for O 0 3.1813961187676654e-11
the O 0 3.073569454503655e-10
HD B-Disease 0 1.0771919960461673e-06
mutation O 0 1.0587409837725659e-09
, O 0 1.185314763008094e-10
we O 0 1.4520452895627756e-10
have O 0 1.845729298566301e-12
assessed O 0 8.04371014240246e-11
the O 0 2.395807337240985e-11
accuracy O 0 6.79346356946553e-10
of O 0 7.029458265472854e-11
results O 0 1.2357047676769817e-11
obtained O 0 8.764920039761037e-11
by O 0 5.152483301129607e-11
linkage O 0 1.4428864325566337e-08
approaches O 0 1.2648995628694593e-08
when O 0 7.644990196453705e-10
requested O 0 7.327494166986526e-09
to O 0 1.3602386994548965e-09
do O 0 4.65899596679975e-10
so O 0 2.9524067218789085e-11
by O 0 3.4115889366997942e-12
the O 0 4.860793365035754e-11
test O 0 5.825358251332347e-11
individuals O 0 1.1598389783318286e-11
. O 0 4.895755356670861e-09

For O 0 1.1951166811741132e-07
six O 0 4.549683740862065e-09
such O 0 1.6772880306881177e-10
individuals O 0 9.24229963394918e-12
, O 0 6.906761967906405e-11
there O 0 6.802964441776638e-11
was O 0 9.87293802268141e-10
significant O 0 4.890834404136513e-10
disparity O 0 5.823486581846282e-09
between O 0 1.1882489436843002e-09
the O 0 6.789266926432447e-10
tests O 0 1.2041926344963372e-09
. O 0 1.3691069389309973e-09

Three O 0 2.3137884852530988e-07
went O 0 4.2229919472447364e-07
from O 0 2.1121342452801173e-09
a O 0 9.922550558982834e-10
decreased O 0 5.2246420523260895e-09
risk O 0 3.3993291514988755e-10
to O 0 8.865071003671954e-12
an O 0 4.0965078551558065e-12
increased O 0 1.3674672505459284e-10
risk O 0 9.626680563812329e-10
, O 0 4.648820911556939e-11
while O 0 2.919281205659985e-10
in O 0 2.0276381962336387e-10
another O 0 1.491489293181658e-10
three O 0 4.328716551871281e-11
the O 0 1.2625529788312662e-10
risk O 0 5.181826079336815e-10
was O 0 1.8732551509970108e-08
decreased O 0 1.2551642214475578e-07
. O 0 8.133867623882907e-08

Knowledge O 0 2.715190566959791e-05
of O 0 1.020384274852404e-06
the O 0 3.3396613474678816e-08
potential O 0 4.4599919313270675e-09
reasons O 0 7.431575355099085e-10
for O 0 2.012237945714368e-11
these O 0 2.137439964605692e-12
changes O 0 3.20117855834301e-11
in O 0 1.6912421116344056e-11
results O 0 1.3956720328056615e-11
and O 0 7.002596853072918e-12
impact O 0 2.5031257622210035e-10
of O 0 3.4670361026556407e-10
these O 0 1.8277620736362188e-11
risk O 0 2.557236922218209e-10
reversals O 0 2.6275661646479875e-09
on O 0 4.5825170325031195e-09
both O 0 2.2288838830153423e-10
patients O 0 3.1109623210845427e-10
and O 0 8.366242421065095e-11
the O 0 2.9364266573850273e-09
counseling O 0 5.1210578000393525e-09
team O 0 3.9463382561777394e-10
can O 0 1.415904980067717e-11
assist O 0 6.950242603664947e-10
in O 0 8.852031607720079e-11
the O 0 1.1042659148197131e-10
development O 0 7.331027451762395e-10
of O 0 2.932195597438181e-09
strategies O 0 4.469452807853713e-09
for O 0 1.322288945004857e-10
the O 0 5.113753864804949e-10
prevention O 0 1.7519903749985133e-08
and O 0 3.362173039977989e-11
, O 0 2.0565216196644087e-11
where O 0 5.184363702226413e-11
necessary O 0 3.582118601741513e-09
, O 0 3.317961183579854e-11
management O 0 1.0012608520071353e-09
of O 0 1.3103989005003314e-09
a O 0 7.709111127240931e-10
risk O 0 6.179858846877551e-10
reversal O 0 2.1313082410046036e-09
in O 0 1.0146755657913786e-10
any O 0 1.4639697787366401e-10
predictive O 0 2.066152582358427e-09
testing O 0 6.030004828794233e-10
program O 0 2.7957000603429094e-10
. O 0 1.7650730876894727e-10
. O 0 4.658207153340754e-09

A O 0 4.134966786750738e-07
novel O 0 1.1457620630039855e-08
common O 0 5.487369669765485e-09
missense O 0 7.54117337464777e-08
mutation O 0 1.2836228746593292e-09
G301C O 0 2.24382379343524e-08
in O 0 8.211801238999783e-10
the O 0 4.107608475578672e-09
N O 0 7.846364837860165e-07
- O 0 4.2660449395270916e-08
acetylgalactosamine O 0 4.786363092534884e-07
- O 0 1.4472004750132328e-07
6 O 0 4.3565248120103206e-07
- O 0 4.0814015278556326e-08
sulfate O 0 1.3089311323710717e-07
sulfatase O 0 5.491544357028033e-07
gene O 0 2.6918799633790513e-08
in O 0 2.9127487977120836e-08
mucopolysaccharidosis B-Disease 0 6.639594357693568e-05
IVA I-Disease 1 0.9997362494468689
. O 0 7.841555998311378e-06

Mucopolysaccharidosis B-Disease 1 0.7471866011619568
IVA I-Disease 1 0.9999994039535522
( O 0 0.0001320795126957819
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 1.0
) O 0 1.3344543248194896e-08
is O 0 2.587977887547055e-10
an O 0 5.122227086928888e-10
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 4.58575232187286e-05
by O 0 1.203210087119544e-09
a O 0 8.635713300009229e-08
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 5.3970563129723814e-08
N O 0 4.7529021685477346e-05
- O 0 4.07338404784241e-07
acetylgalactosamine O 0 1.998430525418371e-05
- O 0 8.436067560069205e-07
6 O 0 4.860985882260138e-06
- O 0 3.4392985526210396e-07
sulfate O 0 1.2320584801273071e-06
sulfatase O 0 5.5208524827321526e-06
( O 0 4.891825611252898e-09
GALNS O 0 4.58910699308035e-06
) O 0 5.684930304283853e-09
. O 0 3.411439664091631e-08

In O 0 8.362105319292823e-08
previous O 0 3.4112900948457536e-08
studies O 0 2.1112088077757107e-08
, O 0 3.0274652229600463e-10
we O 0 1.3645282126439895e-10
have O 0 1.7517138781175667e-11
found O 0 1.280537915288038e-11
two O 0 4.4086297112944095e-12
common O 0 1.1095266198857257e-11
mutations O 0 3.458455050120435e-11
in O 0 2.9098026765872476e-10
Caucasians O 0 9.356361907464361e-09
and O 0 2.9868116313558346e-10
Japanese O 0 4.006317411153759e-08
, O 0 2.902126039483477e-10
respectively O 0 2.748991079215557e-08
. O 0 6.821645825993983e-08

To O 0 1.1705689217933468e-07
characterize O 0 1.4632533975600381e-06
the O 0 2.3054312237036356e-08
mutational O 0 1.2007892564724898e-06
spectrum O 0 3.8406579250249706e-08
in O 0 1.0478457684870435e-10
various O 0 1.4271196724369162e-10
ethnic O 0 1.2002410176847889e-10
groups O 0 4.387072302658446e-12
, O 0 3.6671095847429225e-12
mutations O 0 3.274655546725569e-11
in O 0 8.526240824480169e-11
the O 0 1.0984287923676561e-09
GALNS O 0 4.415228147536254e-07
gene O 0 3.111604973682347e-09
in O 0 2.8272646446225735e-09
Colombian O 0 1.711904246803897e-06
MPS B-Disease 1 0.99997878074646
IVA I-Disease 1 1.0
patients O 0 1.0367832601332339e-06
were O 0 4.731527170065419e-09
investigated O 0 1.4345443055674423e-08
, O 0 3.073743690129582e-11
and O 0 1.065128193977749e-11
genetic O 0 3.874477128018583e-10
backgrounds O 0 5.587905693715811e-10
were O 0 1.9402256190570455e-10
extensively O 0 1.0062475852556929e-10
analyzed O 0 1.9314490284916275e-10
to O 0 7.139593603822103e-12
identify O 0 6.445329686632917e-11
racial O 0 8.308358168118701e-11
origin O 0 2.370796614581394e-11
, O 0 9.413893276022378e-13
based O 0 1.406609637794043e-12
on O 0 1.6155136950413151e-10
mitochondrial O 0 7.317211281332447e-10
DNA O 0 1.8142934377074482e-10
( O 0 1.0106748771221419e-11
mtDNA O 0 7.365867638053913e-11
) O 0 1.6504494992908292e-10
lineages O 0 1.3389056974233426e-08
. O 0 9.259167654818157e-08

Three O 0 1.0790554938466812e-07
novel O 0 1.78527912453319e-07
missense O 0 2.16920193452097e-06
mutations O 0 5.004387659823806e-08
never O 0 2.713650104624321e-08
identified O 0 3.4865677012163587e-09
previously O 0 6.841057498263581e-09
in O 0 3.471032627988535e-10
other O 0 1.4693345498639765e-11
populations O 0 1.471033147723566e-12
and O 0 1.0627236070315238e-11
found O 0 3.0290176616931674e-11
in O 0 1.0046519866024894e-10
16 O 0 1.4867638231663705e-09
out O 0 1.7842688437852416e-10
of O 0 4.7368726718843845e-09
19 O 0 6.303073263325132e-08
Colombian O 0 1.3549708910431946e-06
MPS B-Disease 1 0.9991196990013123
IVA I-Disease 1 1.0
unrelated O 0 4.131121841055574e-06
alleles O 0 6.579231381920181e-09
account O 0 4.498314498668776e-10
for O 0 6.144316722078713e-10
84 O 0 2.1023410567977407e-07
. O 0 1.266935498733801e-07

2 O 0 5.944744316366268e-06
% O 0 9.036243753257622e-09
of O 0 5.134917380189563e-09
the O 0 5.464868557680802e-10
alleles O 0 7.234966792335484e-11
in O 0 4.8079398101696924e-11
this O 0 1.232395348965687e-11
study O 0 2.5867835651283144e-10
. O 0 1.8760109021798144e-09

The O 0 1.1431049529164738e-07
G301C O 0 5.935771127951739e-07
and O 0 2.4084001459812043e-09
S162F O 0 3.980390061997241e-08
mutations O 0 5.433376526475797e-10
account O 0 1.0482655021792908e-10
for O 0 6.685819675666949e-10
68 O 0 4.925383336740197e-07
. O 0 2.896174748912017e-07

4 O 0 6.199324161570985e-06
% O 0 3.746747978539133e-08
and O 0 1.2601652166210897e-08
10 O 0 1.6703020833119808e-07
. O 0 7.103868426838744e-08

5 O 0 1.2085429261787795e-06
% O 0 1.1632037555386887e-08
of O 0 2.44493811862867e-08
mutations O 0 1.0212912737728175e-09
, O 0 3.020739769432623e-10
respectively O 0 1.3630209849679886e-08
, O 0 5.72661973397004e-10
whereas O 0 4.30964153252944e-09
the O 0 1.1026044077766528e-08
remaining O 0 3.238066028643516e-07
F69V O 0 3.842369096673792e-06
is O 0 1.9163159947765962e-10
limited O 0 3.345349344763271e-11
to O 0 4.5968517187189306e-11
a O 0 1.0392155885829979e-10
single O 0 1.697166157610397e-10
allele O 0 2.766047835223162e-08
. O 0 7.416402780791032e-08

The O 0 4.56297364337388e-08
skewed O 0 2.935722420716047e-08
prevalence O 0 4.6420762345178446e-08
of O 0 2.416798094984074e-09
G301C O 0 9.405997758449303e-09
in O 0 1.1880557648780155e-10
only O 0 7.223467657357929e-11
Colombian O 0 1.9718109367516945e-09
patients O 0 7.487230280212032e-11
and O 0 6.342847688051156e-12
haplotype O 0 1.8209184160511427e-10
analysis O 0 2.5825131963475023e-11
by O 0 4.396454120897397e-12
restriction O 0 2.110868563276469e-10
fragment O 0 3.2280722539468343e-10
length O 0 1.4879575349624474e-10
polymorphisms O 0 6.311296485428386e-10
in O 0 3.0438396247944866e-10
the O 0 1.7787888939579943e-09
GALNS O 0 1.7302343167102663e-06
gene O 0 4.061829095292069e-09
suggest O 0 2.873705273742644e-09
that O 0 2.547975372357847e-11
G301C O 0 6.143898279020732e-09
originated O 0 6.868772772783416e-10
from O 0 1.6022691506911713e-10
a O 0 3.5952177346310066e-10
common O 0 9.756667695981491e-10
ancestor O 0 7.567049919998681e-08
. O 0 1.0010744944111138e-07

Investigation O 0 2.4350079002033453e-06
of O 0 5.707270389621044e-08
the O 0 7.315201777657876e-10
genetic O 0 2.8392438400359765e-10
background O 0 3.415588298305572e-11
by O 0 3.151661657346816e-12
means O 0 3.9955455610751756e-10
of O 0 2.2382573572343745e-09
mtDNA O 0 6.546207464985798e-10
lineages O 0 2.5381735602181266e-10
indicate O 0 2.9116070665580196e-10
that O 0 2.7449894787756612e-11
all O 0 9.580296278510758e-11
our O 0 1.4603255271694593e-09
patients O 0 7.940269275419354e-11
are O 0 2.0605843420451464e-12
probably O 0 2.950808000723448e-11
of O 0 5.6575896745236776e-11
native O 0 1.3184206504313067e-10
American O 0 6.835422894369003e-09
descent O 0 1.0205507351201959e-05

Low O 0 4.0878532558963343e-07
frequency O 0 2.5152661464744597e-07
of O 0 6.523391249402266e-08
BRCA1 O 0 1.3455881742174824e-07
germline O 0 1.2397050852541724e-07
mutations O 0 1.754387302099758e-09
in O 0 6.027877641479051e-10
45 O 0 2.385278463634677e-08
German O 0 0.021898694336414337
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.331746197294706e-07
. O 0 3.608859628911887e-07

In O 0 2.4152464916937788e-08
this O 0 1.8242661548040218e-10
study O 0 8.07737973729239e-11
we O 0 1.6272056618804598e-11
investigated O 0 2.648117558567975e-10
45 O 0 7.054766770764331e-10
German O 0 4.8337165026168805e-06
breast B-Disease 1 0.9999985694885254
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.868174055682744e-10
for O 0 8.549352892295303e-10
germline O 0 8.5224812096385e-08
mutations O 0 4.978287226897748e-10
in O 0 3.750705024341272e-10
the O 0 8.966880571392721e-09
BRCA1 O 0 2.9426066916471427e-08
gene O 0 6.851938394447643e-08
. O 0 1.7841284716269001e-07

We O 0 7.145492730842307e-08
identified O 0 2.9032586112975878e-08
four O 0 6.304585742356039e-09
germline O 0 2.1528043703256117e-07
mutations O 0 1.164740037751244e-08
in O 0 3.8127963009060295e-09
three O 0 7.2992327737608775e-09
breast B-Disease 0 2.7753019367082743e-06
cancer I-Disease 0 1.2672318234763225e-06
families O 0 1.0048799986561718e-10
and O 0 2.1177495312940664e-09
in O 0 5.829913334309822e-07
one O 1 0.8285033702850342
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.00996252428740263
. O 0 2.257834197383346e-10
among O 0 4.27022046195491e-12
these O 0 2.2247533676411635e-12
were O 0 1.1706453861837218e-10
one O 0 5.976358297132833e-11
frameshift O 0 1.4652981938922949e-08
mutation O 0 1.810190469742068e-10
, O 0 7.747964769766469e-11
one O 0 1.953478351301996e-10
nonsense O 0 1.2956269834774048e-08
mutation O 0 3.9853467748152127e-10
, O 0 9.386345173334476e-11
one O 0 2.3153780975837535e-11
novel O 0 1.3907063001195041e-10
splice O 0 6.85767487240696e-09
site O 0 8.312801003107495e-10
mutation O 0 8.407834151125115e-11
, O 0 5.7273703141236254e-11
and O 0 3.337766729671898e-10
one O 0 2.534711107671228e-09
missense O 0 1.0767811318146414e-06
mutation O 0 1.4463505237927166e-07
. O 0 5.046033493272262e-07

The O 0 3.066903104809171e-07
missense O 0 2.116684072461794e-06
mutation O 0 5.866777286200886e-09
was O 0 5.377379252990977e-08
also O 0 5.182903550782214e-10
found O 0 3.097238576721395e-10
in O 0 1.112034020422925e-09
2 O 0 5.250878984952578e-07
. O 0 9.052462246472714e-08

8 O 0 6.501233656308614e-06
% O 0 2.7981034378399272e-08
of O 0 1.0341452139073226e-07
the O 0 3.024817507579769e-09
general O 0 3.696172701239675e-09
population O 0 6.817613314169524e-12
, O 0 4.715522070042333e-11
suggesting O 0 2.2282506395576718e-10
that O 0 5.784951944559635e-12
it O 0 3.682606736915561e-12
is O 0 8.979360657801472e-12
not O 0 4.187948945966191e-11
disease O 0 5.162108518419473e-09
associated O 0 3.4741823640160874e-08
. O 0 4.9661537104839226e-08

The O 0 5.6866902298224886e-08
average O 0 1.8021988346106355e-09
age O 0 2.810934818242572e-09
of O 0 3.0917628457416413e-09
disease O 0 2.8262848061899604e-08
onset O 0 2.4352992511467164e-08
in O 0 2.0929641353362172e-10
those O 0 9.135568690421536e-11
families O 0 4.402327894587055e-12
harbouring O 0 6.251563267056781e-09
causative O 0 1.0136804284854861e-08
mutations O 0 5.2083044543849155e-09
was O 0 9.959494207123498e-08
between O 0 1.6412947445587633e-07
32 O 0 9.414414989805664e-07
. O 0 1.66080653229983e-07

3 O 0 8.923510904423892e-06
and O 0 1.4564798789251654e-07
37 O 0 5.266031621431466e-06
. O 0 6.41355256902898e-07

4 O 0 1.6074391169240698e-05
years O 0 1.7600363833025767e-07
, O 0 9.148546920023648e-10
whereas O 0 1.0408744977041806e-09
the O 0 1.2321238473944618e-09
family O 0 6.4998872950639e-10
harbouring O 0 7.318334382944158e-08
the O 0 1.605256372272379e-08
missense O 0 2.5398381353625155e-07
mutation O 0 2.853692171456146e-09
had O 0 2.7496767085466445e-09
an O 0 6.547416081525981e-11
average O 0 1.62641206058467e-10
age O 0 6.858953405242119e-10
of O 0 4.470535497347328e-09
onset O 0 8.633553534309613e-07
of O 0 3.900545095802954e-07
51 O 0 3.5935188407165697e-06
. O 0 6.94937341449986e-07

2 O 0 0.00010535951878409833
years O 0 1.200935798806313e-06
. O 0 1.1742075685106101e-06

These O 0 1.1567190760786161e-08
findings O 0 1.4968257744385483e-08
show O 0 8.993978894977772e-09
that O 0 1.4355719391012656e-10
BRCA1 O 0 6.493728332834792e-10
is O 0 5.175343487096029e-11
implicated O 0 7.281180658402775e-10
in O 0 3.255699321247363e-10
a O 0 1.8066723117549088e-10
small O 0 3.3361865353631615e-11
fraction O 0 2.668348653145358e-09
of O 0 3.615729383454891e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1306194869220576e-09
suggesting O 0 6.029061694334814e-10
the O 0 8.721411093315368e-11
involvement O 0 1.694469453639158e-09
of O 0 7.923873224235933e-10
another O 0 8.797362144319365e-11
susceptibility O 0 5.195869845486811e-10
gene O 0 1.1702039337535552e-09
( O 0 1.189595977280078e-09
s O 0 2.1208151679275034e-07
) O 0 1.175069712644472e-07

Paternal O 0 0.0001068226556526497
transmission O 1 0.9978339076042175
of O 1 0.9460744261741638
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.5577544569969177

We O 0 5.097438702250656e-07
report O 0 3.197886178085696e-09
a O 0 1.4691559080404204e-10
rare O 0 7.235145815798205e-11
case O 0 1.9276694129821692e-10
of O 0 1.196988508311847e-09
paternally O 1 0.9998929500579834
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.890746666002087e-05
DM B-Disease 1 1.0
) O 0 6.72130653356362e-08
. O 0 4.7649390211290665e-08

The O 0 1.8035998436971568e-06
proband O 0 3.2725038181524724e-05
is O 0 7.038131855097163e-09
a O 0 2.644660934691956e-09
23 O 0 6.5561569506655815e-09
year O 0 4.867633518479408e-10
old O 0 3.629102138802409e-06
, O 0 2.46699727313171e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.009204902686178684
who O 0 9.613456768420292e-07
suffers O 1 0.539078414440155
severe O 1 0.9999775886535645
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.00037659102235920727

He O 0 2.162054499876831e-07
presented O 0 6.381314676673355e-08
with O 0 1.604266941512833e-09
respiratory O 1 0.9697564840316772
and O 0 4.1616674550937205e-09
feeding O 0 2.271499255357412e-08
difficulties O 0 8.566938731746632e-07
at O 0 1.83690610811027e-06
birth O 0 2.3936604520713445e-07
. O 0 1.9263633532773383e-07

His O 0 7.712757906119805e-06
two O 0 1.176251998913358e-06
sibs O 0 0.024934733286499977
suffer O 0 1.24638904708263e-06
from O 0 1.1787511056127187e-07
childhood O 0 0.0031700478866696358
onset O 1 0.9999946355819702
DM B-Disease 1 1.0
. O 0 6.303245754679665e-05

Their O 0 6.747059444478509e-08
late O 0 1.4188169188855682e-05
father O 0 3.7433483157656156e-07
had O 0 7.785867062182206e-09
the O 0 2.2663511345388798e-10
adult O 0 2.809812660320432e-10
type O 0 5.2022386398675735e-09
of O 0 1.1086296325402145e-07
DM B-Disease 1 1.0
, O 0 2.0852428672668566e-09
with O 0 1.2929052273236152e-10
onset O 0 4.442866611498175e-06
around O 0 1.5115032780954607e-08
30 O 0 1.7415489494965186e-08
years O 0 6.530846530239387e-09
. O 0 1.42549971826611e-08

Only O 0 3.7296217669791076e-08
six O 0 3.535688630762479e-09
other O 0 1.7038663882584792e-11
cases O 0 2.247748515094017e-11
of O 0 1.9792820160624558e-10
paternal O 0 1.1642851660553788e-07
transmission O 0 0.10675308108329773
of O 0 0.48982495069503784
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 6.766454703210911e-07
been O 0 2.5408195547527157e-09
reported O 0 2.8536148444224807e-10
recently O 0 6.906633598369183e-10
. O 0 1.659775983320344e-09

We O 0 2.9391962641511782e-08
review O 0 2.6943494102482646e-09
the O 0 1.7423114340164858e-10
sex O 0 9.480681517626266e-11
related O 0 1.098719587533381e-10
effects O 0 3.931936998213814e-09
on O 0 3.825193939377414e-09
transmission O 0 2.4715898234717315e-06
of O 0 2.909964962327649e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0007536719786003232

Decreased O 0 7.04644151028333e-07
fertility O 0 6.18403817043145e-08
of O 0 2.9653846045363252e-09
males O 0 3.2572881891734795e-11
with O 0 7.574692956202611e-11
adult O 0 3.332528208943586e-08
onset O 0 4.340943996794522e-05
DM B-Disease 1 1.0
and O 0 1.0104392877963164e-08
contraction O 0 1.4364691658386164e-08
of O 0 3.8833354309986134e-09
the O 0 3.0217769952933793e-10
repeat O 0 1.4966101968827417e-10
upon O 0 2.583095681796266e-10
male O 0 5.572121652974715e-10
transmission O 0 6.52082654539754e-09
contribute O 0 9.331561218184348e-11
to O 0 6.979638395021581e-11
the O 0 4.2223349816516986e-10
almost O 0 4.5091552713927285e-10
absent O 0 8.197420520161813e-10
occurrence O 0 3.7524514051590074e-10
of O 0 3.709299811749389e-10
paternal O 0 1.69706417807447e-08
transmission O 0 5.994473326609295e-07
of O 0 1.2349453299975721e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0002498601679690182

Also O 0 7.725648032419485e-08
the O 0 3.10041592399557e-08
fathers O 0 6.107423899948117e-08
of O 0 7.30029148243716e-09
the O 0 2.6205790870648116e-09
reported O 0 1.8662012379877524e-08
congenitally O 0 3.25592532135488e-06
affected O 0 1.3409010568565805e-09
children O 0 7.64240615236389e-11
showed O 0 1.6046495243671188e-09
, O 0 6.167927280031904e-11
on O 0 6.152013121152322e-09
average O 0 8.337365797750351e-10
, O 0 3.5373196038968047e-10
shorter O 0 1.4605185505445206e-08
CTG O 0 5.387480541685363e-07
repeat O 0 3.5014103616504144e-08
lengths O 0 6.90980130002572e-07
and O 0 3.788220848122137e-10
hence O 0 2.59697841009654e-09
less O 0 1.9445909327231448e-09
severe O 0 3.370178092154674e-08
clinical O 0 6.282153464098883e-08
symptoms O 0 1.5253702301265548e-08
than O 0 6.879687357991271e-12
the O 0 3.906815149168352e-11
mothers O 0 2.0973830311410424e-11
of O 0 6.01396710209201e-11
children O 0 8.710821647328615e-11
with O 0 2.7947697489594248e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.012134370394051075

We O 0 2.2252888243201596e-07
conclude O 0 3.33559398768557e-07
that O 0 1.6775696110027383e-10
paternal O 0 1.2806135885057301e-07
transmission O 0 3.6537894629873335e-05
of O 0 3.386639218661003e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 6.28722375495272e-07
rare O 0 3.2658638016158648e-09
and O 0 2.3002271962169196e-11
preferentially O 0 2.0373842890553107e-10
occurs O 0 5.497399757636856e-11
with O 0 6.081559734971709e-12
onset O 0 3.2920081594056683e-07
of O 0 1.0791136446641758e-06
DM B-Disease 1 1.0
past O 0 7.974536231358798e-08
30 O 0 4.204191661472123e-09
years O 0 1.3406932508619462e-10
in O 0 5.423434271123462e-11
the O 0 1.8395457379583036e-10
father O 0 5.247021928056483e-09
. O 0 8.836314457916217e-10
. O 0 1.9931380990101388e-08

The O 0 1.0118010322912596e-06
RB1 O 0 1.5962874385877512e-05
gene O 0 1.386729220342886e-08
mutation O 0 1.2886025579916804e-09
in O 0 6.482739345337052e-10
a O 0 1.2650919201107058e-09
child O 0 2.0179138360276738e-08
with O 0 2.9370275100859544e-08
ectopic B-Disease 1 0.9999765157699585
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0011368336854502559

The O 0 3.646656523415004e-06
RB1 O 0 5.255721407593228e-05
gene O 0 7.803368617942397e-08
mutation O 0 4.7900319266602764e-09
was O 0 2.6929274810072457e-08
investigated O 0 7.533567725204193e-08
in O 0 1.8971113568966302e-09
a O 0 4.425393829166069e-09
child O 0 2.701462165077828e-08
with O 0 5.71938585380849e-09
ectopic B-Disease 0 0.23147433996200562
intracranial I-Disease 1 0.9998276233673096
retinoblastoma I-Disease 0 0.005571269430220127
using O 0 4.472906489638717e-09
DNA O 0 6.358685800122998e-10
obtained O 0 1.1171596980830145e-09
from O 0 1.38669603577668e-10
both O 0 2.5905064204856387e-10
the O 0 3.0821420970994495e-09
pineal B-Disease 0 1.7684769773040898e-05
and I-Disease 0 2.4879870608174315e-08
retinal I-Disease 1 0.9932478666305542
tumours I-Disease 1 1.0
of O 0 0.03453176096081734
the O 0 2.8847011890320573e-06
patient O 0 1.279321986658033e-05
. O 0 2.8084076575396466e-07

A O 0 1.8632972569321282e-06
nonsense O 0 6.980592957006593e-07
mutation O 0 1.4632670630732036e-09
in O 0 2.4356185956975196e-09
exon O 0 1.253994099670308e-07
17 O 0 4.397972475089773e-08
( O 0 3.185563202112718e-10
codon O 0 3.232664358421289e-09
556 O 0 4.486868654396403e-09
) O 0 5.903806332696604e-10
of O 0 2.4848095137031123e-08
the O 0 8.094279735360033e-08
RB1 O 0 9.155482075584587e-06
gene O 0 5.2734616673433266e-08
was O 0 1.2197652949907933e-06
found O 0 3.7056671065016644e-09
to O 0 5.383959944538219e-11
be O 0 2.578472331482562e-11
present O 0 2.098536483474689e-10
homozygously O 0 1.0040211861905846e-07
in O 0 1.083900080800504e-09
both O 0 5.272128844602264e-10
the O 0 3.0152844665565226e-09
retinal B-Disease 0 2.237867192889098e-06
and I-Disease 0 1.1388965326375455e-08
the I-Disease 0 1.8949683067148726e-07
pineal I-Disease 1 0.8794090151786804
tumours I-Disease 1 1.0
. O 0 3.097351509495638e-05

The O 0 9.202282313935939e-08
same O 0 6.7938557002378275e-09
mutation O 0 3.8864156337581335e-10
was O 0 5.249734869039457e-09
present O 0 4.93557250624832e-10
heterozygously O 0 3.247615154577943e-08
in O 0 6.982024958190891e-10
the O 0 3.8821482140072305e-10
DNA O 0 1.7721944745030527e-10
from O 0 3.865573139361089e-11
the O 0 5.6864214725838025e-11
constitutional O 0 5.3073332395570105e-09
cells O 0 9.625188146511476e-11
of O 0 1.1166526592276682e-09
the O 0 4.167742539973318e-10
patient O 0 2.4067057236010214e-09
, O 0 1.9129781092530607e-10
proving O 0 1.3053455205636055e-08
it O 0 6.983829313467194e-12
to O 0 1.4520168054033e-11
be O 0 5.111850526207107e-11
of O 0 5.693543969620407e-10
germline O 0 1.6050542228640552e-08
origin O 0 3.982309149108687e-09
. O 0 3.51936115805529e-08

The O 0 1.0911942638358596e-07
initial O 0 2.2137859545523497e-08
mutation O 0 1.8550178060294797e-09
was O 0 9.9885983928516e-09
shown O 0 1.0385106108401487e-09
to O 0 6.941866526055662e-11
have O 0 1.9940210940760927e-11
occurred O 0 1.6571692906808266e-09
in O 0 1.6703178770671734e-11
the O 0 1.4407783299752452e-10
paternally O 0 1.7425790588276868e-08
derived O 0 2.9617728269926147e-09
RB1 O 0 9.971780627893168e-07
allele O 0 1.1895992457766624e-07
. O 0 1.9383195137834264e-07

The O 0 3.0725826150046487e-07
mutation O 0 3.7126990370950352e-09
is O 0 4.614026938298821e-10
in O 0 1.8240295385218985e-10
an O 0 4.3303104158010086e-11
area O 0 2.4683464161512347e-09
of O 0 8.907288240322941e-09
the O 0 3.363831213576418e-09
gene O 0 3.2233965496786254e-10
that O 0 1.1711188963037245e-10
encodes O 0 1.038017033438976e-10
the O 0 1.0997558419489906e-09
protein O 0 1.2099183877012365e-09
- O 0 5.352814302916897e-10
binding O 0 1.7228153348369801e-09
region O 0 3.109168389414663e-08
known O 0 2.205246651953985e-09
as O 0 1.0266583139184604e-09
the O 0 5.05806596606817e-09
pocket O 0 0.001319735310971737
region O 0 1.0445003226777771e-06
and O 0 3.350947075375643e-09
has O 0 1.1044428566142628e-10
been O 0 2.2762272969267805e-11
detected O 0 1.6403879643522856e-10
in O 0 5.6124566799597986e-12
other O 0 2.0443460292673965e-12
cases O 0 1.8480836652678967e-11
of O 0 7.310765881562986e-10
retinoblastoma B-Disease 0 3.6215885756973876e-07
. O 0 2.9089439745888512e-09
. O 0 3.699024020420438e-08

Low O 0 2.7801097530755214e-06
levels O 0 2.1931008120645856e-07
of O 0 3.47322171023734e-08
beta O 0 5.4003823635184744e-08
hexosaminidase O 0 2.66699203166354e-07
A O 0 5.294088722962442e-09
in O 0 1.8730531015087593e-10
healthy O 0 3.696184747159492e-10
individuals O 0 1.925282632972425e-12
with O 0 4.2432675428916156e-11
apparent O 0 1.4494755760097178e-06
deficiency O 0 0.035578709095716476
of O 0 6.444785185522051e-07
this O 0 2.5169630823995703e-09
enzyme O 0 7.384601730109353e-08
. O 0 8.01567949793025e-08

Appreciable O 0 7.022185309324414e-05
beta O 0 1.6005464203772135e-05
hexosaminidase O 0 0.00011708201054716483
A O 0 6.2566214182879776e-06
( O 0 3.136727544372775e-09
hex O 0 2.3974848772922996e-07
A O 0 2.5036200668182573e-08
) O 0 2.369286711267904e-11
activity O 0 1.6732587537759969e-10
has O 0 9.39664058369205e-12
been O 0 1.8253964312320292e-11
detected O 0 9.786655930099641e-10
in O 0 2.457160863666985e-10
cultured O 0 2.3195189768898672e-08
skin O 0 2.881500549278826e-08
fibroblasts O 0 3.682403715288274e-08
and O 0 2.185378322749898e-09
melanoma B-Disease 0 4.073912407420721e-07
tissue O 0 1.2144412586678754e-08
from O 0 2.2844467650884326e-08
healthy O 0 8.815658758543066e-10
individuals O 0 1.4477738669374518e-12
previously O 0 4.1245798443334536e-10
reported O 0 1.0258630750437092e-10
as O 0 9.187870603222237e-11
having O 0 3.4546610017116564e-09
deficiency B-Disease 0 9.06892182683805e-06
of I-Disease 0 1.7187584262501332e-06
hex I-Disease 0 4.7588176244062197e-07
A I-Disease 0 5.1299346992550454e-09
activity O 0 7.917890787467741e-10
indistinguishable O 0 4.522143770557818e-10
from O 0 3.037109409451122e-12
that O 0 2.199101361080591e-13
of O 0 2.1436836680766014e-11
patients O 0 3.159265904439934e-10
with O 0 7.359039244647647e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.197639782432816e-07
TSD B-Disease 0 0.00014497016672976315
) O 0 2.4374323004394682e-08
. O 0 1.593883212080982e-07

Identification O 0 1.6006282521630055e-07
and O 0 2.2181732006743005e-08
quantitation O 0 0.0007786177447997034
of O 0 6.1974031268619e-05
hex O 0 5.395918560680002e-05
A O 0 1.619355202819861e-06
, O 0 1.8217184427626876e-09
amounting O 0 1.2089432566142477e-08
to O 0 1.3757112116152825e-09
3 O 0 9.579724746799911e-08
. O 0 6.294927601402378e-08

5 O 0 3.954498424718622e-06
% O 0 6.620447834393417e-08
- O 0 2.5682578552732593e-07
6 O 0 9.068133977052639e-07
. O 0 1.313670878744233e-07

9 O 0 2.489383632564568e-06
% O 0 7.979903848820413e-09
of O 0 1.4762021827152694e-08
total O 0 1.120059267556428e-09
beta O 0 3.3217840922361574e-08
hexosaminidase O 0 7.514968558552937e-08
activity O 0 9.827696434427935e-10
, O 0 1.4648490753721433e-11
has O 0 2.093417236434525e-12
been O 0 4.317294785560755e-12
obtained O 0 1.072375521715685e-10
by O 0 1.0321830196113879e-10
cellulose O 0 7.376745969622789e-08
acetate O 0 4.813425036331864e-08
gel O 0 2.257815481243597e-07
electrophoresis O 0 2.540647301429999e-07
, O 0 2.0733303074393916e-08
DEAE O 0 5.50042386748828e-05
- O 0 1.3562909089159803e-06
cellulose O 0 5.778815648227464e-06
ion O 0 1.7185260730911978e-05
- O 0 1.6766763621944847e-07
exchange O 0 4.6424167976510944e-07
chromatography O 0 1.3242030263427296e-06
, O 0 5.986572348959385e-10
radial O 0 3.399494730160768e-08
immunodiffusion O 0 2.1935107952231192e-07
, O 0 5.278961157095807e-10
and O 0 1.72363046058166e-09
radioimmunoassay O 0 6.285189101618016e-06
. O 0 3.628360900620464e-07

Previous O 0 2.195334673160687e-06
family O 0 2.8044134126048448e-08
studies O 0 4.045206836167381e-09
suggested O 0 5.210895048790576e-10
that O 0 4.503495232982546e-12
these O 0 2.2961099167828625e-12
individuals O 0 3.063406299463889e-12
may O 0 1.7505724647648435e-10
be O 0 9.014595320211427e-11
compound O 0 3.3809799404593832e-09
heterozygotes O 0 6.013125108950135e-09
for O 0 2.814205812828874e-10
the O 0 1.0070583256194254e-09
common O 0 2.0204122819222903e-09
mutant O 0 6.149657139076226e-08
TSD B-Disease 0 6.387354005710222e-07
gene O 0 3.4440095220134026e-09
and O 0 1.1276237721347115e-09
a O 0 1.2486420786217423e-09
rare O 0 1.1106308095421014e-09
( O 0 7.629735038205965e-11
allelic O 0 5.510727429935969e-09
) O 0 5.557729276794987e-10
mutant O 0 3.4114592040168645e-08
gene O 0 1.192682361761399e-07
. O 0 2.5968321892833046e-07

Thus O 0 1.3784667771687964e-06
, O 0 7.45723749417948e-09
the O 0 7.724701767131137e-09
postulated O 0 2.2438929647705663e-07
rate O 0 6.5005600902168226e-09
mutant O 0 1.986976583268074e-09
gene O 0 9.302209558192942e-10
appears O 0 1.1882443917698993e-09
to O 0 5.027024282955317e-11
code O 0 7.995161477314383e-11
for O 0 1.2935386269063986e-11
the O 0 1.815815726946557e-11
expression O 0 8.35460103876251e-11
of O 0 5.724948848317979e-10
low O 0 2.7327733409521215e-09
amounts O 0 3.2397423632701816e-10
of O 0 4.612190185326881e-09
hex O 0 2.78398090358678e-07
A O 0 2.390585223110975e-07
. O 0 1.5040669154586794e-07

Heterozygotes O 0 2.7445768864708953e-05
for O 0 1.6729418916838767e-07
the O 0 8.735609213772477e-08
rare O 0 2.5937326952885087e-08
mutant O 0 4.1707924225420356e-08
may O 0 7.66270247254397e-09
be O 0 3.590003017084342e-10
indistinguishable O 0 2.3654331826605812e-09
from O 0 1.828882323362535e-10
heterozygotes O 0 2.072973570577119e-09
for O 0 4.1229970826339724e-11
the O 0 4.283243759672928e-10
common O 0 9.063136019449303e-09
TSD B-Disease 0 3.637937879830133e-06
mutant O 0 1.888765410740234e-07
. O 0 9.651564170098936e-08

However O 0 1.296477876167046e-07
, O 0 2.115383868073195e-09
direct O 0 2.0770976050243917e-09
visualization O 0 1.7299227295097808e-07
and O 0 3.3359417450640194e-09
quantitation O 0 0.06128884479403496
of O 0 0.0007572658942081034
hex O 0 4.081218139617704e-05
A O 0 9.980298187883818e-08
by O 0 5.557493007457559e-11
the O 0 3.0965180419784133e-10
methods O 0 6.7353567168026984e-09
described O 0 3.081323252107637e-10
may O 0 2.916541314013088e-11
prevent O 0 4.854613239180239e-11
false O 0 7.614484043294567e-11
- O 0 9.57466952944408e-11
positive O 0 2.7259557458525485e-11
prenatal O 0 1.0015898332937923e-08
diagnosis O 0 1.070888622223265e-08
of O 0 1.1065273142207843e-08
TSD B-Disease 0 8.15447037894046e-06
in O 0 5.7212108828252894e-08
fetuses O 0 8.086856695399547e-08
having O 0 4.237513007154803e-09
the O 0 5.4881441613474635e-09
incomplete O 0 1.3548567778798315e-07
hex B-Disease 0 4.791885203303536e-06
A I-Disease 0 1.3976595027997973e-06
deficiency I-Disease 0 0.00032725214259698987
of O 0 1.5447150190084358e-06
the O 0 2.8886816494377854e-08
type O 0 1.9403188389333081e-07
described O 0 3.2114437775732085e-09
in O 0 1.1173850039680744e-10
the O 0 1.5917733797721212e-09
four O 0 6.034460930948171e-09
healthy O 0 6.000364294322935e-08
individuals O 0 3.3214547556781326e-08

The O 0 2.6744243086795905e-07
tumor B-Disease 0 6.194285333549487e-07
suppressor O 0 1.2729028640023898e-06
gene O 0 1.8261937384522753e-07
Smad4 O 0 7.528233709308552e-06
/ O 0 5.051368248132349e-07
Dpc4 O 0 2.6104814878635807e-06
is O 0 7.413454294891153e-10
required O 0 1.4090069111460934e-09
for O 0 3.961828920484578e-10
gastrulation O 0 1.839477903331499e-07
and O 0 5.575502837196211e-10
later O 0 5.4984958808290685e-09
for O 0 3.036718654314541e-10
anterior O 0 2.063786297412662e-08
development O 0 7.051652062273206e-08
of O 0 1.546775791894106e-07
the O 0 1.834152207891293e-08
mouse O 0 2.0920960963621837e-08
embryo O 0 2.994079650875392e-09
. O 0 2.5394012226342966e-08

Mutations O 0 3.0366757641786535e-07
in O 0 2.4155827560434773e-08
the O 0 6.068871272191245e-08
SMAD4 O 0 0.0002786346594803035
/ O 0 5.341098585631698e-06
DPC4 O 0 1.180196431960212e-05
tumor B-Disease 0 1.0735742250744806e-07
suppressor O 0 2.81765210274898e-07
gene O 0 9.643795095826135e-09
, O 0 1.4282286464606386e-09
a O 0 5.78925485328341e-09
key O 0 3.4799529657902895e-07
signal O 0 1.0702107147153583e-06
transducer O 0 5.856314828633913e-07
in O 0 2.243267616108824e-08
most O 0 1.4057078834284198e-09
TGFbeta O 0 8.629832564110984e-07
- O 0 7.587019901222902e-09
related O 0 8.518332705875764e-09
pathways O 0 1.6853636264357874e-09
, O 0 1.9453421512549696e-11
are O 0 4.0252260617539004e-13
involved O 0 1.114672590341037e-11
in O 0 6.9133089010409154e-12
50 O 0 5.2141638229308285e-11
% O 0 1.222963952329792e-10
of O 0 1.5920997498142242e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999992847442627
. O 0 3.0631130357505754e-05

Homozygous O 0 1.9464607248664834e-05
Smad4 O 0 0.0001324172189924866
mutant O 0 3.3730575523804873e-06
mice O 0 5.206172204452741e-07
die O 0 7.704855420342938e-08
before O 0 3.306196916241788e-08
day O 0 1.4423332750368445e-08
7 O 0 8.908005355579007e-08
. O 0 2.9352298369644814e-08

5 O 0 4.508954589255154e-06
of O 0 1.2878484767497866e-06
embryogenesis O 0 6.315369682852179e-05
. O 0 2.052392574114492e-06

Mutant O 0 8.218874540943943e-07
embryos O 0 3.6049996765541437e-08
have O 0 9.979451709440923e-10
reduced O 0 1.4962884264946297e-09
size O 0 1.2638184943014608e-09
, O 0 1.9164439479801842e-10
fail O 0 4.731815828051822e-09
to O 0 4.06412126174871e-10
gastrulate O 0 1.331073917754111e-07
or O 0 3.0713676046900673e-09
express O 0 1.6109882317039137e-09
a O 0 1.1912080211118337e-09
mesodermal O 0 2.9685212510344172e-08
marker O 0 1.8728304951309838e-07
, O 0 3.4199856280281438e-09
and O 0 2.239333385389841e-09
show O 0 4.788581975390116e-08
abnormal O 0 2.3136062736739404e-06
visceral O 0 6.287317773967516e-06
endoderm O 0 2.2413987608160824e-05
development O 0 9.327282555204874e-07
. O 0 3.9572495325046475e-07

Growth B-Disease 1 0.9999978542327881
retardation I-Disease 1 1.0
of O 0 9.405583114130422e-06
the O 0 1.0288017904258595e-07
Smad4 O 0 2.9632330551976338e-05
- O 0 8.521489291979378e-08
deficient O 0 6.405556973732018e-08
embryos O 0 1.8348186858752058e-10
results O 0 1.108655597881203e-10
from O 0 8.798889394867615e-11
reduced O 0 7.135149693304754e-10
cell O 0 2.334666682202169e-09
proliferation O 0 4.976286938074281e-09
rather O 0 2.557289276172714e-11
than O 0 2.7131164068855407e-12
increased O 0 5.914115031036005e-11
apoptosis O 0 2.973865242950069e-08
. O 0 1.7753526648789375e-08

Aggregation O 0 2.2093279028467805e-07
of O 0 2.573072777067864e-07
mutant O 0 2.3854110509091697e-07
Smad4 O 0 4.6631621444248594e-06
ES O 0 2.7210001007915707e-07
cells O 0 1.7107676386629578e-10
with O 0 5.848849876644024e-11
wild O 0 3.5962330335870263e-10
- O 0 6.690105691653514e-10
type O 0 1.0585698539955501e-08
tetraploid O 0 3.1794814958630013e-07
morulae O 0 2.3755135316605447e-06
rescues O 0 2.0999523542286624e-07
the O 0 1.9826504882303198e-08
gastrulation B-Disease 0 1.063526542566251e-05
defect I-Disease 0 2.9116019504726864e-05
. O 0 4.5725403197138803e-07

These O 0 1.2022677076117816e-08
results O 0 1.0794360072452491e-08
indicate O 0 1.0326546728833819e-08
that O 0 1.5667446506828497e-10
Smad4 O 0 6.926124740402884e-08
is O 0 5.883266096518014e-11
initially O 0 7.611158925335815e-11
required O 0 6.398050839129255e-11
for O 0 1.2125115148031718e-11
the O 0 7.306692056952002e-11
differentiation O 0 1.0952739826208813e-09
of O 0 8.713207044763749e-09
the O 0 9.002370404687099e-09
visceral O 0 1.5694028832058393e-07
endoderm O 0 2.124671709680115e-07
and O 0 2.485356920267634e-10
that O 0 1.4255899412340955e-11
the O 0 1.867577481551308e-10
gastrulation B-Disease 0 6.530549256922313e-08
defect I-Disease 0 3.847080520813506e-08
in O 0 5.733526986517745e-10
the O 0 3.6921070645234977e-09
epiblast O 0 6.393900093826232e-07
is O 0 1.423091366969942e-10
secondary O 0 2.471351789878895e-09
and O 0 4.216693660907822e-10
non O 0 3.3850474778773787e-07
- O 0 1.2875423749392212e-07
cell O 0 7.470735567949305e-07
autonomous O 0 3.8071959806984523e-07
. O 0 1.5833688848942984e-07

Rescued O 0 6.603905058000237e-05
embryos O 0 3.885286332661053e-07
show O 0 6.32560727353848e-07
severe O 0 4.321160758991027e-06
anterior O 0 8.108222391456366e-05
truncations O 1 0.8976005911827087
, O 0 2.51851037802453e-08
indicating O 0 7.113902711353148e-08
a O 0 5.481093356962674e-09
second O 0 3.112976099117759e-09
important O 0 1.9397010664334857e-09
role O 0 6.1952043495239195e-09
for O 0 1.865951171353686e-09
Smad4 O 0 1.1151780654472532e-06
in O 0 1.0857150734011611e-08
anterior O 0 2.6574180083116516e-06
patterning O 0 4.6430806833086535e-05
during O 0 6.189624400576577e-06
embryogenesis O 0 1.1895546776941046e-05
. O 0 2.548227655552182e-07

Prevalence O 0 1.0886834616030683e-06
of O 0 6.695843524084921e-08
p16 O 0 1.396681312826331e-07
and O 0 6.996452750485105e-09
CDK4 O 0 3.181565989507362e-05
germline O 0 1.6024656588342623e-06
mutations O 0 1.4407634196800245e-08
in O 0 1.138770677755474e-08
48 O 0 9.654229415900772e-07
melanoma B-Disease 0 0.004216623492538929
- O 0 7.331421784328995e-06
prone O 0 5.994964340061415e-06
families O 0 9.54966522526135e-11
in O 0 2.453340641750401e-09
France O 0 2.3014382577457582e-07
. O 0 6.087559967227207e-08

The O 0 6.468652031799138e-07
French O 0 4.390980757307261e-05
Familial B-Disease 0 0.0219106487929821
Melanoma I-Disease 1 0.7871460318565369
Study O 0 4.966750211110593e-08
Group O 0 1.2924061820740462e-08
. O 0 5.207701647691465e-08

Germline O 0 8.249598613474518e-05
mutations O 0 1.7233199400834565e-07
in O 0 1.8911151755673927e-08
the O 0 1.0411966400170058e-08
p16 O 0 1.1223463047826954e-07
and O 0 2.684992006507514e-09
CDK4 O 0 2.589521955087548e-06
genes O 0 1.5684288312556305e-09
have O 0 1.018299194965877e-10
been O 0 4.826960706139083e-11
reported O 0 1.2182378716918407e-10
in O 0 3.6008845211155105e-11
a O 0 6.322040113637684e-11
subset O 0 1.356971779387095e-08
of O 0 1.3256266129246796e-07
melanoma B-Disease 0 1.2755270290654153e-05
pedigrees O 0 6.684219044927886e-08
, O 0 2.1985512022038023e-10
but O 0 2.115623821963286e-11
their O 0 5.974440560330141e-12
prevalence O 0 3.5110658824777374e-09
is O 0 2.4807794707371045e-12
not O 0 2.3013012936251576e-12
well O 0 5.503159386521794e-11
known O 0 1.1329400750881291e-09
. O 0 1.519191528132069e-08

We O 0 6.18462792090213e-08
searched O 0 5.0863956602142935e-08
for O 0 3.272022375266914e-10
such O 0 1.9373079529483306e-10
germline O 0 6.007567066035335e-08
mutations O 0 3.502343970396282e-09
in O 0 7.674023194681467e-09
48 O 0 2.46566600026199e-07
French O 0 7.531661685789004e-05
melanoma B-Disease 1 0.9998076558113098
- O 0 0.00010185375867877156
prone O 0 1.6429892639280297e-05
families O 0 5.138350855915519e-11
selected O 0 3.411046167745013e-10
according O 0 8.391652650541204e-11
to O 0 1.8953841968150087e-11
two O 0 4.1656580962445844e-11
major O 0 6.397956053838527e-10
criteria O 0 3.6565475092231736e-09
families O 0 7.123040005052594e-12
with O 0 3.2716836184665254e-11
at O 0 1.2993193188037822e-08
least O 0 2.3017062214525374e-11
three O 0 1.5055278204667566e-11
affected O 0 2.7597356691555497e-11
members O 0 4.510770229559924e-11
( O 0 2.511014486616947e-11
n O 0 7.627327214265733e-09
= O 0 4.76143879879487e-09
20 O 0 3.747303356504972e-09
) O 0 2.309437016623228e-11
or O 0 4.426714203531468e-11
families O 0 2.199500998001369e-12
with O 0 2.0407318196413726e-11
two O 0 1.2357855017075536e-10
affected O 0 1.0468329675328292e-10
members O 0 3.439568421748085e-11
, O 0 4.005913656346394e-11
one O 0 4.869014913477798e-11
of O 0 4.248622842428773e-10
them O 0 2.6245830161975015e-11
affected O 0 5.0856412830979636e-11
before O 0 1.7033635613117326e-10
the O 0 1.0798466981709609e-10
age O 0 9.207049567194758e-10
of O 0 1.7768017057662178e-09
50 O 0 5.642989964194101e-10
( O 0 3.825000385870858e-11
n O 0 5.900668398339803e-09
= O 0 8.925314709529175e-09
28 O 0 1.9351901414665917e-08
) O 0 2.2021644230374449e-10
, O 0 1.440591534951352e-10
and O 0 2.638083848593986e-11
one O 0 1.3374105642394163e-11
additional O 0 4.8177715289421386e-11
minor O 0 1.946035155242498e-08
criterion O 0 3.1768060580361634e-05
. O 0 5.54319342427334e-07

Sixteen O 0 7.629521860508248e-06
different O 0 4.3731123611223666e-08
p16 O 0 9.396333098266041e-07
germline O 0 1.4009236792844604e-06
mutations O 0 9.635263253926496e-09
were O 0 2.9365498921407607e-09
found O 0 2.1782695092120719e-10
in O 0 1.0677364548072887e-10
21 O 0 1.4513675816729688e-09
families O 0 4.597998197464204e-12
, O 0 3.268153803137608e-11
while O 0 4.926693497608881e-10
one O 0 5.895535171163147e-10
germline O 0 2.7542078839815076e-08
mutation O 0 5.460690233327625e-10
, O 0 5.039295647435438e-10
Arg24His O 0 1.54754602021967e-07
, O 0 8.265039208588121e-10
was O 0 2.0886753659965507e-08
detected O 0 1.0524878746309696e-08
in O 0 6.375079908416126e-10
the O 0 3.869760067942707e-09
CDK4 O 0 3.311907448733109e-06
gene O 0 9.621859931030485e-08
. O 0 1.335465640295297e-07

The O 0 2.3170958485252413e-08
frequency O 0 7.326798368012533e-08
of O 0 1.0927308835562144e-08
p16 O 0 1.1582733883130913e-08
gene O 0 8.26141433041272e-10
mutation O 0 2.468749926709535e-10
in O 0 1.7502886640041737e-10
our O 0 4.047141510810093e-10
sample O 0 1.7451184941563724e-10
( O 0 3.5807010134725203e-11
44 O 0 5.835770200413037e-10
% O 0 4.745386375515359e-11
) O 0 3.7903000182915036e-11
is O 0 2.9275207258372404e-11
among O 0 3.983032220017391e-12
the O 0 1.0607394823614058e-10
highest O 0 3.5039275925186075e-09
rates O 0 7.33707039568543e-10
yet O 0 2.976124902076549e-11
reported O 0 1.0240958081553231e-10
and O 0 2.3141110555569e-11
the O 0 3.705142026522168e-10
CDK4 O 0 5.428544227470411e-07
mutation O 0 4.686365739914322e-10
is O 0 5.1970067138640275e-11
the O 0 1.0568217828632598e-10
second O 0 2.677023880348628e-10
mutation O 0 6.46712544627448e-11
detected O 0 5.888522447428102e-10
in O 0 5.190300272905901e-11
this O 0 7.777398863817453e-11
gene O 0 1.1042602388044997e-09
worldwide O 0 1.5142901377274143e-09
. O 0 6.903663773982771e-08

In O 0 1.1689106713674846e-06
summary O 0 6.814987955294782e-06
, O 0 2.2644899289048226e-09
our O 0 8.339623436270927e-10
results O 0 1.04788573651593e-10
show O 0 7.762671616617922e-10
frequent O 0 8.881831381479799e-11
involvement O 0 7.789026645887986e-10
of O 0 1.5138165165851092e-09
the O 0 1.5598576874609194e-09
p16 O 0 2.2855189740766946e-08
gene O 0 1.2082400857593711e-08
in O 0 1.5565001731943084e-08
familial B-Disease 0 1.6169005903066136e-05
melanoma I-Disease 0 0.0004640873521566391
and O 0 3.829434991331482e-09
confirm O 0 3.415005611628885e-09
the O 0 1.2683173400418468e-09
role O 0 1.761143764156259e-08
of O 0 7.760355202890423e-08
the O 0 2.5878620135699748e-08
CDK4 O 0 1.88321755558718e-05
gene O 0 1.0895611524119886e-08
as O 0 8.225176983955862e-09
a O 0 2.281302968754062e-08
melanoma B-Disease 0 2.8614485927391797e-05
- O 0 8.404589380006655e-07
predisposing O 0 9.32269415443443e-07
gene O 0 1.6626955812171218e-07
. O 0 6.38538111275011e-08
. O 0 4.665242556711746e-07

Progression O 0 0.00015064881881698966
of O 0 2.9750521207461134e-05
somatic O 0 0.00010903883958235383
CTG O 0 0.00011847834684886038
repeat O 0 1.5973861877682793e-07
length O 0 2.4330011783035843e-08
heterogeneity O 0 1.2469196342124178e-08
in O 0 6.41966590997356e-10
the O 0 2.553230404878093e-10
blood O 0 3.2632715973868187e-10
cells O 0 5.428270055674034e-10
of O 0 7.575027325401607e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.1931404515053146e-05
. O 0 2.635714508869569e-07

The O 0 2.7710219896448507e-08
genetic O 0 3.8755899822717765e-08
basis O 0 3.379618647159077e-07
of O 0 0.06884286552667618
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.005341643933206797
DM B-Disease 1 1.0
) O 0 3.1636575581472925e-09
is O 0 1.0569991409914437e-10
the O 0 4.0320916744329693e-11
expansion O 0 9.648426502195662e-10
of O 0 5.24996535133937e-09
an O 0 1.2602823229457272e-09
unstable O 0 5.579434218816459e-05
CTG O 0 9.927772225637455e-06
repeat O 0 1.492851353646074e-08
in O 0 9.722134208800526e-10
the O 0 3.9894101355741896e-09
34 O 0 1.9892375746621838e-08
UTR O 0 7.429513289025635e-07
of O 0 2.1070253097832392e-08
the O 0 1.22668481594701e-07
DM B-Disease 1 0.9999997615814209
protein O 0 4.6485351390401775e-07
kinase O 0 7.287634673502907e-08
gene O 0 1.1164380531170082e-08
on O 0 1.252380599225944e-07
chromosome O 0 2.02689579964499e-06
19 O 0 2.3914956273074495e-06
. O 0 5.741981112805661e-07

One O 0 3.3062858051380317e-07
of O 0 2.3519608305377915e-07
the O 0 9.262555167310893e-09
principal O 0 3.2010436257223773e-07
features O 0 1.6710533401465e-08
of O 0 1.9854741140079568e-07
the O 0 4.422018264449434e-06
DM B-Disease 1 1.0
mutation O 0 2.1882991418920028e-08
is O 0 1.6034952532439917e-10
an O 0 4.6708716755494706e-11
extraordinarily O 0 1.5662443786368385e-08
high O 0 2.5122352198536646e-08
level O 0 3.2855405152076855e-07
of O 0 8.324865348185995e-07
somatic O 0 1.8521888023315114e-06
mosaicism O 0 3.5002452932531014e-05
, O 0 2.130450704740383e-09
due O 0 2.4138694598718757e-08
to O 0 5.221511001352042e-10
an O 0 9.286799107499633e-11
extremely O 0 1.915487546355621e-09
high O 0 3.3471143634500322e-09
degree O 0 3.95529440311293e-08
of O 0 6.4890270934370164e-09
somatic O 0 1.5123548280371324e-07
instability O 0 6.580552280865959e-08
both O 0 4.0167269510504866e-10
within O 0 2.888508043863425e-10
and O 0 3.809281709510337e-11
between O 0 1.0841481046242052e-09
different O 0 5.978995076816318e-10
tissues O 0 2.0060712202507602e-08
. O 0 4.0189991779016054e-08

This O 0 6.347410419493826e-08
instability O 0 4.327899659983814e-06
appears O 0 2.5077540044549096e-08
to O 0 2.7055641060869107e-10
be O 0 6.281090231263775e-11
biased O 0 3.375089097090722e-10
towards O 0 2.469814353034394e-10
further O 0 3.242331056418912e-11
expansion O 0 1.399409893521053e-10
and O 0 2.8115967887210047e-11
continuous O 0 1.8375478916254906e-09
throughout O 0 3.904433443224775e-10
the O 0 8.030914266932143e-10
life O 0 9.070844630976183e-10
of O 0 2.3434107987441166e-09
an O 0 4.7442098860539517e-11
individual O 0 4.026497191222944e-11
, O 0 2.061148474119534e-10
features O 0 2.543578681013514e-09
that O 0 1.207011157688953e-10
could O 0 2.548229127707913e-10
be O 0 7.099524440556948e-11
associated O 0 8.938427775717628e-10
with O 0 2.077943372924551e-11
the O 0 9.143871770866951e-10
progressive O 0 5.849176432093373e-07
nature O 0 9.324862659809696e-09
of O 0 6.267848906560403e-09
the O 0 9.050681093469848e-09
disease O 0 4.7147153736659675e-07
. O 0 1.9122612826549812e-08

Although O 0 3.536041504048626e-08
increasing O 0 2.2147648159887012e-09
measured O 0 1.2892472867065408e-08
allele O 0 5.547426962237978e-09
size O 0 5.0861408418256815e-09
between O 0 1.6897967469731157e-08
patients O 0 4.050147772716173e-09
clearly O 0 1.6385688361708617e-09
correlates O 0 6.393564566664622e-10
with O 0 2.974607973132981e-12
an O 0 1.6392040719584444e-12
increased O 0 3.6455134050372706e-11
severity O 0 1.1842402614092862e-08
of O 0 6.957989184819269e-10
symptoms O 0 2.5149522464573693e-09
and O 0 7.07956176321245e-12
an O 0 1.857720357753556e-12
earlier O 0 1.2863966836196283e-10
age O 0 9.663362332545944e-10
of O 0 3.618844779396113e-09
onset O 0 3.2587969656106e-08
, O 0 6.052563311653714e-11
this O 0 4.7271088952915985e-12
correlation O 0 3.1320029902914825e-10
is O 0 1.793199790045552e-11
not O 0 6.4026743976097755e-12
precise O 0 1.1822514078829727e-09
and O 0 4.563689010028682e-11
measured O 0 9.719001159425034e-10
allele O 0 1.255963000268423e-09
length O 0 4.5516190816385915e-09
cannot O 0 1.1545298050918973e-09
be O 0 1.0923589116584864e-10
used O 0 8.236912540926511e-11
as O 0 6.578782223848334e-12
an O 0 1.2312387437721228e-12
accurate O 0 1.6075872855125795e-09
predictor O 0 6.57692567074264e-08
of O 0 3.0562208319651063e-09
age O 0 4.080911253367958e-08
of O 0 2.8545764507725835e-07
onset O 0 6.788900645915419e-05
. O 0 4.090262848421844e-07

In O 0 1.223541943318196e-07
order O 0 1.0343874201623748e-08
to O 0 3.679114235488612e-10
further O 0 3.2261887605855577e-10
characterize O 0 1.0279050499661935e-08
the O 0 2.1274579875552035e-09
dynamics O 0 6.1273458413779736e-06
of O 0 1.2473863534978591e-05
DM B-Disease 1 1.0
CTG O 0 0.034083932638168335
repeat O 0 7.837599582671828e-07
somatic O 0 1.07915684566251e-06
instability O 0 1.0160322290175827e-06
, O 0 5.19694010048255e-10
we O 0 1.2203006660715943e-10
have O 0 5.724025853998116e-12
studied O 0 5.118584445185093e-10
repeat O 0 4.7565503619173555e-11
length O 0 1.4237285829443724e-11
changes O 0 1.315895222647745e-11
over O 0 2.4957445832196612e-11
time O 0 1.0267792172058421e-10
in O 0 3.630914735541779e-10
111 O 0 1.2393163160595577e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 2.166686030591336e-08
with O 0 1.67383981675151e-10
varying O 0 2.441558288879264e-09
clinical O 0 3.6430098049322623e-08
severity O 0 1.1485850848202972e-07
and O 0 1.3731866754795874e-09
CTG O 0 5.02427155879559e-07
repeat O 0 4.2467696026449175e-09
size O 0 1.0775861314371582e-09
over O 0 8.879430524189047e-10
time O 0 1.6918858536385528e-09
intervals O 0 3.926556413347271e-09
of O 0 1.6586683138086755e-09
1 O 0 1.9130238726461357e-08
- O 0 3.3486211581390535e-09
7 O 0 1.594600007592817e-08
years O 0 6.431778665216825e-09
. O 0 2.718333114160032e-08

We O 0 2.1385987736266543e-07
have O 0 6.649105155354107e-10
found O 0 1.5323088631280513e-10
a O 0 5.35097417764252e-11
direct O 0 1.5648274342972002e-10
progression O 0 2.532951848266407e-09
of O 0 3.708070961394583e-09
the O 0 1.301938334918873e-09
size O 0 1.2860661424696218e-09
heterogeneity O 0 3.559214922788101e-09
over O 0 4.0130967993157185e-10
time O 0 6.096420035461847e-10
related O 0 1.1420719925325784e-09
to O 0 1.7899749737981807e-10
initial O 0 1.665414250950903e-09
CTG O 0 5.013655481889145e-07
repeat O 0 4.330504843608196e-09
size O 0 9.497428399285468e-10
and O 0 2.031734086527237e-10
the O 0 6.598204205232605e-10
time O 0 1.903516011481088e-09
interval O 0 4.083969162849144e-09
and O 0 6.128162560736783e-11
always O 0 6.233565746915914e-11
biased O 0 9.916755611127925e-11
towards O 0 6.313797401569232e-11
further O 0 3.301069140260182e-11
expansion O 0 7.668375268110594e-09
. O 0 3.317529362334426e-08

Attempts O 0 1.336389800599136e-06
to O 0 9.450396909471692e-09
mathematically O 0 2.395843807789788e-07
model O 0 1.3509546370471526e-08
the O 0 1.0852865273136558e-08
dynamics O 0 3.699111402966082e-05
have O 0 5.335875297163284e-09
proved O 0 2.841750585957925e-07
only O 0 1.326869308870826e-10
partially O 0 7.669589408010324e-09
successful O 0 3.89388965515991e-09
suggesting O 0 1.2151288864004073e-09
that O 0 4.746289299084605e-12
individual O 0 1.8144472469644457e-12
specific O 0 3.1397173055891514e-11
genetic O 0 6.607385749646255e-10
and O 0 2.616552252643345e-10
/ O 0 5.822264892429985e-09
or O 0 2.0914796283744153e-10
environmental O 0 2.219001427050671e-09
factors O 0 5.94614224525003e-09
also O 0 5.075662112830059e-10
play O 0 8.968112474860845e-09
a O 0 8.620893998667611e-10
role O 0 6.18113471517745e-09
in O 0 6.9293326632191565e-09
somatic O 0 5.460424290504307e-07
mosaicism O 0 1.607402191439178e-05
. O 0 2.2244648789637722e-08
. O 0 1.2329500975738483e-07

Aspartylglucosaminuria B-Disease 1 0.9999772310256958
among O 0 1.767760160475973e-08
Palestinian O 0 1.3947352783816314e-07
Arabs O 0 2.311604987426108e-07
. O 0 1.7939899521479674e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9977044463157654
AGU B-Disease 1 1.0
) O 0 4.2251429022144293e-08
is O 0 2.687154054825669e-09
a O 0 2.918836949916681e-09
rare O 0 3.6636359368458216e-07
disorder B-Disease 1 0.9999936819076538
of I-Disease 1 0.9677919745445251
glycoprotein I-Disease 1 0.9749667644500732
metabolism I-Disease 1 0.9999191761016846
caused O 0 2.4143304244717e-07
by O 0 1.7110547700927015e-10
the O 0 3.2756333201433563e-09
deficiency B-Disease 0 0.0007046389509923756
of I-Disease 0 4.921795948575891e-07
the I-Disease 0 5.8608407016436104e-08
lysosomal I-Disease 0 2.1035490135545842e-05
enzyme I-Disease 0 1.5182152424131345e-08
aspartylglucosaminidase I-Disease 0 6.377834438353602e-07
( O 0 1.309769182000764e-09
AGA O 0 6.10782592502801e-07
) O 0 9.854768556749605e-09
. O 0 1.4135466130937857e-07

AGU B-Disease 1 1.0
is O 0 1.0890116755035706e-06
inherited O 0 0.0001726870978018269
as O 0 8.803447748562121e-09
an O 0 6.743004821174736e-09
autosomal O 1 0.9974144697189331
recessive O 0 0.07977177202701569
trait O 0 7.28699433238944e-07
and O 0 2.6204540759522388e-09
occurs O 0 9.843529324982114e-10
with O 0 2.8022651907266827e-11
a O 0 3.3840491520109595e-10
high O 0 2.779166674571343e-09
frequency O 0 8.914527782621917e-09
in O 0 3.206551413281744e-10
Finland O 0 7.0851249311942865e-09
because O 0 1.7877470337435142e-10
of O 0 1.2762702894519862e-08
a O 0 7.847201999311437e-09
founder O 0 1.1736383953575569e-07
effect O 0 2.2046090464300505e-07
. O 0 1.0638836300813637e-07

While O 0 6.336734941214672e-07
very O 0 2.484852146267258e-08
few O 0 1.9185626420892277e-09
patients O 0 2.338066851237386e-09
with O 0 7.099003607180521e-09
AGU B-Disease 1 1.0
have O 0 1.5042893597438933e-09
been O 0 1.6395529378598894e-10
reported O 0 5.274821551770614e-11
from O 0 4.0293549746772683e-11
non O 0 2.588305125783563e-09
- O 0 3.392508773902847e-10
Finnish O 0 3.0038631848583464e-07
origin O 0 1.1207879069274895e-09
, O 0 4.414572873923106e-11
we O 0 6.910386152192416e-11
diagnosed O 0 5.8695301952127465e-09
the O 0 5.511008871472711e-10
disorder O 0 5.6016769889311036e-08
in O 0 2.1424748086751322e-10
8 O 0 1.5762471328173433e-09
patients O 0 5.775153966158797e-11
originating O 0 2.455390057942708e-10
from O 0 2.1531589011747343e-10
3 O 0 3.9274397067856626e-09
unrelated O 0 2.97284863393088e-09
families O 0 6.928688092017188e-12
, O 0 2.751797487793306e-12
all O 0 2.0800520594138616e-12
Palestinian O 0 3.8301492533143744e-10
Arabs O 0 3.69865305049899e-10
from O 0 8.460743911031798e-11
the O 0 8.93443513616532e-11
region O 0 2.6130561603388003e-10
of O 0 8.13113021358447e-10
Jerusalem O 0 9.24155898474055e-08
. O 0 1.0307384457064472e-07

The O 0 3.365887266681966e-07
clinical O 0 3.133621794404462e-05
diagnosis O 1 0.9908159971237183
of O 1 0.9845817685127258
AGU B-Disease 1 1.0
is O 0 3.2962111617962364e-07
often O 0 1.9847041787812714e-09
difficult O 0 3.5829934574849176e-09
, O 0 2.1803425384603337e-11
in O 0 9.019544659760736e-12
particular O 0 6.209002756385473e-11
early O 0 5.543796532947454e-10
in O 0 5.915311296345038e-11
the O 0 5.72528746634049e-10
course O 0 6.758907211690257e-09
of O 0 1.282912998057384e-09
the O 0 6.461703394577967e-10
disease O 0 9.159690783633323e-09
, O 0 1.6376955347396915e-11
and O 0 9.712505105730074e-12
most O 0 2.942484103596321e-11
of O 0 1.8202249707499618e-09
the O 0 1.2272736160667819e-09
patients O 0 1.0329791466645588e-09
are O 0 1.8614347910284046e-11
diagnosed O 0 9.598353223339018e-10
after O 0 1.0568887987005837e-09
the O 0 5.778418854518463e-10
age O 0 3.782591129208868e-09
of O 0 4.737830572310031e-09
5 O 0 1.3071668192310426e-08
years O 0 1.3156637557187878e-08
. O 0 3.0777144388594024e-08

However O 0 1.1328481264172297e-07
, O 0 1.6966006377572285e-09
since O 0 8.657738970185846e-10
these O 0 3.0461785871516156e-11
patients O 0 5.593885424315381e-11
excrete O 0 1.2943863758607677e-09
early O 0 8.666660722411734e-10
large O 0 5.893283777647085e-11
amounts O 0 1.6432502580876474e-10
of O 0 1.73846159690072e-09
aspartylglucosamine O 0 3.620725053110618e-08
in O 0 1.7164841770167527e-10
urine O 0 2.1895955881756635e-10
, O 0 1.322979486378939e-11
biochemical O 0 1.3957206224102237e-10
screening O 0 4.002746190057138e-10
is O 0 5.600215777223916e-11
easy O 0 1.513275893483268e-10
by O 0 2.780351643361101e-11
urine O 0 9.608959183893262e-10
chromatography O 0 1.451017368481189e-07
. O 0 1.3033179868671141e-08
. O 0 7.697364168279819e-08

Detection O 0 1.4102278100835974e-06
of O 0 8.536569851003151e-08
heterozygous O 0 2.9003568435825855e-09
carriers O 0 1.1704786029298475e-09
of O 0 8.556665598291602e-09
the O 0 9.309651431976818e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 8.709835128684063e-07
ATM O 0 5.94771518080961e-06
) O 0 2.950438227067309e-10
gene O 0 2.143096117235288e-10
by O 0 1.0115066423344032e-10
G2 O 0 1.0198336894973181e-06
phase O 0 4.367779638414504e-06
chromosomal O 0 2.988011692650616e-05
radiosensitivity O 0 2.09157110475644e-06
of O 0 1.565907439271541e-07
peripheral O 0 3.190318966517225e-05
blood O 0 1.8160822889967676e-07
lymphocytes O 0 1.0994191512736506e-07
. O 0 2.021300531396264e-07

In O 0 0.00023035291815176606
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999784231185913
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6073427033802545e-08
patients O 0 4.088606342378398e-09
, O 0 2.987391237163628e-11
mutations O 0 7.88552903530082e-11
in O 0 1.1763351404070477e-10
a O 0 2.858653591619742e-10
single O 0 1.1305865965649531e-10
gene O 0 7.190287809599738e-10
, O 0 2.7602792274095123e-10
ATM O 0 2.9770719223165543e-08
, O 0 2.545371899365101e-11
result O 0 7.047863681552968e-11
in O 0 5.405011507808588e-11
an O 0 3.0244901694231885e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.5521071361490613e-07
embraces O 0 1.770395563482907e-08
a O 0 1.6704239380604946e-10
variety O 0 1.447869185655648e-10
of O 0 3.5597902403594617e-10
clinical O 0 3.313196161869314e-09
features O 0 5.446346151849468e-10
and O 0 2.0988286109080434e-10
manifests O 0 1.4039241769125965e-08
extreme O 0 1.3669814791228418e-07
radiosensitivity O 0 6.127125402599631e-07
and O 0 1.8656949318796023e-09
a O 0 1.7208316993588824e-09
strong O 0 2.2448500835992036e-09
pre O 0 2.570502374510397e-06
- O 0 3.11797577978723e-07
disposition O 0 3.2777652450022288e-06
to O 0 1.0765409896862366e-08
malignancy B-Disease 0 1.9643886844278313e-05
. O 0 1.5185432289399614e-07

Heterozygotes O 0 4.184907538729021e-06
for O 0 2.0472455730669026e-08
the O 0 4.0244223953322944e-08
ATM O 0 1.1518751534822513e-06
gene O 0 2.885524930107408e-09
have O 0 5.5532443227201966e-11
no O 0 2.513707644813401e-11
clinical O 0 5.552950321785488e-10
expression O 0 4.856903768057919e-10
of O 0 3.232746337289427e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 2.0087208341124096e-08
may O 0 2.9265132539535443e-09
be O 0 2.974134549749152e-10
cancer B-Disease 0 4.265798825286993e-09
prone O 0 1.6832435445479632e-09
with O 0 3.910945872709348e-11
a O 0 8.156744724097109e-10
moderate O 0 8.918881633235287e-09
increase O 0 3.928501968175624e-10
in O 0 1.498921986531343e-09
in O 0 4.810697173951439e-09
vitro O 0 1.1340090821931881e-07
radiosensitivity O 0 1.3197097814554581e-06
. O 0 6.973779420604842e-08

We O 0 8.769681869580381e-08
performed O 0 1.374453546532095e-07
a O 0 1.506167812692638e-08
blind O 0 2.169769572901714e-07
chromosomal O 0 1.536479885544395e-06
analysis O 0 4.5336083331903865e-08
on O 0 2.795117097775801e-07
G2 O 0 1.202494559038314e-06
- O 0 2.632682738479275e-09
phase O 0 1.7035342025906175e-08
lymphocytes O 0 5.895400279065655e-10
from O 0 1.2810962290998873e-09
7 O 0 4.311345236374109e-08
unrelated O 0 1.8573184661363484e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 1.290289617372764e-07
, O 0 2.964416212503096e-10
13 O 0 3.1024902646947794e-09
obligate O 0 3.516107227596876e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999438524246216
T I-Disease 1 0.9999998807907104
heterozygotes O 0 6.311133233793953e-07
( O 0 1.1881531869484263e-10
parents O 0 1.6993224535855056e-11
of O 0 7.149326963773461e-11
the O 0 1.2676347471707317e-10
patients O 0 2.944702121032705e-11
) O 0 2.4521955646616966e-12
, O 0 6.1138225558587944e-12
and O 0 2.8498602783200155e-11
14 O 0 1.0643657066822243e-09
normal O 0 1.111655034691239e-08
controls O 0 1.1536277710888498e-08
following O 0 6.333218949272634e-10
X O 0 1.5080887294516288e-07
- O 0 4.5210679644469565e-09
irradiation O 0 2.8681854669088125e-09
with O 0 5.0985004412806845e-11
1 O 0 1.2059492959792806e-08
Gy O 0 1.5933627750541746e-08
in O 0 7.388140793596065e-11
order O 0 1.5476943338033067e-10
to O 0 5.900661903535109e-11
evaluate O 0 2.013541555712095e-09
this O 0 1.572921792813986e-10
cytogenetic O 0 1.6561943994020112e-07
method O 0 2.801563958598763e-08
as O 0 8.399823614446689e-10
a O 0 6.070556279880179e-10
tool O 0 1.618522560420388e-08
for O 0 9.714157950257984e-11
detection O 0 1.717894271280329e-08
of O 0 1.8529465961591995e-08
ATM O 0 4.362783784017665e-06
carriers O 0 3.5328199032846896e-07
. O 0 1.6556384707655525e-07

Both O 0 4.081630777363898e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999938011169434
T I-Disease 1 1.0
homozygotes O 0 3.5064781513938215e-06
and O 0 3.8698910742596127e-10
heterozygotes O 0 1.306605934559002e-08
showed O 0 6.129404206411948e-10
significantly O 0 1.0617495077580585e-10
increased O 0 3.635805545521009e-11
levels O 0 2.7078408959546607e-10
of O 0 1.9097955161750946e-10
radiation O 0 2.2637584606854944e-06
- O 0 1.9795709960135355e-08
induced O 0 8.433318754441643e-08
chromatid O 0 3.986198407801567e-06
damage O 0 8.003058837857679e-07
relative O 0 5.0088758030142344e-08
to O 0 1.5120783791733317e-10
that O 0 1.6153557658160622e-11
of O 0 7.415278946432124e-10
normal O 0 5.6469040998763376e-08
controls O 0 2.3377987190542626e-07
. O 0 3.23625002351946e-08

These O 0 2.1946108930137598e-08
results O 0 1.019450657224752e-08
show O 0 8.472315293772681e-09
that O 0 6.92710541705388e-11
the O 0 9.199501160850332e-10
G2 O 0 8.754471423344512e-07
- O 0 3.2530461879787254e-08
phase O 0 2.9424757030938054e-07
chromosomal O 0 5.444346697913716e-07
radiosensitivity O 0 2.841940158759826e-07
assay O 0 2.8428774001554302e-08
can O 0 1.3991109659716727e-10
be O 0 3.1687270862779116e-11
used O 0 1.66411381202769e-11
for O 0 5.8182928960870406e-12
the O 0 1.709471800226403e-11
detection O 0 3.0449267551801995e-09
of O 0 9.779644649654529e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
heterozygotes O 0 5.955617598374374e-05
. O 0 5.750019340666768e-07

In O 0 2.0222337582254113e-07
combination O 0 3.882889529904787e-07
with O 0 3.382979452126733e-09
molecular O 0 4.032470314996317e-06
genetic O 0 7.210717001271405e-08
analyses O 0 2.692920997304782e-09
, O 0 6.693522819345432e-11
this O 0 1.199391454209664e-11
test O 0 1.0377339265676966e-10
may O 0 4.4812535626714833e-11
be O 0 5.545271707096955e-12
of O 0 4.5124567277232686e-11
value O 0 4.2125032628792525e-11
in O 0 7.353875321192138e-12
studies O 0 2.7413321612712593e-11
of O 0 1.098870439086852e-10
familial B-Disease 0 1.210710820487293e-08
and I-Disease 0 1.8013054381427196e-09
sporadic I-Disease 0 9.55230689214659e-07
cancers I-Disease 0 1.0238740060231066e-06
aimed O 0 6.335725544204251e-08
at O 0 2.265368159726222e-08
determination O 0 6.5222822698274285e-09
of O 0 1.9023183028821222e-09
the O 0 6.233649013642761e-11
potential O 0 9.394118122285633e-11
involvement O 0 1.397079674170243e-09
of O 0 2.856742176149396e-09
ATM O 0 2.0288373434595997e-06
mutations O 0 7.650872824171984e-09
in O 0 1.892618950449787e-09
tumor B-Disease 0 3.446495782100101e-07
risk O 0 2.6011939269210416e-08
or O 0 2.8635432913759473e-10
development O 0 1.3799948961334962e-09
. O 0 9.890730456874053e-10
. O 0 1.863021559245226e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 3.621380884055725e-08
identification O 0 7.3717916215798596e-09
and O 0 1.0003974731942478e-10
detection O 0 6.923469442199348e-08
of O 0 2.0895006969112728e-07
founder O 0 1.015258294501109e-05
- O 0 1.6004862857244007e-07
effect O 0 4.3591903704509605e-06
mutations O 0 1.2380610314721707e-08
in O 0 1.1753802375835676e-09
the O 0 2.9717317495681073e-09
ATM O 0 7.275870217426927e-08
gene O 0 1.2616605538084968e-09
in O 0 3.665162340293904e-10
ethnic O 0 4.128137554015865e-10
populations O 0 1.8360439557607577e-10
. O 0 6.956533127322473e-09

To O 0 1.9111457305598378e-08
facilitate O 0 2.996212344896776e-08
the O 0 2.1199966226959077e-09
evaluation O 0 1.0722764898218884e-08
of O 0 6.57905596668229e-09
ATM O 0 2.969150898479711e-07
heterozygotes O 0 6.134790453415917e-08
for O 0 9.75486247334345e-10
susceptibility O 0 2.9781849875121225e-08
to O 0 3.035253437477792e-10
other O 0 1.4248737745248263e-09
diseases O 0 5.1614002586575225e-05
, O 0 8.929528644285867e-11
such O 0 4.990485247269305e-10
as O 0 3.622085387178231e-08
breast B-Disease 0 4.045379318995401e-05
cancer I-Disease 0 4.7545247070956975e-05
, O 0 3.3776618835190675e-08
we O 0 1.8602058560190926e-08
have O 0 2.4411517252076465e-10
attempted O 0 7.2336221457192096e-09
to O 0 9.41503403018018e-11
define O 0 1.00868700059209e-08
the O 0 7.108714727976917e-10
most O 0 2.0179184712088016e-11
common O 0 8.003854523597198e-12
mutations O 0 2.89994308948216e-12
and O 0 1.2532450121074956e-12
their O 0 9.349279163350932e-13
frequencies O 0 1.1938396937694051e-09
in O 0 1.4214759147535005e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999953508377075
telangiectasia I-Disease 1 1.0
( O 0 0.00013025494990870357
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 1.6665898661116785e-09
homozygotes O 0 4.9719062644726364e-08
from O 0 5.918225354228923e-10
10 O 0 4.798716979337314e-10
ethnic O 0 1.1011447309527966e-10
populations O 0 9.344616747064549e-11
. O 0 6.43256337085063e-09

Both O 0 6.101544158809702e-08
genomic O 0 2.2437389191054535e-07
mutations O 0 7.106956356750516e-09
and O 0 2.638618490369282e-10
their O 0 6.017684961445724e-11
effects O 0 2.860669390258863e-08
on O 0 1.144552008724986e-08
cDNA O 0 1.2502536783642881e-08
were O 0 1.474363964248937e-09
characterized O 0 7.781665978257024e-09
. O 0 2.0959824098554236e-08

Protein O 0 9.839180847848183e-07
- O 0 2.4906649187528274e-08
truncation O 0 8.546116703200823e-08
testing O 0 3.6044340845364786e-09
of O 0 2.518706132548232e-09
the O 0 4.4508288721267775e-10
entire O 0 3.586972940894384e-09
ATM O 0 3.3111067665458904e-08
cDNA O 0 6.6031433654245575e-09
detected O 0 6.827240106588306e-09
92 O 0 9.01166519184926e-09
( O 0 8.816545410406107e-11
66 O 0 3.3108336072729116e-09
% O 0 7.35209740310161e-11
) O 0 1.6382797896064005e-11
truncating O 0 1.852405873137286e-08
mutations O 0 6.248556116972281e-10
in O 0 2.3025065187809446e-10
140 O 0 5.951937831483178e-10
mutant O 0 1.4652780100377072e-09
alleles O 0 1.626040746494084e-09
screened O 0 8.310541232958712e-08
. O 0 6.154456144713549e-08

The O 0 2.2509787811486603e-07
haplotyping O 0 1.788988447515294e-05
of O 0 2.7582356665334373e-07
patients O 0 4.628820438057346e-09
with O 0 1.4306245077477797e-10
identical O 0 4.7707501948934805e-08
mutations O 0 2.997405434967959e-09
indicates O 0 9.679134160833769e-10
that O 0 9.29881657785181e-11
almost O 0 2.1295029628554119e-10
all O 0 6.109372729934393e-11
of O 0 1.2895016998637487e-10
these O 0 2.459826396392084e-12
represent O 0 5.8111948413042125e-12
common O 0 1.5245214812775743e-11
ancestry O 0 6.127597994981526e-12
and O 0 8.38451270218643e-12
that O 0 3.792663232082827e-12
very O 0 7.617752956212698e-11
few O 0 8.058667622101723e-11
spontaneously O 0 9.966061309540919e-10
recurring O 0 2.8393062123655e-08
ATM O 0 9.733179240356549e-07
mutations O 0 2.060006920601154e-08
exist O 0 6.741566949131084e-08
. O 0 1.2272066385321523e-07

Assays O 0 7.964175097185944e-07
requiring O 0 2.9192394279675682e-08
minimal O 0 9.537701117778852e-08
amounts O 0 6.658487095023702e-09
of O 0 1.5136231157342195e-09
genomic O 0 9.368321673974833e-10
DNA O 0 5.228577015792268e-10
were O 0 5.713469974910623e-11
designed O 0 1.3333410764371223e-10
to O 0 5.03034029361582e-12
allow O 0 2.915784974577562e-11
rapid O 0 3.576409723926588e-10
screening O 0 1.5722888269120716e-10
for O 0 2.1619312243204014e-11
common O 0 3.10128200897708e-10
ethnic O 0 8.110684346362973e-10
mutations O 0 7.864868756257692e-09
. O 0 1.814630934404704e-08

These O 0 3.2445304221084825e-09
rapid O 0 1.2058250398183645e-08
assays O 0 5.372978062467837e-09
detected O 0 1.736804589036467e-09
mutations O 0 2.071106133816336e-11
in O 0 1.1220322587712772e-10
76 O 0 6.8258079188865395e-09
% O 0 3.158085182253245e-10
of O 0 1.2078622546596307e-08
Costa O 0 9.547608215143555e-07
Rican O 0 1.4372907344295527e-06
patients O 0 3.1317672011255127e-08
( O 0 6.217665965424501e-11
3 O 0 3.4358849099191957e-10
) O 0 1.3746835701017313e-12
, O 0 3.098109876281674e-12
50 O 0 2.0892978319642097e-11
% O 0 6.775728415842064e-12
of O 0 6.956953901848806e-10
Norwegian O 0 1.2846420531786862e-06
patients O 0 5.0342259250157895e-09
( O 0 5.772863437281117e-11
1 O 0 1.7389888418151145e-09
) O 0 3.4138542687189855e-12
, O 0 4.9556027684194426e-12
25 O 0 6.574006616855144e-11
% O 0 1.7682364253368554e-11
of O 0 9.980289927824515e-10
Polish O 0 3.353391662130889e-07
patients O 0 1.0586748366847587e-08
( O 0 8.615563124036996e-11
4 O 0 8.730037248660949e-10
) O 0 5.6364010680987064e-12
, O 0 3.704792115449829e-12
and O 0 4.896635180662301e-12
14 O 0 4.762762961796341e-10
% O 0 1.281139500042272e-10
of O 0 1.2202786336956706e-08
Italian O 0 0.00014158837439026684
patients O 0 1.2130180948588531e-07
( O 0 3.1850955206635945e-10
1 O 0 1.693817530679098e-08
) O 0 2.2929907972368824e-11
, O 0 2.211271790675262e-11
as O 0 3.383505281506771e-11
well O 0 1.576750882636979e-11
as O 0 1.9634587358763333e-11
in O 0 1.847917999175941e-11
patients O 0 3.234122691875285e-11
of O 0 1.9702883768957236e-09
Amish O 0 7.4074373301868945e-09
/ O 0 3.5620064675612184e-09
Mennonite O 0 7.957804193381435e-09
and O 0 8.526192252222842e-11
Irish O 0 4.445731338620362e-09
English O 0 1.286974704584054e-08
backgrounds O 0 5.929451774022709e-08
. O 0 3.919606683666643e-08

Additional O 0 5.036850581063845e-08
mutations O 0 1.3415054844756469e-08
were O 0 1.6175989436817417e-09
observed O 0 4.679312048949669e-09
in O 0 4.5741838095025855e-10
Japanese O 0 1.9443694654341925e-08
, O 0 1.7719138656335787e-10
Utah O 0 1.2526978565574609e-08
Mormon O 0 7.06855907139925e-10
, O 0 1.5899904656779817e-11
and O 0 3.067822385016683e-11
African O 0 1.873011301611882e-09
American O 0 2.724466874326481e-09
patients O 0 8.54272297345915e-09
. O 0 2.009134547620306e-08

These O 0 1.6407579739308176e-09
assays O 0 2.23273155519621e-09
should O 0 2.7708382463464964e-11
facilitate O 0 6.116368522768312e-11
screening O 0 3.9934733297997127e-10
for O 0 1.08002440324384e-09
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9994651675224304
T I-Disease 1 0.9999996423721313
heterozygotes O 0 1.7384533634867694e-07
in O 0 2.2491176976391358e-10
the O 0 1.0058963384462771e-10
populations O 0 4.0445984235415455e-12
studied O 0 2.6818085530067037e-09
. O 0 1.6463622132256717e-10
. O 0 4.465422254185114e-09

The O 0 5.086821147415321e-06
von B-Disease 1 0.9999555349349976
Hippel I-Disease 1 0.99993896484375
- I-Disease 1 0.999879002571106
Lindau I-Disease 1 0.9969431757926941
tumor I-Disease 0 1.9861075998051092e-05
suppressor O 0 2.127977950294735e-06
gene O 0 1.3967340173337561e-08
is O 0 2.3139400118221687e-10
required O 0 2.3121621284261096e-10
for O 0 3.8373884625464427e-10
cell O 0 1.9841145615373534e-08
cycle O 0 1.956858008966833e-09
exit O 0 2.7595068452512805e-09
upon O 0 2.2951458511499823e-09
serum O 0 1.740416699647085e-08
withdrawal O 0 3.53803848440748e-08
. O 0 1.2369969226710964e-07

The O 0 5.907574518460024e-08
inactivation O 0 6.4279201978934e-06
of O 0 4.0059740058495663e-07
the O 0 1.7728663692651025e-07
von B-Disease 1 0.9998968839645386
Hippel I-Disease 1 0.9998787641525269
- I-Disease 1 0.9999966621398926
Lindau I-Disease 1 0.9999884366989136
( I-Disease 0 6.944921437934681e-07
VHL I-Disease 0 0.0001983414840651676
) I-Disease 0 5.396613644848003e-08
tumor I-Disease 0 5.809937192680081e-06
suppressor O 0 8.41664950712584e-05
gene O 0 3.7919946862530196e-06
predisposes O 0 4.5314227463677526e-06
affected O 0 2.8939096452518243e-08
individuals O 0 1.212560607477542e-10
to O 0 1.816093664341878e-10
the O 0 7.631605569713429e-09
human O 0 0.0009982555638998747
VHL B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9959076642990112
and O 0 3.768179934748872e-10
is O 0 1.0618320459010455e-11
associated O 0 3.564178951975805e-10
with O 0 2.478743321709942e-10
sporadic B-Disease 1 0.9998384714126587
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.0001570188906043768
RCC B-Disease 1 0.9993515610694885
) O 0 5.1997417926941125e-08
and O 0 1.0374504455512579e-07
brain B-Disease 1 0.9974499344825745
hemangioblastomas I-Disease 0 0.011929580941796303
. O 0 6.116954978097056e-07

VHL O 0 0.0017171873478218913
- O 0 1.586698454048019e-05
negative O 0 3.5051533586738515e-07
786 O 0 2.916198172897566e-05
- O 0 2.035663965216372e-05
0 O 0 3.2091773505271703e-07
RCC B-Disease 0 3.5953153201262467e-06
cells O 0 2.2177109038068465e-09
are O 0 5.538279834738091e-10
tumorigenic O 0 6.623769195357454e-07
in O 0 2.6466556946047604e-08
nude O 0 2.4293403839692473e-05
mice O 0 1.71805552895421e-07
which O 0 2.04802452774544e-10
is O 0 1.4359875268044053e-11
suppressed O 0 5.413079012805966e-11
by O 0 3.1412730489704943e-12
the O 0 1.1947708100645826e-10
reintroduction O 0 4.2515591047731505e-09
of O 0 2.4841164680822203e-09
VHL B-Disease 0 4.2617530198185705e-06
. O 0 2.7168383098796767e-07

Remarkably O 0 6.349402974592522e-05
, O 0 4.014423460318994e-09
this O 0 1.2544802696634605e-10
occurs O 0 1.466666926797089e-10
without O 0 8.652716043666686e-11
affecting O 0 1.0025119623335854e-10
the O 0 7.748111874317232e-11
growth O 0 7.375300370426885e-11
rate O 0 5.025416194293086e-10
and O 0 6.724977519301234e-11
cell O 0 2.3291202300157465e-09
cycle O 0 8.404839602071945e-10
profile O 0 1.5597527436295167e-10
of O 0 5.57643875520597e-10
these O 0 2.2434267984983158e-11
cells O 0 1.9442218668341837e-11
in O 0 1.7230215865193799e-10
culture O 0 1.072114930167345e-08
. O 0 1.2202483468115588e-08

The O 0 8.314471529047296e-07
786 O 0 1.170012001239229e-05
- O 0 2.9974980861879885e-06
0 O 0 6.526004625584392e-08
cell O 0 2.9324095152105656e-08
line O 0 3.912629864544215e-08
, O 0 1.8530436907138181e-10
like O 0 5.229634503223224e-10
many O 0 1.0145711354381248e-10
cancer B-Disease 0 3.192329955936657e-08
cells O 0 1.0254957993893754e-09
, O 0 1.0339923361968317e-09
fails O 0 9.725217076095305e-09
to O 0 7.519879163808696e-10
exit O 0 5.8160193106004954e-08
the O 0 8.818386909581477e-09
cell O 0 2.948556598880714e-08
cycle O 0 2.5052095953270737e-09
upon O 0 1.4217789168213812e-09
serum O 0 8.427638142904925e-09
withdrawal O 0 1.0506727043946285e-08
. O 0 9.451139248994878e-08

Here O 0 7.827225090295542e-06
, O 0 8.490870229138636e-09
it O 0 8.785960153856465e-11
is O 0 8.936918045876485e-12
shown O 0 1.4625625363584582e-11
that O 0 1.0975537969790117e-12
reintroduction O 0 1.1383807091425169e-10
of O 0 1.4673104398177372e-10
the O 0 3.504740941906448e-10
wild O 0 4.195066238832368e-10
- O 0 4.930550190351823e-09
type O 0 2.4070466508874233e-08
VHL B-Disease 0 1.2536871736301691e-06
gene O 0 2.1909595915303726e-08
restores O 0 1.2057127207754093e-07
the O 0 4.05750055776366e-09
ability O 0 3.424901029447369e-09
of O 0 1.5461829150353879e-07
VHL O 0 0.00029976118821650743
- O 0 2.214774940512143e-05
negative O 0 1.632932651318697e-07
RCC B-Disease 0 0.053096551448106766
cancer I-Disease 0 4.948981882080261e-07
cells O 0 2.4504256956880965e-10
to O 0 6.229016746850391e-10
exit O 0 2.0739076234121967e-08
the O 0 4.591291791200547e-09
cell O 0 3.0700103792469235e-08
cycle O 0 3.8116767520079975e-09
and O 0 8.929256639644834e-11
enter O 0 5.434447114538443e-09
G0 O 0 1.560771238473535e-06
/ O 0 1.5458525126632594e-07
quiescence O 0 9.557455769027001e-07
in O 0 1.060611154457547e-08
low O 0 2.3402635918046144e-07
serum O 0 1.8601319595745736e-07
. O 0 8.265787698746863e-08

Both O 0 2.6912080102192704e-06
VHL O 0 0.0004698051488958299
- O 0 1.3699326473215478e-06
positive O 0 9.121544408685622e-09
and O 0 6.097516269676362e-09
VHL O 0 5.4873311455594376e-05
- O 0 4.5390333980321884e-07
negative O 0 1.2716704134163592e-08
RCC B-Disease 0 2.741704520303756e-05
cells O 0 7.897654086264083e-09
exit O 0 4.9325844742043046e-08
the O 0 2.577014601712335e-09
cell O 0 1.1217808015828723e-08
cycle O 0 4.0736591877532646e-10
by O 0 2.0163063926825764e-11
contact O 0 6.172817368366168e-09
inhibition O 0 8.421745434361583e-08
. O 0 1.0676809125698128e-07

The O 0 1.1592013606787077e-06
cyclin O 0 2.1441164790303446e-05
- O 0 5.238574658505968e-07
dependent O 0 1.3414471311534726e-07
kinase O 0 4.415148282532755e-07
inhibitor O 0 2.2320688231047825e-07
, O 0 1.4173276996487516e-09
p27 O 0 2.6577043854558724e-07
, O 0 7.749889618935413e-10
accumulates O 0 8.978260801484339e-09
upon O 0 1.0938772110336004e-09
serum O 0 2.7002553526500606e-09
withdrawal O 0 1.2753400557841132e-09
, O 0 9.951828250365224e-11
only O 0 1.0540391476299149e-11
in O 0 1.4914600804383227e-11
the O 0 8.99970098444669e-11
presence O 0 8.966910547414386e-10
of O 0 9.518037558109427e-08
VHL B-Disease 0 3.5004941310035065e-06
, O 0 1.9123589378722272e-09
as O 0 6.498585558567527e-10
a O 0 3.325895669981094e-10
result O 0 4.3372311298028876e-10
of O 0 2.8690554376709088e-09
the O 0 1.0695000440819058e-09
stabilization O 0 1.7208596148066135e-07
of O 0 2.3385272385212375e-08
the O 0 1.2611751643021307e-08
protein O 0 6.148847830900195e-08
. O 0 5.539732583770274e-08

We O 0 3.453227463978692e-07
propose O 0 6.603057300935689e-08
that O 0 1.5403377184863842e-10
the O 0 9.188138028193293e-10
loss O 0 3.5359180028393666e-09
of O 0 4.332217073965694e-08
wild O 0 9.046210891483497e-09
- O 0 2.8074856217585875e-08
type O 0 6.994653745096002e-08
VHL B-Disease 0 4.719011030829279e-07
gene O 0 1.6027071891855371e-09
results O 0 1.034738184024775e-09
in O 0 2.750608907309271e-10
a O 0 1.9080988178377112e-10
specific O 0 4.3805381544359534e-10
cellular O 0 6.527860136884556e-07
defect O 0 5.27918302850594e-07
in O 0 5.268321778828522e-09
serum O 0 6.116843564996088e-08
- O 0 1.3061425718774444e-08
dependent O 0 8.804421192110112e-09
growth O 0 1.7114049066790926e-09
control O 0 8.468600753985811e-07
, O 0 1.65378988281617e-10
which O 0 1.5085632396050208e-11
may O 0 2.2418110423583215e-10
initiate O 0 8.299572140657574e-10
tumor B-Disease 0 1.759303991377692e-08
formation O 0 4.2024458934974973e-07
. O 0 9.455066560803971e-07

This O 0 4.902598149669757e-08
is O 0 1.4630325839704028e-09
corrected O 0 6.2655538535238975e-09
by O 0 2.0495749195048596e-11
the O 0 1.1308690789357811e-10
reintroduction O 0 1.5461461000398913e-09
of O 0 2.8587043843231186e-09
wild O 0 3.5271212617260517e-09
- O 0 1.9458793687476827e-08
type O 0 1.6693336419848492e-06
VHL B-Disease 0 0.0017690733075141907
, O 0 3.1379863685288e-07
implicating O 0 0.00026345247169956565
VHL B-Disease 0 0.0007326520280912519
as O 0 1.1699996349534558e-07
the O 0 3.181006391628216e-08
first O 0 4.429886679702122e-09
tumor B-Disease 0 1.3085887040631405e-08
suppressor O 0 1.5450832790975255e-07
involved O 0 2.1104924030623806e-08
in O 0 1.5282816123729503e-09
the O 0 3.334459597326145e-09
regulation O 0 3.993607435859303e-07
of O 0 5.6571991535747657e-08
cell O 0 1.6584924367180065e-07
cycle O 0 8.01764876712241e-09
exit O 0 1.9198484579874275e-08
, O 0 3.338549714460015e-10
which O 0 3.4252111563715104e-11
is O 0 2.031159442028585e-11
consistent O 0 4.110506102161793e-10
with O 0 3.632256648233856e-11
its O 0 6.038058247836986e-11
gatekeeper O 0 2.723439429530572e-08
function O 0 7.677053659449484e-09
in O 0 1.974012509009526e-09
the O 0 6.293916943178601e-09
kidney O 0 3.663835059342091e-06
. O 0 1.092847679018405e-08
. O 0 1.0354715129778924e-07

Piebaldism B-Disease 1 1.0
with O 1 0.9673337340354919
deafness B-Disease 1 1.0
: O 0 1.9078592572441266e-07
molecular O 0 2.1812240902363556e-07
evidence O 0 4.8730517399064865e-09
for O 0 4.609802123356488e-11
an O 0 2.486507874599475e-11
expanded O 0 9.673181722291702e-08
syndrome O 1 0.7057650685310364
. O 0 5.264628271106631e-07

In O 0 1.249364913746831e-07
a O 0 2.403958809793494e-08
South O 0 1.2048088748883856e-08
African O 0 7.264094659120701e-09
girl O 0 6.977408872899105e-09
of O 0 8.134128037795563e-09
Xhosa O 0 6.989038752180932e-07
stock O 0 8.709613585899945e-10
with O 0 1.5403634964772372e-11
severe O 0 2.1556758156293654e-08
piebaldism B-Disease 0 5.910200115977204e-07
and O 0 1.0204350253673056e-08
profound O 1 0.7528294324874878
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 3.5239870612713275e-06
identified O 0 1.3205637472424314e-08
a O 0 2.658507025632417e-10
novel O 0 4.804401321223395e-11
missense O 0 1.735711685491026e-09
substitution O 0 1.9848895860263838e-09
at O 0 3.1602638728145394e-08
a O 0 8.062761569505028e-10
highly O 0 1.2826854023373357e-09
conserved O 0 4.268305708876596e-09
residue O 0 4.2654590970414574e-08
in O 0 4.919407103898266e-10
the O 0 6.630653248684837e-10
intracellular O 0 6.626699189382634e-09
kinase O 0 2.083701389210546e-08
domain O 0 3.385672897593395e-08
of O 0 4.030636802099252e-08
the O 0 2.755847461344274e-08
KIT O 0 9.693128959042951e-05
proto O 0 6.268879951676354e-05
- O 0 3.5824317023980257e-07
oncogene O 0 1.0550543265708257e-06
, O 0 8.451365829387214e-09
R796G O 0 4.5898585199211084e-07
. O 0 1.7445185562792176e-07

Though O 0 6.245600729926082e-07
auditory B-Disease 0 4.6622571971965954e-05
anomalies I-Disease 0 2.1302244931575842e-05
have O 0 6.504686789199354e-10
been O 0 3.4420571948245993e-10
observed O 0 8.029183429236753e-10
in O 0 2.1505729141946262e-10
mice O 0 1.0788075988088508e-09
with O 0 1.494621787445638e-10
dominant O 0 2.1593197743641213e-05
white O 0 9.116747889947874e-08
spotting O 0 0.00011814227036666125
( O 0 7.341091290413715e-09
W O 0 5.770984444097849e-06
) O 0 1.837294621997998e-10
due O 0 4.01434121499733e-08
to O 0 2.350080130497645e-09
KIT O 1 0.902337908744812
mutations O 0 1.3421241419564467e-05
, O 0 8.823520829537301e-07
deafness B-Disease 1 1.0
is O 0 1.0596546751173719e-08
not O 0 9.11682188076135e-11
typical O 0 2.193810466621926e-09
in O 0 1.566404089770046e-10
human O 0 1.2167499230386625e-09
piebaldism B-Disease 0 1.6462297480757115e-07
. O 0 1.4003725290478997e-08

Thus O 0 3.6999063013354316e-07
, O 0 8.217959646117379e-10
the O 0 1.3444036162102435e-10
occurrence O 0 1.0980649278735655e-08
of O 0 5.71606165067351e-07
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.770053353946423e-07
this O 0 2.445560698394189e-10
patient O 0 1.1029067659151792e-09
extends O 0 5.102313710425577e-11
considerably O 0 1.4252400648562258e-10
the O 0 3.5404700005070566e-11
phenotypic O 0 1.5484577176039238e-08
range O 0 8.350848901272911e-09
of O 0 3.7316834067269156e-09
piebaldism B-Disease 0 1.0143247664018418e-07
due O 0 2.3393525339088228e-08
to O 0 1.3279941590838007e-09
KIT O 0 1.7799609395297011e-06
gene O 0 6.9374657130083506e-09
mutation O 0 1.0881878731439087e-09
in O 0 3.5516317664630037e-10
humans O 0 8.722647049097532e-10
and O 0 5.2478774797970473e-11
tightens O 0 4.844044054763685e-10
the O 0 1.5345609505335034e-10
clinical O 0 3.91962728940598e-09
similarity O 0 3.0460247657515538e-09
between O 0 2.8621101932913007e-08
piebaldism B-Disease 0 2.4547702537347504e-07
and O 0 4.682012416656889e-11
the O 0 1.8684777683408704e-11
various O 0 5.552587556412192e-11
forms O 0 6.694573229104606e-10
of O 0 3.941272197494072e-08
Waardenburg B-Disease 1 0.9997813105583191
syndrome I-Disease 0 0.014622270129621029
. O 0 1.6153460791201724e-08
. O 0 1.511665459474898e-07

Cycloheximide O 0 8.15056682768045e-06
facilitates O 0 3.922456315308409e-08
the O 0 1.8920125466337367e-09
identification O 0 3.4531919546054723e-09
of O 0 2.1291963747671616e-08
aberrant O 0 2.96036777314157e-08
transcripts O 0 7.576307581302899e-08
resulting O 0 1.225519774550321e-08
from O 0 6.509071059923599e-09
a O 0 2.938836063393069e-09
novel O 0 8.164932063792207e-10
splice O 0 2.5513882562222534e-08
- O 0 1.8318367933645163e-09
site O 0 4.21827017760279e-10
mutation O 0 1.5687152965515594e-10
in O 0 4.3546222183721284e-10
COL17A1 O 0 5.6902977121353615e-06
in O 0 4.888934146407564e-09
a O 0 2.2710213709586924e-09
patient O 0 8.423797659418142e-09
with O 0 1.6258671076130327e-09
generalized O 1 0.7545537948608398
atrophic B-Disease 1 0.9999998807907104
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999992847442627
bullosa I-Disease 1 0.9996809959411621
. O 0 1.453538061468862e-05

Patients O 0 4.791277063986854e-08
with O 0 7.17497572466641e-09
generalized O 0 0.1913444697856903
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9998854398727417
often O 0 1.7057223189453907e-08
show O 0 2.0606425454872124e-09
decreased O 0 5.68677416268315e-09
expression O 0 1.1741725369773803e-09
of O 0 2.3077002531124435e-09
type O 0 1.7443456101773336e-07
XVII O 0 1.55549896589946e-05
collagen O 0 3.6569474559655646e-07
, O 0 3.899493616899008e-09
a O 0 6.863877466400936e-09
transmembrane O 0 2.2241552599666647e-08
hemidesmosomal O 0 2.8102078886149684e-07
protein O 0 2.875366389432088e-09
encoded O 0 2.058996306786298e-09
by O 0 3.0647140381034887e-09
COL17A1 O 0 4.3103686039103195e-05
. O 0 6.623251351811632e-07

This O 0 4.174843226678604e-08
report O 0 8.514645877255589e-09
documents O 0 9.902211495216307e-09
a O 0 2.8514397509837863e-09
novel O 0 2.4746016347165778e-09
splice O 0 1.6299827620969154e-07
- O 0 1.0861045396381996e-08
site O 0 3.4199856280281438e-09
mutation O 0 3.9997849476947067e-10
in O 0 3.5072889037479626e-10
COL17A1 O 0 7.559313417004887e-06
in O 0 5.878560305205838e-09
a O 0 1.7295253007532096e-09
patient O 0 3.335229203926815e-09
with O 0 1.1435629110323475e-09
generalized O 1 0.8101626634597778
atrophic B-Disease 1 0.9999997615814209
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999996423721313
bullosa I-Disease 1 0.9985253214836121
, O 0 4.086667360070351e-08
and O 0 3.2997504728626836e-09
applies O 0 2.9342615448513243e-08
a O 0 6.480291303567753e-10
new O 0 1.0930716748402958e-10
methodology O 0 1.1339951200284304e-09
to O 0 5.869502106570224e-11
define O 0 7.404653779019554e-09
and O 0 2.6318883183940045e-10
characterize O 0 1.6338509212232566e-08
the O 0 9.986744764489686e-10
resulting O 0 8.889428637637309e-10
mRNA O 0 2.520950781459419e-09
splice O 0 4.752295623688951e-08
variants O 0 6.781689165791249e-08
. O 0 1.2229936885432835e-07

Mutational O 0 1.1113561413367279e-05
analysis O 0 2.3507232072006445e-07
of O 0 1.7041166699982568e-07
COL17A1 O 0 3.5680739529198036e-05
identified O 0 2.2388782383586658e-07
a O 0 7.24230915238877e-08
maternally O 0 8.628763339402212e-07
inherited O 0 5.188829163671471e-05
G O 0 5.3892956202616915e-05
- O 0 7.305977192118007e-07
to O 0 5.1071019413484464e-08
- O 0 3.070677394134691e-06
T O 0 2.0713205231004395e-06
transversion O 0 1.3140809187461855e-06
at O 0 3.542874082995695e-07
the O 0 2.276490107533391e-09
- O 0 1.517736825107363e-09
1 O 0 3.9418641684108024e-09
position O 0 5.465642605173571e-09
of O 0 2.418261146885925e-08
exon O 0 4.0663820755071356e-07
32 O 0 3.065780163069576e-07
. O 0 1.6265074975763127e-07

This O 0 9.896943709009065e-09
acceptor O 0 1.4833712924655629e-08
splice O 0 1.0566151331659057e-06
- O 0 3.4706719276300646e-08
site O 0 1.0489846324901464e-08
mutation O 0 2.4714130741898543e-09
led O 0 3.2441840325247995e-09
to O 0 3.146445326507319e-10
the O 0 2.5961910399274757e-09
formation O 0 1.6210735509503138e-07
of O 0 1.50841799495538e-06
aberrant O 0 4.4143862965029257e-07
transcripts O 0 4.043550916321692e-07
present O 0 2.0724922222825626e-08
at O 0 4.5399943360280304e-07
extremely O 0 1.0871557520886199e-07
low O 0 1.1771649610636814e-07
levels O 0 8.774417636914222e-08
. O 0 6.300765420519383e-08

Based O 0 2.3817942462756037e-07
on O 0 1.5526475749538804e-07
our O 0 1.3832309742056736e-09
recent O 0 7.722292943990183e-11
finding O 0 1.8264978418613964e-10
that O 0 4.235737195018574e-12
cycloheximide O 0 5.485391696424813e-09
stabilized O 0 2.3326920484123548e-07
mutant O 0 4.605810488556017e-08
COL17A1 O 0 5.723524054701556e-07
transcripts O 0 2.9551099345326293e-08
in O 0 8.581127475260075e-10
keratinocytes O 0 8.557922370755477e-09
homozygous O 0 7.225156029022628e-09
for O 0 1.0524451310445215e-09
a O 0 5.81819037392961e-09
frameshift O 0 2.1412517980934354e-07
mutation O 0 1.802412108453666e-09
, O 0 2.0061149963446212e-10
the O 0 7.476745889078984e-10
effects O 0 7.823582564014941e-07
of O 0 3.379814472737053e-08
the O 0 7.5006596489402e-09
splice O 0 6.594284940319994e-08
- O 0 8.587268118809277e-10
site O 0 2.714511670998121e-10
mutation O 0 2.6908131972591676e-11
on O 0 1.227945523041285e-09
splicing O 0 1.4552908211840077e-08
of O 0 3.186100983043616e-08
COL17A1 O 0 2.0665947886300273e-06
transcripts O 0 1.2911993962916313e-07
were O 0 2.8306840205161166e-10
determined O 0 2.0647292209297063e-10
using O 0 1.3788654940061207e-10
reverse O 0 5.680833137233776e-09
transcriptase O 0 1.26633104002849e-08
polymerase O 0 2.187389469554546e-08
chain O 0 3.6260443536662024e-09
reaction O 0 1.8564788595298864e-10
of O 0 3.889985222826908e-09
total O 0 4.87377416202861e-10
RNA O 0 3.0252271798758557e-09
from O 0 1.0934997352052278e-09
keratinocytes O 0 1.7510418004462736e-08
incubated O 0 2.114703256950179e-08
for O 0 1.3629994910502319e-09
2 O 0 1.3900876183470245e-07
. O 0 5.713446071808903e-08

5 O 0 3.23474660035572e-06
h O 0 8.960461741480685e-07
in O 0 6.657827178457865e-09
the O 0 2.5445781037802817e-09
presence O 0 1.3533421050482275e-09
or O 0 6.528700913221996e-10
absence O 0 2.9166459469820438e-08
of O 0 2.3349883804257843e-08
10 O 0 2.0420118929109776e-08
microg O 0 1.2938495785874693e-07
cycloheximide O 0 3.4034854934361647e-07
per O 0 4.115633345236347e-08
ml O 0 6.526030347231426e-07
. O 0 7.361481380030455e-08

Using O 0 3.792012392977995e-08
this O 0 1.8505968979454224e-09
approach O 0 3.3335453508698265e-08
, O 0 5.201452046854627e-10
an O 0 2.531974907515888e-10
abnormally O 0 3.3989305592285746e-08
spliced O 0 5.631738275724274e-08
transcript O 0 2.1707403163873096e-07
was O 0 8.000176876521436e-08
identified O 0 4.4292336465190374e-10
that O 0 2.1056399679419968e-11
contains O 0 8.563101616676505e-12
an O 0 5.621348438816787e-12
extra O 0 1.0620681001327625e-09
264 O 0 1.3322486447364668e-09
bases O 0 5.68580571513877e-10
upstream O 0 6.703329002988312e-09
from O 0 4.0179624072322895e-09
exon O 0 8.779640836564795e-08
32 O 0 2.9580537130868834e-08
, O 0 4.162102329452466e-10
resulting O 0 1.230984647548894e-09
in O 0 1.0289931129392471e-09
a O 0 3.4863347764257924e-09
premature O 0 5.894549293117279e-09
termination O 0 1.2669905125051173e-08
codon O 0 3.499641110238372e-08
27 O 0 8.073400294961175e-07
bp O 0 7.848586847103434e-07
downstream O 0 2.5191789632117434e-07
from O 0 1.596770182743512e-08
the O 0 3.574482931867351e-08
cryptic O 0 3.8050833950364904e-07
splice O 0 9.567816050548572e-07
site O 0 1.6664101565311285e-07
. O 0 2.773587368665176e-07

Three O 0 9.319798266460566e-08
other O 0 2.3385393621566664e-09
splice O 0 2.5457300267817118e-08
variants O 0 3.138463045004869e-09
, O 0 2.532873355498566e-10
including O 0 3.2735501809266765e-11
one O 0 3.2038170727499704e-11
derived O 0 5.878902226141847e-11
from O 0 1.1274813027650765e-10
the O 0 1.356955547926475e-09
skipping O 0 2.7629896592884506e-08
of O 0 4.3740637778455493e-08
exon O 0 2.953505031655368e-07
32 O 0 8.580285282278055e-08
, O 0 2.3460942077946356e-09
were O 0 2.4585637969920526e-09
also O 0 7.39203476207706e-10
identified O 0 1.0233899061518059e-08
. O 0 7.930488266083557e-08

These O 0 1.3058883752137262e-08
results O 0 4.63008298368095e-09
indicate O 0 4.989307189617875e-09
the O 0 7.625810538591793e-10
usefulness O 0 1.9218596492009965e-08
of O 0 9.258258049094081e-10
cycloheximide O 0 1.8866190387711868e-08
treatment O 0 8.566998221937183e-10
in O 0 2.1028305832726524e-11
evaluating O 0 2.5584223628527525e-10
the O 0 9.063663014563517e-11
abnormal O 0 6.306939970279757e-10
processing O 0 3.061751741029184e-09
of O 0 2.534551457600287e-09
mRNA O 0 6.70847988271106e-10
due O 0 4.983194656915657e-08
to O 0 1.8708368187958513e-09
splice O 0 1.7374306082729163e-07
- O 0 4.182157731236202e-09
site O 0 7.125914858185922e-10
mutations O 0 2.744953986333343e-10
, O 0 1.7344400915497715e-10
because O 0 6.99946600679624e-10
( O 0 4.0465319983695736e-10
i O 0 1.7515628059072696e-08
) O 0 1.3010416355374588e-10
aberrant O 0 5.1239306131378726e-09
splicing O 0 2.5998991404208027e-08
often O 0 6.265694074691908e-10
generates O 0 4.176854417892173e-10
a O 0 7.080919739443914e-10
premature O 0 2.561226120079141e-09
termination O 0 3.4741938215177015e-09
codon O 0 3.5886769111925787e-09
, O 0 1.3839092094514172e-09
( O 0 1.2214021460899005e-10
ii O 0 3.3809371302595537e-07
) O 0 6.630792026562915e-10
transcripts O 0 1.990285092290378e-08
with O 0 7.757136044617141e-10
premature O 0 4.3225600876439785e-08
termination O 0 2.1445867304237254e-08
codons O 0 5.907176969799366e-09
can O 0 6.096129157029395e-10
occur O 0 2.663711029526894e-09
at O 0 6.168817634488732e-08
low O 0 2.5344222720491416e-08
or O 0 5.357880805689774e-10
undetectable O 0 2.3174361984956704e-08
levels O 0 1.0376710601889272e-09
due O 0 3.4280576155509834e-09
to O 0 4.4159392809106635e-10
nonsense O 0 2.7232214705463775e-08
- O 0 1.0032067399023958e-09
mediated O 0 6.921974993190361e-09
mRNA O 0 9.040876380872476e-10
decay O 0 1.3858809211342304e-07
, O 0 1.2986094144462612e-10
and O 0 5.5545047727978414e-11
( O 0 4.2995301763326665e-11
iii O 0 6.785505490825017e-08
) O 0 4.9069966839843104e-11
the O 0 3.1378630249712103e-10
levels O 0 9.154590863147405e-09
of O 0 3.755675326289065e-09
these O 0 9.736603884258344e-11
transcripts O 0 2.6198243574526714e-09
can O 0 1.491187034963204e-11
be O 0 2.4717910010463306e-12
increased O 0 1.0343266174106525e-11
by O 0 1.1394988251589577e-11
cycloheximide O 0 6.128696838914038e-08
. O 0 4.083316795799874e-08

A O 0 1.6741659010222065e-06
deletion O 0 4.2696674995568173e-07
mutation O 0 8.233778991950658e-09
in O 0 3.3713656311107343e-09
COL17A1 O 0 3.934673713956727e-06
in O 0 5.96648952466694e-09
five O 0 7.97798216378709e-10
Austrian O 0 4.3307135655368256e-08
families O 0 7.272138186770194e-12
with O 0 4.185425617198035e-11
generalized O 0 0.00010124109394382685
atrophic B-Disease 1 0.9999986886978149
benign I-Disease 1 0.9999997615814209
epidermolysis I-Disease 1 0.9999985694885254
bullosa I-Disease 1 0.925534725189209
represents O 0 1.1083695738989263e-07
propagation O 0 6.632075155721395e-07
of O 0 5.1738613393581545e-08
an O 0 3.05817993151436e-09
ancestral O 0 4.646948355002678e-07
allele O 0 6.324810328806052e-07
. O 0 3.160402854973654e-07

Patients O 0 1.328033221170699e-07
with O 0 4.6470343129101366e-09
generalized O 1 0.9802051186561584
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999895095825195
, O 0 3.133141390776473e-08
a O 0 4.58429161298568e-09
usually O 0 3.5484828964094106e-10
nonlethal O 0 2.3075345723100327e-07
form O 0 7.508647037468563e-09
of O 0 1.600968630555144e-06
junctional B-Disease 1 0.9998164772987366
epidermolysis I-Disease 1 0.9998518228530884
bullosa I-Disease 1 0.5181984305381775
, O 0 7.817742009308404e-09
have O 0 2.9808358559257897e-10
generalized O 0 5.0722320565910195e-08
blistering B-Disease 0 8.526594541535815e-08
, O 0 9.790151800359581e-09
nail B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999867677688599
, O 0 2.2144030253912206e-07
patchy B-Disease 1 0.9995579123497009
alopecia I-Disease 1 1.0
, O 0 1.9884473090314714e-07
and O 0 1.0382298114564037e-06
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9981903433799744

Skin B-Disease 0 0.4737592935562134
fragility I-Disease 0 0.11287936568260193
in O 0 6.470960300930528e-08
most O 0 5.160944449578153e-10
cases O 0 7.845218225055461e-11
is O 0 5.6858324472275346e-12
due O 0 5.730280139282229e-10
to O 0 7.951150848839461e-11
mutations O 0 2.7295471438648633e-10
in O 0 1.9711933474386711e-10
the O 0 3.1393834754034344e-10
gene O 0 2.1647506009969675e-10
encoding O 0 2.0494177022101212e-08
type O 0 1.9521489775797818e-06
XVII O 0 0.0002475170767866075
collagen O 0 3.0178662200341932e-06
( O 0 1.4752957966379654e-08
COL17A1 O 0 4.991055902792141e-06
) O 0 5.534913416482823e-09
. O 0 5.792438528828825e-08

Recently O 0 4.390757567307446e-06
, O 0 1.1850378456301769e-08
we O 0 1.2073801958223385e-09
reported O 0 3.2353147938479765e-10
five O 0 2.5835725919742814e-11
Austrian O 0 5.517764023466043e-09
families O 0 4.244196140368306e-12
with O 0 1.1487456125225393e-10
generalized O 0 0.0001674384984653443
atrophic B-Disease 1 0.9999995231628418
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999988079071045
who O 0 1.5516987161845464e-07
share O 0 9.346854845659891e-09
the O 0 6.782617134604152e-09
same O 0 1.862787257778109e-08
COL17A1 O 0 1.3652810594066978e-05
mutation O 0 2.3904156876142224e-08
. O 0 4.841785639086993e-08

Affected O 0 1.0901437264010383e-07
individuals O 0 7.16553538726572e-10
in O 0 1.8261018253085126e-09
three O 0 4.363451544531216e-10
families O 0 1.1026153948212603e-11
are O 0 2.665795969386542e-12
homozygous O 0 7.292100950850866e-11
for O 0 5.4267867977131345e-11
4003delTC O 0 4.671384168375425e-09
, O 0 7.149176389775747e-11
whereas O 0 1.4538631409877212e-10
those O 0 2.3464497705960596e-11
in O 0 7.232179438654285e-11
two O 0 1.36254382776535e-10
others O 0 8.002759566139162e-11
are O 0 7.200807224799766e-12
compound O 0 3.5902651962516074e-09
heterozygotes O 0 2.491891564204707e-07
. O 0 1.8602933948841383e-07

To O 0 9.297356484694319e-08
determine O 0 1.4636704293025105e-07
if O 0 8.225126135741334e-10
the O 0 1.6232447330732924e-10
occurrence O 0 5.914411738139336e-10
of O 0 4.906896555745277e-10
4003delTC O 0 1.862885623538091e-09
in O 0 2.147014337150477e-11
these O 0 3.583780624691335e-12
unrelated O 0 1.6629629617792574e-10
families O 0 4.85374707006464e-13
signifies O 0 1.217322076474403e-11
propagation O 0 2.5932156422214803e-10
of O 0 3.149807636937396e-10
an O 0 4.05665327718463e-11
ancestral O 0 2.8904494353554355e-09
allele O 0 3.7143921272075886e-09
or O 0 2.0516264243042315e-09
a O 0 5.5571280910271525e-09
mutational O 0 6.428101642086403e-07
hot O 0 1.2420200619089883e-06
spot O 0 3.6085702959098853e-07
, O 0 4.693737065686321e-10
haplotypes O 0 7.337591867440096e-09
were O 0 5.806259362195476e-10
determined O 0 2.8317546085787626e-09
for O 0 1.286310780113098e-10
polymorphisms O 0 6.057281343174736e-09
both O 0 1.9734778256008667e-09
within O 0 3.955022620516502e-08
and O 0 2.8131996288038863e-08
flanking O 0 3.769783506868407e-05
COL17A1 O 0 0.3165537416934967
. O 0 3.0958237857703352e-06

Five O 0 7.169922469074663e-07
intragenic O 0 3.7149720810703e-06
polymorphisms O 0 1.5257462848694558e-07
were O 0 6.7561485295186685e-09
chosen O 0 4.0239984677725715e-09
based O 0 2.2027957236048223e-09
on O 0 1.9065401701823248e-08
their O 0 5.3014450607236085e-09
informativeness O 0 3.7631095892720623e-06
. O 0 6.545963771031893e-08

One O 0 2.8898287496303965e-07
of O 0 1.4862123975944996e-07
these O 0 2.5869170694470256e-10
, O 0 4.219088967083451e-11
not O 0 7.540971319608403e-12
previously O 0 1.5383823381842632e-10
reported O 0 1.1510967873329392e-10
, O 0 2.8083540701273613e-11
was O 0 1.6105037303759673e-08
2988 O 0 2.107520060690149e-07
A O 0 1.1351777118306927e-07
or O 0 6.2317768723119116e-09
C O 0 7.430476216541138e-07
that O 0 1.1235185004565551e-10
introduces O 0 6.053443857290119e-10
a O 0 1.893491752280596e-10
new O 0 1.0027145780355795e-10
restriction O 0 3.6139732872975117e-10
site O 0 3.6882341625243953e-10
for O 0 2.5840665718313005e-10
Eco0109 O 0 1.4906497369793215e-07
I O 0 5.166030405234778e-06
. O 0 3.065595990392467e-07

All O 0 2.8636829796369057e-08
the O 0 4.5436223672368214e-09
4003delTC O 0 2.394824250018246e-08
alleles O 0 4.5347886556967865e-10
showed O 0 4.708414769183378e-10
the O 0 5.6361242062319405e-11
same O 0 4.3374442926236156e-11
haplotype O 0 5.025905247535434e-10
for O 0 5.437240935268761e-11
these O 0 3.148184490875394e-11
five O 0 3.39780592550909e-10
polymorphic O 0 3.427706474212755e-08
markers O 0 2.240433047973056e-07
. O 0 3.1431167712980823e-07

Fourteen O 0 1.152507775259437e-05
microsatellite O 0 3.3739775062713306e-06
polymorphisms O 0 4.6992417424007726e-07
were O 0 1.733317311902738e-08
selected O 0 9.604067541246764e-10
based O 0 1.8636027443452718e-10
on O 0 3.815509685978213e-09
their O 0 1.28797292275884e-10
high O 0 8.092361447609164e-09
heterozygosity O 0 3.441804707904339e-08
and O 0 6.710677846744062e-11
their O 0 3.575848298020823e-11
location O 0 1.4026386718768435e-09
within O 0 8.569907006261701e-10
10q23 O 0 6.89455745828127e-08
- O 0 2.9563558712197846e-08
q25 O 0 3.3293713386228774e-07
near O 0 1.2625538374777534e-06
COL17A1 O 0 6.447619671234861e-05
. O 0 8.856500812726154e-07

Three O 0 3.9498285531180954e-08
families O 0 4.838420220032447e-10
shared O 0 1.7340314073521768e-08
microsatellite O 0 7.044137078082713e-07
polymorphisms O 0 1.437782657376374e-07
covering O 0 2.0524923911580117e-06
at O 0 8.309641088999342e-06
most O 0 4.032465472647573e-09
19 O 0 2.5182510299259775e-08
cM O 0 1.5583299983745746e-08
, O 0 1.9581639087995484e-10
whereas O 0 6.290984955192869e-10
the O 0 5.815325443414565e-10
others O 0 1.1121141507697274e-10
shared O 0 8.700942050188232e-11
smaller O 0 9.499633024656617e-11
regions O 0 2.1466387001289888e-10
consistent O 0 1.7018543241320572e-09
with O 0 1.6875856267972722e-10
cross O 0 7.845345706414264e-09
- O 0 1.0727607691052299e-09
over O 0 3.0468194633925805e-10
events O 0 1.1356287438202273e-10
during O 0 7.266238721825857e-10
passage O 0 3.8581801642401103e-10
of O 0 8.245038679577377e-11
this O 0 2.1655784804286426e-12
mutation O 0 6.3468774506858505e-12
through O 0 2.2380758704643178e-11
several O 0 1.5200246616942081e-10
generations O 0 4.614583826167973e-09
. O 0 2.988153724459153e-08

These O 0 1.7369941929246124e-08
results O 0 3.881950760842301e-09
indicate O 0 3.2061311383557722e-09
that O 0 6.021634579855828e-11
4003delTC O 0 3.4910725421610778e-09
occurs O 0 1.6405256320073391e-10
on O 0 1.0583229848037945e-09
a O 0 6.741299879431395e-11
single O 0 1.4478546833673889e-11
ancestral O 0 5.696987326331282e-10
allele O 0 1.5197877401007531e-09
. O 0 1.5286081289644926e-09
. O 0 2.1427467800094746e-08

The O 0 7.888320965321327e-07
haptoglobin O 0 5.51266894035507e-05
- O 0 4.983822350368428e-07
gene O 0 1.4194764474950716e-08
deletion O 0 5.3133728528109714e-08
responsible O 0 2.1332493105319372e-08
for O 0 4.432650246855019e-09
anhaptoglobinemia B-Disease 0 1.5991992768249474e-05
. O 0 4.856927375840314e-07

We O 0 2.67410797505363e-07
have O 0 6.942438846024857e-10
found O 0 5.6607309117939764e-11
an O 0 5.704124672600841e-12
allelic O 0 1.9274422058401797e-09
deletion O 0 3.979592833047718e-08
of O 0 4.19462224954259e-08
the O 0 7.719948058593218e-08
haptoglobin O 0 2.1610872863675468e-05
( O 0 6.256740459065213e-09
Hp O 0 1.2468724719383317e-07
) O 0 2.636963425395322e-10
gene O 0 1.2819296735244734e-09
from O 0 1.8006184321350815e-09
an O 0 8.350952568347836e-11
individual O 0 2.4384098906704565e-11
with O 0 1.423032358616183e-09
anhaptoglobinemia B-Disease 0 4.9393904191674665e-05
. O 0 6.306531190602982e-07

The O 0 2.9100112897140207e-06
Hp O 0 1.7514211094749044e-06
gene O 0 5.742011310871931e-09
cluster O 0 9.319813365493701e-09
consists O 0 6.777599814711266e-09
of O 0 1.8519360267532647e-08
coding O 0 1.8234734397992725e-06
regions O 0 5.171523298486136e-08
of O 0 4.783716462952725e-07
the O 0 5.814166925688369e-08
alpha O 0 1.1464767339930404e-06
chain O 0 1.1970963775809196e-08
and O 0 1.2118463177390737e-10
beta O 0 2.7327638818519517e-08
chain O 0 1.1876423400281055e-08
of O 0 6.9018173398660565e-09
the O 0 8.530445683163634e-09
haptoglobin O 0 7.402559845104406e-07
gene O 0 6.017805809221954e-09
( O 0 3.16582288162337e-10
Hp O 0 7.200392726502969e-09
) O 0 1.8138530608058367e-11
and O 0 5.484183246418084e-11
of O 0 3.211241494938122e-09
the O 0 1.4882172827412887e-08
alpha O 0 1.1693186934280675e-06
chain O 0 1.9876409851349308e-08
and O 0 1.3083402417013446e-10
beta O 0 3.4688920180769856e-08
chain O 0 1.0983749909598828e-08
of O 0 4.1967651576158005e-09
the O 0 4.78146056082096e-09
haptoglobin O 0 1.5706740441601141e-06
- O 0 8.364909653835184e-09
related O 0 4.361232264216142e-09
gene O 0 3.529779579736214e-09
( O 0 2.290994199904972e-10
Hpr O 0 3.031195205949189e-08
) O 0 1.6507330224957428e-10
, O 0 3.1968236391399785e-10
in O 0 1.5396394159594706e-09
tandem O 0 1.1218405688850908e-06
from O 0 3.4054522757287486e-08
the O 0 5.2885201995422904e-08
5 O 0 1.0978621389767795e-07
side O 0 1.2191310361231444e-07
. O 0 1.1509206387927406e-07

Southern O 0 3.734238362085307e-06
blot O 0 5.032921762904152e-06
and O 0 7.472771734740036e-09
PCR O 0 2.322812875377167e-08
analyses O 0 2.40902031656276e-09
have O 0 2.7991241269287315e-11
indicated O 0 2.926305309181032e-10
that O 0 1.0738508172958294e-11
the O 0 2.30091171810054e-11
individual O 0 1.5772191495552756e-12
with O 0 6.397108103656235e-12
anhaptoglobinemia B-Disease 0 1.1103327146599895e-08
was O 0 2.8083355640973195e-09
homozygous O 0 9.714139909133834e-11
for O 0 4.679458903700251e-11
the O 0 2.3080952427090295e-10
gene O 0 1.7051350609254e-10
deletion O 0 4.331702552207162e-09
and O 0 2.4073013027425816e-10
that O 0 1.8998651610258044e-11
the O 0 3.0506397408203156e-10
gene O 0 1.7564522059032583e-10
deletion O 0 3.717411489745359e-09
was O 0 1.5289966626141904e-08
included O 0 1.3377258190061525e-09
at O 0 2.8624596026816107e-08
least O 0 1.3825524058930228e-10
from O 0 2.0285859103630344e-10
the O 0 6.178727529615458e-10
promoter O 0 4.945914497511694e-06
region O 0 3.8771949562033114e-07
of O 0 3.2735667900851695e-06
Hp O 0 5.560762929235352e-06
to O 0 3.950310656364309e-08
Hpr O 0 4.077436642546672e-06
alpha O 0 3.503640073176939e-06
but O 0 7.156455872348033e-09
not O 0 8.692784825292676e-10
to O 0 1.727461507172734e-09
Hpr O 0 2.8899557946715504e-07
beta O 0 2.5890824417729164e-07
( O 0 2.235995832933213e-09
Hpdel O 0 4.639703661268868e-07
) O 0 2.582574820664263e-09
. O 0 4.1008547668752726e-08

In O 0 2.197438675466401e-07
addition O 0 1.6746140474310778e-08
, O 0 1.6495315113829179e-09
we O 0 7.595587492303935e-10
found O 0 1.0020894530837765e-10
seven O 0 8.928263510454837e-12
individuals O 0 1.4624103794255716e-13
with O 0 7.0172639400623016e-12
hypohaptoglobinemia B-Disease 0 6.880960512489764e-08
in O 0 1.1403132882392697e-09
three O 0 1.9330706479969706e-10
families O 0 2.377034983777615e-12
, O 0 6.529914629849198e-12
and O 0 1.1923524667611929e-11
the O 0 2.4240959239918425e-10
genotypes O 0 3.812127502555995e-09
of O 0 2.5831328187564395e-08
six O 0 3.1468427863501347e-09
of O 0 6.680877184805922e-09
the O 0 1.4824795835366444e-09
seven O 0 3.1488883722730066e-10
individuals O 0 1.2769689819447372e-12
were O 0 4.010081988692349e-10
found O 0 8.585281791040345e-11
to O 0 2.7212648801011596e-11
be O 0 5.566300753656606e-10
Hp2 O 0 1.25514065985044e-06
/ O 0 1.0842271649380564e-06
Hpdel O 0 1.3338837561605033e-05
. O 0 5.80174798869848e-07

The O 0 4.2682426482087976e-08
phenotypes O 0 6.055897472379002e-08
and O 0 5.572717287627427e-10
genotypes O 0 1.4213892285397378e-08
in O 0 3.4014174810081954e-10
one O 0 5.053480550687439e-11
of O 0 3.3904321017352856e-10
these O 0 8.284301196426203e-12
three O 0 7.738142765445488e-11
families O 0 9.599680425576018e-12
showed O 0 1.348184230920424e-09
the O 0 2.003447185927598e-09
father O 0 8.687369046356253e-09
to O 0 5.289150784015817e-10
be O 0 1.227486556842905e-09
hypohaptoglobinemic B-Disease 0 5.192249119545522e-08
( O 0 1.8582500815877978e-10
Hp2 O 0 3.8512141031787905e-08
) O 0 1.5987677848272597e-10
and O 0 7.794391798654488e-10
Hp2 O 0 1.7114373349613743e-06
/ O 0 1.9825489516733796e-07
Hpdel O 0 2.7580672394833528e-06
, O 0 1.079433431527832e-09
the O 0 1.2748561095676791e-09
mother O 0 1.4342151910540224e-09
to O 0 1.3446269098160712e-10
be O 0 8.27234114542108e-10
Hp2 O 0 2.4792856834210397e-07
- O 0 1.609109645528406e-08
1 O 0 3.331911813120314e-08
and O 0 1.2641222513209982e-09
Hp1 O 0 3.005123687671585e-07
/ O 0 3.312597840476883e-08
Hp2 O 0 4.088882405994809e-07
, O 0 2.583056546434648e-10
one O 0 6.028932214574567e-11
of O 0 9.868287298431255e-10
the O 0 7.985792582765328e-10
two O 0 5.598648766813596e-10
children O 0 4.305586442931997e-11
to O 0 4.5175377327844046e-11
be O 0 2.90405310909847e-10
hypohaptoglobinemic B-Disease 0 8.10079754387516e-08
( O 0 1.1863279802959426e-10
Hp2 O 0 2.5647912238468962e-08
) O 0 5.996339536018525e-11
and O 0 3.092174016838811e-10
Hp2 O 0 7.310765113288653e-07
/ O 0 1.0882013157242909e-07
Hpdel O 0 1.48226195051393e-06
, O 0 5.607411757146963e-10
and O 0 2.2513493846965105e-10
the O 0 7.640456600732648e-10
other O 0 1.3853346247927334e-10
child O 0 4.974623490916485e-10
to O 0 4.415810772595563e-11
be O 0 5.419187321109575e-10
Hp1 O 0 1.6949138625932392e-07
and O 0 1.3101238982571317e-09
Hp1 O 0 1.1227385812162538e-06
/ O 0 1.9892837599400082e-07
Hpdel O 0 1.3534740901377518e-06
, O 0 7.439333593595165e-10
showing O 0 2.190122749823331e-09
an O 0 1.4620779587026789e-10
anomalous O 0 1.5405912563437596e-06
inheritance O 0 2.3284610506379977e-06
of O 0 1.2086018159607193e-06
Hp O 0 4.870220209340914e-07
phenotypes O 0 2.922080355460821e-08
in O 0 1.0287204421643992e-09
the O 0 1.4889944832674473e-09
child O 0 3.5822758093218e-09
with O 0 4.538872888648626e-10
Hp1 O 0 1.1266394722042605e-05
. O 0 2.9168080573072075e-07

The O 0 3.1067254440131364e-06
Hp2 O 0 0.00011082887067459524
/ O 0 2.521604528737953e-06
Hpdel O 0 4.2983251660189126e-06
individuals O 0 4.3588846421194205e-10
had O 0 2.0154973245922747e-09
an O 0 9.110720511351644e-11
extremely O 0 8.382606608847709e-09
low O 0 3.685643079620604e-08
level O 0 5.009300707570219e-07
of O 0 3.752956843072752e-07
Hp O 0 2.2236469021663652e-07
( O 0 7.37777686166119e-11
mean O 0 7.758822473391547e-10
+ O 0 3.5111710761093207e-10
/ O 0 2.1513371084580513e-09
- O 0 1.4587999697113219e-09
SD O 0 2.589822400977937e-08
= O 0 5.165023964082138e-09
0 O 0 1.022431361796805e-09
. O 0 5.452704954223009e-11
049 O 0 7.883085295645742e-09
+ O 0 3.134179804575865e-09
/ O 0 2.0091384556053526e-08
- O 0 9.519014021464045e-09
0 O 0 4.7167767469602495e-09
. O 0 3.9489209124887736e-10
043 O 0 3.501331207189651e-07
mg O 0 4.922734433421283e-07
/ O 0 3.0718435795051846e-08
ml O 0 3.161982320420975e-08
; O 0 3.460403352750774e-10
n O 0 1.2984473052313206e-08
= O 0 5.901332311708529e-09
6 O 0 5.2344071299614825e-09
) O 0 1.7572856364500566e-11
, O 0 1.1038484362679846e-11
compared O 0 1.206272443043943e-10
with O 0 2.70233418975252e-11
the O 0 2.4943289655965373e-09
level O 0 1.1338555339079903e-07
( O 0 3.3101799079560124e-11
1 O 0 4.0797010214532747e-10
. O 0 1.3751301312925346e-11
64 O 0 6.581462042021258e-10
+ O 0 2.2782624675699026e-09
/ O 0 9.18446296793718e-09
- O 0 3.4284368677361954e-09
1 O 0 9.175147752671364e-09
. O 0 1.915544944885994e-10
07 O 0 1.3292948075616096e-08
mg O 0 5.8867204444368326e-08
/ O 0 2.0089725438765527e-09
ml O 0 2.1282047235615664e-09
) O 0 7.516315694844344e-12
obtained O 0 2.7441898753366445e-10
from O 0 8.84233297693271e-10
52 O 0 3.038767104612816e-08
healthy O 0 5.5093716255782965e-09
volunteers O 0 2.7335342878131996e-09
having O 0 1.2843458740974256e-08
phenotype O 0 1.624057688331959e-08
Hp2 O 0 1.1277360272288206e-06
, O 0 2.055892345254051e-09
whereas O 0 7.09317005131993e-09
the O 0 6.141555264349563e-09
serum O 0 2.72075002527572e-08
Hp O 0 1.532859883468518e-08
level O 0 7.041383298656001e-08
of O 0 5.5286886180283545e-09
an O 0 3.106987930823202e-11
individual O 0 4.890493825876474e-12
with O 0 4.9382439110123855e-11
Hp1 O 0 2.4021650801842043e-07
/ O 0 5.0267061624253984e-08
Hpdel O 0 5.511386689249775e-07
was O 0 4.150200254571246e-07
0 O 0 9.405408718521358e-08
. O 0 3.0224139635492975e-08

50 O 0 3.7326790334191173e-06
mg O 0 1.762258034432307e-05
/ O 0 2.8097443305341585e-07
ml O 0 1.4714758833633823e-07
, O 0 5.447322592999626e-10
which O 0 5.424262081166198e-11
was O 0 6.400522778449158e-09
approximately O 0 7.004941626753691e-10
half O 0 1.7572766852769206e-10
the O 0 1.4397866232584988e-10
level O 0 9.569750325510995e-09
of O 0 7.960718306776471e-09
Hp O 0 1.2732844112406383e-08
in O 0 4.1936340511306014e-10
control O 0 1.1550572054375152e-07
sera O 0 1.2155658168921946e-07
from O 0 2.668286147589072e-10
the O 0 7.403803126138087e-10
Hp1 O 0 2.8561659703996156e-08
phenotype O 0 4.828316080285333e-10
( O 0 4.436054301670822e-11
1 O 0 1.1452633286168634e-09
. O 0 2.270295756945373e-11
26 O 0 2.0670865019667417e-09
+ O 0 3.19777049284653e-09
/ O 0 1.3493322015278864e-08
- O 0 7.947337898883688e-09
0 O 0 1.3483282268467178e-09
. O 0 9.840652598347432e-11
33 O 0 1.1317398573851278e-08
mg O 0 1.1331183458196392e-07
/ O 0 1.2808305527300945e-08
ml O 0 1.742299815532533e-08
; O 0 2.581076463670229e-10
n O 0 1.375945490877939e-08
= O 0 6.300090227284727e-09
9 O 0 1.347819811314821e-08
) O 0 6.203356578415864e-11
, O 0 7.021364045733947e-11
showing O 0 8.986943411670723e-10
a O 0 1.1328060711690568e-09
gene O 0 2.6420947651928373e-09
- O 0 9.773975406801583e-09
dosage O 0 2.836270596162649e-07
effect O 0 3.8311767980303557e-07
. O 0 8.268798978861014e-08

The O 0 2.464171018345951e-07
other O 0 2.3294490780756405e-09
allele O 0 3.994594877099189e-09
( O 0 4.6253759156122953e-10
Hp2 O 0 7.985084238271156e-08
) O 0 1.0354089113873144e-10
of O 0 9.754378416104714e-10
individuals O 0 3.176569771112803e-11
with O 0 1.1119428711126034e-09
Hp2 O 0 2.9927887226222083e-05
/ O 0 9.469505357628805e-07
Hpdel O 0 6.52341850582161e-06
was O 0 4.03507584678664e-07
found O 0 9.585400251310716e-10
to O 0 3.742221463265416e-11
have O 0 6.668084921029882e-12
, O 0 6.2129919264908295e-12
in O 0 1.70705082014333e-11
all O 0 1.2780447533611294e-10
exons O 0 3.269740700417856e-09
, O 0 8.327030731614116e-11
no O 0 1.0079955620190262e-10
mutation O 0 2.297407923623762e-11
, O 0 1.0997315905147964e-11
by O 0 1.127796901007061e-11
DNA O 0 8.891666847254953e-10
sequencing O 0 1.1989472525897327e-08
. O 0 6.188038526033779e-08

On O 0 7.830278718756745e-07
the O 0 8.388491679056642e-09
basis O 0 3.92792109948914e-08
of O 0 5.381809220494915e-09
the O 0 5.477683306942538e-10
present O 0 2.357212203207837e-10
study O 0 6.407197689073385e-11
, O 0 3.1508740928887224e-12
the O 0 1.5676645745421602e-11
mechanism O 0 1.6578150408008696e-08
of O 0 7.3307231396313455e-09
anhaptoglobinemia B-Disease 0 4.6420407073810566e-08
and O 0 1.3150702748987442e-10
the O 0 1.6929889434802448e-10
mechanism O 0 9.700045211502584e-08
of O 0 8.426979114517508e-09
anomalous O 0 8.863420930538268e-07
inheritance O 0 5.702580097022292e-07
of O 0 2.9669769219253794e-07
Hp O 0 5.668918561241298e-07
phenotypes O 0 6.252030715359069e-08
were O 0 6.198655366773664e-09
well O 0 1.2886025579916804e-09
explained O 0 9.102586773224175e-08
. O 0 4.0191526551325296e-08

However O 0 3.2177550224332663e-07
, O 0 2.4010891053194428e-09
the O 0 7.014126501836415e-10
mechanism O 0 8.508675364282681e-08
of O 0 3.113631308337972e-08
hypohaptoglobinemia B-Disease 0 6.576400664926041e-06
remains O 0 1.0302504733772366e-06
unknown O 0 1.3005937034904491e-05

ATM O 0 2.7693540687323548e-05
mutations O 0 8.664421358162144e-08
and O 0 2.282751321303067e-09
phenotypes O 0 8.220645781875646e-07
in O 0 2.1333037238946417e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 5.593776464252187e-08
in O 0 1.2288997375264898e-08
the O 0 5.5484856709142605e-09
British O 0 6.242329320116369e-09
Isles O 0 1.7316418521318155e-08
: O 0 1.3009094669558241e-11
expression O 0 2.013409855505799e-10
of O 0 1.268102067797372e-09
mutant O 0 2.353251371545184e-09
ATM O 0 3.4586712160944444e-08
and O 0 6.407271241348766e-11
the O 0 4.628206498602516e-11
risk O 0 5.817766268734204e-10
of O 0 7.940974100506537e-09
leukemia B-Disease 1 0.9999994039535522
, O 0 7.237861723297101e-07
lymphoma B-Disease 1 1.0
, O 0 6.190552994667087e-07
and O 0 9.551806670060614e-07
breast B-Disease 1 0.999953031539917
cancer I-Disease 1 0.9999486207962036
. O 0 0.012510770931839943

We O 0 1.0828470919932442e-07
report O 0 1.8608828922239695e-09
the O 0 2.8316127220762155e-10
spectrum O 0 7.292525694424512e-09
of O 0 3.008941762416839e-09
59 O 0 4.592220381738343e-09
ATM O 0 4.830246425058249e-08
mutations O 0 2.800994713947347e-10
observed O 0 7.646613120471102e-09
in O 0 8.501731940668833e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.999824583530426
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.400080826944986e-09
patients O 0 7.208922903068071e-10
in O 0 2.7628800289281052e-11
the O 0 2.3273205584928292e-10
British O 0 6.754744319437123e-09
Isles O 0 2.887046548494254e-07
. O 0 2.385378650160419e-08

Of O 0 4.8120673454832286e-06
51 O 0 3.4555173442640807e-06
ATM O 0 7.0701016738894396e-06
mutations O 0 1.0039021169916396e-08
identified O 0 1.1935694210762904e-08
in O 0 4.8675339314740995e-09
families O 0 4.9906065391347454e-11
native O 0 2.4942944931716227e-10
to O 0 1.7240867067336296e-10
the O 0 1.3128255149652546e-09
British O 0 8.263766559934993e-09
Isles O 0 4.3349526634983704e-08
, O 0 2.2372617647370419e-10
11 O 0 2.0058252836463453e-09
were O 0 1.4450338703397847e-09
founder O 0 5.4384212688773914e-08
mutations O 0 4.2210063222469785e-10
, O 0 6.256534179627238e-10
and O 0 8.962567910053565e-10
2 O 0 2.238669054577258e-07
of O 0 6.691145415516075e-08
these O 0 8.824271868768108e-10
11 O 0 7.621656195055948e-09
conferred O 0 4.553853116817663e-08
a O 0 7.612556696123818e-10
milder O 0 6.799218965625187e-10
clinical O 0 5.788677315266e-10
phenotype O 0 1.5209411508010362e-10
with O 0 2.202545611174056e-11
respect O 0 1.12749476421925e-09
to O 0 1.1590949311468535e-09
both O 0 6.294375509696692e-08
cerebellar B-Disease 1 0.9999918937683105
degeneration I-Disease 1 0.9999934434890747
and O 0 1.8057133388538205e-07
cellular O 0 8.639964107715059e-06
features O 0 4.2275817691006523e-07
. O 0 2.7980667027804884e-07

We O 0 4.4411489596996034e-08
report O 0 1.370585755999798e-09
, O 0 3.327124686869354e-11
in O 0 1.22838059168906e-10
two O 0 5.534699920595187e-10
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9985104203224182
T I-Disease 1 1.0
families O 0 4.871959433105921e-11
, O 0 7.005175085839088e-12
an O 0 6.985747917631624e-12
ATM O 0 1.0254963989098087e-08
mutation O 0 1.1112469278096171e-10
( O 0 4.4241652008558674e-11
7271T O 0 1.4031344086617992e-08
- O 0 1.2520051662079368e-08
- O 0 3.262329073550063e-08
> O 0 2.2600509907988453e-08
G O 0 6.103289962311464e-08
) O 0 6.214274927973662e-11
that O 0 1.9998256522990587e-11
may O 0 8.418328534265385e-11
be O 0 1.3432265716373237e-11
associated O 0 1.0451072646189274e-10
with O 0 3.048996168389384e-12
an O 0 3.4369759642494113e-12
increased O 0 3.7217298687330924e-10
risk O 0 7.154204340054093e-09
of O 0 2.4513026275485572e-08
breast B-Disease 0 2.4907106421778735e-07
cancer I-Disease 0 3.2688319606677396e-08
in O 0 2.7434323701669427e-09
both O 0 2.88609758314351e-09
homozygotes O 0 4.221091387535125e-08
and O 0 1.5121649765692524e-10
heterozygotes O 0 5.409461767413859e-09
( O 0 2.3251364375531658e-11
relative O 0 4.568213807232269e-09
risk O 0 4.079733884054804e-09
12 O 0 2.926546782688888e-09
. O 0 1.2538918514604092e-10
7 O 0 8.314168020717716e-09
; O 0 4.2426706592380015e-10
P O 0 3.3571097901585745e-07
= O 0 1.0255198468200888e-08
. O 0 8.294175346534871e-10
0025 O 0 2.1716368792112917e-07
) O 0 1.792195558625309e-10
, O 0 7.178554278786109e-11
although O 0 1.3727093073345742e-10
there O 0 2.5202331888074525e-10
is O 0 7.59955431917092e-11
a O 0 4.6088638461228015e-10
less O 0 1.077549605099648e-08
severe O 0 2.553661397541873e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999808073043823
T I-Disease 1 0.9999940395355225
phenotype O 0 3.914128576809617e-09
in O 0 5.337009653660907e-11
terms O 0 2.9601782136623456e-10
of O 0 8.33407023947963e-11
the O 0 9.481857660142978e-11
degree O 0 6.590538248474331e-08
of O 0 2.609592186786358e-08
cerebellar B-Disease 1 0.9981861710548401
degeneration I-Disease 1 0.9997941851615906
. O 0 3.053628688576282e-06

This O 0 5.566452632166374e-09
mutation O 0 8.71333560859e-10
( O 0 2.8262386875255174e-10
7271T O 0 4.6576499102002344e-08
- O 0 1.7086170700508774e-08
- O 0 1.4634576217531503e-08
> O 0 4.864137093107956e-09
G O 0 4.059195646277658e-09
) O 0 2.5586247530406947e-12
also O 0 6.634754594683767e-13
allows O 0 7.803245354563726e-13
expression O 0 1.056107892111191e-11
of O 0 4.329082092802139e-10
full O 0 3.9653746952694746e-10
- O 0 4.5957057603907003e-10
length O 0 1.6986105577654342e-10
ATM O 0 2.2900396245972843e-08
protein O 0 2.9720663707877293e-09
at O 0 7.486495867681242e-09
a O 0 3.792138825176039e-10
level O 0 5.343605558039144e-09
comparable O 0 1.9631385406171376e-09
with O 0 8.856384375866e-12
that O 0 3.719795738793552e-12
in O 0 3.5807759535266825e-11
unaffected O 0 2.3623942801975772e-09
individuals O 0 4.7296278005148906e-11
. O 0 1.4076215748559662e-08

In O 0 5.9486641390549266e-08
addition O 0 3.829399020105484e-09
, O 0 3.4537697701786385e-10
we O 0 1.073116179250988e-10
have O 0 6.409724313816145e-12
studied O 0 3.306756646281883e-09
18 O 0 3.026989148224857e-08
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999692440032959
T I-Disease 1 0.9999998807907104
patients O 0 4.208130732763493e-09
, O 0 1.522455425617686e-11
in O 0 2.1250872589417824e-11
15 O 0 2.3800589277200856e-10
families O 0 2.0373470705631336e-12
, O 0 3.0921550042695145e-11
who O 0 1.7090358295224206e-10
developed O 0 1.04492880836915e-06
leukemia B-Disease 1 0.9999998807907104
, O 0 2.7577214495977387e-05
lymphoma B-Disease 1 1.0
, O 0 5.2512068577925675e-06
preleukemic O 1 0.7413663864135742
T O 0 0.45858097076416016
- O 0 3.824397481366759e-06
cell O 0 7.145524705265416e-06
proliferation O 0 0.003274554153904319
, O 0 3.632883993631708e-09
or O 0 2.1069372735382785e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.765476381227927e-07
mostly O 0 5.948374015574132e-10
in O 0 1.5526120389353082e-09
childhood O 0 3.0216395430215925e-07
. O 0 1.1439151847980611e-07

A O 0 1.2467029364415794e-06
wide O 0 2.852279123999324e-08
variety O 0 5.764419164222545e-09
of O 0 6.0003957358389926e-09
ATM O 0 1.307369217329324e-07
mutation O 0 2.26160978833434e-10
types O 0 1.9227963665713332e-10
, O 0 1.1011945695582614e-11
including O 0 8.84754144947486e-11
missense O 0 4.311575807491863e-08
mutations O 0 2.8758218029167892e-09
and O 0 3.290938410671629e-09
in O 0 3.919479496516942e-08
- O 0 1.8300782755886758e-07
frame O 0 0.00015203215298242867
deletions O 0 1.4636452760896645e-07
, O 0 9.470836337399646e-10
were O 0 2.6464208602305916e-10
seen O 0 5.772095579281711e-10
in O 0 4.647402254698285e-11
these O 0 5.618039367050187e-11
patients O 0 6.830314092098888e-09
. O 0 2.334796711522813e-08

We O 0 1.57240521048152e-07
also O 0 6.782587824716302e-10
show O 0 2.7187035955833494e-10
that O 0 1.902122990365962e-12
25 O 0 4.952675769498427e-11
% O 0 1.0439233678882776e-11
of O 0 6.206057889812655e-10
all O 0 5.372414513260537e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999880790710449
T I-Disease 1 0.9999998807907104
patients O 0 6.653358752828353e-09
carried O 0 6.735957347459021e-10
in O 0 2.0835323744083922e-10
- O 0 1.5607564129993534e-09
frame O 0 7.503381738160897e-08
deletions O 0 1.2861232079330875e-08
or O 0 4.553425192455052e-09
missense O 0 1.2163751250682253e-07
mutations O 0 3.2026230556425617e-09
, O 0 2.4722324187820277e-10
many O 0 4.096822533994349e-11
of O 0 9.195014527563217e-09
which O 0 1.0372629838384384e-10
were O 0 9.631432457135602e-11
also O 0 6.050136520246996e-12
associated O 0 2.491288425554572e-11
with O 0 4.3203752207732204e-12
expression O 0 8.857203859236051e-10
of O 0 2.4465661496719804e-08
mutant O 0 7.113264643976436e-08
ATM O 0 4.303165042074397e-06
protein O 0 9.272490046896564e-07
. O 0 2.12823067613499e-07

The O 0 2.508022589609027e-07
DMPK O 0 2.096749267366249e-05
gene O 0 8.80185666574107e-08
of O 0 2.7041642169933766e-07
severely O 1 0.9998371601104736
affected O 1 0.9997015595436096
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 2.8116601242800243e-05
is O 0 9.859544292112332e-09
hypermethylated O 0 7.164686621763394e-07
proximal O 0 8.54050881571311e-07
to O 0 1.0973691955129539e-09
the O 0 3.2919176273793482e-09
largely O 0 7.79844011589148e-09
expanded O 0 6.70685906811741e-09
CTG O 0 2.4442490484943846e-06
repeat O 0 1.3279952781886095e-07
. O 0 1.2347751976449217e-07

Using O 0 2.475552491887356e-07
methylation O 0 1.5383963045678684e-06
- O 0 8.849799826293747e-08
sensitive O 0 2.3473560872844246e-07
restriction O 0 1.2559947748513878e-08
enzymes O 0 1.2351497602480777e-09
, O 0 7.368523152750939e-11
we O 0 3.341376828003284e-11
characterized O 0 1.1936819588331815e-10
the O 0 8.952039109999532e-11
methylation O 0 6.299921917474194e-09
pattern O 0 2.421741562841362e-08
on O 0 4.912211082341855e-08
the O 0 7.295892334724385e-09
5 O 0 8.065934586909407e-09
side O 0 6.67919541896822e-09
of O 0 1.280112460477767e-08
the O 0 9.946353962675403e-09
CTG O 0 1.335098090748943e-06
repeat O 0 5.9376761285534485e-09
in O 0 7.403435642316936e-10
the O 0 6.390553641821839e-10
DMPK O 0 1.2597716647633206e-07
gene O 0 1.092972157223926e-09
of O 0 2.715937030828286e-09
normal O 0 5.4966715623550044e-09
individuals O 0 2.162920016701708e-12
and O 0 1.4501153750012818e-11
of O 0 6.357303017345828e-10
patients O 0 1.8934205314735664e-09
affected O 0 6.510226135958419e-09
with O 0 5.948651846665598e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.6461370044851265e-09
showing O 0 1.0239146197577043e-09
expansions O 0 2.918825847686435e-09
of O 0 5.959188253967795e-09
the O 0 4.551393484319988e-09
repetitive O 0 8.823251391731901e-07
sequence O 0 1.5441987244457778e-08
. O 0 5.669708258437822e-08

The O 0 1.0080293577630073e-06
gene O 0 5.6146735261108915e-08
segment O 0 6.939559682450636e-08
analyzed O 0 6.514525807688187e-08
corresponds O 0 8.501160664309282e-09
to O 0 2.90405310909847e-10
the O 0 8.046783794846135e-10
genomic O 0 8.48342374126787e-09
SacI O 0 2.067440618702676e-06
- O 0 7.863773632266202e-09
HindIII O 0 4.530721042783625e-08
fragment O 0 6.016027231936505e-09
carrying O 0 5.924655432920645e-09
exons O 0 1.9057910805031497e-08
11 O 0 6.533527141527884e-08
- O 0 2.3296767182046096e-08
15 O 0 5.267068203806957e-08
. O 0 3.672149162525784e-08

There O 0 9.474403839249135e-08
is O 0 1.745365629801654e-09
constitutive O 0 1.5838250533306564e-07
methylation O 0 5.644938596560678e-07
in O 0 7.22750144177553e-08
intron O 0 5.41098916073679e-06
12 O 0 1.8753756592104764e-07
at O 0 3.0652419269472375e-08
restriction O 0 6.103971217363835e-10
sites O 0 2.822301004012928e-10
of O 0 1.2892712453194122e-09
SacII O 0 5.932947289011281e-08
and O 0 2.4361250794413536e-09
HhaI O 0 3.9804893958717e-07
, O 0 3.285417771170529e-10
localized O 0 8.504549953158858e-09
1 O 0 6.547124797862125e-08
, O 0 1.9182322397170992e-10
159 O 0 4.068714698490794e-09
- O 0 5.271558300989909e-09
1 O 0 4.787303353737116e-08
, O 0 1.007381067452684e-09
232 O 0 7.55121565276795e-09
bp O 0 7.88754093150601e-08
upstream O 0 6.338699165553408e-08
of O 0 6.733856139362615e-08
the O 0 7.174772775897509e-08
CTG O 0 1.6789124856586568e-05
repeat O 0 4.35487521599498e-08
, O 0 3.4436595242048895e-10
whereas O 0 9.053335303654819e-10
most O 0 4.634558015137458e-11
, O 0 3.380022303711705e-11
if O 0 6.677685487899154e-11
not O 0 1.557038178945369e-11
all O 0 1.2412274333351014e-11
, O 0 1.0706889368161665e-11
of O 0 4.181491611299215e-11
the O 0 1.685159650710588e-11
other O 0 3.0400998558832715e-12
sites O 0 2.879265749433646e-11
of O 0 4.5259745951042873e-10
SacII O 0 8.00709258896859e-08
, O 0 1.3225721628984388e-09
HhaI O 0 2.753751857653697e-07
, O 0 7.056987771925094e-10
and O 0 2.8911484317717395e-10
HpaII O 0 7.343461305708843e-08
in O 0 5.577066031214883e-10
this O 0 6.56733972759227e-11
region O 0 4.295026112544065e-09
are O 0 2.327288362025115e-11
unmethylated O 0 2.9283796720847022e-08
, O 0 2.993425646247161e-11
in O 0 5.112688744590699e-11
normal O 0 6.2509433185198304e-09
individuals O 0 3.4071929305712345e-12
and O 0 3.1933906907699594e-11
most O 0 1.1248901983507142e-11
of O 0 4.1923381433051077e-10
the O 0 1.0284731954968152e-09
patients O 0 9.059730743388172e-09
. O 0 1.1524379672778196e-08

In O 0 5.430088023672397e-08
a O 0 2.338294224912829e-09
number O 0 1.3258245890046538e-10
of O 0 2.3110620972488505e-08
young O 0 5.057931407037586e-09
and O 0 1.0432302133267513e-08
severely O 0 4.063570668222383e-05
affected O 0 1.819115169610086e-08
patients O 0 1.5956733712130244e-09
, O 0 3.819255675607813e-11
however O 0 9.41176581115144e-11
, O 0 7.480817180993693e-12
complete O 0 1.8294127324125498e-10
methylation O 0 5.0875863522037434e-09
of O 0 1.3853855840295637e-09
these O 0 1.5389097982043687e-11
restriction O 0 1.6101579791705234e-10
sites O 0 8.171689713787345e-11
was O 0 1.6754247988970405e-09
found O 0 5.65294061560806e-11
in O 0 4.2551569906512654e-11
the O 0 6.340277192151689e-10
mutated O 0 2.7443010086614095e-09
allele O 0 8.526968287014824e-08
. O 0 1.0612166079226881e-07

In O 0 1.870053409902539e-07
most O 0 2.1868042932027265e-09
of O 0 5.467435837402945e-09
these O 0 3.7709172590050244e-11
patients O 0 9.057372907239625e-11
, O 0 2.4337574056759737e-12
the O 0 2.83915044252403e-11
onset O 0 1.4611934773256507e-07
of O 0 4.06786870854603e-09
the O 0 4.52585657839677e-09
disease O 0 3.2752279821579577e-06
was O 0 5.81665653953678e-06
congenital O 1 0.9999998807907104
. O 0 4.671957867685705e-06

Preliminary O 0 3.164205679695442e-07
in O 0 1.1689513002011154e-07
vivo O 0 2.7587723252509022e-06
footprinting O 0 9.283087820222136e-06
data O 0 6.053056722521433e-08
gave O 0 1.4567015149680174e-08
evidence O 0 3.96799437751838e-09
for O 0 1.9129854644805988e-10
protein O 0 2.768595797064677e-09
- O 0 1.1334545524377404e-09
DNA O 0 1.992753073665199e-09
contact O 0 3.577224916284649e-08
in O 0 9.094699993106303e-10
normal O 0 3.5912393059334136e-08
genes O 0 4.535428699270483e-10
at O 0 6.486638781666443e-09
an O 0 7.767081422471733e-11
Sp1 O 0 3.6053020124882096e-08
consensus O 0 1.686831119229737e-08
binding O 0 9.691756730489942e-09
site O 0 1.4683029903039824e-08
upstream O 0 4.028738587180669e-08
of O 0 2.827260559001843e-08
the O 0 3.6100502143199265e-08
CTG O 0 8.915634680306539e-06
repeat O 0 2.5032761641341494e-08
and O 0 1.4900421174690592e-10
for O 0 6.022024545693228e-11
a O 0 6.95122084892752e-11
significant O 0 2.792074904611752e-11
reduction O 0 1.119044856778828e-09
of O 0 1.0505658565307385e-09
this O 0 1.2201534921318924e-11
interaction O 0 6.760450532716789e-10
in O 0 1.4458630126501504e-10
cells O 0 9.998494220064824e-12
with O 0 3.311133311978409e-11
a O 0 9.279703672149253e-10
hypermethylated O 0 7.340394603261302e-08
DMPK O 0 8.58856708418898e-07
gene O 0 7.971248550120436e-09
. O 0 5.454042106833867e-09
. O 0 4.9049177164306457e-08

The O 0 1.541765777801629e-05
hemochromatosis B-Disease 1 1.0
gene O 0 1.4370834833243862e-07
product O 0 1.7496194715249658e-08
complexes O 0 1.1470434380100869e-08
with O 0 3.110582902365877e-10
the O 0 1.0273366157775854e-08
transferrin O 0 1.6212946718496823e-07
receptor O 0 1.4826329497452662e-08
and O 0 1.1489981188717024e-09
lowers O 0 4.745101644942906e-09
its O 0 1.5716525303410833e-11
affinity O 0 1.190498810643703e-10
for O 0 1.3915553431775862e-10
ligand O 0 1.641265789942281e-08
binding O 0 1.317210944762337e-07
. O 0 2.0196819150442025e-07

We O 0 5.522609285435465e-07
recently O 0 6.855480449985407e-08
reported O 0 2.4033020018521256e-09
the O 0 5.841337968881533e-10
positional O 0 1.5219939086819068e-07
cloning O 0 4.701839362297733e-09
of O 0 1.2669729709813282e-09
a O 0 6.745033420685331e-10
candidate O 0 1.4637024925434616e-09
gene O 0 5.168594441329333e-08
for O 0 1.1817186305052019e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999722242355347
HFE O 1 0.9983041286468506
. O 0 9.671181032899767e-06

The O 0 5.36101481429796e-07
gene O 0 1.4338686682435764e-08
product O 0 6.6175673829604875e-09
, O 0 2.1106190406516845e-10
a O 0 3.113544977395577e-10
member O 0 2.6122599638966904e-09
of O 0 3.5761196670591744e-08
the O 0 6.129597096560246e-08
major O 0 8.88048646174866e-07
histocompatibility O 0 0.00024053255037870258
complex O 0 0.009780000895261765
class O 0 8.244199420914811e-07
I O 0 6.7502651290851645e-06
- O 0 3.954977501052781e-08
like O 0 4.377230522489839e-10
family O 0 1.1334819888242365e-10
, O 0 2.9833996384454053e-11
was O 0 5.567790228866443e-09
found O 0 1.6661662327610571e-10
to O 0 4.433736364162222e-11
have O 0 2.6637593172895713e-11
a O 0 2.0808477163569705e-10
mutation O 0 1.1332507848793583e-10
, O 0 2.84809009709619e-10
Cys O 0 1.5783772369104554e-06
- O 0 9.157266589454593e-08
282 O 0 1.4020621108556952e-07
- O 0 2.757833215127903e-07
- O 0 1.7155407761038077e-07
> O 0 4.179496215783729e-08
Tyr O 0 2.5642049195084837e-07
( O 0 1.1330756471972236e-10
C282Y O 0 3.783298119230949e-09
) O 0 7.775348073724153e-12
, O 0 6.624957527012754e-12
in O 0 2.887338805546147e-11
85 O 0 9.105443621315601e-10
% O 0 2.1780907633051072e-10
of O 0 5.310634154653826e-09
patient O 0 1.3120131825417047e-07
chromosomes O 0 4.047134893880866e-07
. O 0 1.5207112369353126e-07

This O 0 2.8742386248836738e-08
mutation O 0 5.460349505881368e-09
eliminates O 0 4.9701046833661167e-08
the O 0 1.0737494227086586e-09
ability O 0 5.451563644953694e-10
of O 0 2.3103305935023855e-08
HFE O 0 2.1773967091576196e-06
to O 0 7.028768234107474e-09
associate O 0 1.3157696798771212e-07
with O 0 1.2828762496752688e-09
beta2 O 0 1.5289670045603998e-05
- O 0 1.5773027826071484e-06
microglobulin O 0 1.5069764231157023e-05
( O 0 1.416460060355007e-09
beta2m O 0 1.5880750936503318e-07
) O 0 1.7956650055772627e-10
and O 0 3.14769377229851e-10
prevents O 0 2.7072071251410534e-09
cell O 0 1.7687963804746687e-07
- O 0 1.390789883259913e-08
surface O 0 1.1124806320594871e-07
expression O 0 7.46596455769577e-08
. O 0 4.018677302042306e-08

A O 0 1.584161327627953e-05
second O 0 5.052443157183006e-07
mutation O 0 3.039200002774578e-09
that O 0 2.0020402002884907e-10
has O 0 5.366735181255855e-11
no O 0 1.0366696390207153e-10
effect O 0 2.9465592188415712e-09
on O 0 2.6715380130326594e-08
beta2m O 0 4.5690791239394457e-07
association O 0 7.897066112150242e-09
, O 0 2.4559754230324415e-10
H63D O 0 1.7049033829152904e-07
, O 0 1.9872220535788188e-10
was O 0 3.720504127002755e-09
found O 0 1.2434649143688858e-10
in O 0 2.6181681822556868e-11
eight O 0 5.6259535224922885e-11
out O 0 9.655725004276139e-12
of O 0 2.3837296025952526e-10
nine O 0 4.6163423084166766e-10
patients O 0 6.693012116754105e-11
heterozygous O 0 2.727605918906306e-10
for O 0 1.4128573311289472e-10
the O 0 1.7923673656383698e-09
C282Y O 0 2.0829034497182874e-07
mutant O 0 1.3475401772211626e-07
. O 0 9.746074169925123e-08

In O 0 1.2564971996198437e-07
this O 0 8.048549049455289e-10
report O 0 4.4918843644659034e-10
, O 0 3.636179898847125e-11
we O 0 1.4374918790027724e-11
demonstrate O 0 2.2370483243605577e-10
in O 0 1.8539027257791219e-10
cultured O 0 3.3391054365949913e-09
293 O 0 1.6856757101280095e-09
cells O 0 3.228096956409132e-10
overexpressing O 0 4.086192006980127e-08
wild O 0 6.130784213631557e-10
- O 0 2.021615097547169e-09
type O 0 7.755779130036444e-09
or O 0 8.895958969468154e-10
mutant O 0 9.828339031514588e-09
HFE O 0 3.37381237613954e-07
proteins O 0 2.626858175425184e-10
that O 0 2.1227377494659194e-11
both O 0 4.708915896101118e-11
the O 0 3.323834540935877e-10
wild O 0 1.4921210100826698e-10
- O 0 3.4395306047763086e-10
type O 0 3.35775429682883e-09
and O 0 6.340434288709673e-10
H63D O 0 2.919389999078703e-06
HFE O 0 2.3726154267933453e-06
proteins O 0 2.985765190643974e-09
form O 0 2.7181448203350556e-09
stable O 0 2.526160756133322e-07
complexes O 0 5.788614032553596e-09
with O 0 4.840672862549411e-10
the O 0 1.1085192319626458e-08
transferrin O 0 8.24678068056528e-08
receptor O 0 5.1363766573331304e-09
( O 0 4.416672028106916e-10
TfR O 0 5.999230978659398e-08
) O 0 8.581438892818483e-10
. O 0 2.1021199003712354e-08

The O 0 3.518532878388214e-07
C282Y O 0 4.331748186814366e-06
mutation O 0 1.138273386658284e-08
nearly O 0 1.9338164403137625e-09
completely O 0 6.235332250525971e-09
prevents O 0 4.973039202660345e-10
the O 0 4.6034259737481875e-10
association O 0 4.752236382188357e-10
of O 0 2.7625401965991614e-09
the O 0 3.9059546708131165e-09
mutant O 0 1.4385945235062536e-07
HFE O 0 3.537927796060103e-06
protein O 0 1.919266168215472e-08
with O 0 7.814904834368974e-10
the O 0 1.8618850461393777e-08
TfR O 0 3.2100299449666636e-06
. O 0 8.653487526544268e-08

Studies O 0 3.55681834207644e-07
on O 0 3.0427867159232846e-07
cell O 0 9.720547211600206e-08
- O 0 3.5314899893279517e-09
associated O 0 2.696786349787317e-09
transferrin O 0 8.981056254242503e-08
at O 0 1.8301828674793796e-07
37 O 0 3.668928982847319e-08
degrees O 0 1.4649651802756125e-06
C O 0 3.4352339639553975e-07
suggest O 0 5.177014927859602e-10
that O 0 4.380449995788904e-12
the O 0 2.545693378319669e-10
overexpressed O 0 1.466944610228893e-07
wild O 0 3.761475131369707e-09
- O 0 1.1154271284397055e-08
type O 0 6.423762499707664e-08
HFE O 0 1.7142925798907527e-06
protein O 0 1.260297466387783e-08
decreases O 0 3.1266267352947352e-09
the O 0 1.7452249367888584e-10
affinity O 0 2.015712707859052e-09
of O 0 4.540650522244505e-09
the O 0 1.678783556613439e-09
TfR O 0 1.212407454431741e-07
for O 0 1.6179104722624515e-09
transferrin O 0 7.951796874294814e-07
. O 0 1.181988622533936e-07

The O 0 2.3877102648839355e-05
overexpressed O 0 0.003788196947425604
H63D O 0 0.015105544589459896
protein O 0 1.3381828694036813e-06
does O 0 5.303535388634373e-10
not O 0 5.861659768680028e-11
have O 0 1.4463221202284937e-12
this O 0 5.857841880833881e-13
effect O 0 7.83830847450595e-11
, O 0 3.818459871213209e-12
providing O 0 1.0915148992984847e-11
the O 0 1.9449783797420572e-11
first O 0 3.248533733679615e-11
direct O 0 9.48399137001843e-11
evidence O 0 8.82509204602755e-11
for O 0 3.693695002637831e-11
a O 0 7.845338267919999e-11
functional O 0 8.915637295103807e-08
consequence O 0 6.255287132717058e-08
of O 0 1.4475172172012662e-08
the O 0 5.9217741821271375e-09
H63D O 0 6.866040621389402e-06
mutation O 0 4.791907670664841e-08
. O 0 4.2419628698553424e-08

Addition O 0 6.119655893144227e-08
of O 0 3.9579438748660323e-07
soluble O 0 4.169351541349897e-06
wild O 0 4.624322258450775e-08
- O 0 5.593403074044545e-08
type O 0 7.075741450535133e-07
HFE O 0 0.002852337434887886
/ O 0 6.453617970691994e-05
beta2m O 0 4.486496982281096e-05
heterodimers O 0 1.6671505363774486e-05
to O 0 1.5249511875481403e-08
cultured O 0 6.044773215307941e-08
cells O 0 4.5696060824163e-10
also O 0 2.13196474363464e-11
decreased O 0 7.774466070920028e-10
the O 0 2.0548718282498157e-10
apparent O 0 2.545534449893694e-09
affinity O 0 5.965052896073075e-10
of O 0 5.264424007833668e-09
the O 0 1.3797686326810776e-09
TfR O 0 1.1211263029053953e-08
for O 0 6.500838756196003e-11
its O 0 5.537946403538774e-12
ligand O 0 1.1826234436185246e-09
under O 0 1.0552778206829316e-08
steady O 0 6.9549699333038e-08
- O 0 6.564512267104305e-10
state O 0 7.854261685480424e-11
conditions O 0 2.222042327915119e-09
, O 0 2.3250210784420133e-11
both O 0 7.949286368047481e-11
in O 0 1.0072018913342973e-10
293 O 0 1.7782417205403078e-10
cells O 0 2.803174012355747e-11
and O 0 1.4810232207285168e-10
in O 0 7.180995797995138e-10
HeLa O 0 1.3294626910465013e-07
cells O 0 7.950052172134292e-09
. O 0 4.548948240312711e-08

Furthermore O 0 1.7693239442451159e-06
, O 0 3.332915810005943e-08
at O 0 3.4957858474626846e-07
4 O 0 1.1657995457881043e-07
degrees O 0 3.140362423437182e-06
C O 0 2.9478965757334663e-07
, O 0 2.723545833305252e-10
the O 0 4.4840775537124955e-10
added O 0 6.062066848500081e-09
soluble O 0 1.8895576658906066e-08
complex O 0 2.0091006547318102e-07
of O 0 1.8487673969502794e-07
HFE O 0 2.0603803932317533e-05
/ O 0 3.7068855363031616e-07
beta2m O 0 2.494050193035946e-07
inhibited O 0 4.625237526312276e-09
binding O 0 4.688317289947008e-09
of O 0 2.3041256014266764e-08
transferrin O 0 1.77043347093786e-07
to O 0 1.013200989774532e-08
HeLa O 0 5.148993977854843e-07
cell O 0 6.220510329058015e-08
TfR O 0 1.763090580197968e-07
in O 0 1.3136220999854231e-09
a O 0 1.472629906906775e-09
concentration O 0 9.037125892064068e-08
- O 0 7.0995316292510324e-09
dependent O 0 2.4249571239920442e-09
manner O 0 2.5392123959022683e-08
. O 0 9.80315739695925e-09

Scatchard O 0 0.00021344423294067383
plots O 0 2.532567577873124e-06
of O 0 3.141022375530156e-07
these O 0 9.498225539417149e-10
data O 0 3.79043418874403e-09
indicate O 0 3.397243819591722e-09
that O 0 1.2511731928288583e-10
the O 0 1.2259633308531193e-09
added O 0 1.3565990997221888e-08
heterodimer O 0 1.3324729764008225e-08
substantially O 0 5.902108579647347e-09
reduced O 0 1.5820331711324798e-09
the O 0 1.008199426721923e-10
affinity O 0 1.1671635880006193e-09
of O 0 4.57804416598151e-09
TfR O 0 1.487829024426901e-07
for O 0 1.2283108974386892e-09
transferrin O 0 6.95930907568254e-07
. O 0 2.140127008942727e-07

These O 0 6.736461610756805e-09
results O 0 5.334430230874432e-09
establish O 0 1.3020483358161528e-08
a O 0 1.5980399226123154e-09
molecular O 0 4.2693415025496506e-08
link O 0 6.570417809825813e-08
between O 0 5.819503030579654e-07
HFE O 0 5.9574358601821586e-05
and O 0 3.440255724740382e-08
a O 0 4.2806593825162054e-08
key O 0 7.578373129035754e-07
protein O 0 3.820981220314934e-08
involved O 0 2.5789336888237813e-08
in O 0 7.836851168008252e-09
iron O 0 0.001546783372759819
transport O 0 2.1250750137369323e-07
, O 0 4.440907364067215e-10
the O 0 2.5671931247472912e-09
TfR O 0 1.8515127919727092e-07
, O 0 3.1495434038575354e-10
and O 0 1.4259414482520327e-10
raise O 0 2.077211458395567e-10
the O 0 3.13326975476258e-10
possibility O 0 4.673725850778965e-10
that O 0 9.756843770414303e-12
alterations O 0 2.7203543861986645e-09
in O 0 7.764237169860522e-11
this O 0 2.1501534927526045e-11
regulatory O 0 6.466318147602124e-09
mechanism O 0 6.101550411585777e-07
may O 0 8.791265493357514e-09
play O 0 1.448611008925127e-08
a O 0 1.0547319684306444e-09
role O 0 2.8526365714043322e-09
in O 0 2.866412385227335e-10
the O 0 1.1800997956612491e-09
pathogenesis O 0 0.0002956282696686685
of O 0 3.68442342733033e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.879816722474061e-05
. O 0 1.6914725620154059e-06

Genomic O 0 1.329406018157897e-06
organization O 0 9.639196996147348e-09
of O 0 6.415607600729345e-08
the O 0 7.805125079585196e-08
UBE3A O 0 0.0006473182584159076
/ O 0 1.316717953159241e-05
E6 O 0 7.490706593671348e-06
- O 0 2.0732321104333096e-07
AP O 0 1.0656174254108919e-06
gene O 0 1.556294426663385e-09
and O 0 1.7754356318455677e-10
related O 0 1.80028969509749e-08
pseudogenes O 0 1.3280576922625187e-06
. O 0 1.670764078198772e-07

The O 0 4.0477758034285216e-07
UBE3A O 0 1.551788955111988e-05
gene O 0 2.0908196063373907e-08
encodes O 0 4.944714415699991e-09
the O 0 2.2161348312010887e-08
E6 O 0 2.554288812461891e-06
- O 0 7.219957183224324e-07
AP O 0 5.60991657039267e-06
ubiquitin O 0 3.915139075161278e-07
- O 0 2.5593521968403365e-08
protein O 0 6.115324691080559e-09
ligase O 0 5.780647960307306e-09
and O 0 3.223482591963034e-10
has O 0 1.3098334916694654e-10
recently O 0 1.5697725341823343e-09
been O 0 2.62763977243452e-10
shown O 0 1.536441113225706e-10
to O 0 6.2497177572007345e-12
be O 0 5.488533672687312e-12
mutated O 0 5.684992476773232e-10
in O 0 2.7674766922558547e-09
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 4.614903161836992e-07
who O 0 1.3172399837557691e-09
lack O 0 7.661957290849841e-09
15q11 O 0 4.435333167407407e-08
- O 0 3.596865916222214e-09
q13 O 0 9.588477567490372e-09
deletions O 0 2.9183582217484627e-09
or O 0 8.140704776948837e-10
chromosome O 0 2.2602846172503632e-07
15 O 0 2.9846626148355426e-07
paternal O 0 2.4530856990168104e-06
uniparental B-Disease 0 0.0010730281937867403
disomy I-Disease 0 0.00030038884142413735
. O 0 2.3941358904266963e-06

Previous O 0 1.5619998521287926e-06
UBE3A O 0 3.433738311287016e-05
cDNA O 0 2.7839436711474264e-07
analysis O 0 7.722079864436182e-09
has O 0 1.9149530572359907e-10
shown O 0 1.5128112651474623e-10
a O 0 8.857773542425562e-11
coding O 0 1.2606003352289008e-08
region O 0 4.588788460324622e-09
of O 0 7.361085518908794e-09
approximately O 0 6.638283256421573e-10
2 O 0 1.366522610624088e-07
. O 0 2.9587758021420996e-08

6 O 0 2.1564261260209605e-05
kb O 0 4.43724165961612e-05
and O 0 1.2770573221132508e-07
a O 0 1.471780421979929e-07
3 O 0 2.653892750004161e-07
- O 0 3.078113408605532e-08
untranslated O 0 1.5011885807325598e-05
region O 0 7.234701371316987e-08
( O 0 1.3679132826460716e-10
UTR O 0 1.0841738173894555e-07
) O 0 1.884894323955777e-10
of O 0 6.467884894334475e-09
< O 0 2.693195426672901e-07
50 O 0 3.5661138042542007e-08
bp O 0 4.520708074551294e-08
, O 0 1.7678326857950566e-10
whereas O 0 7.030346860226189e-10
Northern O 0 8.650822835853944e-10
analysis O 0 6.188882184510192e-10
has O 0 4.8542430491904653e-11
indicated O 0 1.4450911300922797e-10
mRNA O 0 5.784546452947126e-11
sizes O 0 8.199468881642247e-10
of O 0 2.877154958724759e-09
5 O 0 1.1445214553873484e-08
- O 0 2.059802639564623e-08
8 O 0 7.577449423479266e-08
kb O 0 5.847380634804722e-06
. O 0 5.065252253189101e-07

We O 0 9.601309614026832e-08
have O 0 8.998739947640999e-11
analyzed O 0 1.0457693044862992e-10
additional O 0 1.1124005189211417e-10
cDNA O 0 2.942762478141958e-09
clones O 0 1.1227948570891044e-09
and O 0 6.696268539663208e-11
provide O 0 4.7271925956993144e-11
evidence O 0 6.112543110559088e-11
for O 0 1.497765973745846e-11
an O 0 6.581455866405683e-12
additional O 0 2.4548513222200086e-10
0 O 0 3.4011161886837726e-08
. O 0 2.8156636133758184e-08

5 O 0 2.5033868951140903e-06
kb O 0 1.701939254417084e-05
of O 0 2.2352649011736503e-06
5 O 0 8.698903002368752e-07
- O 0 7.731736673122214e-08
UTR O 0 2.445935024297796e-06
and O 0 3.406392501403843e-09
> O 0 1.405311955693378e-08
2 O 0 1.1042228464930304e-08
kb O 0 3.8560068560400396e-07
of O 0 8.772492776643048e-08
3 O 0 1.8167888811149169e-06
- O 0 8.651405778437038e-07
UTR O 0 3.1343930459115654e-05
. O 0 3.093690850164421e-07

We O 0 1.5146004272992286e-07
have O 0 4.744193926597973e-10
established O 0 6.271457242412737e-10
the O 0 5.86860698925662e-11
genomic O 0 3.9660780215555747e-10
organization O 0 1.8057902395618441e-10
of O 0 1.7584175227014498e-09
UBE3A O 0 6.767551781194925e-07
and O 0 2.1747616207878906e-10
the O 0 6.307914190983865e-10
sequence O 0 2.155321254804221e-09
of O 0 3.293294881245856e-08
intron O 0 4.231355433148565e-06
- O 0 5.304810883899336e-07
exon O 0 1.3393294011621037e-06
borders O 0 4.5707437834607845e-08
. O 0 1.4273217630034196e-07

We O 0 7.556016043963609e-07
have O 0 1.8050129169111528e-09
also O 0 3.402254589168763e-10
mapped O 0 1.975677177412649e-09
two O 0 3.375868196098253e-10
highly O 0 2.589371606021018e-09
homologous O 0 5.239701117432105e-09
processed O 0 6.748035019654708e-09
pseudogenes O 0 2.895284367809836e-08
, O 0 5.808208913826718e-10
UBE3AP1 O 0 2.485436141341779e-07
and O 0 2.8594242529322855e-09
UBE3AP2 O 0 1.616562258277554e-06
, O 0 3.8811787117509766e-10
to O 0 1.8304423254900115e-10
chromosomes O 0 4.973326639401421e-09
2 O 0 1.302420837845375e-08
and O 0 2.953777222813869e-10
21 O 0 5.371922462416023e-09
, O 0 8.274814861097823e-11
respectively O 0 9.894126629106381e-10
, O 0 5.777302594656142e-11
and O 0 1.0258078241009994e-11
determined O 0 2.2690285761406415e-10
their O 0 3.6639861283882524e-11
genomic O 0 4.687843002670888e-09
organization O 0 7.426205761440485e-10
. O 0 8.753384683757304e-09

These O 0 5.209807696360258e-08
results O 0 1.3287473343837064e-08
will O 0 2.4319316005438907e-10
form O 0 2.7917447867342737e-11
the O 0 3.561357111991903e-11
basis O 0 2.0910088938119742e-10
for O 0 1.6014335040351324e-12
studies O 0 6.572285684430801e-12
of O 0 1.019256640893973e-11
mutation O 0 9.759765912109586e-12
and O 0 1.6254499482504237e-11
imprinting O 0 8.83645796534438e-08
of O 0 1.734227623728657e-07
UBE3A O 0 0.0002952953218482435
. O 0 1.6304644532283419e-06

Mutation O 0 9.313123996435024e-07
spectrum O 0 4.751416781800799e-06
and O 0 1.4299357253833023e-08
genotype O 0 1.922619077276977e-07
- O 0 1.7136301266873488e-08
phenotype O 0 1.5327451530211533e-09
analyses O 0 2.243240704302707e-09
in O 0 2.528022791103979e-10
Cowden B-Disease 0 2.3622553271707147e-05
disease I-Disease 0 1.1627118112755852e-07
and O 0 7.564763815359754e-10
Bannayan B-Disease 0 0.4753240942955017
- I-Disease 1 0.9988951086997986
Zonana I-Disease 1 1.0
syndrome I-Disease 1 0.9999980926513672
, O 0 7.83277087634815e-09
two O 0 2.5439680584327107e-08
hamartoma B-Disease 1 0.9987114667892456
syndromes I-Disease 0 0.004480448551476002
with O 0 2.642606204972253e-06
germline O 1 0.9926204681396484
PTEN O 0 0.23833872377872467
mutation O 0 2.346642531847465e-06
. O 0 4.815188958673389e-07

The O 0 6.462230430770433e-06
tumour B-Disease 1 1.0
suppressor O 0 0.0002968806365970522
gene O 0 1.28419128486712e-06
PTEN O 0 2.4682998628122732e-05
, O 0 3.964000239164989e-09
which O 0 6.498049320846633e-11
maps O 0 5.197725805317077e-09
to O 0 2.5057305119702278e-09
10q23 O 0 2.6138095563510433e-06
. O 0 2.3709183949449653e-07

3 O 0 9.9040823897667e-07
and O 0 3.131431114411498e-09
encodes O 0 1.5758594429371442e-09
a O 0 8.852896749012018e-10
403 O 0 6.359947013478973e-10
amino O 0 2.0755253071769175e-09
acid O 0 9.036949855101284e-09
dual O 0 1.2253940440132283e-07
specificity O 0 5.232254238762835e-07
phosphatase O 0 6.803106953157112e-05
( O 0 1.3215792016296746e-08
protein O 0 3.1712778536530095e-07
tyrosine O 0 8.528755301995261e-07
phosphatase O 0 4.459612682694569e-06
; O 0 5.209109144033164e-09
PTPase O 0 5.107939955451002e-07
) O 0 4.769444283958535e-10
, O 0 2.5020563398925333e-10
was O 0 1.3376626917249723e-08
shown O 0 2.4232327255901964e-09
recently O 0 4.923614849161595e-09
to O 0 6.59770127420245e-10
play O 0 8.890997094113118e-08
a O 0 4.6219832405824945e-09
broad O 0 4.089113492256047e-09
role O 0 9.472123529974397e-09
in O 0 2.69113420436895e-09
human O 0 1.625722134690477e-08
malignancy B-Disease 0 2.3218619844556088e-06
. O 0 7.309755289952591e-08

Somatic O 0 0.00022033076675143093
PTEN O 0 0.0001064030802808702
deletions O 0 5.679990522367007e-07
and O 0 4.608207149203736e-09
mutations O 0 2.254788356026438e-09
were O 0 4.370906692141574e-10
observed O 0 2.1145889483875635e-09
in O 0 6.653253503685619e-10
sporadic B-Disease 0 2.7906584364245646e-05
breast I-Disease 0 0.0034738206304609776
, I-Disease 0 4.114754048600844e-08
brain I-Disease 1 0.9999961853027344
, I-Disease 0 2.07277153663199e-07
prostate I-Disease 1 0.9999967813491821
and I-Disease 1 0.9972907900810242
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999947547912598
lines O 0 0.0001633750944165513
and O 0 1.3626518580167613e-08
in O 0 1.7999247647892958e-09
several O 0 1.4954838478686838e-09
primary O 0 1.9840044842567295e-05
tumours B-Disease 1 1.0
such O 0 3.13832693166205e-08
as O 0 1.9383801372896414e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999994039535522
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9999680519104004

In O 0 2.717322900025465e-07
addition O 0 5.079308706967822e-08
, O 0 1.6172881700526887e-08
PTEN O 0 3.646232244136627e-06
was O 0 1.3794645781217696e-07
identified O 0 1.8868302475993914e-09
as O 0 1.2735089371940234e-10
the O 0 8.079013152917369e-11
susceptibility O 0 1.1017986523143009e-09
gene O 0 3.729418718290134e-10
for O 0 1.5568852873570904e-09
two O 0 1.8108661947735527e-07
hamartoma B-Disease 1 0.999994158744812
syndromes I-Disease 1 0.999988317489624
Cowden B-Disease 1 0.9999963045120239
disease I-Disease 0 0.27922993898391724
( O 0 3.1906908226631003e-09
CD B-Disease 0 1.4054038501853938e-06
; O 0 5.069472841512379e-09
MIM O 0 1.3788505839329446e-06
158350 O 0 1.1543986744300128e-07
) O 0 5.429996730033082e-11
and O 0 2.8966842813282767e-10
Bannayan B-Disease 0 3.7564689137070673e-06
- I-Disease 0 1.392565081914654e-06
Zonana I-Disease 0 0.0003178782935719937
( I-Disease 0 2.129357801194942e-09
BZS I-Disease 0 4.493852429732215e-06
) I-Disease 0 6.597046797729433e-10
or I-Disease 0 8.393865602585038e-10
Ruvalcaba I-Disease 0 9.43110308071482e-07
- I-Disease 0 9.133087246482319e-07
Riley I-Disease 0 2.6013285605586134e-05
- I-Disease 0 0.0005654977285303175
Smith I-Disease 0 0.0015267855487763882
syndrome I-Disease 1 0.9387314915657043
( O 0 1.5482804371913517e-08
MIM O 0 1.8378983440925367e-05
153480 O 0 2.789492555166362e-06
) O 0 1.1807759214832458e-08
. O 0 7.296716830751393e-08

Constitutive O 0 3.821568043349544e-06
DNA O 0 8.813430696363866e-08
from O 0 4.5628061329239245e-09
37 O 0 7.284295833187571e-09
CD B-Disease 0 1.7077633529538616e-08
families O 0 3.29792235187476e-11
and O 0 1.0728358479372702e-10
seven O 0 7.005369062618172e-10
BZS B-Disease 0 7.645302844139223e-07
families O 0 4.830736852201589e-11
was O 0 5.787422097114359e-09
screened O 0 1.2179069308615453e-08
for O 0 8.365436343638066e-09
germline O 0 1.2383333341858815e-05
PTEN O 0 0.00016919587505981326
mutations O 0 2.49074923885928e-06
. O 0 1.3310705071489792e-06

PTEN O 0 0.00011890026507899165
mutations O 0 4.472721215620368e-08
were O 0 8.1375111093962e-09
identified O 0 1.7658113860008484e-09
in O 0 3.8013936443093144e-10
30 O 0 4.79547113130252e-09
of O 0 1.426299345297366e-08
37 O 0 2.215032068875189e-08
( O 0 1.4277894144765213e-10
81 O 0 3.872218545808437e-09
% O 0 6.279209791015816e-11
) O 0 5.215265719282769e-12
CD B-Disease 0 2.6165334343630775e-09
families O 0 6.425073580812457e-12
, O 0 7.858423113626944e-12
including O 0 5.599436192493812e-11
missense O 0 5.346564790897901e-08
and O 0 4.46472414594723e-09
nonsense O 0 9.63927163866174e-07
point O 0 7.60268164867739e-07
mutations O 0 1.2569192353595326e-09
, O 0 2.357288808596536e-10
deletions O 0 4.083774651775229e-09
, O 0 5.685773518671056e-10
insertions O 0 2.445432478737075e-08
, O 0 3.06503555869142e-09
a O 0 7.942792201731663e-09
deletion O 0 2.32357990626042e-07
/ O 0 5.180349376132654e-07
insertion O 0 2.893110320201231e-07
and O 0 1.510379377123172e-08
splice O 0 1.5317016277549556e-06
site O 0 1.4079860477522743e-07
mutations O 0 2.8546148200803145e-07
. O 0 6.188014936014952e-07

These O 0 9.428593017446474e-09
mutations O 0 8.543504570468485e-09
were O 0 1.828687867799772e-09
scattered O 0 7.391062206707488e-10
over O 0 1.9122849137520603e-10
the O 0 4.454352997562694e-10
entire O 0 4.32457003540776e-09
length O 0 1.3542561516644014e-09
of O 0 6.118731299409319e-09
PTEN O 0 6.374659733410226e-08
, O 0 8.700045545095847e-11
with O 0 1.4062696319927515e-11
the O 0 3.180839480698694e-10
exception O 0 1.0053502474960396e-09
of O 0 1.3204144444500798e-09
the O 0 9.653801091857872e-10
first O 0 1.10202358349909e-09
, O 0 2.4440358070698665e-10
fourth O 0 1.3087260164468262e-08
and O 0 1.3670246046260104e-09
last O 0 5.6763301614637385e-08
exons O 0 1.0669973562471569e-06
. O 0 1.2454740954126464e-06

A O 0 3.569326509023085e-05
hot O 0 5.2352021157275885e-05
spot O 0 1.752325033521629e-06
for O 0 2.2274623034945762e-08
PTEN O 0 1.9455549136182526e-06
mutation O 0 3.433010986597651e-09
in O 0 3.4549707539355268e-09
CD B-Disease 0 2.8821389719269064e-07
was O 0 3.418729477289162e-07
identified O 0 1.1995671123088414e-08
in O 0 5.793385771113435e-09
exon O 0 1.0974999753443626e-07
5 O 0 6.184578626999837e-09
that O 0 3.93966526068823e-11
contains O 0 2.098303301945048e-11
the O 0 1.531724330705586e-10
PTPase O 0 9.714468518495778e-08
core O 0 7.938388080219738e-08
motif O 0 3.3230123097638398e-09
, O 0 5.454514617753148e-11
with O 0 2.4756424341076944e-11
13 O 0 3.9229557380338065e-09
of O 0 1.279848937940642e-08
30 O 0 1.7626760495659255e-08
( O 0 1.2247473868409742e-10
43 O 0 3.436194884187671e-09
% O 0 1.0126319921477389e-10
) O 0 5.748799700167062e-11
CD B-Disease 0 3.9979585864102773e-08
mutations O 0 2.986790370584913e-09
identified O 0 6.494797588629808e-09
in O 0 8.53278447898731e-10
this O 0 1.7692906029154187e-09
exon O 0 2.6527993668423733e-06
. O 0 1.5141412745833804e-07

Seven O 0 4.086379590262368e-07
of O 0 2.92072741103766e-07
30 O 0 9.230495834344765e-08
( O 0 3.9967421039399653e-10
23 O 0 8.531373829612221e-09
% O 0 1.7808587937651055e-10
) O 0 5.7175250645080666e-11
were O 0 5.515593537452901e-10
within O 0 2.4676400922629682e-09
the O 0 1.6370194089176948e-09
core O 0 6.723191603441592e-08
motif O 0 2.3413198046995376e-09
, O 0 3.2484282624922756e-11
the O 0 7.260555351384923e-11
majority O 0 3.8025159410093323e-11
( O 0 2.1519341864006947e-11
five O 0 1.5322151880603485e-10
of O 0 2.317629421710876e-09
seven O 0 2.9413019242419125e-10
) O 0 1.0622351956368625e-11
of O 0 5.493786536803213e-10
which O 0 2.5099035697029315e-11
were O 0 1.7491182946471895e-09
missense O 0 7.568926463363823e-08
mutations O 0 2.6309610046126863e-09
, O 0 6.455729284482459e-10
possibly O 0 4.642737749804837e-09
pointing O 0 5.1704876824487656e-08
to O 0 2.9287619551787714e-10
the O 0 9.546209378541448e-10
functional O 0 9.310701898357365e-08
significance O 0 1.3299187529014489e-08
of O 0 3.5184266611310022e-09
this O 0 2.1808260752820274e-10
region O 0 1.112543834835833e-08
. O 0 2.809290755578786e-08

Germline O 0 0.0005571945803239942
PTEN O 0 4.490447463467717e-05
mutations O 0 2.710587487797511e-08
were O 0 4.9681592173556055e-09
identified O 0 2.0029580216629483e-09
in O 0 4.960033495038374e-10
four O 0 6.31460772559933e-10
of O 0 8.524363437345528e-09
seven O 0 1.2028955609366676e-09
( O 0 1.5620740811961298e-11
57 O 0 2.245218455598774e-09
% O 0 6.571390098741858e-10
) O 0 1.0807806871682146e-09
BZS B-Disease 0 3.955128704546951e-05
families O 0 6.061419366432119e-09
studied O 0 3.132842039121897e-06
. O 0 2.0458564620184916e-07

Interestingly O 0 2.9641023502335884e-06
, O 0 1.3498342887885428e-08
none O 0 8.341711321691037e-09
of O 0 4.6324504232586605e-09
these O 0 1.3418982591772988e-10
mutations O 0 5.177459017069452e-10
was O 0 2.8246340821880267e-09
observed O 0 9.277101864491044e-10
in O 0 1.8016926839337088e-10
the O 0 1.1015948153669797e-09
PTPase O 0 7.21225660527125e-07
core O 0 6.513501489280316e-07
motif O 0 3.9094268799999554e-07
. O 0 9.039953141609658e-08

It O 0 3.412865012819566e-08
is O 0 7.573569549279568e-10
also O 0 2.2761893758715956e-10
worthy O 0 3.756513322628052e-09
of O 0 1.9902841597030374e-09
note O 0 8.315750310572412e-10
that O 0 1.9007314819297072e-11
a O 0 2.1797075255847176e-10
single O 0 3.11824566168184e-10
nonsense O 0 7.418341141374185e-08
point O 0 3.794689718006339e-08
mutation O 0 5.56530030393354e-11
, O 0 3.8152585257744676e-11
R233X O 0 1.7891600423425302e-09
, O 0 5.881650722017184e-11
was O 0 1.4941438086779613e-09
observed O 0 7.847856253739849e-10
in O 0 3.748588384144824e-10
the O 0 6.501548743820251e-10
germline O 0 2.480068594934437e-09
DNA O 0 9.388785304764724e-10
from O 0 1.7783570449569908e-10
two O 0 2.1739559805111774e-11
unrelated O 0 6.093816007357589e-10
CD B-Disease 0 9.40662570059203e-09
families O 0 4.720264110136263e-11
and O 0 4.386884189244711e-10
one O 0 3.6353862142846083e-09
BZS B-Disease 0 7.758927677059546e-05
family O 0 1.9659448469155905e-07
. O 0 3.272325557190925e-07

Genotype O 0 3.177930921083316e-06
- O 0 1.8911950405708922e-07
phenotype O 0 4.183537960500416e-09
studies O 0 1.0680608619750842e-09
were O 0 2.2061626137048762e-10
not O 0 7.590453439398903e-12
performed O 0 1.7855932010757414e-10
on O 0 8.460264155907282e-10
this O 0 5.8810521556817985e-12
small O 0 2.4876321488842557e-11
group O 0 7.563071002802957e-11
of O 0 1.2612713540249842e-08
BZS B-Disease 0 9.11792230908759e-05
families O 0 6.562050014480292e-09
. O 0 6.485218762009026e-08

However O 0 2.9248082000776776e-07
, O 0 8.88943230137329e-09
genotype O 0 3.2911913194766385e-08
- O 0 3.2146609818539673e-09
phenotype O 0 4.063764602602049e-10
analysis O 0 8.493231118400502e-10
inthe O 0 1.6218483267493866e-07
group O 0 7.241183208606117e-10
of O 0 9.075487028553653e-09
CD B-Disease 0 1.4617917258874513e-06
families O 0 3.670647119591308e-10
revealed O 0 2.3448921027124925e-08
two O 0 8.621826863564053e-11
possible O 0 1.259102128114975e-10
associations O 0 4.9444455474390026e-11
worthy O 0 1.4406525972177064e-09
of O 0 1.6958370263608913e-09
follow O 0 1.2014533812276795e-09
- O 0 1.8130281720374342e-09
up O 0 4.144262988337033e-10
in O 0 1.7293792786698958e-10
independent O 0 3.633380818435228e-10
analyses O 0 1.4129988734623566e-08
. O 0 3.493618905281437e-08

The O 0 1.4042342399989138e-06
first O 0 5.433890137851449e-08
was O 0 1.9351132607425825e-07
an O 0 5.305225148077852e-10
association O 0 9.176963633450441e-10
noted O 0 1.2062937315704403e-09
in O 0 5.960159449314162e-11
the O 0 1.6757244203358113e-10
group O 0 2.812460334067346e-11
of O 0 1.3444427793274372e-09
CD B-Disease 0 2.1992848360241624e-06
families O 0 2.742295834856634e-10
with O 0 1.0104662884202753e-08
breast B-Disease 1 0.9999480247497559
disease I-Disease 1 0.9997115731239319
. O 0 2.5806591565924464e-06

A O 0 8.477715596200142e-07
correlation O 0 2.3085517852905468e-07
was O 0 1.9999475853182958e-07
observed O 0 2.8716412359131027e-08
between O 0 5.882834219761435e-09
the O 0 7.236392596254859e-10
presence O 0 2.9118305544528766e-09
/ O 0 5.7088929139581523e-08
absence O 0 2.4522782382518926e-07
of O 0 1.3469183102188254e-07
a O 0 5.5994764380784545e-08
PTEN O 0 2.0366653643577592e-06
mutation O 0 2.9624958042262506e-09
and O 0 1.7180433464769607e-10
the O 0 2.0034421344128361e-10
type O 0 6.152554732352655e-08
of O 0 2.3277895877527044e-07
breast O 0 9.6427784228581e-06
involvement O 0 7.289744189620251e-06
( O 0 1.013328532195601e-08
unaffected O 0 2.740667696343735e-06
versus O 0 0.009659946896135807
benign O 0 0.10397352278232574
versus O 0 0.004127344116568565
malignant O 0 0.0005873218178749084
) O 0 1.8291633097078375e-08
. O 0 1.0151221374599118e-07

Specifically O 0 7.55773100991064e-07
and O 0 3.800165160328106e-08
more O 0 2.528268705503933e-10
directly O 0 1.2474516974947392e-09
, O 0 6.654620604562567e-11
an O 0 4.705710474062208e-11
association O 0 1.014031858481701e-09
was O 0 3.2995256304957366e-08
also O 0 8.631551029480988e-11
observed O 0 5.379826029106027e-10
between O 0 7.728618300895107e-10
the O 0 1.1297156959910737e-10
presence O 0 1.2982082076007373e-10
of O 0 1.7620535031070972e-09
a O 0 2.3705504226256835e-09
PTEN O 0 1.85163280548295e-05
mutation O 0 1.8611291352499393e-07
and O 0 5.378199574579412e-08
malignant B-Disease 1 0.9999978542327881
breast I-Disease 1 0.9999966621398926
disease I-Disease 1 0.9998520612716675
. O 0 3.56608438778494e-06

Secondly O 0 0.00024034980742726475
, O 0 2.112710006940688e-07
there O 0 1.781387126698064e-08
appeared O 0 2.5406754033951984e-08
to O 0 1.3418521849217768e-10
be O 0 8.844454335577012e-11
an O 0 1.3621073713387943e-10
interdependent O 0 6.73123622618732e-07
association O 0 8.587014121985703e-08
between O 0 3.9505528093286557e-07
mutations O 0 1.9108211901652794e-08
upstream O 0 4.415657173240106e-08
and O 0 6.978190802975348e-10
within O 0 7.648684352545843e-09
the O 0 8.765146830569392e-09
PTPase O 0 3.54788858203392e-06
core O 0 3.663345751192537e-06
motif O 0 1.3382297936459508e-07
, O 0 5.497129973441872e-10
the O 0 4.32894192714528e-10
core O 0 1.7813393426990842e-08
motif O 0 8.196544554195384e-10
containing O 0 9.583124224721296e-12
the O 0 3.924717842385128e-11
majority O 0 5.310973535954666e-11
of O 0 5.491861632123118e-09
missense O 0 5.4791936321407775e-08
mutations O 0 1.6034165106759701e-09
, O 0 1.1334950339447758e-10
and O 0 2.6465506869355337e-11
the O 0 3.3926639275705384e-10
involvement O 0 1.909844726810661e-08
of O 0 8.716813937326151e-09
all O 0 1.5023617072618123e-10
major O 0 2.9217612773635437e-09
organ O 0 0.008400890044867992
systems O 1 0.9999834299087524
( O 0 3.3252188131882576e-06
central O 1 0.9998012185096741
nervous O 1 0.9991390705108643
system O 1 0.9999915361404419
, O 0 0.00017404310347046703
thyroid O 1 1.0
, O 0 0.003144684247672558
breast O 1 1.0
, O 0 0.01720304973423481
skin O 1 1.0
and O 1 0.9999779462814331
gastrointestinal O 1 1.0
tract O 1 0.9999973773956299
) O 0 1.240836240867793e-06
. O 0 3.6822111724177375e-06

However O 0 5.393463879954652e-07
, O 0 7.013514657927544e-09
these O 0 1.0947158457508266e-10
observations O 0 7.763386378201176e-09
would O 0 9.466755157561124e-10
need O 0 6.863062895767769e-10
to O 0 4.023142236020405e-11
be O 0 1.965950666149574e-11
confirmed O 0 4.308363041327645e-11
by O 0 1.30163909164982e-11
studying O 0 5.6047633201217195e-09
a O 0 2.3506530055783514e-10
larger O 0 4.004225423459573e-11
number O 0 4.8808977692882394e-11
of O 0 2.0222128416236274e-09
CD B-Disease 0 2.62175348098026e-07
families O 0 2.0219197427451263e-09
. O 0 2.6622648974239382e-08

Molecular O 0 0.25103560090065
defects O 1 0.9998843669891357
leading O 0 1.8188205785918399e-06
to O 0 3.2248554937552854e-09
human O 0 1.340871591537507e-07
complement B-Disease 0 1.885016172309406e-05
component I-Disease 1 0.9999998807907104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.6205056851958943e-08
an O 0 8.436620846374865e-11
African O 0 9.734937300720503e-10
- O 0 2.007203070419905e-09
American O 0 9.948720736119299e-10
family O 0 4.5214193500342503e-10
. O 0 5.133634406462306e-09

Complement B-Disease 0 0.0004032586875837296
component I-Disease 1 0.9999979734420776
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.4780059132135648e-07
C6D B-Disease 0 9.425785719940905e-06
) O 0 7.796756018585427e-10
was O 0 3.7143653486282346e-08
diagnosed O 0 1.7246811978566257e-07
in O 0 3.9291636610983005e-09
a O 0 2.6404776143351683e-09
16 O 0 4.148923427038653e-09
- O 0 7.151376713032676e-10
year O 0 5.545593984024322e-10
- O 0 1.9067754042367824e-09
old O 0 2.2279678546510695e-08
African O 0 2.0184980353832316e-09
- O 0 2.630493045607807e-10
American O 0 3.881028484697957e-11
male O 0 4.685317758768015e-11
with O 0 4.0546907498217877e-10
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.5168569689194555e-07

The O 0 8.639360089546244e-07
patients O 0 2.663758777998737e-07
father O 0 4.032129652387084e-07
and O 0 1.1058900462046495e-08
two O 0 2.9409459756379874e-08
brothers O 0 5.520261083802325e-07
also O 0 1.2566489182574969e-08
had O 0 2.6443555611876945e-07
C6D B-Disease 0 0.0006946641951799393
, O 0 1.1478021866295762e-09
but O 0 1.2164917684298615e-10
gave O 0 2.305288182569143e-10
no O 0 6.806923774638207e-11
history O 0 1.6123460899741815e-10
of O 0 2.893472350606885e-09
meningitis B-Disease 1 0.9999716281890869
or O 0 1.7851743694397015e-10
other O 0 7.085225461889166e-11
neisserial B-Disease 0 4.537657218861568e-07
infection I-Disease 0 1.313515895162709e-06
. O 0 5.044262962883295e-08

By O 0 5.068621966586306e-09
using O 0 1.5003902120724888e-08
exon O 0 6.890837767059566e-08
- O 0 3.887246080580553e-10
specific O 0 1.1094446195070162e-10
polymerase O 0 7.820992742324506e-09
chain O 0 9.382304932969987e-10
reaction O 0 2.0351111421068602e-11
( O 0 1.2219583851724725e-11
PCR O 0 1.2296676177303567e-10
) O 0 2.1294693439144474e-11
/ O 0 4.293484179296314e-10
single O 0 3.2908739622250494e-10
- O 0 2.4775816953592766e-09
strand O 0 6.658433249207008e-10
conformation O 0 1.2789086456521659e-09
polymorphism O 0 8.61719473554956e-10
as O 0 5.2957190715963165e-11
a O 0 1.20034347045328e-11
screening O 0 1.0729320210067783e-10
step O 0 1.3138919119359826e-10
and O 0 9.044782284250985e-12
nucleotide O 0 1.1109967806843812e-10
sequencing O 0 2.8564028919930706e-10
of O 0 3.772467671581126e-09
target O 0 3.39855299458236e-09
exons O 0 2.448036440227952e-08
, O 0 2.2205342009584683e-09
we O 0 1.0066396605168393e-09
determined O 0 2.837599488714204e-09
that O 0 3.700224848746103e-11
the O 0 2.0650600673910446e-10
proband O 0 7.237848365093669e-08
was O 0 1.6544539960250404e-08
a O 0 5.402128189224698e-10
compound O 0 2.3370101409625477e-09
heterozygote O 0 2.975754931355823e-08
for O 0 1.8219894482029986e-09
two O 0 1.1991965642721425e-08
C6 O 0 7.653434295207262e-05
gene O 0 2.631590518831217e-07
mutations O 0 1.248247798457669e-07
. O 0 2.6091248628290487e-07

The O 0 3.180273040470638e-07
first O 0 1.473437016841217e-08
, O 0 6.607952518500326e-10
1195delC O 0 1.675457639294109e-08
located O 0 3.3414053746128047e-09
in O 0 4.631099059793087e-09
exon O 0 4.701277021013084e-07
7 O 0 2.5250142243748996e-07
, O 0 2.0836208314278792e-09
is O 0 1.955241663020857e-10
a O 0 3.5061520353707465e-10
novel O 0 1.5379071627297236e-10
mutation O 0 4.5110627039379736e-11
, O 0 5.767096869502275e-11
while O 0 1.7205879776494015e-10
the O 0 3.598442099850274e-10
second O 0 9.722522786859145e-10
, O 0 5.1985037802237954e-11
1936delG O 0 4.546890419732108e-09
in O 0 2.5439086392964327e-09
exon O 0 6.301666388708327e-08
12 O 0 3.16755368601207e-08
, O 0 4.682113030618495e-10
has O 0 6.77608108512473e-11
been O 0 2.3133707449662921e-10
described O 0 3.57234630765646e-10
before O 0 4.901125616463275e-10
to O 0 9.166008230199196e-11
cause O 0 1.7435556332046076e-09
C6D B-Disease 0 1.806133553827749e-07
in O 0 5.864144725364895e-10
an O 0 6.410925956767954e-11
unrelated O 0 1.8126003809015856e-08
African O 0 6.022525589344241e-09
- O 0 2.247026342772074e-09
American O 0 8.721998123739638e-10
individual O 0 4.323825464336295e-10
. O 0 2.8424166131912898e-08

Both O 0 1.0372268377523142e-07
mutations O 0 4.5313782948142034e-08
result O 0 4.354457683319879e-09
in O 0 1.4733378961295784e-09
premature O 0 1.795050508235363e-08
termination O 0 2.3346499844478785e-08
codons O 0 3.886019328547263e-08
and O 0 5.769599908944656e-09
C6 O 0 7.214992820081534e-06
null O 0 2.5770411866687937e-06
alleles O 0 2.035351656104467e-07
. O 0 5.423690367933887e-07

Allele O 0 3.2881487754821137e-07
- O 0 1.3871128246023545e-08
specific O 0 5.979725048455009e-10
PCR O 0 4.765472905177148e-09
indicated O 0 2.446326918814634e-09
that O 0 1.7888067763149884e-11
the O 0 4.06616046388919e-10
probands O 0 2.0976666803562694e-07
two O 0 4.957822152817926e-09
brothers O 0 2.981020585934857e-08
also O 0 3.513482282890834e-10
inherited O 0 2.6987327927940896e-08
the O 0 6.71592204071203e-09
1195delC O 0 3.0157227826066446e-08
mutation O 0 1.357594314743693e-10
from O 0 1.3040303559197497e-10
their O 0 3.6848992607252384e-11
heterozygous O 0 2.9245197930016786e-10
mother O 0 3.648248647625252e-10
and O 0 6.69467259406531e-11
the O 0 2.3550505989788917e-10
1936delG O 0 4.768327954707274e-09
mutation O 0 8.650389432540706e-11
from O 0 1.7969670196293919e-10
their O 0 4.4889699596373234e-11
homozygous O 0 1.620517164901969e-09
father O 0 1.552971262697156e-08
. O 0 2.4952855337545543e-09
. O 0 3.220756994437579e-08

PAX6 O 0 0.002483790973201394
mutations O 0 2.7276405489828903e-06
reviewed O 0 4.712436293630162e-06
. O 0 2.1749913230451057e-06

Mutations O 0 2.1030039079050766e-06
in O 0 2.2900076146470383e-07
PAX6 O 0 7.548675057478249e-05
are O 0 1.0807951200675348e-09
responsible O 0 7.00952940135835e-09
for O 0 7.076599306543585e-10
human O 0 1.9268777862180286e-07
aniridia B-Disease 1 1.0
and O 0 7.417011715915578e-08
have O 0 2.9819050006985037e-10
also O 0 1.3783678191880977e-11
been O 0 7.646149338680353e-12
found O 0 2.224049069909917e-12
in O 0 1.2129827307513774e-12
patients O 0 3.7906019469124974e-12
with O 0 1.4978688428479714e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.267800944925739e-09
with O 0 2.435049282212276e-07
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 4.476974208955653e-05
with O 0 4.844741397391772e-06
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 3.738938048059026e-08
and O 0 3.6287979288118777e-09
with O 0 7.702696080968963e-08
isolated B-Disease 1 0.9999998807907104
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.9810549020767212

No O 0 9.173154467134736e-07
locus O 0 1.2162452378561284e-07
other O 0 1.6052157381096777e-09
than O 0 3.5830599598440926e-10
chromosome O 0 1.053064124789671e-08
11p13 O 0 3.2338562050426845e-08
has O 0 1.2752421341133413e-10
been O 0 1.642642272203787e-10
implicated O 0 2.7991695628060143e-09
in O 0 2.436473467426481e-09
aniridia B-Disease 1 1.0
, O 0 6.4121556953011805e-09
and O 0 4.96634022795206e-09
PAX6 O 0 1.720986438158434e-05
is O 0 3.0316908983252233e-09
clearly O 0 2.7954667469742844e-09
the O 0 7.12552072901218e-10
major O 0 5.487505561063699e-09
, O 0 1.2935219562137945e-10
if O 0 3.059939107652454e-11
not O 0 6.908036642716553e-12
only O 0 1.5861678290263193e-11
, O 0 1.783805221589052e-11
gene O 0 3.682259497317375e-10
responsible O 0 1.7776365268673544e-08
. O 0 1.1000652477832773e-07

Twenty O 0 5.178727406018879e-06
- O 0 1.7575774791112053e-07
eight O 0 7.052671779916864e-09
percent O 0 2.2095831830881707e-09
of O 0 3.9011749386475e-09
identified O 0 1.660390935853684e-08
PAX6 O 0 5.260319539956981e-06
mutations O 0 1.4014093885350576e-08
are O 0 3.6027206218314234e-10
C O 0 4.219435595587129e-06
- O 0 2.8216695113769674e-07
T O 0 2.6155225896218326e-07
changes O 0 1.0939488426231492e-08
at O 0 1.0827541530034068e-07
CpG O 0 5.076703502027158e-08
dinucleotides O 0 7.418623937383018e-08
, O 0 2.1194092314491542e-10
20 O 0 3.1356611751576224e-10
% O 0 1.062853277611353e-11
are O 0 4.402697390687438e-12
splicing O 0 7.209513541717172e-10
errors O 0 1.2723837983230624e-08
, O 0 2.1180514286900376e-10
and O 0 5.5470301962845525e-11
more O 0 9.789708106666684e-12
than O 0 1.1436555695520934e-11
30 O 0 1.916498626464147e-10
% O 0 7.175374877599339e-12
are O 0 1.6925739238990434e-12
deletion O 0 1.7548650033116786e-10
or O 0 1.4541959303393526e-10
insertion O 0 4.12035161545532e-09
events O 0 1.8179845184818078e-08
. O 0 1.5444823020516196e-07

There O 0 4.5172131990511843e-07
is O 0 1.001163862923704e-08
a O 0 4.366958794577158e-09
noticeably O 0 8.87171935914921e-08
elevated O 0 1.7117199035965314e-07
level O 0 1.325064147295052e-07
of O 0 1.413759065371778e-08
mutation O 0 2.1171869812874888e-10
in O 0 2.4795471231797706e-10
the O 0 5.54745638314813e-10
paired O 0 1.4256865688011544e-09
domain O 0 6.475550318185697e-09
compared O 0 6.475694980245805e-10
with O 0 1.2648765368439285e-10
the O 0 2.2751791561859136e-09
rest O 0 7.278435187885179e-09
of O 0 4.297452171897476e-09
the O 0 3.810295634565364e-09
gene O 0 1.1391443344166419e-08
. O 0 5.943753222936721e-08

Increased O 0 3.4247133129383656e-08
mutation O 0 7.615959418671991e-09
in O 0 1.3912614393873923e-09
the O 0 6.04278804772207e-09
homeodomain O 0 3.239894397211174e-07
is O 0 1.786482350940588e-10
accounted O 0 1.387530201846232e-09
for O 0 6.664833268610337e-11
by O 0 5.3138105027272786e-11
the O 0 2.8664464135630396e-09
hypermutable O 0 4.1993052946054377e-07
CpG O 0 4.1893054003594443e-07
dinucleotide O 0 2.638637113250297e-07
in O 0 8.938671136604626e-09
codon O 0 1.6099792787827027e-07
240 O 0 2.3509450386427488e-07
. O 0 1.3020847688949289e-07

Very O 0 3.714181957548135e-07
nearly O 0 1.3199039194944362e-08
all O 0 5.256956536747737e-10
mutations O 0 1.4874473874826322e-09
appear O 0 1.564908758133754e-09
to O 0 1.1720373283008456e-10
cause O 0 4.003084086434683e-09
loss O 0 4.066294412297111e-09
of O 0 2.4445604651646136e-08
function O 0 1.437068419818388e-07
of O 0 9.057453809191429e-08
the O 0 1.5373036177379618e-09
mutant O 0 8.045770716336165e-10
allele O 0 1.8806603496734908e-10
, O 0 5.250430298864295e-11
and O 0 8.497726827760843e-12
more O 0 1.3578699796512606e-12
than O 0 2.087587698193505e-12
80 O 0 3.949445978590482e-11
% O 0 8.73432576264932e-12
of O 0 2.1264427718659107e-10
exonic O 0 1.572806418437267e-08
substitutions O 0 1.5041115020153484e-09
result O 0 8.82703299343035e-10
in O 0 1.347767786263887e-09
nonsense O 0 8.059079448230477e-08
codons O 0 1.208915989536763e-07
. O 0 1.1762693929995294e-07

In O 0 5.04857041505602e-07
a O 0 1.032948588886029e-07
gene O 0 3.915965329781557e-09
with O 0 7.37989114263371e-10
such O 0 2.37912045619737e-09
extraordinarily O 0 2.5329441655230767e-07
high O 0 3.7454618961874075e-08
sequence O 0 3.403377579758171e-10
conservation O 0 2.3723992215174405e-10
throughout O 0 6.039532762791566e-11
evolution O 0 7.659878287213928e-10
, O 0 1.7165879828695552e-11
there O 0 3.9119676248366986e-11
are O 0 1.8016265562748046e-11
presumed O 0 1.0480630407982972e-07
undiscovered O 0 2.5977735276683234e-05
missense O 0 3.069418426093762e-06
mutations O 0 2.056144410289562e-08
, O 0 9.863808658749917e-10
these O 0 8.297684067626321e-11
are O 0 1.866308670106509e-11
hypothesized O 0 1.3306387103284578e-09
to O 0 6.556375581334706e-11
exist O 0 1.385208503457136e-09
in O 0 1.8495417419828186e-09
as O 0 4.2442431791300805e-09
- O 0 1.5434890698884374e-08
yet O 0 2.3088053691111554e-09
unidentified O 0 4.275159781741422e-08
phenotypes O 0 1.0592363430816931e-08
. O 0 1.0289441521038611e-09
. O 0 4.0769201348211936e-08

Genetic O 0 1.0114422366314102e-06
heterogeneity O 0 5.091617936159309e-07
and O 0 2.3234452140030726e-09
penetrance O 0 2.842097330812976e-07
analysis O 0 5.301890038111878e-09
of O 0 9.170738834995973e-09
the O 0 5.995167917660638e-09
BRCA1 O 0 2.0944877832107522e-08
and O 0 2.5163580108511496e-09
BRCA2 O 0 1.905481994413094e-08
genes O 0 8.107286397773805e-09
in O 0 8.41799963069434e-09
breast B-Disease 0 1.827587948355358e-05
cancer I-Disease 0 3.3423048080294393e-06
families O 0 5.702411876029601e-10
. O 0 1.0522814619662313e-07

The O 0 3.295110946055502e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.997058567823842e-05
Consortium O 0 2.2946706224047375e-07
. O 0 7.122958578520411e-08

The O 0 6.9118430978676315e-09
contribution O 0 6.675756392127141e-09
of O 0 8.440849796897965e-08
BRCA1 O 0 4.363914030136584e-08
and O 0 5.030549754536651e-09
BRCA2 O 0 9.025550440355801e-08
to O 0 2.6888531579061237e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.06520715355873108
assessed O 0 9.42514475354983e-08
by O 0 1.3544466936910027e-10
linkage O 0 6.23296569912668e-09
and O 0 2.6260351532192416e-11
mutation O 0 1.0855022609945753e-11
analysis O 0 3.2944331290751805e-11
in O 0 5.0851951122199424e-11
237 O 0 2.9945065871395116e-10
families O 0 7.620946408659623e-12
, O 0 6.404713998736655e-12
each O 0 3.739308342132208e-12
with O 0 2.6590282059535397e-11
at O 0 2.3220289691039397e-08
least O 0 1.1756284834518738e-10
four O 0 3.842073534321422e-11
cases O 0 1.364598573028175e-10
of O 0 1.0983560727595432e-08
breast B-Disease 0 1.7003616221700213e-06
cancer I-Disease 0 2.085169086285532e-07
, O 0 1.6412080028338494e-10
collected O 0 4.339330630931393e-11
by O 0 7.276998448269012e-11
the O 0 7.464625895181598e-08
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 1.3311999282450415e-05
Consortium O 0 1.302016556792296e-07
. O 0 4.146528453929932e-08

Families O 0 8.053006261832252e-09
were O 0 6.093040294530283e-09
included O 0 8.216846647535192e-10
without O 0 1.0978109532544522e-09
regard O 0 1.47725764954032e-09
to O 0 1.772315107173572e-11
the O 0 5.7149195098471495e-11
occurrence O 0 8.569847054218371e-09
of O 0 3.2516322789888363e-07
ovarian B-Disease 1 0.9835202097892761
or I-Disease 0 1.4059909290153882e-06
other I-Disease 0 3.945029334317951e-07
cancers I-Disease 1 0.9993829727172852
. O 0 4.193700988253113e-06

Overall O 0 4.168206487520365e-06
, O 0 8.740676094021183e-08
disease O 0 3.921374627680052e-06
was O 0 4.895543384009216e-07
linked O 0 6.35569676887826e-08
to O 0 6.413007902494883e-10
BRCA1 O 0 1.6132390978640387e-09
in O 0 4.186760660385147e-10
an O 0 2.7728526072468007e-11
estimated O 0 8.266706069681717e-11
52 O 0 7.871542306858714e-10
% O 0 1.1280792966417152e-10
of O 0 6.1014948649074086e-09
families O 0 3.865315012507864e-11
, O 0 1.074824673708008e-10
to O 0 1.0293832453101004e-10
BRCA2 O 0 5.145827097763345e-10
in O 0 3.843929896607534e-10
32 O 0 1.7545612740477168e-09
% O 0 8.405684481793685e-11
of O 0 2.4457484926188044e-09
families O 0 2.121920000819344e-11
, O 0 3.093228798101144e-11
and O 0 2.2782296882351005e-11
to O 0 3.733217207591011e-11
neither O 0 1.1223366680468416e-09
gene O 0 1.180081171670011e-10
in O 0 9.371144971126455e-10
16 O 0 5.325941465628148e-09
% O 0 9.233300929389898e-11
( O 0 2.1907767266959866e-11
95 O 0 2.2589812243012375e-09
% O 0 7.263994405981578e-10
confidence O 0 6.883782788236203e-08
interval O 0 1.9879865931216045e-07
[ O 0 3.3130081789067845e-08
CI O 0 1.8381397239863873e-06
] O 0 2.542808630323634e-08
6 O 0 3.407323490023373e-08
% O 0 5.101820077513253e-10
- O 0 1.7722020517751957e-09
28 O 0 6.05475181103543e-09
% O 0 1.7577056476980601e-10
) O 0 3.921148475360958e-11
, O 0 6.069904995298359e-11
suggesting O 0 7.764122678111107e-10
other O 0 2.8575744548398063e-10
predisposition O 0 1.3087689865187713e-07
genes O 0 1.1655383502784389e-07
. O 0 2.3059639886469085e-07

The O 0 1.53480456788202e-07
majority O 0 6.22443607767309e-09
( O 0 3.089898337194086e-10
81 O 0 4.102957529283913e-09
% O 0 9.735007244771055e-11
) O 0 3.134726506148766e-11
of O 0 6.40090158654516e-09
the O 0 3.7003474062657915e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.806280232282916e-09
were O 0 2.2925952247732084e-09
due O 0 2.980315727540983e-08
to O 0 2.8551935815634977e-10
BRCA1 O 0 1.7099553717425664e-10
, O 0 1.850834936700796e-11
with O 0 7.626588596765238e-12
most O 0 7.16088646712798e-11
others O 0 7.896470283208501e-11
( O 0 5.510708642880724e-12
14 O 0 4.2366218866440875e-10
% O 0 3.013694155340474e-11
) O 0 2.0464147737486726e-11
due O 0 2.3714651575801327e-08
to O 0 1.1236095609490349e-08
BRCA2 O 0 3.150724694478413e-07
. O 0 3.1739645578454656e-07

Conversely O 0 1.0422694458611659e-06
, O 0 1.9610801871294825e-09
the O 0 5.746851328147784e-10
majority O 0 2.1766206892426254e-10
of O 0 3.179294383315323e-09
families O 0 3.3572626016026286e-12
with O 0 2.811811374014983e-11
male B-Disease 0 7.567018123211255e-09
and I-Disease 0 5.898698862694118e-09
female I-Disease 0 1.552980819496952e-07
breast I-Disease 0 0.02877064421772957
cancer I-Disease 0 0.05869920551776886
were O 0 1.887628741314984e-06
due O 0 0.011195516213774681
to O 0 4.428089184216333e-08
BRCA2 O 0 5.9525535611726355e-09
( O 0 1.2299139484639454e-10
76 O 0 1.746272282332484e-08
% O 0 1.1861633897325419e-09
) O 0 7.743432561824193e-10
. O 0 3.941385173789058e-08

The O 0 2.1653313808656094e-07
largest O 0 1.9052675881425785e-08
proportion O 0 1.6821297688096593e-09
( O 0 5.70280038469928e-11
67 O 0 1.3482794880559368e-09
% O 0 1.8826511530289913e-11
) O 0 4.8556757573092746e-12
of O 0 3.555569449975593e-10
families O 0 1.1463942642397917e-11
due O 0 1.3927436093297274e-08
to O 0 5.151041260198497e-10
other O 0 1.0291751478819222e-10
genes O 0 1.8455977024434134e-10
was O 0 6.885644499021737e-09
found O 0 1.922503128914954e-10
in O 0 1.9920376459481304e-10
families O 0 6.029803392704203e-12
with O 0 1.6075059686149196e-11
four O 0 3.160019190762142e-10
or O 0 5.012662507297705e-11
five O 0 8.112609542476612e-12
cases O 0 2.6993669452468616e-11
of O 0 1.6511148004383358e-09
female O 0 3.244408475211458e-08
breast B-Disease 0 2.3817041437723674e-05
cancer I-Disease 0 1.2685675756074488e-05
only O 0 1.6853073248057626e-07
. O 0 3.7305508158169687e-06

These O 0 1.2699035600860498e-08
estimates O 0 1.189056675343636e-08
were O 0 8.646929283706584e-10
not O 0 2.3397372581057674e-11
substantially O 0 6.752022829736859e-10
affected O 0 4.582311613487988e-11
either O 0 4.9806974516952707e-11
by O 0 7.869733510690313e-12
changing O 0 9.379013121701973e-10
the O 0 4.1365633141055014e-10
assumed O 0 7.552829472956546e-09
penetrance O 0 9.7455501446575e-09
model O 0 2.2591879478284227e-09
for O 0 5.128747981864024e-10
BRCA1 O 0 3.806211457124675e-10
or O 0 3.2547044920283597e-11
by O 0 2.602604243229223e-11
including O 0 2.991104308680548e-10
or O 0 1.7723575940209457e-09
excluding O 0 1.431439926591338e-07
BRCA1 O 0 4.365120886973273e-08
mutation O 0 6.9780607958591645e-09
data O 0 5.637283351234146e-08
. O 0 9.744587714521913e-08

Among O 0 8.395951489603704e-09
those O 0 3.2112829062569404e-10
families O 0 2.135757889987211e-11
with O 0 8.21830034580806e-11
disease O 0 1.634902275782224e-07
due O 0 3.0683600016345736e-07
to O 0 4.313498003227778e-09
BRCA1 O 0 6.015155040728359e-09
that O 0 1.7521224748850983e-10
were O 0 1.5499246330819005e-10
tested O 0 3.483393087866382e-11
by O 0 2.0638647041382185e-12
one O 0 4.8176128884802605e-12
of O 0 4.6183740859406797e-11
the O 0 1.3485557288916983e-11
standard O 0 4.3496162227540935e-10
screening O 0 8.616073132738933e-11
methods O 0 2.925523989727452e-10
, O 0 3.5578181026285627e-12
mutations O 0 9.383101066962052e-12
were O 0 6.057957607774611e-11
detected O 0 1.1728921167630801e-09
in O 0 7.26536192319216e-11
the O 0 4.510738449425844e-10
coding O 0 1.518536763001066e-08
sequence O 0 3.3085230111140618e-09
or O 0 4.089236449456024e-10
splice O 0 3.2061189259025014e-09
sites O 0 1.8779110211308847e-10
in O 0 2.1596038846105614e-10
an O 0 1.5859409271956615e-11
estimated O 0 1.1812860412074855e-10
63 O 0 1.9388282090915254e-09
% O 0 3.9111416882953165e-10
( O 0 1.1632381169413009e-10
95 O 0 1.8722515093827496e-08
% O 0 2.4393007613809914e-09
CI O 0 2.8226536414877046e-06
51 O 0 1.880232360917944e-07
% O 0 3.026173756026651e-09
- O 0 7.203140306444311e-09
77 O 0 9.915971155294301e-09
% O 0 8.525675720960635e-10
) O 0 4.929513464091428e-10
. O 0 1.602940358225169e-08

The O 0 1.2759592493694072e-07
estimated O 0 1.8268506707386223e-09
sensitivity O 0 1.0994124721719345e-08
was O 0 2.1495447644070964e-09
identical O 0 8.612770219240673e-11
for O 0 1.8931297501856292e-11
direct O 0 8.819034391649438e-11
sequencing O 0 1.8081615371645654e-10
and O 0 1.3364015449823796e-10
other O 0 6.543208336262651e-11
techniques O 0 2.706667032725818e-07
. O 0 4.412432730305227e-08

The O 0 3.7119511375749425e-07
penetrance O 0 2.0324692741269246e-05
of O 0 2.5121498765656725e-06
BRCA2 O 0 9.29331420707058e-08
was O 0 4.3360692814076174e-08
estimated O 0 1.5145840137620326e-10
by O 0 2.121920000819344e-11
maximizing O 0 2.2625700424327988e-08
the O 0 1.3157089640003505e-08
LOD O 0 1.8459906641510315e-05
score O 0 4.7029718786006924e-08
in O 0 3.475578935763224e-09
BRCA2 O 0 1.2461540244146363e-08
- O 0 8.330963474634245e-09
mutation O 0 4.135987385911477e-10
families O 0 1.4149924287831794e-11
, O 0 1.7704806370977266e-11
over O 0 5.7915131024266486e-11
all O 0 5.7621268867436015e-11
possible O 0 7.26143145612923e-10
penetrance O 0 8.395522854698356e-08
functions O 0 4.3441076513772714e-07
. O 0 5.461861860567296e-07

The O 0 2.169295143517047e-08
estimated O 0 1.3058278902633447e-09
cumulative O 0 2.088695083557468e-08
risk O 0 1.5329884917036907e-08
of O 0 1.4199827980121427e-08
breast B-Disease 0 1.1261653298788588e-07
cancer I-Disease 0 1.0982555309624331e-08
reached O 0 5.237106392996793e-08
28 O 0 2.439259993991527e-08
% O 0 3.01083491471843e-10
( O 0 3.778246118746331e-11
95 O 0 3.912829615870805e-09
% O 0 7.055668271860327e-10
CI O 0 9.266116194339702e-07
9 O 0 9.848439930237873e-08
% O 0 9.235330278301035e-10
- O 0 1.180352038332444e-09
44 O 0 3.937901948969369e-10
% O 0 7.01983436657283e-12
) O 0 7.9273989716383e-13
by O 0 2.483326261640273e-12
age O 0 5.728072460797762e-10
50 O 0 2.314942126879771e-10
years O 0 8.051738442649281e-11
and O 0 1.3534801751591274e-11
84 O 0 6.049461487300789e-10
% O 0 4.4044635993945036e-11
( O 0 9.046543028579102e-12
95 O 0 2.461106651807654e-09
% O 0 5.56493129355573e-10
CI O 0 4.0263424239128653e-07
43 O 0 3.2627461621359544e-08
% O 0 7.138511448623319e-10
- O 0 1.2461366383220707e-09
95 O 0 2.5906063960690062e-09
% O 0 3.621119723518085e-11
) O 0 1.897148453958164e-12
by O 0 1.0201299006917797e-11
age O 0 4.106167406092709e-09
70 O 0 5.301222572029474e-09
years O 0 1.0636803438046627e-08
. O 0 3.577729756898407e-08

The O 0 4.752151028242224e-07
corresponding O 1 0.917471706867218
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 1.6747611880418845e-05
were O 0 5.5287333822207074e-08
0 O 0 1.2316480990648415e-07
. O 0 1.8043218474872447e-08

4 O 0 1.6987504523058305e-06
% O 0 4.05767863753681e-09
( O 0 3.44478306990581e-10
95 O 0 8.982354415820737e-09
% O 0 8.437494036783733e-10
CI O 0 1.0062543651656597e-06
0 O 0 1.1232838659225308e-08
% O 0 2.78551764987256e-10
- O 0 7.452882200276179e-10
1 O 0 1.974306051977237e-09
% O 0 3.777091486800721e-12
) O 0 2.9374403300377883e-13
by O 0 7.939822302231725e-13
age O 0 2.140893989865944e-10
50 O 0 2.506651552991457e-10
years O 0 9.940465117708186e-11
and O 0 1.987664546843071e-11
27 O 0 9.929214117576635e-10
% O 0 3.9063682844009406e-11
( O 0 2.4447711216568635e-11
95 O 0 2.593731229794116e-09
% O 0 4.422260613257123e-10
CI O 0 3.659913261344627e-07
0 O 0 7.075158237057622e-09
% O 0 2.376139840443159e-10
- O 0 4.789033614116533e-10
47 O 0 1.7366919013994675e-09
% O 0 1.7992503320574116e-11
) O 0 2.988085039817845e-12
by O 0 1.2872157333088108e-11
age O 0 5.8271196756720656e-09
70 O 0 1.761338452865857e-08
years O 0 2.2822431944291566e-08
. O 0 1.0137445372038201e-07

The O 0 2.538941998864175e-07
lifetime O 0 2.67825299715696e-07
risk O 0 7.427387345160241e-07
of O 0 1.2475188668759074e-06
breast B-Disease 0 0.00037747054011560977
cancer I-Disease 0 9.926588973030448e-07
appears O 0 1.4091448008457519e-08
similar O 0 7.36548808055737e-11
to O 0 5.1268971706930344e-11
the O 0 7.52935214176631e-10
risk O 0 4.52558879260323e-09
in O 0 9.612185492002823e-10
BRCA1 O 0 1.1760238338709428e-09
carriers O 0 7.592227402319907e-10
, O 0 9.337133843878576e-11
but O 0 3.356470310023063e-11
there O 0 3.844617332826594e-11
was O 0 8.695172915018645e-10
some O 0 7.484585000383515e-12
suggestion O 0 4.905951200839809e-10
of O 0 4.3490688828029533e-10
a O 0 3.781716328976614e-10
lower O 0 9.479823148694777e-09
risk O 0 5.825430804407006e-09
in O 0 1.585997000397299e-09
BRCA2 O 0 2.388696351829367e-09
carriers O 0 2.4975901347090712e-09
< O 0 3.621208222170935e-08
50 O 0 2.9995785855163604e-09
years O 0 1.4737342457493696e-09
of O 0 4.618960325331045e-09
age O 0 1.1681466816071406e-07
. O 0 1.3532427090012789e-07

Eye B-Disease 0 0.09981346875429153
movement I-Disease 0 5.7028582887141965e-06
abnormalities I-Disease 0 7.666632882319391e-05
correlate O 0 5.249937373719149e-08
with O 0 3.2600244725955463e-10
genotype O 0 6.062797410777421e-07
in O 0 2.750732441825221e-08
autosomal O 1 0.9999957084655762
dominant O 1 0.999995231628418
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999969005584717
I I-Disease 1 0.9999858140945435
. O 0 3.5468465284793638e-06

We O 0 2.090333737214678e-07
compared O 0 1.0482650480980737e-07
horizontal O 0 2.2292829271464143e-06
eye O 0 0.0001373479753965512
movements O 0 4.77794401376741e-07
( O 0 1.378634761906028e-09
visually O 0 1.0192349186866068e-08
guided O 0 4.117055141250603e-07
saccades O 0 1.2459826166377752e-06
, O 0 3.1705318370711666e-09
antisaccades O 0 2.7767899268837937e-07
, O 0 4.031794065273431e-10
and O 0 1.4889539601270485e-10
smooth O 0 9.007681711636906e-08
pursuit O 0 3.11546664022444e-08
) O 0 3.515149629707004e-11
in O 0 1.2800037418880805e-10
control O 0 2.4002066112416287e-08
subjects O 0 5.4676370098150073e-08
( O 0 3.462686040678342e-11
n O 0 2.35612129806384e-09
= O 0 1.1691576595751485e-09
14 O 0 1.2656758974216586e-09
) O 0 1.4890469066108913e-11
and O 0 2.0516087093080948e-11
patients O 0 2.6205811826107706e-11
with O 0 3.779311065488233e-12
three O 0 1.2926630252318994e-11
forms O 0 9.586131888283944e-10
of O 0 1.089904628770455e-07
autosomal O 1 0.9994522929191589
dominant O 1 0.9990560412406921
cerebellar B-Disease 1 0.9999920129776001
ataxias I-Disease 0 0.002402374055236578
type I-Disease 0 0.0004080382641404867
I I-Disease 0 0.0011768159456551075
spinocerebellar B-Disease 0 0.00045680286712013185
ataxias I-Disease 0 1.1376425391063094e-05
1 I-Disease 0 1.3086656736049918e-06
and I-Disease 0 3.881713617204241e-09
2 I-Disease 0 5.426370819350268e-08
( O 0 1.576059976970967e-10
SCA1 B-Disease 0 1.0332914968103069e-07
, O 0 6.197989899092704e-10
n O 0 1.1289241541589945e-08
= O 0 5.434581673569028e-09
11 O 0 3.861038155861252e-09
; O 0 8.387363720219199e-11
SCA2 B-Disease 0 1.5562899591259338e-07
, O 0 1.2587304532019061e-09
n O 0 1.6126062263310814e-08
= O 0 4.947846576897064e-09
10 O 0 2.014574729258811e-09
) O 0 7.225699899526816e-11
and O 0 1.4620562538425474e-09
SCA3 B-Disease 1 1.0
/ O 0 0.0001939570502145216
Machado B-Disease 0 4.774826084030792e-05
- I-Disease 0 4.439762051333673e-06
Joseph I-Disease 0 0.0008760046330280602
disease I-Disease 0 5.7916702644433826e-05
( O 0 3.544858628856673e-09
MJD B-Disease 1 1.0
) O 0 8.299508302833658e-10
( O 0 1.3115385166795335e-10
n O 0 6.790435769232772e-09
= O 0 9.48917566745422e-09
16 O 0 1.0657903004585023e-08
) O 0 4.917980467311622e-10
. O 0 1.010001948742456e-08

In O 0 1.2532030950751505e-06
SCA1 B-Disease 0 8.45368267619051e-05
, O 0 3.764671063777314e-08
saccade O 0 4.528483543708717e-07
amplitude O 0 8.633308823391417e-08
was O 0 1.2966233420286244e-08
significantly O 0 2.0626547692081942e-10
increased O 0 1.928087377256471e-11
, O 0 4.557780368397157e-12
resulting O 0 2.0450256071891104e-11
in O 0 2.2723936621282803e-10
hypermetria B-Disease 0 4.798090458280058e-07
. O 0 1.2226787760027946e-07

The O 0 5.283721407067787e-07
smooth O 0 1.7441276213503443e-05
pursuit O 0 1.3157236935512628e-06
gain O 0 2.0082309504232398e-07
was O 0 7.879901886553853e-08
decreased O 0 1.418401325281593e-07
. O 0 4.977741951961434e-08

In O 0 2.261095914946054e-06
SCA2 B-Disease 0 0.000180683535290882
, O 0 6.427721643831319e-08
saccade O 0 7.932399626042752e-07
velocity O 0 5.780474339189823e-07
was O 0 2.0444834092359088e-07
markedly O 0 3.5195500913687283e-07
decreased O 0 4.1846175236059935e-07
. O 0 7.221493802944678e-08

The O 0 2.5291691940765304e-07
percentage O 0 2.7752810183301335e-07
of O 0 6.834591204096796e-08
errors O 0 2.058170821328531e-06
in O 0 1.479807743010042e-08
antisaccades O 0 9.367718689645699e-07
was O 0 1.2155669537605718e-07
greatly O 0 3.764820011298298e-09
increased O 0 6.210747471868672e-10
and O 0 4.187549612622021e-11
was O 0 4.0582495697272236e-10
significantly O 0 5.299023719818052e-11
correlated O 0 6.661558527021327e-10
with O 0 3.060575057278747e-11
age O 0 1.9850380894581576e-08
at O 0 4.307938752390328e-07
disease O 0 4.178041876912175e-07
onset O 0 5.465321919473354e-07
. O 0 4.5337120724298074e-08

In O 0 9.384245913679479e-08
addition O 0 9.627327379746475e-09
, O 0 4.760092320310605e-10
a O 0 5.024927696162251e-10
correlation O 0 7.074780761229249e-09
between O 0 6.643875138934163e-08
smooth O 0 5.787319878436392e-06
pursuit O 0 1.6243126310655498e-07
gain O 0 5.053630403040188e-09
and O 0 4.614825882542917e-11
the O 0 6.275892999729749e-11
number O 0 8.143651031300436e-11
of O 0 1.4772894019188243e-08
trinucleotide O 0 1.9893198555109848e-07
repeats O 0 8.851398725084891e-09
was O 0 6.745052161249987e-08
found O 0 1.6753105569478066e-08
. O 0 3.9440621435460343e-08

In O 0 1.4412752534553874e-05
SCA3 B-Disease 1 1.0
, O 0 8.765164238866419e-07
gaze B-Disease 0 0.00022025012003723532
- I-Disease 0 1.3896624295739457e-06
evoked I-Disease 0 1.1750047690384235e-07
nystagmus I-Disease 0 5.253824610917945e-07
was O 0 4.776549999974122e-08
often O 0 1.0873656836052348e-10
present O 0 3.453425739818883e-11
as O 0 5.028674004980971e-11
was O 0 5.100158517734599e-09
saccade O 0 2.1839168695692024e-08
hypometria O 0 1.371967925933859e-07
and O 0 1.4268509707093813e-09
smooth O 0 1.765373212947452e-06
pursuit O 0 8.654211569592007e-07
gain O 0 1.3375790786085417e-07
was O 0 5.979183015369927e-08
markedly O 0 6.040900046855313e-08
decreased O 0 5.279621007048263e-08
. O 0 3.053361297133961e-08

Three O 0 5.238364764181824e-08
major O 0 1.517378578341777e-08
criteria O 0 1.066904964375226e-08
, O 0 1.652781689287508e-09
saccade O 0 8.081860869424418e-08
amplitude O 0 4.41064074152564e-08
, O 0 2.4670612219779287e-09
saccade O 0 2.1616176582028857e-07
velocity O 0 1.267111997549364e-07
, O 0 6.070961511284167e-10
and O 0 6.075488029333442e-11
presence O 0 7.826599368598863e-10
of O 0 5.6231083789271e-08
gaze B-Disease 0 0.00024670988204889
- I-Disease 0 1.0663371767805074e-06
evoked I-Disease 0 6.528033935637723e-08
nystagmus I-Disease 0 3.5915476814807334e-08
, O 0 1.1845417702271988e-10
permitted O 0 5.325054841520682e-10
the O 0 4.1175685083771896e-10
correct O 0 2.894366524230918e-09
assignment O 0 3.682106841651489e-09
of O 0 5.481584963717978e-09
90 O 0 4.194332436924242e-09
% O 0 1.4288191463318611e-10
of O 0 2.3868700349538585e-09
the O 0 2.980411029085417e-09
SCA1 B-Disease 0 1.5398142068079324e-06
, O 0 2.2520064979492105e-10
90 O 0 6.976447197715174e-10
% O 0 3.853846061718791e-11
of O 0 7.168706739335562e-10
the O 0 7.835531667943485e-10
SCA2 B-Disease 0 3.3242028507629584e-07
, O 0 1.1537146238360663e-10
and O 0 1.845498233399301e-11
93 O 0 5.523942414598082e-10
% O 0 1.5073380044139384e-11
of O 0 2.2330028104367017e-10
the O 0 3.717019469995364e-10
patients O 0 7.559195491779747e-10
with O 0 7.463067941415602e-10
SCA3 B-Disease 1 1.0
to O 0 3.3386662323664495e-09
their O 0 1.4668684322760583e-10
genetically O 0 8.641912879747693e-11
confirmed O 0 1.3498586970417392e-10
patient O 0 8.824928010575661e-10
group O 0 3.0699720543481135e-10
and O 0 2.453840186600331e-10
, O 0 1.259313486823288e-10
therefore O 0 1.4114789337327238e-09
, O 0 2.437792467890887e-10
may O 0 1.1269271071867593e-09
help O 0 3.0777889126198943e-09
orient O 0 2.470122490194626e-05
diagnoses O 0 1.1184212098669377e-06
of O 0 4.4317144443084544e-07
SCA1 B-Disease 0 8.675993740325794e-05
, O 0 1.0387389615118536e-08
SCA2 B-Disease 0 4.633655862562591e-06
, O 0 1.8119254985293765e-09
and O 0 3.017637473234913e-09
SCA3 B-Disease 1 1.0
at O 0 7.793104259690153e-07
early O 0 7.842263727297905e-09
clinical O 0 5.035877492787222e-09
stages O 0 5.400338398686699e-09
of O 0 3.11512038386752e-09
the O 0 2.6485178494795036e-09
diseases O 0 3.7581028209388023e-06
. O 0 2.499405793443543e-09
. O 0 5.1908923381915884e-08

Genetic O 0 1.373546751892718e-07
basis O 0 1.686937167733049e-08
and O 0 2.625655803889515e-10
molecular O 0 2.5728265740099232e-08
mechanism O 0 4.1776476678023755e-07
for O 0 6.591380241616207e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999518394470215

Ventricular B-Disease 1 0.9999749660491943
fibrillation I-Disease 1 1.0
causes O 0 0.00032345621730200946
more O 0 1.03344222068813e-09
than O 0 1.0656409088483088e-10
300 O 0 1.204320532188774e-10
, O 0 7.835224656582707e-12
000 O 0 2.4301788359437637e-10
sudden O 0 3.571705708971251e-10
deaths O 0 4.231693467859898e-11
each O 0 5.189525892346225e-12
year O 0 4.841898063046024e-11
in O 0 1.096270435541058e-10
the O 0 1.1607851346795428e-09
USA O 0 9.915971155294301e-09
alone O 0 7.876923113769863e-09
. O 0 1.697792662014308e-08

In O 0 3.7942089647913235e-07
approximately O 0 3.6251815771493057e-08
5 O 0 3.591321728890762e-08
- O 0 2.5106723366974393e-09
12 O 0 9.559401048520044e-10
% O 0 4.437416753488854e-11
of O 0 1.000990956789849e-10
these O 0 2.182380144655216e-12
cases O 0 3.0474962831039676e-12
, O 0 1.0024229710192678e-12
there O 0 2.1739339928911194e-12
are O 0 7.022535764705795e-13
no O 0 3.8062601681598807e-11
demonstrable O 0 7.62234293461006e-08
cardiac O 0 0.005508957896381617
or O 0 3.322795691929059e-07
non O 1 0.5252684354782104
- O 1 0.6499199867248535
cardiac O 1 0.9999998807907104
causes O 0 5.159285137779079e-06
to O 0 6.241602790169054e-09
account O 0 9.926922617253808e-10
for O 0 1.6049677142859764e-09
the O 0 2.458527426085766e-08
episode O 0 4.921242080513366e-08
, O 0 8.773048953969464e-11
which O 0 2.5350069265961395e-12
is O 0 7.826050463059786e-13
therefore O 0 1.8678854036419112e-12
classified O 0 1.9839980353042463e-11
as O 0 2.5691218596968213e-10
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.7255356311798096
IVF B-Disease 1 1.0
) O 0 1.1680215017406681e-08
. O 0 3.8589714534964514e-08

A O 0 4.724973337033589e-07
distinct O 0 2.3161147666428406e-08
group O 0 1.1591352766515683e-08
of O 0 7.554844614787726e-06
IVF B-Disease 1 1.0
patients O 0 4.761150407261994e-08
has O 0 1.0295404112570239e-10
been O 0 5.989584522803071e-11
found O 0 1.319909459507329e-11
to O 0 3.0141644388748112e-12
present O 0 5.367861016791764e-11
with O 0 4.830165087343907e-11
a O 0 2.122314768371325e-09
characteristic O 0 9.51128669157697e-08
electrocardiographic O 0 2.887013124563964e-06
pattern O 0 2.9897128115408123e-06
. O 0 2.5243036816391395e-07

Because O 0 2.0795768307380058e-07
of O 0 3.02757854342417e-07
the O 0 1.765704560341419e-08
small O 0 5.08632247431251e-10
size O 0 5.235585298635215e-09
of O 0 2.122368414347875e-08
most O 0 4.061199709859409e-10
pedigrees O 0 4.621383720149197e-09
and O 0 1.2630781143219139e-10
the O 0 2.0366110187186592e-10
high O 0 6.2394365230034055e-09
incidence O 0 4.917413676253091e-08
of O 0 5.86566928362231e-09
sudden B-Disease 0 6.8641785588852144e-09
death I-Disease 0 2.3061337284246974e-09
, O 0 4.0116562849412674e-11
however O 0 8.114919153312528e-11
, O 0 1.4708487899861566e-11
molecular O 0 7.042774696763843e-10
genetic O 0 2.1969247254727264e-10
studies O 0 1.3406146193162272e-09
of O 0 5.2623487789560386e-08
IVF B-Disease 1 0.9999872446060181
have O 0 8.717008781466973e-10
not O 0 6.318773282387724e-11
yet O 0 1.2708545327200227e-10
been O 0 1.5089898774967025e-10
done O 0 2.0897858998836227e-09
. O 0 3.5734930570185952e-09

Because O 0 3.2933974125626264e-06
IVF B-Disease 1 1.0
causes O 0 4.189659648545785e-06
cardiac O 1 0.9999871253967285
rhythm O 1 0.9999990463256836
disturbance O 1 0.9794489145278931
, O 0 8.228535186560748e-09
we O 0 1.5243339923642907e-09
investigated O 0 5.029343341789172e-08
whether O 0 2.8474289592850255e-09
malfunction O 0 0.0004570145974867046
of O 0 3.219626876216353e-08
ion O 0 1.4106679373071529e-05
channels O 0 1.9734691250050673e-06
could O 0 6.610023195463555e-09
cause O 0 7.557829917459458e-09
the O 0 1.7630644166821696e-10
disorder O 0 5.602903030421658e-09
by O 0 5.186556913117091e-12
studying O 0 2.112875652215962e-09
mutations O 0 1.9606079260103826e-10
in O 0 7.445093153091165e-11
the O 0 8.494688841231834e-10
cardiac O 0 1.0179263881582301e-05
sodium O 0 5.440344921225915e-07
channel O 0 1.03532693174202e-06
gene O 0 4.924829113406304e-07
SCN5A O 0 9.793667413759977e-05
. O 0 1.212575511999603e-06

We O 0 6.267850949370768e-07
have O 0 1.7277580477426113e-09
now O 0 3.4942818083472105e-10
identified O 0 2.3359572609571444e-10
a O 0 3.6035111006249565e-10
missense O 0 2.0857651605865613e-08
mutation O 0 1.489525613962428e-09
, O 0 3.7782627027027615e-10
a O 0 1.865844367898717e-09
splice O 0 7.596681683708084e-08
- O 0 1.2835990048642998e-08
donor O 0 1.62957702887212e-09
mutation O 0 2.246469010813712e-09
, O 0 4.663610053690093e-10
and O 0 3.935529124809989e-10
a O 0 2.65211186345482e-09
frameshift O 0 5.2927685345594e-08
mutation O 0 2.694594825047858e-10
in O 0 1.5159654087604224e-10
the O 0 2.3267703042062493e-10
coding O 0 3.0663350969462044e-08
region O 0 6.7583139085058974e-09
of O 0 4.056077251846091e-09
SCN5A O 0 1.409273181707249e-06
in O 0 6.586941214692388e-09
three O 0 1.9350720137367716e-08
IVF B-Disease 1 0.9998595714569092
families O 0 7.200142149166311e-10
. O 0 2.0933175193249554e-08

We O 0 2.202016275987262e-07
show O 0 1.9686215324554723e-08
that O 0 7.516491595804808e-11
sodium O 0 4.763071603797187e-10
channels O 0 1.7768041205012963e-10
with O 0 9.916883286775757e-12
the O 0 1.8544614455162645e-10
missense O 0 1.3100747153771408e-08
mutation O 0 2.449902503087742e-10
recover O 0 1.2576631291949525e-08
from O 0 9.188435567963893e-10
inactivation O 0 2.562718748322368e-07
more O 0 2.1919020765093222e-10
rapidly O 0 9.267975831228625e-10
than O 0 7.885934960594199e-11
normal O 0 1.964082452232674e-09
and O 0 2.724864257841464e-11
that O 0 8.22372118319814e-12
the O 0 2.3911886359861967e-10
frameshift O 0 1.3626367945107631e-07
mutation O 0 1.96031724186696e-09
causes O 0 1.7588736023199658e-09
the O 0 3.6121765578656095e-09
sodium O 0 2.5817341153810958e-08
channel O 0 2.2210139505318693e-08
to O 0 2.6902605143597214e-10
be O 0 2.4033053325211995e-10
non O 0 2.7887313791552515e-08
- O 0 1.0405692307813297e-08
functional O 0 1.2115132221879321e-06
. O 0 7.778700705785013e-08

Our O 0 1.6129206414916553e-07
results O 0 4.944676668117154e-09
indicate O 0 1.1150883549859714e-09
that O 0 8.040515302176754e-12
mutations O 0 4.6755779803397957e-11
in O 0 1.3959548794684196e-10
cardiac O 0 2.756300091277808e-06
ion O 0 1.8914646716439165e-05
- O 0 1.83231350092683e-05
channel O 0 2.3641862298973138e-06
genes O 0 2.45870435122697e-09
contribute O 0 4.6427886535305163e-10
to O 0 3.522451774706781e-11
the O 0 5.304049213727957e-11
risk O 0 2.0521653820715358e-10
of O 0 1.2324764542270827e-09
developing O 0 8.196427359052905e-08
IVF B-Disease 1 0.9996058344841003
. O 0 1.6115845324904399e-09
. O 0 8.144249719066465e-09

Molecular O 0 3.3422854812670266e-06
heterogeneity O 0 1.326384449384932e-06
in O 0 1.5357827010120673e-07
mucopolysaccharidosis B-Disease 0 1.2479955330491066e-05
IVA I-Disease 0 0.0433180034160614
in O 0 7.958490755299863e-08
Australia O 0 1.1696037471864429e-09
and O 0 4.71155718606564e-11
Northern O 0 1.5955425869407236e-09
Ireland O 0 4.589751245731577e-09
: O 0 2.328447330779415e-11
nine O 0 9.16223277802608e-11
novel O 0 2.5888355695280474e-11
mutations O 0 9.533976386144616e-11
including O 0 1.787539005704275e-10
T312S O 0 9.040142856520106e-08
, O 0 1.087590240089753e-09
a O 0 1.1842170577480715e-09
common O 0 8.521660044280566e-10
allele O 0 1.1294017943086487e-09
that O 0 1.6419092474517782e-10
confers O 0 3.1129243183158906e-08
a O 0 3.5482545790443965e-09
mild O 0 1.5283056598036637e-08
phenotype O 0 6.976065058950098e-09
. O 0 2.0414278267821828e-08

Mucopolysaccharidosis B-Disease 1 0.656087338924408
IVA I-Disease 1 0.9999991655349731
( O 0 0.000395805633161217
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 2.1151789653117703e-08
is O 0 6.112476080843976e-10
an O 0 6.896984650062166e-10
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 4.8723872168920934e-05
by O 0 1.0423286678218346e-09
a O 0 6.807582053625083e-08
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.6865905649865454e-07
N O 0 4.950377842760645e-05
- O 0 4.106303208573081e-07
acetylgalactosamine O 0 2.382322054472752e-05
- O 0 1.429307985745254e-06
6 O 0 8.828892532619648e-06
- O 0 1.7608959979042993e-07
sulfate O 0 3.8491657505801413e-07
sulfatase O 0 2.3113720999390353e-06
( O 0 3.4434182172304872e-09
GALNS O 0 3.3955532217078144e-06
) O 0 3.280879345979315e-09
. O 0 2.7299510207967614e-08

Previous O 0 8.573774579190285e-08
studies O 0 3.1508864850593454e-08
of O 0 1.2474571597920203e-08
patients O 0 6.436376986940218e-10
from O 0 2.3684568195569966e-10
a O 0 2.6518676143894027e-10
British O 0 1.86507942423475e-09
- O 0 1.396434967659843e-09
Irish O 0 2.4555548705507135e-09
population O 0 4.931386787636327e-13
showed O 0 7.711724314685142e-11
that O 0 4.542055533768297e-12
the O 0 7.789899281185342e-11
I113F O 0 4.279171239573998e-09
mutation O 0 5.422368803964517e-11
is O 0 4.59733162996856e-12
the O 0 5.6756691360626554e-12
most O 0 1.5779323377443366e-12
common O 0 4.730906204980512e-12
single O 0 4.301201322193249e-12
mutation O 0 6.123349050035642e-11
among O 0 1.1211572642499945e-10
MPS B-Disease 0 0.013219131156802177
IVA I-Disease 1 1.0
patients O 0 2.7859086912940256e-06
and O 0 2.505152085774398e-09
produces O 0 2.8658983519669334e-10
a O 0 2.730812798112936e-10
severe O 0 3.471215137551553e-08
clinical O 0 4.408748210948943e-08
phenotype O 0 4.778126694304774e-08
. O 0 4.444335033326752e-08

We O 0 1.651960559456711e-07
studied O 0 3.2028665941652434e-07
mutations O 0 1.2984366914992052e-09
in O 0 2.671392551611973e-10
the O 0 1.1802754329437448e-09
GALNS O 0 1.8313491523258563e-07
gene O 0 3.389152014587893e-10
from O 0 4.504187023357531e-10
23 O 0 6.794905527129913e-09
additional O 0 3.2178448794439873e-09
MPS B-Disease 0 0.3812662661075592
IVA I-Disease 1 1.0
patients O 0 1.4537587276208797e-06
( O 0 3.4193120557191037e-10
15 O 0 1.5601849812085788e-09
from O 0 2.6226426586006824e-10
Australia O 0 1.0659560040204852e-10
, O 0 2.0377368195600987e-11
8 O 0 4.3748771272333897e-10
from O 0 1.6276595349307144e-10
Northern O 0 2.8748345926032925e-09
Ireland O 0 1.1334242433491681e-09
) O 0 2.5149927279644047e-11
, O 0 1.0738692053646748e-11
with O 0 9.503126584264887e-12
various O 0 1.7529322438036843e-09
clinical O 0 2.509994203592214e-07
phenotypes O 0 1.6439265948520188e-07
( O 0 2.037692237166766e-09
severe O 0 6.162538852549915e-07
, O 0 8.20705725601556e-10
16 O 0 4.608216030987933e-09
cases O 0 3.037297913177639e-10
; O 0 1.8672273796593863e-11
intermediate O 0 5.473550501733371e-09
, O 0 3.2351961387622197e-11
4 O 0 6.553953491028608e-10
cases O 0 9.249976479219768e-11
; O 0 3.4310238677948135e-11
mild O 0 2.1472459366123076e-09
, O 0 5.277820888660578e-11
3 O 0 6.408239494604118e-10
cases O 0 3.641329945902605e-11
) O 0 5.606628702969907e-11
. O 0 2.7988704687231802e-09

We O 0 3.013429363818432e-07
found O 0 7.744382024554852e-09
two O 0 2.461781334339719e-10
common O 0 2.1162786800754674e-10
mutations O 0 3.698728823220421e-11
that O 0 5.990415195139542e-12
together O 0 1.6544231262738407e-11
accounted O 0 2.3066383525449652e-10
for O 0 1.4274163795402472e-10
32 O 0 2.325857284546373e-09
% O 0 2.2013288414335364e-10
of O 0 3.3579208302825236e-09
the O 0 2.5187878449628442e-09
44 O 0 3.6303002826088004e-09
unrelated O 0 3.5646838814074044e-09
alleles O 0 4.311924983735338e-10
in O 0 4.307280643267575e-10
these O 0 2.2707907776364777e-10
patients O 0 8.07430744487192e-09
. O 0 3.220941380277509e-08

One O 0 2.1792196491787763e-07
is O 0 3.578431106987523e-09
the O 0 2.6821973531099275e-09
T312S O 0 1.4463215336490975e-07
mutation O 0 1.0265447381030413e-09
, O 0 7.487644532178095e-11
a O 0 1.7716400568801305e-10
novel O 0 1.178774161614271e-10
mutation O 0 4.378815018912796e-11
found O 0 3.8892538495316487e-11
exclusively O 0 3.5740910231396583e-10
in O 0 3.990442698498242e-10
milder O 0 1.0527488214506775e-08
patients O 0 1.3897258899220333e-09
. O 0 1.508617231138487e-08

The O 0 1.362894522571878e-06
other O 0 9.718356785981541e-09
is O 0 2.842066582076086e-10
the O 0 2.781307684163181e-10
previously O 0 3.029142048305289e-09
described O 0 1.7716342837204024e-09
I113F O 0 1.093327206547201e-08
that O 0 3.58765343821954e-11
produces O 0 4.23016031925183e-11
a O 0 1.634803264982665e-10
severe O 0 1.3291580280849757e-08
phenotype O 0 2.7872211205703934e-08
. O 0 6.369506877490494e-08

The O 0 1.5568035394153412e-07
I113F O 0 4.6081743221293436e-07
and O 0 1.413494099544721e-09
T312S O 0 2.323690218020147e-08
mutations O 0 2.0077151052788622e-10
accounted O 0 1.3010743593611096e-09
for O 0 1.4948499382771985e-10
8 O 0 7.041488725434419e-09
( O 0 6.0011794145165e-11
18 O 0 1.356360468385276e-09
% O 0 6.340588470932218e-11
) O 0 1.08532427836594e-11
and O 0 1.0118327009589478e-10
6 O 0 7.543600410997442e-09
( O 0 4.9473793117815745e-11
14 O 0 1.0611022061013387e-09
% O 0 4.673937625820912e-11
) O 0 9.735707032221264e-12
of O 0 5.738877151273414e-10
44 O 0 3.0306215315079044e-09
unrelated O 0 4.546534704275018e-09
alleles O 0 2.287187994554074e-09
, O 0 2.2455692860745557e-09
respectively O 0 1.2423656414739526e-07
. O 0 2.8192323497933103e-07

The O 0 2.74610982842205e-07
relatively O 0 9.773197007234558e-08
high O 0 1.0775212189173544e-07
residual O 0 1.440168034605449e-06
GALNS O 0 3.11164171762357e-06
activity O 0 1.7556928133544147e-09
seen O 0 4.4674819399403987e-10
when O 0 3.464033573874481e-11
the O 0 4.7179867651570007e-11
T312S O 0 1.2024942153132656e-09
mutant O 0 3.2267793992346583e-10
cDNA O 0 6.0148108715907256e-09
is O 0 2.1407345340840322e-10
overexpressed O 0 9.120522292960231e-08
in O 0 1.2915355451781352e-09
mutant O 0 2.6553717002997246e-09
cells O 0 1.0540999323405131e-10
provides O 0 4.464600564246801e-11
an O 0 2.426443160979952e-12
explanation O 0 6.764548643456436e-11
for O 0 1.2106766110464573e-11
the O 0 2.4712609736354807e-10
mild O 0 1.5894493499146733e-09
phenotype O 0 2.801283094377993e-10
in O 0 1.1338992939036174e-10
patients O 0 1.951436755243119e-11
with O 0 1.6490067774807549e-12
this O 0 1.1614572151263935e-11
mutation O 0 2.6938548614019453e-10
. O 0 2.576336477488894e-09

The O 0 8.420877151138484e-08
distribution O 0 6.7869012632115755e-09
and O 0 1.693447604367293e-10
relative O 0 1.546028904897412e-08
frequencies O 0 1.4918635216076837e-08
of O 0 2.014862943156004e-09
the O 0 5.126097324392731e-10
I113F O 0 5.5764628470456046e-09
and O 0 1.2968619234055012e-10
T312S O 0 6.1416369767641754e-09
mutations O 0 1.214887218603522e-10
in O 0 1.979289510067872e-10
Australia O 0 8.442496007843303e-11
corresponded O 0 7.428245241136722e-10
to O 0 6.655966056090534e-11
those O 0 2.757252412499689e-11
observed O 0 4.226404226592706e-10
in O 0 2.104709601047361e-10
Northern O 0 3.738950482556902e-09
Ireland O 0 2.909499086101164e-09
and O 0 8.489760283669767e-11
are O 0 5.947516784621243e-12
unique O 0 9.01232630190485e-11
to O 0 3.203474985280508e-11
these O 0 1.3284234823274232e-11
two O 0 2.169482302138981e-11
populations O 0 5.940793863790095e-12
, O 0 9.77012134389943e-12
suggesting O 0 1.9352065783184713e-10
that O 0 1.1280270988123231e-11
both O 0 4.491590432920134e-11
mutations O 0 8.499351916713138e-11
were O 0 1.8321399952725415e-10
probably O 0 6.395427243344187e-11
introduced O 0 5.167962845858964e-12
to O 0 1.939842600787167e-12
Australia O 0 4.5255533803918724e-13
by O 0 5.427175093879189e-13
Irish O 0 4.472981152137123e-10
migrants O 0 2.164973478269161e-10
during O 0 9.995282379549053e-10
the O 0 1.155065043612069e-09
19th O 0 4.863619906814165e-08
century O 0 6.373602445819415e-08
. O 0 4.9468962259879845e-08

Haplotype O 0 1.137919298344059e-06
analysis O 0 8.835867504330963e-08
using O 0 7.078819663774993e-08
6 O 0 2.6347345283284085e-07
RFLPs O 0 1.01731973245478e-06
provides O 0 2.008275101772483e-09
additional O 0 5.436092687105543e-10
data O 0 8.512302529517513e-10
that O 0 2.6107779133033304e-11
the O 0 1.500111146413019e-10
I113F O 0 7.81008058226007e-09
mutation O 0 1.5314147172595938e-10
originated O 0 3.919498059445914e-10
from O 0 1.285229284109235e-10
a O 0 6.129404206411948e-10
common O 0 1.2885533751116895e-09
ancestor O 0 5.304168482211935e-08
. O 0 8.024674258422237e-08

The O 0 2.5968321892833046e-07
other O 0 4.575285483809921e-09
9 O 0 3.686254501644726e-08
novel O 0 5.740836694911877e-10
mutations O 0 1.1913164899013395e-10
identified O 0 3.606206167017234e-10
in O 0 9.587114435660737e-11
these O 0 3.958828057037955e-11
23 O 0 2.3137867177780436e-09
patients O 0 3.5326133684954186e-10
were O 0 3.59525215154477e-10
each O 0 1.2778369508359422e-11
limited O 0 4.300202555151955e-11
to O 0 3.194627548608331e-11
a O 0 2.822973799165851e-10
single O 0 1.8697977888226802e-10
family O 0 2.9501301401779756e-09
. O 0 5.450737461387689e-08

These O 0 7.654960221259444e-09
data O 0 5.256708401901733e-09
provide O 0 2.604616800017112e-10
further O 0 6.182308137647752e-11
evidence O 0 4.639849338072821e-10
for O 0 2.106411225999416e-11
extensive O 0 1.2607463961700205e-09
allelic O 0 1.795094917156348e-08
heterogeneity O 0 6.566934729335117e-08
in O 0 4.193470104496555e-08
MPS B-Disease 1 0.9002962708473206
IVA I-Disease 1 1.0
in O 0 3.230169554058193e-08
British O 0 6.883271197466456e-08
- O 0 3.1702658276344664e-09
Irish O 0 2.225987394410822e-09
patients O 0 3.061772016477171e-11
and O 0 1.096884649082197e-11
provide O 0 7.631477914882279e-12
evidence O 0 7.781197214340452e-11
for O 0 1.819473391395654e-11
their O 0 2.1407745368073883e-11
transmission O 0 4.43131442651179e-09
to O 0 2.4981926249889597e-11
Australia O 0 2.822034272931262e-12
by O 0 1.5453800348771973e-12
British O 0 5.944688075132376e-10
- O 0 2.7328864171671796e-10
Irish O 0 4.4879791549767845e-10
migrants O 0 5.0914644028621225e-11
. O 0 3.5348491495001966e-11
. O 0 1.8280358338174096e-09

Identification O 0 6.767926663542312e-08
of O 0 1.6972512639767956e-07
constitutional O 0 4.460065611056052e-05
WT1 O 0 0.0001229650224559009
mutations O 0 2.6108518014211768e-08
, O 0 1.1528413640382595e-10
in O 0 9.645367143873429e-11
patients O 0 7.425072223732343e-10
with O 0 7.624385567339687e-10
isolated O 0 0.00042834231862798333
diffuse B-Disease 1 0.9999808073043823
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 7.286699688080489e-09
and O 0 4.369720904562335e-11
analysis O 0 1.6602055841197227e-10
of O 0 1.4927479252691e-09
genotype O 0 1.7022967924162913e-08
/ O 0 1.879998734466426e-08
phenotype O 0 1.1688588985592219e-09
correlations O 0 1.356494916393558e-09
by O 0 1.4270099858715302e-11
use O 0 1.953061185000493e-10
of O 0 2.1502788438709786e-09
a O 0 7.503059840097137e-10
computerized O 0 8.836389753241747e-08
mutation O 0 1.689518858150052e-09
database O 0 1.5248087237296204e-08
. O 0 1.0159531882436568e-07

Constitutional O 0 2.8887019652756862e-05
mutations O 0 1.8062404194552073e-07
of O 0 1.0348397694315281e-07
the O 0 1.9667112383103813e-08
WT1 O 0 7.792412475282617e-07
gene O 0 2.7130275803699533e-09
, O 0 2.2190257964460613e-10
encoding O 0 9.573692949516044e-09
a O 0 6.893203163826911e-08
zinc O 0 0.00011003278632415459
- O 0 6.505414148705313e-06
finger O 0 0.0014417031779885292
transcription O 0 7.551912858616561e-06
factor O 0 1.1450131864876312e-07
involved O 0 4.128519393020724e-08
in O 0 8.365196535464747e-09
renal O 1 1.0
and O 0 1.4782563994231168e-05
gonadal O 1 0.9999998807907104
development O 1 0.9036604762077332
, O 0 6.921671680260033e-09
are O 0 9.21635164019552e-12
found O 0 3.536703568896016e-11
in O 0 1.8860440986756544e-11
most O 0 5.844742658606128e-12
patients O 0 3.534147974271207e-11
with O 0 2.469315030229069e-10
Denys B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999998807907104
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 6.055805101823353e-08
DDS B-Disease 1 1.0
) O 0 2.1097907865197385e-09
, O 0 6.002007224559236e-10
or O 0 9.321342808732425e-09
diffuse B-Disease 1 0.9353528022766113
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 7.850511565266061e-07
DMS B-Disease 0 3.405399911571294e-05
) O 0 8.537029416721964e-11
associated O 0 7.87187259820854e-10
with O 0 6.468214297505881e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.9515161966410233e-06
/ O 0 0.0010112384334206581
or O 0 1.7596538270936435e-07
Wilms B-Disease 1 0.9999499320983887
tumor I-Disease 0 0.004900074098259211
( O 0 2.5450751195421617e-07
WT B-Disease 1 0.9999980926513672
) O 0 2.3264485449203676e-08
. O 0 4.850807400202939e-08

Most O 0 4.495709138296888e-09
mutations O 0 6.677373765029415e-09
in O 0 7.644352706392965e-09
DDS B-Disease 1 1.0
patients O 0 6.384126436387305e-07
lie O 0 1.37040308345604e-06
in O 0 9.077339768737147e-09
exon O 0 3.8171864957803336e-07
8 O 0 1.387907246908071e-07
or O 0 3.719248242717299e-09
exon O 0 6.977158761856117e-08
9 O 0 6.54563905300165e-08
, O 0 1.006092542610304e-09
encoding O 0 1.2652982661620626e-07
zinc O 0 0.00015528604853898287
finger O 0 0.10532631725072861
2 O 0 0.000138229297590442
or O 0 8.59269619013503e-07
zinc O 0 0.009080976247787476
finger O 0 0.0344206765294075
3 O 0 4.6778598061791854e-07
, O 0 3.2440275465894786e-10
respectively O 0 5.630048871552162e-09
, O 0 1.608512767425907e-10
with O 0 1.2999228082843928e-10
a O 0 1.7732714852058962e-08
hot O 0 4.6847083012835355e-07
spot O 0 3.720335328694091e-08
( O 0 4.3510580555183864e-11
R394W O 0 1.8029278070486043e-09
) O 0 2.92577906346736e-11
in O 0 4.842547474126491e-10
exon O 0 3.0810920748081116e-07
9 O 0 1.042587541633111e-06
. O 0 2.0382302068355784e-07

We O 0 9.479085605335058e-08
analyzed O 0 2.3847642083296705e-08
a O 0 4.613217585713869e-10
series O 0 8.578211058152263e-11
of O 0 6.401752461471233e-10
24 O 0 2.1190222909694967e-09
patients O 0 1.6634704724793892e-10
, O 0 4.738313907903802e-11
10 O 0 3.1260230515250953e-10
with O 0 2.728079429026309e-10
isolated B-Disease 0 9.390715831614216e-07
DMS I-Disease 1 0.6562321782112122
( O 0 9.513605014888071e-09
IDMS B-Disease 0 4.5864117055316456e-06
) O 0 1.2437407770349296e-09
, O 0 6.881807346204027e-10
10 O 0 1.554214978938262e-09
with O 0 2.492444306501085e-10
DDS B-Disease 1 1.0
, O 0 2.269778587304927e-09
and O 0 1.262422943959507e-10
4 O 0 3.1524176602459875e-09
with O 0 1.581042935461241e-10
urogenital B-Disease 1 0.8004007339477539
abnormalities I-Disease 1 0.9999986886978149
and O 0 4.6505133468599524e-06
/ O 0 0.35868486762046814
or O 0 9.445063915336505e-05
WT B-Disease 1 1.0
. O 0 2.5636329610279063e-06

We O 0 3.6046284890289826e-07
report O 0 2.840156554384521e-08
WT1 O 0 3.873916284646839e-06
heterozygous O 0 2.913882291011305e-08
mutations O 0 3.0890396907068407e-09
in O 0 1.8224550757395264e-09
16 O 0 1.7727169066006354e-08
patients O 0 1.1447762737759604e-09
, O 0 2.352698313945467e-10
4 O 0 1.3644151586333919e-08
of O 0 3.714776397600872e-08
whom O 0 2.2898824170169974e-08
presented O 0 6.8882613390997e-08
with O 0 3.2707337283000015e-08
IDMS B-Disease 0 0.001269942382350564
. O 0 1.7551532209836296e-06

One O 0 1.1000526001225808e-07
male O 0 1.0593919519408246e-08
and O 0 3.582513175004465e-10
two O 0 1.2433565288461068e-09
female O 0 3.388470304344082e-08
IDMS B-Disease 0 0.058438628911972046
patients O 0 2.1586572529486148e-07
with O 0 2.1107942060893947e-08
WT1 O 1 0.9992169141769409
mutations O 0 3.953521627408918e-06
underwent O 0 2.081337515846826e-05
normal O 0 2.1992886104271747e-05
puberty O 0 1.6304213204421103e-05
. O 0 1.1802877253330735e-07

Two O 0 1.4435669015711028e-07
mutations O 0 4.943717257788194e-08
associated O 0 3.449356711371365e-07
with O 0 1.1348482154005524e-08
IDMS B-Disease 0 0.004315664991736412
are O 0 7.236198862337062e-10
different O 0 1.2523049264245856e-10
from O 0 2.350733496747637e-10
those O 0 3.939041801070964e-11
described O 0 2.3791248970894685e-09
in O 0 4.444586920726579e-09
DDS B-Disease 1 1.0
patients O 0 1.012376287690131e-06
. O 0 1.2502802348990372e-07

No O 0 3.165426733175991e-06
WT1 O 0 6.248742283787578e-05
mutations O 0 5.466896624284345e-08
were O 0 1.6367166510988795e-09
detected O 0 1.153825923694285e-08
in O 0 2.2701628077381741e-10
the O 0 7.357993658807516e-10
six O 0 3.0363263014976383e-09
other O 0 7.563638049212784e-10
IDMS B-Disease 0 0.0002644271298777312
patients O 0 5.239673939172462e-08
, O 0 4.907261264008866e-10
suggesting O 0 2.7679094571908536e-09
genetic O 0 3.4531062453879713e-09
heterogeneity O 0 1.037271868398193e-08
of O 0 1.0381110193691256e-08
this O 0 1.913227354322089e-09
disease O 0 2.1385387753980467e-06
. O 0 2.722577541192095e-08

We O 0 2.437493549223291e-07
analyzed O 0 2.0773013886810077e-07
genotype O 0 1.5048446755372424e-07
/ O 0 8.792376604560559e-08
phenotype O 0 1.032126917266396e-08
correlations O 0 1.0446224507631996e-07
, O 0 5.649752887748605e-10
on O 0 1.682373573785867e-09
the O 0 1.1240629260722557e-10
basis O 0 9.857245020228333e-10
of O 0 3.882777710462193e-10
the O 0 9.864048466923236e-11
constitution O 0 4.579404355720129e-10
of O 0 4.065146441689649e-09
a O 0 1.73732139785443e-09
WT1 O 0 7.576741012371713e-08
mutation O 0 1.7025644782897587e-10
database O 0 1.268571359069881e-09
of O 0 2.2204886818144587e-08
84 O 0 1.2746618267556187e-06
germ O 0 0.4725874066352844
- O 0 1.361266549793072e-05
line O 0 1.6848589439177886e-06
mutations O 0 1.7238473981606717e-09
, O 0 1.1981733660793026e-10
to O 0 8.529184303274207e-11
compare O 0 1.1664447185921745e-09
the O 0 5.134444536203375e-10
distribution O 0 2.8481459413143284e-09
and O 0 5.341816919357534e-11
type O 0 4.581374568601859e-08
of O 0 4.176922274723438e-08
mutations O 0 9.169019987709248e-10
, O 0 3.1537078504229044e-11
according O 0 1.820375794547857e-11
to O 0 2.2095809557032275e-11
the O 0 1.7593894396927823e-10
different O 0 2.225036599412533e-09
symptoms O 0 1.393775505675876e-06
. O 0 4.947736087501653e-08

This O 0 1.930000159688916e-08
demonstrated O 0 8.091948444644004e-08
( O 0 6.725263124174319e-10
1 O 0 4.479813853208725e-09
) O 0 1.420885544639594e-11
the O 0 1.4739640064043158e-10
association O 0 1.402046811982416e-10
between O 0 9.223730113028239e-10
mutations O 0 2.521949593603523e-10
in O 0 1.8453801819973137e-09
exons O 0 1.2716850683602843e-08
8 O 0 3.5247555985051804e-08
and O 0 1.4573177109511448e-09
9 O 0 1.8848211880140298e-07
and O 0 1.3515242258677063e-08
DMS B-Disease 0 3.146708331769332e-05
; O 0 2.028211598670282e-09
( O 0 2.6580151968325083e-10
2 O 0 1.4668866121780866e-08
) O 0 9.224411512409603e-11
among O 0 7.428752057947463e-11
patients O 0 7.225344766936814e-10
with O 0 1.1666984045533013e-09
DMS B-Disease 0 0.000966694438830018
, O 0 1.179082942392995e-09
a O 0 1.393515441927562e-10
higher O 0 5.16160392205478e-10
frequency O 0 6.1493965475278856e-09
of O 0 5.393482549465034e-09
exon O 0 8.624109426591531e-08
8 O 0 3.675232562727615e-08
mutations O 0 4.385807272910824e-09
among O 0 4.742963799486688e-10
46 O 0 1.8677466684380306e-08
, O 0 1.3456973313452636e-09
XY O 0 1.9200742826797068e-05
patients O 0 1.0255530646929856e-08
with O 0 7.849592642550363e-10
female O 0 1.8702910331569456e-09
phenotype O 0 5.626267229885684e-10
than O 0 6.493452303635294e-11
among O 0 2.507477558921778e-11
46 O 0 2.7344209119206653e-09
, O 0 2.7742400043884174e-10
XY O 0 6.703538019792177e-06
patients O 0 3.646671409285318e-09
with O 0 1.0965506280768977e-10
sexual O 0 1.1295315793802274e-08
ambiguity O 0 4.479574933213826e-09
or O 0 7.433868798312204e-11
male O 0 2.5257899938235795e-11
phenotype O 0 1.5157767402351752e-11
; O 0 6.026951507309697e-12
and O 0 4.5101849338591293e-11
( O 0 1.724207408793088e-11
3 O 0 4.4193348980314795e-10
) O 0 3.689419429686591e-12
statistically O 0 3.685152183408036e-11
significant O 0 7.512187920333258e-12
evidence O 0 1.0299017194626003e-10
that O 0 1.999092514790024e-12
mutations O 0 1.3849428548429188e-11
in O 0 1.9765204750665788e-10
exons O 0 5.521048507262094e-09
8 O 0 1.8173256677300742e-08
and O 0 7.270314350549256e-10
9 O 0 2.0246142540258916e-08
preferentially O 0 1.2118313463815866e-08
affect O 0 6.032495036834007e-08
amino O 0 3.069940035516083e-08
acids O 0 1.1619436524057392e-09
with O 0 7.741490608281776e-12
different O 0 5.568270670941455e-12
functions O 0 2.1869168698174235e-09
. O 0 2.4175253465763547e-10
. O 0 3.5207894377720095e-09

The O 0 9.201305601891363e-07
185delAG O 0 6.189683062984841e-06
BRCA1 O 0 1.002260958671286e-07
mutation O 0 1.856210629647137e-09
originated O 0 7.500484122680007e-10
before O 0 3.314370167206704e-10
the O 0 3.598151984696152e-11
dispersion O 0 1.7359699233665538e-09
of O 0 6.996181967089399e-10
Jews O 0 1.2797254922425338e-10
in O 0 3.348292476612613e-11
the O 0 9.957657615133897e-11
diaspora O 0 8.926787087304433e-11
and O 0 1.081656569867917e-10
is O 0 3.167627271594142e-11
not O 0 9.38549932216759e-12
limited O 0 1.4438017448270557e-10
to O 0 7.145690705812058e-10
Ashkenazim O 0 1.7609626183912042e-06
. O 0 2.2539518340636278e-07

The O 0 1.2591134179729124e-07
185delAG O 0 1.4195489939083927e-06
mutation O 0 7.424311831982777e-09
in O 0 2.7510775879591165e-09
BRCA1 O 0 2.252617647968691e-09
is O 0 8.556216152255658e-11
detected O 0 1.0833377528385313e-09
in O 0 2.0462000149823467e-11
Ashkenazi O 0 3.1802208089182216e-10
Jews O 0 6.041087768915432e-11
both O 0 5.973588984575784e-11
in O 0 9.623798424840402e-10
familial B-Disease 1 0.6864407062530518
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.00043291490874253213
in O 0 4.0922362387618705e-08
the O 0 5.730698138251e-09
general O 0 4.900660321993655e-09
population O 0 1.5389568092105677e-11
. O 0 5.576004991070249e-09

All O 0 8.40956246861424e-08
tested O 0 6.437156230276742e-08
Ashkenazi O 0 3.756028021939528e-08
mutation O 0 2.6840398792415954e-09
carriers O 0 1.7590513490262083e-09
share O 0 8.376560556300205e-10
the O 0 4.821819055145227e-10
same O 0 2.6515847850738794e-10
allelic O 0 9.577766135748789e-09
pattern O 0 1.6383548029352824e-07
at O 0 4.749323423425267e-08
the O 0 2.9913855836838366e-09
BRCA1 O 0 1.1697225410500778e-08
locus O 0 4.9727031381507913e-08
. O 0 1.3706275581171212e-07

Our O 0 1.1305530733807245e-06
previous O 0 1.4304627882211207e-07
study O 0 1.3578003610348333e-08
showed O 0 3.207281107364679e-09
that O 0 7.840547655568741e-12
this O 0 5.124733536837622e-12
Ashkenazi O 0 9.074166973377373e-10
mutation O 0 1.7813571798197536e-11
also O 0 2.140623268920283e-11
occurs O 0 3.247647636928086e-11
in O 0 3.768473033627373e-11
Iraqi O 0 5.461536556339297e-09
Jews O 0 8.485050162487795e-11
with O 0 8.285123455353816e-12
a O 0 1.7454803227789917e-11
similar O 0 1.4033518271061585e-11
allelic O 0 1.9447513821546636e-08
pattern O 0 3.6938354242010973e-07
. O 0 1.8467549978140596e-07

We O 0 2.616206131733634e-07
extended O 0 6.069774372008396e-08
our O 0 3.4171556695383742e-09
analysis O 0 1.701554730448862e-10
to O 0 1.509006461453133e-11
other O 0 6.0526527366489e-12
non O 0 1.0394420879578092e-09
- O 0 3.058639175268496e-10
Ashkenazi O 0 5.750425691175565e-10
subsets O 0 2.171546276130698e-09
354 O 0 9.631693220768511e-10
of O 0 4.838789369188135e-10
Moroccan O 0 1.2063932963712887e-08
origin O 0 1.0626247798350974e-10
, O 0 3.2225035140331926e-11
200 O 0 3.8029732141176e-11
Yemenites O 0 1.9972443254800964e-08
and O 0 5.759204224631276e-11
150 O 0 4.317389223906787e-10
Iranian O 0 2.662359888105925e-09
Jews O 0 8.788947347682097e-10
. O 0 5.579207318362478e-09

Heteroduplex O 0 4.537743370747194e-05
analysis O 0 2.2303410673885082e-07
complemented O 0 3.2655478321430564e-08
by O 0 2.6093605054455793e-10
direct O 0 1.0272792616561333e-09
DNA O 0 4.352579130451062e-10
sequencing O 0 8.862036660062245e-10
of O 0 1.192785870074431e-09
abnormally O 0 1.5258757590785876e-09
migrating O 0 1.2766049328760687e-10
bands O 0 3.3403668719955704e-09
were O 0 3.3420810563455916e-09
employed O 0 1.020879309976408e-07
. O 0 1.9378717297513504e-08

Four O 0 4.130394160029027e-08
of O 0 2.8107592697779182e-08
Moroccan O 0 2.2033142954569485e-07
origin O 0 1.008765404542089e-09
( O 0 1.7847648706159625e-11
1 O 0 2.4929530662021193e-10
. O 0 3.4000324257432712e-12
1 O 0 5.166597705219544e-10
% O 0 4.7538908573563354e-12
) O 0 2.8491358577964476e-12
and O 0 2.0513151940959595e-11
none O 0 6.152056641894887e-10
of O 0 2.5536945891246887e-09
the O 0 1.9796833061747066e-09
Yemenites O 0 2.0754121976551687e-07
or O 0 9.778315934738657e-10
Iranians O 0 2.92726687334266e-09
was O 0 5.513671297308065e-09
a O 0 2.919197661377382e-10
carrier O 0 7.362569998115021e-10
of O 0 1.0456779886425238e-09
the O 0 1.3663338238600886e-09
185delAG O 0 8.716003208064649e-08
mutation O 0 9.163850123172779e-09
. O 0 3.821170579954014e-08

BRCA1 O 0 5.62337754672626e-06
allelic O 0 1.6552011175008374e-06
patterns O 0 1.5536384978531714e-07
were O 0 3.4781919566739816e-09
determined O 0 1.8494183962047828e-09
for O 0 7.059110934681812e-11
four O 0 9.946685142203648e-11
of O 0 4.795935315549116e-10
these O 0 4.903289579916148e-12
individuals O 0 4.695128834331097e-12
and O 0 1.4903283468425954e-11
for O 0 3.6873181591401405e-11
12 O 0 1.5848775070104182e-10
additional O 0 4.520520069384304e-11
non O 0 1.9479440283021177e-08
- O 0 3.2360694124378142e-09
Ashkenazi O 0 9.86426051952094e-10
185delAG O 0 2.1655031101630584e-09
mutation O 0 1.531981486113665e-10
carriers O 0 2.147523270323859e-10
who O 0 8.966756781525476e-10
had O 0 3.561196990631288e-07
breast B-Disease 1 0.9999988079071045
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9550978541374207

Six O 0 1.604269982635742e-06
non O 0 6.3415986915060785e-06
- O 0 2.7235077482146153e-07
Ashkenazi O 0 1.0178690779127919e-08
individuals O 0 2.0052418059357535e-11
shared O 0 3.00562491561962e-10
the O 0 2.334683280036387e-10
common O 0 3.957312810776159e-10
Ashkenazi O 0 9.71057012577603e-10
haplotype O 0 9.87181270062365e-09
, O 0 1.1815862732689197e-09
four O 0 2.7883204634093772e-09
had O 0 1.043805397671349e-08
a O 0 1.5746305370711866e-09
closely O 0 8.038867904680558e-10
related O 0 6.792975071334695e-09
pattern O 0 4.606127035344798e-08
, O 0 7.06827235630314e-11
and O 0 6.244109396202902e-11
the O 0 1.9507166992838165e-09
rest O 0 1.5388270213634314e-08
( O 0 8.75861952409629e-11
n O 0 1.2995325704423522e-08
= O 0 5.324996887878797e-09
6 O 0 9.871172323983046e-09
) O 0 4.6563905509167114e-11
displayed O 0 4.9338613195004655e-09
a O 0 2.810993660062877e-09
distinct O 0 7.612850794203041e-09
BRCA1 O 0 6.438592947688448e-08
allelic O 0 2.565797387887869e-07
pattern O 0 2.905330347857671e-06
. O 0 2.958963420951477e-07

We O 0 1.2274828975478158e-07
conclude O 0 9.491731844946116e-08
that O 0 1.3998158188144316e-10
the O 0 4.3059253385102636e-10
185delAG O 0 1.0158674790261557e-08
BRCA1 O 0 6.191704371438789e-10
mutation O 0 2.109941735217724e-11
occurs O 0 1.5320158336384893e-11
in O 0 2.9403021684082375e-11
some O 0 1.0727636660934348e-11
non O 0 8.807949036793161e-09
- O 0 2.0255712662731185e-09
Ashkenazi O 0 1.41217892934975e-09
populations O 0 3.153160371693886e-11
at O 0 1.219065959290333e-09
rates O 0 4.333832459568754e-10
comparable O 0 1.0743128608936559e-09
with O 0 1.3687033277587357e-11
that O 0 8.524810024557183e-11
of O 0 6.715101807941437e-09
Ashkenazim O 0 1.0769506388896843e-06
. O 0 1.2812562033559516e-07

The O 0 1.0942434158778269e-07
majority O 0 4.003839926269848e-09
of O 0 1.827681295196726e-08
Jewish O 0 2.2167510049797556e-09
185delAG O 0 3.523088665247087e-08
mutation O 0 6.641817096308955e-10
carriers O 0 2.461307269108204e-10
have O 0 2.9785212490862634e-11
a O 0 9.412592233415396e-11
common O 0 2.825683576013205e-10
allelic O 0 7.713747862680975e-09
pattern O 0 5.513810918955642e-08
, O 0 1.1372543878840347e-10
supporting O 0 4.5632303491416337e-10
the O 0 1.0150773555039905e-08
founder O 0 4.2547091538835957e-07
effect O 0 5.820124329147802e-07
notion O 0 1.3519861852273607e-07
, O 0 3.295327344332577e-10
but O 0 6.290717946555446e-11
dating O 0 2.3061030862692178e-09
the O 0 6.564584292823028e-11
mutations O 0 2.7059136181728505e-11
origin O 0 2.921763872509864e-11
to O 0 1.3598430541328366e-11
an O 0 1.3740342197365862e-11
earlier O 0 3.036677853618386e-10
date O 0 1.1564390334228847e-08
than O 0 3.0230223879712526e-10
currently O 0 3.035479367863303e-10
estimated O 0 1.0496185032238259e-09
. O 0 3.9991252975823954e-08

However O 0 3.1429701152774214e-07
, O 0 1.6837540250946859e-09
the O 0 5.46680756219331e-10
different O 0 9.58539567164074e-11
allelic O 0 1.7301795551816213e-08
pattern O 0 7.943613411498518e-08
at O 0 7.990050931994119e-08
the O 0 1.6969080585127472e-09
BRCA1 O 0 4.0087513863973356e-10
locus O 0 3.0054297939230423e-10
even O 0 8.794979328152763e-11
in O 0 2.9213017421758636e-11
some O 0 2.211970840867994e-12
Jewish O 0 1.388746669744867e-11
mutation O 0 2.9092577305545042e-11
carriers O 0 1.704829333259994e-10
, O 0 1.0711735665136501e-10
might O 0 3.972033812971176e-11
suggest O 0 9.821432556123e-11
that O 0 2.7387384894661526e-12
the O 0 2.275558734499139e-11
mutation O 0 2.713180027869022e-11
arose O 0 2.126661763357518e-10
independently O 0 8.697229603171763e-10
. O 0 7.568082827091871e-10
. O 0 1.4242250934159983e-08

Crystal O 1 0.8960683345794678
structure O 0 0.0004400891193654388
of O 0 0.001116893719881773
the O 0 0.0006128015811555088
hemochromatosis B-Disease 1 1.0
protein O 0 5.1719540351768956e-05
HFE O 0 5.396680353442207e-05
and O 0 3.5885880933506087e-09
characterization O 0 2.694772049949279e-08
of O 0 2.9954165814416456e-09
its O 0 1.2552510419983065e-10
interaction O 0 5.171687966765148e-09
with O 0 8.659341022010381e-10
transferrin O 0 3.5432998402029625e-07
receptor O 0 1.2078638178536494e-07
. O 0 2.1109840986355266e-07

HFE O 0 0.004576400853693485
is O 0 7.861539756959246e-07
an O 0 3.2160549778836867e-08
MHC O 0 4.916438410873525e-05
- O 0 0.00045878501259721816
related O 0 0.0008979363483376801
protein O 0 1.8733520334990317e-07
that O 0 1.1041016712010077e-10
is O 0 1.0959603884141966e-11
mutated O 0 3.285986413525954e-11
in O 0 8.615809454770584e-11
the O 0 2.4449833269102328e-09
iron B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999186992645264
overload I-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9510038495063782

HFE O 0 0.0002325958776054904
binds O 0 6.655924380538636e-07
to O 0 7.732636220225686e-08
transferrin O 0 3.4199163678749755e-07
receptor O 0 7.969165771726239e-09
( O 0 7.001602075895619e-10
TfR O 0 4.0563033820717465e-08
) O 0 4.814428022914541e-11
and O 0 5.507979142227448e-11
reduces O 0 6.989340217700146e-10
its O 0 1.2052851772192952e-11
affinity O 0 3.048981900288794e-10
for O 0 1.7025166831885485e-09
iron O 0 6.705654959660023e-05
- O 0 3.529195780060945e-08
loaded O 0 1.0510674997021852e-08
transferrin O 0 4.949519905039779e-08
, O 0 1.6184075191105762e-09
implicating O 0 5.392584512264875e-07
HFE O 0 8.649262599647045e-05
in O 0 9.428809448763786e-07
iron O 1 0.9999837875366211
metabolism O 1 0.8354285359382629
. O 0 8.667112751936656e-07

The O 0 2.4705411760805873e-06
2 O 0 1.9376631826162338e-05
. O 0 5.968421419311198e-07

6 O 0 0.00014639890287071466
A O 0 1.1060840733989608e-05
crystal O 1 0.522926390171051
structure O 0 0.00023764932120684534
of O 0 0.00017852372548077255
HFE O 0 0.0009127215598709881
reveals O 0 1.1800852206533818e-07
the O 0 1.291153850502269e-09
locations O 0 8.523598715726166e-09
of O 0 8.134408631121914e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 2.3122320271795616e-06
and O 0 7.288579695341468e-08
a O 0 1.2099874879822892e-07
patch O 0 0.004397563170641661
of O 1 0.9517690539360046
histidines O 1 0.9838764071464539
that O 0 7.653383704564476e-09
could O 0 6.208520364481274e-10
be O 0 2.3187765943455396e-11
involved O 0 6.733012064552568e-11
in O 0 2.5512675305705557e-11
pH O 0 3.6444902207222185e-08
- O 0 4.8704986710390585e-08
dependent O 0 2.78947069887181e-08
interactions O 0 7.940538182538148e-08
. O 0 3.740029086429786e-08

We O 0 7.306325642275624e-07
also O 0 1.2334060883745224e-08
demonstrate O 0 2.7157520676723834e-08
that O 0 5.02166030980078e-10
soluble O 0 6.893321824463783e-08
TfR O 0 7.251396141327859e-07
and O 0 7.031945692403951e-09
HFE O 0 4.389091827761149e-06
bind O 0 5.102856803773648e-08
tightly O 0 3.229726530662447e-07
at O 0 5.961043569868707e-08
the O 0 4.4413051014657867e-10
basic O 0 1.4315867602476828e-08
pH O 0 2.4171635359948596e-08
of O 0 2.207103300122526e-08
the O 0 5.747424314250793e-09
cell O 0 3.896514400025808e-08
surface O 0 1.7436138932680478e-07
, O 0 4.947863230242433e-10
but O 0 1.457842457863734e-10
not O 0 1.0832545277450478e-10
at O 0 7.91931409338531e-09
the O 0 9.749746565645978e-10
acidic O 0 4.3828807250179125e-09
pH O 0 1.3184501312935026e-07
of O 0 1.4342793974719825e-07
intracellular O 0 2.48018682214024e-06
vesicles O 0 9.358857823826838e-06
. O 0 2.565388740549679e-06

TfR O 0 0.000296017766231671
HFE O 0 0.0002306751412106678
stoichiometry O 0 3.913275577360764e-06
( O 0 5.624727705821897e-08
2 O 0 3.33991664547284e-07
1 O 0 6.018497344939533e-08
) O 0 1.3189287162429508e-10
differs O 0 2.1603341338050086e-09
from O 0 1.7516155192964789e-09
TfR O 0 7.749999753059456e-08
transferrin O 0 2.642388530205153e-08
stoichiometry O 0 2.055975656389819e-08
( O 0 9.40333810817151e-10
2 O 0 3.3467074445070466e-08
2 O 0 1.868687427020177e-08
) O 0 1.0625720442414277e-10
, O 0 1.5599282976452855e-10
implying O 0 1.2781259384198052e-09
a O 0 9.76442537936606e-11
different O 0 1.6046141845804662e-11
mode O 0 1.938847660198917e-08
of O 0 2.944952059991124e-09
binding O 0 7.956104219886129e-09
for O 0 2.8558975184722613e-09
HFE O 0 1.3684935993296676e-06
and O 0 5.808499903281472e-09
transferrin O 0 1.2292402118418977e-07
to O 0 4.263602360055074e-09
TfR O 0 3.8774092558924167e-07
, O 0 2.0265709943512178e-10
consistent O 0 1.8223612618939455e-09
with O 0 8.22771087372054e-11
our O 0 1.330268117882838e-09
demonstration O 0 3.1672859890363725e-09
that O 0 1.2884593392215038e-10
HFE O 0 1.753114560187896e-07
, O 0 5.577662220979107e-10
transferrin O 0 1.4211885890347276e-08
, O 0 3.695543593362771e-10
and O 0 2.9428845471635157e-10
TfR O 0 6.80001619457471e-08
form O 0 1.0846092912686345e-09
a O 0 3.1674856071362e-09
ternary O 0 4.134730318128277e-07
complex O 0 4.710226130555384e-05
. O 0 6.791266287109465e-07

Identification O 0 2.7832800242322264e-07
of O 0 2.9689240932384564e-07
three O 0 1.2645683389322926e-09
novel O 0 4.847131029883656e-10
mutations O 0 1.024912585356752e-10
and O 0 4.948634210744096e-11
a O 0 1.6225111532097714e-10
high O 0 4.230051420250902e-09
frequency O 0 3.056431907566548e-08
of O 0 3.798453107606292e-09
the O 0 4.856736679492712e-10
Arg778Leu O 0 1.9494009961817937e-08
mutation O 0 9.703436665287057e-11
in O 0 4.314201426658393e-11
Korean O 0 1.63243676354341e-08
patients O 0 1.4566861605835868e-10
with O 0 1.39171466018162e-10
Wilson B-Disease 0 4.0836758330442535e-07
disease I-Disease 0 2.528865479689557e-06
. O 0 7.922128020254604e-08

Four O 0 3.1884846407592704e-07
mutations O 0 1.4524290214978919e-08
- O 0 3.9491883541131756e-08
- O 0 1.8780417221364587e-08
R778L O 0 9.34478947556272e-08
, O 0 6.416923659102736e-10
A874V O 0 8.394286155066766e-09
, O 0 9.941469175656081e-11
L1083F O 0 2.2096253715631065e-09
, O 0 2.7593777957024557e-11
and O 0 1.2066008782396498e-11
2304delC O 0 1.6880049580336731e-09
- O 0 4.760818961280222e-10
- O 0 2.2953372535994276e-10
in O 0 8.13570252833351e-11
the O 0 2.5025970185055257e-09
copper O 0 4.360918808288261e-07
- O 0 1.3320174963027398e-09
transporting O 0 1.8033473603296102e-09
enzyme O 0 3.334241494012957e-10
, O 0 2.7824642589990844e-10
P O 0 1.0207337481915602e-06
- O 0 2.618856598246566e-08
type O 0 1.5687713528222957e-07
ATPase O 0 4.159559523486678e-07
( O 0 1.241906022464434e-09
ATP7B O 0 3.6728081909132015e-07
) O 0 5.4097042817558005e-11
, O 0 9.205530435152376e-12
were O 0 7.678726578197459e-12
identified O 0 1.5926189186887818e-11
in O 0 2.3040650984351707e-11
Korean O 0 2.922793918003208e-08
Patients O 0 2.869771087432582e-10
with O 0 1.5502586714344346e-10
Wilson B-Disease 0 8.007181691027654e-07
disease I-Disease 0 1.2415817764122039e-05
. O 0 1.5055795188345655e-07

Arg778Leu O 0 0.0002476946101523936
, O 0 3.220376143531212e-08
the O 0 6.165415733505597e-09
most O 0 1.614321731846502e-10
frequently O 0 6.282132453128142e-11
reported O 0 1.77235569970291e-11
mutation O 0 1.1459744611586054e-11
of O 0 1.640250296697232e-10
this O 0 8.355457818687295e-12
enzyme O 0 2.2382894149242105e-11
, O 0 1.1606467523184172e-11
was O 0 6.81048495376757e-10
found O 0 4.077979273708898e-11
in O 0 4.003354939219328e-11
six O 0 1.400803917306348e-10
of O 0 1.3074478166785752e-09
eight O 0 1.2136834870446478e-09
unrelated O 0 2.2587151704556163e-08
patients O 0 7.871287510674563e-10
studied O 0 1.5108577500200226e-08
, O 0 1.9083417138188175e-11
an O 0 2.6553878453711155e-12
allele O 0 1.5794032748317477e-10
frequency O 0 1.3816101152031024e-08
of O 0 1.4654352398224546e-08
37 O 0 3.28082194300805e-07
. O 0 1.3114826913351862e-07

5 O 0 8.396895282203332e-06
% O 0 2.0609737916288395e-08
, O 0 1.5691977717224859e-09
which O 0 1.0903916658477897e-10
is O 0 1.3466434564679552e-11
considerably O 0 4.513061591104872e-10
higher O 0 4.902115935401241e-10
than O 0 3.219632459944277e-12
those O 0 1.8840799146518927e-12
in O 0 8.894269869219595e-12
other O 0 8.983746038748741e-12
Asian O 0 1.3302775547785473e-10
populations O 0 3.5515888840986776e-11
. O 0 1.9830694863998133e-09

The O 0 4.728561364686357e-08
novel O 0 3.778386936659217e-09
single O 0 2.677432164865934e-10
nucleotide O 0 2.547720256984576e-09
deletion O 0 9.028663150445482e-09
, O 0 1.5156705057695063e-10
2304delC O 0 7.1651835575892164e-09
, O 0 2.177609065290298e-10
was O 0 1.3927835773586139e-08
found O 0 8.982830590475999e-10
in O 0 5.873469488548722e-10
one O 0 1.4178224150285246e-09
patient O 0 1.2210439592763578e-07
. O 0 9.693405189636906e-08

Since O 0 1.7338140878564445e-07
a O 0 8.277048380023189e-09
mutation O 0 7.320952732925434e-10
at O 0 3.04345384449789e-08
cDNA O 0 3.767874900972856e-08
nucleotide O 0 9.530953803960074e-08
2302 O 0 9.96241760731209e-06
( O 0 4.613096571404185e-09
2302insC O 0 1.553804480636245e-07
) O 0 1.177918540484768e-09
had O 0 1.2317627806623932e-08
been O 0 7.315090200243901e-10
previously O 0 8.81742401315222e-10
described O 0 4.141907927746047e-10
, O 0 9.229369872520987e-12
this O 0 5.1423683020135336e-12
region O 0 8.473910462214462e-10
of O 0 2.8412985297876503e-09
the O 0 6.053504808534171e-09
ATP7B O 0 7.150562851165887e-06
gene O 0 1.0679432449478554e-08
may O 0 8.557873520942394e-09
be O 0 6.66636246204888e-10
susceptible O 0 5.976751982217365e-09
to O 0 7.419508896155946e-10
gene O 0 5.166771188669372e-07
rearrangements O 0 0.00010630055476212874
causing O 0 2.6800698833540082e-05
Wilson B-Disease 0 4.4723488827003166e-05
disease I-Disease 0 0.00011745505617000163
. O 0 4.456746012238e-07

Disruption O 0 2.6941434043692425e-05
of O 0 3.6192440688864735e-07
splicing O 0 9.296381620060856e-08
regulated O 0 1.8738125717732146e-08
by O 0 1.9039506082840774e-10
a O 0 1.8742871699117813e-09
CUG O 0 5.165046559341135e-07
- O 0 7.092750831105832e-09
binding O 0 1.2030086260494954e-08
protein O 0 2.162699274776969e-06
in O 0 3.5208458371016604e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.0916081919276621e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9782975316047668
DM B-Disease 1 1.0
) O 0 1.7861152912246325e-07
is O 0 4.3786689829516945e-09
caused O 0 5.6105924350902114e-09
by O 0 2.6531882246771943e-10
a O 0 7.2562569286560574e-09
CTG O 0 1.0988610483764205e-06
expansion O 0 2.0930421840148483e-08
in O 0 8.853589528179384e-10
the O 0 1.6000650804315342e-09
3 O 0 1.5314542523015007e-08
untranslated O 0 1.3120622952556005e-06
region O 0 8.559734254731666e-09
of O 0 1.870680854665352e-08
the O 0 9.74494014371885e-08
DM B-Disease 1 1.0
gene O 0 7.578553891107731e-07
. O 0 1.8643588362010632e-07

One O 0 9.599514783076302e-08
model O 0 3.639884766926116e-07
of O 0 9.835213859332725e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9997535347938538
suggests O 0 1.6185246920485952e-07
that O 0 5.683659098920657e-10
RNAs O 0 4.1571951214791625e-08
from O 0 6.645466399390898e-10
the O 0 2.856904157688689e-10
expanded O 0 9.817911067466767e-11
allele O 0 1.1463466981220805e-10
create O 0 9.23507936789747e-11
a O 0 3.6248465340449343e-10
gain O 0 4.291570654402221e-09
- O 0 3.895033628964484e-09
of O 0 2.133033660811634e-08
- O 0 2.4235700113450775e-09
function O 0 1.2443529540107079e-09
mutation O 0 2.839453498715283e-11
by O 0 6.480445520484768e-12
the O 0 6.412173569891877e-11
inappropriate O 0 1.98085792213476e-09
binding O 0 1.9078849611275928e-09
of O 0 3.0708755538455534e-09
proteins O 0 9.813006657255485e-11
to O 0 2.2972776458907163e-10
the O 0 3.477847121402533e-09
CUG O 0 2.6513425837038085e-06
repeats O 0 1.0591842425355935e-07
. O 0 4.622505400675436e-08

Data O 0 4.786810450241319e-07
presented O 0 1.341111897090741e-07
here O 0 7.803916624027352e-09
indicate O 0 9.063235717476914e-10
that O 0 3.073075474646636e-11
the O 0 1.8374697596801326e-10
conserved O 0 1.1840437963428485e-08
heterogeneous O 0 6.513631234383865e-08
nuclear O 0 7.090737312864803e-07
ribonucleoprotein O 0 9.348783436280428e-08
, O 0 8.563567077679579e-10
CUG O 0 5.155981739335402e-07
- O 0 1.7669343321813358e-08
binding O 0 6.2586380522589025e-09
protein O 0 5.296040583857575e-08
( O 0 8.221063274582718e-10
CUG O 0 2.0716918243124383e-06
- O 0 1.0601665678677819e-07
BP O 0 5.245823899713287e-07
) O 0 2.6398266905758305e-10
, O 0 2.76135891930096e-10
may O 0 3.559194494684448e-09
mediate O 0 1.0703352018026635e-06
the O 0 2.500914604297577e-07
trans O 0 2.4233647764049238e-06
- O 0 5.468189812063429e-08
dominant O 0 1.5833916222618427e-07
effect O 0 6.13359674161984e-08
of O 0 7.420064562779771e-09
the O 0 1.8535217805037973e-09
RNA O 0 1.1304583047433425e-08
. O 0 8.913388249709442e-09

CUG O 1 0.6921273469924927
- O 0 0.0007757501443848014
BP O 0 0.0002598081773612648
was O 0 2.991221435877378e-06
found O 0 1.939579163945382e-09
to O 0 8.425589392846433e-11
bind O 0 1.320665660164977e-10
to O 0 5.4432902629741875e-11
the O 0 2.4026089451290034e-10
human O 0 1.3459239056601291e-08
cardiac O 0 0.02094297483563423
troponin O 0 3.422903682803735e-05
T O 0 1.1605530971792177e-06
( O 0 3.6418870696941497e-10
cTNT O 0 7.924980671702997e-09
) O 0 4.8409380670744184e-11
pre O 0 1.684532158208185e-08
- O 0 2.8479449909468713e-09
messenger O 0 9.053455762852991e-10
RNA O 0 7.527485301750403e-10
and O 0 3.5237958384559676e-11
regulate O 0 3.0201521838968404e-10
its O 0 2.8668699358913585e-11
alternative O 0 7.037322946601421e-10
splicing O 0 2.2526274179313077e-08
. O 0 2.5076392518030843e-08

Splicing O 0 2.533852693886729e-06
of O 0 3.897845033407066e-07
cTNT O 0 2.25167536882509e-06
was O 0 1.395155891259492e-06
disrupted O 0 4.279053428035695e-06
in O 0 8.0329591867212e-08
DM B-Disease 1 1.0
striated O 0 9.773563215276226e-05
muscle O 0 3.6229055240255548e-06
and O 0 3.7185390322491685e-09
in O 0 1.4259856628839884e-09
normal O 0 2.6596511659704447e-08
cells O 0 3.435221551661982e-11
expressing O 0 5.779517489590269e-11
transcripts O 0 9.321622362890025e-10
that O 0 7.7144280546948e-12
contain O 0 1.517293096719996e-10
CUG O 0 3.3799247489696427e-07
repeats O 0 4.0164930936725796e-08
. O 0 2.499020901325366e-08

Altered O 0 3.3130658039226546e-07
expression O 0 6.400647833970652e-08
of O 0 4.900905636873176e-08
genes O 0 4.647398021973004e-09
regulated O 0 2.9771799248123898e-08
posttranscriptionally O 0 4.7065970676385405e-08
by O 0 9.206435058750628e-10
CUG O 0 0.0003597628674469888
- O 0 1.866979346232256e-06
BP O 0 2.1421028577606194e-06
therefore O 0 7.438301530271474e-09
may O 0 1.1081064954510111e-09
contribute O 0 3.815595339684563e-10
to O 0 5.83009907018095e-09
DM B-Disease 1 1.0
pathogenesis O 0 0.4375036358833313
. O 0 1.7404365948436862e-08
. O 0 5.302539918261573e-08

Identification O 0 1.0117453541624855e-07
of O 0 1.0353688395525751e-07
a O 0 3.3778213559543246e-09
novel O 0 1.1671991151374073e-09
nonsense O 0 5.193573571204979e-09
mutation O 0 1.1323583737343768e-10
and O 0 6.626136445087027e-11
a O 0 6.73182121158078e-10
missense O 0 1.7217191228269257e-08
substitution O 0 8.746624757804966e-09
in O 0 2.5197488540129598e-09
the O 0 1.442352637326394e-08
vasopressin O 0 2.48296714744356e-07
- O 0 1.0382164816746808e-07
neurophysin O 0 1.092580760087003e-06
II O 0 0.0003765472210943699
gene O 0 2.733523851716768e-09
in O 0 7.51643802754387e-10
two O 0 7.193645679137717e-11
Spanish O 0 2.7332005547719973e-09
kindreds O 0 4.453652380220774e-08
with O 0 9.324663263754474e-10
familial B-Disease 1 0.9967036843299866
neurohypophyseal I-Disease 1 0.9999995231628418
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9997397065162659
. O 0 1.6684292859281413e-05

Familial B-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.095548395824153e-05
FNDI B-Disease 1 1.0
) O 0 2.075062122131044e-09
is O 0 5.458323723561698e-11
an O 0 8.712899152163445e-11
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 2.8638303319894476e-06
by O 0 1.0408902628711303e-09
deficiency O 1 0.8444700241088867
in O 0 2.7914028422060255e-08
the O 0 3.8443084804384853e-07
antidiuretic O 0 1.2221232736919774e-06
hormone O 0 4.2987085890899834e-08
arginine O 0 8.259546291355946e-08
vasopressin O 0 2.3908540924821864e-07
( O 0 1.367321922352005e-09
AVP O 0 1.0227873303847446e-07
) O 0 4.286788979346312e-11
encoded O 0 1.5872218817047923e-10
by O 0 1.2616190037118002e-10
the O 0 7.551388847559792e-09
AVP O 0 1.1721864211722277e-05
- O 0 4.59894636151148e-07
neurophysin O 0 5.797926405648468e-06
II O 1 0.9999879598617554
( O 0 3.6611833564847984e-08
AVP O 0 7.759666004858445e-06
- O 0 1.755590659513473e-07
NPII O 0 4.7902443611747e-07
) O 0 8.149587255035229e-11
gene O 0 1.5478714143757344e-10
on O 0 3.1259470567590597e-09
chromosome O 0 1.1357320772731327e-07
20p13 O 0 7.537024089288025e-07
. O 0 1.042228277015056e-07

In O 0 1.1893769169546431e-07
this O 0 1.2145727756873725e-09
study O 0 8.713202381827045e-10
, O 0 2.0882101603447722e-11
we O 0 1.1422211267098081e-11
analyzed O 0 1.0733863797796062e-10
two O 0 1.6210440975661378e-11
families O 0 1.5727522366046354e-12
with O 0 4.2242261771852085e-11
FNDI B-Disease 1 0.9999598264694214
using O 0 5.386040058397157e-09
direct O 0 2.0671377942704794e-09
automated O 0 4.085420357569092e-08
fluorescent O 0 4.4086871930915095e-09
, O 0 3.273027404659956e-10
solid O 0 8.48235615080739e-09
phase O 0 4.0416452407043835e-08
, O 0 9.931765826420857e-11
single O 0 5.517726553438962e-11
- O 0 1.594017695616401e-10
stranded O 0 3.797377343128794e-11
DNA O 0 2.8966481990799764e-12
sequencing O 0 1.3894674473491353e-11
of O 0 1.2261637538646397e-10
PCR O 0 8.652455973923168e-10
- O 0 3.0369287085108e-09
amplified O 0 4.246480145297937e-08
AVP O 0 9.045478691405151e-06
- O 0 4.919589855489903e-07
NPII O 0 5.749653610109817e-06
DNA O 0 1.851520039508614e-07
. O 0 5.595579821715546e-08

In O 0 2.750502687831613e-07
one O 0 6.085328685401237e-09
of O 0 9.066109640798459e-09
the O 0 1.764478341215181e-09
families O 0 7.284326787593276e-12
, O 0 4.1485690750742155e-12
affected O 0 1.7673756338640323e-12
individuals O 0 8.181970996990612e-14
presented O 0 7.579187277784172e-11
a O 0 6.734604540703515e-11
novel O 0 3.323053290871236e-11
nonsense O 0 4.293509159314368e-10
mutation O 0 5.346238209080756e-12
in O 0 1.3922163422108724e-10
exon O 0 1.0405613259933943e-08
3 O 0 1.077300915142132e-08
of O 0 5.7090967509054735e-09
the O 0 1.4848140494905238e-09
gene O 0 2.657650211013163e-10
, O 0 6.209109615351593e-11
consisting O 0 2.6696048149865703e-10
in O 0 1.8260389866853188e-09
a O 0 7.11970971067899e-09
G O 0 1.155717768597242e-06
to O 0 9.069624695712264e-08
T O 0 1.777787292667199e-05
transition O 0 2.8509999538073316e-05
at O 0 2.529202902223915e-06
nucleotide O 0 3.3554513834133104e-08
2101 O 0 1.2676210872086813e-06
, O 0 5.503928424133164e-10
which O 0 3.0319483035334827e-11
produces O 0 1.7768644194893213e-11
a O 0 5.417830420406666e-11
stop O 0 3.3557551182283873e-10
signal O 0 9.029800018822698e-09
in O 0 5.887400011950206e-10
codon O 0 4.878361714588664e-09
82 O 0 1.8579265770313214e-07
( O 0 2.5794044677951433e-09
Glu O 0 6.949552471269271e-07
) O 0 2.194501025343243e-09
of O 0 2.5036399620148586e-07
NPII O 0 0.000735341920517385
. O 0 2.647989504112047e-06

The O 0 3.7078366403875407e-06
premature O 0 3.1135298286244506e-06
termination O 0 3.3011880873345945e-07
eliminates O 0 1.87028888376517e-07
part O 0 9.251343691119018e-09
of O 0 2.8496090820340214e-08
the O 0 9.249032650870959e-09
C O 0 2.6362954486103263e-06
- O 0 8.136455953433597e-09
terminal O 0 1.1189493775987103e-08
domain O 0 1.4178636931205801e-08
of O 0 1.0682121853733406e-08
NPII O 0 7.461294444510713e-07
, O 0 5.545350845181929e-10
including O 0 1.4958481675542146e-10
a O 0 5.428508198512816e-10
cysteine O 0 5.640775846416091e-09
residue O 0 1.6781001477284008e-07
in O 0 1.8768020471071623e-09
position O 0 8.686462393825423e-08
85 O 0 5.6326079800328444e-08
, O 0 9.286378888084812e-10
which O 0 7.290933135006838e-11
could O 0 8.394101386199893e-11
be O 0 3.294137879139569e-11
involved O 0 9.494814656729744e-11
in O 0 5.6283897681419504e-11
the O 0 3.0069896572726407e-10
correct O 0 3.2007193340177764e-08
folding O 0 8.642606985631573e-07
of O 0 1.160865892302354e-07
the O 0 1.8380259803052468e-07
prohormone O 0 0.0001632153580430895
. O 0 8.31047600513557e-07

In O 0 1.3582800306721765e-07
the O 0 6.638935445835159e-08
second O 0 5.32248130014068e-08
family O 0 6.111590122870325e-10
, O 0 8.042513877093427e-11
a O 0 1.766073259856782e-10
G279A O 0 1.9835195708139963e-09
substitution O 0 1.065074473061145e-09
at O 0 1.8690759162609538e-08
position O 0 3.684342786414163e-08
- O 0 6.118894724238544e-09
1 O 0 1.890844636420752e-08
of O 0 1.5632173333557375e-09
the O 0 4.954625043573913e-10
signal O 0 8.019116926050174e-09
peptide O 0 7.411432578763311e-10
was O 0 1.3805268039845942e-09
observed O 0 4.5064987852505567e-10
in O 0 7.081753933269042e-11
all O 0 5.708524972170004e-11
affected O 0 2.367472051734154e-10
individuals O 0 1.4773555989666676e-10
. O 0 2.0732352723484837e-08

This O 0 5.123678548102362e-08
missense O 0 2.3426757707056822e-06
mutation O 0 1.767706336863739e-08
, O 0 1.0177289011537027e-09
which O 0 6.006289909876728e-10
replaces O 0 2.6725783754955046e-06
Ala O 0 5.144417627889197e-06
with O 0 2.25114558105588e-08
Thr O 0 6.754256901331246e-05
, O 0 2.4610971038896423e-09
is O 0 2.16115722539989e-10
frequent O 0 1.4463353847915528e-09
among O 0 1.4105208112624723e-09
FNDI B-Disease 1 1.0
patients O 0 5.005767525290139e-05
and O 0 5.772750810706384e-08
is O 0 7.64258878405144e-09
thought O 0 2.8958131448320046e-09
to O 0 5.3144797590443105e-11
reduce O 0 1.744290711869212e-09
the O 0 4.263112363123156e-10
efficiency O 0 9.128227951293866e-09
of O 0 1.8930521594739957e-09
cleavage O 0 2.2292419021852083e-09
by O 0 2.0516605081510875e-10
signal O 0 1.1482587325417626e-07
peptidases O 0 6.409761681425152e-07
. O 0 8.172539089912334e-09
. O 0 4.855213475707387e-08

Genetic O 0 3.092496001499967e-07
heterogeneity O 0 5.941338372394966e-07
of O 0 7.280075919879891e-07
Saethre B-Disease 1 0.9994157552719116
- I-Disease 1 0.9961695075035095
Chotzen I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999924898147583
, O 0 6.310200695303081e-10
due O 0 7.992657202748887e-08
to O 0 2.1786985548999382e-09
TWIST O 0 1.2034811334160622e-06
and O 0 1.8725863082380556e-09
FGFR O 0 1.3442172530631069e-05
mutations O 0 3.764354872259901e-08
. O 0 4.210942705640264e-08

Thirty O 0 7.858785829739645e-05
- O 0 2.976898258566507e-06
two O 0 2.6210238424084764e-09
unrelated O 0 7.156158687848801e-08
patients O 0 2.5349661258999845e-10
with O 0 2.4385726077325032e-11
features O 0 6.3922995785503645e-09
of O 0 3.187194351994549e-06
Saethre B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999889135360718
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
, O 0 9.489570240717171e-10
a O 0 1.1638844332750864e-09
common O 0 1.4217205546174227e-07
autosomal B-Disease 1 0.9827173352241516
dominant I-Disease 0 0.34314313530921936
condition I-Disease 1 0.9925734996795654
of O 0 0.01158370915800333
craniosynostosis B-Disease 1 0.999982476234436
and O 0 7.611342880409211e-07
limb B-Disease 1 0.9988178610801697
anomalies I-Disease 1 0.8740406632423401
, O 0 3.2553473250374054e-09
were O 0 1.3945238297452534e-09
screened O 0 4.827747979163632e-09
for O 0 2.2785612285858292e-10
mutations O 0 5.685111825748379e-10
in O 0 2.036161461660413e-09
TWIST O 0 2.0812117895729898e-07
, O 0 4.669110653665598e-10
FGFR2 O 0 6.150889362288581e-07
, O 0 6.850285338977358e-10
and O 0 1.795385173863906e-09
FGFR3 O 0 2.99579569400521e-05
. O 0 2.4069188953035336e-07

Nine O 0 6.771309131181624e-07
novel O 0 9.0414879139189e-08
and O 0 2.5112756318890206e-09
three O 0 1.86792381562384e-09
recurrent O 0 8.628763339402212e-07
TWIST O 0 6.094420541558065e-07
mutations O 0 1.0585430310072752e-09
were O 0 3.032568363092736e-10
found O 0 3.0933998418358755e-11
in O 0 1.6435260097313886e-10
12 O 0 5.2116333471019516e-09
families O 0 1.7771939475608178e-10
. O 0 2.5119236468640338e-08

Seven O 0 2.1678067696484504e-07
families O 0 4.791866348163865e-10
were O 0 2.3768389478817653e-09
found O 0 3.1788865983983783e-10
to O 0 5.391851895519828e-11
have O 0 3.148526925289552e-11
the O 0 5.228636967835598e-10
FGFR3 O 0 3.299551565305592e-07
P250R O 0 2.5505709544404453e-08
mutation O 0 2.1892740398321564e-10
, O 0 6.220844672721881e-11
and O 0 3.092933548165533e-11
one O 0 5.280609977065254e-11
individual O 0 9.333301492775448e-12
was O 0 1.3365227147232872e-08
found O 0 2.6660376684084497e-10
to O 0 2.812229615845041e-11
have O 0 5.178639201491864e-12
an O 0 1.5768379657554732e-11
FGFR2 O 0 9.542723233835204e-08
VV269 O 0 7.346262975715945e-08
- O 0 2.893738759723874e-08
270 O 0 4.5162846795676614e-09
deletion O 0 5.43644063100146e-08
. O 0 4.295872813031565e-08

To O 0 5.531897784294415e-08
date O 0 3.792859502027568e-07
, O 0 9.572866943585723e-10
our O 0 1.90756022089289e-10
detection O 0 3.772935297519098e-09
rate O 0 2.5903285072459425e-10
for O 0 7.915953309511892e-11
TWIST O 0 3.947283033767235e-08
or O 0 8.231670900471499e-10
FGFR O 0 4.0851639937500295e-07
mutations O 0 8.861191780340505e-10
is O 0 7.157199138907444e-11
68 O 0 3.2712752506824927e-09
% O 0 2.724112324603567e-10
in O 0 3.6543007508882397e-10
our O 0 1.3194056514009844e-08
Saethre B-Disease 0 0.0001114384358515963
- I-Disease 0 8.186259947251529e-06
Chotzen I-Disease 0 0.06743627786636353
syndrome I-Disease 0 0.2743825912475586
patients O 0 1.1475460581777952e-09
, O 0 2.964516132575312e-11
including O 0 2.8202492424744818e-11
our O 0 9.213337870406235e-10
five O 0 1.688638395780373e-10
patients O 0 3.595655023724831e-11
elsewhere O 0 2.7951974068685104e-11
reported O 0 1.9474654527895652e-11
with O 0 2.0040104992125052e-11
TWIST O 0 5.857610858583939e-07
mutations O 0 8.105986992745784e-09
. O 0 3.331740217049628e-08

More O 0 1.2281218708665165e-08
than O 0 8.316638488992112e-10
35 O 0 3.3689102618694733e-09
different O 0 1.5549257714742026e-10
TWIST O 0 2.4275129462125733e-08
mutations O 0 4.272872888844148e-10
are O 0 1.810952776626351e-11
now O 0 2.3741996216242178e-11
known O 0 1.3339865670425333e-11
in O 0 1.3136032192551106e-11
the O 0 3.280796467830527e-10
literature O 0 4.118685836829172e-09
. O 0 6.427718801660376e-09

The O 0 3.55795151563143e-07
most O 0 8.957747876792155e-10
common O 0 2.568034118688445e-10
phenotypic O 0 1.5932441144173026e-08
features O 0 1.1867857807601467e-09
, O 0 6.109139583099221e-11
present O 0 1.312471797909609e-10
in O 0 3.200545106718522e-10
more O 0 1.3532220483059021e-11
than O 0 5.229988751104253e-12
a O 0 3.5352807487010196e-11
third O 0 1.7118871598054142e-10
of O 0 2.585699654389373e-09
our O 0 1.694769991011924e-09
patients O 0 1.5556377019887435e-10
with O 0 5.610832631841589e-11
TWIST O 0 8.603719692246159e-08
mutations O 0 6.897366011671124e-10
, O 0 8.944427143386946e-11
are O 0 2.141117491638589e-11
coronal B-Disease 0 1.6978744099560572e-07
synostosis I-Disease 0 7.667616728213034e-07
, O 0 3.480089771912276e-09
brachycephaly B-Disease 0 3.465616146058892e-06
, O 0 3.025690276103887e-08
low B-Disease 0 5.92856049479451e-05
frontal I-Disease 1 0.9999996423721313
hairline I-Disease 1 1.0
, O 0 8.395229087909684e-06
facial B-Disease 1 0.9999954700469971
asymmetry I-Disease 1 0.9999966621398926
, O 0 3.2471575650561135e-07
ptosis B-Disease 0 0.00031548264087177813
, O 0 4.3431629848100783e-08
hypertelorism B-Disease 0 0.00015981709293555468
, O 0 3.767041079072442e-08
broad B-Disease 0 1.1719689609890338e-06
great I-Disease 0 9.986972872866318e-05
toes I-Disease 0 0.007006704341620207
, O 0 3.2948199724103233e-09
and O 0 4.523345253915068e-09
clinodactyly B-Disease 0 2.0201983716106042e-05
. O 0 7.16759188890137e-07

Significant O 0 6.858180654489843e-07
intra O 0 0.0002114151429850608
- O 0 3.2737227684265235e-06
and O 0 6.156825715919467e-09
interfamilial O 0 5.769976496594609e-07
phenotypic O 0 1.2525924830697477e-06
variability O 0 7.267714181580232e-07
is O 0 1.1247320436114094e-10
present O 0 3.949972987582484e-11
for O 0 6.109163175338495e-11
either O 0 5.148411474920067e-09
TWIST O 0 4.7219552357091743e-07
mutations O 0 3.0627329561383476e-09
or O 0 1.2242014069130391e-09
FGFR O 0 3.123129090454313e-06
mutations O 0 1.4484790256119595e-07
. O 0 6.027043752965255e-08

The O 0 7.809852036189113e-07
overlap O 0 4.7646710754634114e-07
in O 0 2.7502800037382258e-09
clinical O 0 6.4079497263946905e-09
features O 0 7.609290419985371e-10
and O 0 2.2022822454559332e-10
the O 0 4.08963390929884e-10
presence O 0 5.180471607246773e-10
, O 0 3.377379972913097e-11
in O 0 3.7828178089949205e-11
the O 0 1.125212631403194e-10
same O 0 5.577340325690905e-11
genes O 0 3.624471209273672e-11
, O 0 1.7088620449245973e-11
of O 0 1.8680156033124007e-10
mutations O 0 6.254741863331859e-11
for O 0 3.3226746354309e-10
more O 0 5.658723142842881e-11
than O 0 4.588853602660592e-11
one O 0 1.0986524884293303e-10
craniosynostotic B-Disease 0 2.5690997773608615e-08
condition I-Disease 0 2.0430762504020095e-07
- O 0 4.921811846969604e-09
such O 0 2.485266714646883e-10
as O 0 1.7045214129041142e-09
Saethre B-Disease 0 1.068398432835238e-06
- I-Disease 0 6.75045797038365e-08
Chotzen I-Disease 0 1.2419916401995579e-06
, I-Disease 0 2.0214954155051146e-09
Crouzon I-Disease 0 1.2172192782600177e-06
, I-Disease 0 3.3127411924738226e-09
and I-Disease 0 6.954118170199308e-09
Pfeiffer I-Disease 0 0.006293208338320255
syndromes I-Disease 0 0.00014450740127358586
- O 0 1.264725369765074e-06
support O 0 4.77745203397717e-08
the O 0 3.7774600514239864e-07
hypothesis O 0 2.1048441212201396e-08
that O 0 8.585446242825867e-11
TWIST O 0 2.3385629432937094e-08
and O 0 1.5116662088754396e-10
FGFRs O 0 6.248991013535488e-08
are O 0 1.906475324831014e-11
components O 0 6.78197054071461e-09
of O 0 1.6148984371966435e-09
the O 0 1.5899488670090278e-10
same O 0 1.220770845522523e-10
molecular O 0 1.9492587544078788e-09
pathway O 0 6.710668687404109e-10
involved O 0 1.7256558682010592e-10
in O 0 1.5610228387696878e-11
the O 0 5.593949262139297e-11
modulation O 0 4.386445340287537e-08
of O 0 2.880649390135659e-07
craniofacial O 1 0.9999855756759644
and O 0 1.3886993883716059e-06
limb O 0 0.05807537958025932
development O 0 6.144176722955308e-07
in O 0 1.3229334960840333e-08
humans O 0 5.507921674308136e-09
. O 0 2.7903673815998786e-10
. O 0 2.7155953041813063e-09

Mutation O 0 2.4749050808736683e-08
analysis O 0 9.655684252152241e-09
of O 0 2.29427605802357e-08
UBE3A O 0 0.004655920900404453
in O 0 6.014199243509211e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00011083986464655027
. O 0 6.840472792646324e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.009392940439283848
AS B-Disease 1 1.0
) O 0 3.462055309100265e-09
is O 0 3.0967187147901143e-10
caused O 0 7.080055430819243e-10
by O 0 8.745198315507352e-11
chromosome O 0 1.5822881493932073e-07
15q11 O 0 5.328210477273387e-07
- O 0 9.986959703667253e-09
q13 O 0 3.202221421361173e-08
deletions O 0 5.961325655334804e-09
of O 0 7.894607745306814e-10
maternal O 0 2.537729582030579e-09
origin O 0 1.551903605623295e-10
, O 0 1.1998948709623924e-11
by O 0 6.925811313340802e-11
paternal O 0 2.9928372669019154e-07
uniparental B-Disease 0 0.0007946672267280519
disomy I-Disease 0 0.0009800941916182637
( O 0 2.930867140094051e-07
UPD B-Disease 1 0.9999992847442627
) O 0 1.3357581707396093e-08
15 O 0 1.8566010950848977e-08
, O 0 1.0751444873280391e-10
by O 0 1.59286889234167e-10
imprinting O 0 0.00026184957823716104
defects O 1 0.9439212083816528
, O 0 1.5526978591751117e-09
and O 0 1.3598437653694617e-10
by O 0 5.140370074041556e-11
mutations O 0 2.589638281591533e-09
in O 0 1.7419800046880596e-09
the O 0 4.4387945763446623e-08
UBE3A O 0 4.706436811829917e-05
gene O 0 2.5998056685239135e-07
. O 0 3.443144862558256e-07

UBE3A O 0 0.0005913638742640615
encodes O 0 1.1761262612708379e-06
a O 0 8.052730890995008e-07
ubiquitin O 0 1.397383584844647e-06
- O 0 3.769568195366446e-07
protein O 0 4.7906830502597586e-08
ligase O 0 2.22347651401833e-08
and O 0 7.135870783159248e-10
shows O 0 1.1677363076501024e-08
brain O 0 2.8272229428694118e-06
- O 0 9.783245324967993e-09
specific O 0 4.65587968179193e-09
imprinting O 0 3.2655220820743125e-06
. O 0 1.1422167744967737e-07

Here O 0 2.1585801732726395e-06
we O 0 4.853555779504859e-08
describe O 0 6.545663921997402e-08
UBE3A O 0 1.068544588633813e-05
coding O 0 4.634389370039571e-06
- O 0 4.5038308371658786e-07
region O 0 5.991294926843693e-08
mutations O 0 1.27955535056401e-09
detected O 0 3.4505058810196942e-09
by O 0 3.287378008698383e-11
SSCP O 0 1.1108352282462874e-07
analysis O 0 1.5660523988714203e-09
in O 0 7.126526591072491e-10
13 O 0 1.0415898366034071e-08
AS B-Disease 1 0.9969710111618042
individuals O 0 1.8940986279414318e-10
or O 0 3.3600480175977054e-09
families O 0 2.454102199234143e-10
. O 0 9.942048961875116e-09

Two O 0 1.401321583216486e-07
identical O 0 3.321918029541848e-07
de O 0 1.4361727153300308e-05
novo O 0 3.830727109743748e-06
5 O 0 9.62230728873692e-07
- O 0 1.824192139565639e-07
bp O 0 9.862839078778052e-08
duplications O 0 4.1127540839625e-07
in O 0 2.8153520403861876e-08
exon O 0 1.3653311725647654e-06
16 O 0 1.8828448844487866e-07
were O 0 2.6849422241070897e-08
found O 0 1.515047642897116e-08
. O 0 3.8484895270585184e-08

Among O 0 5.102642575138816e-08
the O 0 9.24615761732639e-09
other O 0 3.2559352436400957e-10
11 O 0 1.0029657104837497e-09
unique O 0 3.460891850881609e-10
mutations O 0 2.00878758072065e-10
, O 0 3.6584346663204315e-11
8 O 0 2.142230615120866e-09
were O 0 6.177406919327666e-10
small O 0 3.8573191862845135e-10
deletions O 0 3.9756913317035014e-09
or O 0 1.5413701426325588e-09
insertions O 0 7.152269176913251e-08
predicted O 0 1.6194834984162298e-07
to O 0 4.372301631860864e-09
cause O 0 4.5729237285740965e-07
frameshifts O 0 1.1034732779080514e-05
, O 0 7.900184506581809e-09
1 O 0 9.933352629332148e-08
was O 0 7.043519900662432e-08
a O 0 8.739099999210964e-10
mutation O 0 2.7235186328411487e-11
to O 0 6.415157988159947e-11
a O 0 1.1235061769809818e-09
stop O 0 1.978124331003528e-09
codon O 0 1.1548425549179342e-09
, O 0 5.980146933204367e-10
1 O 0 1.9514432736400522e-08
was O 0 2.7634904142814776e-08
a O 0 3.941736270718366e-09
missense O 0 1.1111802145080674e-08
mutation O 0 3.0672622775007596e-10
, O 0 2.8166488585945615e-10
and O 0 3.165744333344378e-10
1 O 0 9.285253810276117e-08
was O 0 2.8482946845542756e-07
predicted O 0 5.3843375980022756e-08
to O 0 1.006332572828228e-09
cause O 0 3.695242112300434e-09
insertion O 0 4.542634268744905e-09
of O 0 7.505514076910913e-08
an O 0 3.4741871601795538e-09
isoleucine O 0 3.2070431643660413e-06
in O 0 3.857065422607775e-08
the O 0 8.125959993776632e-08
hect O 0 1.7689259266262525e-06
domain O 0 5.772623694610957e-07
of O 0 2.7427387294665095e-07
the O 0 9.392805111474445e-08
UBE3A O 0 1.2000923561572563e-05
protein O 0 2.3248295732969382e-08
, O 0 2.1704685271295432e-10
which O 0 3.8668178901912764e-12
functions O 0 2.4934632136819346e-09
in O 0 2.8318520861603247e-09
E2 O 0 3.717378262990678e-07
binding O 0 4.495082972511e-09
and O 0 2.090842610158461e-09
ubiquitin O 0 1.7478993186159641e-07
transfer O 0 9.92950390354963e-07
. O 0 1.7942123520242603e-07

Eight O 0 3.107289501258492e-07
of O 0 5.0663530259953404e-08
the O 0 2.7110309552824674e-09
cases O 0 5.16178155773872e-10
were O 0 1.2692218109844333e-10
familial O 0 6.1615015312099786e-09
, O 0 7.497233389663904e-11
and O 0 5.074885303657517e-11
five O 0 1.8647938748728166e-10
were O 0 6.805096486317552e-10
sporadic O 0 4.7262443558793166e-07
. O 0 1.1673538580225795e-07

In O 0 2.33354654710638e-07
two O 0 1.2765235091194427e-08
familial O 0 1.3367402971198317e-06
cases O 0 1.152433615203563e-08
and O 0 4.605094361398443e-10
one O 0 7.028787274432347e-11
sporadic O 0 2.3143131855363208e-08
case O 0 4.490001703771895e-09
, O 0 1.2157774786913933e-10
mosaicism O 0 2.892219299610588e-07
for O 0 6.491206239189751e-09
UBE3A O 0 1.3027935892750975e-05
mutations O 0 5.513786760502626e-09
was O 0 2.8938103469045018e-08
detected O 0 6.56566800927294e-09
in O 0 1.2135069338281568e-10
the O 0 9.12519393381217e-10
mother O 0 2.8184239386774834e-09
of O 0 2.6889651394412795e-08
three O 0 9.533113853876785e-09
AS B-Disease 1 1.0
sons O 0 9.375834224556456e-07
, O 0 2.71228622894526e-10
in O 0 1.7864074108864259e-10
the O 0 3.2278524297879585e-09
maternal O 0 6.333454507512215e-07
grandfather O 0 3.208903535778518e-06
of O 0 7.329570053116186e-06
two O 0 1.9444810561708437e-07
AS B-Disease 1 1.0
first O 0 5.040233190811705e-07
cousins O 0 5.018830862013601e-08
, O 0 2.3734220144788765e-10
and O 0 1.4548230675703877e-10
in O 0 1.4417301796854076e-09
the O 0 3.628612788020291e-08
mother O 0 3.854197316854879e-08
of O 0 1.8397868473130075e-07
an O 0 2.7293403093153756e-09
AS B-Disease 1 1.0
daughter O 0 0.00033339601941406727
. O 0 1.8247712887387024e-06

The O 0 6.994280710159728e-08
frequencies O 0 2.7339634556255987e-08
with O 0 1.3542245103081996e-10
which O 0 2.3824192618704387e-11
we O 0 2.3819739583541555e-11
detected O 0 4.291762778496633e-11
mutations O 0 6.5195852189114945e-12
were O 0 9.379938492592999e-11
5 O 0 2.2401909494096373e-10
( O 0 7.2125604100303775e-12
14 O 0 2.7228133636647556e-10
% O 0 2.148411309965681e-11
) O 0 9.195789962834766e-12
of O 0 7.267749735362372e-10
35 O 0 1.6177007511330999e-09
in O 0 2.74133354905004e-10
sporadic O 0 8.44216607731596e-09
cases O 0 1.6538277691768855e-10
and O 0 6.336405705686943e-11
8 O 0 1.2936410831443368e-09
( O 0 1.990225345638308e-11
80 O 0 2.664040099631393e-10
% O 0 1.5319837412541837e-11
) O 0 7.714987503015802e-12
of O 0 4.4952441768941753e-10
10 O 0 5.384352408377424e-10
in O 0 1.3870081472244777e-10
familial O 0 2.1197429589392414e-08
cases O 0 2.113190067376536e-09
. O 0 5.154972559928694e-10
. O 0 1.2193084764078321e-08

The O 0 2.1148754967725836e-05
hemochromatosis B-Disease 1 1.0
845 O 0 3.266524072387256e-05
G O 0 6.6309066824032925e-06
- O 0 1.999573839839286e-07
- O 0 1.1839760283294254e-08
> O 0 3.835978201749413e-09
A O 0 1.146052253098162e-09
and O 0 1.8207369639755555e-11
187 O 0 2.2610104066789205e-10
C O 0 1.3765859563363847e-08
- O 0 1.7560243259495678e-09
- O 0 9.934669753519643e-10
> O 0 1.3849839053392543e-09
G O 0 4.410739329330227e-09
mutations O 0 2.8165187196393937e-11
: O 0 1.0543783728056422e-12
prevalence O 0 9.154302316183305e-11
in O 0 2.0414947510261072e-11
non O 0 1.4545609161586981e-08
- O 0 1.8049036043521482e-08
Caucasian O 0 2.245189456573371e-08
populations O 0 5.483307696785289e-10
. O 0 1.1237553110277076e-08

Hemochromatosis B-Disease 1 0.9999730587005615
, O 0 1.725316138845301e-07
the O 0 3.086219976466964e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 5.166021921354513e-08
leads O 0 1.8607227048050845e-07
, O 0 4.246931695206513e-09
if O 0 1.920310239711398e-07
untreated O 1 0.9999958276748657
, O 0 3.441763540834586e-09
to O 0 7.639396670811038e-09
progressive O 1 0.9999998807907104
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 0.00026486944989301264
premature B-Disease 0 9.627999679651111e-05
death I-Disease 0 2.195483375544427e-06
. O 0 2.884756895582541e-07

The O 0 0.0003373041108716279
hemochromatosis B-Disease 1 1.0
gene O 0 3.097761236858787e-06
, O 0 3.466358577952633e-08
HFE O 0 3.575226946850307e-05
, O 0 6.487096637641798e-09
recently O 0 1.0238760950187498e-08
has O 0 1.154245171663959e-10
been O 0 3.8985821515513663e-11
identified O 0 4.9811536839694526e-11
, O 0 1.4419872414184187e-11
and O 0 1.365441353734509e-11
characterization O 0 5.763232113764616e-09
of O 0 2.5481153187456584e-08
this O 0 2.3354493339233784e-10
gene O 0 1.3077721128240682e-09
has O 0 1.0754357820941252e-10
shown O 0 7.312268152093182e-11
that O 0 1.4445907577792516e-12
it O 0 3.260591666456869e-13
contains O 0 2.261364787916817e-13
two O 0 2.361862333315201e-13
mutations O 0 3.1398936727565496e-13
that O 0 2.4610733373106597e-13
result O 0 1.3384313622688548e-11
in O 0 5.653285825579779e-11
amino O 0 1.5230428029866516e-10
acid O 0 3.543396964733603e-10
substitutions O 0 8.372184057137133e-10
- O 0 1.0221311574909464e-09
cDNA O 0 2.320491354623755e-09
nucleotides O 0 7.131965573670129e-10
845 O 0 8.891619884821012e-09
G O 0 8.206783519426608e-08
- O 0 1.0724319210453359e-08
- O 0 6.1877405421739695e-09
> O 0 6.219309067745371e-09
A O 0 4.50387993566892e-09
( O 0 1.9317353272541027e-11
C282Y O 0 8.350048985583669e-10
) O 0 3.986802207811557e-12
and O 0 2.9023018363605324e-11
187 O 0 3.347585264545927e-10
C O 0 1.9014230190350645e-08
- O 0 3.3580362934770847e-09
- O 0 2.3738080390245386e-09
> O 0 2.9204965112938908e-09
G O 0 2.939128940226965e-08
( O 0 2.3277423044643086e-10
H63D O 0 4.6855748792040686e-07
) O 0 2.076590455146743e-09
. O 0 4.2630599494941634e-08

Although O 0 6.241761730052531e-05
hemochromatosis B-Disease 1 1.0
is O 0 3.532232639713584e-08
common O 0 7.6583486219306e-09
in O 0 2.7024091853178334e-09
Caucasians O 0 3.7254693552313256e-08
, O 0 2.2743709693351377e-10
affecting O 0 7.638271126708673e-10
> O 0 4.683106347158628e-09
= O 0 4.689515442635184e-09
1 O 0 1.0184090015741276e-08
/ O 0 9.288823599185037e-10
300 O 0 3.865072151221227e-11
individuals O 0 1.3483570813696555e-12
of O 0 5.530531588249232e-10
northern O 0 5.257688173720965e-10
European O 0 4.013893106780131e-10
origin O 0 4.994103464106558e-10
, O 0 2.5729746458424962e-11
it O 0 1.670087570841694e-12
has O 0 9.13395661189531e-13
not O 0 5.660260671627726e-13
been O 0 9.055653362594063e-13
recognized O 0 2.6391293664329574e-12
in O 0 8.216070185307345e-12
other O 0 2.255878817081225e-11
populations O 0 4.341971920895915e-11
. O 0 3.1025730873324164e-09

The O 0 3.6359359967264027e-08
present O 0 1.1102135877294472e-09
study O 0 7.509670663097268e-11
used O 0 1.9101551937406036e-11
PCR O 0 8.317729144335928e-11
and O 0 8.405521070842248e-12
restriction O 0 4.1201217437780713e-10
- O 0 2.407783417091025e-10
enzyme O 0 4.7184998963611946e-11
digestion O 0 3.9111416882953165e-10
to O 0 2.93056585942697e-11
analyze O 0 2.572259627520168e-10
the O 0 7.517251404687286e-11
frequency O 0 2.1266464145242026e-09
of O 0 1.0660337057544211e-09
the O 0 5.352314147444304e-10
845 O 0 3.649823554496834e-09
G O 0 1.2993838893748944e-08
- O 0 2.22615725853359e-09
- O 0 4.6427708899621223e-10
> O 0 2.697495005143935e-10
A O 0 1.4111363466629e-10
and O 0 5.758904637886975e-12
187 O 0 1.021440779180871e-10
C O 0 3.4963101303020494e-09
- O 0 7.127749501734115e-10
- O 0 5.807599401386199e-10
> O 0 9.38876754119633e-10
G O 0 6.022123244520117e-09
mutations O 0 2.0232689135202264e-10
in O 0 3.841745532806584e-10
HLA O 0 1.7427053577989682e-08
- O 0 1.6641219513502392e-09
typed O 0 1.3001367760168137e-09
samples O 0 4.6418299759487525e-11
from O 0 1.4686796223628562e-10
non O 0 1.5310307688309877e-08
- O 0 2.7526465551375168e-09
Caucasian O 0 3.8977980842958004e-09
populations O 0 5.921460804331202e-12
, O 0 2.318916976842833e-12
comprising O 0 4.751832607952089e-12
Australian O 0 2.2864060644778306e-10
Aboriginal O 0 3.0338080936331835e-09
, O 0 2.739163063036898e-11
Chinese O 0 3.447175322968121e-10
, O 0 3.257772523967972e-11
and O 0 1.5657439234040282e-10
Pacific O 0 3.639328838289657e-08
Islanders O 0 6.124408855612273e-07
. O 0 2.615506922154509e-08

Results O 0 1.0695336527533073e-07
showed O 0 4.366178174564084e-08
that O 0 7.8039977258193e-11
the O 0 1.2347682876168165e-09
845 O 0 1.7335883839564303e-08
G O 0 2.620221266624867e-07
- O 0 3.9578225141667644e-08
- O 0 1.3118674146994636e-08
> O 0 4.118026364352545e-09
A O 0 1.264430893321844e-09
mutation O 0 1.5577926101850714e-11
was O 0 3.776123302934309e-10
present O 0 1.971049365390165e-11
in O 0 9.704319813008677e-12
these O 0 7.147697147699694e-13
populations O 0 1.1565021943577003e-13
( O 0 1.0530474197712261e-13
allele O 0 3.1372612840918634e-12
frequency O 0 4.668522790574059e-10
0 O 0 2.1283660944781957e-10
. O 0 1.2619336131614034e-11
32 O 0 8.472165191619752e-10
% O 0 4.8407715336207247e-11
) O 0 3.2893663487465474e-11
, O 0 1.0906246739050829e-10
and O 0 2.223164707881864e-10
, O 0 2.1623282331351135e-10
furthermore O 0 3.0376701154466446e-09
, O 0 8.061527140279523e-11
it O 0 1.3618858644981469e-11
was O 0 4.664572728074745e-09
always O 0 3.697503692112747e-10
seen O 0 5.818296192061645e-11
in O 0 3.754409109990586e-12
conjunction O 0 4.466610414866068e-11
with O 0 1.3075039315135761e-11
HLA O 0 6.639859861934383e-08
haplotypes O 0 2.5972079598091113e-08
common O 0 4.908574435802393e-09
in O 0 2.558101508398636e-09
Caucasians O 0 1.9884941693248948e-08
, O 0 1.533782406637485e-10
suggesting O 0 5.66256985745639e-10
that O 0 4.532711359028774e-11
845 O 0 4.2613095274646184e-09
G O 0 2.83821606217316e-07
- O 0 9.667223821452353e-08
- O 0 9.511630594261078e-08
> O 0 7.11357728278017e-08
A O 0 3.124148406641325e-08
may O 0 6.102597316370861e-10
have O 0 9.154892122165137e-12
been O 0 4.9632364190754785e-12
introduced O 0 2.997132056425933e-12
into O 0 3.209336821904246e-13
these O 0 2.367169096373703e-14
populations O 0 1.0250708024376817e-14
by O 0 2.1345106671760705e-12
Caucasian O 0 9.241396980996797e-09
admixture O 0 3.2550948958487425e-07
. O 0 1.9493829483963054e-07

187 O 0 1.9195499589841347e-06
C O 0 4.16879902331857e-06
- O 0 1.0982077469634532e-07
- O 0 2.4055825775803896e-08
> O 0 7.146526037615786e-09
G O 0 2.8550223518664097e-08
was O 0 1.58488209223151e-08
present O 0 7.352480291267227e-10
at O 0 5.5977968926868016e-09
an O 0 1.879701949647483e-11
allele O 0 1.6835347005361712e-10
frequency O 0 1.4875475073949929e-08
of O 0 2.6280885023766132e-08
2 O 0 4.971769271833182e-07
. O 0 1.855125475458408e-07

68 O 0 6.2694507505511865e-06
% O 0 1.707255314897793e-08
in O 0 7.493110132372749e-09
the O 0 1.9627566238966665e-09
two O 0 1.0873864308980075e-10
populations O 0 1.6950034041271489e-12
analyzed O 0 1.3057227521429127e-10
( O 0 1.3228399495593401e-12
Australian O 0 3.209034080131623e-11
Aboriginal O 0 4.4723924563783157e-10
and O 0 4.4509621682786715e-11
Chinese O 0 8.310295784852428e-10
) O 0 8.021433517413357e-11
. O 0 2.3766895118626508e-09

In O 0 2.3375907431955056e-08
the O 0 1.583805420146689e-09
Australian O 0 1.0781473491761062e-09
Aboriginal O 0 3.3419900180575723e-10
samples O 0 2.1120234033888963e-11
, O 0 6.9413598133283294e-12
187 O 0 1.4650312907260599e-10
C O 0 2.0094642394496987e-08
- O 0 6.091076532044326e-09
- O 0 6.338177094278308e-09
> O 0 8.883822566474464e-09
G O 0 5.738850461511902e-08
was O 0 5.154879900715059e-08
found O 0 1.2586481856757814e-10
to O 0 6.320831011374928e-12
be O 0 6.143642452410836e-12
associated O 0 1.8512526234193416e-10
with O 0 4.4753600131342e-11
HLA O 0 6.363089823935297e-07
haplotypes O 0 2.0799259914383583e-07
common O 0 3.414994154127271e-08
in O 0 1.0149166840278667e-08
Caucasians O 0 7.967664572561262e-08
, O 0 1.9465901113235873e-10
suggesting O 0 3.886556632082261e-10
that O 0 1.6591348087069413e-11
it O 0 4.063109224072825e-12
was O 0 1.068323068897925e-10
introduced O 0 8.187193110964497e-12
by O 0 1.1945917345601575e-12
recent O 0 3.635687584324643e-11
admixture O 0 2.0405673595291773e-08
. O 0 4.4634575147028954e-08

In O 0 1.0331574173960689e-07
the O 0 6.274188280031012e-09
Chinese O 0 1.5408438969188865e-09
samples O 0 2.265589452155048e-11
analyzed O 0 1.4267005632451202e-10
, O 0 9.85740482295494e-12
187 O 0 1.3456324943206255e-10
C O 0 1.3270048171420967e-08
- O 0 2.893913775281476e-09
- O 0 2.726380010642515e-09
> O 0 2.0620460894349435e-09
G O 0 1.0297378061352447e-08
was O 0 3.237989654181206e-09
present O 0 1.2169583396559602e-10
in O 0 5.016022042170221e-10
association O 0 4.703648581738662e-10
with O 0 5.3456489235159665e-11
a O 0 6.872101221411242e-10
wide O 0 8.96012319895334e-10
variety O 0 7.398664458868609e-10
of O 0 7.600040596855706e-09
HLA O 0 1.9992191369055945e-07
haplotypes O 0 3.705781637108885e-08
, O 0 5.311097117655095e-10
showing O 0 3.333573694863645e-10
this O 0 9.422107191681128e-12
mutation O 0 1.7886907233144456e-11
to O 0 9.171110051942044e-12
be O 0 3.616833221808946e-11
widespread O 0 1.3947014376736178e-10
and O 0 1.1226573143341412e-10
likely O 0 4.373266748736171e-10
to O 0 1.8025074488559056e-10
predate O 0 1.92126243803159e-08
the O 0 1.1804397459513893e-09
more O 0 4.325159674856138e-11
genetically O 0 5.606810155045494e-11
restricted O 0 1.8309416482953367e-10
845 O 0 9.164933700844813e-09
G O 0 2.0880504791875865e-07
- O 0 3.771145884456928e-08
- O 0 2.3244881575124055e-08
> O 0 1.3470076609678472e-08
A O 0 4.241151430051104e-09
mutation O 0 3.1218656548759327e-09
. O 0 7.3728609883971785e-09

Genotype O 0 6.906718681420898e-06
- O 0 3.092012548222556e-07
phenotype O 0 1.876630939534607e-08
correlations O 0 5.126103133079596e-07
in O 0 5.84885846421912e-08
attenuated B-Disease 0 0.01626794971525669
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999862909317017
coli I-Disease 1 0.9999922513961792
. O 0 5.851658897881862e-06

Germ O 1 0.9936071634292603
- O 0 2.5891420591506176e-05
line O 0 6.498839297819359e-07
mutations O 0 3.5369434048249104e-09
of O 0 3.464406983511026e-09
the O 0 6.014429509981767e-10
tumor B-Disease 0 2.0273501988299358e-08
suppressor O 0 4.2099955521734955e-07
APC O 0 7.283854586148664e-08
are O 0 3.620514166247091e-10
implicated O 0 1.7672114438482822e-07
in O 0 1.3768833184713003e-07
attenuated B-Disease 1 0.9999963045120239
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 2.346366090932861e-05
AAPC B-Disease 1 1.0
) O 0 8.409413609911098e-09
, O 0 3.054645425493163e-10
a O 0 1.3620007899284303e-10
variant O 0 2.8656779704760993e-07
of O 0 0.04007578268647194
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 6.73558986363787e-07
FAP B-Disease 0 8.306847121275496e-07
) O 0 1.1100405039599082e-08
. O 0 7.678463020965864e-08

AAPC B-Disease 1 0.9999998807907104
is O 0 4.903299100078584e-08
recognized O 0 2.1641284320139675e-09
by O 0 3.447489169139395e-11
the O 0 1.8944672219856074e-10
occurrence O 0 2.596364456763922e-09
of O 0 1.161591889342617e-08
< O 0 1.9161832653935562e-07
100 O 0 1.1354283735443005e-08
colonic B-Disease 0 9.444387387702591e-07
adenomas I-Disease 0 1.2624262808458298e-06
and O 0 7.257859313547499e-10
a O 0 5.006454140144001e-10
later O 0 1.0814080297905093e-08
onset O 0 0.01610459014773369
of O 1 0.9867376685142517
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.8822355613300488e-09
age O 0 6.031020127750253e-09
> O 0 3.716390528651914e-09
40 O 0 3.520196911743767e-10
years O 0 2.0924571797475977e-10
) O 0 1.1315919035137512e-10
. O 0 4.6247259355425285e-09

The O 0 4.410842961988237e-07
aim O 0 4.3607772681752976e-07
of O 0 2.5614131260454087e-08
this O 0 5.264469415955375e-11
study O 0 5.712249770417621e-11
was O 0 3.657689706670908e-10
to O 0 1.3024585750198714e-11
assess O 0 4.4754497885435285e-09
genotype O 0 1.8321033579127288e-08
- O 0 7.409853619577689e-09
phenotype O 0 2.9660860434432834e-09
correlations O 0 1.971579308701621e-07
in O 0 6.430185806038935e-08
AAPC B-Disease 1 0.9999996423721313
families O 0 1.1166958024944051e-08
. O 0 1.3902547379984753e-07

By O 0 3.010676863368644e-08
protein O 0 7.711295069157131e-08
- O 0 1.0690192731033221e-08
truncation O 0 1.1867710014712429e-07
test O 0 5.201782116159848e-09
( O 0 6.418279796527315e-11
PTT O 0 8.502603066062875e-09
) O 0 1.6128896829226136e-11
assay O 0 1.2697138895845228e-09
, O 0 2.1708398967312803e-11
the O 0 1.5652452944880935e-10
entire O 0 2.1837240904432065e-09
coding O 0 5.066169705969514e-08
region O 0 1.4761233124716e-08
of O 0 1.0172015230125453e-08
the O 0 3.078663768363299e-09
APC B-Disease 0 8.227624803680555e-09
gene O 0 6.087856330161401e-10
was O 0 4.324256508425606e-09
screened O 0 9.060504013724824e-10
in O 0 6.306095229335895e-11
affected O 0 4.0143041668549984e-11
individuals O 0 5.60787700998322e-12
from O 0 1.4445378226923822e-09
11 O 0 5.711560220333922e-07
AAPC B-Disease 1 1.0
kindreds O 0 5.125564712216146e-05
, O 0 2.2752053574492948e-09
and O 0 9.982645959860648e-11
their O 0 2.926633241306931e-11
phenotypic O 0 2.988883807120146e-07
differences O 0 1.4811355697474937e-07
were O 0 7.763519604964131e-09
examined O 0 3.4126185255445307e-07
. O 0 2.878633154068666e-08

Five O 0 3.268651767029951e-07
novel O 0 3.105659800439753e-07
germ O 0 5.3259223932400346e-05
- O 0 5.048763114245958e-07
line O 0 2.10574214065673e-07
APC B-Disease 0 3.367992817970844e-08
mutations O 0 1.2518469594269277e-09
were O 0 3.9459319145507266e-10
identified O 0 1.1343390671214593e-09
in O 0 1.6891258391993347e-09
seven O 0 2.4801172671118366e-08
kindreds O 0 1.7990595324590686e-06
. O 0 3.071504295348859e-07

Mutations O 0 6.092043491889854e-08
were O 0 1.817429762240863e-08
located O 0 1.3430466516695105e-08
in O 0 4.517350382648999e-10
three O 0 3.83375067802838e-11
different O 0 2.24044637009424e-11
regions O 0 5.115158852042612e-10
of O 0 1.0273972783636509e-08
the O 0 8.252394323449153e-09
APC B-Disease 0 1.9507472970303752e-08
gene O 0 5.635872213360926e-09
( O 0 5.115022294610583e-10
1 O 0 2.252661879253992e-08
) O 0 5.7365539402054466e-11
at O 0 9.084111241008941e-09
the O 0 1.5485218662902867e-09
5 O 0 4.433360345501569e-09
end O 0 1.5993336432984506e-08
spanning O 0 3.8885776376673675e-08
exons O 0 1.5719006540848568e-08
4 O 0 2.1575022657316367e-08
and O 0 1.620869549689985e-09
5 O 0 1.4658825264746156e-08
, O 0 9.16680009677151e-10
( O 0 6.552612619170617e-11
2 O 0 3.1565874358818746e-09
) O 0 6.54750281769978e-11
within O 0 2.8146955877161872e-09
exon O 0 5.0500389647822885e-08
9 O 0 5.394133495428832e-08
, O 0 1.4663347203125454e-09
and O 0 5.764899668747603e-10
( O 0 1.395060594822084e-10
3 O 0 8.562968112357794e-09
) O 0 1.3209527915947206e-10
at O 0 2.518981112586971e-08
the O 0 6.347867120837236e-09
3 O 0 5.903823208086578e-08
distal O 0 3.200606784048432e-07
end O 0 1.9733080591777252e-07
of O 0 7.03418905345643e-08
the O 0 1.844068897582929e-08
gene O 0 3.36369829767591e-08
. O 0 1.7157240961296338e-07

Variability O 0 2.4630700863781385e-05
in O 0 2.0333720485155027e-08
the O 0 2.934467113746564e-09
number O 0 6.170957522755316e-09
of O 0 0.0006897212006151676
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.007396842818707228
most O 0 6.392710805158686e-10
apparent O 0 4.3543999517225984e-09
in O 0 6.184890793958786e-11
individuals O 0 1.1293354489419483e-12
with O 0 1.5578401416083132e-11
mutations O 0 5.933721847206641e-10
in O 0 5.710120376534178e-09
region O 0 2.1386233584053116e-07
1 O 0 2.296247430422227e-06
, O 0 1.1800458388222523e-09
and O 0 4.3689336592933614e-09
upper O 1 0.9977579712867737
- O 0 0.0012323150876909494
gastrointestinal O 1 0.9965665340423584
manifestations O 0 0.010059526190161705
were O 0 3.305042994838914e-08
more O 0 1.695023808812035e-11
severe O 0 4.924553653751218e-09
in O 0 3.1311789272514545e-10
them O 0 2.838068946520167e-10
. O 0 9.928537103576218e-09

In O 0 2.5834875572172677e-08
individuals O 0 6.218887210751589e-11
with O 0 3.625460001654979e-11
mutations O 0 4.5722908792455996e-10
in O 0 9.566514247438818e-10
either O 0 7.564708859320035e-09
region O 0 8.222937708524114e-08
2 O 0 1.4000339376707416e-07
or O 0 1.0835485841909076e-09
region O 0 1.4693255501185831e-08
3 O 0 9.623325247787307e-09
, O 0 2.0930149974285328e-11
the O 0 4.750040638601405e-11
average O 0 2.0763984281968462e-11
number O 0 2.7789466908179072e-11
of O 0 2.9094933129414358e-09
adenomas B-Disease 0 8.992418543130043e-07
tended O 0 2.4315767177540693e-08
to O 0 8.786433247642833e-10
be O 0 5.243657730247264e-10
lower O 0 9.62764001855021e-09
than O 0 6.805754571015399e-11
those O 0 3.001338066965786e-11
in O 0 2.6393621663234335e-11
individuals O 0 2.266928181629546e-12
with O 0 2.0850977194841747e-11
mutations O 0 2.66912103530359e-10
in O 0 5.202175912266682e-10
region O 0 1.3557610145653598e-08
1 O 0 2.8823361475360798e-08
, O 0 9.702973841063667e-11
although O 0 3.038317653025757e-10
age O 0 4.356393468185615e-09
at O 0 4.8009372477508805e-08
diagnosis O 0 1.1550858403097664e-07
was O 0 1.5978059764165664e-08
similar O 0 3.455873587299152e-09
. O 0 3.901347866985816e-08

In O 0 1.7378015400026925e-06
all O 0 1.6389421944040805e-06
AAPC B-Disease 1 1.0
kindreds O 0 4.3937448936048895e-05
, O 0 2.611642235805789e-09
a O 0 9.301801551231392e-10
predominance O 0 1.183245004199307e-07
of O 0 8.529902402187872e-07
right O 1 0.9999134540557861
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999932050704956
rectal B-Disease 1 1.0
polyp I-Disease 1 0.6279687285423279
sparing O 0 1.0181330480918405e-06
was O 0 2.0201790107421402e-07
observed O 0 8.47990122565534e-08
. O 0 4.3260900639552347e-08

No O 0 2.1907353584538214e-05
desmoid B-Disease 1 0.9967126846313477
tumors I-Disease 1 1.0
were O 0 1.1558087464891287e-07
found O 0 9.819751678463717e-10
in O 0 1.9193302502884535e-10
these O 0 2.2604454419372644e-10
kindreds O 0 3.6785431234420685e-07
. O 0 5.675540037941573e-08

Our O 0 4.566752807022567e-07
data O 0 1.6512794687173482e-08
suggest O 0 3.3371061469722463e-09
that O 0 4.3858947723629527e-11
, O 0 9.670272221873333e-11
in O 0 4.330430236620941e-09
AAPC B-Disease 1 1.0
families O 0 6.049034606547821e-10
, O 0 6.575034960931703e-11
the O 0 5.1662601280311193e-11
location O 0 3.329616582448125e-09
of O 0 1.0539743300341797e-08
the O 0 8.102261972453562e-09
APC B-Disease 0 2.200771120897116e-07
mutation O 0 1.5546309128922076e-08
may O 0 5.6448654639496e-09
partially O 0 1.9633867864854437e-08
predict O 0 5.029177518878214e-09
specific O 0 1.014169193069847e-09
phenotypic O 0 3.327225499560882e-07
expression O 0 1.8931511647224397e-07
. O 0 3.8870280150149483e-07

This O 0 5.6000217796281504e-08
should O 0 9.576231363439547e-09
help O 0 7.33870741953524e-10
in O 0 1.3189135894542403e-10
the O 0 1.5860053548255593e-10
design O 0 2.6222103599593538e-08
of O 0 3.5172054158039145e-09
tailored O 0 1.1561296364703821e-09
clinical O 0 2.8058474654812926e-08
- O 0 1.4351674293422434e-09
management O 0 2.020300593486013e-09
protocols O 0 1.2198067622648523e-07
in O 0 7.92843499186624e-11
this O 0 2.8267913183832594e-12
subset O 0 1.0707124076247965e-09
of O 0 3.353189670374235e-10
FAP B-Disease 0 5.696848770497809e-09
patients O 0 1.03285702213185e-09
. O 0 8.08907052451957e-10
. O 0 1.8053823325203666e-08

Wilms B-Disease 1 0.9994105100631714
' I-Disease 0 2.5788171114982106e-05
tumor I-Disease 0 6.9091961449885275e-06
1 O 0 1.4251008906285278e-05
and O 0 1.478411917332778e-07
Dax O 0 0.4159896671772003
- O 0 3.0434127893386176e-06
1 O 0 4.633208448012738e-07
modulate O 0 9.799234845786486e-08
the O 0 2.998253378905247e-08
orphan O 0 1.0110798598361725e-07
nuclear O 0 1.232884301316517e-07
receptor O 0 2.7713431549614143e-09
SF O 0 4.821777679353545e-07
- O 0 1.1968429802777791e-08
1 O 0 6.412889330675853e-09
in O 0 5.7970607481028225e-11
sex O 0 4.304915313113611e-10
- O 0 2.778994222241149e-11
specific O 0 8.330203714324025e-12
gene O 0 3.487809485669402e-10
expression O 0 5.375807354823792e-09
. O 0 5.963283200571823e-08

Products O 0 6.168318122945493e-07
of O 0 2.635900671066338e-07
steroidogenic O 0 1.3647787454829086e-05
factor O 0 4.491289189445524e-07
1 O 0 1.0085967687700759e-06
( O 0 1.3735901305267362e-09
SF O 0 2.591661541373469e-06
- O 0 1.0221652502195866e-07
1 O 0 7.959538095292373e-08
) O 0 9.86034240368916e-11
and O 0 7.458428874507206e-10
Wilms B-Disease 0 0.00015987305960152298
tumor I-Disease 0 4.4175717448524665e-06
1 O 0 8.066373084147926e-06
( O 0 2.4650153029881494e-09
WT1 O 0 3.3307813396277197e-07
) O 0 4.223245086976135e-10
genes O 0 2.5890245503035203e-10
are O 0 1.284944199653193e-11
essential O 0 8.588660338482157e-10
for O 0 1.1725828641395708e-10
mammalian O 0 2.8751870218002296e-08
gonadogenesis O 0 7.18550978717758e-08
prior O 0 1.1140132372133849e-08
to O 0 5.261721058857916e-10
sexual O 0 5.452439832964728e-09
differentiation O 0 4.4656545128418657e-08
. O 0 6.271677932545572e-08

In O 0 1.6953890735749155e-07
males O 0 1.0402060546255143e-08
, O 0 5.139277448051871e-09
SF O 0 1.5027441804704722e-05
- O 0 2.9918584232291323e-07
1 O 0 1.0696886221239765e-07
participates O 0 5.591722640474472e-10
in O 0 7.624890302482257e-11
sexual O 0 1.1850569137106248e-10
development O 0 3.152258315486378e-11
by O 0 4.9786433656273665e-12
regulating O 0 5.3409054956432556e-09
expression O 0 1.5139435260991263e-09
of O 0 2.8935824847309277e-09
the O 0 7.101075727433681e-09
polypeptide O 0 6.039195454832225e-07
hormone O 0 4.733858460781448e-08
Mullerian O 0 2.941087018371036e-07
inhibiting O 0 7.807239654766818e-08
substance O 0 6.664683382950898e-07
( O 0 2.5890751764734432e-09
MIS O 0 2.1609737359540304e-06
) O 0 5.721229712207787e-09
. O 0 7.488369391239758e-08

Here O 0 2.456810307194246e-06
, O 0 8.47921821645059e-09
we O 0 2.076625982283531e-09
show O 0 1.8171723015214525e-09
that O 0 1.1217540785146696e-10
WT1 O 0 1.201265718009381e-06
- O 0 5.271672307571862e-07
KTS O 0 2.8064689104212448e-05
isoforms O 0 2.3285757322355494e-07
associate O 0 3.1391476795761264e-07
and O 0 1.4059358122153753e-09
synergize O 0 3.4333214671278256e-07
with O 0 5.55215917685814e-09
SF O 0 0.0016849265666678548
- O 0 2.4758126073720632e-06
1 O 0 5.854137157257355e-07
to O 0 7.151826353357649e-10
promote O 0 1.9920245009075188e-08
MIS O 0 1.179429000330856e-05
expression O 0 1.9856673816320836e-07
. O 0 1.8355456177232554e-07

In O 0 1.320556606287937e-07
contrast O 0 2.14469352499691e-07
, O 0 1.9264620121361986e-08
WT1 O 0 9.01929524843581e-05
missense O 0 5.65559821552597e-06
mutations O 0 1.6991306139857443e-08
, O 0 2.604676474504686e-10
associated O 0 6.687735698562847e-09
with O 0 1.0593146360093897e-09
male B-Disease 0 6.830923666711897e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 0.0003027282655239105
Denys B-Disease 1 1.0
- I-Disease 1 0.9999980926513672
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.3254609143587004e-07
fail O 0 1.2063861731803627e-06
to O 0 1.29442661034318e-08
synergize O 0 8.969105692813173e-06
with O 0 2.5639064915594645e-07
SF O 1 0.999446451663971
- O 0 0.00024208714603446424
1 O 0 2.5567196644260548e-05
. O 0 9.601694017646878e-08

Additionally O 0 1.4812784456808004e-06
, O 0 9.442595150233046e-09
the O 0 5.761407351201342e-09
X O 0 2.3222661184263416e-05
- O 0 6.126576295173436e-07
linked O 0 1.0318557031041564e-07
, O 0 1.0293813024198073e-10
candidate O 0 2.728896553172433e-10
dosage O 0 2.5831131011955222e-08
- O 0 1.8257813039213033e-09
sensitive O 0 1.1984557346522706e-08
sex O 0 1.7721514256052728e-09
- O 0 2.7723146001079613e-10
reversal O 0 7.243835531411946e-10
gene O 0 1.4251176627677609e-10
, O 0 7.813891755859004e-10
Dax O 0 0.00011035463830921799
- O 0 3.954993417210062e-07
1 O 0 3.048095891244884e-07
, O 0 1.969709728655289e-09
antagonizes O 0 1.648020315769827e-07
synergy O 0 2.384273898314859e-07
between O 0 2.1946134154404717e-07
SF O 0 7.142970571294427e-05
- O 0 8.472147214888537e-07
1 O 0 2.620243719775317e-07
and O 0 1.547506123245057e-09
WT1 O 0 1.0435813919684733e-06
, O 0 8.772433890413822e-10
most O 0 2.86799126114623e-11
likely O 0 4.020956137495979e-11
through O 0 3.128926631679185e-11
a O 0 1.9898389880257383e-10
direct O 0 3.9475728241811225e-10
interaction O 0 2.7746329678279835e-09
with O 0 1.9833266140523165e-09
SF O 0 6.024357571732253e-05
- O 0 1.8564029460321763e-06
1 O 0 1.2204018275951967e-06
. O 0 3.8125801182786745e-08

We O 0 2.6939250119539793e-07
propose O 0 6.137259589422683e-08
that O 0 1.2919051384230329e-09
WT1 O 0 1.3919171806264785e-06
and O 0 2.362773976471999e-08
Dax O 0 0.05013348534703255
- O 0 8.939610438574164e-07
1 O 0 5.328728036602115e-08
functionally O 0 2.147004352082149e-09
oppose O 0 2.588511072154631e-10
each O 0 8.553976103831129e-12
other O 0 5.298121316665849e-12
in O 0 1.9389408481562675e-11
testis O 0 5.231253208393127e-09
development O 0 1.0179166537449547e-10
by O 0 4.102147441176207e-11
modulating O 0 8.401225670695567e-08
SF O 0 5.123180017108098e-05
- O 0 1.6194355794141302e-06
1 O 0 3.0278090434876503e-06
- O 0 2.1337335454063577e-08
mediated O 0 1.5194848401733907e-07
transactivation O 0 4.163244739174843e-06
. O 0 1.150564621354988e-08
. O 0 4.101730866068465e-08

A O 0 1.8666481764739729e-06
mouse O 0 1.1420555523500298e-07
model O 0 7.669343915495119e-08
for O 0 2.3670641269291082e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999988079071045
- O 0 0.09515846520662308
centre O 0 9.304285777034238e-05
mutations O 0 1.597170040668061e-07
. O 0 1.3573063029070909e-07

Imprinting O 0 1.4021202332514804e-05
in O 0 6.119025641737608e-08
the O 0 1.9989744970416723e-08
15q11 O 0 3.0537228212779155e-07
- O 0 1.3527131415003169e-08
q13 O 0 3.158389816348972e-08
region O 0 1.372374991426284e-09
involves O 0 3.2345190414950764e-10
an O 0 2.3502704990518986e-11
imprinting O 0 1.1285327872201378e-07
centre O 0 1.4317840850708308e-06
( O 0 6.96438906544472e-10
IC O 0 8.368967030492058e-08
) O 0 1.2257757309175332e-10
, O 0 3.150022603870539e-11
mapping O 0 1.2971544949280656e-09
in O 0 1.4021919181317344e-09
part O 0 3.4779463753409345e-09
to O 0 5.941117597885182e-10
the O 0 3.3855098724444588e-09
promoter O 0 4.606804395734798e-06
and O 0 2.962026846020649e-09
first O 0 1.2197457266438505e-08
exon O 0 7.872643550399516e-07
of O 0 3.433976303313102e-07
SNRPN O 0 0.00034988843253813684
. O 0 3.114239461865509e-06

Deletion O 0 3.2717189242248423e-06
of O 0 4.738492691558349e-07
this O 0 3.827310468551559e-09
IC O 0 3.0641365356132155e-06
abolishes O 0 3.363737164363556e-07
local O 0 1.0845933040570799e-08
paternally O 0 3.575471652084161e-08
derived O 0 3.5201161430187256e-10
gene O 0 2.1615652323614398e-10
expression O 0 2.7753355169579663e-10
and O 0 2.770288685949307e-11
results O 0 3.848170115894334e-10
in O 0 7.185646921925581e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.6111089587211609
PWS B-Disease 1 1.0
) O 0 5.618722411782073e-07
. O 0 4.122630343772471e-07

We O 0 2.9736449391748465e-07
have O 0 7.482494623900493e-10
created O 0 4.958756183448543e-10
two O 0 1.4679543691720198e-10
deletion O 0 1.432258667222186e-08
mutations O 0 3.920374691546158e-09
in O 0 4.196228253761092e-09
mice O 0 2.6390742036142e-08
to O 0 6.35665164949728e-09
understand O 0 1.5764637737447629e-06
PWS B-Disease 1 1.0
and O 0 1.863575294080988e-09
the O 0 3.098408474233594e-10
mechanism O 0 1.0562787089440917e-08
of O 0 1.9622625746507083e-09
this O 0 1.9514115323637782e-10
IC O 0 7.75387263729499e-07
. O 0 3.9584264754921605e-08

Mice O 0 8.662883374199737e-06
harbouring O 0 7.265091880981345e-06
an O 0 9.07309782860466e-09
intragenic O 0 2.2698070551996352e-06
deletion O 0 3.039428122519894e-07
in O 0 6.888823289585844e-09
Snrpn O 0 5.612287168332841e-06
are O 0 1.0044187703783791e-09
phenotypically O 0 2.2356189219863154e-06
normal O 0 6.168277195683913e-07
, O 0 4.139396880820101e-10
suggesting O 0 3.2472094457780543e-10
that O 0 1.2407871605168985e-11
mutations O 0 4.3088091428167274e-10
of O 0 5.665629743134559e-09
SNRPN O 0 2.0048871647304622e-06
are O 0 1.613675165712536e-10
not O 0 4.501582093197065e-11
sufficient O 0 1.6588137530249014e-09
to O 0 1.3526143538555857e-09
induce O 0 6.991766099417873e-07
PWS B-Disease 1 0.9999996423721313
. O 0 5.773208613391034e-06

Mice O 0 2.47949174081441e-06
with O 0 5.277936754310986e-09
a O 0 4.68440175538376e-09
larger O 0 1.0578851128428823e-09
deletion O 0 3.2928738846749184e-08
involving O 0 2.133241139290476e-08
both O 0 9.855140037373644e-10
Snrpn O 0 3.6175808304506063e-07
and O 0 1.0842101660912817e-09
the O 0 7.3794450550224155e-09
putative O 0 6.411638651115936e-07
PWS O 1 0.9999995231628418
- O 0 7.708213161095046e-07
IC O 0 1.4010105360284797e-06
lack O 0 3.343058097016183e-08
expression O 0 1.1781634556840004e-09
of O 0 1.4588584784647196e-09
the O 0 4.425315114353623e-10
imprinted O 0 3.1397322519666204e-09
genes O 0 1.688136963551301e-09
Zfp127 O 0 2.4440154788862856e-07
( O 0 5.868922570151369e-10
mouse O 0 1.0412323447894778e-08
homologue O 0 4.615374393779348e-07
of O 0 2.9443791049743595e-07
ZNF127 O 0 9.982346091419458e-05
) O 0 2.2198916482807363e-08
, O 0 3.542278648183128e-08
Ndn O 0 2.2988500859355554e-05
and O 0 1.2790123093964212e-07
Ipw O 0 2.217945620941464e-05
, O 0 8.482777147378329e-09
and O 0 4.400502184864763e-10
manifest O 0 1.309884734013167e-08
several O 0 1.4503402645527075e-10
phenotypes O 0 2.327229609022652e-08
common O 0 6.311925648816441e-09
to O 0 3.775147661144729e-08
PWS B-Disease 1 1.0
infants O 1 0.603876531124115
. O 0 9.958561122402898e-07

These O 0 9.863681427191295e-09
data O 0 1.2860741804843201e-08
demonstrate O 0 1.3264456200090535e-08
that O 0 8.289963854268834e-11
both O 0 2.0724665039661971e-10
the O 0 5.32075050685421e-10
position O 0 3.410925586422309e-08
of O 0 1.8025298587076577e-08
the O 0 1.366659674317816e-09
IC O 0 4.53885142803756e-08
and O 0 2.7219086359830946e-11
its O 0 1.0114038079267473e-11
role O 0 1.8558804493196135e-10
in O 0 1.8375844249018947e-11
the O 0 2.0583149767938735e-11
coordinate O 0 3.8885733522064925e-10
expression O 0 6.121460005559243e-10
of O 0 5.241260314647889e-09
genes O 0 3.7912853412258585e-10
is O 0 1.3758863492974172e-10
conserved O 0 5.319048312912855e-09
between O 0 1.6272640124270765e-08
mouse O 0 2.574628332752127e-08
and O 0 9.619283147799251e-10
human O 0 2.949426702869573e-09
, O 0 6.273739167061976e-11
and O 0 3.374733478778147e-11
indicate O 0 3.1694782909319485e-10
that O 0 2.8423360887153137e-11
the O 0 6.378096384374032e-10
mouse O 0 3.2112781322979345e-09
is O 0 8.2335194218075e-11
a O 0 9.367565750872942e-11
suitable O 0 3.424110772698441e-09
model O 0 2.896934692131481e-09
system O 0 9.734496764224332e-09
in O 0 6.849946165843335e-10
which O 0 2.6857575191607808e-11
to O 0 6.540934027049472e-12
investigate O 0 3.173271090339824e-10
the O 0 4.21194884525633e-11
molecular O 0 3.0979137033426696e-09
mechanisms O 0 2.677353272417804e-08
of O 0 1.1003564281963918e-08
imprinting O 0 6.18146742681347e-08
in O 0 6.839618871268272e-10
this O 0 6.381536271637955e-11
region O 0 7.455085992980059e-10
of O 0 4.425619037906614e-10
the O 0 1.4670502312963407e-10
genome O 0 4.243882328891502e-11
. O 0 2.1324700338887226e-10
. O 0 6.9924106504970496e-09

Mutations O 0 2.3570738960643212e-07
of O 0 9.311465021255572e-08
the O 0 1.4267945047663488e-08
ATM O 0 2.3429231532645645e-07
gene O 0 1.0615496259802626e-09
detected O 0 4.433724054564436e-09
in O 0 2.0413322421308777e-10
Japanese O 0 0.000409600674174726
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.055720001459121704
: O 0 8.235109816290276e-10
possible O 0 3.0159514885497174e-09
preponderance O 0 4.368092049844563e-06
of O 0 2.981299473958643e-08
the O 0 1.5226785166078116e-08
two O 0 7.2659656069617995e-09
founder O 0 7.883434705036052e-08
mutations O 0 9.800403821813575e-10
4612del165 O 0 5.643673617328204e-08
and O 0 4.473486914235991e-09
7883del5 O 0 1.794877903193992e-06
. O 0 1.7017325149026874e-07

The O 0 1.2630957826331723e-06
ATM O 0 6.448499334510416e-05
( O 0 6.97959364970302e-07
A O 1 1.0
- O 1 0.9999984502792358
T O 1 1.0
, O 0 9.117157029336909e-10
mutated O 0 4.7219839149903464e-11
) O 0 2.2880571135669436e-12
gene O 0 2.3316159766806344e-11
on O 0 7.343314289975922e-10
human O 0 4.4257544851156183e-10
chromosome O 0 6.4030530211312e-08
11q22 O 0 5.370459916775872e-07
. O 0 5.052698170970871e-08

3 O 0 4.1908700950443745e-05
has O 0 1.1710820757571128e-08
recently O 0 4.4988572867055154e-09
been O 0 2.793781039844845e-10
identified O 0 1.7370686833384497e-10
as O 0 2.2787207884511496e-11
the O 0 2.3239039165234843e-11
gene O 0 2.1722812784674694e-11
responsible O 0 6.134056457218762e-11
for O 0 3.770613595660555e-12
the O 0 1.275312633275405e-10
human O 0 8.792457606432436e-07
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9977589845657349
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.161348706091303e-07
. O 0 6.710533995146761e-08

In O 0 1.6001611413685168e-07
order O 0 9.382936205781789e-09
to O 0 9.162219871683419e-10
define O 0 9.18061004995252e-09
the O 0 6.82429446285937e-10
types O 0 4.1465977318466685e-09
of O 0 3.219663469167244e-08
disease O 0 1.1109492561445222e-06
- O 0 5.561889171445955e-09
causing O 0 4.3006336269968415e-09
ATM O 0 7.561193626770546e-08
mutations O 0 2.2277533984205178e-10
in O 0 5.157205218431216e-10
Japanese O 0 2.0482862055359874e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 7.719550865203928e-08
as O 0 1.4325365338407892e-09
well O 0 2.59866683727239e-10
as O 0 5.98574662058482e-11
to O 0 1.2526864094641876e-11
look O 0 7.891802489279343e-11
for O 0 1.766153195914555e-11
possible O 0 4.663734398668851e-10
mutational O 0 3.502372081243266e-08
hotspots O 0 2.798039311358025e-08
, O 0 3.9159261944199386e-10
reverse O 0 1.9356624747501883e-08
- O 0 6.424066167909359e-09
transcribed O 0 6.2147793578049004e-09
RNA O 0 1.9159331898777054e-09
derived O 0 2.0116594501295992e-10
from O 0 2.2055610116034075e-10
ten O 0 6.779807271151128e-10
patients O 0 7.246774708091763e-11
belonging O 0 8.091431968892948e-10
to O 0 1.7671650254236226e-10
eight O 0 1.6881788189593294e-09
unrelated O 0 9.690300117881634e-08
Japanese O 0 8.7862899817992e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999953508377075
T I-Disease 1 1.0
families O 0 1.3303690094002008e-10
was O 0 1.6029242377868513e-09
analyzed O 0 9.133165057573223e-11
for O 0 3.7616485447367065e-12
mutations O 0 1.6729888958552652e-12
by O 0 1.4144926549497505e-12
the O 0 3.080035185232255e-11
restriction O 0 1.348533368306093e-10
endonuclease O 0 1.6351875409270633e-09
fingerprinting O 0 9.321129645911697e-09
method O 0 2.2025488988219877e-08
. O 0 4.826332755669682e-08

As O 0 4.6501756401085004e-07
has O 0 1.828381113178068e-09
been O 0 1.3115533659124878e-10
reported O 0 2.2712920086376265e-11
by O 0 1.5682260177951601e-12
others O 0 5.475675468602503e-11
, O 0 7.324716354284444e-12
mutations O 0 1.455449476217563e-11
that O 0 2.1893981419496278e-11
lead O 0 2.0839228120905773e-09
to O 0 2.000239751609456e-09
exon O 0 1.499611244071275e-06
skipping O 0 1.0363996807427611e-06
or O 0 8.319724287275676e-08
premature O 0 1.443535211365088e-07
protein O 0 4.320977353700073e-08
truncation O 0 2.2217560058379604e-07
were O 0 2.4099730211446513e-08
also O 0 1.901483859256814e-09
predominant O 0 4.609114867548669e-08
in O 0 2.198875082015661e-09
our O 0 1.7688327247356028e-08
mutants O 0 9.65870938784974e-08
. O 0 3.685586591473111e-08

Six O 0 3.0234982517640674e-08
different O 0 2.0759242935763922e-10
mutations O 0 1.4380494017807166e-10
were O 0 7.583916133979685e-11
identified O 0 8.186166328139066e-11
on O 0 4.646733220425858e-09
12 O 0 2.978109536755369e-09
of O 0 1.600077292884805e-09
the O 0 1.5519991958257151e-09
16 O 0 1.0572865249969254e-08
alleles O 0 3.119865477074768e-09
examined O 0 1.2549694474728312e-06
. O 0 3.377849679964129e-07

Four O 0 4.707737559783709e-07
were O 0 2.2160250523484137e-08
deletions O 0 4.9112177435972626e-08
involving O 0 6.558798304467928e-08
a O 0 4.096404548903365e-09
loss O 0 2.1423952389909573e-08
of O 0 3.632546849985374e-07
a O 0 2.887288097497276e-08
single O 0 1.0588788512677638e-08
exon O 0 4.4060581672056287e-07
exon O 0 3.9719344613331486e-07
7 O 0 2.4560603151257965e-07
, O 0 6.864977475373735e-09
exon O 0 5.47080787782761e-07
16 O 0 1.4967351091854653e-07
, O 0 1.4586532870453084e-08
exon O 0 1.4256050917538232e-06
33 O 0 1.0442533948662458e-06
or O 0 1.0758065371874181e-07
exon O 0 6.529630354634719e-06
35 O 0 2.962367261716281e-06
. O 0 1.3365121276365244e-06

The O 0 3.765619283058186e-07
others O 0 2.257332631927511e-08
were O 0 4.1916532467212164e-09
minute O 0 7.385640543589034e-09
deletions O 0 2.9496292075492647e-09
, O 0 2.440090629551861e-10
4649delA O 0 1.844255237415382e-08
in O 0 2.6567192890070146e-09
exon O 0 1.7497572457614297e-07
33 O 0 5.8178610373715856e-08
and O 0 1.3363359308016243e-09
7883del5 O 0 1.130556839257224e-07
in O 0 9.632121766856017e-09
exon O 0 1.6670204558977275e-06
55 O 0 7.841995852686523e-07
. O 0 3.396138481548405e-07

The O 0 4.0578828475190676e-07
mutations O 0 2.152421885170952e-08
4612del165 O 0 5.2344898193723566e-08
and O 0 1.9148838070748297e-10
7883del5 O 0 1.4077210508389726e-08
were O 0 7.999284568072085e-10
found O 0 1.1305865965649531e-10
in O 0 2.3865125153843536e-11
more O 0 1.4684848389373562e-12
than O 0 2.4054857498262416e-12
two O 0 1.3243983167099405e-11
unrelated O 0 3.9466843682056663e-10
families O 0 4.122043418403054e-12
; O 0 7.323430924188745e-12
44 O 0 3.126750525161981e-10
% O 0 1.4695930583563666e-10
( O 0 1.7704443466826092e-10
7 O 0 1.6343433273391383e-08
of O 0 4.723324309452437e-08
16 O 0 2.30120065225492e-08
) O 0 5.193370386513685e-11
of O 0 5.127995250653328e-10
the O 0 6.609058439410731e-11
mutant O 0 4.0025321945691417e-10
alleles O 0 1.3122841702184473e-10
had O 0 8.842147569687597e-10
one O 0 7.092405135411539e-11
of O 0 2.9355068376091253e-10
the O 0 4.2609824002504126e-10
two O 0 8.38804026237483e-10
mutations O 0 6.8073200409912715e-09
. O 0 5.779130063388038e-08

The O 0 1.554207500475968e-07
4612del165 O 0 8.07042908945732e-07
mutations O 0 8.720721922372832e-09
in O 0 1.0399318073339714e-09
three O 0 1.2926069936636253e-10
different O 0 5.185540885577211e-11
families O 0 1.3283601649205501e-11
were O 0 6.80126441277018e-11
all O 0 1.4464497308241953e-11
ascribed O 0 8.69917082813032e-10
to O 0 2.0307642720207575e-11
the O 0 1.4035506090692706e-10
same O 0 2.045526859006941e-09
T O 0 8.617170976776833e-08
- O 0 8.295255149448622e-09
- O 0 3.1433273761649616e-09
> O 0 7.766047804835807e-10
A O 0 3.859857988786075e-10
substitution O 0 6.294954835173172e-11
at O 0 7.643926047684602e-10
the O 0 6.004752250987622e-11
splice O 0 1.2966102636013943e-09
donor O 0 3.0448094046064966e-10
site O 0 1.4055317798522537e-08
in O 0 1.376108205164428e-08
intron O 0 1.6132316886796616e-05
33 O 0 1.5305515262298286e-05
. O 0 3.812111344814184e-06

Microsatellite O 0 3.9303660742007196e-05
genotyping O 0 3.898413069691742e-06
around O 0 5.882579046101455e-08
the O 0 1.9889569102815585e-08
ATM O 0 5.888736041015363e-07
locus O 0 3.38093606444545e-08
also O 0 7.766255416541412e-10
indicated O 0 2.3487984890380176e-09
that O 0 4.042795959113832e-11
a O 0 2.1703525088234699e-10
common O 0 1.9460667799453546e-10
haplotype O 0 9.586355709245709e-09
was O 0 5.918909096180869e-08
shared O 0 7.955933689629546e-10
by O 0 2.8096079282557973e-11
the O 0 1.9194619504947497e-10
mutant O 0 6.401105201447876e-10
alleles O 0 3.6246941559348045e-10
in O 0 3.895967715106252e-10
both O 0 8.53436787906503e-09
mutations O 0 4.054787439145002e-08
. O 0 1.334157104793121e-07

This O 0 1.1032064861637991e-07
suggests O 0 5.258997504142826e-08
that O 0 1.419751261000357e-10
these O 0 6.81911263566981e-11
two O 0 3.7454866985697777e-10
founder O 0 2.6012186182811092e-08
mutations O 0 5.880778086719829e-10
may O 0 3.6313929641096365e-10
be O 0 3.0578851950568975e-11
predominant O 0 1.2244163460906066e-09
among O 0 3.21124268669315e-12
Japanese O 0 1.1421983359127807e-09
ATM O 0 2.791019682035767e-08
mutant O 0 9.60542756445193e-09
alleles O 0 1.4701357464730336e-08
. O 0 5.766522193084711e-08

W474C O 0 3.256713898736052e-05
amino O 0 8.268624469565111e-07
acid O 0 5.161058069802493e-08
substitution O 0 1.105542057899811e-08
affects O 0 2.6252766627266055e-09
early O 0 9.878305951005473e-10
processing O 0 2.6962361232563126e-09
of O 0 1.2752841005436721e-09
the O 0 5.679746672981878e-10
alpha O 0 1.54538319918629e-08
- O 0 5.93929294634421e-10
subunit O 0 2.5953097448905282e-09
of O 0 1.2569533858197701e-08
beta O 0 2.5404824555153027e-07
- O 0 3.677370941090885e-08
hexosaminidase O 0 9.493523833725703e-08
A O 0 5.241940215228169e-09
and O 0 3.627542016770846e-11
is O 0 1.1367268237805206e-11
associated O 0 5.716644935205295e-10
with O 0 1.2934979753964626e-09
subacute O 0 0.0005241297767497599
G B-Disease 0 0.001566305523738265
( I-Disease 0 1.8033276205642323e-08
M2 I-Disease 0 2.6655934561858885e-06
) I-Disease 0 1.226242307694747e-08
gangliosidosis I-Disease 0 3.971592832385795e-06
. O 0 4.0516877675145224e-07

Mutations O 0 1.675055756322763e-07
in O 0 1.5662562802276625e-08
the O 0 3.790652769453118e-08
HEXA O 0 1.2667026112467283e-06
gene O 0 1.4740743070618123e-09
, O 0 6.703514132677668e-11
encoding O 0 2.9883159835542017e-10
the O 0 1.4646799328943416e-09
alpha O 0 6.686935449806697e-08
- O 0 2.625331951833232e-09
subunit O 0 5.845955719507856e-09
of O 0 3.0203914036519564e-08
beta O 0 6.051083687452774e-07
- O 0 1.2447434016849002e-07
hexosaminidase O 0 2.5753558929864084e-06
A O 0 5.608026754089224e-07
( O 0 7.240354427118234e-10
Hex O 0 7.942477253664038e-08
A O 0 2.263852039163794e-08
) O 0 8.086228214798652e-11
, O 0 3.3251137954160015e-11
that O 0 2.1002252020840828e-11
abolish O 0 1.2078184674635395e-08
Hex O 0 1.4090372424391262e-08
A O 0 7.558850212419088e-10
enzyme O 0 3.341193433037404e-10
activity O 0 8.274996687873681e-09
cause O 0 0.4141274690628052
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.9564788544812473e-07
TSD B-Disease 0 7.027618266874924e-05
) O 0 8.973480847274118e-10
, O 0 2.0051854621172538e-10
the O 0 2.4914854623858673e-09
fatal O 0 6.283135735429823e-05
infantile B-Disease 0 6.470487278420478e-06
form I-Disease 0 5.60777095870435e-08
of I-Disease 0 0.0032438766211271286
G I-Disease 0 0.0379810631275177
( I-Disease 0 5.778333367345567e-09
M2 I-Disease 0 1.775814126858677e-07
) I-Disease 0 6.014498343809294e-10
gangliosidosis I-Disease 0 7.958172432154242e-08
, I-Disease 0 3.8582462225100755e-10
Type I-Disease 0 2.693497869188377e-08
1 I-Disease 0 3.8779270994382387e-07
. O 0 2.6906532113457615e-08

Less O 0 2.615719722598442e-06
severe O 0 8.767764666117728e-05
, O 0 1.5631881566946504e-08
subacute O 0 0.0003280837263446301
( O 0 1.561876850075805e-08
juvenile O 0 0.00012991779658477753
- O 0 4.4160873358123354e-07
onset O 0 0.031698085367679596
) O 0 3.305785423179941e-09
and O 0 5.364389465967179e-08
chronic O 1 0.9999997615814209
( O 0 6.818118070128776e-09
adult O 0 2.2876174909924885e-07
- O 0 1.916070004881476e-07
onset O 0 5.5536720537929796e-06
) O 0 4.382182117179667e-11
variants O 0 1.8519660804905413e-10
are O 0 2.25418295141111e-12
characterized O 0 9.964397362782762e-12
by O 0 3.226647031159824e-12
a O 0 1.1568856289612128e-10
broad O 0 7.260378964701886e-10
spectrum O 0 2.0780969833822382e-08
of O 0 1.2403459370702308e-09
clinical O 0 8.299370080067092e-09
manifestations O 0 7.280406943976914e-09
and O 0 8.11428493840971e-11
are O 0 1.7302220853970818e-12
associated O 0 5.5448298730276235e-11
with O 0 8.95599566730354e-12
residual O 0 1.1144869631607435e-06
levels O 0 1.7115796424604923e-07
of O 0 9.488817909186764e-08
Hex O 0 1.756377798756148e-07
A O 0 1.0631793223581099e-08
enzyme O 0 4.570078981913639e-09
activity O 0 7.963907755481614e-09
. O 0 2.4942638177094523e-08

We O 0 2.8562376996887906e-07
identified O 0 7.099331611470916e-08
a O 0 2.0309650849981153e-08
1422 O 0 4.5026808948023245e-06
G O 0 1.743847860780079e-06
- O 0 2.013354816199353e-07
- O 0 4.710315337774773e-08
> O 0 7.577474647746385e-09
C O 0 5.452692519725133e-08
( O 0 2.4952925142818216e-11
amino O 0 2.94808122358603e-10
acid O 0 2.592538128620703e-10
W474C O 0 2.2800012988710705e-09
) O 0 2.795531818186592e-12
substitution O 0 5.810422282204186e-11
in O 0 3.987382299341924e-11
the O 0 7.905663623741788e-11
first O 0 1.4144967142026843e-10
position O 0 5.690495630261694e-09
of O 0 1.2643182500937655e-08
exon O 0 2.3513457847457175e-08
13 O 0 4.558972221957447e-08
of O 0 5.003099445843873e-08
HEXA O 0 7.723929593339562e-05
of O 0 1.2902813750770292e-06
a O 0 3.093327549663627e-08
non O 0 3.0454546617875167e-07
- O 0 2.8212166824914675e-08
Jewish O 0 3.3183948922044237e-09
proband O 0 1.440554001419514e-06
who O 0 2.3152877393073368e-09
manifested O 0 2.7068573160704545e-08
a O 0 3.3617530981189248e-09
subacute O 0 9.744408089318313e-07
variant O 0 2.1920845938439015e-07
of O 0 1.160668944066856e-05
G B-Disease 0 0.0005760555504821241
( I-Disease 0 5.268834257776689e-09
M2 I-Disease 0 1.0683995697036153e-06
) I-Disease 0 8.337480927878005e-09
gangliosidosis I-Disease 0 2.446263806632487e-06
. O 0 1.9414831342601246e-07

On O 0 7.130609446903691e-06
the O 0 1.2553988426589058e-07
second O 0 2.76731498161098e-07
maternally O 0 8.49448440476408e-07
inherited O 0 4.723563051811652e-07
allele O 0 1.7390229700708915e-08
, O 0 4.784669882518244e-10
we O 0 1.2109728497744499e-10
identified O 0 1.323944426312451e-10
the O 0 1.8370807652878796e-10
common O 0 5.59623103413287e-08
infantile O 0 0.3150201737880707
disease O 0 0.0036989841610193253
- O 0 3.646541699708905e-07
causing O 0 2.8757137897628127e-06
4 O 0 8.476539733237587e-06
- O 0 3.2694870810701104e-07
bp O 0 7.409036584249407e-08
insertion O 0 1.3327729142531552e-08
, O 0 7.04551528230013e-10
+ O 0 1.1050782511290436e-08
TATC O 0 9.570623660692945e-06
1278 O 0 2.393400609435048e-05
, O 0 8.200474077568742e-09
in O 0 1.0188481169848274e-08
exon O 0 1.8942993165182997e-06
11 O 0 7.281061584762938e-07
. O 0 2.708053443711833e-07

Pulse O 0 0.0021385224536061287
- O 0 3.410218369026552e-06
chase O 0 1.7092632731419144e-07
analysis O 0 3.356409816746009e-09
using O 0 3.250067770466103e-09
proband O 0 1.2637835311579693e-07
fibroblasts O 0 1.078221956163361e-08
revealed O 0 1.7193233503576266e-08
that O 0 4.13514882058319e-11
the O 0 2.48627646248778e-10
W474C O 0 4.067737258139914e-09
- O 0 1.4147072402437288e-10
containing O 0 4.1936398798014807e-11
alpha O 0 3.4103582180478043e-09
- O 0 2.4875382309552663e-10
subunit O 0 2.2717709935449193e-09
precursor O 0 1.1889568440892617e-08
was O 0 2.353607264637958e-08
normally O 0 2.688485545299102e-10
synthesized O 0 1.496202828299431e-09
, O 0 7.877756780239054e-11
but O 0 4.418953397644643e-11
not O 0 2.0930070177005433e-11
phosphorylated O 0 4.721175672628419e-10
or O 0 1.0368712832775628e-10
secreted O 0 1.843237090737304e-10
, O 0 5.189429441720961e-11
and O 0 3.4996557735089695e-11
the O 0 8.831225750682847e-10
mature O 0 2.4535150799920302e-08
lysosomal O 0 3.0487344702123664e-06
alpha O 0 1.1332679150655167e-06
- O 0 1.2859661779884846e-08
subunit O 0 3.3428221968279104e-08
was O 0 1.3474604543262103e-07
not O 0 3.7403200536800796e-09
detected O 0 1.5127066887998808e-07
. O 0 4.2408789369119404e-08

When O 0 6.874414992807942e-08
the O 0 1.1204080330173838e-08
W474C O 0 5.6246850732577514e-08
- O 0 5.214912390805182e-10
containing O 0 9.63815832699666e-11
alpha O 0 8.611202417796449e-09
- O 0 4.4634360096829084e-10
subunit O 0 5.661946023138853e-09
was O 0 1.4277600257628364e-07
transiently O 0 6.40440873667103e-08
co O 0 1.5682232401559304e-08
- O 0 4.275000353715086e-10
expressed O 0 4.797423916458321e-11
with O 0 2.486000467982752e-11
the O 0 5.175445072502782e-10
beta O 0 1.3376550533905629e-08
- O 0 9.53447210072511e-10
subunit O 0 1.7717221023616503e-09
to O 0 1.9016424546158817e-10
produce O 0 4.739680870002871e-10
Hex O 0 4.0489755548378525e-08
A O 0 3.5696185562983374e-08
( O 0 1.2347087241515453e-10
alphabeta O 0 1.7097875115723582e-08
) O 0 1.5477592818502472e-10
in O 0 2.9792572853182264e-09
COS O 0 0.00010182034748140723
- O 0 1.6981738326649065e-06
7 O 0 1.8699820714118687e-07
cells O 0 7.364648890728631e-10
, O 0 3.7447939194024116e-10
the O 0 2.490715855785197e-09
mature O 0 3.593533248746894e-09
alpha O 0 7.137006718949124e-08
- O 0 1.060960652665699e-09
subunit O 0 2.2978134950335516e-09
was O 0 3.012526761381196e-08
present O 0 9.649787635623852e-10
, O 0 8.086783326310965e-11
but O 0 1.0946108602860605e-11
its O 0 8.046345707779512e-12
level O 0 4.13936707133189e-09
was O 0 1.1130341093235074e-08
much O 0 6.992633139191184e-10
lower O 0 1.7244262684457112e-09
than O 0 1.2895231757403813e-11
that O 0 3.020339403927985e-12
from O 0 3.5347547805431034e-11
normal O 0 8.46097414353153e-10
alpha O 0 6.092133908452979e-09
- O 0 3.522386271548328e-10
subunit O 0 4.825140287323393e-10
transfections O 0 3.429764694473647e-09
, O 0 9.08635059554408e-12
although O 0 5.558656833437592e-12
higher O 0 3.8834643834029237e-11
than O 0 2.00817270798459e-12
in O 0 3.2087446848877432e-12
those O 0 2.9879139527150267e-12
cells O 0 2.8146914052978866e-12
transfected O 0 2.5943683312767973e-10
with O 0 4.446208592273626e-12
an O 0 1.8418268646347435e-11
alpha O 0 1.2488689193901337e-08
- O 0 1.5123965413366136e-09
subunit O 0 5.2307642661730824e-09
associated O 0 4.1015276508460374e-08
with O 0 4.668687481057532e-08
infantile O 0 0.011061581782996655
TSD B-Disease 0 0.0013034212170168757
. O 0 2.3884392703621415e-06

Furthermore O 0 1.2960566664332873e-06
, O 0 5.484189102844539e-09
the O 0 3.1286491175563924e-09
precursor O 0 7.311216076999472e-09
level O 0 2.3617781508278313e-08
of O 0 8.005882179418222e-09
the O 0 1.7823581499598617e-09
W474C O 0 8.115082827941933e-09
alpha O 0 5.953938675418158e-09
- O 0 2.3237588242519536e-10
subunit O 0 7.612164787396125e-10
was O 0 1.0376616899065993e-08
found O 0 7.174940502840954e-11
to O 0 1.495237093862567e-11
accumulate O 0 1.8185790373603794e-10
in O 0 5.983144535370855e-11
comparison O 0 1.1611433342606503e-10
to O 0 1.0884073503580893e-10
the O 0 1.7245544992050554e-09
normal O 0 1.263228028847152e-07
alpha O 0 5.856689426764206e-07
- O 0 1.3279087163198255e-08
subunit O 0 4.0992826910724034e-08
precursor O 0 1.6504930044902721e-07
levels O 0 1.576316321916238e-07
. O 0 5.4395105308913116e-08

We O 0 6.623100148317462e-07
conclude O 0 5.404291982813447e-07
that O 0 5.00322783203444e-10
the O 0 1.81348469574516e-09
1422 O 0 2.572135599621106e-06
G O 0 1.9396929928916506e-06
- O 0 2.592417729374574e-07
- O 0 1.0144215423224523e-07
> O 0 1.700920471137124e-08
C O 0 1.677675953715152e-07
mutation O 0 1.5032015909799412e-10
is O 0 2.7894665743932734e-11
the O 0 7.560028297826094e-11
cause O 0 3.5038274504017863e-09
of O 0 1.6742053077223318e-08
Hex B-Disease 0 4.27274108005804e-06
A I-Disease 0 3.06889160128776e-06
enzyme I-Disease 1 0.9999967813491821
deficiency I-Disease 1 1.0
in O 0 7.942961843809826e-08
the O 0 5.643221356876893e-08
proband O 0 7.953382919367868e-06
. O 0 1.4875651288548397e-07

The O 0 3.751066657287083e-08
resulting O 0 4.104812489913456e-09
W474C O 0 6.805777275076252e-08
substitution O 0 5.638774780436506e-09
clearly O 0 2.7527413681838198e-09
interferes O 0 4.38507985478509e-09
with O 0 1.83340884141181e-10
alpha O 0 1.0026544927654868e-08
- O 0 2.5568222539185115e-10
subunit O 0 1.083277911817504e-09
processing O 0 3.6527416646947586e-09
, O 0 2.6813147188664566e-11
but O 0 3.1804055916628826e-12
because O 0 8.515444425982732e-12
the O 0 7.859356915274063e-11
base O 0 3.3790054088100874e-10
substitution O 0 6.972656341197592e-10
falls O 0 9.202067552394055e-09
at O 0 1.3344772398227178e-08
the O 0 9.513437815300563e-10
first O 0 4.936532294053109e-10
position O 0 2.8021570841474386e-08
of O 0 1.530517579340085e-07
exon O 0 6.016098836880701e-07
13 O 0 1.2146526273681957e-07
, O 0 6.674738095568955e-09
aberrant O 0 8.380739302538132e-08
splicing O 0 3.235503811538365e-07
may O 0 3.760816724707183e-08
also O 0 1.6428999272122269e-09
contribute O 0 2.5740081177616503e-09
to O 0 2.5845754425546374e-09
Hex B-Disease 0 6.962163297430379e-06
A I-Disease 0 1.973207417904632e-06
deficiency I-Disease 0 1.4227870451577473e-05
in O 0 2.8926554485053657e-09
this O 0 2.230185064400203e-10
proband O 0 1.2360158052615589e-07
. O 0 9.618256191501473e-10
. O 0 8.573803000899716e-09

Two O 0 5.6335643705551774e-08
frequent O 0 1.2869752197275375e-07
missense O 0 1.4509083712255233e-06
mutations O 0 1.4302091244644544e-07
in O 0 2.3085384270871145e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.006905409274623e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.131969788545575e-08
an O 0 1.1370622132744757e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0009534154669381678
by O 0 1.1550534140258861e-10
early O 0 7.81143796757533e-07
childhood O 1 0.9999855756759644
deafness B-Disease 1 1.0
and O 1 0.5140023231506348
goiter B-Disease 1 1.0
. O 0 0.03237653896212578

A O 0 3.814839146798477e-06
century O 0 4.0836525272425206e-07
after O 0 5.7836699873803354e-09
its O 0 4.0905293041682e-11
recognition O 0 1.0770641045709795e-09
as O 0 1.715719011308181e-09
a O 0 8.843569432315235e-09
syndrome O 0 3.987950947248464e-08
by O 0 4.247350804398309e-10
Vaughan O 0 9.464106369705405e-07
Pendred O 0 2.2208926111488836e-06
, O 0 1.6692303095311445e-09
the O 0 5.033342631577398e-09
disease O 0 2.596426043055544e-07
gene O 0 4.217837634712396e-09
( O 0 1.7992795031673836e-09
PDS O 0 5.063523076387355e-07
) O 0 2.70471783858639e-10
was O 0 7.591753004021484e-09
mapped O 0 2.7035278460374457e-09
to O 0 7.785684874583865e-10
chromosome O 0 2.1029785557402647e-07
7q22 O 0 9.311551707469334e-07
- O 0 1.6545810410661943e-07
q31 O 0 1.2927903298987076e-06
. O 0 8.585605826283427e-08

1 O 0 1.922091541928239e-05
and O 0 1.8884982466715883e-08
, O 0 1.2788720082923533e-09
recently O 0 3.717304908334995e-09
, O 0 1.3799389408930551e-10
found O 0 7.604281093698262e-11
to O 0 6.078872821779768e-11
encode O 0 2.4386819230670653e-09
a O 0 1.099236346391308e-08
putative O 0 4.444759440502821e-07
sulfate O 0 2.0058644167875173e-06
transporter O 0 7.938535418361425e-05
. O 0 1.3062056041235337e-06

We O 0 1.5498648053835495e-07
performed O 0 2.3363115886354535e-08
mutation O 0 6.834702803715231e-10
analysis O 0 2.47152964760744e-10
of O 0 1.4817472804296017e-09
the O 0 4.09011180479979e-09
PDS B-Disease 0 6.168265258565953e-07
gene O 0 1.63894386950858e-09
in O 0 5.882236364662674e-10
patients O 0 4.685901111578517e-10
from O 0 3.533947579015262e-10
14 O 0 2.450062597247893e-09
Pendred B-Disease 0 1.573472374616358e-08
families O 0 1.0241851637615706e-11
originating O 0 1.1258889653920079e-10
from O 0 1.241573927002193e-10
seven O 0 5.880428088911316e-11
countries O 0 7.0258755410779195e-12
and O 0 3.090250624837587e-11
identified O 0 4.891216875968496e-10
all O 0 3.2501404345630647e-10
mutations O 0 3.949427451743759e-09
. O 0 1.6733498142684766e-08

The O 0 1.220902987597583e-07
mutations O 0 1.0243741854765176e-08
include O 0 1.5902772432241363e-09
three O 0 4.6060433245287413e-10
single O 0 5.158563021190332e-10
base O 0 1.4940676251740115e-08
deletions O 0 2.852311631329485e-08
, O 0 1.8196104623058318e-09
one O 0 2.5119642477200443e-10
splice O 0 1.8631565623650204e-08
site O 0 2.5646089696351737e-09
mutation O 0 5.444788508945919e-10
and O 0 9.416332158451723e-10
10 O 0 7.096528520378342e-08
missense O 0 2.2335325411404483e-06
mutations O 0 8.328398735102382e-07
. O 0 7.060809821268776e-07

One O 0 5.860594569639943e-07
missense O 0 1.5413671690112096e-06
mutation O 0 4.443646339780116e-09
( O 0 1.1434734270565627e-09
L236P O 0 3.4044067120930777e-08
) O 0 2.2955869150020902e-10
was O 0 1.450314091044902e-08
found O 0 4.459224101083237e-10
in O 0 1.526879317426122e-10
a O 0 1.0524526389277256e-10
homozygous O 0 1.0536477246247955e-10
state O 0 4.9858683154324623e-11
in O 0 7.533672297110883e-11
two O 0 5.111138595692566e-11
consanguineous O 0 2.1059189236893872e-07
families O 0 1.4113751833910726e-11
and O 0 3.2608686584278956e-11
in O 0 9.924778360259623e-11
a O 0 2.540140042750494e-10
heterozygous O 0 1.735859789242511e-10
state O 0 1.0078148732217684e-10
in O 0 4.3667628540910997e-11
five O 0 1.1694330399880659e-11
additional O 0 1.6163697116877707e-11
non O 0 1.673946670166515e-08
- O 0 1.1137289135376705e-07
consanguineous O 0 5.135329956829082e-06
families O 0 2.5542012949131276e-09
. O 0 4.23718375941462e-08

Another O 0 9.8315456398268e-07
missense O 0 3.1886961551208515e-06
mutation O 0 7.690566405926802e-09
( O 0 9.918652565943376e-10
T416P O 0 6.367854865629852e-08
) O 0 2.750971117571055e-10
was O 0 1.8302767301747735e-08
found O 0 4.3036837982235454e-10
in O 0 2.311051072734216e-10
a O 0 3.3984215441762444e-10
homozygous O 0 1.2161490703377353e-09
state O 0 4.943825904213384e-10
in O 0 8.401425666271223e-10
one O 0 3.726219055533164e-10
family O 0 1.0951627799071773e-10
and O 0 3.2567164243157976e-11
in O 0 1.4704455708614006e-10
a O 0 1.5178691636918984e-10
heterozygous O 0 8.360977882260201e-11
state O 0 5.996008550779308e-11
in O 0 2.463514670036915e-10
four O 0 4.105334960868845e-10
families O 0 5.969397198768434e-11
. O 0 7.1418382319166085e-09

Pendred B-Disease 0 5.6241733545903116e-05
patients O 0 6.643520578109019e-08
in O 0 4.207657333665793e-09
three O 0 1.3836347623197298e-09
non O 0 1.6604455765900639e-07
- O 0 8.181308430721401e-08
consanguineous O 0 7.906646715127863e-06
families O 0 1.0955074347673843e-10
were O 0 2.8948782260229677e-10
shown O 0 1.3952468347344649e-10
to O 0 3.902778447639754e-11
be O 0 5.9020129061782e-11
compound O 0 2.814378730064959e-09
heterozygotes O 0 8.45060821319521e-09
for O 0 7.406967261758268e-10
L236P O 0 7.855366845888057e-08
and O 0 3.070196097354483e-09
T416P O 0 7.612301828885393e-07
. O 0 7.088966924584383e-08

In O 0 2.0417068924416526e-07
total O 0 1.0113571313752345e-08
, O 0 8.256263450689971e-10
one O 0 1.9705354015187027e-10
or O 0 5.993423812800103e-11
both O 0 7.798700574213058e-11
of O 0 2.8566479737257566e-10
these O 0 5.8751441212034905e-12
mutations O 0 2.8932470568648894e-12
were O 0 1.6972688879346443e-11
found O 0 1.3979552758447422e-11
in O 0 1.117979320230944e-11
nine O 0 1.887700551428395e-10
of O 0 1.1237976105249459e-09
the O 0 1.0720447862766491e-09
14 O 0 8.076371571519303e-09
families O 0 4.4060935455725314e-11
analyzed O 0 2.4915772556255433e-08
. O 0 8.096579762195688e-08

The O 0 1.190297904685167e-08
identification O 0 2.1313498521635665e-08
of O 0 1.7658864592817736e-08
two O 0 2.2254864617821113e-09
frequent O 0 1.797914883638896e-08
PDS B-Disease 0 2.6997267923434265e-06
mutations O 0 3.791576830280974e-09
will O 0 8.238529997095512e-11
facilitate O 0 1.6772472299919627e-09
the O 0 8.126386230600247e-10
molecular O 0 9.157283642480252e-08
diagnosis O 0 2.3727534426143393e-06
of O 0 1.6393986470575328e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.1197178537258878e-05

Insertional O 0 1.8976401406689547e-05
mutation O 0 3.232925038787471e-08
by O 0 1.3168429680021632e-09
transposable O 0 2.2983525923336856e-05
element O 0 2.3989903183974093e-06
, O 0 1.1663296106689813e-08
L1 O 0 4.374624495540047e-06
, O 0 3.873430021172908e-09
in O 0 2.9772406762162973e-09
the O 0 1.1571057711989852e-07
DMD B-Disease 1 1.0
gene O 0 7.142260560755176e-09
results O 0 1.2535099624955137e-09
in O 0 1.828904139244969e-09
X B-Disease 1 0.9995087385177612
- I-Disease 1 0.9344397783279419
linked I-Disease 0 0.30320510268211365
dilated I-Disease 1 0.9845773577690125
cardiomyopathy I-Disease 1 1.0
. O 0 0.0005771126016043127

X B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999995231628418
linked I-Disease 1 0.9999947547912598
dilated I-Disease 1 0.9999990463256836
cardiomyopathy I-Disease 1 1.0
( O 0 6.860777648398653e-05
XLDCM B-Disease 1 0.9933191537857056
) O 0 4.26900559347132e-09
is O 0 4.0491568431555436e-10
a O 0 5.388811619155831e-10
clinical O 0 2.8608438285004922e-08
phenotype O 0 1.789771886251401e-08
of O 0 2.851507190371194e-07
dystrophinopathy B-Disease 0 3.538299097272102e-06
which O 0 9.195374323089922e-11
is O 0 3.125852875152102e-12
characterized O 0 3.4416534292619483e-12
by O 0 1.513265641267525e-12
preferential O 0 1.3462936543362503e-08
myocardial B-Disease 0 5.755897655035369e-05
involvement I-Disease 0 1.847501351903702e-08
without O 0 3.9879016755506314e-10
any O 0 1.251053843853711e-10
overt O 0 2.067642501657474e-09
clinical O 0 7.817114955344096e-09
signs O 0 2.1146265183347168e-08
of O 0 2.5563481358403806e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9515582323074341

To O 0 1.1492354623499068e-08
date O 0 1.1974714198004222e-07
, O 0 9.168281411842116e-11
several O 0 1.3949641788912892e-11
mutations O 0 3.1419714052738357e-10
in O 0 6.06709515960091e-10
the O 0 5.206467903917655e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999963045120239
gene O 0 3.872579327435233e-06
, O 0 3.5328972103343403e-07
DMD O 1 1.0
, O 0 4.59714577516479e-09
have O 0 2.752160999097697e-11
been O 0 2.2548119621434992e-11
identified O 0 2.039377694496025e-11
in O 0 4.336178638375543e-11
patients O 0 5.4227306672816056e-11
with O 0 9.368673892229396e-11
XLDCM B-Disease 0 0.0025207384023815393
, O 0 6.621388992655852e-10
but O 0 2.573956499329899e-11
a O 0 9.764383746002636e-12
pathogenic O 0 2.7795774362737724e-11
correlation O 0 2.469154880557767e-10
of O 0 1.4395531988675714e-10
these O 0 1.0098540059733097e-11
cardiospecific O 0 2.7666125390624074e-08
mutations O 0 4.564434163967235e-09
in O 0 9.533295930452823e-09
DMD O 1 0.9999891519546509
with O 0 4.408905684982756e-09
the O 0 1.589647347088885e-08
XLDCM B-Disease 0 3.0887460980011383e-06
phenotype O 0 8.643389115547961e-09
has O 0 8.467205825368751e-10
remained O 0 2.758024386650959e-08
to O 0 1.4829198979882108e-10
be O 0 6.030281274327365e-10
elucidated O 0 2.475670953572262e-06
. O 0 1.373373805790834e-07

We O 0 1.82041731022764e-07
report O 0 2.8026099219147227e-09
here O 0 2.195835457907691e-10
the O 0 3.365207418282168e-11
identification O 0 1.563115054059594e-10
of O 0 9.762084474118637e-10
a O 0 1.145601946639374e-09
unique O 0 3.368807233172788e-09
de O 0 1.1997819910902763e-06
novo O 0 7.463756901415763e-07
L1 O 0 1.8000152977037942e-06
insertion O 0 8.218719216301906e-08
in O 0 1.8797836176531746e-08
the O 0 2.255090691960504e-08
muscle O 0 2.5099751610468957e-07
exon O 0 5.305200829752721e-07
1 O 0 3.064774602989928e-07
in O 0 1.09766071787476e-08
DMD O 1 0.9999998807907104
in O 0 2.965080625472183e-08
three O 0 3.8837648652645385e-09
XLDCM B-Disease 0 1.2376617632980924e-06
patients O 0 7.330314133469074e-10
from O 0 3.6523148394529414e-10
two O 0 1.3246162500202274e-10
unrelated O 0 9.075089124621627e-09
Japanese O 0 4.2572988689926206e-08
families O 0 5.544737446960823e-10
. O 0 1.076101607822011e-08

The O 0 2.660321456460224e-07
insertion O 0 2.661189171249134e-07
was O 0 1.4038847666597576e-06
a O 0 2.7153843618066276e-08
5 O 0 2.648519270564975e-08
- O 0 1.1670143740261096e-09
truncated O 0 2.431710166561629e-09
form O 0 1.968267548946301e-09
of O 0 1.2048364972372383e-08
human O 0 5.470774055993388e-09
L1 O 0 1.774524207576178e-07
inversely O 0 3.492866085252899e-08
integrated O 0 1.0035843267530709e-08
in O 0 4.748123005882121e-10
the O 0 9.544826040652765e-10
5 O 0 3.6152574267589443e-09
- O 0 1.1687251166847545e-09
untranslated O 0 4.506730704179063e-07
region O 0 6.952022957307236e-09
in O 0 6.805979113622129e-10
the O 0 3.5422633715143093e-09
muscle O 0 7.391421519287178e-08
exon O 0 1.729472387523856e-07
1 O 0 1.0116161064388507e-07
, O 0 1.945298366834436e-10
which O 0 1.2459143959586694e-11
affected O 0 3.720947161500732e-11
the O 0 7.641254295975841e-11
transcription O 0 5.369195643645241e-10
or O 0 1.8917374611238102e-10
the O 0 5.409304670855875e-10
stability O 0 3.4242407309648115e-07
of O 0 3.6641800704728666e-08
the O 0 3.2802973670698066e-09
muscle O 0 3.732295361658089e-09
form O 0 3.1858502502757347e-09
of O 0 1.1381630571349888e-07
dystrophin O 0 1.1158077768413932e-06
transcripts O 0 3.452239525358891e-07
but O 0 5.655219070810347e-10
not O 0 2.997407877458613e-11
that O 0 7.863461617962919e-12
of O 0 7.12857883833351e-10
the O 0 1.7149273112693209e-09
brain O 0 4.202392119623255e-06
or O 0 7.055994899474172e-09
Purkinje O 0 2.133397174475249e-06
cell O 0 1.5936840327412938e-06
form O 0 2.1573169917132873e-08
, O 0 1.2382918024300693e-09
probably O 0 1.1287922818681295e-09
due O 0 2.970473644836602e-09
to O 0 6.473567515374867e-11
its O 0 7.720315706172265e-12
unique O 0 4.1656900151565424e-11
site O 0 1.2160511486669634e-10
of O 0 2.7722668605179024e-10
integration O 0 1.0620042445452782e-07
. O 0 1.540495730978364e-07

We O 0 1.3562896583607653e-06
speculate O 0 2.8481318281592394e-07
that O 0 5.261287239211043e-11
this O 0 1.325839091292913e-11
insertion O 0 8.316384803030985e-10
of O 0 2.042762625720229e-09
an O 0 3.2668465155261117e-10
L1 O 0 5.79572031256248e-07
sequence O 0 1.7458527068470175e-08
in O 0 5.955123327794354e-08
DMD O 1 1.0
is O 0 1.1068059357910442e-08
responsible O 0 3.333073372857598e-09
for O 0 9.181791438273024e-11
some O 0 3.639023110624251e-12
of O 0 5.819494885983545e-11
the O 0 5.373656814661176e-12
population O 0 1.3334967082379717e-13
of O 0 1.576738913044995e-11
Japanese O 0 9.500000786033524e-10
patients O 0 2.6261454816323138e-11
with O 0 2.2776691990800124e-11
XLDCM B-Disease 0 3.476211247743777e-07
. O 0 1.7151824405203797e-09
. O 0 2.2718111836184107e-08

Severe O 0 0.0004533554892987013
early O 0 0.009983750060200691
- O 1 0.99960857629776
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 2.339842467335984e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9967999458312988
red O 0 0.1037348285317421
hair O 1 0.9374569058418274
pigmentation O 1 0.9895596504211426
caused O 0 4.872538852396247e-07
by O 0 2.4496280559560546e-09
POMC O 0 5.825614061905071e-05
mutations O 0 1.032414420620853e-08
in O 0 2.2139874378268587e-09
humans O 0 1.8237983567814808e-08
. O 0 1.0391650206997838e-08

Sequential O 0 4.110983809368918e-06
cleavage O 0 9.108002245739044e-07
of O 0 5.68841414860799e-07
the O 0 1.723305942391562e-08
precursor O 0 2.9242382737493244e-08
protein O 0 3.6139338188689862e-09
pre O 0 5.419263970907195e-07
- O 0 2.621145824832638e-07
pro O 0 1.891183273983188e-05
- O 0 1.5657088852094603e-06
opiomelanocortin O 0 2.249777708129841e-06
( O 0 7.417513825380695e-10
POMC O 0 7.591525275074673e-08
) O 0 4.93133520129696e-11
generates O 0 1.4412565585431025e-10
the O 0 3.5538405551704955e-10
melanocortin O 0 1.89674381090299e-07
peptides O 0 1.3853591607215776e-09
adrenocorticotrophin O 0 2.495763453680411e-07
( O 0 2.397939069531674e-10
ACTH O 0 1.49480019473458e-08
) O 0 1.984150344025437e-10
, O 0 4.720059343377159e-10
melanocyte O 0 5.707651098418864e-07
- O 0 5.668874791808776e-07
stimulating O 0 3.6418879290067707e-07
hormones O 0 4.3176079600470985e-08
( O 0 3.79588721566293e-10
MSH O 0 1.637558142419948e-07
) O 0 1.9969680076226126e-10
alpha O 0 2.6716294954098885e-08
, O 0 3.7955977250092587e-10
beta O 0 5.084559884238615e-09
and O 0 3.773192869260811e-10
gamma O 0 7.676555391356032e-09
as O 0 3.4894049455447274e-11
well O 0 1.5972672837150093e-11
as O 0 5.461997173994426e-12
the O 0 3.56601345674612e-11
opioid O 0 2.2418944922719675e-08
- O 0 7.4032140418012204e-09
receptor O 0 1.873411425989957e-09
ligand O 0 1.0005953754443908e-07
beta O 0 4.975614956492791e-06
- O 0 1.042587541633111e-06
endorphin O 0 8.294882718473673e-06
. O 0 2.7492225740388676e-07

While O 0 4.907303718937328e-07
a O 0 9.01424357380165e-09
few O 0 3.28700344720545e-10
cases O 0 3.252136893117097e-10
of O 0 1.0193963007054663e-08
isolated O 0 5.663093247676443e-07
ACTH B-Disease 0 4.212748535792343e-05
deficiency I-Disease 0 0.18417440354824066
have O 0 7.364143184140914e-10
been O 0 4.87045681563103e-10
reported O 0 3.0756161506495516e-10
( O 0 3.1349121215606957e-11
OMIM O 0 5.326634777702566e-08
201400 O 0 6.205921465607389e-08
) O 0 2.348232996940425e-10
, O 0 2.8105845428783027e-10
an O 0 2.142541477567761e-09
inherited O 1 0.9990214109420776
POMC O 1 0.9999843835830688
defect O 1 0.9987327456474304
has O 0 2.58957051357811e-08
not O 0 4.044355961241308e-10
been O 0 2.7215465991936583e-10
described O 0 2.9538843593357456e-10
so O 0 6.895284343499952e-11
far O 0 4.865999825298672e-10
. O 0 2.4394217756906755e-09

Recent O 0 7.399716395184441e-08
studies O 0 1.973388386034003e-08
in O 0 8.092713166263366e-10
animal O 0 4.858237701022006e-10
models O 0 8.395242279135573e-10
elucidated O 0 4.549963819044933e-07
a O 0 4.0579264393159065e-09
central O 0 1.1741327909930988e-08
role O 0 2.414398991845701e-08
of O 0 2.3237794266606215e-07
alpha O 0 1.7050795577233657e-05
- O 0 6.441602522500034e-07
MSH O 0 3.1404790661326842e-06
in O 0 1.1553690226762114e-09
the O 0 8.578378007939591e-10
regulation O 0 1.8746419527815306e-08
of O 0 9.096209341308281e-10
food O 0 5.403259090153156e-11
intake O 0 6.819720569511967e-12
by O 0 4.113763095361239e-13
activation O 0 6.442395505956711e-10
of O 0 1.5815905030081012e-08
the O 0 1.955705997147561e-08
brain O 0 1.529399810351606e-06
melanocortin O 0 2.9983157219248824e-06
- O 0 7.732710116670205e-08
4 O 0 1.1679729539082473e-07
- O 0 3.696807082675946e-09
receptor O 0 3.121518599158435e-10
( O 0 3.753582167309588e-10
MC4 O 0 2.160736585210543e-06
- O 0 9.398414846373271e-08
R O 0 9.227430268765602e-07
; O 0 1.5038303935455133e-09
refs O 0 6.949015869395225e-07
3 O 0 5.0736829848574416e-08
- O 0 1.5766711269904476e-09
5 O 0 5.652620038709699e-10
) O 0 2.2432971279184866e-12
and O 0 7.703591237140373e-12
the O 0 5.7071854187018545e-11
linkage O 0 1.5788206297884244e-08
of O 0 6.870557900384711e-09
human O 0 2.1914804904099583e-07
obesity B-Disease 1 0.9999995231628418
to O 0 2.3679971317136506e-09
chromosome O 0 1.2121576276058477e-07
2 O 0 2.1782140890991286e-07
in O 0 9.662722177949945e-09
close O 0 1.5183982782218663e-07
proximity O 0 1.827054347813828e-07
to O 0 5.81659254095257e-09
the O 0 4.222863125846743e-08
POMC O 0 1.4447749663304421e-06
locus O 0 2.386161135348175e-08
, O 0 3.3172116165047782e-09
led O 0 1.6194975360761532e-09
to O 0 1.9265850026428666e-10
the O 0 6.411797204286529e-10
proposal O 0 1.5723976565240605e-09
of O 0 2.599892745536181e-09
an O 0 1.3060763581762558e-10
association O 0 3.111830348956346e-09
of O 0 1.911061886517018e-08
POMC O 0 9.483979738433845e-06
with O 0 8.362452952326294e-09
human O 0 9.285504347644746e-05
obesity B-Disease 1 1.0
. O 0 8.501154411533207e-07

The O 0 2.8304773991294496e-07
dual O 0 6.876669544908509e-07
role O 0 3.0140844842208026e-07
of O 0 8.840315217639727e-07
alpha O 0 1.790309397620149e-05
- O 0 2.991079384173645e-07
MSH O 0 3.379890358701232e-06
in O 0 1.1597250937356307e-09
regulating O 0 1.7552659414832306e-07
food O 0 1.2562290097051232e-09
intake O 0 1.897100476710989e-09
and O 0 3.625849065436171e-10
influencing O 0 1.1884895911862259e-06
hair O 0 9.72314069258573e-07
pigmentation O 0 5.149242497282103e-06
predicts O 0 1.9154482444605492e-08
that O 0 6.010561492963973e-11
the O 0 2.136582161194056e-10
phenotype O 0 8.080203728333402e-10
associated O 0 2.26645191503394e-09
with O 0 1.2568010521185613e-10
a O 0 4.833165423434593e-09
defect O 0 3.490609117307031e-07
in O 0 1.5684475940247466e-08
POMC O 0 7.753349564154632e-06
function O 0 8.834272762214823e-07
would O 0 5.480947251612633e-09
include O 0 4.3255042214696005e-08
obesity B-Disease 1 1.0
, O 0 1.2410203975576906e-09
alteration O 0 1.4767605307497433e-06
in O 0 2.1587581500170927e-07
pigmentation O 1 0.9673095345497131
and O 0 2.8040822144248523e-06
ACTH B-Disease 0 0.002055493649095297
deficiency I-Disease 1 0.7554341554641724
. O 0 7.302396625163965e-07

The O 0 3.483512216462259e-07
observation O 0 7.235583325382322e-05
of O 0 3.1476312756240077e-07
these O 0 2.462167580929986e-09
symptoms O 0 3.7291880516931997e-07
in O 0 1.7600347845814213e-09
two O 0 1.5109778983557476e-09
probands O 0 2.786865707093966e-07
prompted O 0 1.869164156786951e-09
us O 0 3.4820135663693463e-10
to O 0 4.312276577489449e-11
search O 0 7.113651889767425e-10
for O 0 1.18124093839711e-10
mutations O 0 8.42581782123375e-10
within O 0 3.1323033056196437e-09
their O 0 2.5913577950120725e-09
POMC O 0 8.946672096499242e-06
genes O 0 8.343943136424059e-08
. O 0 2.2245586706048925e-07

Patient O 0 4.476735193748027e-05
1 O 0 2.4449662305414677e-05
was O 0 2.2549352252099197e-06
found O 0 3.352736976935944e-09
to O 0 7.095232734677381e-11
be O 0 9.506050113738951e-11
a O 0 1.790756987141151e-10
compound O 0 4.887197868619353e-10
heterozygote O 0 4.256557328830013e-09
for O 0 2.78772366302249e-10
two O 0 1.2499995483139514e-10
mutations O 0 1.5819448528908708e-10
in O 0 2.7082709408432493e-09
exon O 0 8.006175988839459e-08
3 O 0 5.1239133824765304e-08
( O 0 4.1612607803998003e-10
G7013T O 0 2.4126265429913474e-08
, O 0 9.171539083752123e-10
C7133delta O 0 5.705899397412395e-08
) O 0 1.1184383280626875e-10
which O 0 3.225325909128607e-11
interfere O 0 9.170524339907615e-10
with O 0 1.1969827039270964e-11
appropriate O 0 4.000098030587651e-10
synthesis O 0 7.928519174527082e-09
of O 0 8.82311557148796e-09
ACTH O 0 7.802252355304518e-08
and O 0 6.5800347393008e-09
alpha O 0 9.419944035471417e-06
- O 0 1.8617927253217204e-06
MSH O 0 5.7272241974715143e-05
. O 0 4.308016627874167e-07

Patient O 0 8.10420260677347e-06
2 O 0 1.6408047258664737e-06
was O 0 9.053947280790453e-08
homozygous O 0 2.9578435256638613e-09
for O 0 2.688152200835958e-10
a O 0 6.84700685038564e-10
mutation O 0 1.976030589156963e-10
in O 0 2.5870512398995515e-09
exon O 0 2.097002607115428e-07
2 O 0 1.454669700251543e-07
( O 0 4.554561172653848e-10
C3804A O 0 1.4696226457999728e-08
) O 0 1.0341989764572901e-10
which O 0 1.9647933280353413e-10
abolishes O 0 2.0920289500736544e-07
POMC O 0 7.6594560596277e-06
translation O 0 6.895306796650402e-07
. O 0 7.962162840158271e-07

These O 0 9.022087077426022e-09
findings O 0 1.9588819455407247e-09
represent O 0 7.907175469945571e-10
the O 0 2.351971395420094e-10
first O 0 9.564503355985465e-11
examples O 0 1.125900150888981e-09
of O 0 6.368836125147936e-09
a O 0 5.820235671194496e-08
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 3.18792530151768e-07
the O 0 4.451851864928358e-08
POMC O 0 1.395787990077224e-06
gene O 0 7.287964898239352e-09
and O 0 4.700554945280544e-10
define O 0 2.465561976805475e-08
a O 0 2.224862738486877e-09
new O 0 3.203932052997516e-08
monogenic B-Disease 1 0.9999998807907104
endocrine I-Disease 1 0.9999995231628418
disorder I-Disease 0 0.2811344563961029
resulting O 0 5.784265511010744e-09
in O 0 6.475460168076097e-10
early O 0 1.139755795520614e-06
- O 0 0.00015217500913422555
onset O 1 0.9999966621398926
obesity B-Disease 1 1.0
, O 0 3.2256893973681144e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9991138577461243
red O 0 0.004191864747554064
hair O 0 0.00023599019914399832
pigmentation O 0 0.00010546596604399383
. O 0 1.774509783558642e-08
. O 0 5.5090065842478e-08

A O 0 3.6816737747358275e-07
European O 0 6.74898998909157e-08
multicenter O 0 6.7285163822816685e-06
study O 0 4.320046187444859e-08
of O 0 2.167105321859708e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.462972627716226e-08
classification O 0 2.820970053107885e-07
of O 0 1.1778207209545144e-07
105 O 0 2.927978357547545e-07
mutations O 0 4.147617804761694e-09
and O 0 6.26801333059035e-10
a O 0 7.518072830947631e-10
general O 0 2.7336020114177018e-09
system O 0 1.5714869405769605e-08
for O 0 9.249768173624773e-10
genotype O 0 8.847364618702613e-09
- O 0 9.207189455295861e-10
based O 0 2.6990390478154325e-10
prediction O 0 1.5471586678472704e-08
of O 0 7.343486263522436e-09
metabolic O 0 2.5962628569686785e-05
phenotype O 0 2.2120180176443682e-07
. O 0 1.9238039783431304e-07

Phenylketonuria B-Disease 0 0.002134614624083042
( O 0 3.362678739904368e-07
PKU B-Disease 0 4.031972275697626e-05
) O 0 1.995264398146901e-08
and O 0 5.085823318040639e-08
mild B-Disease 0 0.11891057342290878
hyperphenylalaninemia I-Disease 1 1.0
( O 0 8.818709829938598e-06
MHP B-Disease 1 1.0
) O 0 2.318673031354024e-09
are O 0 1.621675849161619e-10
allelic B-Disease 0 5.30572378920624e-06
disorders I-Disease 1 0.9885834455490112
caused O 0 7.732736229115744e-09
by O 0 1.8160339551598348e-11
mutations O 0 1.0597001054435395e-10
in O 0 4.750140558673621e-11
the O 0 1.319057085780173e-10
gene O 0 3.8615738384706333e-10
encoding O 0 2.2955891409992546e-08
phenylalanine O 0 7.526942226832034e-06
hydroxylase O 0 2.7148667868459597e-05
( O 0 5.07978334951531e-08
PAH O 0 1.981321292987559e-05
) O 0 6.738699909192292e-08
. O 0 5.364511821426277e-07

Previous O 0 8.158998525686911e-07
studies O 0 8.807885620853995e-08
have O 0 1.411209066271013e-10
suggested O 0 3.814925597644958e-10
that O 0 1.4052340020775933e-12
the O 0 2.515299947492e-11
highly O 0 3.463460351849079e-10
variable O 0 5.495563115687219e-08
metabolic O 0 7.884510705480352e-05
phenotypes O 0 1.9121905552310636e-06
of O 0 8.913210876926314e-06
PAH B-Disease 1 0.9999830722808838
deficiency I-Disease 1 0.9992683529853821
correlate O 0 1.4347105206979904e-05
with O 0 3.666551151582098e-07
PAH O 1 0.9232726693153381
genotypes O 0 0.00011100466508651152
. O 0 3.232846893297392e-06

We O 0 1.5308678769088147e-07
identified O 0 1.2971898222247091e-08
both O 0 6.439458966056577e-10
causative O 0 2.4468555182011187e-08
mutations O 0 2.5171933426548776e-09
in O 0 1.1451061210365765e-09
686 O 0 3.447395968692035e-08
patients O 0 5.125885049750423e-09
from O 0 1.5513540452261054e-09
seven O 0 2.2131851906692646e-09
European O 0 7.495697396109335e-09
centers O 0 3.8895787923820535e-08
. O 0 3.0047793586618354e-08

On O 0 1.1785595006585936e-06
the O 0 5.458589580342732e-09
basis O 0 5.793010071641902e-09
of O 0 4.675687614863477e-10
the O 0 2.6354335380673888e-11
phenotypic O 0 6.498093618745315e-09
characteristics O 0 4.786698148961932e-09
of O 0 1.0406287387354496e-08
297 O 0 1.221100554005261e-08
functionally O 0 1.1746439554372046e-07
hemizygous O 0 4.248546190410707e-07
patients O 0 2.2652890674379478e-09
, O 0 2.333014059718863e-10
105 O 0 9.120292077113845e-09
of O 0 4.881721693550389e-09
the O 0 2.8780935412697772e-09
mutations O 0 5.143884207470251e-10
were O 0 5.742424313837091e-10
assigned O 0 2.9006943513820715e-09
to O 0 9.130830813663948e-11
one O 0 6.636773075552327e-11
of O 0 4.3635928204110996e-10
four O 0 1.4021511729467306e-10
arbitrary O 0 3.7538827601935054e-10
phenotype O 0 1.4820292215667052e-10
categories O 0 6.115628004010887e-09
. O 0 1.8613523167232415e-08

We O 0 3.8583166883654485e-07
proposed O 0 5.488900711725364e-08
and O 0 7.843696248066578e-10
tested O 0 8.321319744375444e-10
a O 0 5.252323576065976e-11
simple O 0 9.51634951396052e-12
model O 0 4.3290884765845306e-11
for O 0 7.740161810099178e-12
correlation O 0 5.753234000316354e-10
between O 0 3.447722773941564e-09
genotype O 0 9.659847144405376e-09
and O 0 1.5669000819062973e-10
phenotypic O 0 1.433453462595935e-07
outcome O 0 6.627029165429121e-07
. O 0 1.6352795739749126e-07

The O 0 9.848307769289022e-08
observed O 0 2.4382879715290073e-08
phenotype O 0 2.5899149491692697e-09
matched O 0 3.872071108190767e-09
the O 0 4.004212517116912e-10
predicted O 0 7.561056225569018e-10
phenotype O 0 1.364307139484211e-10
in O 0 1.5715125034621025e-10
79 O 0 3.2361868740338195e-09
% O 0 2.2335565341702335e-10
of O 0 3.5587330859954136e-09
the O 0 8.118252736721843e-10
cases O 0 2.874049331857975e-10
, O 0 8.220208368159287e-12
and O 0 1.482797565288685e-11
in O 0 6.296996257759702e-11
only O 0 5.7115524115802785e-11
5 O 0 6.581022948815018e-10
of O 0 9.723024607666275e-10
184 O 0 1.280463401975851e-09
patients O 0 6.308058519977067e-10
was O 0 6.174701194794352e-09
the O 0 5.578066342160071e-10
observed O 0 9.301766024094604e-10
phenotype O 0 2.1825073692749442e-10
more O 0 8.445858595829137e-12
than O 0 7.154247680385417e-12
one O 0 1.0704173658560023e-11
category O 0 2.595298698171433e-10
away O 0 4.110357332276493e-10
from O 0 6.089433124412125e-11
that O 0 8.11140304229907e-12
expected O 0 2.63494848162793e-09
. O 0 1.316210873625323e-08

Among O 0 8.041038057626793e-08
the O 0 1.5544351583685057e-08
seven O 0 1.3025940326372165e-09
contributing O 0 1.7527517215398802e-09
centers O 0 6.551478803906718e-10
, O 0 8.606722973203418e-12
the O 0 5.0748950181089825e-11
proportion O 0 7.001562107866732e-10
of O 0 4.2463725868913116e-09
patients O 0 5.142696823945414e-10
for O 0 2.4615467997257667e-10
whom O 0 8.172411081197595e-10
the O 0 5.871844677152183e-10
observed O 0 5.182342555087871e-09
phenotype O 0 6.359886506324131e-10
did O 0 4.22150592260806e-10
not O 0 6.6964857270424e-11
match O 0 2.299260115634638e-09
the O 0 3.1119121168821096e-10
predicted O 0 7.56294582515693e-10
phenotype O 0 8.280514468550493e-11
was O 0 6.48306430761636e-09
4 O 0 3.402782056127762e-09
% O 0 1.5332209113427808e-10
- O 0 8.234010140384385e-10
23 O 0 7.627138032262337e-09
% O 0 7.205390173403714e-10
( O 0 3.939592263524361e-10
P O 0 1.232957743013685e-06
< O 0 5.7139690312624225e-08
. O 0 1.099862756426262e-09
0001 O 0 5.972219128125289e-07
) O 0 1.8123531841940377e-10
, O 0 3.206751530981933e-11
suggesting O 0 2.134390719721324e-10
that O 0 3.904481772620816e-12
differences O 0 3.635322043393785e-10
in O 0 4.3123914161835586e-11
methods O 0 6.368055527339322e-10
used O 0 2.3695037251747486e-11
for O 0 1.4423889166392811e-11
mutation O 0 5.909785855129357e-11
detection O 0 1.7110304284528866e-08
or O 0 2.034918067383984e-10
phenotype O 0 1.5920191831497732e-09
classification O 0 2.6018422971674227e-09
may O 0 3.0237662373977514e-10
account O 0 3.4853474273344176e-11
for O 0 3.9336658930189117e-11
a O 0 5.8138362180049086e-11
considerable O 0 5.391463941961661e-10
proportion O 0 8.421688901805169e-10
of O 0 3.3042535374505633e-09
genotype O 0 1.55368297782843e-07
- O 0 1.8236353582778975e-07
phenotype O 0 3.880700916170099e-08
inconsistencies O 0 9.106656762014609e-07
. O 0 2.0393112265537638e-07

Our O 0 9.725348490974284e-07
data O 0 8.161031672671015e-08
indicate O 0 1.6732029095578582e-08
that O 0 4.75174732894601e-10
the O 0 8.457831768282631e-09
PAH O 0 1.6433354176115245e-05
- O 0 3.909818246938812e-07
mutation O 0 1.826589435260928e-09
genotype O 0 4.035581202543881e-09
is O 0 5.215526621693556e-11
the O 0 8.145453062047281e-11
main O 0 3.4886096234032493e-09
determinant O 0 1.3313606928022637e-07
of O 0 7.20195902914611e-09
metabolic O 0 3.3211811114597367e-06
phenotype O 0 1.0388078175438409e-09
in O 0 2.745771110479467e-10
most O 0 7.429063614283749e-11
patients O 0 1.096592927574136e-09
with O 0 1.5724284097018426e-08
PAH B-Disease 1 0.9999978542327881
deficiency I-Disease 1 1.0
. O 0 0.0019694415386766195

In O 0 8.600815704085107e-08
the O 0 7.693339298953106e-09
present O 0 1.7118650941227997e-09
study O 0 2.5150084792535665e-10
, O 0 3.878799191558979e-12
the O 0 1.2710138497240564e-11
classification O 0 8.039143795102177e-10
of O 0 2.8896790738031086e-08
105 O 0 1.2478293456297251e-06
PAH O 0 2.052316631306894e-05
mutations O 0 2.1082392720472853e-08
may O 0 1.6613468378778862e-09
allow O 0 3.364907519287641e-10
the O 0 6.324237800114929e-10
prediction O 0 1.4310217011370696e-08
of O 0 1.737851640370991e-09
the O 0 6.775554006743789e-10
biochemical O 0 3.654553326626342e-09
phenotype O 0 4.024948152547836e-10
in O 0 6.559793819249649e-10
> O 0 1.3482825522714847e-08
10 O 0 4.133181796817098e-09
, O 0 2.372783913795473e-10
000 O 0 5.7052109703192855e-09
genotypes O 0 5.6435553119627e-08
, O 0 2.3120574343948874e-09
which O 0 3.4072678012364577e-10
may O 0 6.854415368628963e-10
be O 0 1.2931272719285403e-10
useful O 0 3.5590297375875934e-10
for O 0 2.0745695092361238e-11
the O 0 1.578824987413796e-10
management O 0 1.5155736221572624e-08
of O 0 3.310310958681839e-08
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.42143576908893e-07
newborns O 0 1.9127544703678723e-07
. O 0 5.2030646457978946e-08

Somatic O 0 0.00011154623643960804
instability O 0 5.56810773559846e-05
of O 0 8.398852173741034e-07
the O 0 1.227567167916277e-07
CTG O 0 2.266426781716291e-05
repeat O 0 3.37763630398058e-08
in O 0 2.612035698845716e-09
mice O 0 2.0998267569183326e-09
transgenic O 0 1.900642754293358e-09
for O 0 1.0644164438744497e-09
the O 0 1.5349612567661097e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.948851033579558e-05
is O 0 2.292424472472021e-09
age O 0 2.8369284699181208e-09
dependent O 0 1.1158053370152743e-09
but O 0 3.178788135493882e-11
not O 0 2.755915287644406e-12
correlated O 0 3.953862584560319e-11
to O 0 6.545726634332727e-12
the O 0 6.982221745222006e-11
relative O 0 1.28927926112965e-08
intertissue O 0 4.2301987690507303e-08
transcription O 0 2.7226086274367844e-08
levels O 0 1.577812192010697e-08
and O 0 2.441292723531774e-09
proliferative O 0 3.482794636511244e-05
capacities O 0 1.3881596714782063e-05
. O 0 4.833923981095722e-07

A O 0 4.6804139856249094e-05
( O 0 4.164782296811609e-08
CTG O 0 3.1880697406450054e-06
) O 0 1.7017797171448024e-09
nexpansion O 0 1.201103856374175e-07
in O 0 1.3458077985362138e-09
the O 0 4.500101624671515e-09
3 O 0 7.354885411814394e-08
- O 0 1.143035799344716e-08
untranslated O 0 5.861338649992831e-06
region O 0 4.245500306865324e-08
( O 0 1.588663645080146e-10
UTR O 0 1.6978680150714354e-07
) O 0 1.895059803525001e-10
of O 0 1.3102445350909875e-08
the O 0 4.933158379571978e-07
DM O 1 1.0
protein O 0 1.365114439977333e-05
kinase O 0 7.003718565101735e-07
gene O 0 6.071175562283315e-08
( O 0 1.352758904893392e-09
DMPK O 0 6.538626280416793e-07
) O 0 2.560238410165283e-10
is O 0 3.194627548608331e-11
responsible O 0 6.002556229844913e-10
for O 0 3.981853513579381e-09
causing O 1 0.9999570846557617
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.3006239391397685e-05
DM B-Disease 1 1.0
) O 0 6.696367194081176e-08
. O 0 9.11196735842168e-08

Major O 0 3.330945037305355e-05
instability O 0 0.005278363358229399
, O 0 2.9912673227272535e-08
with O 0 4.1186051791264333e-10
very O 0 1.1584053716262588e-09
large O 0 3.5613387239230576e-10
expansions O 0 6.852183709327164e-09
between O 0 4.5583721686170975e-08
generations O 0 3.1136591083225085e-09
and O 0 9.951277302189254e-11
high O 0 2.659010567285236e-09
levels O 0 2.3231438994741893e-09
of O 0 4.666370401196218e-09
somatic O 0 6.487853454473225e-08
mosaicism O 0 9.179245239465672e-07
, O 0 1.7769838378534075e-10
is O 0 1.0534843830622975e-11
observed O 0 5.790632418012365e-10
in O 0 3.762427314146777e-10
patients O 0 6.352579351442955e-09
. O 0 3.065119003053951e-08

There O 0 1.449916311457855e-07
is O 0 5.850015583064305e-09
a O 0 1.3096242978960504e-09
good O 0 1.9426225073004844e-09
correlation O 0 3.5131426656676012e-09
between O 0 9.7764738526962e-09
repeat O 0 4.117680418858072e-09
size O 0 2.245967856140396e-09
( O 0 2.792177322685774e-10
at O 0 6.2750378226894554e-09
least O 0 1.8282440839012537e-10
in O 0 4.0542108559193935e-10
leucocytes O 0 3.2631071178457205e-08
) O 0 7.028948256770917e-11
, O 0 2.8227141110614973e-11
clinical O 0 2.0784607368540264e-09
severity O 0 8.497837100662764e-09
and O 0 5.992909640761823e-11
age O 0 5.373685496579128e-09
of O 0 1.6772961686228882e-08
onset O 0 5.252058144833427e-06
. O 0 1.2552480654903775e-07

The O 0 3.6835249375144485e-06
trinucleotide O 0 0.0003734613419510424
repeat O 0 2.4534551812394056e-06
instability O 0 9.70251585385995e-06
mechanisms O 0 2.0293200577725656e-05
involved O 0 1.224676680067205e-07
in O 0 2.619016470362112e-08
DM B-Disease 1 1.0
and O 0 6.137701902275694e-09
other O 0 1.0184784127176272e-09
human O 0 4.751334199681878e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.6289029286807875e-10
unknown O 0 3.6384335544425994e-08
. O 0 1.615540057287035e-08

We O 0 1.0946901340957993e-07
studied O 0 1.0830821111085243e-06
somatic O 0 4.764330299167341e-07
instability O 0 1.0234840175371573e-07
by O 0 4.981194345887729e-10
measuring O 0 1.8268101484864019e-06
the O 0 1.2686184902577224e-07
CTG O 0 8.69967698235996e-06
repeat O 0 4.309372414468271e-08
length O 0 4.8652504247570505e-09
at O 0 5.5683000432793506e-09
several O 0 3.9297214787792356e-11
ages O 0 2.342726013182528e-10
in O 0 1.1397793299450232e-11
various O 0 1.262984161698455e-10
tissues O 0 1.9890697977587024e-09
of O 0 2.556498301942156e-08
transgenic O 0 1.2697316087439958e-08
mice O 0 2.6764430671732953e-09
carrying O 0 4.605087866593749e-09
a O 0 3.3959157708096654e-09
( O 0 2.196384185637612e-10
CTG O 0 1.8649917876700783e-07
) O 0 2.0488137575380705e-10
55expansion O 0 5.2376854853264376e-08
surrounded O 0 9.116848609380668e-09
by O 0 7.31539717691021e-10
45 O 0 1.666844973158277e-08
kb O 0 3.4976239930983866e-06
of O 0 2.0628228014629713e-07
the O 0 2.1515024428708784e-08
human O 0 8.229088166444853e-08
DM B-Disease 1 1.0
region O 0 1.4676309945116373e-08
, O 0 2.2801902727076495e-11
using O 0 6.073749836410514e-11
small O 0 2.1461761534613544e-10
- O 0 2.107639174298015e-09
pool O 0 3.502372081243266e-08
PCR O 0 3.739636866839646e-08
. O 0 2.3499648449387678e-08

These O 0 7.33591534185507e-08
mice O 0 6.047228851002728e-08
have O 0 1.308133185107252e-10
been O 0 5.453703461055781e-11
shown O 0 2.2838290286708585e-11
to O 0 3.3048978050759237e-12
reproduce O 0 6.144618841519289e-11
the O 0 8.27075907761099e-11
intergenerational O 0 4.7521391266514e-09
and O 0 1.914445546535859e-10
somatic O 0 2.047756986200966e-08
instability O 0 3.8933048784883795e-08
of O 0 9.1168139704223e-09
the O 0 8.113117289099137e-09
55 O 0 8.50468353519318e-08
CTG O 0 2.4693845261936076e-06
repeat O 0 3.019118466340842e-08
suggesting O 0 4.399866249116258e-09
that O 0 2.7309259020835697e-11
surrounding O 0 4.441804979382624e-10
sequences O 0 3.7568484434480354e-10
and O 0 4.42923128729511e-11
the O 0 8.531332584826856e-11
chromatin O 0 6.472327562789815e-09
environment O 0 4.7614205911372665e-09
are O 0 1.6468387417645225e-11
involved O 0 6.118351658646048e-11
in O 0 7.397391033059364e-11
instability O 0 2.2710511871082417e-07
mechanisms O 0 5.279890956444433e-06
. O 0 2.6325693625040003e-07

As O 0 6.457077006416512e-08
observed O 0 2.1063501165485832e-08
in O 0 7.032666671236143e-10
some O 0 3.903195128218684e-11
of O 0 6.138589081494672e-10
the O 0 2.1729620880428513e-10
tissues O 0 1.9332115908099468e-09
of O 0 3.1385309284814866e-07
DM B-Disease 1 1.0
patients O 0 1.195121228647622e-07
, O 0 7.285635983400596e-11
there O 0 2.6126061383746624e-11
is O 0 1.2184278759541645e-11
a O 0 5.3606376282377965e-11
tendency O 0 8.938901008281874e-11
for O 0 4.341557668929852e-11
repeat O 0 6.854742329309715e-10
length O 0 9.981241388956619e-10
and O 0 6.439090372012402e-10
somatic O 0 4.743538539742076e-08
mosaicism O 0 4.2335571492913004e-07
to O 0 1.1677558919842568e-09
increase O 0 7.442129135171172e-10
with O 0 1.1767233021320322e-10
the O 0 1.7814778541236365e-09
age O 0 1.56339101664571e-08
of O 0 4.263943864657449e-09
the O 0 4.1710683795770365e-09
mouse O 0 6.50454410333623e-08
. O 0 3.712240470576944e-08

Furthermore O 0 1.5530652035522508e-06
, O 0 3.792242075917329e-09
we O 0 6.060260071549806e-10
observed O 0 1.4010335946945673e-10
no O 0 3.3085322675985296e-11
correlation O 0 1.8457595174492525e-10
between O 0 1.580762465369645e-10
the O 0 1.9501576742353421e-10
somatic O 0 3.2158693485939693e-09
mutation O 0 6.054941964483973e-11
rate O 0 4.111525564454155e-10
and O 0 7.879409624766964e-11
tissue O 0 4.924610497170079e-09
proliferation O 0 7.15170983767166e-07
capacity O 0 8.655699446080689e-08
. O 0 5.5241063279254377e-08

The O 0 4.592117619495184e-08
somatic O 0 2.269291172751764e-07
mutation O 0 3.882513421871181e-09
rates O 0 2.455348813157343e-09
in O 0 5.4472579225084417e-11
different O 0 1.9551549615415276e-11
tissues O 0 7.046631056439878e-10
were O 0 4.848277335156581e-10
also O 0 1.1715494893649314e-11
not O 0 2.3708858227361462e-12
correlated O 0 8.247570681962912e-11
to O 0 4.2386729542931434e-11
the O 0 8.765543291211486e-10
relative O 0 1.1941281172767049e-06
inter O 0 0.30679941177368164
- O 0 7.662822554266313e-08
tissue O 0 1.302453167539852e-08
difference O 0 3.066224252279426e-08
in O 0 2.527492382053964e-10
transcriptional O 0 2.0870414285667493e-09
levels O 0 2.6847923884076863e-09
of O 0 2.0608470485683483e-09
the O 0 9.363998465516943e-10
three O 0 2.1544487027735926e-10
genes O 0 1.3594754488810423e-10
( O 0 1.3487648498067273e-10
DMAHP O 0 1.641488864834173e-07
, O 0 1.1491494422699589e-09
DMPK O 0 1.204450313707639e-06
and O 0 4.540148257348164e-09
59 O 0 2.124790654534081e-08
) O 0 2.0713480930467654e-10
surrounding O 0 6.324507140220703e-09
the O 0 1.951665717925266e-09
repeat O 0 8.102849058388983e-09
. O 0 2.0576771397884386e-09
. O 0 1.5062884273220334e-08

A O 0 7.130005883482227e-07
novel O 0 3.785061153394054e-08
missense O 0 2.779418082354823e-07
mutation O 0 3.189504438338986e-09
in O 0 6.53648857262823e-10
patients O 0 3.659715419601639e-09
from O 0 6.180545408795979e-09
a O 0 3.67734998008018e-08
retinoblastoma B-Disease 0 0.0006852829246781766
pedigree O 0 1.2959253581357189e-07
showing O 0 1.046261122183978e-08
only O 0 4.5169887274987275e-10
mild O 0 8.556061636966206e-09
expression O 0 1.4721636132364324e-09
of O 0 8.910839177644903e-09
the O 0 1.921734105181372e-09
tumor B-Disease 0 2.1144852979659845e-08
phenotype O 0 9.168237724566097e-09
. O 0 2.6639817463092186e-08

We O 0 9.776422160712173e-08
have O 0 1.4997419972573311e-10
used O 0 5.0289040293138854e-11
single O 0 2.244723677768956e-11
strand O 0 1.9576261445219956e-10
conformation O 0 1.273883082353322e-10
polymorphism O 0 5.61238722163182e-10
analysis O 0 5.8019498927475155e-11
to O 0 1.3091009179455604e-11
study O 0 5.22045323636533e-11
the O 0 2.3441340535335087e-10
27 O 0 1.810872518603901e-08
exons O 0 5.2837009434369975e-08
of O 0 5.481378195781872e-08
the O 0 3.1970582625717725e-08
RB1 O 0 9.154688314083614e-07
gene O 0 3.6661289559702936e-09
in O 0 1.089691559208461e-09
individuals O 0 2.6387378393444294e-11
from O 0 6.00354388424762e-09
a O 0 7.198333484836894e-09
family O 0 6.418980347255854e-10
showing O 0 4.15737533288052e-09
mild O 0 1.0767134739353423e-08
expression O 0 4.6852419721687966e-09
of O 0 2.294678758119062e-08
the O 0 1.772723656756625e-08
retinoblastoma B-Disease 0 7.323497811739799e-06
phenotype O 0 6.947439601390215e-08
. O 0 7.689249059694703e-08

In O 0 2.49037100275018e-07
this O 0 2.8566113918770952e-09
family O 0 1.0799420246954128e-09
affected O 0 1.6875920105796638e-10
individuals O 0 7.847174299246973e-12
developed O 0 3.793965674958599e-08
unilateral B-Disease 0 1.516345491836546e-05
tumors I-Disease 1 1.0
and O 0 2.180903777571075e-07
, O 0 2.6594859647843805e-10
as O 0 9.605674589074908e-11
a O 0 3.7313662576421436e-11
result O 0 1.482328843005476e-10
of O 0 3.9025813691750955e-09
linkage O 0 1.7879022706779324e-08
analysis O 0 1.0155725149729733e-09
, O 0 1.4351010657609464e-10
unaffected O 0 2.237420693163017e-09
mutation O 0 1.9499792058841336e-10
carriers O 0 3.406026849450683e-10
were O 0 2.55890059142061e-10
also O 0 2.8384572470230296e-11
identified O 0 1.7761062065524413e-10
within O 0 1.5129361097265814e-09
the O 0 4.561909960898447e-09
pedigree O 0 1.1653049369897417e-07
. O 0 5.341764008903738e-08

A O 0 7.374782740043884e-07
single O 0 1.6005358816073567e-08
band O 0 1.4383421387265116e-07
shift O 0 1.525446435834965e-07
using O 0 9.632286968042081e-09
SSCP O 0 8.58845282891707e-07
was O 0 4.156933641752403e-08
identified O 0 7.65630314703003e-09
in O 0 2.080031258344661e-09
exon O 0 4.9562082438114885e-08
21 O 0 1.3007229071604343e-08
which O 0 2.731592729787735e-11
resulted O 0 1.14788756278017e-09
in O 0 2.5067473097273307e-10
a O 0 2.101072649196567e-09
missense O 0 3.699080508567931e-08
mutation O 0 2.4781205976154297e-09
converting O 0 1.48789993659193e-07
a O 0 8.718696875575915e-08
cys O 0 6.544772622874007e-05
- O 0 2.46796730607457e-06
- O 0 1.2670795968006132e-06
> O 0 5.878530018321726e-08
arg O 0 1.0888070889336632e-08
at O 0 2.2415951761445285e-08
nucleotide O 0 5.7694680144493304e-09
position O 0 2.925649766893912e-08
28 O 0 5.232533339949441e-08
in O 0 2.6903541616718485e-09
the O 0 5.2370459968642535e-08
exon O 0 3.775504410441499e-06
. O 0 7.367837042693282e-07

The O 0 4.785733267453907e-07
mutation O 0 7.408129665265051e-09
destroyed O 0 1.1904595709211208e-07
an O 0 1.1114764664199583e-09
NdeI O 0 2.1872774880193901e-07
restriction O 0 7.101766286154998e-09
enzyme O 0 2.0732304761850173e-09
site O 0 6.439610178432531e-09
. O 0 2.7400240298902645e-08

Analysis O 0 3.1680798429079005e-07
of O 0 3.835373263427755e-07
all O 0 1.0174945330732044e-08
family O 0 1.7112644634664775e-09
members O 0 6.720297235363049e-11
demonstrated O 0 3.506713808221207e-10
that O 0 4.353297236581177e-12
the O 0 1.4762401023826754e-10
missense O 0 1.168335650447716e-08
mutation O 0 8.086802893991774e-10
co O 0 7.157319004136298e-08
- O 0 1.366191781926318e-07
segregated O 0 2.419798192931921e-07
with O 0 1.8261644418871015e-09
patients O 0 1.6891304710497934e-07
with O 0 4.1861105160023726e-07
tumors B-Disease 1 1.0
or O 1 0.9999465942382812
who O 0 2.8636775368795497e-06
, O 0 1.3956414912641435e-09
as O 0 4.782844675865761e-10
a O 0 2.1903556746138975e-10
result O 0 1.0010813289440534e-09
of O 0 3.7024118881845425e-08
linkage O 0 6.460884094394714e-08
analysis O 0 3.2491753731989093e-09
had O 0 2.2426844825673697e-09
been O 0 4.263209785193567e-10
predicted O 0 9.163863001759864e-10
to O 0 4.676505710454748e-11
carry O 0 2.2647178576917781e-10
the O 0 8.119614980373058e-10
predisposing O 0 5.409154368862801e-07
mutation O 0 6.182882117400368e-08
. O 0 1.841025891735626e-07

These O 0 3.65676555702521e-08
observations O 0 3.420797156650224e-07
point O 0 1.397771285382987e-07
to O 0 2.614277405665888e-10
another O 0 2.5148311211253827e-10
region O 0 1.5606343994889471e-09
of O 0 7.286269365636144e-09
the O 0 3.4705067264440004e-08
RB1 O 0 4.866793460678309e-06
gene O 0 3.4199093335018915e-08
where O 0 1.2420344752683832e-08
mutations O 0 2.0550534607366444e-09
only O 0 1.691130152581266e-10
modify O 0 7.691984826863063e-10
the O 0 4.521022445302947e-10
function O 0 1.0271132389050308e-08
of O 0 1.3680790722503389e-08
the O 0 2.291322909186988e-09
gene O 0 5.849031259330673e-10
and O 0 1.761581991388539e-10
raise O 0 6.211596514926754e-11
important O 0 9.547843765611574e-11
questions O 0 4.548924084635253e-11
for O 0 4.0336744361324506e-12
genetic O 0 1.5952647536288111e-10
counseling O 0 3.1682814705114026e-10
in O 0 6.45135611598846e-11
families O 0 2.2241338545198053e-12
with O 0 9.143304169345612e-12
these O 0 1.0420573258451693e-11
distinctive O 0 3.788553082362256e-10
phenotypes O 0 3.721206676132738e-09
. O 0 7.164250859226229e-10
. O 0 1.3753210126310478e-08

Maternal B-Disease 0 6.024944013915956e-05
disomy I-Disease 0 0.0014931514160707593
and O 0 5.8591202105162665e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9374808073043823
with O 0 2.2630100460219182e-08
gamete O 0 1.2438465091690887e-05
complementation O 0 9.875289833871648e-06
in O 0 2.258416786915518e-09
a O 0 1.0735876632139707e-09
case O 0 4.235945372244032e-09
of O 0 6.8659464780296275e-09
familial O 0 1.028415255177606e-07
translocation O 0 9.351958141223804e-08
( O 0 5.081319254252037e-10
3 O 0 4.963385702438927e-09
; O 0 4.1904337638731803e-11
15 O 0 8.483096447520211e-10
) O 0 1.1731437002393541e-11
( O 0 7.590844619542736e-12
p25 O 0 2.2682336009438586e-09
; O 0 3.7299788258060573e-11
q11 O 0 3.225993694400131e-09
. O 0 1.3523067388110377e-10
2 O 0 7.841187255053228e-09
) O 0 2.3042331931399929e-10
. O 0 1.0363602420682128e-08

Maternal B-Disease 0 0.004738813266158104
uniparental I-Disease 1 0.9968908429145813
disomy I-Disease 1 0.9389072060585022
( I-Disease 0 2.352946239625453e-06
UPD I-Disease 1 0.999998927116394
) I-Disease 0 2.3650416736131774e-08
for I-Disease 0 9.534350198237007e-09
chromosome I-Disease 0 9.528388318358338e-07
15 I-Disease 0 5.905625144464466e-08
is O 0 2.3269300375439173e-10
responsible O 0 3.4131478199306287e-10
for O 0 5.809446673721297e-11
an O 0 1.599718621458912e-11
estimated O 0 4.8577718236852974e-11
30 O 0 1.674583804955887e-10
% O 0 7.037744952781422e-12
of O 0 2.1353179641137032e-11
cases O 0 4.4254565290113845e-11
of O 0 7.40701651125164e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.790562237147242e-05
PWS B-Disease 1 1.0
) O 0 4.341895376569482e-08
. O 0 7.573706994890017e-08

We O 0 2.1865642452212342e-07
report O 0 3.775289414420513e-09
on O 0 2.746657568053479e-09
an O 0 2.131305895658464e-11
unusual O 0 1.592376785986005e-10
case O 0 6.647088990341388e-10
of O 0 1.6771256605707663e-09
maternal B-Disease 0 7.513635580380651e-08
disomy I-Disease 0 2.219224143118481e-06
15 I-Disease 0 9.350994645274113e-08
in O 0 4.2128387889306396e-08
PWS B-Disease 1 1.0
that O 0 3.450123964299223e-09
is O 0 7.051292882920279e-11
most O 0 1.482888117854131e-11
consistent O 0 1.1242579783798945e-10
with O 0 7.289705297730542e-12
adjacent O 0 3.846894802705947e-09
- O 0 6.724433010418807e-09
1 O 0 6.256802009829698e-08
segregation O 0 4.943189679806892e-08
of O 0 4.348141846577391e-09
a O 0 2.22298779384289e-09
paternal O 0 7.708115035143237e-09
t O 0 2.1587082343899056e-08
( O 0 1.5730057534302233e-10
3 O 0 3.409239335283587e-09
; O 0 8.74198005651472e-11
15 O 0 1.3604308790604591e-09
) O 0 2.495130664581513e-11
( O 0 2.7051499928987255e-11
p25 O 0 5.9470384172755075e-09
; O 0 9.430688868716786e-11
q11 O 0 9.522518773508182e-09
. O 0 9.262651756714035e-11
2 O 0 5.635782951429746e-10
) O 0 1.6063925363518639e-12
with O 0 3.0684935928976254e-12
simultaneous O 0 7.139615010309797e-10
maternal O 0 4.1517751014907844e-08
meiotic O 0 5.540645702239999e-07
nondisjunction O 0 5.505613671630272e-07
for O 0 1.1926158727249003e-08
chromosome O 0 8.418610946137051e-07
15 O 0 4.554921702037973e-07
. O 0 1.3545415811222483e-07

The O 0 1.4209928167474573e-06
patient O 0 9.37976949444419e-07
( O 0 3.1789670895676636e-09
J O 0 4.799326234206092e-07
. O 0 3.493302036527979e-10
B O 0 8.537217155435428e-09
. O 0 1.639480044779429e-11
) O 0 5.086627733602578e-12
, O 0 7.100360230327674e-12
a O 0 1.0869883465547403e-10
17 O 0 2.974238189068501e-09
- O 0 1.7406945884701486e-09
year O 0 2.03627403827511e-09
- O 0 4.894721428172488e-08
old O 0 2.7264965751783166e-07
white O 0 7.124868472985213e-10
male O 0 5.07977881980537e-10
with O 0 4.028496425334538e-10
PWS B-Disease 1 1.0
, O 0 7.72958053119055e-09
was O 0 1.224255186116352e-07
found O 0 8.198687284632911e-10
to O 0 1.5981091450179008e-10
have O 0 1.4895588928975911e-10
47 O 0 2.6549664688957364e-09
chromosomes O 0 3.670215020790124e-09
with O 0 8.061654122037964e-10
a O 0 1.2343050137531009e-08
supernumerary O 0 1.166942524832848e-06
, O 0 5.717836870644533e-09
paternal O 0 3.897815474829258e-07
der O 0 7.353346882155165e-05
( O 0 7.659177181373877e-10
15 O 0 1.7143060304647406e-09
) O 0 9.743695433828137e-12
consisting O 0 1.7730363011114747e-10
of O 0 5.279688686243844e-09
the O 0 1.9936095441153157e-08
short O 0 2.0751700802179585e-08
arm O 0 2.4975918222480686e-07
and O 0 2.1172406050595782e-09
the O 0 1.0737499778201709e-08
proximal O 0 1.3892322385800071e-05
long O 0 1.5578788747916406e-07
arm O 0 3.771747287828475e-07
of O 0 1.1807763655724557e-07
chromosome O 0 1.6319611972903658e-07
15 O 0 3.374912438403044e-08
, O 0 5.462742480588645e-10
and O 0 2.385322828146741e-09
distal O 0 1.1856904166052118e-05
chromosome O 0 0.00013956232578493655
arm O 0 0.002057883655652404
3p O 0 0.0027608841191977262
. O 0 6.729183496645419e-06

The O 0 1.5048235582071356e-05
t O 0 5.936189609201392e-06
( O 0 3.13355830172668e-09
3 O 0 2.5909439926863342e-08
; O 0 2.1592289067839943e-10
15 O 0 1.4740377807243021e-09
) O 0 2.713516390751014e-11
was O 0 2.602472681800805e-09
present O 0 3.016479288575624e-10
in O 0 1.9016496710655417e-10
the O 0 2.61938831735975e-10
balanced O 0 4.3346096156859915e-10
state O 0 2.854690962783568e-11
in O 0 1.4028485838257776e-11
the O 0 7.855115863319995e-11
patients O 0 1.499824986428422e-10
father O 0 2.160391865402289e-09
and O 0 7.371787624776971e-10
a O 0 4.906515194136318e-09
sister O 0 7.788363518557162e-07
. O 0 5.339584276953246e-07

Fluorescent O 0 1.8689994476517313e-06
in O 0 5.091219534847369e-08
situ O 0 1.2708868553090724e-06
hybridization O 0 1.8259772360806892e-08
analysis O 0 2.8593805101451153e-09
demonstrated O 0 9.988173621522378e-10
that O 0 4.30344371249447e-11
the O 0 2.3448056829522557e-09
PWS B-Disease 1 0.9999936819076538
critical O 0 1.4673797466002725e-07
region O 0 2.925694175814897e-08
resided O 0 1.0071898515207067e-07
on O 0 2.319656111637869e-08
the O 0 2.0032560055227577e-09
derivative O 0 3.5880145077271663e-08
chromosome O 0 4.867248648565692e-08
3 O 0 2.289969636137812e-08
and O 0 4.783227702809256e-10
that O 0 9.296582254014751e-11
there O 0 2.213285527075115e-10
was O 0 1.103433344695759e-08
no O 0 4.748585413771877e-10
deletion O 0 3.962103090060509e-09
of O 0 4.360366734346144e-09
the O 0 9.003538359309005e-09
PWS B-Disease 1 1.0
region O 0 2.073734464147492e-07
on O 0 6.944471664382945e-08
the O 0 4.422145316596016e-09
normal O 0 2.937257193025289e-08
pair O 0 6.336641433790646e-09
of O 0 1.4471246423397588e-09
15s O 0 5.050867457612185e-08
present O 0 1.3248367958240692e-09
in O 0 3.3837928015145735e-09
J O 0 3.7068552046548575e-05
. O 0 3.32600109231862e-07

B O 0 0.0011162252631038427
. O 0 7.229311904666247e-06

Methylation O 0 6.346041914184752e-07
analysis O 0 1.5316943802190508e-07
at O 0 1.2617809943549219e-06
exon O 0 1.3583930922322907e-06
alpha O 0 3.2264293281514256e-07
of O 0 9.001018241860947e-08
the O 0 1.1467983895840916e-08
small O 0 6.325399759532502e-09
nuclear O 0 3.903417677975085e-07
ribonucleoprotein O 0 5.554121074169416e-08
- O 0 1.6723215034986083e-09
associated O 0 4.044928836322015e-09
polypeptide O 0 1.295080380714353e-07
N O 0 8.765582606429234e-07
( O 0 3.695550532256675e-10
SNRPN O 0 1.4204519516169967e-07
) O 0 6.299483157334862e-11
gene O 0 4.627793981359929e-10
showed O 0 1.5932040131616532e-09
a O 0 4.3758199841370526e-10
pattern O 0 1.6822653492454265e-08
characteristic O 0 5.589499707525647e-08
of O 0 9.716484505872813e-09
only O 0 1.1778281128194124e-10
the O 0 2.858037695396831e-10
maternal O 0 6.028030075100332e-09
chromosome O 0 1.1840302072130271e-08
15 O 0 1.1062994076382893e-08
in O 0 7.211800490125597e-09
J O 0 3.451123848208226e-05
. O 0 4.0437822690364555e-07

B O 0 0.001278433483093977
. O 0 8.155893738148734e-06

Maternal B-Disease 0 2.2683425413561054e-05
disomy I-Disease 0 1.7387152183800936e-05
was O 0 2.475066196439002e-07
confirmed O 0 2.9911688681494297e-09
by O 0 3.0277180068649656e-11
polymerase O 0 5.152763549176598e-09
chain O 0 3.0470109768643283e-10
reaction O 0 2.011842602234193e-11
analysis O 0 4.087739036151561e-10
of O 0 4.957992683074508e-09
microsatellite O 0 9.337520623375895e-08
repeats O 0 1.886395928352158e-08
at O 0 2.2531903454137137e-08
the O 0 1.8444160643227292e-09
gamma O 0 4.859975888393819e-07
- O 0 3.3288181100488146e-08
aminobutyric O 0 1.3387045783019857e-07
acid O 0 5.2618545076654755e-09
receptor O 0 8.601057643886634e-09
beta3 O 0 2.950273483293131e-07
subunit O 0 1.871893147153969e-07
( O 0 3.1388103227669717e-09
GABRB3 O 0 1.0955961897707311e-06
) O 0 3.874250253943501e-09
locus O 0 1.3947446575457434e-07
. O 0 3.062513087570551e-07

A O 0 9.134222636930645e-05
niece O 0 5.12376609549392e-05
( O 0 9.670096723368715e-09
B O 0 1.0385274151758495e-07
. O 0 1.917178776844608e-10
B O 0 1.8919656952220976e-09
. O 0 3.672674577653856e-12
) O 0 1.1949974430131016e-12
with O 0 8.898478308372315e-12
45 O 0 5.18966924989428e-10
chromosomes O 0 7.823883207969118e-10
and O 0 1.6879268815994664e-10
the O 0 6.057347956556214e-10
derivative O 0 1.4014895022285145e-08
3 O 0 3.814978555283233e-09
but O 0 2.2001523866665984e-11
without O 0 1.5390955176997068e-10
the O 0 6.459929258184616e-10
der O 0 9.56770691118436e-07
( O 0 1.3471400384101884e-10
15 O 0 1.1248999509660962e-09
) O 0 5.2020450447276545e-11
demonstrated O 0 2.2927526543981003e-09
a O 0 1.6149600545745102e-09
phenotype O 0 2.2311434921817863e-09
consistent O 0 9.335201944793425e-09
with O 0 3.384654015392563e-11
that O 0 7.100658169084673e-12
reported O 0 3.365856204862183e-11
for O 0 2.2841601873824224e-11
haploinsufficiency O 0 4.6999947045378576e-08
of O 0 3.313728669240845e-08
distal O 0 1.3957206647319254e-05
3 O 0 2.901736843341496e-05
p O 0 0.00012031485675834119
. O 0 8.90875071490882e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999992847442627
associated O 0 1.2609763189175283e-06
with O 0 1.73948322412798e-09
unbalanced O 0 0.00011987442121608183
segregation O 0 4.8078520194394514e-05
of O 0 1.1458521953500167e-07
non O 0 8.21172932319314e-07
- O 0 3.997462982852085e-08
Robertsonian O 0 1.3858270904165693e-06
translocations O 0 4.607857988503383e-07
has O 0 4.488329985452566e-10
been O 0 3.9741349100452794e-10
reported O 0 3.9042916122333793e-10
previously O 0 2.6304542988242474e-09
but O 0 2.639574947504997e-10
has O 0 5.7176562096028505e-11
not O 0 1.7513664130053286e-11
, O 0 6.0898009725252056e-12
to O 0 1.924174881928753e-11
our O 0 2.5047255935994883e-10
knowledge O 0 2.8699367327078562e-09
, O 0 1.6278202744079984e-11
been O 0 8.003472884432483e-12
observed O 0 8.474488472076658e-11
in O 0 4.696636135559373e-11
a O 0 2.0705541448062803e-10
case O 0 2.695017542464484e-09
of O 0 3.762876232826784e-08
PWS B-Disease 1 0.9999998807907104
. O 0 2.661148755578324e-06

Furthermore O 0 2.1450798158184625e-05
, O 0 6.071071112501158e-08
our O 0 1.219871403890238e-08
findings O 0 1.1303240565752048e-09
are O 0 5.852663405997438e-12
best O 0 6.841542957158886e-12
interpreted O 0 4.022114238888541e-11
as O 0 4.144284568297074e-11
true O 0 5.927737745103911e-10
gamete O 0 2.132358467576978e-08
complementation O 0 2.0047978921411413e-07
resulting O 0 3.809278226185597e-09
in O 0 6.952447506591852e-09
maternal B-Disease 0 3.1813353416509926e-05
UPD I-Disease 1 1.0
15 I-Disease 0 2.5390356313437223e-05
and O 0 6.243335519684479e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.998908519744873
- I-Disease 1 0.9999061822891235
Jampel I-Disease 1 0.9999948740005493
syndrome I-Disease 1 0.999996542930603
type I-Disease 0 0.19419823586940765
2 I-Disease 0 0.0001770171948010102
and O 0 1.2850075670201022e-08
Stuve B-Disease 1 0.9991713762283325
- I-Disease 1 0.9997320771217346
Wiedemann I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999948740005493
: O 0 3.062357589733722e-10
a O 0 2.1404365779797985e-10
case O 0 7.456348039003302e-11
for O 0 1.6763052751445073e-11
" O 0 3.7136888009214886e-10
lumping O 0 6.610199498879865e-09
" O 0 7.181506500586465e-09
. O 0 1.0253692117601076e-08

Recent O 0 3.085931865598468e-08
studies O 0 5.714947182156038e-09
demonstrated O 0 1.1052443404935275e-09
the O 0 4.4439915636296234e-10
existence O 0 2.575137658666904e-09
of O 0 9.136292611344743e-09
a O 0 3.137553106213886e-09
genetically O 0 1.571035801450904e-10
distinct O 0 1.7121419559895656e-10
, O 0 6.846062605703196e-11
usually O 0 3.8291904369547325e-11
lethal O 0 3.0888142044105393e-10
form O 0 4.1814197937473097e-11
of O 0 5.997154994830112e-10
the O 0 2.434559664976632e-09
Schwartz B-Disease 0 2.513807703508064e-05
- I-Disease 0 7.627313607372344e-05
Jampel I-Disease 0 0.09159554541110992
syndrome I-Disease 0 0.04111737757921219
( O 0 2.242034558008754e-09
SJS B-Disease 0 3.9908645703690127e-05
) O 0 2.235936102934488e-09
of O 0 1.106854483623465e-06
myotonia B-Disease 1 0.9999990463256836
and O 0 0.00028830915107391775
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.1624007356658694e-06
which O 0 1.6253718371217474e-08
we O 0 3.0622263835766717e-08
called O 0 9.394274513851997e-08
SJS B-Disease 0 0.4268527626991272
type I-Disease 0 0.002591207390651107
2 I-Disease 0 6.0195106925675645e-05
. O 0 2.071034685968698e-07

This O 0 9.952847790373198e-08
disorder O 0 0.3054129481315613
is O 0 6.476378100472857e-09
reminiscent O 0 4.324714609538205e-06
of O 0 1.4282380789154558e-07
another O 0 1.5839051181743002e-09
rare O 0 2.5906263800834495e-09
condition O 0 2.0032919678669714e-07
, O 0 1.937555532682822e-10
the O 0 2.9216664643172408e-09
Stuve B-Disease 1 0.9934325218200684
- I-Disease 1 0.9999841451644897
Wiedemann I-Disease 1 0.9999988079071045
syndrome I-Disease 1 0.9999994039535522
( O 0 1.7982717537279314e-08
SWS B-Disease 0 3.183630724379327e-06
) O 0 6.701830201905068e-10
, O 0 1.665883542223412e-10
which O 0 2.488927640376115e-11
comprises O 0 1.3652683428233559e-09
campomelia B-Disease 0 1.570021140651079e-06
at O 0 5.45825855624571e-07
birth O 0 1.0639303127391031e-07
with O 0 9.149999868895975e-09
skeletal B-Disease 1 0.9999985694885254
dysplasia I-Disease 1 0.9999998807907104
, O 0 1.4056770680781483e-07
contractures B-Disease 0 0.02613794431090355
, O 0 4.088497540521985e-09
and O 0 6.419690334880102e-10
early B-Disease 0 1.0725713650572288e-07
death I-Disease 0 1.230866075729864e-07
. O 0 5.578359463243032e-08

To O 0 4.903795058908145e-08
test O 0 4.190893410083163e-09
for O 0 7.576281962906606e-11
possible O 0 2.6341079317759863e-10
nosologic O 0 5.122203461382924e-08
identity O 0 8.152393426996696e-09
between O 0 2.591507275440108e-08
these O 0 9.571606840452773e-10
disorders O 0 1.1398154128983151e-05
, O 0 5.165954469754652e-11
we O 0 2.953184224940841e-11
reviewed O 0 1.8980370053434115e-10
the O 0 4.12974168750857e-11
literature O 0 2.4412995930367387e-11
and O 0 3.1048121972715448e-12
obtained O 0 5.87393675366421e-11
a O 0 3.141736176770493e-11
follow O 0 2.1500223476578206e-11
- O 0 4.9107138494486335e-11
up O 0 4.6506121870182326e-11
of O 0 2.7105384603487437e-10
the O 0 7.910369581587418e-11
only O 0 1.652225231629778e-11
two O 0 2.01958953033321e-11
surviving O 0 1.5234649097806141e-09
patients O 0 3.1051530791081916e-10
, O 0 9.786763066621518e-11
one O 0 6.067184948888027e-11
with O 0 1.6743609831948447e-09
SJS B-Disease 0 0.008716005831956863
type I-Disease 0 0.0010016737505793571
2 I-Disease 0 7.354221907007741e-06
at O 0 6.914838195370976e-07
age O 0 5.705627259544599e-08
10 O 0 3.3133227272941213e-09
years O 0 5.705936834132785e-10
and O 0 1.2021587891819507e-10
another O 0 2.2548475586692263e-10
with O 0 3.1751720697137387e-10
SWS B-Disease 0 7.290594794540084e-07
at O 0 2.4467206571898714e-07
age O 0 6.842182642685657e-08
7 O 0 1.1715292913550002e-07
years O 0 7.206372032442232e-08
. O 0 1.1521989051743731e-07

Patients O 0 4.5701335693593137e-07
reported O 0 2.8042368427350084e-08
as O 0 1.9556565256095837e-09
having O 0 1.2086112555209638e-08
either O 0 3.2307002584275324e-07
neonatal O 1 0.999994158744812
SJS B-Disease 1 0.9999759197235107
or O 0 2.029797315117321e-06
SWS B-Disease 0 2.141768163710367e-05
presented O 0 1.3271015575355705e-07
a O 0 2.920451880328301e-09
combination O 0 1.0731706190370005e-08
of O 0 9.81926984167103e-09
a O 0 1.271415084325156e-09
severe O 0 8.706565068905547e-08
, O 0 5.730170782314303e-10
prenatal O 0 0.00012172688730061054
- O 0 7.696387910982594e-06
onset O 1 0.9999548196792603
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 2.5014481153107226e-08
with O 0 1.6647614131670707e-07
congenital B-Disease 1 1.0
joint I-Disease 1 0.9999996423721313
contractures I-Disease 1 1.0
, O 0 1.0489151463843882e-05
respiratory O 1 1.0
and O 0 2.2943715975998202e-06
feeding O 0 4.137704672757536e-05
difficulties O 1 0.8288027048110962
, O 0 1.0230113645093297e-08
tendency O 0 1.6733624264020364e-08
to O 0 2.3395609893839264e-09
hyperthermia B-Disease 1 0.9999231100082397
, O 0 7.475747243468334e-10
and O 0 1.6399406832512398e-10
frequent O 0 2.044750813112728e-09
death O 0 1.8024334025312783e-08
in O 0 9.657489918879492e-09
infancy O 0 5.038402264290198e-07
) O 0 1.592181594900488e-11
with O 0 2.0192930660911657e-11
a O 0 5.438913763811115e-10
distinct O 0 3.848583229881797e-09
campomelic B-Disease 0 4.3653493776218966e-05
- I-Disease 0 4.944249303662218e-05
metaphyseal I-Disease 0 0.0004717842675745487
skeletal I-Disease 1 0.9999568462371826
dysplasia I-Disease 1 0.9999994039535522
. O 0 6.110217509558424e-05

The O 0 1.032147025625818e-07
similarity O 0 1.8448028527018323e-07
of O 0 1.9445978693966026e-07
the O 0 9.907539677556088e-09
clinical O 0 8.061938672199176e-08
and O 0 1.9272244911050507e-10
radiographic O 0 1.6373175526496198e-07
findings O 0 1.6958985327164555e-09
is O 0 2.3249735470187716e-10
so O 0 3.8098118410045956e-11
extensive O 0 1.7126031703895706e-09
that O 0 6.741197877691008e-11
these O 0 5.428901772575045e-10
disorders O 0 4.687615000875667e-05
appear O 0 8.61504645399691e-09
to O 0 1.4931972325271659e-10
be O 0 2.0755520913073866e-10
a O 0 2.818588973330094e-10
single O 0 2.9287730574090176e-10
entity O 0 1.6916229128582927e-07
. O 0 1.0869997595364111e-06

The O 0 7.35452033495676e-07
follow O 0 9.610434403839463e-08
- O 0 3.550971428012417e-08
up O 0 2.454431102805188e-09
observation O 0 5.066107178208767e-07
of O 0 8.170513154936998e-09
an O 0 3.4412351440638034e-11
identical O 0 2.9397709266909544e-10
and O 0 3.302738291188767e-11
unique O 0 1.7478767044831756e-10
pattern O 0 1.2511797820025095e-07
of O 0 4.444895012056804e-07
progressive O 1 0.999984860420227
bone B-Disease 1 0.9999998807907104
dysplasia I-Disease 1 0.9999992847442627
in O 0 7.306088605218974e-07
the O 0 1.487956865275919e-06
two O 0 5.702787575501134e-08
patients O 0 2.4012138055695686e-08
( O 0 1.0604501998745519e-10
one O 0 6.046425166106317e-11
with O 0 3.364458156518424e-10
SJS B-Disease 0 0.0014501666883006692
type I-Disease 0 0.0012918063439428806
2 I-Disease 0 4.058117610838963e-06
, O 0 3.0199678868747526e-10
one O 0 1.8014074953942583e-10
with O 0 6.095966509356288e-10
SWS B-Disease 0 1.8203771787739242e-06
) O 0 1.5692158683577873e-09
surviving O 0 4.040023782181379e-07
beyond O 0 6.010930519551039e-06
infancy O 0 1.9134965896228096e-06
adds O 0 7.656255629484576e-10
to O 0 3.512093740831723e-11
the O 0 5.6981249579868276e-11
evidence O 0 1.6957941995077164e-10
in O 0 2.0267051925593194e-11
favor O 0 4.105147055621927e-10
of O 0 4.222004967857629e-10
identity O 0 3.735635356605371e-09
. O 0 3.9665511764042094e-08

The O 0 3.0933574635128025e-07
hypothesis O 0 2.3675609384099516e-07
that O 0 5.0660120543000176e-09
SWS B-Disease 0 8.078736755123828e-06
and O 0 5.380713830049899e-08
SJS B-Disease 0 0.11795306205749512
type I-Disease 0 0.0008491428452543914
2 I-Disease 0 2.628395350257051e-06
are O 0 4.0121305583395994e-11
the O 0 3.984518270883086e-10
same O 0 9.354809371586725e-09
disorder O 0 1.2716469655060791e-06
should O 0 2.7162000426628197e-10
be O 0 3.48021889085004e-11
testable O 0 1.865423510105657e-10
by O 0 2.895416545412033e-12
molecular O 0 1.957391804197073e-09
methods O 0 8.341234369879658e-09
. O 0 9.749059337593735e-10
. O 0 1.8203994756049724e-08

A O 0 7.153400929382769e-07
mouse O 0 2.0374834264202946e-08
model O 0 1.1102480712565921e-08
of O 0 4.651568374924864e-08
severe O 1 0.999006450176239
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 1.2659949106819113e-06
defects O 0 0.24791674315929413
in O 0 7.688824155138718e-08
hemostasis O 1 0.9969416260719299
and O 0 2.9863529107387876e-06
thrombosis B-Disease 1 0.9992532134056091
. O 0 7.791233656462282e-06

von B-Disease 1 0.9969872832298279
Willebrand I-Disease 1 0.999261200428009
factor I-Disease 0 0.00011371860455255955
( I-Disease 0 2.3314912311889202e-07
vWf I-Disease 0 0.0001305115583818406
) I-Disease 0 2.0450247575354297e-06
deficiency I-Disease 1 1.0
causes O 1 0.999841570854187
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0006345041911117733
humans O 0 4.574416379909962e-06
. O 0 6.219217141278932e-08

We O 0 4.864501761403517e-07
generated O 0 1.8381761890395865e-08
a O 0 4.1802676875590805e-09
mouse O 0 1.6130360380728348e-09
model O 0 4.4718467817617125e-10
for O 0 3.0054285449221396e-11
this O 0 1.585357366218343e-11
disease O 0 5.985929807383883e-11
by O 0 1.3423422529773577e-12
using O 0 1.0017053159172562e-10
gene O 0 5.957275783785576e-10
targeting O 0 1.007946615061428e-08
. O 0 2.0156367241952466e-08

vWf B-Disease 0 0.006338650826364756
- I-Disease 1 0.9073982238769531
deficient I-Disease 0 0.4895203113555908
mice O 0 3.598093371692812e-06
appeared O 0 2.042764464249558e-07
normal O 0 2.398362823896605e-07
at O 0 4.79753197168975e-08
birth O 0 3.110808277639876e-10
; O 0 3.6066015625391135e-12
they O 0 5.0425210881832605e-12
were O 0 5.065214914168337e-11
viable O 0 5.038039319060772e-09
and O 0 4.042936818660081e-10
fertile O 0 3.710081841745705e-08
. O 0 4.9771248455954265e-08

Neither O 0 7.95055748312734e-05
vWf O 0 0.00036841168184764683
nor O 0 4.596382859745063e-05
vWf O 0 0.00011827754497062415
propolypeptide O 0 0.00026042715762741864
( O 0 3.177165694978612e-07
von B-Disease 0 0.0006816496606916189
Willebrand I-Disease 0 9.562833292875439e-05
antigen O 0 1.1031896463009616e-07
II O 1 0.5774648189544678
) O 0 3.123807434946002e-09
were O 0 2.2800317189819452e-09
detectable O 0 3.455499708593379e-08
in O 0 1.9145478258320026e-10
plasma O 0 1.2864077802987595e-08
, O 0 4.234616476916919e-11
platelets O 0 3.0628893865625173e-10
, O 0 8.129187600847132e-11
or O 0 3.074435844796497e-11
endothelial O 0 1.8047675853782863e-10
cells O 0 9.268784351146309e-11
of O 0 1.9369321702100706e-09
the O 0 1.268847138469198e-09
homozygous O 0 8.123569372742168e-09
mutant O 0 9.677629009274824e-08
mice O 0 8.768160597583119e-08
. O 0 2.327673520596818e-08

The O 0 6.427789571716858e-07
mutant O 0 1.2480423947636154e-06
mice O 0 2.6384810780655243e-07
exhibited O 0 6.075525220694544e-07
defects O 0 3.29659778799396e-05
in O 0 1.624395373767129e-08
hemostasis O 0 3.236749398638494e-05
with O 0 5.134819236474186e-09
a O 0 5.5840011725649674e-08
highly O 0 5.137691005074885e-06
prolonged O 0 0.006850713863968849
bleeding O 0 0.19349339604377747
time O 0 1.283202948343387e-07
and O 0 6.212903524982494e-10
spontaneous O 0 4.6364281303112875e-09
bleeding O 0 2.796415685679676e-07
events O 0 1.2564638218748314e-09
in O 0 4.1965306230018484e-10
approximately O 0 3.3141045463480623e-10
10 O 0 3.3940619759142976e-10
% O 0 7.102910620782055e-11
of O 0 3.421173122575283e-09
neonates O 0 4.282758254703367e-07
. O 0 2.2074029004670592e-07

As O 0 1.5051402613153186e-07
in O 0 1.3535313314605446e-08
the O 0 5.988036733128865e-09
human O 0 2.4352761585078042e-08
disease O 0 1.336135202478772e-08
, O 0 1.2306006907936151e-11
the O 0 1.6839522831713083e-10
factor O 0 7.839986992941306e-10
VIII O 0 1.4040895166544942e-06
level O 0 1.1761902669604751e-06
in O 0 3.6258300806224497e-09
these O 0 3.8555464376699433e-10
mice O 0 2.4365571782425377e-09
was O 0 4.260626962349079e-09
reduced O 0 1.8556194358865241e-09
strongly O 0 2.0501897401992153e-10
as O 0 5.986923456990922e-11
a O 0 4.3660717402582705e-11
result O 0 1.2872901355986954e-10
of O 0 3.073018506327685e-10
the O 0 7.45721540074129e-11
lack O 0 1.7866672585853394e-09
of O 0 2.7698729421210544e-10
protection O 0 7.897333342832269e-10
provided O 0 2.0695631319789243e-10
by O 0 1.8553884817418265e-10
vWf O 0 1.1039512628485681e-06
. O 0 4.0896546238400333e-07

Defective O 1 0.99726402759552
thrombosis B-Disease 1 0.9495909810066223
in O 0 2.346521569052129e-06
mutant O 0 1.484890731262567e-06
mice O 0 8.389952199649997e-08
was O 0 2.512402907939304e-08
also O 0 3.5185302588169876e-11
evident O 0 5.092544719254022e-10
in O 0 2.246522586013544e-11
an O 0 4.096007821113856e-12
in O 0 2.867411343088211e-11
vivo O 0 7.277157987317651e-09
model O 0 2.023093159664313e-08
of O 0 3.8583718264817435e-07
vascular B-Disease 1 0.999985933303833
injury I-Disease 1 0.9999887943267822
. O 0 2.9021823138464242e-05

In O 0 9.06505874809227e-08
this O 0 6.374714645041024e-10
model O 0 5.57801582701245e-09
, O 0 2.589498615535035e-10
the O 0 1.1564980084699528e-09
exteriorized O 0 5.426090865512379e-07
mesentery O 0 3.527029775796109e-06
was O 0 6.809548835917667e-07
superfused O 0 1.0994228887284407e-06
with O 0 7.1405854562556215e-09
ferric O 0 7.998130604391918e-05
chloride O 0 8.855284363562532e-07
and O 0 1.3155433187250765e-08
the O 0 1.4161205541540767e-08
accumulation O 0 6.2378367147175595e-06
of O 0 1.8218766854261048e-05
fluorescently O 0 2.4778846636763774e-05
labeled O 0 1.0918000725723687e-07
platelets O 0 8.257971728653501e-08
was O 0 3.9150414465893846e-08
observed O 0 1.7392709494856717e-09
by O 0 1.0701443203808836e-10
intravital O 0 6.264600216354665e-08
microscopy O 0 2.990474570196966e-07
. O 0 8.720758870595091e-08

We O 0 8.77908519214543e-07
conclude O 0 9.73171268014994e-07
that O 0 3.292229822093873e-10
these O 0 8.887525437817345e-11
mice O 0 2.9605977669433514e-09
very O 0 2.375310503843764e-10
closely O 0 4.979828549522836e-09
mimic O 0 1.0103893828272703e-06
severe O 0 3.6156721762381494e-05
human O 0 2.991695873788558e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.0533598217298277e-06
will O 0 4.11398337618607e-09
be O 0 1.7226797766056734e-10
very O 0 3.0648802940014264e-11
useful O 0 3.325018732569518e-11
for O 0 5.759684829770295e-12
investigating O 0 1.1046324965846566e-10
the O 0 3.077204810408851e-11
role O 0 1.1516222420127065e-09
of O 0 2.8337212576445836e-09
vWf O 0 1.0252248472397696e-07
in O 0 3.3069837979127215e-09
normal O 0 2.8075504587832256e-07
physiology O 0 1.894769638965954e-07
and O 0 1.0162697072768623e-10
in O 0 2.4145485610915784e-10
disease O 0 2.536142407194575e-09
models O 0 6.295810539569402e-10
. O 0 3.7930864005275566e-10
. O 0 1.166881347103299e-08

Oral O 0 0.0013156597269698977
contraceptives O 0 0.0005742255016230047
and O 0 2.3113594371793056e-10
the O 0 1.6347105891156843e-09
risk O 0 3.8809830016361957e-07
of O 0 4.9208945711143315e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.8960249423980713

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999749660491943
Clinical O 0 7.901008211774752e-05
Study O 0 3.645643786853725e-08
Group O 0 8.212746038793739e-09
. O 0 4.035029022020353e-08

BACKGROUND O 0 3.986624051321996e-06
Women O 0 1.706033869730561e-09
with O 0 9.23948417774767e-11
mutations O 0 7.321203643329e-10
in O 0 9.682513679720728e-10
either O 0 5.6880646859269746e-09
the O 0 4.9203407570530544e-08
BRCA1 O 0 1.5860795343769496e-08
or O 0 3.4119715941471895e-09
the O 0 1.1298891600119987e-08
BRCA2 O 0 2.570662127610035e-09
gene O 0 9.369965914274303e-10
have O 0 3.2464708005219833e-11
a O 0 4.9458697554127795e-11
high O 0 1.1355578699578928e-09
lifetime O 0 1.0273283335138217e-09
risk O 0 2.9522480460286715e-08
of O 0 1.3723615666094702e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.3911357099423185e-05

Oral O 1 0.9965882301330566
contraceptives O 1 0.9999386072158813
protect O 0 0.002714306116104126
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 1 0.7856753468513489
general O 0 5.2207091357558966e-05
, O 0 3.7022052090662783e-09
but O 0 1.4294325445529665e-10
it O 0 1.5093978150693133e-11
is O 0 6.097390821413473e-12
not O 0 9.186025204388493e-12
known O 0 1.0716558196399717e-10
whether O 0 1.5127707420070635e-10
they O 0 1.5084164819989532e-11
also O 0 8.59233777877888e-12
protect O 0 7.249567612888086e-11
against O 0 2.5497524092088497e-09
hereditary B-Disease 1 0.5650174021720886
forms I-Disease 0 0.00010799414303619415
of I-Disease 1 0.9999840259552002
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.20369750726968e-05

METHODS O 0 6.414949439204065e-06
We O 0 1.758519019290361e-08
enrolled O 0 2.1587823084701085e-08
207 O 0 4.718138058024124e-08
women O 0 5.960105742275346e-10
with O 0 1.0051455667792197e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.522665322947432e-07
161 O 0 8.103176440954485e-08
of O 0 9.770847952950135e-08
their O 0 6.561449161779365e-09
sisters O 0 5.453513907127672e-08
as O 0 1.8697345893770034e-09
controls O 0 9.55801169766346e-07
in O 0 4.9050368211567275e-09
a O 0 4.010650034302898e-09
case O 0 1.1746121408862109e-08
- O 0 3.217120791987327e-09
control O 0 7.822026049097985e-08
study O 0 4.878092152438285e-09
. O 0 9.854261406871956e-09

All O 0 2.3114237635013524e-08
the O 0 4.9158264125992446e-09
patients O 0 1.6241552547313631e-10
carried O 0 6.237050459434457e-11
a O 0 8.630855578839469e-12
pathogenic O 0 4.7339597519791e-11
mutation O 0 9.711393147981973e-12
in O 0 1.29555643990642e-10
either O 0 7.696887016628295e-10
BRCA1 O 0 4.579098489276845e-10
( O 0 9.535559147844097e-11
179 O 0 1.9123369554563396e-09
women O 0 1.7660935214269813e-10
) O 0 8.177582916379933e-11
or O 0 4.4675330101995314e-10
BRCA2 O 0 2.203472293516029e-09
( O 0 4.662044639225371e-10
28 O 0 4.7115552348486744e-08
women O 0 1.5497628735872127e-09
) O 0 1.3085755812269895e-09
. O 0 3.181995822387762e-08

The O 0 2.822256135459611e-07
control O 0 4.330926458351314e-06
women O 0 2.3262831660986194e-09
were O 0 9.071606243971075e-10
enrolled O 0 7.376120270130571e-10
regardless O 0 1.7626249348978718e-09
of O 0 9.555882751755007e-10
whether O 0 2.0799548194894157e-10
or O 0 2.5342540566075655e-11
not O 0 6.930948003025517e-12
they O 0 5.835408545262766e-12
had O 0 1.1781380038211609e-10
either O 0 4.1673292594524014e-10
mutation O 0 1.2065629606539119e-09
. O 0 1.1315671066824962e-08

Lifetime O 0 9.564951142237987e-07
histories O 0 9.062220556188549e-07
of O 0 2.8142790142737795e-07
oral O 0 5.219503236730816e-06
- O 0 3.670412951350954e-08
contraceptive O 0 2.4929223130243372e-08
use O 0 1.5648990436822885e-10
were O 0 8.563236925107631e-11
obtained O 0 7.569580379174212e-11
by O 0 5.661732367656658e-12
interview O 0 1.0479801471063865e-09
or O 0 1.700690803463356e-11
by O 0 8.913404953361792e-13
written O 0 2.07947287861332e-12
questionnaire O 0 7.591365903947267e-12
and O 0 3.754580847614708e-12
were O 0 1.999558678356106e-11
compared O 0 2.2367369068021503e-10
between O 0 5.646771938927486e-09
patients O 0 1.0763330227092638e-09
and O 0 5.745993611472322e-11
control O 0 5.580046945397044e-06
women O 0 3.1744029627134296e-10
, O 0 2.2028061666401477e-11
after O 0 1.6503771960163505e-10
adjustment O 0 3.6406808678890457e-09
for O 0 3.556103675417255e-11
year O 0 2.929045547772624e-11
of O 0 2.952881550388753e-10
birth O 0 5.162165139793728e-10
and O 0 7.31998905934006e-10
parity O 0 5.415224109128758e-07
. O 0 5.7000903552761883e-08

RESULTS O 0 1.0500455118744867e-06
The O 0 9.264679334819448e-08
adjusted O 0 2.2297157897810393e-07
odds O 0 7.423889769597736e-07
ratio O 0 1.435587648757064e-07
for O 0 2.3609814547853603e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 3.085369371547131e-06
with O 0 2.150008171497575e-09
any O 0 8.536988893581565e-09
past O 0 1.232257851313534e-09
use O 0 2.3308835417346074e-10
of O 0 1.0752455592566434e-09
oral O 0 6.421618792273875e-08
contraceptives O 0 1.1357624174479497e-07
was O 0 5.2856766075137784e-08
0 O 0 2.723044900676541e-08
. O 0 1.4797343794725748e-08

5 O 0 5.237525897427986e-07
( O 0 2.6505442285440495e-09
95 O 0 7.160418391549683e-08
percent O 0 9.713630788610317e-09
confidence O 0 4.1379877302460955e-08
interval O 0 3.23479376618252e-08
, O 0 2.2371977881352478e-10
0 O 0 3.397559733553379e-10
. O 0 2.208982649576363e-11
3 O 0 6.22858931098591e-10
to O 0 7.42171324397134e-11
0 O 0 7.172098470675792e-10
. O 0 8.586805572141643e-11
8 O 0 7.089166587093132e-09
) O 0 5.936416358487406e-10
. O 0 2.1586545884133557e-08

The O 0 3.0777030701756303e-07
risk O 0 4.81681432518144e-08
decreased O 0 4.247336704565896e-09
with O 0 1.6953599982216794e-11
increasing O 0 1.1209541628254271e-10
duration O 0 1.7507870708755036e-09
of O 0 7.778199612173964e-11
use O 0 6.034719252090426e-11
( O 0 9.175676711492553e-12
P O 0 7.497113152510337e-09
for O 0 8.290818725997795e-11
trend O 0 2.1249961790203997e-09
, O 0 5.446831874422742e-11
< O 0 1.470541577397455e-09
0 O 0 5.27012822271189e-10
. O 0 1.3862060804781251e-11
001 O 0 4.23672119609364e-09
) O 0 1.1472998766304254e-11
; O 0 4.178722905895382e-12
use O 0 3.6998577812585864e-11
for O 0 1.4567028139289562e-10
six O 0 1.1360798968240715e-09
or O 0 1.6712270456409328e-10
more O 0 5.275976270452398e-12
years O 0 5.365301952720003e-11
was O 0 5.425526694580185e-10
associated O 0 1.6007296876896504e-10
with O 0 1.1050618753394303e-11
a O 0 4.043970158740251e-10
60 O 0 5.762580412849161e-10
percent O 0 2.8348823288837366e-10
reduction O 0 8.85264839212141e-09
in O 0 4.37379421569517e-09
risk O 0 1.7951913378055906e-07
. O 0 9.278650026089963e-08

Oral O 0 0.00034334190422669053
- O 0 1.2422759709806996e-06
contraceptive O 0 2.4507468765477824e-07
use O 0 2.931558107377441e-09
protected O 0 7.688470873290498e-07
against O 1 0.9997208714485168
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 6.8141552844736e-08
for O 0 9.54187728829936e-10
carriers O 0 3.416144034318336e-10
of O 0 3.7344172199027525e-09
the O 0 1.7185586287382648e-09
BRCA1 O 0 2.75615474887303e-10
mutation O 0 1.1131449928480919e-11
( O 0 3.722990232074563e-12
odds O 0 8.695587583318343e-10
ratio O 0 2.031730200746651e-10
, O 0 4.1728471372737275e-11
0 O 0 1.2025165585516362e-10
. O 0 6.322434763228468e-12
5 O 0 8.56144044547591e-11
; O 0 3.603651665268215e-12
95 O 0 9.510843224092014e-10
percent O 0 1.6181080919608348e-09
confidence O 0 1.517494396807706e-08
interval O 0 2.43064484095612e-08
, O 0 5.923827539611182e-10
0 O 0 5.769014155276864e-10
. O 0 7.098360094159872e-11
3 O 0 1.5558878629917672e-09
to O 0 3.017595617826885e-10
0 O 0 1.3675774956922737e-09
. O 0 5.2266399541700537e-11
9 O 0 1.732635590556697e-09
) O 0 9.848721664595939e-12
and O 0 1.0613460631192506e-11
for O 0 1.982099206987442e-11
carriers O 0 4.1061241212725363e-11
of O 0 7.134523527518866e-10
the O 0 1.449472541992236e-09
BRCA2 O 0 1.3991917624522898e-09
mutation O 0 6.354257398033525e-11
( O 0 4.370245831886166e-11
odds O 0 6.9348859987883316e-09
ratio O 0 2.469071391786315e-09
, O 0 2.9793240097220064e-10
0 O 0 5.763866606223189e-10
. O 0 3.5782841967257895e-11
4 O 0 9.728886585236296e-10
; O 0 6.153696302524381e-11
95 O 0 6.641288408104629e-09
percent O 0 4.7032382433087605e-09
confidence O 0 4.506597761633202e-08
interval O 0 5.052601892430175e-08
, O 0 7.805088242385239e-10
0 O 0 6.939394059379822e-10
. O 0 5.1224004204986073e-11
2 O 0 2.8671245377864807e-09
to O 0 1.9103747750381928e-10
1 O 0 1.137713301346821e-08
. O 0 4.485120885799887e-10
1 O 0 2.674918420098038e-08
) O 0 1.0711536102547825e-09
. O 0 2.5722426855168123e-08

CONCLUSIONS O 0 3.648166966740973e-05
Oral O 0 0.0001891039137262851
- O 0 7.347327368734113e-07
contraceptive O 0 1.3210504334892903e-07
use O 0 1.087781087427686e-09
may O 0 2.735979220958029e-10
reduce O 0 5.605059194557782e-10
the O 0 4.3230502511093505e-10
risk O 0 1.0773547387543658e-07
of O 0 8.10136625659652e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.235100838443032e-07
women O 0 6.07029843058271e-11
with O 0 3.951991078138262e-12
pathogenic O 0 1.7302437260724446e-10
mutations O 0 3.84339296499725e-11
in O 0 3.314475777171921e-11
the O 0 1.3669358978063428e-09
BRCA1 O 0 3.286849903361144e-08
or O 0 6.997709789402506e-08
BRCA2 O 0 9.094010806620645e-07
gene O 0 2.8575379474204965e-05

A O 0 3.2223535981756868e-06
Japanese O 0 4.530364094534889e-06
family O 0 3.728839104155668e-08
with O 0 8.310490073881738e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.28828379075685e-08
a O 0 3.066703513354696e-08
codon O 0 1.2155861206508689e-08
291 O 0 8.201146428632455e-09
deletion O 0 8.506889770387716e-08
: O 0 3.4003666549153877e-10
a O 0 2.142311328334756e-10
clinical O 0 7.2638597359286905e-09
, O 0 1.5513236528708063e-10
biochemical O 0 8.651309713059163e-08
, O 0 6.135639218918243e-10
pathological O 0 3.8596452213823795e-05
, O 0 1.1849716763379092e-09
and O 0 4.5993533981381063e-10
genetic O 0 6.201801294736242e-09
report O 0 2.036208091027447e-09
. O 0 1.3665143683283532e-08

We O 0 2.228665074710534e-08
report O 0 9.5558283508268e-10
a O 0 3.911805324108286e-10
Japanese O 0 1.2528078130458198e-08
family O 0 1.663909232618721e-09
with O 0 1.4561570615967412e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 1.9706517377926502e-06
ALD B-Disease 1 1.0
) O 0 1.961555362584022e-09
with O 0 8.631242387480142e-10
a O 0 9.724345773065579e-09
three O 0 1.8432625426001437e-09
base O 0 1.0047296328252742e-08
pair O 0 8.180746391417415e-08
deletion O 0 3.418180938297155e-08
( O 0 2.3027875439840528e-10
delGAG O 0 1.5753462534462415e-08
291 O 0 1.0901280989017437e-09
) O 0 7.319343048317606e-11
in O 0 7.51639472884591e-10
the O 0 5.8649451517567286e-08
ALD B-Disease 1 1.0
gene O 0 7.757343155390117e-06
. O 0 1.2735779364447808e-06

A O 0 5.963374860584736e-07
variety O 0 1.931679349809201e-08
of O 0 5.7676632359005e-09
phenotypes O 0 4.369508754820117e-09
were O 0 4.4574977042799446e-10
observed O 0 7.523581202484309e-10
within O 0 2.018855083107951e-10
this O 0 4.461033972780193e-11
family O 0 6.284005538148563e-10
. O 0 7.494010745290325e-09

While O 0 3.7854189827157825e-07
the O 0 1.3529394493616564e-07
proband O 0 2.6241894374834374e-05
( O 0 6.808566599403321e-09
patient O 0 4.432068934079325e-08
1 O 0 2.516576103062107e-07
) O 0 1.4320140906409762e-10
was O 0 8.279068985928006e-09
classified O 0 1.82114867630645e-09
as O 0 5.415415338383411e-10
having O 0 8.402900042447925e-10
a O 0 2.3028491613619195e-10
rare O 0 9.016350166479725e-11
intermediate O 0 8.822252373086314e-10
type O 0 1.5352789040079529e-09
of O 0 5.399483082868528e-09
adult O 0 5.12743270064675e-08
cerebral O 0 0.0008149469504132867
and O 0 1.180316555604577e-08
cerebello O 0 0.0007421431946568191
- O 0 5.771946689492324e-07
brain O 0 1.8836005892808316e-06
stem O 0 1.8812389424027742e-09
forms O 0 8.72537597729206e-10
, O 0 2.8723161002441877e-11
his O 0 6.859895429478513e-10
younger O 0 1.05156274798901e-08
brother O 0 1.2090335133052577e-07
( O 0 1.6875405239868968e-10
patient O 0 6.4979568392686815e-09
2 O 0 4.9724565798214826e-08
) O 0 1.1189163484637277e-10
and O 0 1.5976712175458374e-09
nephew O 0 8.578322194807697e-06
( O 0 1.0975722553041578e-09
patient O 0 5.243493106377173e-08
3 O 0 1.8522368350204488e-07
) O 0 2.817191757653603e-10
had O 0 3.807914339404306e-08
a O 0 1.0246872506058935e-07
childhood O 0 0.00022616486239712685
ALD B-Disease 1 1.0
type O 0 0.020703190937638283
. O 0 2.034694944086368e-06

Another O 0 1.5389408872579224e-05
nephew O 0 0.0021693564485758543
( O 0 6.034796484755134e-08
patient O 0 9.988369811253506e-07
4 O 0 1.0152078857572633e-06
) O 0 6.75749844969431e-10
of O 0 1.0561421248667102e-07
patient O 0 2.1253151771816192e-06
1 O 0 3.228317837056238e-06
was O 0 1.5741321135465114e-07
classified O 0 2.286054012756722e-09
as O 0 3.3362773654843636e-10
having O 0 3.89180854210025e-10
an O 0 1.7679674391146705e-10
adolescent O 0 5.02881576380787e-08
form O 0 1.0059722832522766e-08
. O 0 1.1056100390760548e-07

The O 0 5.114720806886908e-07
tau O 0 1.768686388459173e-06
level O 0 5.759179089181998e-07
in O 0 3.1226636831860333e-09
the O 0 1.018603246194516e-08
cerebrospinal O 0 1.1955618901993148e-05
fluid O 0 4.2128209315706044e-05
( O 0 1.0241163472812786e-08
CSF O 0 5.535482614504872e-06
) O 0 5.489481647025229e-10
in O 0 3.219293720491123e-09
patient O 0 1.9286500219095615e-07
1 O 0 5.285545512379031e-07
was O 0 1.5258045493737882e-07
as O 0 4.009562126761068e-10
high O 0 2.3584816322141933e-09
as O 0 6.113332496476831e-12
that O 0 9.193277649560683e-13
of O 0 6.697328802651725e-11
patients O 0 1.1205138206182852e-10
with O 0 7.680813762789285e-10
Alzheimers B-Disease 1 0.9999481439590454
disease I-Disease 0 7.953480576361471e-07
( O 0 6.035835720119564e-11
AD B-Disease 0 6.29726715217771e-09
) O 0 3.8004294156124274e-10
. O 0 9.931055977574488e-09

His O 0 1.5797204468981363e-06
brain O 0 1.5451936633326113e-05
magnetic O 0 5.828222583659226e-06
resonance O 0 1.5592388535878854e-06
image O 0 6.360134818805818e-08
( O 0 2.9115182487160496e-10
MRI O 0 3.7964420585012704e-07
) O 0 1.4952976357118786e-10
showed O 0 2.0860664307065235e-09
abnormalities B-Disease 0 1.7802173033487634e-06
in I-Disease 0 6.769947935580944e-10
the I-Disease 0 2.8802902285463006e-09
bilateral I-Disease 1 0.9881314039230347
cerebellar I-Disease 1 0.9999933242797852
hemispheres I-Disease 0 0.00043449338409118354
and O 0 1.970755469926644e-08
brain O 0 4.2146662053710315e-06
stem O 0 6.059142076964008e-09
, O 0 2.45523393282987e-11
but O 0 5.629675111501475e-12
not O 0 4.094539377691442e-12
in O 0 4.2636141145413475e-11
the O 0 1.4207596210624729e-09
cerebral O 0 1.0782037861645222e-05
white O 0 2.5334059294834788e-09
matter O 0 8.206889390294236e-09
, O 0 5.851491166608547e-12
where O 0 2.505616590944837e-12
marked O 0 2.2644143504724212e-11
reductions O 0 3.871507836539223e-10
of O 0 8.715828614391796e-10
the O 0 2.530638809616903e-09
cerebral O 0 1.3568161421062541e-06
blood O 0 2.7212365694140317e-09
flow O 0 1.8980641058874426e-08
and O 0 1.1457396142944276e-09
oxygen O 0 5.11857711771313e-09
metabolism O 0 1.1267454880226069e-07
were O 0 4.5253531477662534e-10
clearly O 0 1.0638314534849869e-10
demonstrated O 0 1.575725661062677e-11
by O 0 2.723626229064746e-12
positron O 0 1.2259726567265261e-09
emission O 0 1.2710805741278364e-09
tomography O 0 1.4479486765139882e-07
( O 0 5.37172528680685e-10
PET O 0 8.092871262022072e-09
) O 0 5.932092594918004e-10
. O 0 9.469395934047498e-09

In O 0 8.776104891694558e-07
patients O 0 6.368784397636773e-07
2 O 0 3.549174607542227e-06
and O 0 1.8188826444998085e-08
3 O 0 7.648104372037778e-08
, O 0 5.7597097230521754e-11
the O 0 8.645688331920809e-11
autopsy O 0 1.0793782756479686e-08
findings O 0 4.870930325751033e-10
showed O 0 2.9757702968424837e-09
massive O 0 5.127012414618548e-08
demyelination B-Disease 1 1.0
of I-Disease 0 0.019785357639193535
the I-Disease 0 5.749737465521321e-05
cerebral I-Disease 1 0.9999773502349854
white I-Disease 0 1.2344372635197942e-07
matter I-Disease 0 6.631126581169156e-08
with O 0 4.208977263941982e-11
sparing O 0 2.4894002415010164e-09
of O 0 1.034896524032547e-08
the O 0 6.086120407644557e-08
U O 1 0.768442690372467
- O 0 4.200793682684889e-06
fibers O 0 6.455894663304207e-08
, O 0 6.939615548873235e-11
compatible O 0 7.778901411903405e-10
with O 0 4.905758958784201e-12
the O 0 7.223508596831962e-11
findings O 0 1.0796655236511299e-10
of O 0 2.6848947509705567e-09
childhood O 0 3.400543391762767e-06
ALD B-Disease 1 1.0
. O 0 3.4509730539866723e-06

Oleic O 0 0.0028127890545874834
and O 0 5.897964456380578e-06
erucic O 0 0.026963286101818085
acids O 0 1.6343112747563282e-06
( O 0 5.9282161402052225e-09
Lorenzos O 0 7.53148412968585e-07
Oil O 0 3.262727332753457e-08
) O 0 2.1813575251661277e-11
were O 0 2.4648951282846276e-11
administered O 0 6.450913414557391e-11
to O 0 2.2605736726966086e-11
patients O 0 2.2986364200949794e-10
1 O 0 9.446558202341748e-09
and O 0 4.497859862340192e-10
4 O 0 8.04302846546534e-09
, O 0 4.7187788398961317e-11
but O 0 1.9484315202933367e-11
sufficient O 0 4.081841253888996e-10
effectiveness O 0 1.1862426596565001e-09
was O 0 8.111349369954723e-10
not O 0 2.2178609643264124e-11
obtained O 0 8.973720100335925e-10
. O 0 5.5439155488556935e-09

The O 0 1.5368624417533283e-07
findings O 0 2.1204181521738974e-08
in O 0 1.2889024292306317e-09
this O 0 2.9059202266701334e-10
family O 0 5.856465867815075e-10
suggest O 0 9.536181844183034e-10
that O 0 2.2665402540922308e-11
delGAG291 O 0 2.170150947833349e-09
is O 0 3.744613299994093e-11
part O 0 4.01134993277541e-11
of O 0 8.613103563703817e-10
the O 0 3.596150599527448e-10
cause O 0 2.5255997293527344e-09
of O 0 5.835394834008412e-09
Japanese O 0 1.2007984651063452e-06
ALD B-Disease 1 0.9999997615814209
with O 0 1.0527543281568796e-09
phenotypic O 0 1.9028908582185977e-06
variations O 0 4.112377496312547e-07
. O 0 1.0466866484648563e-07

Moreover O 0 1.5068508218973875e-06
, O 0 2.467560156205195e-09
although O 0 3.7272568365054326e-10
the O 0 1.556338252717282e-10
scale O 0 9.790469768233834e-09
of O 0 1.0876940459425555e-09
the O 0 2.6897578608853223e-10
study O 0 3.175752022466227e-11
is O 0 1.4531853368207615e-12
limited O 0 1.1268959723698124e-11
, O 0 1.952516447134567e-11
there O 0 7.33426791521552e-11
is O 0 6.335837410276213e-11
a O 0 4.1988923449309823e-10
possibility O 0 2.6500488470304617e-09
that O 0 3.98364424780695e-10
PET O 0 4.299791100947914e-08
can O 0 2.5879384746296807e-10
detect O 0 7.770945131824192e-08
an O 0 2.6369344485743795e-09
insidious B-Disease 0 1.3984194993099663e-06
lesion I-Disease 0 4.88463047076948e-06
which O 0 1.5200776193324828e-09
is O 0 1.3453912983685257e-10
undetectable O 0 6.714192757328874e-09
by O 0 3.466716844147122e-11
computed O 0 6.460280133069318e-08
tomogram O 0 1.6105977920233272e-06
( O 0 2.4852204738579076e-09
CT O 0 3.2354130325984443e-06
) O 0 6.012777498121125e-10
or O 0 3.298603612478246e-10
MRI O 0 2.452902890581754e-06
analysis O 0 8.321434208369283e-09
, O 0 1.6485586507020145e-10
and O 0 4.12960811380092e-11
that O 0 7.606628001088911e-12
the O 0 7.068690077716155e-11
higher O 0 4.243561058103751e-10
level O 0 1.9392127903472556e-09
of O 0 4.42199943329058e-10
tau O 0 2.1490980106619872e-09
reflects O 0 8.770054127360538e-11
the O 0 7.044110954257388e-12
process O 0 2.635600626632595e-10
of O 0 2.179712632610631e-09
neuronal B-Disease 0 1.6969887610684964e-06
degeneration I-Disease 0 0.05269268900156021
in O 0 1.1537749742274173e-06
ALD B-Disease 1 1.0
. O 0 1.0100115105160512e-05

Lorenzos O 0 0.0010642228880897164
Oil O 0 5.463348770717857e-06
should O 0 1.7350960668238713e-09
be O 0 2.9097238507524992e-11
given O 0 1.4645109777666754e-11
in O 0 7.584664667159569e-12
the O 0 1.21534084879249e-11
early O 0 6.152924836300144e-10
stage O 0 1.4853267504832957e-09
. O 0 3.5598649028578677e-10
. O 0 5.375807354823792e-09

Nonsense O 0 1.215853808389511e-05
mutation O 0 5.217156129333489e-08
in O 0 1.188689324749248e-08
exon O 0 1.8397918211121578e-06
4 O 0 3.506323480451101e-07
of O 0 1.5830639199521102e-07
human O 0 8.49839238981076e-08
complement O 0 3.561064545465342e-07
C9 O 0 5.220365710556507e-05
gene O 0 4.293980282454868e-08
is O 0 3.237049239768197e-10
the O 0 2.931221099178316e-10
major O 0 1.9059538391985598e-09
cause O 0 5.1542183854280665e-09
of O 0 6.796577967094208e-09
Japanese O 0 1.712952553134528e-06
complement B-Disease 0 5.8406253629073035e-06
C9 I-Disease 0 0.058674272149801254
deficiency I-Disease 0 0.3819057047367096
. O 0 2.3973664156073937e-06

Deficiency B-Disease 1 0.9998651742935181
of I-Disease 0 0.00254568993113935
the I-Disease 0 3.634734184743138e-06
ninth I-Disease 0 2.2213500869838754e-06
component I-Disease 0 1.0776996077765943e-06
of I-Disease 0 6.821691158620524e-07
human I-Disease 0 6.858711287804908e-08
complement I-Disease 0 4.006012090940203e-07
( O 0 3.908324774926086e-09
C9 O 0 2.238592969661113e-06
) O 0 2.3788424008408526e-10
is O 0 3.537546991450036e-11
the O 0 8.156927217006782e-11
most O 0 8.294994552349166e-11
common O 0 3.403354753572785e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.43152597237895e-08
Japan O 0 6.398704233134822e-09
but O 0 1.2825495873669546e-11
is O 0 8.802203757540816e-13
rare O 0 2.187547885890151e-12
in O 0 1.5335702542931817e-12
other O 0 5.036485117848599e-12
countries O 0 3.674554063803903e-11
. O 0 4.958285781953009e-09

We O 0 2.1793070459352748e-07
studied O 0 2.6315404966226197e-07
the O 0 7.218636799422029e-10
molecular O 0 8.521258365590256e-09
basis O 0 8.823922925671468e-09
of O 0 2.608969928985516e-08
C9 B-Disease 0 0.0009598401375114918
deficiency I-Disease 0 0.0008098975522443652
in O 0 3.102953627376337e-08
four O 0 7.72395125636649e-09
Japanese O 0 3.676319693113328e-07
C9 B-Disease 0 0.02674913965165615
- I-Disease 0 5.3759922593599185e-06
deficient I-Disease 0 0.0007250219350680709
patients O 0 1.741820256029314e-06
who O 0 1.5770057260056092e-08
had O 0 1.7711697353206546e-07
suffered O 0 0.004140618722885847
from O 0 1.6063061138993362e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.2480622046950884e-07

Direct O 0 1.1547554379376379e-07
sequencing O 0 4.5247794844271993e-08
of O 0 9.965575031856133e-08
amplified O 0 1.9961080965913425e-07
C9 O 0 3.1380691325466614e-06
cDNA O 0 7.136693369602654e-08
and O 0 1.0381858706054459e-09
DNA O 0 2.4951567478836978e-09
revealed O 0 4.290801491890761e-09
a O 0 8.382122218542065e-10
nonsense O 0 6.782746808653428e-09
substitution O 0 1.3182904767816694e-09
( O 0 1.0226045010774953e-10
CGA O 0 1.750166092051586e-07
- O 0 9.51538403626273e-09
- O 0 5.72744207616438e-09
> O 0 2.4324200431635745e-09
TGA O 0 1.0434152208915748e-08
) O 0 3.033579290545596e-11
at O 0 1.839350227683667e-09
codon O 0 9.209279450139718e-10
95 O 0 8.966043019142944e-09
in O 0 3.0623592550682588e-09
exon O 0 1.0706500574997335e-07
4 O 0 4.843254686193177e-08
in O 0 3.1111182519083513e-09
the O 0 1.4638093404073516e-08
four O 0 4.950445031681738e-08
C9 B-Disease 0 0.00010900724009843543
- I-Disease 0 2.397238404228119e-06
deficient I-Disease 0 1.3422576330412994e-06
individuals O 0 1.6405889979864696e-09
. O 0 9.606108619664155e-08

An O 0 2.0778513132313492e-08
allele O 0 5.0746219670827486e-08
- O 0 1.8915299548893927e-08
specific O 0 3.028466144527897e-09
polymerase O 0 1.4944957626994437e-07
chain O 0 1.4805388914851392e-08
reaction O 0 1.7356180381788988e-10
system O 0 2.073942573233012e-09
designed O 0 1.3354473971105563e-08
to O 0 3.70082658962545e-10
detect O 0 2.143924149322629e-08
exclusively O 0 2.7551891879085133e-09
only O 0 1.6720942686010432e-10
one O 0 5.885061188370955e-11
of O 0 3.1929295318811057e-10
the O 0 3.8245501210454336e-10
normal O 0 4.729117986101983e-09
and O 0 5.475863165682604e-11
mutant O 0 2.7652274914302666e-10
alleles O 0 2.5882530493848144e-11
indicated O 0 3.884429722322835e-10
that O 0 1.3342129484561482e-11
all O 0 2.5591336341723725e-11
the O 0 8.527899914012593e-11
four O 0 4.2767844821156586e-11
patients O 0 1.9632151807003062e-11
were O 0 2.9691568648182454e-11
homozygous O 0 2.375857496850209e-11
for O 0 2.1936742353179106e-11
the O 0 1.4342829701696758e-10
mutation O 0 7.127379242355403e-11
in O 0 5.687443849211604e-10
exon O 0 6.553884190907411e-08
4 O 0 2.4543385990227762e-08
and O 0 3.294560457778317e-10
that O 0 1.8342893176592767e-11
the O 0 1.7690433840034103e-10
parents O 0 3.4737063919765276e-11
of O 0 3.159109362993462e-10
patient O 0 2.660126785514194e-09
2 O 0 4.081284998846968e-08
were O 0 6.343098934991076e-09
heterozygous O 0 2.964899614710248e-08
. O 0 3.8669064394980524e-08

The O 0 1.682076913311903e-07
common O 0 1.6875262076609943e-08
mutation O 0 1.1462030213849062e-09
at O 0 1.6213558495792313e-08
codon O 0 2.6544095810265844e-09
95 O 0 2.615127847604981e-08
in O 0 1.486220213564593e-08
exon O 0 1.696917479421245e-06
4 O 0 3.4459438325029623e-07
might O 0 2.5791193625224196e-09
be O 0 2.2206261829360585e-10
responsible O 0 2.0571228054322432e-10
for O 0 4.642148471178942e-11
most O 0 2.553897926471649e-10
Japanese O 0 2.3455947939510224e-07
C9 B-Disease 0 0.000303772249026224
deficiency I-Disease 0 1.295308265980566e-05
. O 0 9.687431301586003e-09
. O 0 4.584958546161033e-08

BRCA1 O 0 2.1249472581530426e-07
required O 0 1.5793688135090633e-08
for O 0 1.582482811457453e-09
transcription O 0 8.555516046726552e-07
- O 0 1.0049626553154667e-06
coupled O 0 1.5426112440763973e-06
repair O 0 0.0003236221382394433
of O 0 1.23582663036359e-06
oxidative O 0 6.923456112417625e-06
DNA O 0 2.8747655278493767e-07
damage O 0 1.1484637070680037e-05
. O 0 1.6130252333823591e-07

The O 0 1.147174430116138e-06
breast B-Disease 1 0.9999973773956299
and I-Disease 1 0.9998261332511902
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.999195396900177
gene O 0 1.1791664746851893e-06
BRCA1 O 0 1.8902898091255338e-07
encodes O 0 2.597534987103245e-08
a O 0 2.0116006282933085e-07
zinc O 0 1.4587456462322734e-05
finger O 0 2.6800342311616987e-05
protein O 0 1.6997489638015395e-07
of O 0 5.474680975225965e-08
unknown O 0 1.3481700023021403e-07
function O 0 9.869205541690462e-07
. O 0 1.3769174245226168e-07

Association O 0 3.9312874378083507e-07
of O 0 7.3973308190034e-07
the O 0 2.3295352491459198e-07
BRCA1 O 0 1.7184120792990143e-08
protein O 0 2.775966789769768e-09
with O 0 1.6310688910614601e-10
the O 0 3.6322467256155733e-09
DNA O 0 2.391195685902403e-08
repair O 0 1.6018116184568498e-06
protein O 0 9.592651650791595e-08
Rad51 O 0 2.5664118652457546e-07
and O 0 5.549488091283195e-10
changes O 0 6.407579467015978e-10
in O 0 3.3704508628495944e-10
the O 0 2.0727589089553078e-10
phosphorylation O 0 3.1119729015927078e-09
and O 0 3.5796923758546484e-10
cellular O 0 3.563829054087364e-08
localization O 0 3.70458133147622e-06
of O 0 1.0821058538112993e-07
the O 0 2.8839307830708094e-08
protein O 0 9.657600053003534e-09
after O 0 1.0129266314606866e-08
exposure O 0 4.1448675602850926e-08
to O 0 4.866194669439494e-10
DNA O 0 1.7849581368523104e-08
- O 0 9.290440416975798e-09
damaging O 0 7.842593241491613e-09
agents O 0 9.056875804880349e-10
are O 0 6.1580259121118974e-12
consistent O 0 1.7869355994903913e-10
with O 0 4.96718551706854e-12
a O 0 8.459436623420302e-11
role O 0 5.074693998352586e-10
for O 0 9.57980805793568e-10
BRCA1 O 0 1.5934592534350145e-09
in O 0 2.7952213876858423e-09
DNA O 0 6.56659722153563e-08
repair O 0 7.209555042209104e-05
. O 0 6.342066853903816e-07

Here O 0 8.914751106203767e-07
, O 0 8.809019624855807e-10
it O 0 8.661264414011605e-12
is O 0 3.6071107038793127e-12
shown O 0 2.3061974205318414e-11
that O 0 6.771477475964183e-12
mouse O 0 1.4306333895319767e-09
embryonic O 0 5.605158559518486e-09
stem O 0 1.305850316768442e-09
cells O 0 1.2616743760851534e-10
deficient B-Disease 0 2.5665823244480634e-08
in I-Disease 0 1.6414591907931708e-09
BRCA1 I-Disease 0 2.6177364720325613e-09
are O 0 3.6017088617112947e-11
defective O 0 1.4450896479445419e-08
in O 0 2.2468880922499324e-10
the O 0 9.995658467598645e-11
ability O 0 9.02603252556089e-12
to O 0 1.2815494325468801e-11
carry O 0 2.427925915871043e-11
out O 0 1.3227625592082681e-11
transcription O 0 5.985479223369339e-09
- O 0 5.721186191465222e-09
coupled O 0 4.111404194873103e-08
repair O 0 1.3977907656226307e-05
of O 0 7.328349056479055e-07
oxidative O 0 1.4635547813668381e-06
DNA O 0 8.674690121779349e-08
damage O 0 2.8015829229843803e-06
, O 0 7.48600570421587e-10
and O 0 5.6539140036449e-10
are O 0 1.0398103211795018e-10
hypersensitive O 0 2.570982644556352e-07
to O 0 6.8437326916637176e-09
ionizing O 0 0.00048358968342654407
radiation O 0 0.00044791941763833165
and O 0 2.608262050785015e-09
hydrogen O 0 6.06787375900808e-09
peroxide O 0 1.0080008649993033e-07
. O 0 3.7094377347557383e-08

These O 0 8.785247196385626e-09
results O 0 1.039969976801558e-08
suggest O 0 1.3731296988339636e-08
that O 0 2.046076363892979e-10
BRCA1 O 0 2.164499690593402e-09
participates O 0 3.715389107483702e-10
, O 0 9.762302771720854e-11
directly O 0 2.187458270075382e-10
or O 0 1.3549635025089657e-10
indirectly O 0 6.016093179184168e-10
, O 0 3.767452322334108e-11
in O 0 1.5054539559411495e-10
transcription O 0 3.7550546494458104e-07
- O 0 4.424619817200437e-07
coupled O 0 7.518602842537803e-07
repair O 0 0.00024480934371240437
of O 0 4.88568332457362e-07
oxidative O 0 1.288359612772183e-06
DNA O 0 3.609919119185179e-08
damage O 0 7.170312414928048e-07
. O 0 2.4754136518367886e-09
. O 0 3.2280450312782705e-08

Truncation O 0 2.9703178370255046e-05
mutations O 0 1.6568736782573978e-07
in O 0 7.2838788334195215e-09
the O 0 6.937213914426366e-09
transactivation O 0 2.4023782316362485e-05
region O 0 2.7389174306335917e-07
of O 0 2.266920517968174e-07
PAX6 O 0 1.1888448170793708e-05
result O 0 2.3514623137543822e-08
in O 0 9.529132150021269e-09
dominant O 0 5.37460800842382e-06
- O 0 9.50269125610248e-08
negative O 0 6.120552509258914e-09
mutants O 0 7.111813715710014e-08
. O 0 3.466636044890947e-08

PAX6 O 0 0.0004884281079284847
is O 0 6.929071361128081e-08
a O 0 5.142513082034839e-09
transcription O 0 1.1727496307400997e-08
factor O 0 2.250938324621643e-09
with O 0 6.567965615822402e-11
two O 0 1.0222300783624405e-10
DNA O 0 2.0742341177992785e-10
- O 0 1.2385321934704763e-10
binding O 0 3.9753478286996824e-10
domains O 0 2.995075121248192e-08
( O 0 5.890432031030457e-10
paired O 0 7.964090720236072e-09
box O 0 2.5247493340430083e-07
and O 0 9.197259842608219e-09
homeobox O 0 1.0375513426197358e-07
) O 0 2.996100589847117e-10
and O 0 1.0798102412223898e-09
a O 0 1.7214563996503784e-08
proline O 0 1.8513586610424682e-06
- O 0 6.956455536055728e-07
serine O 0 1.5335638181568356e-06
- O 0 1.526951507457852e-07
threonine O 0 2.973009713969077e-07
( O 0 1.3428667067216793e-09
PST O 0 7.215295681817224e-06
) O 0 5.406934899809812e-09
- O 0 1.7235985083630112e-08
rich O 0 7.165033455436287e-09
transactivation O 0 3.858518994093174e-06
domain O 0 3.209781880286755e-06
. O 0 5.528337396754068e-07

PAX6 O 0 0.003795298980548978
regulates O 0 4.667735538532725e-06
eye O 0 1.3541695807361975e-05
development O 0 4.077565662896632e-08
in O 0 2.0274342205084395e-09
animals O 0 3.293408948334964e-11
ranging O 0 2.3468282872585178e-09
from O 0 8.052675193326309e-11
jellyfish O 0 1.8233433859982107e-11
to O 0 1.7261027676629404e-11
Drosophila O 0 1.2107170821451518e-09
to O 0 2.9658298039692e-10
humans O 0 1.1478618944238406e-08
. O 0 2.4863075154257785e-08

Heterozygous O 0 9.206966637975711e-07
mutations O 0 7.547058089585335e-08
in O 0 5.96687632636872e-09
the O 0 5.248933732104888e-09
human O 0 8.88111095775912e-09
PAX6 O 0 9.36608444135345e-07
gene O 0 3.3776024199738686e-09
result O 0 1.3790555364323609e-09
in O 0 2.0918226872890244e-10
various O 0 4.662080721473671e-10
phenotypes O 0 4.444476786602536e-09
, O 0 5.0511102245298645e-11
including O 0 1.887016654045226e-10
aniridia B-Disease 1 1.0
, O 0 1.4655196878265997e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.6745058789856557e-07
autosomal B-Disease 1 0.9976031184196472
dominant I-Disease 1 0.9955138564109802
keratitis I-Disease 1 0.9999926090240479
, O 0 4.6751303273140365e-08
and O 0 5.089035326477642e-08
familial B-Disease 1 0.9999713897705078
foveal I-Disease 1 0.9999997615814209
dysplasia I-Disease 1 1.0
. O 0 0.019646551460027695

It O 0 3.2910783431816526e-08
is O 0 2.7764752719150465e-09
believed O 0 6.686852738191362e-10
that O 0 6.237320989560535e-12
the O 0 3.873499784812218e-11
mutated O 0 6.997006446463061e-11
allele O 0 1.4080558941031995e-09
of O 0 1.0664532368309665e-08
PAX6 O 0 3.401866933927522e-06
produces O 0 2.0592201277480626e-09
an O 0 2.5980326223695727e-10
inactive O 0 1.492347934117788e-07
protein O 0 1.4650139235072857e-07
and O 0 1.376108205164428e-08
aniridia B-Disease 1 1.0
is O 0 1.8654965572295623e-08
caused O 0 7.418889946819718e-09
due O 0 2.3150285244355473e-08
to O 0 1.7180507017044988e-09
genetic O 0 2.547609767589165e-08
haploinsufficiency O 0 1.286971951230953e-06
. O 0 1.9509637638748245e-07

However O 0 5.677424042005441e-08
, O 0 1.082850142886116e-09
several O 0 1.6481059572637236e-10
truncation O 0 7.293683523812433e-08
mutations O 0 3.889970123793773e-09
have O 0 2.052572556365817e-10
been O 0 2.0390208965714862e-10
found O 0 1.7670226393207145e-11
to O 0 3.813081361075943e-12
occur O 0 3.437935006123105e-11
in O 0 1.165825769255946e-10
the O 0 1.4381021928855375e-09
C O 0 3.0041376248846063e-06
- O 0 2.8061577950211358e-08
terminal O 0 7.98004435864641e-08
half O 0 1.038554131582714e-09
of O 0 1.0187970467256946e-09
PAX6 O 0 3.237417445234314e-07
in O 0 1.2620070544144824e-09
patients O 0 4.476471970882301e-10
with O 0 2.9589028449628074e-10
Aniridia B-Disease 1 0.9999996423721313
resulting O 0 1.851084974191508e-08
in O 0 9.51773881929796e-10
mutant O 0 2.424670464407086e-09
proteins O 0 1.8114719446682415e-10
that O 0 7.51143314214886e-11
retain O 0 1.5149488330479244e-09
the O 0 5.012713022445325e-10
DNA O 0 1.1206169325816973e-09
- O 0 5.513900447340347e-10
binding O 0 2.2624264683912543e-09
domains O 0 4.518880203363551e-08
but O 0 2.2866863957915484e-09
have O 0 3.357919498014894e-10
lost O 0 4.8158379506446636e-09
most O 0 1.5774275982649577e-11
of O 0 1.7678999930659245e-10
the O 0 2.9690561120787606e-10
transactivation O 0 3.642151966687379e-07
domain O 0 4.852745973948913e-07
. O 0 1.4673740622583864e-07

It O 0 1.0209727463461604e-07
is O 0 5.9895790549546746e-09
not O 0 3.3918617914352467e-10
clear O 0 2.1015416074021687e-09
whether O 0 3.1472913164520833e-10
such O 0 9.983368992605435e-11
mutants O 0 1.4328270125929521e-08
really O 0 7.900244902714348e-09
behave O 0 7.385270173188019e-10
as O 0 3.800828263234024e-10
loss O 0 1.930444470943371e-09
- O 0 4.683347487599576e-09
of O 0 7.089926867820395e-08
- O 0 2.0855303262123925e-08
function O 0 1.2403536864269427e-08
mutants O 0 1.2475427801916794e-08
as O 0 7.499740273253508e-10
predicted O 0 7.476293362174147e-09
by O 0 1.7810056762712634e-09
haploinsufficiency O 0 2.32880074690911e-06
. O 0 4.0185398120229365e-07

Contrary O 0 2.2233189156395383e-06
to O 0 3.4483016442266035e-09
this O 0 3.1395749888751823e-10
theory O 0 5.408783820826102e-08
, O 0 1.5966589161919842e-10
our O 0 2.9752239560920657e-10
data O 0 2.5514146351213185e-10
showed O 0 5.842876182882151e-10
that O 0 4.523329627525996e-12
these O 0 2.335972778058637e-12
mutants O 0 2.520814945672356e-10
are O 0 5.825132910752817e-12
dominant O 0 3.782778534855424e-09
- O 0 4.3197204147027435e-10
negative O 0 1.0967618480073327e-10
in O 0 2.5548382853735063e-10
transient O 0 1.3462422288057496e-08
transfection O 0 2.6059014501811362e-08
assays O 0 2.662781550810678e-09
when O 0 7.558042525168673e-10
they O 0 5.86582032946481e-11
are O 0 3.0702209437988293e-12
coexpressed O 0 1.3685899080684294e-09
with O 0 5.0941261625636614e-11
wild O 0 1.1604265326425889e-09
- O 0 8.939387008410904e-09
type O 0 2.3983034225238953e-07
PAX6 O 0 0.00019778363639488816
. O 0 9.024333849083632e-07

We O 0 2.930663072220341e-07
found O 0 1.3724927860891967e-09
that O 0 1.13840612284144e-11
the O 0 2.642839558308907e-10
dominant O 0 5.2347591150692097e-08
- O 0 2.3287913819558526e-09
negative O 0 1.157614074043245e-10
effects O 0 2.0953628165898408e-08
result O 0 2.2456626835865023e-10
from O 0 1.272190686130159e-10
the O 0 3.664559281024715e-11
enhanced O 0 1.7243924343990358e-10
DNA O 0 5.7829140781562316e-11
binding O 0 9.529268346630815e-11
ability O 0 7.211545943741626e-11
of O 0 4.500425865305857e-10
these O 0 9.697423419829931e-11
mutants O 0 2.5505416445525952e-08
. O 0 1.8937139856234353e-08

Kinetic O 0 1.4201923477230594e-05
studies O 0 8.521700323171899e-08
of O 0 1.7240456173794882e-08
binding O 0 1.0040285935986049e-08
and O 0 4.191307023670987e-10
dissociation O 0 3.111462421045985e-09
revealed O 0 6.372526950571e-10
that O 0 1.1052236599876086e-12
various O 0 1.0201026655332068e-11
truncation O 0 2.7749609277094578e-09
mutants O 0 1.3571678225687833e-09
have O 0 3.578263380044078e-11
3 O 0 9.688259083873163e-10
- O 0 2.4115615060438245e-10
5 O 0 1.061027377069479e-09
- O 0 1.9597966305351378e-10
fold O 0 1.5499543315478093e-10
higher O 0 1.4644445378575455e-10
affinity O 0 3.204514084642618e-11
to O 0 1.5269776762472098e-11
various O 0 2.3869540025089897e-11
DNA O 0 1.5342184467304065e-10
- O 0 4.798375932701937e-11
binding O 0 4.270214737367439e-11
sites O 0 5.1402524597898847e-11
when O 0 5.876166914164926e-11
compared O 0 2.1866365662592813e-10
with O 0 4.3920728165502965e-11
the O 0 1.0669003458474435e-09
wild O 0 1.6800905111580278e-09
- O 0 9.233890985171911e-09
type O 0 1.0927896454404618e-07
PAX6 O 0 2.6245723347528838e-05
. O 0 3.912630859304045e-07

These O 0 1.999508292271912e-08
results O 0 8.559913666772445e-09
provide O 0 1.4358465527664066e-09
a O 0 1.0967561303587559e-09
new O 0 1.40234907020087e-10
insight O 0 1.1278646905310552e-09
into O 0 9.142140516837927e-11
the O 0 9.584645577209727e-11
role O 0 1.2874331600798428e-09
of O 0 1.5530238206551417e-09
mutant O 0 2.3885471378548573e-08
PAX6 O 0 1.9025768551728106e-06
in O 0 1.6590423257412112e-08
causing O 0 1.4243994428397855e-07
aniridia B-Disease 1 0.9999953508377075
. O 0 2.7004473324154787e-08
. O 0 9.653773247464414e-08

Reversal O 0 1.1447393262642436e-05
of O 0 2.150823092961218e-06
severe O 1 0.9830301403999329
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 0.0001466580870328471
excellent O 0 6.081390893086791e-06
neuropsychologic O 0 3.300491880509071e-05
outcome O 0 1.047718797053676e-06
in O 0 3.385290270330188e-09
very B-Disease 0 4.896763883266431e-09
- I-Disease 0 6.138020580692682e-08
long I-Disease 0 3.9105337634737225e-08
- I-Disease 0 6.35510204460843e-08
chain I-Disease 0 1.1928911192171654e-08
acyl I-Disease 0 2.1982964337752264e-09
- I-Disease 0 2.2185826509257822e-09
coenzyme I-Disease 0 6.887220571627495e-09
A I-Disease 0 1.3990569414090714e-07
dehydrogenase I-Disease 0 2.0973675418645144e-06
deficiency I-Disease 0 0.00017118098912760615
. O 0 5.211711027186539e-07

Very B-Disease 0 1.3629464774567168e-06
- I-Disease 0 2.1736580038123066e-06
long I-Disease 0 1.1654561404839114e-07
- I-Disease 0 3.946086124528847e-08
chain I-Disease 0 1.4197525821657564e-08
acyl I-Disease 0 1.893886381054699e-09
- I-Disease 0 8.805223217223102e-10
coenzyme I-Disease 0 1.1217353712567046e-09
A I-Disease 0 7.1321055727935345e-09
dehydrogenase I-Disease 0 6.619586656597676e-09
( I-Disease 0 2.1928805993276512e-10
VLCAD I-Disease 0 1.2866748875239864e-06
) I-Disease 0 7.988367189959433e-10
deficiency I-Disease 0 2.3882273580966284e-06
is O 0 8.524098649154155e-10
a O 0 6.553531939346158e-09
disorder O 1 0.9925876259803772
of O 0 6.091635805205442e-05
fatty O 0 1.826546031225007e-05
acid O 0 4.255423675658676e-07
beta O 0 1.5043224266264588e-07
oxidation O 0 1.0679635842336666e-08
that O 0 8.313050248176523e-11
reportedly O 0 9.794948185870567e-10
has O 0 2.1489307729105622e-12
high O 0 6.076113917563575e-11
rates O 0 3.8317619910355205e-11
of O 0 5.991698109886201e-11
morbidity O 0 3.943157800279096e-09
and O 0 1.7464969748193226e-10
mortality O 0 1.0521871018909223e-07
. O 0 3.3534870880203016e-08

We O 0 2.363166657914917e-07
describe O 0 6.401368324304713e-08
the O 0 2.4964899036916677e-09
outcome O 0 4.5508492974022374e-08
of O 0 1.419048789585986e-08
a O 0 3.2350264689284813e-09
5 O 0 4.540243292439072e-09
- O 0 6.927030060666084e-10
year O 0 7.93936472121004e-10
- O 0 9.479840912263171e-09
old O 0 7.377083477422275e-08
girl O 0 2.14168842660456e-08
with O 0 1.2782387592835676e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.519339795981068e-05
was O 0 6.055012818251271e-06
first O 0 9.505117581909417e-09
seen O 0 2.6892987392557188e-08
at O 0 3.572309026367293e-08
5 O 0 2.109042496201141e-09
months O 0 2.0611799766978578e-10
of O 0 5.811732761706878e-10
age O 0 5.157040572356664e-09
with O 0 5.56728829703701e-10
severe O 1 0.6239887475967407
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999755620956421
hepatomegaly B-Disease 1 1.0
, O 1 0.9995182752609253
encephalopathy B-Disease 0 0.4500214457511902
, O 0 4.181960377991345e-08
and O 0 5.758432735092356e-07
hypotonia B-Disease 1 0.9992651343345642
. O 0 2.1919182472629473e-05

Biochemical O 0 2.425842649245169e-05
studies O 0 1.5382701121779974e-06
indicated O 0 0.0002803871175274253
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0001094325925805606
by O 0 2.509446650478253e-09
a O 0 1.6358653098791365e-08
stable O 0 2.119570581271546e-06
yet O 0 1.9844817344960575e-08
inactive O 0 1.7371904448282294e-07
enzyme O 0 3.8367918619997e-08
. O 0 7.016127057113408e-08

Molecular O 0 7.456858384102816e-06
genetic O 0 2.79211178622063e-07
analysis O 0 5.244103107315823e-08
of O 0 1.2451661746126774e-07
her O 0 1.736275478947391e-08
VLCAD O 0 7.645796722499654e-05
gene O 0 2.3119527625681258e-08
revealed O 0 2.074810510066527e-07
a O 0 7.024452575166151e-09
T1372C O 0 4.407983311693897e-08
( O 0 1.4033764428322826e-10
F458L O 0 2.1128123250946373e-08
) O 0 4.5406914339629623e-10
missense O 0 7.310229221957343e-08
mutation O 0 5.407388314893069e-09
and O 0 8.34660951465338e-10
a O 0 2.4812290888576172e-08
1668 O 0 6.903329631313682e-05
ACAG O 0 0.0003074606356676668
1669 O 0 0.00013440847396850586
splice O 0 8.484967111144215e-06
site O 0 3.9742039348311664e-07
mutation O 0 2.3887847078185587e-07
. O 0 3.959876835324394e-07

After O 0 1.0272938766320294e-07
initial O 0 1.029023088960912e-08
treatment O 0 4.441623246975723e-08
with O 0 8.594788769578088e-10
intravenous O 0 1.8692149978960515e-06
glucose O 0 6.3666075220680796e-06
and O 0 2.4993103142634254e-09
carnitine O 0 2.6952406528835127e-07
, O 0 2.0513123144549894e-10
the O 0 6.782950312533842e-10
patient O 0 3.234681189567823e-09
has O 0 1.1777696873327415e-10
thrived O 0 3.2029345842232715e-09
on O 0 2.352748662559634e-09
a O 0 9.9688557408939e-10
low O 0 2.3402273896522274e-08
- O 0 7.708658600336094e-09
fat O 0 5.760506294194556e-09
diet O 0 3.0296837261190035e-10
supplemented O 0 4.152529362033697e-11
with O 0 2.6994339055730343e-11
medium O 0 2.1136827399459435e-08
- O 0 5.174203732138949e-09
chain O 0 6.697386201182098e-09
triglyceride O 0 2.1424769514055697e-08
oil O 0 1.0204973754923685e-08
and O 0 1.768986068739764e-10
carnitine O 0 2.501944429411651e-08
and O 0 2.8941496421630575e-10
avoidance O 0 6.945477935005329e-07
of O 0 5.68276519175015e-08
fasting O 0 2.4824703359627165e-07
. O 0 2.853013469916732e-08

Her O 0 4.757393071486149e-06
ventricular O 0 0.053121212869882584
hypertrophy O 1 0.9635483026504517
resolved O 0 0.002866526134312153
significantly O 0 2.9755798891528684e-07
over O 0 3.418226413032244e-08
1 O 0 1.8052617178909713e-08
year O 0 1.3593018377555666e-10
, O 0 6.375173999817463e-11
and O 0 1.1384328202357352e-10
cognitively O 0 2.819372184603708e-07
, O 0 8.137553408893439e-10
she O 0 6.022602416777545e-10
is O 0 5.277367778888653e-11
in O 0 2.1454353571481732e-10
the O 0 4.583493862231336e-10
superior O 0 2.5776040502023534e-07
range O 0 4.118489549398419e-09
for O 0 2.5637078571172367e-10
age O 0 2.8809894914161305e-08
. O 0 3.796253267296379e-08

Clinical O 0 6.0460579334176145e-06
recognition O 0 1.0607632248138543e-05
of O 1 0.9999910593032837
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.1108528269687667e-05
important O 0 1.3712146085254062e-07
because O 0 9.876196527258685e-10
it O 0 1.1620644550791592e-11
is O 0 3.8832626350626676e-12
one O 0 1.9031863758567358e-12
of O 0 9.238144971224216e-11
the O 0 1.4827530869787608e-10
few O 0 1.1867126725739752e-10
directly O 0 4.5255343916750235e-10
treatable O 0 1.8104101400240324e-06
causes O 0 3.411099624983649e-09
of O 0 5.1658052058201065e-08
cardiomyopathy B-Disease 1 1.0
in O 0 2.538104808991193e-06
children O 0 1.5077858961376478e-08
. O 0 2.20917018012301e-09
. O 0 2.5894916433344406e-08

Cloning O 0 7.227356491057435e-07
of O 0 1.2229516244133265e-07
a O 0 3.4828520067975433e-09
novel O 0 6.244171846248037e-10
member O 0 1.688417072820414e-09
of O 0 3.853122265695674e-09
the O 0 7.963907755481614e-09
low O 0 3.695054147101473e-07
- O 0 6.841200939078362e-09
density O 0 1.1307467184806796e-09
lipoprotein O 0 1.6971233662843588e-07
receptor O 0 1.3136181564732397e-07
family O 0 8.262509254564065e-08
. O 0 2.7755297082876496e-07

A O 0 6.792186582060822e-07
gene O 0 1.1145977474313895e-08
encoding O 0 1.0094264979443324e-07
a O 0 5.248325862794445e-08
novel O 0 2.1813274742044086e-08
transmembrane O 0 1.807253511287854e-07
protein O 0 7.856490213953293e-08
was O 0 2.410267185837256e-08
identified O 0 2.703650359148213e-10
by O 0 4.82303736878964e-12
DNA O 0 3.95390803431539e-11
sequence O 0 2.6550549953041624e-11
analysis O 0 3.362031833487045e-11
within O 0 2.5611356785359973e-11
the O 0 1.0947116824144842e-10
insulin B-Disease 0 0.00010843982454389334
- I-Disease 0 0.48234233260154724
dependent I-Disease 1 0.9999988079071045
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.974540436184725e-08
IDDM B-Disease 0 1.2400246305332985e-06
) O 0 1.21473428538188e-10
locus O 0 2.0127850497431155e-09
IDDM4 O 0 7.103760140125814e-07
on O 0 1.3851726521352248e-07
chromosome O 0 8.025712645576277e-07
11q13 O 0 1.5950647593854228e-06
. O 0 1.3048432379036967e-07

Based O 0 1.7600935109385318e-07
on O 0 1.3185808711568825e-07
its O 0 1.2123531067942395e-09
chromosomal O 0 3.6760079638042953e-06
position O 0 3.0956084628996905e-06
, O 0 1.3923392438996984e-09
this O 0 4.859755306507729e-11
gene O 0 2.9294994208228786e-10
is O 0 1.1773226837874518e-10
a O 0 2.505504415051263e-10
candidate O 0 1.8567974935379539e-10
for O 0 5.823892063050451e-11
conferring O 0 6.063120849830739e-08
susceptibility O 0 7.70583881148923e-07
to O 0 2.3691050898833055e-08
diabetes B-Disease 1 0.9765182137489319
. O 0 1.376089358018362e-06

The O 0 1.6804349911581085e-07
gene O 0 1.5417942478279656e-08
, O 0 1.3399167331229478e-09
termed O 0 2.0412487700127713e-08
low O 0 8.18928569401578e-08
- O 0 2.7933613200303853e-09
density O 0 5.96090121707249e-10
lipoprotein O 0 3.804415271702055e-08
receptor O 0 7.303327720364905e-09
related O 0 7.961208581264145e-08
protein O 0 3.580440122163964e-08
5 O 0 1.5958688592832004e-08
( O 0 6.160766341523072e-11
LRP5 O 0 2.0901737229905848e-08
) O 0 4.8173950939478516e-11
, O 0 2.8627827539096096e-11
encodes O 0 7.566765269917397e-11
a O 0 6.02012162342902e-10
protein O 0 8.079129365512472e-09
of O 0 2.6039538525424177e-08
1615 O 0 2.7710422727977857e-05
amino O 0 1.7612386216114828e-07
acids O 0 4.5761758826756704e-09
that O 0 3.6032822559040056e-11
contains O 0 3.0057036720654295e-11
conserved O 0 2.0439319126097644e-09
modules O 0 2.2841624147673656e-09
which O 0 3.362761241340606e-12
are O 0 2.213324196229799e-13
characteristic O 0 3.2913997916050874e-11
of O 0 3.3526972864628135e-10
the O 0 4.5038775486894167e-10
low O 0 2.5453317675783182e-08
- O 0 9.377116860775914e-10
density O 0 1.2079923172869655e-10
lipoprotein O 0 3.464236897343653e-08
( O 0 4.774605155688505e-10
LDL O 0 3.607613052736269e-08
) O 0 1.2566530038782275e-09
receptor O 0 2.7419009285267748e-08
family O 0 1.3298629752966917e-08
. O 0 4.7677115588840024e-08

These O 0 3.923172453568213e-09
modules O 0 8.836743603524155e-08
include O 0 4.396846442489277e-09
a O 0 7.017328496061737e-09
putative O 0 5.0545587271244585e-08
signal O 0 2.395802596311114e-07
peptide O 0 1.736613164382561e-08
for O 0 2.5756188293257765e-09
protein O 0 8.05925992608536e-09
export O 0 9.176950754863356e-09
, O 0 2.925167053025035e-10
four O 0 3.5726460678731087e-10
epidermal O 0 3.3162121937380107e-09
growth O 0 1.8242913846222564e-09
factor O 0 4.5504995327405595e-09
( O 0 2.5693178140606676e-10
EGF O 0 1.3235191609339836e-08
) O 0 2.5304588979757625e-10
repeats O 0 2.1831494390056605e-09
with O 0 1.5405052233852246e-10
associated O 0 2.5572639117399376e-08
spacer O 0 1.5861270412642625e-06
domains O 0 1.841933681134833e-06
, O 0 1.989802989044165e-08
three O 0 1.574811570037582e-08
LDL O 0 1.4824724985373905e-06
- O 0 3.0593303108616965e-06
receptor O 0 3.792533220803307e-08
( O 0 2.860788050895735e-09
LDLR O 0 1.3892066590415197e-06
) O 0 9.519899313303881e-10
repeats O 0 6.876405223010806e-09
, O 0 2.8758914694115845e-10
a O 0 3.778687918121193e-10
single O 0 7.306890648095532e-10
transmembrane O 0 6.799406548907427e-08
spanning O 0 4.311041266191751e-07
domain O 0 2.2302771185422898e-07
, O 0 7.280264169295947e-10
and O 0 2.4016877375743206e-10
a O 0 1.0365811542456527e-09
cytoplasmic O 0 3.342038112918999e-08
domain O 0 1.1821323369076708e-06
. O 0 4.1945983753066685e-07

The O 0 3.6354302324070886e-07
encoded O 0 1.1028340907159873e-07
protein O 0 2.3065005905209546e-07
has O 0 3.49744899708071e-10
a O 0 1.2182287123518876e-10
unique O 0 8.004560902996616e-11
organization O 0 2.4189136804686484e-10
of O 0 1.536858817985376e-08
EGF O 0 3.4966262774105417e-07
and O 0 1.8562470671668052e-08
LDLR O 0 2.632704308780376e-05
repeats O 0 2.488504335929065e-08
; O 0 1.4101704526314762e-10
therefore O 0 1.2621057532413715e-09
, O 0 2.581332370077405e-10
LRP5 O 0 5.507293963091797e-07
likely O 0 3.2117131176789826e-09
represents O 0 3.691534855576606e-10
a O 0 1.4158166306010855e-10
new O 0 6.991776602127686e-11
category O 0 3.484573074530317e-09
of O 0 3.805763260089634e-09
the O 0 7.014638647717675e-09
LDLR O 0 3.075911081396043e-05
family O 0 3.136011272886208e-08
. O 0 5.3344841433045076e-08

Both O 0 3.3146079658763483e-07
human O 0 1.0344469814071999e-07
and O 0 6.025512533369692e-09
mouse O 0 4.552932608703486e-08
LRP5 O 0 3.4368074466328835e-06
cDNAs O 0 2.600738184810325e-07
have O 0 1.4136659898245085e-10
been O 0 9.091226382818007e-11
isolated O 0 1.0582175413720307e-10
and O 0 8.937719488122386e-12
the O 0 8.831962244881808e-11
encoded O 0 2.9505844989508034e-10
mature O 0 3.2890540291319326e-10
proteins O 0 5.2480374213015324e-11
are O 0 7.37929248956215e-12
95 O 0 3.8712122396589166e-10
% O 0 3.917627680594116e-11
identical O 0 1.3523305808504915e-09
, O 0 1.1606805794261987e-10
indicating O 0 2.4520447894360586e-09
a O 0 1.4793244407229622e-09
high O 0 1.5140598108587255e-08
degree O 0 8.168537846131585e-08
of O 0 2.426909784247755e-09
evolutionary O 0 1.1938191546434496e-09
conservation O 0 2.0746100670709922e-10
. O 0 1.0511025383408423e-10
. O 0 3.317363495014547e-09

The O 0 3.820930771780695e-07
APC B-Disease 0 2.135289349780578e-07
variants O 0 1.5131041308791282e-08
I1307K O 0 8.259908668151184e-08
and O 0 4.485411764232339e-10
E1317Q O 0 1.383355741069181e-08
are O 0 1.734075383286182e-11
associated O 0 9.188496363776721e-08
with O 0 0.07908555865287781
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.21881870925426483
but O 0 2.0952828805320678e-08
not O 0 1.1926403198359026e-09
always O 0 6.234805449700787e-10
with O 0 2.2126597429283912e-11
a O 0 8.701377951503275e-10
family O 0 1.5424957144904994e-10
history O 0 2.6361548499664877e-09
. O 0 5.110841083677542e-09

Classical O 1 0.9999984502792358
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 6.437232514144853e-06
FAP B-Disease 0 9.513551617601479e-07
) O 0 1.1763109375451108e-09
is O 0 2.794340592249256e-10
a O 0 1.916832470527652e-09
high O 0 0.00046765245497226715
- O 1 0.9999312162399292
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9989539384841919
that O 0 1.2043602781730556e-09
predisposes O 0 8.868483725166243e-09
to O 0 2.210872040997458e-10
hundreds O 0 7.80188413873617e-11
or O 0 4.3418890011137634e-11
thousands O 0 8.694255732022427e-11
of O 0 9.528026566840708e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999959468841553
carcinoma I-Disease 1 1.0
and O 0 5.474648787640035e-07
that O 0 1.2727416343061293e-10
results O 0 3.573756846009246e-10
from O 0 3.206979681813493e-10
truncating O 0 8.765046466407966e-09
mutations O 0 1.905352958742057e-10
in O 0 1.0870131877949163e-10
the O 0 1.8944861235326016e-09
APC B-Disease 0 9.048940796674287e-08
gene O 0 1.329010075323822e-07
. O 0 3.152594274524745e-07

A O 0 5.447831767924072e-07
variant O 0 3.6692267713078763e-07
of O 0 9.610836571027903e-08
FAP B-Disease 0 8.554226837986789e-07
is O 0 4.937121289572133e-08
attenuated B-Disease 0 0.34187373518943787
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999731779098511
coli I-Disease 1 0.9999210834503174
, O 0 7.95710608514355e-09
which O 0 1.3225158468355147e-10
results O 0 3.7792283191784293e-10
from O 0 8.312994737025292e-09
germ O 0 0.00013193476479500532
- O 0 1.456235452224064e-07
line O 0 3.052080543852753e-08
mutations O 0 1.8768367415766818e-10
in O 0 2.7494290177898506e-10
the O 0 7.789724976170476e-10
5 O 0 2.578371516293032e-09
and O 0 8.664673145641899e-11
3 O 0 1.6272941882888858e-09
regions O 0 1.4490848798676126e-10
of O 0 5.203250719176822e-09
the O 0 8.934784467840018e-09
APC B-Disease 0 2.2148888945139333e-07
gene O 0 1.1419030698789356e-07
. O 0 2.244689198960259e-07

Attenuated B-Disease 1 0.9999948740005493
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 1.9921403691114392e-06
have O 0 3.7625708104727096e-10
" O 0 1.1662133481138426e-09
multiple O 0 4.497135108749717e-08
" O 0 0.0018707436975091696
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 6.79685214777237e-08
typically O 0 1.1753914508361163e-09
fewer O 0 1.5718511214846131e-10
than O 0 1.6262623192542236e-11
100 O 0 5.5172214019627575e-11
) O 0 1.0089447723474199e-12
without O 0 2.06958582216199e-11
the O 0 4.2490337637257625e-11
florid O 0 3.280335114652644e-09
phenotype O 0 1.7157215925767133e-10
of O 0 1.274907179826812e-09
classical O 0 3.1571434533361753e-07
FAP B-Disease 0 4.6122721641950193e-07
. O 0 1.003115812636679e-07

Another O 0 2.4184231506296783e-07
group O 0 4.56521753733341e-09
of O 0 3.568100481743386e-08
patients O 0 6.096016136325488e-09
with O 0 7.823286463093382e-10
multiple O 0 1.0678718354029115e-06
adenomas B-Disease 0 0.4167311191558838
has O 0 1.2435801721721873e-08
no O 0 3.2003819594450533e-09
mutations O 0 3.321647956688878e-10
in O 0 7.715848515665868e-10
the O 0 2.8586280009790244e-09
APC B-Disease 0 1.1112904374499522e-08
gene O 0 1.956257156265906e-09
, O 0 2.792134856655082e-10
and O 0 6.113021200349067e-11
their O 0 3.71849287472692e-11
phenotype O 0 2.904513018986421e-10
probably O 0 2.1687759921285021e-10
results O 0 5.873040942461216e-11
from O 0 1.7991104439563088e-10
variation O 0 6.808384522827282e-09
at O 0 3.476508680932966e-08
a O 0 6.493455773082246e-10
locus O 0 6.019685860891855e-10
, O 0 2.3323598608016027e-10
or O 0 4.312161391850644e-11
loci O 0 2.825699674247062e-10
, O 0 7.739486135305285e-11
elsewhere O 0 2.863297376975993e-10
in O 0 1.0419803214700707e-10
the O 0 1.5347665360820884e-09
genome O 0 4.912958040392823e-09
. O 0 6.163195820363399e-08

Recently O 0 1.3256812962936237e-06
, O 0 7.282878744518939e-09
however O 0 2.8613882374628474e-09
, O 0 2.6365054583976644e-10
a O 0 1.2265808368994158e-09
missense O 0 5.296980276625618e-08
variant O 0 7.846112737297517e-08
of O 0 1.3803814908897039e-05
APC B-Disease 0 3.423104772082297e-06
( O 0 1.1595465920777315e-08
I1307K O 0 2.5008813508975436e-07
) O 0 4.3717740538795624e-10
was O 0 2.617358418888216e-08
described O 0 1.1086096485257713e-09
that O 0 3.4196282958087743e-12
confers O 0 1.6809358072134017e-10
an O 0 1.3375579940508309e-12
increased O 0 4.600579639468805e-11
risk O 0 1.2031601492878963e-08
of O 0 0.0007173273479565978
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.3046493424772052e-07
including O 0 2.1343347089697318e-09
multiple O 0 6.881695924221276e-08
adenomas B-Disease 0 0.004590411204844713
, O 0 2.8016922115625675e-08
in O 0 1.7511061400909966e-07
Ashkenazim O 0 0.0009016928379423916
. O 0 2.617813379401923e-06

We O 0 4.4770655449610786e-07
have O 0 7.35732030854308e-10
studied O 0 3.7649865447519915e-08
a O 0 2.4351901051211655e-10
set O 0 2.562553780283139e-10
of O 0 1.3473763771365554e-10
164 O 0 5.346937337336044e-10
patients O 0 1.1185578158157128e-10
with O 0 1.254145398643658e-10
multiple O 1 0.9999116659164429
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9951776266098022
/ I-Disease 1 0.9999847412109375
or I-Disease 0 0.0004024510853923857
carcinoma I-Disease 1 1.0
and O 0 5.976423835818423e-07
analyzed O 0 4.5290019556887273e-07
codons O 0 1.7197997692619538e-07
1263 O 0 2.0028728613397107e-06
- O 0 9.497581743289629e-08
1377 O 0 3.975731488026213e-06
( O 0 5.021183913100913e-09
exon O 0 3.2447121611767216e-07
15G O 0 6.552259605996369e-07
) O 0 3.6413663750956005e-10
of O 0 9.372901565996017e-09
the O 0 1.0524456861560338e-08
APC B-Disease 0 1.3124486031301785e-07
gene O 0 2.5083377153123365e-08
for O 0 1.2422122885880071e-08
germ O 0 2.2838426957605407e-05
- O 0 8.106964344278822e-08
line O 0 1.5560518207280438e-08
variants O 0 2.5398614766913852e-08
. O 0 1.8698568027275542e-08

Three O 0 1.437091725620121e-07
patients O 0 8.506934712215752e-09
with O 0 1.324356180276709e-10
the O 0 2.093196727059876e-09
I1307K O 0 7.395254186803868e-09
allele O 0 3.824243421934881e-10
were O 0 1.8073684215913488e-10
detected O 0 8.760863146051179e-10
, O 0 6.035233944545748e-12
each O 0 2.1716339664024087e-12
of O 0 3.611988763640994e-10
Ashkenazi O 0 2.1125059035398408e-08
descent O 0 4.467239307359705e-07
. O 0 2.0765129704614083e-07

Four O 0 1.276396460525575e-06
patients O 0 7.013730964899878e-07
had O 0 3.275741562447365e-07
a O 0 8.767424475308871e-08
germ O 0 3.567033490980975e-05
- O 0 2.0713429194074706e-07
line O 0 1.2830633977500838e-07
E1317Q O 0 1.6628384003070096e-07
missense O 0 6.594033408191535e-08
variant O 0 5.344209697000224e-08
of O 0 1.1760405982386146e-07
APC O 0 9.641425435802375e-08
that O 0 8.706541043679294e-10
was O 0 1.4367897094302862e-08
not O 0 5.985050649526258e-11
present O 0 5.0841084814345905e-11
in O 0 9.160170538757839e-11
controls O 0 2.225547035550335e-08
; O 0 5.799372440606909e-11
one O 0 7.393243656172999e-11
of O 0 1.2861225417992728e-09
these O 0 3.206904533592514e-11
individuals O 0 7.235626160728703e-12
had O 0 6.217396042451639e-10
an O 0 2.959386555256849e-11
unusually O 0 1.4120732361178057e-10
large O 0 2.1664966695644772e-11
number O 0 6.466829849394173e-11
of O 0 5.175773143406559e-09
metaplastic B-Disease 0 9.054929250851274e-07
polyps I-Disease 0 1.324489318221822e-07
of I-Disease 0 8.987191080223056e-08
the I-Disease 0 8.052042232975509e-08
colorectum I-Disease 0 2.051623960142024e-05
. O 0 2.4671666665199155e-07

There O 0 1.507427214164636e-07
is O 0 8.525203876175169e-10
increasing O 0 2.2189919346438103e-10
evidence O 0 4.683970988850206e-10
that O 0 5.684737403033324e-12
there O 0 4.39465408508255e-11
exist O 0 7.390991707545425e-10
germ O 0 1.2253121894900687e-07
- O 0 1.5458571089865814e-09
line O 0 8.335218626420726e-10
variants O 0 1.1382293996220483e-09
of O 0 1.7244131678140207e-09
the O 0 2.3634487700263662e-09
APC B-Disease 0 1.4583974028425928e-08
gene O 0 3.456599007023442e-09
that O 0 1.5119745733205292e-10
predispose O 0 6.605750613175587e-09
to O 0 1.8344092911348753e-10
the O 0 1.2705951568658946e-10
development O 0 1.546001549002085e-09
of O 0 5.164031691151649e-08
multiple O 1 0.9999970197677612
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
, O 0 2.2478091068478534e-06
but O 0 1.2927785064675845e-08
without O 0 7.26922300131605e-09
the O 0 2.240521101981585e-09
florid O 0 8.572907717052658e-08
phenotype O 0 6.324913925936926e-10
of O 0 2.3683945915564664e-09
classical O 0 1.052638793908045e-07
FAP B-Disease 0 5.513902667786397e-09
, O 0 8.559546127440143e-11
and O 0 1.0523236795845214e-11
possibly O 0 1.0066622535553904e-10
with O 0 6.131152009702934e-12
importance O 0 1.472826482995515e-07
for O 0 7.0238243097264785e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0003289346641395241
in O 0 2.961241696297634e-09
the O 0 7.520940537020238e-10
general O 0 1.3396713738345056e-09
population O 0 3.4999412222569415e-12
. O 0 1.9050840072143416e-10
. O 0 8.39723313106333e-09

Genomic O 0 2.6475752292753896e-06
structure O 0 5.253093036117207e-07
of O 0 6.701708343825885e-08
the O 0 2.5468080977475438e-08
human O 0 0.25946930050849915
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.0006627999828197062
CLD B-Disease 1 0.9997592568397522
) O 0 1.924757775384478e-08
gene O 0 1.1256543075433001e-07
. O 0 1.5150916965467331e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9876406788825989
CLD B-Disease 1 0.9999984502792358
) O 0 8.709783116955805e-09
is O 0 2.3767607326696805e-10
caused O 0 2.3892737788244744e-10
by O 0 7.593928957883023e-12
mutations O 0 4.621883709088337e-10
in O 0 8.399358430999371e-10
a O 0 3.8920758282934287e-10
gene O 0 1.0869385252965102e-10
which O 0 3.929864073048961e-11
encodes O 0 1.8630340326009076e-10
an O 0 2.222978190413727e-10
intestinal O 0 4.294367045076797e-06
anion O 0 1.020797071760171e-06
transporter O 0 9.882009180728346e-05
. O 0 1.1299430298095103e-06

We O 0 2.0732599637085514e-07
report O 0 8.151554098390079e-09
here O 0 1.8084590491795893e-09
the O 0 1.0631742014544088e-10
complete O 0 3.193020847724881e-10
genomic O 0 1.1816155831567698e-09
organization O 0 3.593188802053504e-10
of O 0 2.4959898592413765e-09
the O 0 3.741162046821955e-09
human O 0 3.66559227416019e-08
CLD B-Disease 0 5.156943643669365e-06
gene O 0 1.167068308660646e-08
which O 0 9.23970011612596e-10
spans O 0 8.959734287827814e-09
approximately O 0 8.185511296554537e-11
39kb O 0 9.799736133686565e-09
, O 0 4.720489277243445e-11
and O 0 6.056686402411415e-11
comprises O 0 1.7189160095298917e-09
21 O 0 8.213626045971978e-08
exons O 0 8.353869702659722e-07
. O 0 3.967009263305954e-07

All O 0 6.266261038945231e-07
exon O 0 3.097469380008988e-05
/ O 0 6.247099918255117e-06
intron O 0 1.3821188986185007e-05
boundaries O 0 1.680774772694349e-07
conform O 0 2.413170250292751e-07
to O 0 1.0288857765772264e-08
the O 0 2.3354115086249294e-08
GT O 0 3.965245923609473e-06
/ O 0 2.4342789401998743e-06
AG O 0 1.1203886970179155e-05
rule O 0 5.313382871463546e-07
. O 0 2.060723005570253e-07

An O 0 1.080537970210571e-08
analysis O 0 1.1790610265904888e-08
of O 0 1.9921650107335154e-08
the O 0 1.15955103296983e-08
putative O 0 2.0024134528284776e-07
promoter O 0 5.8966597862308845e-06
region O 0 3.2530401483654714e-08
sequence O 0 1.1930071153187782e-08
shows O 0 5.889056708952012e-08
a O 0 3.055458464018557e-08
putative O 0 4.0347410390495497e-07
TATA O 0 9.661279364081565e-06
box O 0 2.3584211703564506e-06
and O 0 2.1578520303933146e-08
predicts O 0 4.0027885006566066e-08
multiple O 0 4.17472989511225e-09
transcription O 0 5.6111730373231694e-08
factor O 0 7.43801775726638e-09
binding O 0 6.870702229377912e-09
sites O 0 2.7319979167828023e-08
. O 0 1.275599146310924e-07

The O 0 7.120309675201497e-08
genomic O 0 2.1108874648234632e-07
structure O 0 2.2206798178103782e-07
was O 0 8.74697931863011e-08
determined O 0 3.1009108614199477e-09
using O 0 3.5144809285014844e-10
DNA O 0 3.4670957771432143e-10
from O 0 4.663696512308135e-11
several O 0 5.5814237780171805e-12
sources O 0 7.322610573456956e-11
including O 0 4.686826014094203e-12
multiple O 0 1.3945737620257859e-10
large O 0 2.1615953471609828e-09
- O 0 3.1598961669487835e-08
insert O 0 2.459507619789747e-08
libaries O 0 5.470917017191823e-07
and O 0 2.896253514794722e-10
genomic O 0 2.0887378493483766e-09
DNA O 0 6.469324520530506e-10
from O 0 7.046576655511672e-10
Finnish O 0 1.71462343132589e-05
CLD B-Disease 0 0.09382717311382294
patients O 0 1.1287017542827016e-07
and O 0 4.747247039915692e-09
controls O 0 4.4161015466670506e-06
. O 0 2.0988633764318365e-07

Exon O 0 1.8156533769797534e-05
- O 0 8.394290063051812e-08
specific O 0 1.5899314087519656e-09
primers O 0 1.5137333164716438e-08
developed O 0 1.044223152391055e-09
in O 0 1.81074200772402e-11
this O 0 2.1657686494896966e-12
study O 0 1.8416396879716856e-12
will O 0 2.658589494386465e-13
facilitate O 0 9.74020170074752e-12
mutation O 0 2.796070666666317e-12
screening O 0 9.621939356385667e-11
studies O 0 1.6439899441778039e-10
of O 0 1.8271530122238033e-10
patients O 0 1.4187793995201758e-10
with O 0 1.1585742781816677e-11
the O 0 4.331983660676997e-09
disease O 0 3.03241563415213e-07
. O 0 1.1480151940190808e-08

Genomic O 0 3.3665551768535806e-07
sequencing O 0 1.2517656955424172e-07
of O 0 1.52126972352562e-06
a O 0 1.989387556022848e-06
BAC O 1 0.9882060289382935
clone O 0 9.491987293586135e-05
H O 1 0.9999998807907104
_ O 0 1.1109496966810184e-07
RG364P16 O 0 1.6076440090273536e-07
revealed O 0 2.7261211954510145e-08
the O 0 8.137445162148538e-10
presence O 0 1.0125630334201219e-09
of O 0 1.0477228862271204e-08
another O 0 7.18676451683109e-10
, O 0 1.0363928465428884e-10
highly O 0 5.040564632352584e-10
homologous O 0 1.6435488525701203e-09
gene O 0 5.726950025319866e-09
3 O 0 9.523339628003669e-08
of O 0 8.50787955641863e-08
the O 0 2.8340156177364406e-07
CLD B-Disease 0 0.0001639729889575392
gene O 0 5.640413291985169e-08
, O 0 9.84807457804493e-10
with O 0 9.587370480845792e-11
a O 0 4.132659492395163e-10
similar O 0 1.0512329201572967e-10
genomic O 0 4.932779518185271e-09
structure O 0 6.405458918834483e-08
, O 0 1.0179690423939292e-10
recently O 0 6.261366425341919e-11
identified O 0 4.7950272225039114e-11
as O 0 6.83802389711552e-11
the O 0 2.0612764828342733e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 9.073263527170639e-07
( O 0 8.44177971970339e-09
PDS B-Disease 0 1.4123301070867456e-06
) O 0 6.332880331250124e-10
. O 0 1.4666089453996278e-09
. O 0 2.1620376600139934e-08

The O 0 2.807502426094288e-07
APCI1307K O 0 3.263939288444817e-05
allele O 0 1.1917840225805776e-07
and O 0 2.4579542845515334e-09
cancer B-Disease 0 1.5105096906609106e-07
risk O 0 5.662885715906896e-09
in O 0 6.138097252694763e-10
a O 0 1.1416603218350474e-09
community O 0 2.803628509906453e-11
- O 0 1.481885031351382e-10
based O 0 1.9438102169533344e-11
study O 0 1.978642943933906e-11
of O 0 1.5547953202688092e-10
Ashkenazi O 0 3.6464002928227046e-09
Jews O 0 1.8954549041438895e-09
. O 0 4.944478604329561e-09

Mutations O 0 4.450952246770612e-07
in O 0 1.4038411322303546e-08
APC O 0 7.377140320841136e-08
are O 0 9.206658352356456e-11
classically O 0 7.326574547050768e-08
associated O 0 8.818566357149393e-07
with O 0 7.913064473541453e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.1201367417233996e-06
FAP B-Disease 0 2.1417788786948222e-07
) O 0 4.5886286437202273e-10
, O 0 8.587672933879631e-11
a O 0 4.793612173870088e-10
highly O 0 2.0638708519982174e-06
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9678110480308533
by O 0 1.0162551689063548e-08
multiple O 0 2.1699013359466335e-06
intestinal O 1 0.9999885559082031
polyps B-Disease 0 1.8431584976497106e-05
and O 0 1.3913045826541293e-08
, O 0 4.5302067652741584e-10
without O 0 1.4720914265353713e-08
surgical O 1 0.9933307766914368
intervention O 0 0.0011678114533424377
, O 0 7.309340632755124e-11
the O 0 1.295435425596736e-10
development O 0 1.0044598042213693e-07
of O 1 0.9999703168869019
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 9.967474170480273e-07
CRC B-Disease 0 3.5097934869554592e-06
) O 0 1.55046653294022e-09
. O 0 1.528935378303231e-08

APC B-Disease 0 2.4569566448917612e-05
is O 0 1.9881818502653914e-07
a O 0 2.384987851655751e-07
tumour O 1 1.0
- O 0 1.2235143913130742e-05
suppressor O 0 1.3742912869929569e-06
gene O 0 1.4355103772345501e-08
, O 0 8.403156503966613e-10
and O 0 9.616420992841768e-10
somatic O 0 4.50728521173005e-07
loss O 0 1.3771222029390628e-07
occurs O 0 3.062069140469248e-07
in O 0 1.6700884941656113e-07
tumours B-Disease 1 1.0
. O 0 4.431030174600892e-05

The O 0 9.213236808136571e-06
germline O 0 4.888882176601328e-05
T O 0 7.87960016168654e-06
- O 0 2.7284153603091e-08
to O 0 1.0531238103794749e-09
- O 0 1.8323540462716892e-09
A O 0 1.6107394307240952e-09
transversion O 0 5.2556257124081185e-09
responsible O 0 4.4209366723002574e-10
for O 0 6.443780231624174e-11
the O 0 5.057562146859595e-10
APC O 0 1.037576602413992e-08
I1307K O 0 1.4310407969730932e-08
allele O 0 5.869124075630339e-10
converts O 0 1.460428666888447e-09
the O 0 2.7956681414309514e-10
wild O 0 1.552756395684085e-10
- O 0 9.802175043871486e-11
type O 0 2.4220253580509166e-10
sequence O 0 4.1875833356463943e-10
to O 0 3.876975962491258e-10
a O 0 5.7632094652149135e-09
homopolymer O 0 9.08058700588299e-06
tract O 0 1.1994698070338927e-05
( O 0 1.0666525440683472e-08
A8 O 0 4.402765227951022e-07
) O 0 1.8198420548287686e-10
that O 0 3.1853672477488715e-11
is O 0 7.478894586965268e-11
genetically O 0 1.307577601750154e-09
unstable O 0 2.368428795307409e-06
and O 0 1.3315482050302307e-08
prone O 0 7.758636684229714e-07
to O 0 4.084802718296032e-09
somatic O 0 2.4267549179057823e-06
mutation O 0 7.435353666096489e-08
. O 0 8.972563847464698e-08

The O 0 3.6707564277094207e-07
I1307K O 0 7.12881615072547e-07
allele O 0 4.2794919608013515e-08
was O 0 1.1115918852055984e-07
found O 0 5.953220694188133e-10
in O 0 1.193336540694645e-09
6 O 0 2.0489923713284952e-07
. O 0 9.798748834555226e-08

1 O 0 4.246502612659242e-06
% O 0 1.4494456301861192e-08
of O 0 3.066885057023683e-08
unselected O 0 0.0001442616485292092
Ashkenazi O 0 2.9981620741637016e-07
Jews O 0 3.3029998736111565e-09
and O 0 6.832261839617715e-11
higher O 0 1.1065942606691692e-09
proportions O 0 5.879760234250853e-09
of O 0 7.613810026896317e-09
Ashkenazim O 0 9.882668194904909e-08
with O 0 1.1609069261453442e-09
family O 0 1.8080485997273854e-09
or O 0 1.1307828284845556e-10
personal O 0 6.1318865540727074e-09
histories O 0 1.3848287849782537e-08
of O 0 6.432541681533621e-07
CRC B-Disease 0 2.2373196770786308e-05
( O 0 3.127479830666857e-09
ref O 0 2.0085717267193104e-07
. O 0 1.1339691408096542e-09
2 O 0 4.3261234594638154e-08
) O 0 8.816246621634605e-10
. O 0 1.6664667867871685e-08

To O 0 3.2247278625163744e-08
evaluate O 0 9.751485663400672e-08
the O 0 4.30371915882688e-09
role O 0 6.914018246817477e-09
of O 0 1.6268730362867245e-08
I1307K O 0 8.0738331575958e-08
in O 0 2.196481663219174e-09
cancer B-Disease 0 1.667315707720718e-08
, O 0 2.3104693158693124e-10
we O 0 7.027424198113863e-10
genotyped O 0 6.61225740827831e-08
5 O 0 8.057353895196684e-09
, O 0 1.185704201489557e-09
081 O 0 1.4808207424721331e-06
Ashkenazi O 0 5.87541393315405e-08
volunteers O 0 1.310382025110357e-08
in O 0 1.9905574966117e-09
a O 0 3.4572249507647257e-09
community O 0 9.006471679562367e-10
survey O 0 7.09882730376421e-09
. O 0 3.9956031372412326e-08

Risk O 0 2.113898062816588e-06
of O 0 1.737672278068203e-06
developing O 1 0.9443816542625427
colorectal B-Disease 1 1.0
, I-Disease 0 1.6485311107317102e-06
breast I-Disease 0 0.0078666927292943
and I-Disease 0 1.7439332111734984e-07
other I-Disease 0 4.023133115538258e-08
cancers I-Disease 1 0.9780248403549194
were O 0 6.219976000920724e-08
compared O 0 1.9429865716347194e-08
between O 0 1.1244504349861018e-07
genotyped O 0 2.06160734705918e-07
I1307K O 0 2.5395161529218058e-09
carriers O 0 2.4084989211359265e-11
and O 0 5.373769138006246e-12
non O 0 7.802185564287356e-10
- O 0 8.907737741870037e-11
carriers O 0 1.3237367799123767e-11
and O 0 7.816029941321023e-12
their O 0 3.3810326500322008e-12
first O 0 6.113149569886289e-11
- O 0 1.9857783473131718e-10
degree O 0 1.3036586032910691e-08
relatives O 0 3.5802130149420464e-09
. O 0 1.5408476272682492e-08

Sperm O 0 1.50292223111137e-08
DNA O 0 5.706461969623433e-09
analysis O 0 1.0903132841022511e-09
in O 0 4.481786053389669e-10
a O 0 1.4942242998472466e-08
Friedreich B-Disease 0 0.00034784633317030966
ataxia I-Disease 0 0.4328908920288086
premutation O 0 0.000565422757063061
carrier O 0 3.692930249599158e-06
suggests O 0 8.667330320122346e-08
both O 0 6.414651032571328e-09
meiotic O 0 3.941065187973436e-06
and O 0 3.0287261587602643e-09
mitotic O 0 7.06025176100411e-08
expansion O 0 2.976220159212062e-08
in O 0 4.206212711466151e-09
the O 0 7.800166734739378e-09
FRDA B-Disease 0 6.054285677237203e-06
gene O 0 1.0695826091478011e-07
. O 0 1.7629459136969672e-07

Friedreich B-Disease 1 0.9999892711639404
ataxia I-Disease 1 0.9999997615814209
is O 0 6.184266567288432e-06
usually O 0 2.037588409109503e-08
caused O 0 3.4316032238024263e-09
by O 0 2.165088074101984e-11
an O 0 1.7954722777990817e-11
expansion O 0 4.239817386064715e-09
of O 0 1.304002239521651e-07
a O 0 9.737620132455049e-08
GAA O 0 1.7068213082893635e-06
trinucleotide O 0 8.69134851200215e-07
repeat O 0 2.0447791015953953e-08
in O 0 1.2214452560499467e-08
intron O 0 7.98576763827441e-07
1 O 0 1.8909570087544125e-07
of O 0 3.2195714538829634e-08
the O 0 1.9946250873204008e-08
FRDA B-Disease 0 1.839227115851827e-05
gene O 0 1.5761675342673698e-07
. O 0 2.6216960691272106e-07

Occasionally O 0 1.255685447176802e-06
, O 0 8.239890547656614e-09
a O 0 1.1270776534288984e-09
fully O 0 1.2537538784940239e-09
expanded O 0 2.581765912168521e-10
allele O 0 2.7816737802055513e-10
has O 0 3.041238441636729e-11
been O 0 1.513116368312417e-11
found O 0 1.598135859759431e-11
to O 0 6.955381149503781e-12
arise O 0 2.792757969327653e-10
from O 0 1.6512179124017479e-10
a O 0 5.606535236069021e-10
premutation O 0 7.50122097770145e-08
of O 0 2.811767174648594e-08
100 O 0 2.456563485964125e-08
or O 0 2.621688866000227e-09
less O 0 1.805392635390035e-08
triplet O 0 1.3518202877094154e-06
repeats O 0 3.506136181385955e-07
. O 0 1.421628326170321e-07

We O 0 7.111710829121876e-07
have O 0 8.720833499786806e-10
examined O 0 2.054098047210573e-08
the O 0 5.708157280182036e-10
sperm O 0 1.439476315923116e-10
DNA O 0 3.8117761724798527e-10
of O 0 1.9142127882787463e-09
a O 0 3.4620026845288976e-09
premutation O 0 4.7028461835907365e-07
carrier O 0 4.211240423046547e-07
. O 0 1.709876187305781e-07

This O 0 3.874089671285219e-08
mans O 0 3.2692801141820382e-06
leucocyte O 0 2.9936478540548705e-07
DNA O 0 4.2047769710507055e-09
showed O 0 1.5114910434377293e-09
one O 0 2.4535767514932694e-11
normal O 0 4.3741596456037257e-10
allele O 0 1.1556793022560186e-10
and O 0 1.5401166453266057e-11
one O 0 4.748489362133013e-12
allele O 0 4.263760872147415e-11
of O 0 8.086910585625162e-10
approximately O 0 1.743188926539574e-10
100 O 0 1.4022882854902718e-09
repeats O 0 1.025664531084658e-08
. O 0 1.4154777794317397e-08

His O 0 1.3510766621038783e-06
sperm O 0 1.361145240963424e-08
showed O 0 3.5888412242002232e-09
an O 0 1.956214183695959e-11
expanded O 0 7.800039780736512e-11
allele O 0 2.5962987315608643e-10
in O 0 5.13535547419508e-10
a O 0 2.436431723040755e-09
tight O 0 4.832329025816762e-08
range O 0 9.313078308537115e-09
centering O 0 2.379212560299493e-08
on O 0 3.802795411900206e-09
a O 0 2.6154595156313576e-10
size O 0 2.633680773467262e-10
of O 0 1.235314739389537e-09
approximately O 0 6.859725565355745e-10
320 O 0 1.0193282662385172e-08
trinucleotide O 0 9.791459660846158e-07
repeats O 0 1.4091399691551487e-07
. O 0 1.0463932653692609e-07

His O 0 4.823507424589479e-06
affected O 0 4.785770215676166e-07
son O 0 4.4254061322135385e-06
has O 0 5.212824061295862e-10
repeat O 0 1.602575627757119e-09
sizes O 0 1.5744473502721235e-09
of O 0 5.207599240719674e-09
1040 O 0 1.3872271154014015e-07
and O 0 5.820055104521771e-09
540 O 0 1.6099330935048783e-07
. O 0 4.188921565173587e-08

These O 0 1.9208765689171514e-09
data O 0 5.364233501836679e-09
suggest O 0 4.6036016665418344e-10
that O 0 4.408806653088959e-12
expansion O 0 2.6685001430770683e-10
occurs O 0 9.564083552904279e-11
in O 0 5.239676054147324e-11
two O 0 4.934854261340327e-11
stages O 0 1.1518508369334768e-09
, O 0 2.3306643073817135e-11
the O 0 9.842003600990523e-11
first O 0 2.1804268113267966e-10
during O 0 2.002369825504502e-09
meiosis O 0 2.1749118062075468e-09
followed O 0 4.865842173629176e-10
by O 0 8.49358292032143e-11
a O 0 1.1891649887019184e-09
second O 0 3.976661666627024e-09
mitotic O 0 5.2548465134805156e-08
expansion O 0 2.7815210046355787e-07
. O 0 7.809501312294742e-07

We O 0 1.513609930725579e-07
also O 0 8.360917513883237e-10
show O 0 5.776920053435219e-10
that O 0 5.644017805200852e-12
in O 0 2.2253143772132944e-11
all O 0 2.0994641788951718e-11
informative O 0 3.7543196329536954e-10
carrier O 0 3.709780815874808e-10
father O 0 1.357582046779271e-09
to O 0 1.983015279760636e-10
affected O 0 8.801226969445963e-10
child O 0 1.2292982631834093e-08
transmissions O 0 5.711484618586837e-08
, O 0 8.617173641312093e-11
with O 0 1.3361383180421349e-11
the O 0 2.0862843397306818e-10
notable O 0 1.975600932846433e-10
exception O 0 7.163321602554618e-10
of O 0 9.140912027305603e-09
the O 0 7.654915812338459e-09
premutation O 0 5.025834184380074e-07
carrier O 0 1.3877240689907921e-08
, O 0 1.7802066765160163e-10
the O 0 3.0146560248134335e-10
expansion O 0 2.3950146310625087e-09
size O 0 9.143104051645423e-10
decreases O 0 5.695653726434102e-09
. O 0 1.4207108822716918e-09
. O 0 3.4688124372905804e-08

The O 0 4.518087735050358e-07
R496H O 0 2.743685627137893e-06
mutation O 0 1.2680010819110521e-08
of O 0 8.036008836143083e-08
arylsulfatase O 0 2.1748943254351616e-05
A O 0 3.3174825375681394e-07
does O 0 1.5657716234684926e-09
not O 0 1.162721807723699e-09
cause O 0 3.8709066529918346e-07
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
. O 0 5.9212961787125096e-06

Deficiency B-Disease 1 0.9996391534805298
of I-Disease 0 0.007944087497889996
arylsulfatase I-Disease 1 0.9963659048080444
A I-Disease 0 5.18829510838259e-05
( O 0 4.496429895084475e-09
ARSA O 0 2.755233026618953e-06
) O 0 1.0840957992419575e-10
enzyme O 0 4.975707845744637e-09
activity O 0 8.517102401128795e-08
causes O 0 8.17108139017364e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 9.988893907575402e-07
MLD B-Disease 1 0.9999984502792358
) O 0 9.004812540069906e-08
. O 0 1.222520182864173e-07

A O 0 4.2246193743267213e-07
number O 0 9.380878296383344e-09
of O 0 1.769884789837306e-07
ARSA O 0 0.0001688769116299227
gene O 0 8.532060746802017e-08
mutations O 0 8.038871790461144e-09
responsible O 0 1.50127483777851e-08
for O 0 7.754536568427284e-09
MLD B-Disease 1 1.0
have O 0 2.829546597027388e-09
been O 0 2.0727471128356711e-10
identified O 0 1.8767090104176987e-09
. O 0 4.684884480354867e-09

Recently O 0 8.571138891966257e-07
, O 0 8.383230110098339e-09
the O 0 2.494024542443185e-09
R496H O 0 7.795767231755235e-08
mutation O 0 2.7289914772410384e-09
of O 0 3.473890686223058e-08
ARSA O 0 4.778565562446602e-05
was O 0 8.063919949563569e-07
proposed O 0 2.155256417779583e-08
to O 0 1.5306561573780186e-09
be O 0 8.025478059892066e-10
a O 0 1.0374158199155659e-09
cause O 0 9.209617957139926e-09
of O 0 3.619137203259015e-07
MLD B-Disease 1 1.0
( O 0 1.579802599849245e-08
Draghia O 0 1.4440641962210066e-06
et O 0 7.151982686082192e-07
al O 0 1.388492449905243e-07
. O 0 1.189373710630548e-09
, O 0 2.2694483792218278e-10
1997 O 0 3.1254523413792867e-09
) O 0 1.7782900707530302e-09
. O 0 8.953212216056272e-08

We O 0 3.662909193735686e-07
have O 0 1.0220687629569625e-09
investigated O 0 3.153067140715393e-09
the O 0 2.4834947986995815e-10
R496H O 0 3.594993414068881e-09
mutation O 0 5.187845986132089e-11
and O 0 1.3261273155984465e-11
found O 0 9.553849898702449e-12
this O 0 7.672572971927083e-13
mutation O 0 8.929830833115382e-12
at O 0 7.09989400604627e-10
a O 0 5.301722949546672e-11
relatively O 0 4.9365674742452015e-11
high O 0 5.54711485079018e-11
frequency O 0 1.543649513768841e-10
in O 0 1.5106076112214595e-11
an O 0 1.692845082862382e-12
African O 0 8.861690027617275e-12
American O 0 8.199664038033294e-12
population O 0 3.1551901391070614e-13
( O 0 3.3425922620067272e-12
f O 0 8.44124858900841e-09
= O 0 2.9185807104425976e-09
0 O 0 1.5084872240223035e-09
. O 0 7.743827107331569e-11
09 O 0 7.011762281905476e-09
, O 0 8.099198534061713e-10
n O 0 3.4166035334237677e-08
= O 0 2.438217983069535e-08
61 O 0 5.439168049292675e-08
subjects O 0 1.4864292552374536e-07
) O 0 4.691188326688689e-09
. O 0 6.451500667026266e-08

The O 0 1.9903172869817354e-06
ARSA O 0 5.060656985733658e-05
enzyme O 0 4.081159943325474e-08
activity O 0 2.042713020955489e-08
in O 0 1.1680075795439393e-09
subjects O 0 1.4359212485715034e-08
with O 0 6.688329057258358e-11
and O 0 7.106867871975453e-11
without O 0 1.6851314788013383e-10
the O 0 1.8463582052152816e-10
R496H O 0 1.2942777960489593e-09
mutation O 0 2.8847734964698724e-11
was O 0 4.518671214981396e-09
determined O 0 5.5702016332759285e-09
and O 0 2.0996654415128546e-10
found O 0 2.42416975382298e-10
to O 0 1.1395429738714213e-10
be O 0 5.976851236155767e-10
normal O 0 1.9020512809220236e-07
. O 0 9.307274950742794e-08

It O 0 4.268217779213046e-08
is O 0 1.3467861270655135e-09
therefore O 0 8.045371591158812e-10
concluded O 0 1.4401362324889533e-09
that O 0 9.175309817477384e-12
the O 0 1.175861769064923e-10
R496H O 0 1.3590906178251316e-08
mutation O 0 7.102968768712969e-10
of O 0 1.2144250938206369e-08
ARSA O 0 3.3050669117073994e-06
does O 0 1.3684803290558989e-09
not O 0 8.804210832602521e-11
negatively O 0 2.1857440857253607e-10
influence O 0 2.2206401162350176e-09
the O 0 7.758404335644897e-11
activity O 0 3.9781469785005186e-10
of O 0 3.805618042918013e-09
ARSA O 0 4.0390132198808715e-06
and O 0 2.9305462501127977e-09
is O 0 1.165314372775228e-10
not O 0 7.653083722303222e-11
a O 0 9.480886076218553e-10
cause O 0 5.085949084104868e-08
of O 0 4.226298187859356e-06
MLD B-Disease 1 1.0

Down O 0 7.972535058797803e-06
- O 0 1.1251562881398058e-07
regulation O 0 1.1509776953744222e-07
of O 0 3.7461404645000584e-08
transmembrane O 0 8.945672789195669e-07
carbonic O 0 7.803829066688195e-05
anhydrases O 0 3.492676478344947e-05
in O 0 6.022700063113007e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999986886978149
lines O 0 6.097495770518435e-07
by O 0 6.704553578984473e-10
wild O 0 8.020616171222628e-09
- O 0 2.3740991395015953e-08
type O 0 3.213724630768411e-05
von B-Disease 1 0.9999953508377075
Hippel I-Disease 1 0.9999732971191406
- I-Disease 1 0.9999005794525146
Lindau I-Disease 1 0.9984164237976074
transgenes O 0 0.0010142062092199922
. O 0 1.8492095250621787e-06

To O 0 1.1373253983038012e-07
discover O 0 5.867630292755166e-08
genes O 0 9.33178423423442e-09
involved O 0 1.1524863730016932e-08
in O 0 1.931104520735971e-08
von B-Disease 1 0.999408483505249
Hippel I-Disease 1 0.999994158744812
- I-Disease 1 0.9999995231628418
Lindau I-Disease 1 0.9999992847442627
( O 0 1.3822026403431664e-06
VHL B-Disease 0 0.0005683182971552014
) O 0 1.3991797231938108e-07
- O 0 6.982143531786278e-06
mediated O 0 0.0914996787905693
carcinogenesis O 1 0.9999741315841675
, O 0 1.3108520491300624e-08
we O 0 1.3162604339811423e-09
used O 0 3.118594094075888e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999990463256836
lines O 0 0.0002601661253720522
stably O 0 4.937402991345152e-05
transfected O 0 2.114364718863726e-07
with O 0 7.282263680963297e-10
wild O 0 2.8992619416357e-09
- O 0 4.9787742817386516e-09
type O 0 2.2713091141213226e-07
VHL O 0 2.735035195655655e-05
- O 0 3.6229289435141254e-07
expressing O 0 1.0022261243136654e-08
transgenes O 0 2.2581652956432663e-06
. O 0 9.57875627705107e-08

Large O 0 2.731748907081055e-07
- O 0 1.6286246307117835e-07
scale O 0 2.695893499549129e-07
RNA O 0 2.143666399945232e-08
differential O 0 6.177212696911738e-08
display O 0 2.6290949417528964e-09
technology O 0 9.295669123332573e-09
applied O 0 4.39672076524289e-09
to O 0 3.0582352622543496e-11
these O 0 3.3649489444842473e-12
cell O 0 4.412251397578615e-10
lines O 0 4.2361995855610957e-11
identified O 0 1.0380758752592811e-11
several O 0 1.432255789662884e-12
differentially O 0 1.1872181016059358e-09
expressed O 0 6.57526116887297e-11
genes O 0 4.875045506169684e-11
, O 0 1.3122784109365071e-11
including O 0 8.271086072986211e-12
an O 0 7.969643694982764e-11
alpha O 0 2.396694526396459e-06
carbonic O 0 0.00019795606203842908
anhydrase O 0 0.00017701482283882797
gene O 0 1.889511338504235e-07
, O 0 1.6027660976192237e-08
termed O 0 1.063903368958563e-06
CA12 O 0 0.00018779454694595188
. O 0 1.521382841929153e-06

The O 0 3.454953230175306e-07
deduced O 0 3.426517594107281e-07
protein O 0 6.712528310970356e-09
sequence O 0 1.6924409651508654e-09
was O 0 8.982012467129152e-09
classified O 0 1.8229489029408796e-09
as O 0 4.020421218164927e-10
a O 0 9.976711679016148e-10
one O 0 1.0453828913625784e-09
- O 0 3.0239597492709436e-08
pass O 0 5.5381160990464195e-08
transmembrane O 0 8.64498929331603e-07
CA O 0 1.5750210877740756e-06
possessing O 0 1.28933876908377e-07
an O 0 7.06362635050084e-10
apparently O 0 2.2118403109061546e-08
intact O 0 1.6960191473458508e-08
catalytic O 0 6.953312237101272e-08
domain O 0 6.861407086944382e-08
in O 0 4.2233683217318685e-09
the O 0 6.43887299034418e-09
extracellular O 0 7.991222446435131e-06
CA O 0 5.952223000349477e-05
module O 0 2.3959126338013448e-05
. O 0 4.139417342230445e-07

Reintroduced O 0 7.020328212092863e-06
wild O 0 5.348054514797695e-07
- O 0 5.397735094447853e-07
type O 0 1.7952511370822322e-06
VHL B-Disease 0 1.7394533642800525e-05
strongly O 0 1.1334680749541803e-08
inhibited O 0 2.906459517504345e-09
the O 0 4.983379819911704e-10
overexpression O 0 5.599142927081857e-09
of O 0 4.911365092397091e-09
the O 0 1.1368429531088964e-09
CA12 O 0 2.2537625454788213e-07
gene O 0 2.939215815178642e-10
in O 0 3.901766063019174e-11
the O 0 1.1979790770499932e-10
parental O 0 8.480936486421342e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999953508377075
lines O 0 0.00027714305906556547
. O 0 1.9469246126391226e-06

Similar O 0 5.248683709879742e-09
results O 0 1.480154221411567e-09
were O 0 1.9051457633700863e-10
obtained O 0 3.9019765196712797e-10
with O 0 5.4595626630682403e-11
CA9 O 0 5.577663159783697e-06
, O 0 8.757455316477092e-10
encoding O 0 2.815110455856029e-08
another O 0 6.221518589200059e-08
transmembrane O 0 9.593371714800014e-07
CA O 0 5.50403797205945e-07
with O 0 6.034549526745536e-10
an O 0 1.099927815495505e-09
intact O 0 2.847629616553604e-07
catalytic O 0 9.607132369637839e-07
domain O 0 3.228363993912353e-06
. O 0 4.380442248930194e-07

Although O 0 3.614170509536052e-07
both O 0 2.6787935425431897e-08
domains O 0 7.50799017623649e-07
of O 0 9.471564226259943e-07
the O 0 2.213490972735599e-07
VHL B-Disease 0 2.677428346942179e-05
protein O 0 3.4384846969715e-08
contribute O 0 2.7932387514084667e-09
to O 0 9.80496572822176e-10
regulation O 0 2.728405661400757e-07
of O 0 5.522304746818918e-08
CA12 O 0 5.14653766003903e-06
expression O 0 8.60888693665629e-09
, O 0 6.954296860595122e-11
the O 0 2.0567501868296034e-10
elongin O 0 1.4817424620616748e-08
binding O 0 3.6324681040866835e-09
domain O 0 7.306368132731222e-08
alone O 0 1.762061074828125e-08
could O 0 1.01470132296555e-09
effectively O 0 1.843203634166457e-08
regulate O 0 1.3545415811222483e-07
CA9 O 0 9.250877337763086e-05
expression O 0 3.083137869452912e-07
. O 0 3.0398979333767784e-07

We O 0 4.3820637074531987e-07
mapped O 0 6.376861279022705e-07
CA12 O 0 2.397979005763773e-05
and O 0 3.511911472742213e-08
CA9 O 0 4.964305117027834e-05
loci O 0 5.6025641015367e-08
to O 0 2.2289869949787544e-09
chromosome O 0 9.831848046815139e-08
bands O 0 7.61063390086747e-08
15q22 O 0 2.436916872738948e-07
and O 0 4.264871122927616e-09
17q21 O 0 3.8868017782078823e-07
. O 0 3.3532121079815624e-08

2 O 0 5.474349109135801e-06
respectively O 0 3.699948649682483e-07
, O 0 5.678720604862519e-09
regions O 0 9.710426240872039e-09
prone O 0 7.720802130961602e-08
to O 0 1.7743657931834633e-10
amplification O 0 2.3279799421516145e-08
in O 0 1.306854402471913e-09
some O 0 2.719377778515053e-10
human O 0 1.2746840916122437e-08
cancers B-Disease 0 1.1427998288127128e-05
. O 0 7.272637958521955e-08

Additional O 0 1.3815500210512255e-07
experiments O 0 5.716040050174342e-07
are O 0 1.848031727647026e-10
needed O 0 1.6432886162931482e-09
to O 0 5.044332312964528e-11
define O 0 1.1944165656530004e-08
the O 0 1.7591285095264197e-09
role O 0 3.5828723099484705e-08
of O 0 2.723326133491355e-07
CA O 0 3.496430053928634e-06
IX O 0 2.536939427955076e-05
and O 0 4.9928132739296416e-08
CA O 0 3.50060673781627e-07
XII O 0 5.392980142460146e-07
enzymes O 0 3.655360181209488e-10
in O 0 6.368638949538763e-10
the O 0 2.7767280141866024e-10
regulation O 0 9.45531919427367e-09
of O 0 1.9061501266293135e-09
pH O 0 2.6259291630026382e-08
in O 0 1.4745861198761645e-09
the O 0 1.1051409787299349e-09
extracellular O 0 6.852317113725803e-08
microenvironment O 0 1.8914873578523839e-07
and O 0 4.4407041932537084e-10
its O 0 1.3494537952352115e-11
potential O 0 1.3211998162176997e-10
impact O 0 2.3248283298471506e-09
on O 0 6.418985520895149e-08
cancer B-Disease 0 1.172857437836683e-07
cell O 0 9.517020771454554e-08
growth O 0 4.022104960199613e-08
. O 0 8.997825062806442e-08

A O 0 7.022371164566721e-07
gene O 0 4.5622080335760984e-08
encoding O 0 9.806150274016545e-07
a O 0 4.004507161425863e-07
transmembrane O 0 7.415405320898572e-07
protein O 0 3.299519235611115e-08
is O 0 4.76568610963124e-11
mutated O 0 5.7796940844401234e-11
in O 0 2.402607453266814e-11
patients O 0 8.278054908217314e-10
with O 0 6.207353919762681e-08
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9990259408950806
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.112807682256971e-08
. O 0 1.6328453966707457e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0007741145673207939
WFS B-Disease 1 0.9940949082374573
; O 0 4.896010068478063e-07
OMIM O 0 0.00011844637629110366
222300 O 0 1.8873065528168809e-06
) O 0 2.6152799370571245e-10
is O 0 6.90103391098873e-11
an O 0 1.1352806472686439e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999961853027344
defined O 0 5.7022219834834686e-08
by O 0 1.9408324947178812e-10
young O 0 2.7093043364345704e-09
- O 0 6.469799984643032e-08
onset O 1 0.9991390705108643
non O 1 0.9991523027420044
- O 1 0.5923702120780945
immune O 0 0.0994093269109726
insulin B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.5315719246864319
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 9.228541603079066e-05

Linkage O 0 8.92787011252949e-06
to O 0 5.050375762039039e-08
markers O 0 2.502021345662797e-07
on O 0 5.349901357476483e-07
chromosome O 0 2.1544649371207925e-06
4p O 0 2.456427137076389e-05
was O 0 1.2079904365691618e-07
confirmed O 0 9.950054113971873e-09
in O 0 9.122340660638883e-10
five O 0 1.1291496626597564e-09
families O 0 8.611900081945123e-11
. O 0 1.6065428098954726e-08

On O 0 6.446039719776309e-07
the O 0 1.0212430012757068e-08
basis O 0 4.349272231252144e-08
of O 0 2.4860563385686874e-08
meiotic O 0 2.828865217452403e-05
recombinants O 0 2.8580230718944222e-05
and O 0 1.388642889565972e-08
disease O 0 2.2166752842167625e-06
- O 0 7.599068929664554e-09
associated O 0 8.270360751794215e-08
haplotypes O 0 2.92676958224547e-07
, O 0 3.462735653769755e-09
the O 0 3.581594398838206e-08
WFS B-Disease 0 2.3112721464713104e-05
gene O 0 2.025788425896735e-08
was O 0 2.011063600093621e-07
localized O 0 2.000336678520398e-07
to O 0 1.809308614042493e-08
a O 0 1.9109894822122442e-07
BAC O 0 0.00045766591210849583
/ O 0 3.8285028836071433e-07
P1 O 0 4.51344612883986e-06
contig O 0 1.2123789474571822e-06
of O 0 2.836853951748708e-08
less O 0 5.594850804868656e-09
than O 0 1.4430610872917526e-10
250 O 0 9.318813498637724e-10
kb O 0 5.409463597061404e-07
. O 0 1.1091732687873446e-07

Mutations O 0 6.729040933350916e-07
in O 0 3.097029122045569e-08
a O 0 6.806904373490852e-09
novel O 0 1.3232104301152958e-09
gene O 0 4.376111972792529e-10
( O 0 7.8904480171893e-11
WFS1 O 0 6.563379173485373e-08
) O 0 1.356411510888833e-10
encoding O 0 1.7126204454598337e-08
a O 0 3.3146012157203586e-08
putative O 0 1.3569309942340624e-07
transmembrane O 0 1.562270881549921e-07
protein O 0 3.157732919589762e-08
were O 0 1.8573474980243532e-09
found O 0 1.9361147407526147e-10
in O 0 3.566299339174961e-11
all O 0 2.4722309269198384e-11
affected O 0 3.132975476272115e-11
individuals O 0 6.285054074406382e-12
in O 0 2.840283841454294e-10
six O 0 6.288864984327347e-09
WFS B-Disease 0 2.0137113097007386e-06
families O 0 1.605769128776302e-10
, O 0 5.325458823923768e-11
and O 0 1.4372780743343583e-11
these O 0 7.650555536309334e-12
mutations O 0 4.5531429321288286e-11
were O 0 5.759731580567973e-11
associated O 0 4.610560822015941e-10
with O 0 3.297997985818313e-11
the O 0 8.233182136052619e-09
disease O 0 5.576932835538173e-07
phenotype O 0 1.8701349802086042e-08
. O 0 5.354279863922784e-08

WFS1 O 0 0.00027029149350710213
appears O 0 9.571706982569594e-08
to O 0 1.9846158050285112e-10
function O 0 3.1559008739634464e-09
in O 0 6.388006235091837e-10
survival O 0 1.1832111823650848e-07
of O 0 2.8684224773201095e-08
islet O 0 1.781187393135042e-07
beta O 0 1.0475508815943613e-06
- O 0 7.102337917785917e-08
cells O 0 2.559945311286782e-10
and O 0 3.0664490391352217e-10
neurons O 0 4.676956155691414e-09
. O 0 6.08865791118518e-10
. O 0 3.88595111644463e-09

Stable O 0 0.00013016420416533947
interaction O 0 1.681006892795267e-06
between O 0 8.870636492019912e-08
the O 0 1.6546931602690051e-09
products O 0 7.150353642515483e-10
of O 0 1.206197142167298e-09
the O 0 6.264307961245663e-10
BRCA1 O 0 1.6153328674661793e-09
and O 0 4.4793077580429497e-10
BRCA2 O 0 6.580521128007888e-10
tumor B-Disease 0 2.9649038779666625e-09
suppressor O 0 1.7096080995315788e-08
genes O 0 9.562756142500461e-10
in O 0 1.1179910330838538e-09
mitotic O 0 6.978370237220588e-08
and O 0 1.1965690660531436e-08
meiotic O 0 1.9524339222698472e-05
cells O 0 1.0621095469787178e-07
. O 0 6.370362939378538e-07

BRCA1 O 0 1.99001697183121e-05
and O 0 4.7732441998959985e-08
BRCA2 O 0 1.922314396551883e-08
account O 0 1.4453142849202294e-10
for O 0 3.689730812550529e-11
most O 0 3.805162348408109e-12
cases O 0 1.2465585855214734e-11
of O 0 2.7524091339437007e-10
familial O 0 3.03012583913187e-08
, O 0 1.8865847772886468e-10
early O 0 7.225833797974701e-08
onset O 0 0.0013688832987099886
breast B-Disease 0 5.017471266910434e-06
and I-Disease 0 4.982937298336765e-06
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.00044964681728743017
encode O 0 4.3036305186205936e-08
products O 0 3.307363982685274e-08
that O 0 3.1446435733162303e-11
each O 0 2.106242610877551e-11
interact O 0 2.1082130485794437e-10
with O 0 6.649887585030712e-11
hRAD51 O 0 5.38731654842195e-08
. O 0 1.220457868100766e-08

Results O 0 9.668588774047748e-08
presented O 0 7.906186993977826e-08
here O 0 2.9790882649649575e-08
show O 0 4.355795280019947e-09
that O 0 6.058107487882936e-11
BRCA1 O 0 1.793215465006881e-09
and O 0 1.6646266587372338e-09
BRCA2 O 0 9.962169755795003e-09
coexist O 0 1.2488094114360138e-08
in O 0 1.3672722953828043e-09
a O 0 1.2250260805757307e-09
biochemical O 0 4.728119407104714e-08
complex O 0 1.620101528487794e-07
and O 0 1.21092258442701e-09
colocalize O 0 1.835139471495495e-07
in O 0 3.6774043810083867e-09
subnuclear O 0 9.70196651906008e-07
foci O 0 2.7674495868268423e-06
in O 0 1.799928206480672e-09
somatic O 0 1.4945948478839455e-08
cells O 0 3.580982732565019e-10
and O 0 4.3680484229646765e-10
on O 0 4.102268746919435e-09
the O 0 2.1526495863621875e-10
axial O 0 8.131844086989304e-10
elements O 0 1.1915284314767405e-09
of O 0 5.791350177197785e-10
developing O 0 6.201978486330972e-09
synaptonemal O 0 3.035181634913897e-07
complexes O 0 1.21624765370143e-07
. O 0 7.095405152313106e-08

Like O 0 3.002442099386826e-06
BRCA1 O 0 1.4868576272419887e-06
and O 0 1.2502671609126992e-07
RAD51 O 0 0.00026407488621771336
, O 0 7.523143352727857e-08
BRCA2 O 0 9.597977168596117e-08
relocates O 0 1.5657850838124432e-07
to O 0 4.412573861856117e-09
PCNA O 0 2.556538220233051e-06
+ O 0 1.7668231322431893e-08
replication O 0 6.650871409163983e-09
sites O 0 3.467479359198222e-10
following O 0 4.3563080920350217e-10
exposure O 0 6.75429561169949e-08
of O 0 1.0009427597879039e-07
S O 0 8.2575127180462e-07
phase O 0 1.2025735713905306e-06
cells O 0 2.616608485439542e-09
to O 0 4.621648397318268e-09
hydroxyurea O 0 6.267563890105521e-07
or O 0 6.417257392143938e-09
UV O 0 3.2886234748730203e-06
irradiation O 0 3.3289330758634605e-07
. O 0 2.0490972474362934e-08

Thus O 0 2.307856902916683e-06
, O 0 9.643834886219338e-08
BRCA1 O 0 7.28898328361538e-08
and O 0 4.474536297038867e-09
BRCA2 O 0 2.1758994606102533e-09
participate O 0 3.023958194958709e-09
, O 0 3.6457722951688254e-10
together O 0 2.0541274237118046e-10
, O 0 8.67620003619507e-11
in O 0 3.3571123658759916e-10
a O 0 1.926810044849958e-09
pathway O 0 2.0757746632682483e-09
( O 0 1.0720074133940827e-10
s O 0 8.466705114784645e-10
) O 0 6.064254567256233e-12
associated O 0 8.393221534452877e-11
with O 0 2.1695898549944914e-11
the O 0 3.520969071857394e-10
activation O 0 6.1326002054329365e-09
of O 0 3.311453866672309e-08
double O 0 9.486733176800044e-09
- O 0 4.2398276889343833e-08
strand O 0 7.529902035230407e-09
break O 0 2.601213644481959e-08
repair O 0 8.221226153182215e-07
and O 0 3.0775246795400335e-09
/ O 0 1.843548886881763e-07
or O 0 3.5987184343611034e-09
homologous O 0 8.294499309613457e-08
recombination O 0 1.767026134302796e-07
. O 0 1.0296596286707427e-07

Dysfunction O 1 0.9996978044509888
of O 0 0.000543455476872623
this O 0 1.0171669373448822e-07
pathway O 0 8.995334610517602e-07
may O 0 1.506839986120667e-08
be O 0 2.527796028051199e-10
a O 0 2.100562779272508e-10
general O 0 7.588042971740094e-10
phenomenon O 0 1.707889607516222e-09
in O 0 5.7811824771825115e-11
the O 0 6.469716429258199e-11
majority O 0 9.615531461337756e-12
of O 0 1.3384422736795187e-10
cases O 0 1.7921408801413463e-10
of O 0 3.361002809398883e-09
hereditary B-Disease 1 0.9999651908874512
breast I-Disease 1 0.995505690574646
and I-Disease 0 0.06399787217378616
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.3589041531085968
. O 0 7.991672646312509e-06

A O 0 1.2366825785647961e-06
novel O 0 3.071650311881058e-08
Arg362Ser O 0 3.8654286527162185e-07
mutation O 0 2.1337811517696537e-09
in O 0 5.136727154742005e-10
the O 0 1.950999584110491e-09
sterol O 0 5.9413046926692914e-08
27 O 0 2.2883416761487752e-07
- O 0 1.193599388216171e-07
hydroxylase O 0 3.762582423405547e-07
gene O 0 4.019842592128953e-08
( O 0 2.5133457537407367e-09
CYP27 O 0 2.020850843109656e-06
) O 0 4.843840328838667e-10
: O 0 2.5167683909144145e-11
its O 0 8.625391199890142e-12
effects O 0 6.8706231814985586e-09
on O 0 6.556269749324883e-09
pre O 0 3.935675607635858e-08
- O 0 3.5024225186752744e-10
mRNA O 0 1.2065001775418693e-10
splicing O 0 6.902446392231809e-10
and O 0 1.6130036542549853e-11
enzyme O 0 2.0088028462872387e-10
activity O 0 8.442585297530059e-09
. O 0 1.8993606687445208e-08

A O 0 2.0980678527848795e-06
novel O 0 6.817757025601168e-08
C O 0 7.011844900262076e-07
to O 0 1.0828130614370934e-09
A O 0 2.0690746893592404e-09
mutation O 0 5.978262329620065e-11
in O 0 9.405323742051053e-11
the O 0 5.785906753708048e-10
sterol O 0 3.2200627941847415e-08
27 O 0 1.3563384015924385e-07
- O 0 5.123795787653762e-08
hydroxylase O 0 2.909701208864135e-07
gene O 0 9.663496669531924e-09
( O 0 1.7342622893323778e-09
CYP27 O 0 1.040227857629361e-06
) O 0 5.78300518583319e-10
was O 0 9.103469089666305e-09
identified O 0 2.2096832696938407e-10
by O 0 2.73550834761771e-11
sequencing O 0 1.8664529921608164e-09
amplified O 0 8.883317548225023e-08
CYP27 O 0 6.97866255450208e-07
gene O 0 5.109671352698797e-09
products O 0 3.3859877124342574e-09
from O 0 6.371651539716083e-10
a O 0 7.656065781347365e-10
patient O 0 2.8092892456754726e-09
with O 0 6.0515539246353e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 5.093404809031199e-08
CTX B-Disease 0 5.922708623984363e-06
) O 0 5.043403916715761e-09
. O 0 4.124772701175061e-08

The O 0 1.003762690743315e-07
mutation O 0 9.270844536501954e-09
changed O 0 1.9915875171250264e-08
the O 0 5.137199554638983e-09
adrenodoxin O 0 3.342835839248437e-07
cofactor O 0 3.420418082100696e-08
binding O 0 1.822796846795427e-08
residue O 0 1.626084156214347e-07
362Arg O 0 7.271541591080677e-08
to O 0 1.8942873936111937e-09
362Ser O 0 2.6735520464171714e-07
( O 0 6.277647734975744e-09
CGT O 0 3.0780981887801317e-06
362Arg O 0 6.529541565214458e-07
to O 0 1.9299337239431225e-08
AGT O 0 1.2862190487794578e-05
362Ser O 0 7.357592721746187e-07
) O 0 4.615241799843517e-10
, O 0 1.1321553416987484e-10
and O 0 6.678271130544644e-11
was O 0 1.2494860257561413e-08
responsible O 0 1.310894504058524e-08
for O 0 7.485366992909803e-09
deficiency O 0 9.525300265522674e-05
in O 0 3.504190004832708e-08
the O 0 5.446362294492246e-08
sterol O 0 4.206648327453877e-07
27 O 0 2.3823874073514162e-07
- O 0 1.221263623563118e-08
hydroxylase O 0 1.9835097475606744e-07
activity O 0 2.971663803919e-09
, O 0 6.301934668551112e-11
as O 0 7.569836250886919e-12
confirmed O 0 1.8436476303951288e-11
by O 0 2.2736229132042096e-12
expression O 0 8.35849028879565e-11
of O 0 6.296591026355713e-10
mutant O 0 7.967748127946095e-10
cDNA O 0 3.7524103824182475e-09
into O 0 4.718927471003553e-09
COS O 0 1.6349209545296617e-05
- O 0 2.71509520644031e-07
1 O 0 1.6322226770171255e-07
cells O 0 4.688907040417689e-09
. O 0 3.6925314361724304e-08

Quantitative O 0 9.587334943716996e-07
analysis O 0 3.973017470570994e-08
showed O 0 1.2991558051567154e-08
that O 0 2.27588000528689e-11
the O 0 1.896347107122054e-10
expression O 0 2.6250548956774367e-10
of O 0 7.979656935219737e-10
CYP27 O 0 2.242805585694896e-08
gene O 0 5.958147863971419e-11
mRNA O 0 9.135307788010749e-11
in O 0 1.1153195728086374e-10
the O 0 1.7109079430976948e-10
patient O 0 1.0311720366473764e-09
represented O 0 2.663228304555787e-09
52 O 0 1.8225401277049968e-07
. O 0 9.012304502675761e-08

5 O 0 1.3489252523868345e-06
% O 0 1.1498296537126862e-08
of O 0 2.5345139320620547e-08
the O 0 9.167818504351999e-09
normal O 0 5.567856078414479e-07
level O 0 1.4963583225835464e-06
. O 0 5.7357532057267235e-08

As O 0 2.894229922389968e-08
the O 0 4.851683499396131e-09
mutation O 0 6.82256362516398e-10
occurred O 0 1.983138453454103e-08
at O 0 5.097601007975072e-09
the O 0 3.384268421058323e-10
penultimate O 0 3.223780709049606e-08
nucleotide O 0 3.2240559111329503e-09
of O 0 2.1912144987368265e-08
exon O 0 1.3979285995446844e-07
6 O 0 3.879273435813957e-07
( O 0 2.7106068500870606e-09
- O 0 1.0983225884331205e-08
2 O 0 2.803782273019806e-08
position O 0 2.175846702812123e-08
of O 0 9.666099032301645e-08
exon O 0 7.124914418454864e-07
6 O 0 3.406632686164812e-06
- O 0 1.0224883908449556e-06
intron O 0 1.8209624386145151e-06
6 O 0 5.759420673712157e-07
splice O 0 3.378184487701219e-07
site O 0 2.459653103414894e-08
) O 0 4.5756937128160757e-10
of O 0 1.4040366203005306e-08
the O 0 2.645202101803079e-08
gene O 0 1.2013118499965003e-08
, O 0 3.617064647798429e-09
we O 0 9.715312998537229e-10
hypothesized O 0 6.1600680112405826e-09
that O 0 3.682257623816021e-11
the O 0 3.1452213056226697e-10
mutation O 0 3.4985633834416774e-10
may O 0 3.3418817713126714e-10
partially O 0 3.799830228246037e-09
affect O 0 1.0681708850768246e-09
the O 0 8.693946118576434e-10
normal O 0 9.025219682712304e-09
splicing O 0 2.9876452423138744e-09
efficiency O 0 4.892049432214662e-09
in O 0 1.9983901200504306e-09
exon O 0 4.7334072661442406e-08
6 O 0 1.4123036962132574e-08
and O 0 5.425454530083584e-10
cause O 0 8.720218436231164e-10
alternative O 0 2.3188928555128996e-10
splicing O 0 2.0634625119697603e-09
elsewhere O 0 5.491125332213187e-10
, O 0 1.2271037484745673e-11
which O 0 7.291607096761299e-13
resulted O 0 7.277206615086129e-11
in O 0 3.823352051623985e-11
decreased O 0 4.439232981212626e-09
transcript O 0 3.537457970992364e-08
in O 0 4.6553891297484995e-10
the O 0 1.0887920565139098e-09
patient O 0 2.6641442829600237e-08
. O 0 5.8173284855911334e-08

Transfection O 0 0.0001018451148411259
of O 0 1.8620004311742377e-06
constructed O 0 7.197998002084205e-06
minigenes O 0 2.0864768885076046e-05
, O 0 2.4660968822587392e-09
with O 0 2.5764482214363227e-10
or O 0 2.932238618580385e-10
without O 0 4.4626616291232324e-10
the O 0 2.7907665067772314e-10
mutation O 0 7.712283589533797e-11
, O 0 1.2060354104281856e-10
into O 0 4.0518783883669585e-09
COS O 0 0.00013670290354639292
- O 0 7.034805662442523e-07
1 O 0 1.2980169117327023e-07
cells O 0 9.538360379313104e-11
confirmed O 0 2.786548491950924e-10
that O 0 5.494556198915035e-12
the O 0 2.1801553617972758e-11
mutant O 0 1.3711688451323312e-09
minigene O 0 4.50268835550105e-08
was O 0 1.1802220534207208e-08
responsible O 0 3.3692506562488234e-09
for O 0 4.2395645327708564e-10
a O 0 7.06244063231054e-10
mRNA O 0 2.66912103530359e-10
species O 0 6.539786073789244e-12
alternatively O 0 4.215038984511921e-09
spliced O 0 4.5136687276681187e-08
at O 0 3.81344555933083e-08
an O 0 9.743221784930256e-10
activated O 0 2.83172482795635e-07
cryptic O 0 3.0454518196165736e-07
5 O 0 4.7857515284022156e-08
splice O 0 9.376356047141599e-08
site O 0 1.060490149029647e-07
88 O 0 3.9326033629549784e-07
bp O 0 5.032318313169526e-07
upstream O 0 1.2056185028086475e-07
from O 0 1.3076206784035094e-08
the O 0 1.239209179715317e-08
3 O 0 4.0875093532122264e-08
end O 0 4.804757125498327e-08
of O 0 8.566598097559108e-08
exon O 0 4.1545879980731115e-07
6 O 0 1.0254884728055913e-06
. O 0 2.3583982056152308e-07

Our O 0 7.16635440767277e-07
data O 0 3.2260874860412514e-08
suggest O 0 4.016138976936645e-09
that O 0 3.390999633867686e-11
the O 0 3.0766370007206945e-10
C O 0 3.444372609351376e-08
to O 0 1.5663444152824724e-10
A O 0 3.738052090085375e-09
mutation O 0 1.9400517303758136e-10
at O 0 7.0787895545265656e-09
the O 0 4.518574125977892e-10
penultimate O 0 2.2389288645285887e-08
nucleotide O 0 8.152968966612661e-09
of O 0 1.9911659876470367e-08
exon O 0 2.2377213326763012e-07
6 O 0 1.6938054159254534e-07
of O 0 7.583970784708072e-08
the O 0 5.464029584345553e-08
CYP27 O 0 2.1070081857033074e-05
gene O 0 1.8222266362499795e-08
not O 0 9.685856561247874e-10
only O 0 4.0792497157937646e-10
causes O 0 3.6180649587436164e-09
the O 0 3.0182074617357557e-09
deficiency B-Disease 0 1.2906371011922602e-06
in I-Disease 0 5.7307860679145506e-09
the I-Disease 0 1.0589151777651296e-08
sterol I-Disease 0 5.434719341224081e-08
27 I-Disease 0 7.021254333494653e-08
- I-Disease 0 6.695470844420015e-09
hydroxylase I-Disease 0 2.80717301848199e-07
activity I-Disease 0 2.3548015093410868e-08
, O 0 6.586963197108275e-10
but O 0 1.9605930767774282e-10
also O 0 3.5684100119226514e-10
partially O 0 4.240941375854845e-09
leads O 0 1.0801521899139743e-09
to O 0 1.418295064725683e-10
alternative O 0 2.9823730152145345e-09
pre O 0 3.818416516310208e-08
- O 0 1.1605394423241933e-09
mRNA O 0 5.939961300605034e-10
splicing O 0 1.1673265909450947e-08
of O 0 2.7524524881528123e-09
the O 0 4.449582924337392e-09
gene O 0 2.437892554496557e-08
. O 0 8.499867476530198e-08

To O 0 3.9413291119672067e-07
our O 0 1.3531807496747206e-07
knowledge O 0 2.3845873897698766e-07
, O 0 2.20942625306364e-10
this O 0 1.6279755321590983e-11
is O 0 8.534599242604468e-12
the O 0 1.1061794709388284e-11
first O 0 9.80804326644602e-12
report O 0 3.902351965873185e-12
regarding O 0 5.827958948767531e-11
effects O 0 1.156491347131805e-09
on O 0 3.930400005458523e-09
pre O 0 1.3113771402117891e-08
- O 0 2.1186130627626198e-10
mRNA O 0 7.381253941396437e-11
splicing O 0 1.137812621898604e-09
of O 0 1.031315699506763e-09
a O 0 4.4558656764337456e-10
mutation O 0 5.824824650391136e-11
at O 0 1.1174416059134273e-08
the O 0 5.000787783870919e-09
- O 0 1.5650618578888498e-08
2 O 0 3.083572153173009e-08
position O 0 1.229859378781839e-07
of O 0 4.3211915823349045e-08
a O 0 1.808028926575389e-08
5 O 0 8.738491885651456e-08
splice O 0 3.903752485712175e-07
site O 0 1.365569062272698e-07
. O 0 2.235183131915619e-07

ATM O 0 0.00011731569975381717
germline O 0 6.092373951105401e-06
mutations O 0 3.6811606207720615e-08
in O 0 5.640711453480662e-09
classical O 1 0.9999980926513672
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.006827826611697674
in O 0 1.8012272562373255e-08
the O 0 9.976469428352175e-09
Dutch O 0 1.7760287391865859e-06
population O 0 1.1577547948116163e-11
. O 0 1.1951223344297546e-09

Germline O 0 5.564381353906356e-05
mutations O 0 2.3363254797459376e-07
in O 0 2.1270411210139173e-08
the O 0 1.8198786477796602e-08
ATM O 0 4.028562443636474e-07
gene O 0 6.832695520486709e-10
are O 0 7.239653212857966e-13
responsible O 0 8.078438959446821e-12
for O 0 3.2865676326265802e-12
the O 0 6.133877406000465e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9953672885894775
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.555134746122349e-07
. O 0 2.876405460483511e-07

In O 0 1.3427081739791902e-06
our O 0 1.5128840402667265e-07
study O 0 5.839904115845229e-09
, O 0 1.7740849067582332e-10
we O 0 6.860834123045834e-11
have O 0 1.7368184798347008e-12
determined O 0 2.406299291768388e-11
the O 0 2.9388779604344606e-11
ATM O 0 7.980756500103325e-09
mutation O 0 9.316072219212046e-11
spectrum O 0 2.5015518545501436e-09
in O 0 2.502748563948387e-10
19 O 0 1.5696176802748596e-08
classical O 0 4.47698294010479e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 1.4917240775957907e-08
, O 0 1.4493108102531238e-11
including O 0 2.250449826490808e-12
some O 0 1.1601017455703522e-12
immigrant O 0 2.220701400545977e-11
populations O 0 5.803991727330871e-13
, O 0 2.3582219076806465e-12
as O 0 6.448018768229202e-12
well O 0 4.046529777923524e-11
as O 0 3.811272825116063e-11
12 O 0 3.4418209948761103e-10
of O 0 3.2094701896134836e-10
Dutch O 0 6.32651193654965e-08
ethnic O 0 3.263670167452659e-10
origin O 0 1.0644489734090712e-09
. O 0 6.180616463069555e-09

Both O 0 3.1956264479049423e-07
the O 0 5.767644495335844e-08
protein O 0 1.2503609703173879e-08
truncation O 0 1.2209042665745073e-07
test O 0 1.1301521496420719e-08
( O 0 1.525909815169868e-10
PTT O 0 2.6470342362472365e-08
) O 0 4.843949200084019e-11
and O 0 2.027873008403347e-11
the O 0 8.889423919189454e-11
restriction O 0 2.718864300366164e-10
endonuclease O 0 1.123608983633062e-09
fingerprinting O 0 4.763219152437159e-09
( O 0 1.8791793121586409e-10
REF O 0 2.3887796629651348e-08
) O 0 3.230657755204369e-11
method O 0 1.056987497527473e-09
were O 0 2.0734350347773045e-10
used O 0 6.559728454869074e-11
and O 0 6.802766249619507e-12
compared O 0 3.74059429264495e-11
for O 0 1.7434874724497895e-11
their O 0 2.437019509804461e-11
detection O 0 1.4629684130795795e-09
efficiency O 0 1.022397860817037e-10
, O 0 3.76572601226699e-12
identifying O 0 1.356287304687953e-10
76 O 0 2.2661881260432892e-09
% O 0 4.9912442234845145e-11
and O 0 1.2319423259299356e-10
60 O 0 9.107701814947688e-10
% O 0 7.90364301783697e-11
of O 0 1.1303240565752048e-09
the O 0 8.360024894571438e-10
mutations O 0 6.476078007189301e-10
, O 0 2.1841146946588452e-10
respectively O 0 2.473173310590937e-08
. O 0 9.140740786506285e-08

Most O 0 7.613363095515524e-08
patients O 0 8.109513061071993e-09
were O 0 2.9220288411124784e-09
found O 0 2.720757785734662e-10
to O 0 6.10673941969786e-11
be O 0 1.308250452414228e-10
compound O 0 1.5011602627623688e-08
heterozygote O 0 6.657917879238084e-07
. O 0 1.6595082286130491e-07

Seventeen O 0 1.3913238490204094e-06
mutations O 0 1.5802216424276594e-08
were O 0 2.275240218452268e-09
distinct O 0 1.1604774918794192e-09
, O 0 9.352034424647826e-11
of O 0 1.826519824277284e-09
which O 0 5.963445709467052e-11
10 O 0 3.6300215611184683e-10
were O 0 8.660840100649381e-11
not O 0 1.2018095719990018e-11
reported O 0 1.0906975322910739e-10
previously O 0 2.982702751452848e-09
. O 0 1.2768108348382157e-08

Mutations O 0 9.985017186409095e-07
are O 0 3.88713683463493e-09
small O 0 5.963395111052705e-09
deletions O 0 1.3679178323400265e-07
or O 0 4.763421301845483e-08
point O 0 3.179656005158904e-06
mutations O 0 3.451856755987137e-08
frequently O 0 6.978926325729162e-09
affecting O 0 6.416596587399681e-09
splice O 0 6.064161794938627e-08
sites O 0 1.6544856151767817e-08
. O 0 5.7471861936164714e-08

Moreover O 0 8.771571629040409e-06
, O 0 3.7612039704981726e-08
a O 0 4.418319576870999e-08
16 O 0 2.0979146597710496e-07
. O 0 1.1134167010595775e-07

7 O 0 1.0618432497722097e-05
- O 0 3.7524878848671506e-07
kb O 0 3.2006694254960166e-06
genomic O 0 2.9451402383529057e-07
deletion O 0 3.9361341919175175e-07
of O 0 2.6297539079678245e-07
the O 0 2.574343405115087e-08
3 O 0 7.837272875121926e-08
end O 0 3.6583632123665666e-08
of O 0 8.506399140628673e-09
the O 0 9.119243693511692e-10
gene O 0 1.6132628566367657e-10
, O 0 4.683503931901534e-11
most O 0 1.9112520593944637e-11
likely O 0 1.2932802051501824e-10
a O 0 4.55746967942261e-11
result O 0 2.0770013486881567e-10
of O 0 3.5261120689966674e-09
recombination O 0 8.799351469690464e-09
between O 0 3.517502378258541e-08
two O 0 3.031523254648505e-09
LINE O 0 2.1980548581268522e-07
elements O 0 1.2723356235255778e-07
, O 0 5.225616050985593e-10
was O 0 1.3695462541818415e-08
identified O 0 3.5852920632351015e-08
. O 0 1.0084661994369526e-07

The O 0 4.0087635966301605e-07
most O 0 1.9174906107366496e-09
frequently O 0 2.6409346931544064e-10
found O 0 1.763157675416238e-11
mutation O 0 4.5804388927594974e-12
, O 0 1.6027842031016148e-12
identified O 0 1.3718973006227042e-11
in O 0 5.838038386052347e-11
three O 0 5.155196061701339e-11
unrelated O 0 7.767148701987026e-09
Turkish O 0 7.286042205123522e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
individuals O 0 7.500512988478647e-10
, O 0 5.825505633438866e-10
was O 0 2.6705395228532325e-08
previously O 0 6.9872512220570115e-09
described O 0 9.352859597910879e-10
to O 0 1.0426145363728878e-10
be O 0 1.4024560679448683e-10
a O 0 6.957352471914646e-10
Turkish O 0 9.479664697664703e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999915361404419
T I-Disease 1 1.0
founder O 0 2.523778675822541e-05
mutation O 0 2.6472211089867415e-08
. O 0 1.4234815637337306e-07

The O 0 2.4960203859336616e-07
presence O 0 5.53052608154303e-08
of O 0 1.4623199717789248e-07
a O 0 3.324243280644623e-08
founder O 0 9.45846068134415e-08
mutation O 0 8.046630584068737e-10
among O 0 9.782839469063553e-12
relatively O 0 1.4100171030762e-10
small O 0 1.3087389678922978e-11
ethnic O 0 1.9887263710827163e-11
population O 0 4.1816943245794047e-13
groups O 0 5.372731339686743e-13
in O 0 3.703041692726394e-11
Western O 0 4.3524566173402945e-09
Europe O 0 2.975111712544276e-09
could O 0 1.927445147931195e-10
indicate O 0 3.645056201317942e-10
a O 0 1.1605499200539882e-10
high O 0 6.602169921876566e-10
carrier O 0 1.9537317597073667e-10
frequency O 0 2.751502359288338e-09
in O 0 5.916958589757826e-11
such O 0 5.248177240013696e-11
communities O 0 1.4408937931698063e-10
. O 0 7.132540336129978e-09

In O 0 8.98196503840154e-08
patients O 0 1.4465016739961811e-08
of O 0 2.2824085732509047e-08
Dutch O 0 5.686760687240167e-06
ethnic O 0 2.3313915242795247e-09
origin O 0 5.007314007876573e-10
, O 0 1.6286121756747818e-11
however O 0 5.308502595835485e-11
, O 0 1.1906843566666936e-11
no O 0 4.017812818557509e-11
significant O 0 1.2840979390915663e-09
founder O 0 1.5542342168828327e-07
effect O 0 3.3204040050804906e-07
could O 0 7.693470749359221e-09
be O 0 1.467297172652593e-09
identified O 0 9.351954766145809e-09
. O 0 2.158292389253802e-08

The O 0 1.898519030874013e-07
observed O 0 1.1317467851768015e-07
genetic O 0 1.282377937172896e-08
heterogeneity O 0 1.2184157682781915e-08
including O 0 2.2680377020911635e-10
the O 0 6.621123649352967e-10
relative O 0 2.2497081886285741e-07
high O 0 2.465327497702674e-07
percentage O 0 2.250754960186896e-08
of O 0 4.872496717212016e-08
splice O 0 4.5904278067609994e-07
- O 0 3.7398081076389644e-08
site O 0 6.870977120598809e-09
mutations O 0 9.758808205972969e-10
had O 0 3.2810731909194146e-09
no O 0 4.27623991772208e-10
reflection O 0 2.6329187718943103e-09
on O 0 1.1024740231846408e-08
the O 0 4.272337150723615e-09
phenotype O 0 2.2631093443692407e-08
. O 0 4.39846736810523e-08

All O 0 1.5080592774552315e-08
patients O 0 1.7805981133989235e-09
manifested O 0 6.4409979572133125e-09
classical O 0 1.3376724382396787e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.6921908855438232
T I-Disease 1 0.9999990463256836
and O 0 8.037273624417196e-10
increased O 0 1.0815828233035063e-09
cellular O 0 3.114373825496841e-08
radioresistant O 0 2.221717210204588e-08
DNA O 0 4.294665956194876e-09
synthesis O 0 1.849355868444036e-08
. O 0 1.0606759026643431e-08

Determination O 0 7.853859642636962e-06
of O 0 4.4997520376455213e-07
the O 0 1.0906070713190275e-08
genomic O 0 3.943234716530242e-08
structure O 0 6.674269314999037e-08
of O 0 3.5267866849153506e-08
the O 0 5.179357831508469e-09
COL4A4 O 0 1.96779160432925e-06
gene O 0 8.304211762677483e-10
and O 0 2.1667570515582213e-11
of O 0 1.6622683784994763e-10
novel O 0 9.396167177655457e-10
mutations O 0 1.613960733948261e-07
causing O 0 5.707580044145288e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.447179890121333e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.3974917101886604e-08
a O 0 1.3305961665821542e-08
progressive O 1 0.9880048632621765
hematuric B-Disease 1 0.9999986886978149
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.32888075709342957
by O 0 7.67508012700091e-08
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999825954437256
abnormalities I-Disease 1 0.9999995231628418
and O 0 4.4234461427095084e-08
associated O 0 4.073524166869902e-07
with O 0 4.312511237003491e-09
mutations O 0 3.2148321338354435e-07
in O 0 6.220474091378492e-08
either O 0 1.6071473396550573e-07
the O 0 1.50573896462447e-07
COL4A3 O 0 4.773087130161002e-05
or O 0 3.0139848394838964e-09
the O 0 2.6039423950408036e-09
COL4A4 O 0 2.8757199288520496e-07
gene O 0 5.29922827841034e-10
, O 0 1.0540275596770954e-10
which O 0 7.613202603062863e-12
encode O 0 1.5456941282465664e-10
the O 0 1.1633030094770902e-09
alpha3 O 0 5.557330950978212e-07
and O 0 1.9850561194800775e-09
alpha4 O 0 1.2727014109259471e-06
type O 0 1.0144076441065408e-05
IV O 1 0.9999971389770508
collagen O 0 0.0007315165712498128
chains O 0 7.624698810104746e-06
, O 0 3.5241354279236248e-09
respectively O 0 1.2400442983562243e-07
. O 0 1.282302548588632e-07

To O 0 4.7689578508425257e-08
date O 0 2.498401840966835e-07
, O 0 6.004113872748462e-10
mutation O 0 7.967182469315048e-11
screening O 0 2.3547106486887515e-09
in O 0 8.946546836696712e-10
the O 0 3.28652238756888e-09
two O 0 7.440993932128492e-10
genes O 0 1.0763926416856862e-09
has O 0 2.025122014526204e-10
been O 0 2.1389143234351593e-10
hampered O 0 2.1452494891605056e-08
by O 0 3.212328666957198e-11
the O 0 1.5228859839844233e-10
lack O 0 2.852429847877147e-09
of O 0 3.882525967391359e-10
genomic O 0 1.6332644126038076e-09
structure O 0 1.0077409129394255e-08
information O 0 9.35464861129276e-09
. O 0 7.504856114337599e-08

We O 0 3.475508663086657e-07
report O 0 1.187907372468544e-08
here O 0 3.011846994027678e-09
the O 0 2.4879559523682815e-10
complete O 0 2.237254381753928e-09
characterization O 0 9.95299664907634e-09
of O 0 3.6304457218250263e-09
the O 0 3.584469832063064e-09
48 O 0 2.5547091553335122e-08
exons O 0 1.508499281044351e-08
of O 0 3.646283985858645e-08
the O 0 2.4993688896302046e-08
COL4A4 O 0 1.9748435079236515e-05
gene O 0 7.708761629032779e-09
, O 0 6.441817634872393e-10
a O 0 7.01760594079559e-10
comprehensive O 0 6.4143446110165314e-09
gene O 0 1.1960983314907025e-09
screen O 0 3.168230762184976e-07
, O 0 1.3528647091476387e-09
and O 0 3.0025423813917484e-10
the O 0 1.178587644146134e-10
subsequent O 0 8.905376436274537e-11
detection O 0 2.2253081599643565e-09
of O 0 2.3090021561422702e-10
10 O 0 4.552239835087235e-11
novel O 0 1.460552512266844e-11
mutations O 0 4.1094381370010424e-11
in O 0 2.0793151922493536e-11
eight O 0 5.769850153214406e-10
patients O 0 6.7641692247377705e-09
diagnosed O 0 2.4775226847850718e-06
with O 0 2.545230586292746e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.4096674931352027e-05

Furthermore O 0 1.9968745164078427e-06
, O 0 2.283971944905261e-08
we O 0 4.819899590557952e-09
identified O 0 5.506598732551993e-09
a O 0 2.9411799662426574e-09
glycine O 0 1.1055526272230054e-08
to O 0 8.389768324512659e-10
alanine O 0 2.1943472816587928e-08
substitution O 0 5.2128392269423784e-08
in O 0 5.075722953051809e-09
the O 0 1.1282762280018233e-08
collagenous O 0 1.469434323553287e-06
domain O 0 3.616990795762831e-08
that O 0 3.500096740216563e-11
is O 0 2.972925031152762e-11
apparently O 0 3.7137598551950646e-10
silent O 0 8.727240041750406e-10
in O 0 8.580190724583048e-11
the O 0 4.2262912613999504e-10
heterozygous O 0 5.640944933382741e-10
carriers O 0 4.1590628163667986e-10
, O 0 1.6286472170889965e-10
in O 0 3.70990849152264e-10
11 O 0 6.108868433329917e-08
. O 0 1.2860685671967076e-07

5 O 0 4.855010047322139e-07
% O 0 4.0636041198638395e-09
of O 0 1.882578537504287e-08
all O 0 4.3630934976057745e-10
control O 0 7.202744711776177e-08
individuals O 0 5.074824675072032e-12
, O 0 2.3147995673045152e-11
and O 0 1.4028085117134825e-11
in O 0 7.101556148692012e-11
one O 0 2.100910244384746e-11
control O 0 7.406288915490222e-10
individual O 0 4.832393166176452e-12
homozygous O 0 1.329369531122282e-10
for O 0 3.1949446560597394e-11
this O 0 4.243461831920925e-11
glycine O 0 1.776284186405519e-08
substitution O 0 4.873723469245306e-08
. O 0 9.014625845793489e-08

There O 0 3.281351155237644e-07
has O 0 2.2352923956248105e-09
been O 0 3.855943342401247e-10
no O 0 5.510395958974179e-11
previous O 0 1.8702045467833273e-10
finding O 0 1.2508875046890466e-09
of O 0 3.0832827402349494e-09
a O 0 1.7160725063192217e-09
glycine O 0 1.8887757136099026e-08
substitution O 0 8.271146434424281e-09
that O 0 3.2526456528181313e-10
is O 0 1.241374919525029e-10
not O 0 3.35458223699181e-11
associated O 0 2.8783994632242127e-10
with O 0 9.484529481240678e-12
any O 0 1.7687971920476997e-10
obvious O 0 6.03598837578545e-10
phenotype O 0 1.1836226443406872e-10
in O 0 1.2055202669447596e-10
homozygous O 0 2.5389399471720253e-09
individuals O 0 1.4895050470808968e-10
. O 0 4.584923729566981e-08

Founder O 0 0.002655207645148039
BRCA1 O 0 6.078167189116357e-06
and O 0 7.960342429669254e-08
BRCA2 O 0 4.3611759537043326e-08
mutations O 0 2.6205140279955685e-09
in O 0 1.421122108880013e-10
French O 0 9.842186443620449e-08
Canadian O 0 5.531873284780886e-06
breast B-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.7057349396054633e-05
. O 0 3.4160123050241964e-06

We O 0 1.7205971403200238e-07
have O 0 1.5107437523198541e-10
identified O 0 2.1433167740614323e-10
four O 0 4.539000772463275e-11
mutations O 0 1.1275796268916949e-11
in O 0 1.402118438714739e-11
each O 0 9.576546153300391e-12
of O 0 5.7317697255143685e-09
the O 0 5.909140554649639e-08
breast B-Disease 0 0.005591706372797489
cancer I-Disease 0 0.00027515264810062945
- O 0 8.29820510261925e-06
susceptibility O 0 1.1008813999069389e-05
genes O 0 1.8688727010385264e-08
, O 0 6.941102137503208e-10
BRCA1 O 0 2.6032769273598433e-09
and O 0 2.4870924764108793e-10
BRCA2 O 0 4.765033922993211e-10
, O 0 7.772175264486592e-12
in O 0 9.243833129501944e-12
French O 0 2.597901627154897e-08
Canadian O 0 6.463293971137318e-07
breast B-Disease 1 0.990922749042511
cancer I-Disease 1 0.9993757605552673
and O 1 0.9942816495895386
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.0357764419240993e-07
from O 0 1.8665362233605265e-07
Quebec O 0 9.288490218750667e-06
. O 0 2.9178542604313407e-07

To O 0 1.732599201886842e-07
identify O 0 2.7890164346899837e-06
founder O 0 3.784260115935467e-05
effects O 1 0.5607686042785645
, O 0 2.8479083979959796e-08
we O 0 2.327827708370478e-09
examined O 0 7.980101912608006e-09
independently O 0 1.5530828845200517e-09
ascertained O 0 1.1674579525333684e-08
French O 0 2.2807320476658788e-09
Canadian O 0 2.1186383758475813e-09
cancer B-Disease 0 1.8101844467821593e-09
families O 0 2.1638279276009476e-12
for O 0 2.0045946239749535e-12
the O 0 1.6885314327308443e-11
distribution O 0 5.351446508150559e-10
of O 0 5.541787584384394e-10
these O 0 2.8645415900419025e-11
eight O 0 9.713144732970136e-10
mutations O 0 1.4891051725030024e-09
. O 0 7.888049324833446e-09

Mutations O 0 4.616831361659024e-08
were O 0 3.516252844448786e-09
found O 0 6.256522522285479e-10
in O 0 2.500553653028703e-10
41 O 0 2.971448420652223e-09
of O 0 6.144718511791325e-09
97 O 0 1.57098710928949e-07
families O 0 1.3166622236937542e-09
. O 0 6.004897556977085e-08

Six O 0 2.430633969652263e-07
of O 0 8.521912064907156e-08
eight O 0 4.7350661169787145e-09
mutations O 0 6.988273293373481e-10
were O 0 4.706358636141772e-10
observed O 0 4.09582634475214e-09
at O 0 1.906169089238574e-08
least O 0 1.040777131144921e-09
twice O 0 2.0135999534431903e-08
. O 0 2.6162801702867e-08

The O 0 3.8446751204901375e-06
BRCA1 O 0 5.669837719324278e-07
C4446T O 0 5.462033527692256e-07
mutation O 0 2.6265287722537778e-09
was O 0 8.775986160003413e-09
the O 0 4.2166289904166376e-10
most O 0 4.1654041327277014e-11
common O 0 5.433477626159977e-11
mutation O 0 2.153962772033502e-11
found O 0 3.096871023511305e-11
, O 0 5.807870677443372e-12
followed O 0 1.47151648505206e-11
by O 0 1.0305064093718563e-11
the O 0 9.91585258347527e-10
BRCA2 O 0 5.0030202203288354e-09
8765delAG O 0 1.0763483970777088e-07
mutation O 0 4.511964490916398e-08
. O 0 1.5733711222765123e-07

Together O 0 3.213480113117839e-07
, O 0 2.033472057405561e-09
these O 0 4.3996438436888496e-11
mutations O 0 1.1886405748562368e-10
were O 0 8.311654836612448e-11
found O 0 2.7499518287510405e-11
in O 0 4.441209899841425e-11
28 O 0 2.243441876714769e-09
of O 0 1.2443298835762562e-08
41 O 0 1.9330798295413842e-08
families O 0 1.8124661493867933e-11
identified O 0 4.180696067113132e-10
to O 0 1.518445508219557e-10
have O 0 1.4688757155045806e-10
a O 0 1.5117418428189922e-09
mutation O 0 3.9727501288666645e-09
. O 0 3.785718050153264e-08

The O 0 4.859567752646399e-07
odds O 0 1.6849198800628074e-06
of O 0 1.1376851460909165e-08
detection O 0 1.1673894562136411e-07
of O 0 3.0879909740377798e-09
any O 0 5.528042468228023e-10
of O 0 9.113093391022176e-09
the O 0 6.156144483071557e-09
four O 0 3.6021248206452583e-09
BRCA1 O 0 1.019457962492254e-09
mutations O 0 6.856599177318401e-10
was O 0 7.158793380313e-08
18 O 0 3.0113147886368097e-07
. O 0 1.9452528476904263e-07

7x O 0 0.044700268656015396
greater O 0 1.2532434993772767e-05
if O 0 8.912356008750066e-08
one O 0 9.005217682656053e-10
or O 0 3.890671118611522e-11
more O 0 9.132790010357716e-13
cases O 0 5.0831391179562146e-11
of O 0 7.695529546936086e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.900494445791992e-07
also O 0 1.0687123408459342e-10
present O 0 1.8260374115564026e-11
in O 0 3.694223399408614e-11
the O 0 1.114652370404201e-09
family O 0 1.6056077578596728e-09
. O 0 1.1744396566371051e-08

The O 0 5.990256113364012e-07
odds O 0 1.754373442963697e-06
of O 0 1.2536205851176874e-08
detection O 0 8.11860019211963e-08
of O 0 1.4221260835611815e-09
any O 0 3.8774047861345196e-10
of O 0 5.362279509313339e-09
the O 0 4.513924789506518e-09
four O 0 2.8641948812691e-09
BRCA2 O 0 6.202519609033175e-10
mutations O 0 7.279486458067197e-10
was O 0 7.055123063537394e-08
5 O 0 8.15998859593492e-08
. O 0 9.764308828152934e-08

3x O 0 0.0012110709212720394
greater O 0 1.5776607824591338e-06
if O 0 1.1627356855115067e-08
there O 0 2.3762769529867e-09
were O 0 6.898523974285808e-10
at O 0 1.701250584851266e-09
least O 0 3.88772434384288e-12
five O 0 3.292339924992893e-12
cases O 0 9.551336284385759e-12
of O 0 6.418527376261807e-10
breast B-Disease 0 3.560038308592084e-08
cancer I-Disease 0 5.868581709478349e-08
in O 0 1.4248147550688373e-08
the O 0 2.641381513512897e-07
family O 0 6.191591950255315e-08
. O 0 7.905403265340283e-08

Interestingly O 0 1.970086259461823e-06
, O 0 4.646679929720676e-09
the O 0 8.925361560940814e-10
presence O 0 1.5155787735920967e-09
of O 0 7.847145155892576e-08
a O 0 1.1766598362328295e-07
breast B-Disease 0 5.935023182246368e-06
cancer I-Disease 0 7.001233939263329e-07
case O 0 2.1211144485278055e-07
< O 0 3.800259662511962e-08
36 O 0 6.368994220906643e-09
years O 0 7.538505375492832e-10
of O 0 2.1900561364418536e-09
age O 0 3.055579345101478e-09
was O 0 4.872493963858915e-09
strongly O 0 8.915607141446458e-11
predictive O 0 1.433739349465668e-09
of O 0 5.375568878918102e-10
the O 0 1.2249366798666728e-10
presence O 0 2.836813284279316e-10
of O 0 9.401508460626928e-10
any O 0 3.661067837779086e-10
of O 0 1.0719630738620367e-09
the O 0 3.0688246388521634e-10
eight O 0 3.880860077742909e-10
mutations O 0 3.216640287462269e-10
screened O 0 2.2797546961328408e-08
. O 0 7.512689847999354e-08

Carriers O 0 4.3312422803865047e-07
of O 0 1.9486060409690253e-07
the O 0 3.1553291091057645e-09
same O 0 1.6707966954410125e-10
mutation O 0 8.5557221030097e-12
, O 0 2.89896427176084e-12
from O 0 5.829356962416821e-12
different O 0 9.890305588400317e-12
families O 0 1.1364142049261061e-12
, O 0 4.740317947199424e-12
shared O 0 1.5774125061707167e-11
similar O 0 2.308151239582834e-11
haplotypes O 0 1.3580507829402677e-09
, O 0 7.996717177327639e-11
indicating O 0 3.0062097255978415e-10
that O 0 1.9848761523277858e-11
the O 0 2.2402336929960853e-10
mutant O 0 1.2838969887241092e-09
alleles O 0 5.587532658779537e-10
were O 0 1.8398483847548164e-09
likely O 0 3.1059466110150424e-10
to O 0 2.2091259377354788e-11
be O 0 3.42146345977401e-11
identical O 0 7.736386531398409e-11
by O 0 2.6676537714931392e-11
descent O 0 3.5821734467589295e-09
for O 0 2.4260338182813257e-10
a O 0 2.508172280979437e-10
mutation O 0 5.152493015581072e-11
in O 0 1.38834749252581e-10
the O 0 1.8076796726163025e-09
founder O 0 4.894301142144286e-08
population O 0 2.8114947869806173e-11
. O 0 1.9217644364744046e-08

The O 0 4.500848138633273e-09
identification O 0 4.823735189063427e-09
of O 0 1.5862791968856982e-08
common O 0 4.6533607189758186e-08
BRCA1 O 0 1.199313715005701e-07
and O 0 1.1565028934512611e-08
BRCA2 O 0 1.8626876041594187e-08
mutations O 0 3.893813327326967e-10
will O 0 3.086421743181411e-11
facilitate O 0 6.144761921511588e-10
carrier O 0 1.3274067400814715e-09
detection O 0 4.104225403978035e-09
in O 0 1.1214289219463325e-10
French O 0 1.0720538767827748e-07
Canadian O 0 1.4785291568841785e-06
breast B-Disease 1 0.99934321641922
cancer I-Disease 1 0.9996935129165649
and O 1 0.9686633348464966
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.74121407023631e-06
. O 0 1.4609693153033732e-06

Are O 0 1.3273440124805802e-08
Dp71 O 0 2.739883484537131e-06
and O 0 8.214595226263555e-09
Dp140 O 0 2.5421838927286444e-06
brain O 0 7.369161721726414e-06
dystrophin O 0 2.4042302015914174e-07
isoforms O 0 1.7883795777606792e-08
related O 0 1.5904592087778724e-09
to O 0 8.447440663639227e-11
cognitive B-Disease 0 1.6254998627118766e-05
impairment I-Disease 1 0.9997785687446594
in O 0 0.0005127532640472054
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.00047177710803225636

Molecular O 0 4.049400104122469e-06
study O 0 3.3497407514460065e-08
and O 0 9.318067428765175e-10
neuropsychological O 0 2.9194065831461558e-08
analysis O 0 2.3251907343979639e-10
were O 0 2.5701054132132306e-11
performed O 0 1.078241385066292e-10
concurrently O 0 1.2704207130731504e-10
on O 0 1.7316345024553925e-09
49 O 0 2.4537536447155617e-08
patients O 0 3.690947281143053e-08
with O 0 1.0686241694202181e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.0647545423125848e-05
DMD B-Disease 1 1.0
) O 0 2.1557444718212082e-09
in O 0 9.274200296616186e-10
order O 0 2.438741153465429e-10
to O 0 5.6254598201910255e-11
find O 0 2.369165974513976e-10
a O 0 1.184162351508533e-10
molecular O 0 2.1222299473322437e-09
explanation O 0 3.574827101004985e-10
for O 0 2.2383575895568164e-11
the O 0 1.0368159802931487e-10
cognitive B-Disease 0 3.878267591517215e-07
impairment I-Disease 0 3.651674660432036e-07
observed O 0 1.607795785396604e-09
in O 0 3.7717751144583644e-10
most O 0 1.484162903686581e-09
DMD B-Disease 1 0.9999998807907104
patients O 0 8.220914793355405e-08
. O 0 4.7209645970269776e-08

Complete O 0 2.417210396288283e-07
analysis O 0 7.666828594210529e-08
of O 0 8.031948084408214e-08
the O 0 2.4076388882576794e-08
dystrophin O 0 3.4149496741520124e-07
gene O 0 1.592967713293092e-08
was O 0 3.1015932222544507e-07
performed O 0 5.8004097525099496e-08
to O 0 1.645744651668224e-09
define O 0 3.45600064122209e-08
the O 0 4.587370483477571e-09
localization O 0 1.8203841136710253e-06
of O 0 1.3749248850558615e-08
deletions O 0 5.133027336512441e-09
and O 0 3.041402130143922e-10
duplications O 0 1.8133404111608797e-08
in O 0 7.432511273108844e-10
relation O 0 5.612168507695969e-08
to O 0 3.4262256920492007e-10
the O 0 1.5361723004758687e-09
different O 0 2.5696976990730036e-08
DMD B-Disease 1 1.0
promoters O 0 1.6046071323216893e-05
. O 0 2.2120475762221758e-07

Qualitative O 0 2.2854374037706293e-06
analysis O 0 1.3688601541161916e-07
of O 0 8.04682187549588e-08
the O 0 4.711618117880789e-08
Dp71 O 0 1.9099595647276146e-06
transcript O 0 2.3878965293988585e-07
and O 0 6.023751497608032e-10
testing O 0 1.6239817823837654e-10
for O 0 1.2331336472770627e-11
the O 0 3.622632749333832e-11
specific O 0 3.731551179164683e-11
first O 0 2.6393787155853943e-10
exon O 0 1.4779544699194958e-08
of O 0 1.8919990907306783e-08
Dp140 O 0 9.953626545211591e-08
were O 0 3.2111007186585994e-09
also O 0 1.1534617011532688e-10
carried O 0 3.6527397773156167e-10
out O 0 3.0945576656726814e-10
. O 0 4.030343170313699e-09

Neuropsychological O 0 3.565080987755209e-05
analysis O 0 1.8183351357947686e-07
assessed O 0 5.925335813117272e-07
verbal O 0 4.1842343989628716e-07
and O 0 1.1396637411564825e-08
visuospatial O 0 4.5687207602895796e-05
intelligence O 0 1.1391099263846627e-07
, O 0 8.123395289771906e-10
verbal O 0 2.652032549121941e-08
memory O 0 5.092510036774911e-06
, O 0 5.145280201901414e-09
and O 0 1.4725513031166315e-09
reading O 0 9.067338169188588e-07
skills O 0 3.4931825211970136e-05
. O 0 1.6337051533810154e-07

Comparison O 0 6.368268259393517e-07
of O 0 2.1242077252736635e-07
molecular O 0 6.571539188371389e-07
and O 0 4.118607677128239e-09
psychometric O 0 7.661418521820451e-07
findings O 0 3.5004208420730265e-09
demonstrated O 0 4.664466146664381e-09
that O 0 6.352572634593656e-11
deletions O 0 1.3374783502939636e-09
and O 0 1.814854239112762e-10
duplications O 0 1.9223950431523917e-08
that O 0 6.804132951510056e-11
were O 0 1.4723257335536033e-10
localized O 0 7.197948459491954e-09
in O 0 5.128747981864024e-10
the O 0 4.424271171643568e-09
distal O 0 6.441928235290106e-07
part O 0 2.848283209289093e-08
of O 0 4.3691107975973864e-07
the O 0 9.560267244523857e-08
gene O 0 2.4395811593080907e-08
seemed O 0 1.2040696617532376e-07
to O 0 4.530299746452471e-11
be O 0 1.768550063341312e-11
preferentially O 0 1.064444365983519e-10
associated O 0 1.43706579969205e-09
with O 0 3.256811209606525e-10
cognitive B-Disease 0 0.00872803945094347
impairment I-Disease 1 0.7720600962638855
. O 0 5.4067490964371245e-06

Two O 0 6.879805880544154e-08
altered O 0 9.19961422596316e-08
Dp71 O 0 2.514177595003275e-06
transcripts O 0 2.159614638230778e-07
and O 0 6.048838652183974e-10
two O 0 1.6825461857106205e-10
deleted O 0 1.3511497476415002e-09
Dp140 O 0 2.8872426671711082e-09
DNA O 0 7.509670663097268e-11
sequences O 0 6.168785621207817e-11
were O 0 2.4313738522518946e-11
found O 0 2.961790751890292e-12
in O 0 1.9464915790301518e-12
four O 0 9.127657830954039e-12
patients O 0 5.1538787126936825e-11
with O 0 3.414235283383249e-10
severe O 1 0.9999568462371826
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 0.9999997615814209
. O 0 8.004555638763122e-06

These O 0 1.4610311183105296e-08
findings O 0 1.6622731635607124e-08
suggest O 0 3.4941769477825346e-09
that O 0 2.0867927177925516e-11
some O 0 5.174363975485319e-12
sequences O 0 7.267150076151196e-11
located O 0 3.7956629506119555e-10
in O 0 2.0541116030337037e-10
the O 0 1.2887008127293598e-09
distal O 0 8.884840667633398e-07
part O 0 4.443792533947999e-08
of O 0 7.973076776579546e-08
the O 0 6.485240788833835e-09
gene O 0 4.5205050813734715e-10
and O 0 1.6570958494277477e-10
, O 0 2.3382292629881007e-11
in O 0 2.7005410060954027e-11
particular O 0 2.780920493883343e-10
, O 0 3.8642023608703724e-11
some O 0 3.4622499311964816e-11
DMD B-Disease 1 0.9917084574699402
isoforms O 0 5.332480057518296e-08
expressed O 0 3.5844356371939057e-09
in O 0 2.1334800592853753e-09
the O 0 1.3921115815662688e-08
brain O 0 9.908572246786207e-05
may O 0 4.831718136699692e-09
be O 0 7.687654679511269e-11
related O 0 2.196254289543731e-10
to O 0 1.9003144544060824e-11
the O 0 2.385849295905018e-10
cognitive B-Disease 0 2.3540842448710464e-06
impairment I-Disease 0 1.3615806892630644e-05
associated O 0 1.0814884490173426e-06
with O 0 1.0947444195608114e-07
DMD B-Disease 1 1.0
. O 0 4.80963500137932e-08
. O 0 4.644174822487912e-08

I1307K O 0 1.800481550162658e-05
APC O 0 9.956499980035005e-07
and O 0 6.88747059385264e-09
hMLH1 O 0 1.1473589722754696e-07
mutations O 0 2.398081955234943e-09
in O 0 7.098823751050531e-10
a O 0 1.300560770189918e-09
non O 0 1.0053395982367874e-07
- O 0 8.852919286539418e-09
Jewish O 0 3.7750499948252525e-10
family O 0 3.1952735596307846e-11
with O 0 1.4369217621323926e-11
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9985957741737366

We O 0 7.555786396551412e-08
describe O 0 2.929055575862094e-08
a O 0 5.525596646904773e-10
French O 0 1.4102955248063154e-08
Canadian O 0 5.561605576076545e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.03367455676198006
HNPCC B-Disease 1 0.9693436622619629
) O 0 6.377126382517417e-09
kindred O 0 9.766653192855301e-07
which O 0 6.121891882315822e-10
carries O 0 9.746270457355877e-10
a O 0 8.310038074332837e-11
novel O 0 6.281533626584235e-11
truncating O 0 8.746542157211934e-09
mutation O 0 2.501560070200526e-10
in O 0 9.94092475004038e-10
hMLH1 O 0 2.4029279188653163e-07
. O 0 1.2143954108978505e-07

Interestingly O 0 8.495813403897046e-07
, O 0 7.470876361992396e-09
the O 0 4.802161779338121e-09
I1307K O 0 9.947780910124493e-08
APC O 0 2.6869708236176848e-08
polymorphism O 0 3.1947362089113085e-08
, O 0 1.1683322365119153e-10
associated O 0 2.402810450607973e-10
with O 0 4.350690814558522e-12
an O 0 6.5883132283062196e-12
increased O 0 2.363633511137664e-09
risk O 0 1.5303262443921994e-06
of O 1 0.9856459498405457
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 9.280827129032332e-08
is O 0 6.603891739009882e-11
also O 0 8.200226955801249e-12
present O 0 4.354594809741208e-11
in O 0 1.7405842045459252e-10
this O 0 2.1181847942308707e-10
family O 0 1.8575458948788537e-09
. O 0 8.390812489267319e-09

The O 0 3.769183649637853e-07
I1307K O 0 8.406320830545155e-07
polymorphism O 0 1.2739432975195086e-07
has O 0 4.619451210441383e-10
previously O 0 8.139866558565245e-10
only O 0 2.451555972116104e-11
been O 0 2.3823240255516076e-11
identified O 0 4.178509968588706e-11
in O 0 1.9993678587737485e-11
individuals O 0 5.699589671753769e-12
of O 0 2.7860187490347244e-09
self O 0 3.644156265636411e-08
- O 0 9.084216046062465e-09
reported O 0 6.726982304527951e-10
Ashkenazi O 0 1.437600372078407e-09
Jewish O 0 3.361373124288747e-10
origins O 0 8.098290926739082e-09
. O 0 8.623382008465796e-09

In O 0 8.327820921749662e-08
addition O 0 4.61015003949683e-09
, O 0 3.372103429821749e-10
in O 0 3.1949096146455247e-10
this O 0 1.3767105511153233e-10
family O 0 5.490224941340216e-10
, O 0 1.030300636473136e-10
there O 0 1.2249039282874463e-10
appears O 0 9.347349561039664e-10
to O 0 3.855014918396904e-11
be O 0 3.376814938782502e-10
no O 0 4.1732631239632667e-10
relationship O 0 1.777981539774487e-09
between O 0 2.613022465070003e-09
the O 0 2.8996638423706145e-10
I1307K O 0 2.271173027423856e-09
polymorphism O 0 6.736072255542069e-10
and O 0 8.063341661035395e-11
the O 0 1.8171712745651547e-10
presence O 0 6.691024401206391e-10
or O 0 3.736937981280164e-10
absence O 0 2.7236474409164657e-08
of O 0 1.3274655152883952e-08
cancer B-Disease 0 2.8947210850560623e-08
. O 0 2.9032958259733732e-09
. O 0 5.084475063199534e-08

Identification O 0 6.754798391739314e-07
of O 0 4.021361519335187e-07
a O 0 7.370273280571382e-09
novel O 0 1.4326213548798705e-09
mutation O 0 8.690133057598359e-10
of O 0 8.34987723408176e-09
the O 0 7.793651946030877e-09
CPO O 0 1.8240459098706197e-07
gene O 0 2.179554758896529e-09
in O 0 7.029247184320297e-10
a O 0 7.934701784506615e-10
Japanese O 0 7.823487635505444e-08
hereditary B-Disease 1 0.9490030407905579
coproporphyria I-Disease 0 0.26568523049354553
family O 0 2.83245384480324e-07
. O 0 1.550166359720606e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999992847442627
( O 0 2.164263241866138e-05
HCP B-Disease 1 0.9634465575218201
) O 0 5.886572118640743e-09
is O 0 6.762681525884773e-10
an O 0 2.178008662312436e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
characterized O 0 3.1008715950520127e-07
by O 0 3.7811753728078656e-10
a O 0 1.508412950101956e-08
deficiency B-Disease 0 0.03541051596403122
of I-Disease 0 0.002113982569426298
coproporphyrinogen I-Disease 0 0.0002581542939879
oxidase I-Disease 0 7.358951670255465e-09
( O 0 1.1979607583700869e-10
CPO O 0 1.5724584301324285e-08
) O 0 1.9484872049169155e-11
caused O 0 9.038268744543387e-11
by O 0 1.5641970357860302e-11
a O 0 2.2618168449284326e-10
mutation O 0 5.2316567744625786e-11
in O 0 6.364169746753134e-10
the O 0 7.509506794178833e-09
CPO O 0 1.272986537514953e-06
gene O 0 4.208349579926107e-08
. O 0 8.119157968167201e-08

Only O 0 2.497284583569126e-07
11 O 0 1.27250316950267e-07
mutations O 0 9.406177170490082e-09
of O 0 2.6898835159272494e-08
the O 0 4.5145962523918115e-09
gene O 0 8.835994158573612e-10
have O 0 1.858458179015976e-11
been O 0 2.676327909290066e-11
reported O 0 1.1024686719096621e-10
in O 0 3.736503328966023e-10
HCP B-Disease 0 0.0003485803317744285
patients O 0 5.423938773674308e-07
. O 0 5.707487389372545e-07

We O 0 1.037145764826164e-07
report O 0 2.037777724339662e-09
another O 0 8.477560320407918e-11
mutation O 0 5.790375123826408e-11
in O 0 1.6644924327735566e-10
a O 0 1.1951086786865517e-09
Japanese O 0 2.671971799372841e-07
family O 0 1.0638223635339727e-08
. O 0 5.225800947528114e-08

Polymerase O 0 4.333830929681426e-06
chain O 0 1.1434548952138357e-07
reaction O 0 1.7937148433233574e-09
- O 0 9.93105153668239e-10
single O 0 1.3202576532034271e-10
strand O 0 1.0097702674016773e-09
conformational O 0 4.983512491563147e-10
polymorphism O 0 4.4311432301213927e-10
and O 0 3.5622744337659995e-11
direct O 0 6.393414964112054e-11
sequence O 0 1.818391687224974e-10
analyses O 0 8.676567797571977e-10
demonstrated O 0 9.097284592307631e-10
a O 0 1.2657798142967636e-09
C O 0 3.49672539812218e-08
to O 0 6.366306926075538e-10
T O 0 1.214404221627774e-08
substitution O 0 7.437361282391919e-10
in O 0 1.2003149585382289e-09
exon O 0 2.343519334147004e-08
1 O 0 2.446813596179709e-08
of O 0 5.550877979487723e-09
the O 0 8.315485189314131e-09
CPO O 0 9.013147206360372e-08
gene O 0 2.1024757490550883e-09
at O 0 3.500108292087134e-08
nucleotide O 0 1.1772318231351164e-08
position O 0 1.4847546481178142e-07
85 O 0 4.6790553653863753e-08
, O 0 7.349647557219896e-10
which O 0 1.2154667550223763e-10
lies O 0 2.3943844684737314e-09
in O 0 9.511635923331596e-11
the O 0 8.944533447241554e-10
putative O 0 9.84237047418901e-09
presequence O 0 1.0452144039163613e-07
for O 0 1.7233018345663709e-09
targeting O 0 1.2977194430163763e-08
to O 0 6.8033867428596295e-09
mitochondria O 0 2.2902324303686328e-07
. O 0 1.8814323254900955e-07

This O 0 4.959761046308131e-09
mutation O 0 5.613575715379682e-10
changes O 0 3.573886464547371e-10
the O 0 3.3478472771797385e-10
codon O 0 8.795202344202835e-10
for O 0 1.6840519256877684e-10
glutamine O 0 2.158336620539103e-09
to O 0 3.3770081175887867e-10
a O 0 1.6266518132468377e-09
termination O 0 1.2907162449948828e-08
codon O 0 6.021470966288689e-08
at O 0 4.835196136809827e-07
amino O 0 6.632568982922749e-08
acid O 0 6.26987173291127e-08
position O 0 5.541200494008081e-07
29 O 0 4.139028533245437e-06
. O 0 8.593909797127708e-07

MaeI O 0 1.1511084267112892e-05
restriction O 0 1.364176398510608e-07
analysis O 0 1.1372165431566827e-08
showed O 0 1.5248980966831027e-09
two O 0 5.299154864912836e-11
other O 0 1.3403830996516763e-11
carriers O 0 5.306437234064987e-11
in O 0 8.344090696166262e-11
the O 0 1.750222855534389e-09
family O 0 4.208692949703163e-09
. O 0 2.996892334294898e-08

The O 0 4.137410542170983e-06
C O 1 0.8532460331916809
- O 0 6.668809510301799e-05
T O 0 6.896003128531447e-07
mutation O 0 2.801224530113444e-10
is O 0 3.26122288896169e-11
located O 0 1.5749150594768224e-10
within O 0 1.4026139971701213e-10
a O 0 4.55104148811003e-11
recently O 0 9.059618333306929e-11
proposed O 0 1.0474860562270649e-10
putative O 0 3.288809502510759e-10
alternative O 0 1.0548280304778501e-10
translation O 0 2.543960597733985e-10
initiation O 0 1.2673379012895225e-09
codon O 0 4.104405260108024e-09
( O 0 6.263017326979536e-10
TIC O 0 3.001223092269356e-07
- O 0 3.812289151028381e-08
1 O 0 3.241661872266377e-08
) O 0 5.5738198778687575e-11
, O 0 5.5331978582318087e-11
supporting O 0 9.258258049094081e-10
that O 0 4.687152332927269e-10
TIC O 0 3.224806732760044e-06
- O 0 1.2728746412449254e-07
1 O 0 6.284250986254847e-08
is O 0 7.063703788556808e-11
the O 0 2.2039881031332698e-10
real O 0 1.5091015370671812e-07
TIC O 0 3.6315077522885986e-07
rather O 0 3.464948994391648e-09
than O 0 2.9890512287522597e-10
TIC O 0 8.14844867136344e-08
- O 0 5.91320770126913e-09
2 O 0 4.189758762151996e-09
. O 0 6.213397851784208e-11
. O 0 2.5454325314200332e-09

Human B-Disease 0 3.4829337636210767e-08
complement I-Disease 0 2.2915499187092792e-07
factor I-Disease 0 9.50364483287558e-06
H I-Disease 1 1.0
deficiency I-Disease 1 0.916227400302887
associated O 0 4.012560566479806e-06
with O 0 1.6656867956044152e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9994004964828491

This O 0 8.110037974518036e-09
study O 0 8.124542150156344e-10
reports O 0 2.0113487264605823e-10
on O 0 1.0302874109413551e-09
six O 0 7.197776402678713e-11
cases O 0 9.444314774675888e-11
of O 0 1.1881129413637836e-09
deficiency B-Disease 0 1.968981905520195e-06
in I-Disease 0 3.205862242339208e-09
the I-Disease 0 6.892411530401432e-09
human I-Disease 0 2.379034302890659e-09
complement I-Disease 0 4.498085015569586e-09
regulatory I-Disease 0 5.4498954682458134e-08
protein I-Disease 0 3.729806508090405e-08
Factor I-Disease 0 2.3328033194047748e-07
H I-Disease 1 0.9999839067459106
( O 0 5.9072786662284216e-09
FH O 0 4.051037905128396e-08
) O 0 4.391235292056095e-11
in O 0 1.9820653798796606e-11
the O 0 1.1880075048709138e-11
context O 0 2.1483345657991038e-10
of O 0 1.0245060355629221e-10
an O 0 1.696052881472454e-10
acute B-Disease 1 0.9999966621398926
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0002266240189783275

Five O 0 4.796562507181079e-07
of O 0 1.0402978034562693e-07
the O 0 9.381089238758022e-10
cases O 0 9.605601730688917e-11
were O 0 1.8082365466076666e-11
observed O 0 2.5360866184875874e-11
in O 0 2.664428573606603e-12
children O 0 5.403789395119762e-13
presenting O 0 5.156337162803837e-11
with O 0 7.1851058436323e-10
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.3471755087375641
HUS B-Disease 1 1.0
) O 0 1.5357356915046694e-06
. O 0 2.967049340441008e-06

Two O 0 2.0788105459246253e-08
of O 0 4.5420645022886674e-08
the O 0 2.9449860328156774e-09
children O 0 1.5891454818728334e-10
exhibited O 0 5.219674292789023e-08
a O 0 2.125374365391508e-08
homozygous O 0 3.229021103834384e-07
deficiency O 0 0.00010891746933339164
characterized O 0 3.242762858235437e-08
by O 0 3.566661410658867e-10
the O 0 8.582572874615835e-09
absence O 0 1.1090822482628937e-07
of O 0 8.503511672586228e-09
the O 0 1.2310574781793093e-09
150 O 0 4.182299229160691e-10
- O 0 1.0360015623156471e-10
kD O 0 2.0428601033017912e-09
form O 0 1.0396873639795245e-10
of O 0 4.280338750106694e-09
Factor O 0 3.707641127448369e-08
H O 1 0.9999953508377075
and O 0 1.8106092181113809e-09
the O 0 6.366404070590193e-10
presence O 0 1.0616564571908071e-10
, O 0 4.552098715332464e-12
upon O 0 6.883037889648946e-11
immunoblotting O 0 4.445392498553247e-09
, O 0 2.735591614344557e-11
of O 0 2.841253621266304e-10
the O 0 5.798346802698973e-10
42 O 0 1.0095820179856219e-08
- O 0 2.3045727548520745e-09
kD O 0 6.590085632751652e-08
Factor O 0 5.4298496365845494e-08
H O 1 0.9999932050704956
- O 0 5.848506816619192e-07
like O 0 4.737089831508001e-09
protein O 0 2.522043551778097e-08
1 O 0 3.434238067256956e-07
( O 0 2.8530158791006954e-10
FHL O 0 1.4736315279151313e-07
- O 0 2.4380414131996986e-08
1 O 0 2.841115609442113e-08
) O 0 5.09099810919178e-11
and O 0 6.480411346432291e-11
other O 0 1.6943489666854106e-10
FH O 0 2.0453649085538927e-07
- O 0 1.9738928713763926e-08
related O 0 1.8241809840446876e-08
protein O 0 1.0191590682495644e-08
( O 0 1.169542934720269e-10
FHR O 0 9.981116733115414e-08
) O 0 2.845657598449236e-10
bands O 0 1.1118802234477698e-07
. O 0 9.766581143821895e-08

Southern O 0 1.9285319012851687e-06
blot O 0 5.378609557737946e-07
and O 0 8.00081001450792e-10
PCR O 0 8.751910862692114e-10
analysis O 0 1.2125098147741653e-10
of O 0 1.7236197191738967e-10
DNA O 0 2.951237310089283e-10
of O 0 1.5328005531500821e-09
one O 0 1.1822799683702812e-10
patient O 0 1.4488976685100852e-09
with O 0 1.3587478919774298e-09
homozygous O 0 9.406194863004202e-07
deficiency O 0 0.22100062668323517
ruled O 0 4.579820142680546e-06
out O 0 5.388318680132897e-10
the O 0 1.3935128051478785e-10
presence O 0 1.822662853978585e-10
of O 0 1.3965948397753891e-09
a O 0 1.5794243690692156e-10
large O 0 5.874833258756595e-11
deletion O 0 2.1951036544010094e-09
of O 0 6.713783307077392e-09
the O 0 2.978257196417644e-09
FH O 0 2.168232668964265e-07
gene O 0 1.0264605831977747e-09
as O 0 2.7383964540383943e-10
the O 0 1.349290346119858e-09
underlying O 0 5.253190920484485e-06
defect O 0 1.0412968549644575e-06
for O 0 4.235945372244032e-09
the O 0 1.5191109525858337e-07
deficiency O 1 0.9979124665260315
. O 0 6.73380600346718e-06

The O 0 1.3020860478718532e-07
other O 0 1.3481636917944684e-09
four O 0 3.5058575487134647e-10
children O 0 7.423875750256492e-12
presented O 0 4.709960199633656e-10
with O 0 8.790619621112938e-11
heterozygous O 0 2.9187440020450595e-08
deficiency O 0 0.0003018964780494571
and O 0 4.73481343021831e-09
exhibited O 0 7.958731202961644e-07
a O 0 3.2965550289532075e-09
normal O 0 1.9400005157876876e-07
immunoblotting O 0 1.6231109611908323e-07
pattern O 0 1.256725656872959e-08
of O 0 1.6539610792065673e-09
proteins O 0 6.914183114936634e-11
of O 0 4.41114300642198e-09
the O 0 4.794721064627083e-09
FH O 0 2.153355580958305e-06
family O 0 8.637670134703512e-09
. O 0 2.5968610373183765e-08

Factor B-Disease 1 0.9983532428741455
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
is O 0 6.486678927331013e-08
the O 0 1.9430755671123734e-08
only O 0 2.2927929776983547e-08
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
associated O 0 1.6825608327053487e-05
with O 0 1.8715842031724605e-07
HUS B-Disease 1 1.0
. O 0 8.166391125996597e-06

These O 0 1.7392915552250088e-08
observations O 0 1.4305459217212046e-07
suggest O 0 5.5764837192384675e-09
a O 0 5.378707479408718e-10
role O 0 1.9578509924400578e-09
for O 0 2.0690706925563518e-09
FH O 0 1.0445472753417562e-06
and O 0 1.2130338511440186e-08
/ O 0 9.94601464299194e-07
or O 0 8.722984112807808e-09
FH O 0 1.7126016871316097e-07
receptors O 0 2.86603119015183e-09
in O 0 6.790898954278646e-10
the O 0 1.1804330846132416e-09
pathogenesis O 0 1.877346949186176e-05
of O 0 1.805303497803834e-07
idiopathic O 0 0.001372828846797347
HUS B-Disease 1 0.9999982118606567
. O 0 3.101540073657816e-07
. O 0 6.673237749055261e-07

Further O 0 5.767787314425732e-08
evidence O 0 1.4305086004640089e-08
for O 0 1.3558683342740352e-10
a O 0 1.1170057240272868e-10
major O 0 3.1160338198610305e-10
ancient O 0 3.5768358941368206e-08
mutation O 0 3.987396439697477e-07
underlying O 1 0.5516589879989624
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.4860581738248584e-07
linkage O 0 9.60230863711331e-06
disequilibrium O 0 4.296226961741922e-06
studies O 0 1.4148077154274574e-09
in O 0 3.62642103846067e-11
the O 0 5.310466996699681e-11
Japanese O 0 2.6089088667191618e-09
population O 0 3.716661527153331e-12
. O 0 8.912806603866841e-10

The O 1 0.7830882668495178
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0006132158450782299
DM B-Disease 1 1.0
) O 0 2.251240083239736e-08
mutation O 0 3.6369049993822955e-09
is O 0 5.39073397032297e-10
an O 0 6.85618117834963e-10
unstable O 0 0.0002627355861477554
( O 0 2.001320709155152e-08
CTG O 0 7.474836820620112e-06
) O 0 8.455424693742941e-10
n O 0 6.229462456985857e-08
repeat O 0 1.1277276001919745e-08
, O 0 3.0866056932588037e-10
present O 0 6.594769175194415e-10
at O 0 1.2501153001664989e-08
a O 0 1.4130351055907653e-10
copy O 0 2.3529048154280474e-10
number O 0 2.4953020552609395e-11
of O 0 1.952421557760431e-09
5 O 0 6.979684830099586e-09
- O 0 4.282560084334364e-09
37 O 0 2.188464964802961e-09
repeats O 0 2.11116368831199e-09
on O 0 8.215988778204064e-09
normal O 0 7.474553420649954e-09
chromosomes O 0 1.494622647868482e-09
but O 0 1.339568594938001e-10
amplified O 0 8.181098021253774e-10
to O 0 2.562456358212728e-10
50 O 0 5.443272499405793e-10
- O 0 9.611172274714974e-11
3000 O 0 1.3195526615827902e-10
copies O 0 4.142050036293199e-10
on O 0 1.0615627132892769e-07
DM B-Disease 1 0.999962568283081
chromosomes O 0 2.292713588758488e-06
. O 0 5.500098154698208e-07

Previous O 0 4.740879333553494e-08
findings O 0 6.699021781741976e-09
in O 0 5.39806976895818e-10
Caucasian O 0 8.630078873750335e-09
populations O 0 5.5546952454355036e-11
of O 0 3.3704285584690297e-08
a O 0 1.9142630662827287e-06
DM B-Disease 1 1.0
founder O 1 0.9993834495544434
chromosome O 0 6.250780279515311e-05
raise O 0 6.045983269586941e-08
a O 0 7.270748447751885e-09
question O 0 2.0896384622659525e-09
about O 0 1.1394597938807483e-11
the O 0 2.4363410594530066e-11
molecular O 0 7.905305854372102e-10
events O 0 1.5568370204110948e-10
involved O 0 3.9471889645703584e-10
in O 0 3.440808402088713e-11
the O 0 2.0130987155031477e-10
expansion O 0 7.0431678267368625e-09
mutation O 0 4.0182612792705186e-09
. O 0 4.003864972901283e-08

To O 0 7.100604193510662e-08
investigate O 0 1.9109349125301378e-07
whether O 0 3.806541926110185e-08
a O 0 2.6196907754183485e-08
founder O 0 2.4140587129295454e-07
chromosome O 0 4.2329027394316654e-08
for O 0 4.777704898373258e-09
the O 0 1.2735667098695558e-07
DM B-Disease 1 1.0
mutation O 0 1.4047912832992893e-09
exists O 0 2.8283095310221995e-10
in O 0 1.624544769540659e-11
the O 0 1.7298336374427237e-11
Japanese O 0 1.701895568917422e-10
population O 0 1.0879947116848587e-13
, O 0 1.82170858259445e-12
we O 0 1.2781367977887648e-11
genotyped O 0 2.5082407262289053e-09
families O 0 4.32487682819338e-12
using O 0 1.5816974119342575e-10
polymorphic O 0 4.866679947923558e-09
markers O 0 1.9524671657222825e-08
near O 0 1.8995423545220547e-07
the O 0 3.308209173269461e-08
( O 0 2.7033888461147626e-09
CTG O 0 6.368923664012982e-07
) O 0 9.477341134100925e-10
n O 0 1.0099022063059238e-07
repeat O 0 2.5886420118581555e-08
region O 0 2.0499024699915935e-08
and O 0 1.4535201930954145e-09
constructed O 0 1.4023322592038312e-07
haplotypes O 0 8.275550271719112e-07
. O 0 5.932641329309263e-07

Six O 0 4.0729720041099426e-08
different O 0 7.711523086761929e-10
haplotypes O 0 9.986083071567009e-09
were O 0 3.3313065639362094e-09
found O 0 3.390212555132166e-10
and O 0 1.8755270947412583e-10
DM B-Disease 1 0.9999995231628418
alleles O 0 2.590586856143773e-09
were O 0 4.914026519031722e-09
always O 0 2.5681576865110856e-09
haplotype O 0 2.1616871848095798e-08
A O 0 1.4417233273888996e-07
. O 0 1.0886996193448795e-07

To O 0 4.274866327591553e-08
find O 0 8.040159649169709e-09
an O 0 4.3054056847458e-11
origin O 0 2.947142252462953e-10
of O 0 2.6317239498752087e-09
the O 0 3.0719125021505533e-09
( O 0 4.074117709862435e-10
CTG O 0 2.2510474195769348e-07
) O 0 2.7080782061261743e-10
n O 0 5.722858631429517e-08
repeat O 0 9.298453562678333e-09
mutation O 0 8.858200284400652e-10
and O 0 1.7640533478413545e-10
to O 0 4.892632479713832e-11
investigate O 0 2.1285861961928276e-09
the O 0 5.805771974287666e-10
mechanism O 0 5.6888382005126914e-08
of O 0 1.0395634575388613e-08
the O 0 4.879764370357975e-10
expansion O 0 3.625427180686813e-10
mutation O 0 1.6119886675491912e-11
in O 0 1.7474457644772734e-11
the O 0 2.0381448265216484e-11
Japanese O 0 1.3467880977113822e-10
population O 0 1.7643400846215074e-13
we O 0 6.770044160692157e-12
have O 0 7.192663890702444e-13
studied O 0 3.895588851499099e-10
90 O 0 3.335125786652071e-10
Japanese O 0 4.466717218321037e-09
DM B-Disease 1 0.6532256603240967
families O 0 2.152570482971683e-11
comprising O 0 1.9573050125121227e-10
190 O 0 3.656615565894583e-10
affected O 0 7.384844125102319e-11
and O 0 9.883295570833894e-11
130 O 0 1.0665157645917134e-09
unaffected O 0 2.165054269198663e-08
members O 0 8.52709070020552e-10
. O 0 4.506511785962175e-08

The O 0 5.486858754011337e-07
results O 0 3.736314369007232e-08
suggest O 0 6.438455546486921e-09
that O 0 2.96209723416041e-11
a O 0 1.17645629349461e-10
few O 0 3.239691501177866e-11
common O 0 5.030928104665655e-11
ancestral O 0 1.2494854040312475e-09
mutations O 0 2.7225330323510377e-10
in O 0 2.7589319717691296e-10
both O 0 3.1471655836945445e-10
Caucasian O 0 1.3706282331327202e-08
and O 0 2.135820131865529e-10
Japanese O 0 8.902413028977207e-09
populations O 0 3.941331636059253e-12
have O 0 9.243986869370002e-13
originated O 0 1.180433463650321e-12
by O 0 6.90513184825603e-14
expansion O 0 3.988896019047061e-11
of O 0 1.303224611559628e-10
an O 0 1.4586510818648257e-11
ancestral O 0 1.0166035790959427e-09
n O 0 1.1928456444820768e-08
= O 0 3.4926577185956376e-09
5 O 0 2.6001507613671038e-09
repeat O 0 1.2129383053505194e-09
to O 0 5.589600449162901e-10
n O 0 4.1782925563893514e-08
= O 0 2.2645084030159524e-08
19 O 0 7.153197145726153e-08
- O 0 1.6286675119658867e-08
37 O 0 1.033190510923987e-08
copies O 0 1.0616635570670496e-08
. O 0 5.99839609094488e-08

These O 0 2.482330785369413e-09
data O 0 1.8268367929508145e-09
support O 0 3.59068774713478e-10
multistep O 0 7.872961305110948e-08
models O 0 2.2591935433524668e-08
of O 0 1.7243456795767997e-07
triplet O 0 6.936839781701565e-06
repeat O 0 2.1678191330920527e-07
expansion O 0 1.180681792334326e-07
that O 0 3.5076100357578355e-10
have O 0 1.5585118265382114e-11
been O 0 5.305786626025322e-12
proposed O 0 1.2421700820719472e-11
for O 0 1.969061719231391e-11
both O 0 1.6889808440723186e-09
DM B-Disease 1 1.0
and O 0 1.3357229988741892e-07
Friedreichs B-Disease 0 9.4680130132474e-05
ataxia I-Disease 0 9.197800682159141e-05
. O 0 3.595481956608637e-08
. O 0 2.8980642241549504e-07

The O 0 2.0580747772669383e-08
molecular O 0 9.810848666802485e-08
basis O 0 2.8980642241549504e-07
of O 0 5.113774022902362e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 5.6220248012550655e-08
the O 0 3.0372586667937185e-09
western O 0 1.6268845159927992e-09
Cape O 0 1.114172576421879e-08
, O 0 1.7720313064129023e-11
South O 0 2.832174772482432e-10
Africa O 0 8.959661901286609e-10
. O 0 3.163241002468453e-09

Deficiency B-Disease 1 0.9997394680976868
of I-Disease 0 0.00043402021401561797
the I-Disease 0 7.75806654473854e-07
sixth I-Disease 0 4.7183721108012833e-07
component I-Disease 0 2.1400434491170017e-07
of I-Disease 0 3.3745138239282824e-07
human I-Disease 0 3.977665485876969e-08
complement I-Disease 0 2.5955944238376105e-07
( O 0 5.8144298265006e-09
C6 O 0 7.351946464950743e-07
) O 0 1.992679909967876e-10
has O 0 2.5430860542408062e-11
been O 0 1.2076415388528883e-11
reported O 0 2.253186873191204e-11
in O 0 2.240308416209813e-12
a O 0 3.630191199727184e-12
number O 0 2.105333702512313e-12
of O 0 4.866055891561416e-10
families O 0 2.13173185700799e-12
from O 0 2.5823603672092688e-11
the O 0 1.2692895345889355e-10
western O 0 1.0076213197152128e-09
Cape O 0 5.884439158165833e-09
, O 0 4.4521678010944754e-11
South O 0 6.489283554955705e-10
Africa O 0 1.2967883433745442e-09
. O 0 4.71487915376656e-09

Meningococcal B-Disease 1 0.9984831213951111
disease I-Disease 0 0.0009655176545493305
is O 0 1.0140337458608428e-09
endemic O 0 6.690565323985709e-10
in O 0 1.4196212261285979e-10
the O 0 2.0762775942984035e-09
Cape O 0 1.036702670376144e-07
and O 0 8.437811560568775e-11
almost O 0 8.177739041492771e-11
all O 0 1.9004811613321237e-11
pedigrees O 0 2.3966140183517837e-09
of O 0 2.772717833110505e-09
total O 0 2.540118941851688e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.934300624701791e-08
C6Q0 O 0 2.5208471470250515e-06
) O 0 1.5969146838212822e-10
have O 0 1.0821306524466667e-11
been O 0 5.220022331053897e-12
ascertained O 0 1.5061583091835473e-09
because O 0 4.041701001655795e-11
of O 0 9.663546629568032e-10
recurrent O 0 6.72777832733118e-06
disease O 0 2.7344665795681067e-05
. O 0 1.337068908924266e-07

We O 0 2.9247746624605497e-07
have O 0 4.2464676219822195e-10
sequenced O 0 1.1247518472146112e-09
the O 0 4.5659989678092927e-10
expressed O 0 4.2095335550662583e-10
exons O 0 4.4567453727495376e-08
of O 0 3.874828280459042e-08
the O 0 4.466727787644231e-08
C6 O 0 2.689688926693634e-06
gene O 0 2.6585034174075872e-09
from O 0 6.746178615735232e-10
selected O 0 7.764000553578398e-11
cases O 0 4.2909526626333516e-11
and O 0 1.1863183178861814e-11
have O 0 3.098564807513249e-12
found O 0 7.65436412170084e-12
three O 0 1.383195207677046e-11
molecular O 0 2.722871670357563e-07
defects O 0 0.00726139172911644
leading O 0 2.2154974033128383e-07
to O 0 4.0915164589705455e-09
total O 0 2.1322084364783223e-07
deficiency O 1 0.9999945163726807
879delG O 0 0.0031189245637506247
, O 0 7.723155448502439e-09
which O 0 9.243696780236732e-11
is O 0 3.4786395985975105e-11
the O 0 1.2442551156066628e-10
common O 0 3.625200806212092e-09
defect O 0 2.223150019631248e-08
in O 0 4.15089213001707e-10
the O 0 2.117321429295771e-09
Cape O 0 3.780753488058508e-08
and O 0 5.00639425748961e-11
hitherto O 0 7.577446226036955e-09
unreported O 0 5.809818404145517e-09
, O 0 3.7428494331637197e-11
and O 0 6.117231721169958e-11
1195delC O 0 9.653769339479368e-09
and O 0 6.994687606898253e-10
1936delG O 0 5.6801642500659e-08
, O 0 1.96058932977472e-10
which O 0 1.0182675883041448e-11
have O 0 2.1148965825140698e-12
been O 0 1.7090340644412838e-12
previously O 0 8.575016564871252e-12
reported O 0 6.033150975331969e-12
in O 0 9.793517559419929e-12
African O 0 1.0781596726516796e-09
- O 0 6.709904187829352e-09
Americans O 0 1.3839989154718069e-09
. O 0 8.239717352864773e-09

We O 0 1.1659535630315077e-06
also O 0 1.1260983256988766e-08
show O 0 1.932304760643433e-09
that O 0 8.662255808478125e-12
the O 0 5.676613692995325e-11
879delG O 0 3.425221217767671e-09
and O 0 1.8394054335235666e-10
1195delC O 0 9.020593694231138e-08
defects O 0 5.166889422980603e-07
are O 0 2.87217367944681e-11
associated O 0 2.30851027183121e-09
with O 0 2.237924512371592e-09
characteristic O 1 0.9995085000991821
C6 O 1 0.9999940395355225
/ O 0 0.052797574549913406
C7 O 0 0.00019262675778008997
region O 0 2.0728913696643758e-08
DNA O 0 2.3932202886101095e-09
marker O 0 4.66014427047412e-09
haplotypes O 0 7.214057351490055e-09
, O 0 2.390180831035593e-10
although O 0 2.4589658087492694e-10
small O 0 1.3077315619280938e-10
variations O 0 4.207745707418553e-09
were O 0 3.0511884130390854e-09
observed O 0 3.24887921010486e-08
. O 0 2.9357057229617567e-08

The O 0 1.0611826155582094e-06
1936delG O 0 1.0954000572382938e-05
defect O 0 1.6491947462782264e-05
was O 0 8.388237802137155e-07
observed O 0 3.1915934783910416e-08
only O 0 6.765042415146638e-10
once O 0 1.5563211830382784e-09
in O 0 1.5914962403495991e-10
the O 0 4.0884876040259144e-10
Cape O 0 3.959392813612794e-08
, O 0 2.055925568678063e-11
but O 0 4.496182506169566e-12
its O 0 2.2448765936433634e-12
associated O 0 2.91314583567015e-10
haplotype O 0 5.1892659058694335e-09
could O 0 1.0560726737551818e-09
be O 0 1.138413918688741e-09
deduced O 0 8.077591928667971e-08
. O 0 3.970153628074513e-08

The O 0 2.2864395532451454e-07
data O 0 1.9486575908445047e-08
from O 0 2.1155694973629124e-09
the O 0 1.3373201435129545e-09
haplotypes O 0 1.2607278776499697e-08
indicate O 0 6.676456720811075e-09
that O 0 4.8672874758404205e-11
these O 0 4.576363246688864e-11
three O 0 2.5371862943934786e-10
molecular O 0 1.2825520911974309e-07
defects O 0 1.4080936807658873e-06
account O 0 3.0885785595735626e-10
for O 0 4.5909484547301815e-10
the O 0 4.162543021379861e-08
defects O 0 0.0001641998387640342
in O 0 9.318960714210789e-09
all O 0 7.601935747558741e-10
the O 0 3.7251266515880843e-09
38 O 0 1.3160402545508987e-08
unrelated O 0 2.3337328514116962e-08
C6Q0 O 0 3.1528227850685653e-07
individuals O 0 1.3896112038835895e-10
we O 0 4.180449042490153e-10
have O 0 2.6583233878052503e-11
studied O 0 2.182487524038379e-09
from O 0 8.497860748413189e-11
the O 0 3.8348713093938613e-10
Cape O 0 6.753316483809613e-08
. O 0 9.250779697822509e-09

We O 0 2.004235852837155e-07
have O 0 2.8057320355934223e-10
also O 0 8.119854615074029e-12
observed O 0 5.183296153399297e-11
the O 0 2.4992981642601997e-11
879delG O 0 1.641286884179749e-09
defect O 0 5.121897572735179e-09
in O 0 5.076765674516537e-10
two O 0 8.97250984621678e-09
Dutch O 1 0.9999973773956299
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.026369737461209297
, O 0 9.198553030387302e-10
but O 0 8.073467588909367e-11
the O 0 3.017123773041419e-10
879delG O 0 4.5969024142777926e-08
defect O 0 7.042028471460071e-08
in O 0 1.6624689402888748e-09
the O 0 9.544612211698222e-09
Cape O 0 1.4718381180500728e-06
probably O 0 4.902604544554379e-09
did O 0 2.408380439522517e-10
not O 0 1.4689983604543322e-11
come O 0 2.1881082015728914e-11
from O 0 6.755738763547514e-12
The O 0 2.753190210535994e-11
Netherlands O 0 1.5485690507688332e-09
. O 0 1.8497772757974928e-10
. O 0 5.807724523521074e-09

Complement B-Disease 1 0.9999926090240479
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.0360621871541298e-07
seven O 0 2.915220509436267e-09
further O 0 8.667371265147494e-10
molecular O 0 3.5942755971518636e-07
defects O 0 1.5247265992002212e-06
and O 0 2.7186775053422707e-10
their O 0 2.57457166696895e-10
associated O 0 6.68254926949885e-08
marker O 0 3.855683132769627e-07
haplotypes O 0 2.1742591798101785e-06
. O 0 9.037743780027085e-07

Seven O 0 5.722814933051268e-08
further O 0 3.869088160968204e-09
molecular O 0 1.2336558086190053e-07
bases O 0 1.6345273579077002e-08
of O 0 0.0003258586802985519
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.4487573685737516e-08
described O 0 2.893391695124592e-07
. O 0 4.586095769809617e-08

All O 0 2.0020461732883632e-08
these O 0 2.1969581709413433e-10
new O 0 7.954961689371487e-10
molecular O 0 1.0175317299854214e-07
defects O 0 8.260649764224581e-08
involve O 0 2.6434054944957097e-09
single O 0 7.876168051090815e-10
- O 0 4.267474817964967e-09
nucleotide O 0 4.152303834104032e-09
events O 0 3.0494529124069913e-10
, O 0 6.66885227595948e-11
deletions O 0 3.1090405250289166e-10
and O 0 2.7166560667701845e-10
substitutions O 0 4.519085106124976e-09
, O 0 6.757817222480256e-11
some O 0 1.2056369791402233e-11
of O 0 3.7795891416614324e-10
which O 0 3.2508950392751146e-11
alter O 0 3.9116057060084586e-09
splice O 0 2.287869804717957e-08
sites O 0 1.287968509622317e-09
, O 0 2.310685254247602e-10
and O 0 4.252554697270483e-10
others O 0 3.595384212573549e-09
codons O 0 1.9242480675529805e-07
. O 0 2.4656989694449294e-07

They O 0 3.6884402199177657e-09
are O 0 1.5145195861321348e-11
distributed O 0 1.0353945131824638e-11
along O 0 1.2786934011632667e-10
the O 0 1.130099902546533e-09
C7 O 0 2.6830488764062466e-07
gene O 0 3.986304342173952e-10
, O 0 2.3537652729666014e-11
but O 0 3.952759994318988e-12
predominantly O 0 1.264077644641537e-11
towards O 0 2.387319508745378e-10
the O 0 5.286416859817678e-10
3 O 0 1.6266060498537627e-08
end O 0 6.283148223928947e-08
. O 0 5.739572728202802e-08

All O 0 2.1696552110483935e-08
were O 0 3.0056090949415193e-09
found O 0 2.9308633298086306e-10
in O 0 1.0242246634151186e-10
compound O 0 3.1040412462601807e-09
heterozygous O 0 2.3310269270382378e-09
individuals O 0 3.776439994052083e-10
. O 0 1.7551478492805472e-08

The O 0 5.717400927096605e-05
C6 O 1 0.9960203766822815
/ O 0 0.0005060567636974156
C7 O 0 7.076372276060283e-05
marker O 0 2.913477885613247e-07
haplotypes O 0 1.252595609457785e-07
associated O 0 1.272095460080891e-07
with O 0 1.0161582686407655e-08
most O 0 3.150165639453917e-07
C7 B-Disease 1 0.9999772310256958
defects I-Disease 1 0.9720497131347656
are O 0 9.39688327150634e-10
tabulated O 0 1.7384864747782558e-07
. O 0 2.187442671441886e-09
. O 0 1.706568397707997e-08

A O 0 5.141122073837323e-06
genome O 0 3.817746829781754e-08
- O 0 1.2439502761196763e-08
wide O 0 2.396879361654669e-09
search O 0 2.1392583260393394e-09
for O 0 3.025941164302992e-10
chromosomal O 0 3.314520654384978e-06
loci O 0 2.9893541864112194e-07
linked O 0 1.3167717725082184e-06
to O 0 3.386788627324222e-09
mental O 1 0.9981075525283813
health O 0 9.730506462801713e-07
wellness O 0 1.956189407792408e-06
in O 0 2.8509830052314555e-09
relatives O 0 1.6570651517611168e-09
at O 0 1.71562835049599e-08
high O 0 2.595905357338779e-08
risk O 0 1.1468203275910582e-08
for O 0 3.72414810101418e-08
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9996126294136047
among O 0 4.7051651463903e-10
the O 0 1.2652607850327513e-09
Old O 0 4.387608498745976e-08
Order O 0 2.4535045106688358e-09
Amish O 0 2.3989937147916862e-08
. O 0 7.578964122956222e-09

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.01867012307047844
BPAD B-Disease 1 1.0
; O 1 0.9998841285705566
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 2.0557992641556666e-08
is O 0 5.350732079634213e-10
characterized O 0 5.354529597489943e-10
by O 0 1.538193877825833e-11
episodes O 0 3.461713760088969e-08
of O 0 9.588261207227333e-08
mania B-Disease 0 1.110953462557518e-06
and O 0 2.5784061552514004e-09
/ O 0 4.4420386302590487e-07
or O 0 7.312331629094615e-09
hypomania B-Disease 0 2.848472649930045e-05
interspersed O 0 1.5648080164964995e-08
with O 0 7.827551107286723e-11
periods O 0 3.617253128140874e-07
of O 0 3.2053569043455354e-07
depression B-Disease 0 0.0299178846180439
. O 0 3.561241044280905e-07

Compelling O 0 1.7394214637533878e-06
evidence O 0 7.365007093085296e-08
supports O 0 6.774859784286491e-09
a O 0 8.660546724215124e-10
significant O 0 1.1415057787900196e-09
genetic O 0 4.838237810389501e-09
component O 0 5.345270182033346e-08
in O 0 1.0285202689530593e-09
the O 0 2.9904729803575947e-09
susceptibility O 0 7.164639725942834e-08
to O 0 4.6483732418778345e-09
develop O 0 1.4287002159107942e-06
BPAD B-Disease 1 1.0
. O 0 6.136773208709201e-06

To O 0 3.0953636098729476e-08
date O 0 1.419498687482701e-07
, O 0 2.5884813736887224e-10
however O 0 1.310163227907779e-10
, O 0 2.174503285767848e-11
linkage O 0 2.398534704184385e-09
studies O 0 2.6282814813427535e-10
have O 0 2.5600563335892446e-11
attempted O 0 2.2834569790575188e-09
only O 0 4.568043512898079e-11
to O 0 7.947208863212651e-11
identify O 0 9.05574015774846e-09
chromosomal O 0 9.15922828426119e-06
loci O 0 1.6301008542995987e-07
that O 0 2.7466733332204285e-09
cause O 0 2.5870578568287783e-08
or O 0 7.651653616269627e-11
increase O 0 5.023861188169221e-11
the O 0 1.209587707773352e-10
risk O 0 1.2495807721890628e-09
of O 0 2.5581259333051776e-09
developing O 0 3.956403986649093e-07
BPAD B-Disease 1 1.0
. O 0 1.6213563185374369e-06

To O 0 6.560237864050578e-08
determine O 0 4.964505819771148e-07
whether O 0 1.5479203696600052e-08
there O 0 1.886455880395488e-09
could O 0 1.3719973768200333e-10
be O 0 2.522554561068535e-11
protective O 0 3.505222501143379e-10
alleles O 0 2.6958990595460364e-11
that O 0 1.3977659307773393e-11
prevent O 0 2.990300229654963e-10
or O 0 7.295982568100712e-11
reduce O 0 1.1962831836243026e-09
the O 0 3.580941931868864e-10
risk O 0 1.7470642710293305e-09
of O 0 4.537187514586094e-09
developing O 0 3.256430147757783e-07
BPAD B-Disease 1 1.0
, O 0 9.978271542365746e-10
similar O 0 7.091188053420794e-11
to O 0 1.2797979689893602e-11
what O 0 5.5073042480591194e-12
is O 0 1.5887277929858834e-13
observed O 0 1.0050271379014042e-11
in O 0 1.2407493435451222e-11
other O 0 3.884644272922344e-10
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.1177735403933298e-09
we O 0 2.69467698155168e-10
used O 0 2.678087307472765e-09
mental O 0 0.0001251304493052885
health O 0 1.3482265615039069e-07
wellness O 0 4.3500568835952436e-07
( O 0 7.387548905946062e-11
absence O 0 3.956952543404668e-09
of O 0 5.642282197015902e-09
any O 0 9.134271117261505e-09
psychiatric B-Disease 0 0.057047974318265915
disorder I-Disease 0 9.930851518902273e-08
) O 0 5.992015043865262e-12
as O 0 2.8520788161734423e-11
the O 0 3.9142813990089564e-11
phenotype O 0 1.6181626871780708e-10
in O 0 2.1444575282192346e-10
our O 0 1.2304283147912543e-09
genome O 0 2.9486885155805e-10
- O 0 9.668007505680976e-10
wide O 0 2.070847493484962e-09
linkage O 0 9.19180553893284e-09
scan O 0 9.730472072533303e-08
of O 0 1.7040703070847485e-08
several O 0 7.805668889027118e-10
large O 0 1.2953297323647917e-09
multigeneration O 0 2.3017763339794328e-07
Old O 0 8.981638899285826e-08
Order O 0 4.512151541291587e-09
Amish O 0 8.933864314997209e-09
pedigrees O 0 2.748072436276061e-09
exhibiting O 0 2.856328062961211e-09
an O 0 4.0809206708347645e-11
extremely O 0 2.193617953949456e-09
high O 0 1.302589858198644e-08
incidence O 0 8.697832640791603e-07
of O 0 8.160360494002816e-07
BPAD B-Disease 1 1.0
. O 0 3.7040829283796484e-06

We O 0 3.7889910231569957e-07
have O 0 4.78257100589019e-10
found O 0 1.1496267826593964e-10
strong O 0 1.5008086787227093e-11
evidence O 0 9.24676515912104e-11
for O 0 1.2113880211439554e-11
a O 0 1.2067602472853878e-10
locus O 0 7.191165440900704e-10
on O 0 6.478097702711239e-08
chromosome O 0 3.2287533713315497e-07
4p O 0 9.767484698386397e-06
at O 0 5.69349424495158e-07
D4S2949 O 0 2.2669853194656753e-07
( O 0 6.710770827922374e-10
maximum O 0 1.6279283698850122e-08
GENEHUNTER O 0 4.1550714513505227e-07
- O 0 6.997013191067936e-09
PLUS O 0 1.061250554101889e-08
nonparametric O 0 3.901332945588365e-08
linkage O 0 1.4664697012278793e-08
score O 0 8.90350015936292e-09
= O 0 2.6791551199778496e-09
4 O 0 3.0089131186628038e-09
. O 0 1.6198239971565442e-10
05 O 0 2.365682405525149e-08
, O 0 2.941471732853529e-09
P O 0 2.961187419714406e-07
= O 0 6.068799685010617e-09
5 O 0 2.3335269272450887e-09
. O 0 9.18224662971312e-11
22 O 0 2.6288140553276662e-09
x O 0 3.957444860702708e-08
10 O 0 2.7556266601891366e-08
( O 0 3.8009514979897574e-10
- O 0 1.7996913959095195e-09
4 O 0 3.319072128249445e-09
) O 0 2.698985999971537e-11
; O 0 3.4280543681486364e-11
SIBPAL O 0 2.7119009260445637e-08
Pempirical O 0 4.232830264072618e-08
value O 0 1.27874111299775e-08
< O 0 1.5271982789499816e-08
3 O 0 7.1662498157820664e-09
x O 0 2.4739659210126774e-08
10 O 0 1.6008444347903605e-08
( O 0 3.131734038763767e-10
- O 0 8.653578409401064e-10
5 O 0 6.75486999668351e-10
) O 0 9.634477243780637e-12
) O 0 4.8722822651448006e-12
and O 0 2.0008101078716756e-11
suggestive O 0 2.3891064682146634e-09
evidence O 0 5.406395331419844e-10
for O 0 2.4114776148165262e-11
a O 0 1.142358915795505e-10
locus O 0 5.85356263460568e-10
on O 0 8.9699291550005e-08
chromosome O 0 7.388657650153618e-07
4q O 0 7.159858341765357e-07
at O 0 1.517431371667044e-07
D4S397 O 0 6.905586502625738e-08
( O 0 2.0911446185767346e-10
maximum O 0 5.3000293043226065e-09
GENEHUNTER O 0 5.696557536793989e-07
- O 0 1.492976586803252e-08
PLUS O 0 1.5240587458720256e-08
nonparametric O 0 2.886506322852256e-08
linkage O 0 7.477861885263337e-09
score O 0 9.080196150534903e-09
= O 0 2.586646896673983e-09
3 O 0 1.502459934243916e-09
. O 0 4.7375728340348644e-11
29 O 0 6.504318417199784e-09
, O 0 9.009202828202945e-10
P O 0 2.596723049919092e-07
= O 0 1.1999973459353441e-08
2 O 0 8.767487180705302e-09
. O 0 8.96661564442347e-11
57 O 0 2.131552268025416e-09
x O 0 4.4972551904720603e-08
10 O 0 2.8233753113227067e-08
( O 0 4.824505239753307e-10
- O 0 1.6116705747748483e-09
3 O 0 3.067328169237271e-09
) O 0 2.7677587652319424e-11
; O 0 7.233007248697021e-11
SIBPAL O 0 9.15103299803377e-08
Pempirical O 0 6.942723729252975e-08
value O 0 2.051408287684353e-08
< O 0 4.888470073183271e-08
1 O 0 1.4725520358638278e-08
x O 0 4.0181255656079884e-08
10 O 0 2.191858250455425e-08
( O 0 3.8710501470973213e-10
- O 0 2.441479018955306e-09
3 O 0 2.7217192943851387e-09
) O 0 1.476126686161816e-11
) O 0 4.10791539673383e-12
that O 0 3.7152086962422e-12
are O 0 2.452508899089545e-12
linked O 0 5.447738371522348e-10
to O 0 2.9459620853877766e-10
mental O 0 0.0049478705041110516
health O 0 6.616338623643969e-07
wellness O 0 4.1793914533627685e-06
. O 0 8.67573248797271e-08

These O 0 5.0841745036223074e-08
findings O 0 2.0234946163100176e-08
are O 0 1.1855746939737344e-10
consistent O 0 1.180671782563536e-09
with O 0 1.824975240372062e-11
the O 0 2.2935650600963697e-10
hypothesis O 0 1.5133305719672308e-10
that O 0 8.627822306421506e-13
certain O 0 2.5019262703263045e-11
alleles O 0 3.612981025469253e-10
could O 0 5.565939931173602e-10
prevent O 0 2.485770478344307e-09
or O 0 2.5101776213176663e-10
modify O 0 4.906496542389505e-09
the O 0 4.3875372779389465e-10
clinical O 0 4.531211406089142e-09
manifestations O 0 9.479899887310239e-08
of O 0 1.2865334042544418e-07
BPAD B-Disease 1 1.0
and O 0 2.9799791523288377e-09
perhaps O 0 2.6618304782566327e-10
other O 0 3.27149626833112e-11
related O 0 1.0321233645527172e-07
affective B-Disease 0 0.0013237009989097714
disorders I-Disease 1 0.9996126294136047
. O 0 1.0268408914271276e-06

Segregation O 0 0.001257584081031382
distortion O 1 0.993179440498352
in O 0 0.00018581940094009042
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 8.892000914784148e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9987530708312988
DM B-Disease 1 1.0
) O 0 1.0185706145193762e-07
is O 0 3.691058125809832e-09
an O 0 1.8852690519821635e-09
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999959468841553
which O 0 1.7245150862876812e-09
, O 0 3.316341298797987e-11
in O 0 5.93685517413789e-11
the O 0 9.095133535197419e-10
typical O 0 1.9033572939974874e-08
pedigree O 0 1.0884950718548225e-09
, O 0 1.9064897230358646e-11
shows O 0 1.461888249343346e-10
a O 0 1.5331157177111976e-10
three O 0 1.097726701204671e-10
generation O 0 6.650009432007664e-09
anticipation O 0 2.408433630307627e-08
cascade O 0 4.884318514086772e-07
. O 0 2.1433807262383198e-07

This O 0 1.6924271706297844e-10
results O 0 5.133984348759668e-10
in O 0 1.6646773959294592e-09
infertility B-Disease 1 0.9999377727508545
and O 1 0.8850081562995911
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.2228681043779943e-05
CDM B-Disease 0 0.0047636027447879314
) O 0 2.2722854153833794e-10
with O 0 2.9787540489767395e-11
the O 0 1.890403833471055e-09
disappearance O 0 9.423688851484258e-08
of O 0 1.071667554697342e-07
DM B-Disease 1 1.0
in O 0 1.0643195658133209e-08
that O 0 3.104981272095131e-10
pedigree O 0 1.6195107477301462e-08
. O 0 1.2768400559082238e-08

The O 0 1.5178533985249487e-08
concept O 0 2.9915870669583455e-08
of O 0 5.5001038390400936e-08
segregation O 0 9.55146106207394e-07
distortion O 0 1.038504137795826e-06
, O 0 1.4359498312632724e-10
where O 0 5.474839678831778e-11
there O 0 1.0932671434815688e-11
is O 0 3.851243109143088e-12
preferential O 0 8.288814079548956e-10
transmission O 0 1.4261742009580303e-08
of O 0 9.307782322665048e-10
the O 0 2.5276081228042813e-10
larger O 0 1.6384305023819934e-10
allele O 0 5.624346544053083e-10
at O 0 3.592959174625321e-08
the O 0 7.700620585637807e-09
DM B-Disease 1 0.9998401403427124
locus O 0 1.7038981781070106e-08
, O 0 1.1362467633446727e-09
has O 0 1.3167845980266435e-10
been O 0 3.420962679800965e-10
put O 0 2.32868035965339e-09
forward O 0 1.1760961982076878e-08
to O 0 2.118528269479114e-10
explain O 0 2.022459533179699e-09
partially O 0 3.638389811655429e-09
the O 0 1.5317455082097808e-09
maintenance O 0 4.161823653703323e-06
of O 0 4.302746219764231e-06
DM B-Disease 1 1.0
in O 0 3.208696242040787e-08
the O 0 2.4873165749284e-09
population O 0 3.155314204361659e-11
. O 0 3.1758820018268352e-09

In O 0 2.8487593795034627e-07
a O 0 2.493017525750929e-08
survey O 0 5.617820431069731e-09
of O 0 3.926265890186187e-08
DM B-Disease 1 1.0
in O 0 2.546191346652904e-08
Northern O 0 1.7578415167918138e-08
Ireland O 0 5.494952493023675e-09
, O 0 1.3566496537276151e-10
59 O 0 8.284313679496336e-09
pedigrees O 0 2.46137066284291e-08
were O 0 3.916906798906439e-09
ascertained O 0 1.839542619563872e-06
. O 0 1.6949074677086173e-07

Sibships O 0 3.672972889035009e-05
where O 0 2.906821272574689e-08
the O 0 1.3612327931511459e-09
status O 0 4.4254360176410046e-09
of O 0 1.143879835296957e-08
all O 0 1.7135663721301597e-10
the O 0 3.1666744226832577e-10
members O 0 5.2732929134435835e-11
had O 0 2.672248811119715e-10
been O 0 7.446484401318898e-11
identified O 0 1.3306176993577168e-10
were O 0 8.482752000826821e-11
examined O 0 1.2164877993825485e-09
to O 0 2.9714567612026954e-11
determine O 0 7.397592538538333e-10
the O 0 4.091358363211839e-10
transmission O 0 6.120986739688306e-08
of O 0 1.4344047727377074e-08
the O 0 1.2335777732630504e-08
DM B-Disease 1 0.9999998807907104
expansion O 0 1.500164756862432e-07
from O 0 6.086477544187119e-09
affected O 0 1.4190750796672091e-09
parents O 0 5.237727612739107e-11
to O 0 2.9535221490739616e-11
their O 0 1.566290569465778e-10
offspring O 0 2.0761943275715566e-09
. O 0 1.293345697206405e-08

Where O 0 2.618817234179005e-07
the O 0 4.137790199365554e-08
transmitting O 0 6.0070342442486435e-06
parent O 0 2.732748427547449e-08
was O 0 4.761068908010202e-07
male O 0 2.627958295420285e-08
, O 0 3.146362503869682e-09
58 O 0 2.8722143952109036e-07
. O 0 1.819147001924648e-07

3 O 0 1.811392849049298e-06
% O 0 8.270673035326581e-09
of O 0 3.746841059637518e-08
the O 0 9.349012231041343e-09
offspring O 0 9.500671360740398e-10
were O 0 4.5302758766574414e-10
affected O 0 7.41010031113376e-11
, O 0 1.2811535686496622e-11
and O 0 5.69768754746236e-12
in O 0 4.079060700323822e-11
the O 0 6.357094017861442e-11
case O 0 3.984495233755325e-10
of O 0 1.686716877280503e-10
a O 0 8.348516322698174e-11
female O 0 2.318698427705712e-10
transmitting O 0 9.48751477380938e-08
parent O 0 5.364786392902943e-09
, O 0 4.603419423432342e-09
68 O 0 1.1453172419351176e-06
. O 0 9.070226951735094e-07

7 O 0 5.4458650993183255e-06
% O 0 4.073515569302799e-08
were O 0 2.3558841988347012e-08
affected O 0 3.311845730991081e-08
. O 0 1.0417770823778483e-07

Studies O 0 6.241450591915054e-07
on O 0 8.162493259078474e-07
meiotic O 0 2.1231242499197833e-05
drive O 0 5.127364488544117e-07
in O 0 7.240610244707568e-08
DM B-Disease 1 1.0
have O 0 1.2851900099697389e-10
shown O 0 3.3055364001555176e-11
increased O 0 1.2559975628989584e-11
transmission O 0 4.0505704346216476e-10
of O 0 6.447210820770266e-11
the O 0 2.297543752471931e-11
larger O 0 2.2212690020673165e-11
allele O 0 1.4662361602635343e-10
at O 0 1.1180192771576003e-08
the O 0 3.9059546708131165e-09
DM B-Disease 1 0.9616575241088867
locus O 0 7.446946614919625e-09
in O 0 6.568085186842154e-09
non O 0 1.7285337889916264e-06
- O 0 5.342066742741736e-06
DM O 1 0.9999996423721313
heterozygotes O 0 2.8154972824268043e-06
for O 0 3.591376440681415e-08
CTGn O 0 2.1605063011520542e-05
. O 0 2.6304314815206453e-07

This O 0 9.833326153341204e-09
study O 0 4.145071397232414e-09
provides O 0 2.410209531955587e-10
further O 0 4.9430404214234613e-11
evidence O 0 2.0400633959916092e-10
that O 0 1.3122183895042383e-11
the O 0 1.2853794695288911e-09
DM B-Disease 1 1.0
expansion O 0 3.268978900905495e-07
tends O 0 5.4219295719803995e-09
to O 0 9.50166265112351e-11
be O 0 1.404560079354411e-10
transmitted O 0 7.656825729007721e-10
preferentially O 0 2.1070161171365953e-09
. O 0 1.1510277175830197e-08

Diagnosis O 0 0.2793302536010742
of O 0 0.0010323608294129372
hemochromatosis B-Disease 1 1.0
. O 0 0.0002539207343943417

If O 0 5.335667447070591e-05
untreated O 1 0.9999994039535522
, O 0 4.314588750276016e-06
hemochromatosis B-Disease 1 1.0
can O 0 9.252665222447831e-06
cause O 0 0.00022955704480409622
serious O 0 0.00023297274310607463
illness O 0 0.004129067528992891
and O 0 4.725373980996039e-10
early B-Disease 0 4.898317129686802e-08
death I-Disease 0 6.537726360278384e-09
, O 0 2.4838532272641878e-11
but O 0 2.31340484962983e-11
the O 0 3.369062806513057e-10
disease O 0 8.55338555538765e-09
is O 0 2.2164273888458652e-11
still O 0 3.3620703443482114e-11
substantially O 0 4.148208998522307e-10
under O 0 2.6911150641240056e-08
- O 0 7.110999149517738e-07
diagnosed O 0 1.7327540717815282e-06
. O 0 7.181796490840497e-08

The O 0 8.032267260205117e-07
cornerstone O 0 5.6703578593442217e-05
of O 0 7.064252827149176e-08
screening O 0 1.49426142570519e-08
and O 0 1.085629156016843e-10
case O 0 2.0926967103651606e-10
detection O 0 5.009099801611683e-10
is O 0 3.296361230850642e-12
the O 0 1.3219906939976322e-11
measurement O 0 1.9951006180463082e-08
of O 0 1.2335801713447836e-08
serum O 0 9.696933922498374e-09
transferrin O 0 3.3149802902698866e-08
saturation O 0 6.176588129847005e-08
and O 0 2.5577795437214945e-09
the O 0 9.768421627143198e-09
serum O 0 1.0884254919574232e-07
ferritin O 0 1.2333881613812991e-06
level O 0 8.370337809537887e-07
. O 0 1.1521814258230734e-07

Once O 0 1.816035364754498e-06
the O 0 4.432297018297504e-08
diagnosis O 0 1.2057098501827568e-06
is O 0 2.4685239963240235e-10
suspected O 0 7.817533287379774e-09
, O 0 2.0859022842323327e-10
physicians O 0 1.8299789461551086e-09
must O 0 3.6188155250194143e-10
use O 0 1.2597944909487069e-09
serum O 0 2.126505727062522e-08
ferritin O 0 7.739953957752732e-07
levels O 0 7.71485488826329e-08
and O 0 1.3352155825430145e-08
hepatic O 1 0.9990276098251343
iron O 1 0.9999644756317139
stores O 0 1.9694577702011884e-07
on O 0 4.629520162779954e-07
liver O 0 1.2568831664339086e-07
biopsy O 0 3.3063294324620074e-08
specimens O 0 7.68588470645426e-10
to O 0 8.376077609284494e-11
assess O 0 1.3891355621353796e-08
patients O 0 7.629738507652917e-10
for O 0 1.2977700858396446e-10
the O 0 3.853906638262572e-10
presence O 0 7.012538105755084e-09
of O 0 3.958208196763735e-07
iron B-Disease 1 0.991929292678833
overload I-Disease 0 6.688846042379737e-05
. O 0 4.58813445902706e-07

Liver O 0 0.00029649253701791167
biopsy O 0 0.00014143441512715071
is O 0 5.1141689993983164e-08
also O 0 8.242511118083939e-10
used O 0 4.900115868622379e-10
to O 0 1.5812962050887336e-10
establish O 0 1.01197459301261e-08
the O 0 4.353419846836459e-09
presence O 0 3.5852629753918563e-09
or O 0 4.581494295052835e-09
absence O 0 5.013444592805172e-07
of O 0 7.355221782745502e-07
cirrhosis B-Disease 1 0.9999796152114868
, O 0 2.4395845343860856e-09
which O 0 7.65918786727049e-11
can O 0 1.7055383494390952e-10
affect O 0 7.54692486282238e-09
prognosis O 0 1.37003283384729e-07
and O 0 3.352442767834418e-09
management O 0 1.0068457640954875e-06
. O 0 1.6169032335255906e-07

A O 0 1.2634307040571002e-06
DNA O 0 2.264219212122498e-08
- O 0 2.2347423911384112e-09
based O 0 1.5003458198048492e-10
test O 0 8.967863951436783e-11
for O 0 3.51796682063199e-11
the O 0 1.2553857953179204e-09
HFE O 0 6.454417302848015e-07
gene O 0 7.576492322414197e-09
is O 0 1.6436796368424211e-10
commercially O 0 4.321978608334831e-10
available O 0 2.6112823015012054e-10
, O 0 2.909540663953436e-11
but O 0 8.456012799695767e-12
its O 0 5.242702105778818e-12
place O 0 3.381384339196103e-10
in O 0 3.738917855877766e-11
the O 0 1.8988734196145884e-10
diagnosis O 0 1.4479127230515587e-07
of O 0 1.1301784752504318e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.2852159336773639e-08
still O 0 9.014136104212866e-10
being O 0 5.645497958006729e-10
evaluated O 0 2.6217202631073633e-08
. O 0 1.7583074551907885e-08

Currently O 0 1.589279577274283e-06
, O 0 6.3624621127189585e-09
the O 0 1.8283706770816366e-09
most O 0 1.4289991412397285e-10
useful O 0 1.297288054757928e-09
role O 0 6.309899824863408e-10
for O 0 7.459875772664049e-11
this O 0 5.3493390272940644e-12
test O 0 2.089166166452383e-11
is O 0 1.670001593609416e-12
in O 0 2.7511254992867995e-12
the O 0 1.2069069701969859e-11
detection O 0 8.002248641503229e-09
of O 0 1.7063861434962746e-08
hemochromatosis B-Disease 1 1.0
in O 0 4.13465031101623e-08
the O 0 1.673790350764648e-08
family O 0 4.1525075045178994e-10
members O 0 1.1908098118684762e-10
of O 0 6.818729580970739e-09
patients O 0 2.5936421899075413e-09
with O 0 6.065880020500458e-10
a O 0 7.0732153467645276e-09
proven O 0 2.2943642363770778e-07
case O 0 2.1426966867466035e-09
of O 0 9.721466964762726e-10
the O 0 1.2707120911059633e-09
disease O 0 2.090606727733757e-07
. O 0 1.3375911933621865e-08

It O 0 4.571979683731797e-09
is O 0 1.2906367086173987e-09
crucial O 0 4.400170894314215e-08
to O 0 5.564828153836743e-09
diagnose O 1 0.9999996423721313
hemochromatosis B-Disease 1 1.0
before O 1 0.9999971389770508
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 6.975554697419284e-06
because O 0 6.21901463659924e-08
phlebotomy O 1 0.7590630650520325
therapy O 0 0.0067484090104699135
can O 0 5.293301352793378e-09
avert O 0 1.633606871109805e-06
serious O 0 0.0014392388984560966
chronic O 1 1.0
disease O 1 0.8999769687652588
and O 0 1.749198341727265e-09
can O 0 2.0218068885746732e-10
even O 0 2.259897963208246e-10
lead O 0 2.2431841106840267e-10
to O 0 3.1821243556828804e-11
normal O 0 7.1162503445521e-08
life O 0 3.1218299056945398e-09
expectancy O 0 4.290932498207667e-09
. O 0 2.624224171299261e-10
. O 0 7.188605266605919e-09

Prevalence O 0 2.7148435037815943e-05
of O 0 4.912604936180287e-07
the O 0 4.194702185600363e-08
I1307K O 0 8.18019827875105e-07
APC B-Disease 0 2.6855822454763256e-08
gene O 0 5.651747403412344e-10
variant O 0 6.256450912900391e-10
in O 0 4.5660836223149204e-11
Israeli O 0 1.9064871903395897e-10
Jews O 0 3.878541932067492e-11
of O 0 3.494060249464859e-11
differing O 0 3.3945960192099944e-12
ethnic O 0 1.2445504696256826e-12
origin O 0 1.6239895712921726e-12
and O 0 2.306539508001304e-12
risk O 0 3.7759576021478836e-10
for O 0 1.2538333926670475e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.017591947689652443

BACKGROUND O 0 4.1217908801627345e-06
& O 0 7.039852221168985e-07
AIMS O 0 1.4347056875863018e-08
Israeli O 0 7.271802271446859e-09
Jews O 0 9.772759268500408e-10
of O 0 2.910337082440151e-09
European O 0 2.0574730807965125e-09
birth O 0 8.696370734639913e-09
, O 0 4.3323120091365297e-10
i O 0 2.7245448119828097e-09
. O 0 4.180144078103076e-11
e O 0 2.8272847951704705e-10
. O 0 2.5521825972041334e-11
, O 0 8.624671810064655e-11
Ashkenazim O 0 1.2414850480979567e-08
, O 0 8.381351168651463e-11
have O 0 1.2813220970353534e-11
the O 0 2.0699578162641785e-10
highest O 0 4.638147402147297e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.003759990679100156
of O 0 1.074010125279301e-08
any O 0 1.7088142012511298e-10
Israeli O 0 4.114477647476633e-09
ethnic O 0 4.698540223557757e-09
group O 0 7.81929188065078e-09
. O 0 1.5901839844900678e-08

The O 0 1.3467426924762549e-06
I1307K O 0 3.1381318876810838e-06
APC B-Disease 0 1.4088631417052966e-07
gene O 0 4.269298692349821e-09
variant O 0 2.108737895412105e-08
was O 0 3.326311315277053e-08
found O 0 5.195135988067534e-10
in O 0 7.324891249105292e-10
6 O 0 1.5672041797643033e-07
. O 0 5.1228973063643934e-08

1 O 0 1.9813385279121576e-06
% O 0 1.977682906328937e-09
of O 0 5.287488669125651e-09
American O 0 7.113815092552045e-10
Jews O 0 8.788909183765625e-11
, O 0 3.0007929734815475e-12
28 O 0 1.9693556507771603e-10
% O 0 3.2552634199323194e-11
of O 0 2.5311261975247135e-09
their O 0 1.133314952994624e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.506669261492789e-06
, O 0 2.6780128462022823e-11
but O 0 3.161782684626968e-12
not O 0 2.2319019462452294e-12
in O 0 1.474674549140076e-11
non O 0 4.15746281845486e-09
- O 0 4.9221497988583e-09
Jews O 0 6.0518740019333e-10
. O 0 3.320598240819095e-09

We O 0 2.2915914144050475e-07
assessed O 0 3.1227074259732035e-07
the O 0 3.334745812821893e-09
I1307K O 0 9.312190130117415e-09
prevalence O 0 1.6333540076018949e-10
in O 0 1.6740423066860521e-12
Israeli O 0 3.138890883325196e-11
Jews O 0 9.302608162953252e-12
of O 0 4.942556780518359e-12
differing O 0 1.0609002825540115e-12
ethnic O 0 8.880415933859576e-13
origin O 0 1.706434798152967e-12
and O 0 2.0753401167722396e-12
risk O 0 3.35342614787848e-10
for O 0 1.0908005165788381e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0009429124183952808

METHODS O 0 4.696105690982222e-07
DNA O 0 2.3167632257070636e-09
samples O 0 1.8570985027555054e-10
from O 0 1.4183329510863985e-10
500 O 0 2.6883507572850185e-11
unrelated O 0 4.2774553343782884e-10
Jews O 0 2.8745630875626205e-11
of O 0 4.1390726956969104e-10
European O 0 6.363357063499109e-10
or O 0 9.798698658025629e-11
non O 0 8.497946790697597e-10
- O 0 2.627528229715015e-11
European O 0 1.959960319042331e-11
origin O 0 8.063368549249272e-12
, O 0 8.882821778480321e-13
with O 0 5.836195242359121e-13
or O 0 1.0363290954551463e-11
without O 0 1.5994265634144966e-10
a O 0 2.2037907609906426e-10
personal O 0 5.272181802240539e-09
and O 0 2.3814767935448344e-09
/ O 0 1.339406878742011e-07
or O 0 2.5607473919109225e-09
family O 0 3.9332551104998004e-10
history O 0 1.3580120361567083e-09
of O 0 6.5855974007433815e-09
neoplasia B-Disease 0 7.299590265574807e-07
, O 0 8.902935055843386e-10
were O 0 3.3434502388907106e-10
examined O 0 8.32419644325455e-09
for O 0 1.610879901692286e-10
the O 0 2.468707460678843e-10
I1307K O 0 1.203012578443463e-09
variant O 0 6.375903277566763e-11
by O 0 1.2602787737014953e-11
the O 0 1.5020408528076956e-10
allele O 0 1.1720976966778096e-10
- O 0 1.0742835787613814e-10
specific O 0 2.3931311793345955e-11
oligonucleotide O 0 1.9675479023817388e-08
( O 0 1.9928585170969626e-10
ASO O 0 2.4400330289608974e-07
) O 0 1.8721460492976405e-10
method O 0 2.8127704609914872e-08
. O 0 3.108000257157073e-08

RESULTS O 0 1.2622803069461952e-07
In O 0 9.399396816434091e-09
persons O 0 3.158701300520761e-09
at O 0 2.390215314562738e-08
average O 0 1.1701571933642185e-09
risk O 0 8.23311907538482e-09
for O 0 9.021626112826198e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.6222762506431536e-08
I1307K O 0 1.5140372511268652e-07
was O 0 4.1094914138284366e-08
found O 0 2.492472894743969e-10
in O 0 1.421986972616196e-10
5 O 0 1.0862287957991157e-08
. O 0 8.128699491294356e-09

0 O 0 1.0837309218914015e-06
% O 0 1.1584147863175076e-08
of O 0 2.667652765353523e-08
120 O 0 6.280509889933228e-09
European O 0 2.5156334793052793e-09
and O 0 1.019401563162603e-09
1 O 0 2.306285153963472e-07
. O 0 1.4524400349102962e-08

6 O 0 3.2967816423479235e-06
% O 0 5.985695938903746e-09
of O 0 1.034730701121589e-08
188 O 0 5.831467309036498e-09
non O 0 1.311552200178312e-08
- O 0 1.0470211364577153e-09
European O 0 6.642171812565323e-10
Jews O 0 1.582847325432013e-10
( O 0 1.6343783965089287e-11
P O 0 2.0115578536206158e-08
= O 0 1.52786772122937e-09
0 O 0 1.1143186373629987e-09
. O 0 3.951329541340698e-11
08 O 0 5.025534211000604e-09
) O 0 5.085449283903642e-10
. O 0 1.7846586430891875e-08

It O 0 2.5127860681095626e-08
occurred O 0 6.409229627024615e-07
in O 0 7.250640088329874e-09
15 O 0 6.502646243689014e-08
. O 0 5.349319209813075e-08

4 O 0 8.448611197309219e-07
% O 0 2.4112223329098015e-09
of O 0 9.901096831299583e-09
52 O 0 6.033551436246398e-09
Ashkenazi O 0 4.716012025340888e-09
Israelis O 0 7.094766552029341e-09
with O 0 1.7889008052662803e-09
familial O 0 2.0445527297852095e-06
cancer B-Disease 0 2.9912898753536865e-06
( O 0 2.415853295190118e-09
P O 0 4.305989477870753e-06
= O 0 2.3362311196706287e-08
0 O 0 2.3445463348537032e-09
. O 0 6.032233046404656e-11
02 O 0 5.122992252637459e-09
) O 0 5.4648660596789966e-11
and O 0 2.798997422726046e-10
was O 0 1.1024866353182006e-08
not O 0 8.627288466955818e-11
detected O 0 1.593754128670355e-09
in O 0 9.984340437751982e-11
51 O 0 4.824388000201907e-09
non O 0 2.4146846300254765e-08
- O 0 1.5741139502978285e-09
European O 0 7.939833790437945e-10
Jews O 0 1.6422005422178643e-10
at O 0 1.4843497542216255e-09
increased O 0 8.028110953794965e-10
cancer B-Disease 0 3.8296050774988544e-08
risk O 0 2.0516470300435685e-08
. O 0 3.180096541655075e-08

Colorectal B-Disease 1 0.9998812675476074
neoplasia I-Disease 1 0.9977434873580933
occurred O 1 0.7420388460159302
personally O 0 1.3930937257100595e-06
or O 0 1.2292320494822206e-09
in O 0 1.4069571896424549e-10
the O 0 7.319998773791525e-11
families O 0 1.1284913975506683e-12
of O 0 5.451604723205605e-10
13 O 0 2.532140275235406e-09
of O 0 2.281934108339101e-08
20 O 0 1.6528455049069635e-08
Ashkenazi O 0 4.283098764545912e-09
I1307K O 0 1.3131917775410784e-08
carriers O 0 3.211607368935887e-10
, O 0 8.211562679827367e-11
8 O 0 2.216628436357837e-09
of O 0 5.032382510705702e-09
whom O 0 2.3052157516190164e-08
also O 0 6.042257805205509e-09
had O 0 1.0308441211748232e-08
a O 0 1.1224544627097544e-09
personal O 0 1.5887136939340962e-08
or O 0 1.6222119203490593e-09
family O 0 2.130591675308935e-10
history O 0 1.1802957500250955e-09
of O 0 8.924259553566571e-09
noncolonic O 0 3.5601174204202835e-06
neoplasia B-Disease 0 0.00015402933058794588
. O 0 3.17447779707436e-06

CONCLUSIONS O 0 4.151801931584487e-06
The O 0 1.628360593031175e-07
I1307K O 0 5.934961677667161e-07
APC O 0 7.3134373224093e-08
variant O 0 5.204970676686571e-08
may O 0 4.040495049650872e-09
represent O 0 6.961281551198795e-10
a O 0 2.017401135034902e-09
susceptibility O 0 2.5077779852722415e-08
gene O 0 1.6611130249089e-08
for O 0 8.885130853286682e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.4017482499184553e-06
or I-Disease 0 6.580690126156696e-08
other I-Disease 0 7.834863424704963e-09
, I-Disease 0 2.788650199647691e-09
cancers I-Disease 0 1.8570970496512018e-05
in O 0 1.765239865392232e-08
Ashkenazi O 0 1.3847130730937351e-07
Jews O 0 4.5299151096855894e-09
, O 0 6.520819301192304e-11
and O 0 5.2155862961811295e-11
partially O 0 1.3350933691924638e-08
explains O 0 4.334386460858042e-10
the O 0 4.57076286541902e-11
higher O 0 6.382793737991221e-10
incidence O 0 4.1132091155304806e-07
of O 0 9.367825555273157e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.476986165651397e-08
European O 0 9.816085722036405e-09
Israelis O 0 2.4058669723103776e-08
. O 0 2.691895417683554e-08

Systematic O 0 2.382141239820612e-08
analysis O 0 3.6345058074260805e-09
of O 0 7.146757408094118e-09
coproporphyrinogen O 0 1.3143002206561505e-06
oxidase O 0 3.1717013371235225e-07
gene O 0 8.834432492221822e-07
defects O 0 0.001105711911804974
in O 0 1.5812442200058285e-07
hereditary B-Disease 1 0.9999995231628418
coproporphyria I-Disease 1 0.9972002506256104
and O 0 5.940737679566155e-08
mutation O 0 4.5262451564553885e-09
update O 0 4.515563034601655e-08
. O 0 1.592734406585805e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.999997615814209
( O 0 4.307751169108087e-06
HC B-Disease 1 1.0
) O 0 5.494934285366071e-08
is O 0 1.3975860468917745e-09
an O 0 6.426428833528064e-10
acute O 1 0.9999998807907104
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.2658056616783142
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 0 0.3080834448337555
caused O 0 7.627753007000138e-08
by O 0 3.9843413290885366e-11
deficient B-Disease 0 5.963374860584736e-08
activity I-Disease 0 7.387542133585612e-09
of I-Disease 0 1.7725680478974937e-08
coproporphyrinogen I-Disease 0 1.7121556084020995e-06
III I-Disease 0 0.015429657883942127
oxidase I-Disease 0 4.016072097101642e-08
( O 0 1.4005722137611087e-09
CPO O 0 2.0315661686254316e-07
) O 0 1.6339374298013354e-09
. O 0 1.717589448446688e-08

Clinical O 0 0.0001278926501981914
manifestations O 0 0.030080242082476616
of O 0 1.5198083929135464e-05
the O 0 5.326594418875175e-07
disease O 0 2.3374239390250295e-05
are O 0 3.918619768950027e-12
characterized O 0 3.2676240185880445e-11
by O 0 3.745683017225554e-12
acute O 0 1.703849011391867e-05
attacks O 0 9.564950609330936e-09
of O 0 5.036581114836736e-06
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999996423721313
often O 0 1.1111653819284584e-08
precipitated O 0 3.106114032647156e-09
by O 0 2.011769743848202e-11
drugs O 0 3.6984364459868857e-09
, O 0 1.3535239769268959e-11
fasting O 0 9.961044211692638e-10
, O 0 1.0295560931572467e-10
cyclical O 0 5.074651312497735e-07
hormonal O 0 1.3442415365716442e-05
changes O 0 8.823035102523136e-08
, O 0 6.085966841595791e-09
or O 0 3.579408769383008e-08
infectious B-Disease 0 0.06883583962917328
diseases I-Disease 0 0.024075154215097427
. O 0 2.3058497333749983e-07

Skin O 1 0.9997870326042175
photosensitivity O 1 0.9999732971191406
may O 0 3.5964878861705074e-06
also O 0 2.8443567501312828e-09
be O 0 4.23501428370443e-10
present O 0 4.747581883179919e-09
. O 0 3.957746841365406e-08

The O 0 1.3768690223514568e-06
seven O 0 1.9458687461337831e-07
exons O 0 1.8676242063975224e-07
, O 0 2.714683811078089e-09
the O 0 1.2723036846296054e-08
exon O 0 5.964932938695711e-07
/ O 0 2.255101918535729e-07
intron O 0 1.1554035381777794e-06
boundaries O 0 1.614677636041506e-08
and O 0 1.7648889016896874e-09
part O 0 3.5315641522259966e-09
of O 0 9.611149209831638e-08
3 O 0 2.892784891628253e-07
noncoding O 0 6.220011528057512e-07
sequence O 0 1.0486485457761319e-08
of O 0 4.9034305504847e-08
the O 0 1.3755413696969754e-08
CPO O 0 2.0250783450137533e-07
gene O 0 1.460356169324939e-09
were O 0 1.2311701658163088e-09
systematically O 0 5.580588213760507e-10
analyzed O 0 2.511997831966539e-10
by O 0 1.2966979920370214e-11
an O 0 1.3826254377513614e-11
exon O 0 2.702001955512401e-09
- O 0 1.5352554783021333e-09
by O 0 1.3071536075770496e-09
- O 0 1.807429299560681e-07
exon O 0 1.0945007034024457e-06
denaturing O 0 1.0959517567243893e-05
gradient O 0 1.4239461734177894e-06
gel O 0 2.880149168049684e-06
electrophoresis O 0 7.552730494353455e-07
( O 0 2.827156508899975e-09
DGGE O 0 7.141227342799539e-07
) O 0 1.2508941105160432e-10
strategy O 0 1.5430909883207278e-09
followed O 0 1.0232810258858915e-11
by O 0 8.606488460273509e-13
direct O 0 1.879662397952231e-11
sequencing O 0 1.146163025600444e-10
in O 0 3.115457336555494e-10
seven O 0 3.826463590428375e-09
unrelated O 0 8.995147737778098e-08
heterozygous O 0 8.911182902693326e-08
HC B-Disease 1 0.999976634979248
patients O 0 1.1826081163235358e-06
from O 0 2.7161405569131603e-08
France O 0 4.304320100345649e-08
, O 0 2.2828590406920313e-10
Holland O 0 1.1161081836519315e-08
, O 0 6.118526518772427e-11
and O 0 1.352536277421379e-10
Czech O 0 7.258557275235944e-07
Republic O 0 3.013945843122201e-06
. O 0 1.0640221717039822e-06

Seven O 0 7.217747821641751e-08
novel O 0 3.904003342825035e-09
mutations O 0 1.7002451668801655e-09
and O 0 9.806813000556858e-11
two O 0 5.865473384769615e-11
new O 0 5.839511652006024e-10
polymorphisms O 0 1.2403845062181063e-08
were O 0 1.5395109187466005e-08
detected O 0 1.0095668585563544e-06
. O 0 1.4314780116819747e-07

Among O 0 1.717527275957309e-08
these O 0 4.537678566229886e-10
mutations O 0 3.5978656165447376e-10
two O 0 1.59242841135665e-10
are O 0 3.713304663754968e-11
missense O 0 9.378086751610226e-09
( O 0 2.2694526813360483e-10
G197W O 0 2.732362780477615e-08
, O 0 9.008017110012645e-10
W427R O 0 2.7350951725679806e-08
) O 0 1.3183955316353746e-10
, O 0 1.0885609774691218e-10
two O 0 6.274396974204066e-11
are O 0 5.4286710543527406e-11
nonsense O 0 2.868743687045594e-09
( O 0 1.8212754221424987e-11
Q306X O 0 2.9188480521469273e-09
, O 0 5.859546875486288e-11
Q385X O 0 2.252007469394357e-09
) O 0 4.169227116324059e-11
, O 0 4.627367933274229e-11
two O 0 5.0146897051517314e-11
are O 0 8.507944349034346e-12
small O 0 2.9092409037367872e-11
deletions O 0 6.586661216445577e-10
( O 0 1.1507061276061492e-10
662de14bp O 0 7.6605983778677e-09
; O 0 2.2970980673164831e-10
1168del3bp O 0 8.24207830874002e-08
removing O 0 9.638466025307935e-08
a O 0 6.584956135924358e-09
glycine O 0 1.9144582807939514e-08
at O 0 1.854011344448736e-07
position O 0 4.5712319263202517e-08
390 O 0 4.838367484438777e-09
) O 0 3.9130348267191195e-11
, O 0 2.7068737876168036e-11
and O 0 3.521175712117852e-11
one O 0 5.981455608594644e-11
is O 0 1.572024281581985e-11
a O 0 2.003537752370832e-10
splicing O 0 8.865553846604257e-10
mutation O 0 1.5404583164624341e-10
( O 0 1.0077265411023717e-10
IVS1 O 0 1.5859683344388031e-07
- O 0 3.357800792969101e-08
15c O 0 7.368730052803585e-07
- O 0 4.3853326303633366e-08
- O 0 1.9735653111752072e-08
> O 0 1.209937394719418e-08
g O 0 8.051393329822076e-09
) O 0 4.269164188830388e-11
which O 0 2.4518179153609765e-11
creates O 0 3.423841488103818e-10
a O 0 9.697460195967622e-11
new O 0 2.556817535470657e-10
acceptor O 0 4.491952920737674e-10
splice O 0 1.7033562471624464e-07
site O 0 4.470622982921668e-08
. O 0 1.223513947934407e-07

The O 0 1.5534666886196646e-07
pathological O 0 3.471940726740286e-05
significance O 0 3.987168497587845e-07
of O 0 6.025606325010813e-08
the O 0 1.6493750365498272e-08
point O 0 6.801936791589469e-08
mutations O 0 5.338068875815338e-11
G197W O 0 1.7378316563565477e-09
, O 0 7.522787948133214e-11
W427R O 0 6.360678206362991e-09
, O 0 1.4967044270619567e-10
and O 0 6.604370522689251e-11
the O 0 1.2233425383811891e-09
in O 0 2.6710575973254436e-09
- O 0 9.514657506315416e-09
frame O 0 3.879488303937251e-07
deletion O 0 3.5459088110201264e-08
390delGly O 0 3.012733529317302e-08
were O 0 2.969611223591073e-10
assessed O 0 5.432309602149132e-10
by O 0 4.4324908327064705e-12
their O 0 5.531749537601716e-12
respective O 0 3.3668978716150377e-10
expression O 0 2.703923474012271e-10
in O 0 1.4541266801781916e-10
a O 0 1.0563541708030755e-10
prokaryotic O 0 1.6422632698187556e-10
system O 0 1.1413642253543799e-09
using O 0 8.687049968258975e-10
site O 0 1.3407654986252737e-09
- O 0 8.723246014419317e-10
directed O 0 6.872428737203506e-10
mutagenesis O 0 3.735360110113106e-07
. O 0 1.0824010843180076e-07

These O 0 2.5015851612408824e-09
mutations O 0 5.3470929906040965e-09
resulted O 0 7.025979797958826e-09
in O 0 5.677710523954715e-10
the O 0 1.3953194155646997e-09
absence O 0 3.480409915823657e-08
or O 0 6.609162106485655e-10
a O 0 3.1820229784429443e-10
dramatic O 0 1.2587353381832145e-09
decrease O 0 5.876453101905099e-09
of O 0 5.097865951597669e-08
CPO O 0 1.232832005371165e-06
activity O 0 1.2006388772078935e-07
. O 0 6.086085591050505e-08

The O 0 1.4375275725342362e-07
two O 0 4.217250548776974e-09
polymorphisms O 0 3.6891225629887003e-09
were O 0 5.54960466470078e-10
localized O 0 1.6678500358580095e-08
in O 0 2.9336388873701935e-09
noncoding O 0 7.367907528532669e-07
part O 0 1.6131098679039724e-09
of O 0 1.8937898360604777e-08
the O 0 3.3328826365419673e-09
gene O 0 2.554005062993525e-10
1 O 0 9.47394873662688e-09
) O 0 3.5852317642470766e-11
a O 0 1.909945757105902e-09
C O 0 1.2783878844402352e-07
/ O 0 2.6564620725366694e-08
G O 0 7.137428781334165e-08
polymorphism O 0 1.9786725147241668e-08
in O 0 1.4588306118668015e-09
the O 0 5.05892483460002e-09
promotor O 0 1.4457768884312827e-05
region O 0 1.8348350749874953e-07
, O 0 1.5091748961637563e-09
142 O 0 2.8621757408586745e-08
bp O 0 1.501266808645596e-07
upstream O 0 1.396837934208861e-08
from O 0 1.220459622253145e-09
the O 0 1.1372961461475484e-09
transcriptional O 0 7.2364096936894384e-09
initiation O 0 5.8091091936773864e-09
site O 0 3.904182310776605e-09
( O 0 1.7200367519176751e-10
- O 0 2.3471280474751666e-09
142C O 0 3.466841036470214e-08
/ O 0 1.8157249925820906e-08
G O 0 8.263565121069405e-08
) O 0 1.7136382590710042e-10
, O 0 2.708057667000219e-10
and O 0 3.787823388279321e-10
2 O 0 3.4766546974651646e-08
) O 0 1.0067870148677827e-10
a O 0 1.1752344653004343e-09
6 O 0 1.4218556110279224e-08
bp O 0 6.645115124825907e-09
deletion O 0 7.771945864654128e-10
polymorphism O 0 2.1872632594011066e-09
in O 0 6.760063619992707e-10
the O 0 4.138458908897746e-09
3 O 0 7.834493231939632e-08
noncoding O 0 5.241423082225083e-07
part O 0 7.789432210358882e-09
of O 0 2.7117510015273183e-08
the O 0 1.9406199314175865e-08
CPO O 0 1.8211675012480555e-07
gene O 0 3.073148846510776e-09
, O 0 8.462200939973741e-10
574 O 0 2.040695790128666e-08
bp O 0 1.5637823480574298e-07
downstream O 0 5.577465600481446e-08
of O 0 6.068269442494056e-08
the O 0 1.3063169213012316e-08
last O 0 6.3386842441559565e-09
base O 0 3.4646185920195194e-09
of O 0 2.3487625178120197e-09
the O 0 2.918423558373462e-10
normal O 0 6.907757477137011e-09
termination O 0 6.578751432506635e-10
codon O 0 3.837271334017345e-10
( O 0 6.941681257588428e-11
+ O 0 7.032254334404797e-09
574 O 0 1.1088178553109174e-07
delATTCTT O 0 9.555415090289898e-07
) O 0 2.363215578782274e-08
. O 0 3.0847144216750166e-07

Five O 0 1.1540589639480459e-06
intragenic O 0 5.402040551416576e-05
dimorphisms O 0 3.4241278626723215e-05
are O 0 4.501853112515164e-09
now O 0 2.014409528072747e-09
well O 0 5.245278100751705e-10
characterized O 0 6.051854128941159e-09
and O 0 2.5986471308137027e-10
the O 0 6.181768430479906e-10
high O 0 1.4886089694243765e-08
degree O 0 1.0026720786981969e-07
of O 0 1.6492326393446888e-09
allelic O 0 9.975155812469438e-09
heterogeneity O 0 2.0038493531160384e-08
in O 0 5.957323967464845e-09
HC B-Disease 1 0.9998921155929565
is O 0 8.433588050138496e-09
demonstrated O 0 1.4059814423816874e-09
with O 0 2.5977687015399376e-11
seven O 0 5.844098815988019e-11
new O 0 2.0192389427187152e-11
different O 0 6.965338462255888e-12
mutations O 0 2.906140779412869e-11
making O 0 5.54073870118188e-11
a O 0 7.691233067097514e-11
total O 0 1.4782293444870476e-10
of O 0 5.637248001733042e-09
nineteen O 0 2.460948849147826e-07
CPO O 0 2.365846285101725e-06
gene B-Disease 0 3.8619981523879687e-07
defects I-Disease 0 3.41232316714013e-06
reported O 0 1.7469785618118294e-08
so O 0 1.7054027079410616e-09
far O 0 1.4696163175287325e-09
. O 0 5.198228514302627e-10
. O 0 8.757359282185462e-09

Coincidence O 0 2.281711385876406e-05
of O 0 3.701833293234813e-07
two O 0 2.15624229582545e-09
novel O 0 8.927421579763006e-10
arylsulfatase O 0 6.011326547650242e-08
A O 0 2.2264927679316315e-09
alleles O 0 1.0609863682065068e-10
and O 0 2.463035331246033e-10
mutation O 0 1.777895747290259e-10
459 O 0 3.494383449265115e-09
+ O 0 2.65521595821383e-08
1G O 0 1.4890173360981862e-06
> O 0 1.1490320872553639e-07
A O 0 3.193621367358901e-08
within O 0 7.792002598705494e-09
a O 0 3.243584068002292e-09
family O 0 5.657603829867242e-10
with O 0 3.6085130439289514e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 8.997131373256195e-10
molecular O 0 4.811935738757711e-09
basis O 0 3.3411122757343037e-09
of O 0 1.9353809666000643e-09
phenotypic O 0 6.611576282011811e-07
heterogeneity O 0 5.27753991264035e-06
. O 0 8.112848490782198e-07

In O 0 1.345507712358085e-06
a O 0 4.854037456425431e-07
family O 0 8.813763940906938e-09
with O 0 7.782670619072007e-10
three O 0 8.006737495236393e-09
siblings O 0 1.340270205929528e-08
, O 0 5.6645976104219287e-11
one O 0 7.844914821919513e-12
developed O 0 7.34910132749178e-10
classical O 0 0.00013388466322794557
late O 1 0.9993265867233276
infantile O 1 0.9999996423721313
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.4556947525743453e-07
MLD B-Disease 1 0.9999998807907104
) O 0 1.905873681096182e-09
, O 0 5.934186475542447e-10
fatal O 0 1.1464773308489384e-07
at O 0 1.2723454290153313e-07
age O 0 8.383441496562227e-08
5 O 0 1.232488866520498e-08
years O 0 9.628240427161927e-10
, O 0 4.512267642864387e-11
with O 0 7.50876860688976e-11
deficient O 0 8.584219699514506e-07
arylsulfatase O 0 5.642603355227038e-06
A O 0 6.492427928606048e-07
( O 0 4.831015587569709e-10
ARSA O 0 1.134387659362801e-07
) O 0 1.2907092929170805e-11
activity O 0 5.358317609061025e-11
and O 0 5.955042882421768e-12
increased O 0 2.5111976387215407e-10
galactosylsulfatide O 0 2.124916704815405e-07
( O 0 2.0678476708724247e-09
GS O 0 0.004923571366816759
) O 0 2.369926477285844e-09
excretion O 0 1.351450009678956e-07
. O 0 7.488626607710103e-08

The O 0 1.4443752149873035e-07
two O 0 2.7996287510489992e-09
other O 0 1.976219049515393e-10
siblings O 0 3.1753977225434937e-09
, O 0 2.0615613383068165e-10
apparently O 0 4.3191480614268585e-08
healthy O 0 5.8023768012560595e-09
at O 0 1.0821302112162812e-06
12 O 0 4.8555744314171534e-08
( O 0 3.685857175028673e-10
1 O 0 4.4297784995706024e-08
/ O 0 7.1724310934939695e-09
2 O 0 1.6763781474082862e-08
) O 0 3.368919726520758e-11
and O 0 1.2481532474239998e-10
15 O 0 1.1918352971207469e-09
years O 0 6.827223786309844e-10
, O 0 3.376954965661483e-11
respectively O 0 7.450807193443154e-10
, O 0 4.4604809429360515e-11
and O 0 3.069479045936241e-11
their O 0 1.0849274256763408e-10
father O 0 1.8794285239209785e-08
, O 0 3.4106295565550226e-10
apparently O 0 9.168324766051228e-09
healthy O 0 5.1646570353725e-10
as O 0 3.2034155883486903e-10
well O 0 4.1734299349727166e-10
, O 0 1.377306879657425e-10
presented O 0 2.321776371161377e-08
ARSA O 0 1.9476454326650128e-05
and O 0 1.4716471241627005e-07
GS O 1 0.9999145269393921
values O 0 3.4650827984705757e-08
within O 0 7.519334599415117e-10
the O 0 2.0129223288201104e-10
range O 0 2.1705441888286714e-09
of O 0 4.638630368702934e-09
MLD B-Disease 1 0.9999996423721313
patients O 0 1.6226387060669367e-06
. O 0 2.4920865371313994e-07

Mutation O 0 4.9591584172503644e-08
screening O 0 2.7402904834161745e-08
and O 0 5.005346692676937e-10
sequence O 0 6.617664749519747e-10
analysis O 0 3.6633732158897203e-10
disclosed O 0 5.0618300662108595e-09
the O 0 4.788294205582133e-10
involvement O 0 1.2908861535265714e-08
of O 0 1.0472074762901684e-08
three O 0 1.0467755551246682e-09
different O 0 4.048418045243807e-09
ARSA O 0 8.901870387489907e-06
mutations O 0 7.057892936757071e-09
being O 0 5.623316812197743e-10
the O 0 1.0356537849531833e-10
molecular O 0 5.977695005654482e-10
basis O 0 2.367518403545432e-09
of O 0 1.7047229183830837e-09
intrafamilial O 0 4.4017448885824706e-07
phenotypic O 0 3.7672032249247422e-06
heterogeneity O 0 1.201088434754638e-05
. O 0 1.5930884273984702e-06

The O 0 2.413087258901214e-07
late O 0 3.714721606229432e-05
infantile O 0 0.0009286387357860804
patient O 0 1.7062060351236141e-06
inherited O 0 0.00017999537521973252
from O 0 2.0596225169811078e-07
his O 0 7.475441066162603e-08
mother O 0 1.0071548928181073e-08
the O 0 2.8520381611940593e-09
frequent O 0 2.3667598991750083e-09
0 O 0 1.7694391507561136e-09
- O 0 4.639902628778003e-10
type O 0 2.2041870550992826e-09
mutation O 0 4.270860332056259e-10
459 O 0 5.9386504602798595e-09
+ O 0 1.4982196816504256e-08
1G O 0 3.2808253536131815e-07
> O 0 5.778314005056018e-08
A O 0 1.3925311570517351e-08
, O 0 1.8400335421997482e-10
and O 0 1.7631518467453589e-10
from O 0 1.0123699656361396e-09
his O 0 2.1654589232866783e-08
father O 0 3.9412569208252535e-08
a O 0 5.980751449641275e-10
novel O 0 7.079403729903788e-11
, O 0 9.907184447821571e-12
single O 0 4.073462747666845e-11
basepair O 0 3.091162881219134e-08
microdeletion O 0 7.64524514806908e-08
of O 0 1.6004291225613088e-08
guanine O 0 1.5348522452995894e-08
at O 0 1.1377940722923086e-07
nucleotide O 0 4.260123365185109e-09
7 O 0 1.9253489469406304e-08
in O 0 4.302586287252552e-09
exon O 0 2.4809364163047576e-07
1 O 0 2.5785064394767687e-07
( O 0 1.3117842367904586e-09
7delG O 0 7.465737184020327e-08
) O 0 5.696588090131627e-09
. O 0 6.22367863911677e-08

The O 0 9.358030297335063e-07
two O 0 5.5036402102359716e-08
clinically O 0 2.6161136702285148e-05
unaffected O 0 5.714453550353937e-07
siblings O 0 1.1486635642654619e-08
carried O 0 1.019226592013922e-09
the O 0 6.600155422198384e-10
maternal O 0 1.3806827681150935e-08
mutation O 0 2.9409316648632e-10
459 O 0 5.618999043832673e-09
+ O 0 3.6967456651382236e-08
1G O 0 8.564700237911893e-07
> O 0 5.426474558589689e-08
A O 0 2.7968921401111402e-08
and O 0 2.08245587440814e-10
, O 0 2.042659444367878e-11
on O 0 9.398298805862737e-10
their O 0 2.2672927771361095e-11
paternal O 0 7.022252224153647e-10
allele O 0 5.508780653862289e-10
, O 0 1.2138774707626254e-10
a O 0 2.5968585615210316e-10
novel O 0 2.150331024353136e-10
cytosine O 0 1.9185002475552437e-09
to O 0 1.6785232925808913e-10
thymidine O 0 7.059404083520349e-08
transition O 0 8.708357199793682e-07
at O 0 7.997367106327147e-07
nucleotide O 0 2.0194083560909348e-07
2435 O 0 9.09824393602321e-06
in O 0 1.66774185572649e-08
exon O 0 6.318311420727696e-07
8 O 0 4.453652380220774e-08
, O 0 1.8047607852622605e-10
resulting O 0 7.944238322732389e-11
in O 0 1.131911370189087e-10
substitution O 0 1.234584545706241e-09
of O 0 1.6222242438246326e-09
alanine O 0 4.723430091502223e-09
464 O 0 4.11093159513598e-09
by O 0 1.3278118604631572e-09
valine O 0 2.561932205935591e-06
( O 0 2.5167132822190297e-09
A464V O 0 2.543245898323221e-07
) O 0 3.5157299294041877e-09
. O 0 5.1821572810695216e-08

The O 0 1.025905135065841e-06
fathers O 0 4.3748983102886996e-07
genotype O 0 7.861152084842615e-08
thus O 0 1.6258926649470595e-08
was O 0 4.368944317434398e-08
7delG O 0 4.5184751229498943e-07
/ O 0 3.5817930665871245e-07
A464V O 0 1.5449949160029064e-06
. O 0 1.3775398599591426e-07

Mutation O 0 1.8526009171182523e-07
A464V O 0 1.281720983570267e-06
was O 0 8.565748998989875e-08
not O 0 6.453645257087359e-11
found O 0 8.006881269118082e-11
in O 0 6.21659876354208e-11
18 O 0 3.8831871052025235e-09
unrelated O 0 3.7435447097777796e-07
MLD B-Disease 1 1.0
patients O 0 1.797908133482906e-08
and O 0 1.6464384300363122e-09
50 O 0 9.760115382562162e-09
controls O 0 3.794552583258337e-07
. O 0 1.2525120496320596e-07

A464V O 0 1.4305695003713481e-05
, O 0 2.4131928455517482e-08
although O 0 5.76843373067959e-09
clearly O 0 2.6695005317378673e-08
modifying O 0 1.2705014569291961e-06
ARSA O 0 0.0020088818855583668
and O 0 1.3022540770180058e-06
GS O 1 0.9999992847442627
levels O 0 1.0125856533704791e-05
, O 0 1.9276296114867364e-09
apparently O 0 7.512371169582366e-09
bears O 0 1.8204853180492364e-09
little O 0 4.179651624802716e-10
significance O 0 1.3910200769018388e-09
for O 0 3.534244286118593e-10
clinical O 0 1.9136368933914127e-08
manifestation O 0 1.3890819161588297e-07
of O 0 3.9876474033917475e-07
MLD B-Disease 1 1.0
, O 0 1.8852125194257496e-08
mimicking O 0 1.208540254538093e-07
the O 0 1.1469121652396552e-08
frequent O 0 7.704399962449315e-08
ARSA O 0 1.2362188499537297e-05
pseudodeficiency O 0 1.994543026739848e-06
allele O 0 7.689028507229523e-07
. O 0 4.856241844208853e-07

Our O 0 1.6229313359872322e-07
results O 0 4.290621635760772e-09
demonstrate O 0 7.472981677913992e-10
that O 0 4.350375528566763e-12
in O 0 5.6069996735852445e-12
certain O 0 5.7450072477038816e-11
genetic O 0 1.5095088512495636e-09
conditions O 0 1.592048164411608e-07
MLD B-Disease 1 1.0
- O 0 9.037571544467937e-06
like O 0 8.097768500192615e-08
ARSA O 0 0.0005905325524508953
and O 0 7.300196784854052e-07
GS O 1 1.0
values O 0 7.64196386171534e-07
need O 0 6.6762146921917065e-09
not O 0 1.8283407773878046e-11
be O 0 6.913783781592464e-12
paralleled O 0 9.64899202204883e-11
by O 0 1.0527371509250205e-11
clinical O 0 5.148600834559147e-08
disease O 0 1.7464721224769164e-08
, O 0 1.1300858686336124e-11
a O 0 3.8971475352367335e-11
finding O 0 6.152651998991843e-11
with O 0 3.7408561491536485e-12
serious O 0 3.900296974279627e-09
diagnostic O 0 2.6018936338800813e-08
and O 0 5.737453845355844e-10
prognostic O 0 1.1640386219369248e-05
implications O 0 8.825817872093467e-07
. O 0 3.7715707890129124e-07

Moreover O 0 2.756542244242155e-06
, O 0 9.493159147666574e-09
further O 0 7.897518194965869e-09
ARSA O 0 1.6284147932310589e-06
alleles O 0 5.154139781637923e-09
functionally O 0 2.75739324706592e-08
similar O 0 7.510046473591103e-10
to O 0 6.117281126094554e-10
A464V O 0 6.998630652788052e-08
might O 0 6.315871714512866e-10
exist O 0 3.0843869125440904e-10
which O 0 2.6053506574363894e-11
, O 0 1.0488570081901294e-11
together O 0 3.261154887801432e-11
with O 0 1.446285036177386e-10
0 O 0 2.031108436995055e-08
- O 0 1.0091735225259413e-09
type O 0 7.585311934121819e-09
mutations O 0 4.573023626441852e-10
, O 0 1.201420629648453e-10
may O 0 2.7993938278569885e-09
cause O 0 6.355308812544536e-08
pathological O 0 0.08180921524763107
ARSA O 0 0.06582607328891754
and O 0 3.209377609891817e-06
GS O 1 0.9999998807907104
levels O 0 4.89617787025054e-06
, O 0 3.790417701932114e-10
but O 0 6.24802510076905e-12
not O 0 1.9456302888243293e-12
clinical O 0 1.8157716996647366e-10
outbreak O 0 1.6319362527994485e-11
of O 0 1.1844875080768702e-10
the O 0 5.372760014665801e-10
disease O 0 1.1262486943053318e-08
. O 0 2.7375818278940756e-10
. O 0 1.1926204024348408e-08

Human O 0 0.0003445488982833922
MLH1 O 1 0.999993085861206
deficiency O 1 0.9999829530715942
predisposes O 0 3.0121071176836267e-05
to O 0 1.385582351076664e-07
hematological B-Disease 1 0.9996461868286133
malignancy I-Disease 1 0.9974396228790283
and O 0 5.621777745545842e-07
neurofibromatosis B-Disease 1 0.9998635053634644
type I-Disease 1 0.978160560131073
1 I-Disease 1 0.7332257032394409
. O 0 1.2302880350034684e-06

Heterozygous O 0 1.9928658730350435e-05
germ O 0 0.0016938990447670221
- O 0 1.199912389893143e-06
line O 0 4.571013789700373e-08
mutations O 0 1.9852633426076238e-10
in O 0 2.3735655801937483e-11
the O 0 7.558038223054453e-11
DNA O 0 1.3355568206918633e-08
mismatch O 0 3.948021912947297e-05
repair O 0 2.1419296899694018e-05
genes O 0 1.4259076586142783e-08
lead O 0 4.891399285611442e-08
to O 0 1.1559516011061532e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9672005772590637

The O 0 2.1993864152136666e-07
disease O 0 4.0611229223941336e-07
susceptibility O 0 1.28659237930151e-07
of O 0 8.952167007691969e-09
individuals O 0 1.3061111914236534e-10
who O 0 5.399184654919509e-09
constitutionally O 0 1.0319477041775826e-06
lack O 0 1.5165286981755344e-07
both O 0 9.370751952175738e-10
wild O 0 2.121403192001381e-10
- O 0 1.4333911835251456e-10
type O 0 4.385010687890656e-10
alleles O 0 1.040306243926814e-10
is O 0 6.860284562648644e-11
unknown O 0 4.147754495420486e-08
. O 0 1.4757039146218176e-08

We O 0 2.87255687680954e-07
have O 0 3.434450224215624e-10
identified O 0 9.377438825453055e-10
three O 0 4.7988335527549e-11
offspring O 0 2.131484919121185e-11
in O 0 3.535031295465174e-11
a O 0 3.443786145140848e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.02353929914534092
who O 0 2.8596000234415442e-08
developed O 0 2.7895616767636966e-06
hematological B-Disease 1 0.9150761365890503
malignancy I-Disease 1 0.5836487412452698
at O 0 1.84101900231326e-05
a O 0 3.185905095293151e-09
very O 0 2.8439428589877025e-10
early O 0 1.8149761693564415e-09
age O 0 3.3785110264972218e-09
, O 0 5.1095593034400366e-11
and O 0 6.07429453958197e-11
at O 0 1.709660324422657e-08
least O 0 5.623818077893361e-11
two O 0 2.8293116113853323e-11
of O 0 3.2650523951183175e-10
them O 0 6.910658677250492e-12
displayed O 0 2.3196635723365944e-09
signs O 0 4.029435896057976e-09
of O 0 3.3334121241068715e-08
neurofibromatosis B-Disease 0 0.00011399763025110587
type I-Disease 0 5.042150223744102e-05
1 I-Disease 0 1.8867051039705984e-05
( O 0 3.845442630989737e-09
NF1 B-Disease 0 2.4131479676725576e-06
) O 0 1.542023575495932e-08
. O 0 1.3903196816045238e-07

DNA O 0 2.21756408791407e-08
sequence O 0 1.7260946005848155e-09
analysis O 0 1.430228852017379e-10
and O 0 1.6561944524151606e-11
allele O 0 3.7220834053774965e-11
- O 0 1.479464120657248e-11
specific O 0 1.2907118082661206e-11
amplification O 0 1.1559885271239523e-09
in O 0 2.9427496550660237e-10
two O 0 6.995861667746794e-10
siblings O 0 1.4713195106708099e-08
revealed O 0 6.248966855082472e-08
a O 0 2.1136346006755957e-08
homozygous O 0 9.717285820443067e-08
MLH1 O 0 1.2056835657858755e-05
mutation O 0 4.537490383427212e-09
( O 0 7.915580413353496e-10
C676T O 0 1.8410030122595344e-07
- O 0 5.393331292680159e-08
- O 0 3.1953941714846223e-08
> O 0 3.2085001322457174e-08
Arg226Stop O 0 3.539335011737421e-07
) O 0 2.083159866828055e-09
. O 0 2.5023549454772365e-08

Thus O 0 1.381585775561689e-06
, O 0 2.5954895122026755e-08
a O 0 3.655447500250375e-08
homozygous O 0 1.9673495899041882e-07
germ O 0 0.00029316285508684814
- O 0 1.472492272114323e-06
line O 0 4.5396870973490877e-07
MLH1 O 0 3.0342138416017406e-05
mutation O 0 2.6484923143499373e-09
and O 0 1.2306600183364935e-10
consequent O 0 2.420258169877343e-06
mismatch O 1 0.999997615814209
repair O 1 0.9999984502792358
deficiency O 1 0.999560534954071
results O 0 1.712967616640526e-07
in O 0 1.7950094743923728e-08
a O 0 1.5860614155371877e-08
mutator O 0 3.242409002268687e-05
phenotype O 0 1.4084408306302976e-08
characterized O 0 7.2606876067027315e-09
by O 0 8.663024742006087e-10
leukemia B-Disease 1 0.9999945163726807
and O 0 3.4709216834016843e-06
/ O 1 0.9999336004257202
or O 1 0.6857439875602722
lymphoma B-Disease 1 1.0
associated O 1 0.9999523162841797
with O 0 2.150964519387344e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9999556541442871
1 I-Disease 1 0.5462591052055359
. O 0 3.0143368690005445e-08
. O 0 7.318642047948742e-08

Missense O 0 9.366110316477716e-05
mutations O 0 5.453024414237007e-07
in O 0 1.805626759221468e-08
the O 0 1.5079326232125823e-08
most O 0 2.44128217641304e-10
ancient O 0 1.0945812256579757e-08
residues O 0 1.0577225850738614e-07
of O 0 2.012632549508453e-08
the O 0 3.61997898323807e-08
PAX6 O 0 4.016184902866371e-05
paired O 0 2.511574734853639e-07
domain O 0 1.453464960832207e-06
underlie O 0 3.1600486636307323e-06
a O 0 1.934413962345616e-09
spectrum O 0 1.8564776382845594e-07
of O 0 6.767758975456672e-08
human O 0 0.012597384862601757
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0005890423199161887

Mutations O 0 8.191986466954404e-07
of O 0 8.66210783101451e-08
the O 0 6.4952558886943734e-09
human O 0 3.7913469697059554e-08
PAX6 O 0 0.00028486756491474807
gene O 0 1.4419158105738461e-05
underlie O 1 0.9990673661231995
aniridia B-Disease 1 1.0
( O 0 0.00017443667456973344
congenital B-Disease 1 1.0
absence I-Disease 1 0.997787356376648
of I-Disease 1 0.6890108585357666
the I-Disease 0 6.475018381024711e-06
iris I-Disease 0 4.246960088494234e-06
) O 0 1.3122196662607166e-09
, O 0 2.3095483858703858e-10
a O 0 8.326256906165952e-10
rare O 0 7.94931267478205e-08
dominant O 1 0.9999265670776367
malformation B-Disease 1 1.0
of I-Disease 1 0.999981164932251
the I-Disease 1 0.8749924898147583
eye I-Disease 1 0.9999825954437256
. O 0 3.4748861708067125e-06

The O 0 1.3878437243874941e-07
spectrum O 0 6.5673380049702246e-06
of O 0 2.0343308904102742e-07
PAX6 O 0 6.914306140970439e-05
mutations O 0 8.639634785367889e-08
in O 0 2.1399898741947254e-08
aniridia B-Disease 1 1.0
patients O 0 1.2932747495142394e-07
is O 0 2.3033498719460255e-10
highly O 0 5.456494145406054e-10
biased O 0 1.0602788647062766e-09
, O 0 1.2052438040643931e-11
with O 0 7.052674416696547e-12
92 O 0 3.1024371960342023e-09
% O 0 1.197618115789112e-10
of O 0 1.3900334216998544e-09
all O 0 1.2986738073816895e-10
reported O 0 5.482700959902331e-10
mutations O 0 2.3956028827321063e-10
leading O 0 1.3492981176810304e-09
to O 0 3.2046071352098693e-10
premature O 0 2.507983687394244e-08
truncation O 0 6.17263197000284e-07
of O 0 1.466295884711144e-06
the O 0 2.1533750782509742e-07
protein O 0 8.171202381390685e-08
( O 0 8.93420115666288e-10
nonsense O 0 6.642377758936391e-09
, O 0 3.636499087966705e-11
splicing O 0 4.5123557668169667e-10
, O 0 7.7150057176123e-11
insertions O 0 3.6608446829511365e-10
and O 0 4.0763385722453194e-11
deletions O 0 2.724585002056301e-10
) O 0 8.889695229941097e-11
and O 0 7.535270740710587e-10
just O 0 8.059429568163523e-09
2 O 0 3.555186367520946e-08
% O 0 2.4901208872663005e-10
leading O 0 1.233398272404429e-09
to O 0 4.506823039762686e-11
substitution O 0 3.521703151321276e-09
of O 0 2.3231052637129324e-08
one O 0 2.2458510051670544e-10
amino O 0 4.628358807323707e-10
acid O 0 2.241396374058624e-10
by O 0 3.590980637846464e-11
another O 0 8.714332588866114e-10
( O 0 7.621825948156413e-10
missense O 0 4.530790320700362e-08
) O 0 3.7041265610326946e-09
. O 0 1.0819345419577076e-07

The O 0 2.345965555150542e-08
extraordinary O 0 2.022684419955567e-08
conservation O 0 2.6859856561145534e-09
of O 0 5.255635926459945e-09
the O 0 1.5021683452687284e-08
PAX6 O 0 1.8009537598118186e-05
protein O 0 4.154128703248716e-07
at O 0 3.5370470641282736e-07
the O 0 9.042623538846328e-09
amino O 0 1.9190245836853137e-08
acid O 0 1.3438461898829246e-08
level O 0 5.407226311149316e-08
amongst O 0 3.6250760171441243e-09
vertebrates O 0 2.4223975714221524e-08
predicts O 0 9.3788745658685e-09
that O 0 2.2682193623335678e-10
pathological O 0 6.0985639720456675e-05
missense O 0 1.915167104016291e-06
mutations O 0 1.6236240796274615e-08
should O 0 1.7995471779386207e-09
in O 0 7.978864791091667e-10
fact O 0 1.020697304454643e-09
be O 0 3.1206615069834243e-10
common O 0 4.0502226572591837e-10
even O 0 3.7764812110818724e-11
though O 0 2.3963008660699003e-11
they O 0 8.564293371704501e-12
are O 0 6.342060990954801e-12
hardly O 0 6.450251999190471e-10
ever O 0 1.6532758495557687e-10
seen O 0 4.5983186702791556e-10
in O 0 1.1871683636144326e-09
aniridia B-Disease 1 0.9999996423721313
patients O 0 3.912630859304045e-07
. O 0 9.457270522261751e-08

This O 0 3.557730465786335e-08
indicates O 0 1.7622795667193714e-08
that O 0 1.2336753840713754e-10
there O 0 9.918571519662578e-11
is O 0 5.7575236245277495e-11
a O 0 2.2150677125853946e-10
heavy O 0 8.16793033209251e-08
ascertainment O 0 9.341862096334808e-06
bias O 0 5.145832204789258e-08
in O 0 1.3135512122453008e-10
the O 0 6.380769523861574e-11
selection O 0 1.7963672216403381e-10
of O 0 4.2681319589732425e-10
patients O 0 1.4654784330492276e-10
for O 0 3.203800558182479e-10
PAX6 O 0 4.5148183858145785e-07
mutation O 0 4.523894592267652e-10
analysis O 0 4.5249043401085487e-10
and O 0 2.6663768415424727e-11
that O 0 1.5620055596188287e-11
the O 0 4.2726855387087426e-10
missing O 0 8.786274463545851e-08
PAX6 O 0 0.0001323162578046322
missense O 0 6.6762950154952705e-06
mutations O 0 2.1164852626043285e-07
frequently O 0 9.116588373103696e-09
may O 0 1.0917601045434822e-08
underlie O 0 2.9564219516942103e-07
phenotypes O 0 6.122341034142664e-08
distinct O 0 6.012597086879623e-09
from O 0 1.978257380130799e-08
textbook O 0 5.845930445502745e-06
aniridia B-Disease 1 0.9999996423721313
. O 0 1.6280172303595464e-06

Here O 0 4.501925104705151e-06
we O 0 3.2327214682936756e-08
present O 0 5.416648019007653e-09
four O 0 2.816843647224232e-09
novel O 0 3.181957586306794e-09
PAX6 O 0 6.386711447703419e-06
missense O 0 1.4145770137474756e-06
mutations O 0 1.6785987710932204e-08
, O 0 2.066341764361823e-09
two O 0 2.954256006493239e-10
in O 0 1.5363335048590443e-09
association O 0 1.4894148137045704e-09
with O 0 2.0378933263121013e-10
atypical O 0 3.647519406513311e-06
phenotypes O 0 3.9688748643129657e-07
ectopia B-Disease 0 4.677637662098277e-06
pupillae I-Disease 0 2.7410962957219454e-06
( O 0 7.352462388920955e-11
displaced B-Disease 0 7.746752545001456e-11
pupils I-Disease 0 3.389022673605524e-10
) O 0 9.064856504314989e-11
and O 0 6.415703523998673e-09
congenital B-Disease 1 1.0
nystagmus I-Disease 0 0.0005581561126746237
( O 0 5.438646422106785e-09
searching B-Disease 0 1.240844085259596e-07
gaze I-Disease 0 1.0365756679675542e-06
) O 0 9.675327206082329e-11
, O 0 5.119119364516145e-11
and O 0 7.566635512601394e-11
two O 0 9.387723931553182e-11
in O 0 5.101226108195078e-10
association O 0 3.0308913712140395e-10
with O 0 4.02922417652718e-11
more O 0 1.6631340749029278e-10
recognizable O 0 1.732541363708151e-07
aniridia B-Disease 1 0.9999992847442627
phenotypes O 0 6.239044523681514e-06
. O 0 2.9962183134557563e-07

Strikingly O 0 5.3888652473688126e-06
, O 0 1.3782568863973665e-08
all O 0 1.5862965385693428e-09
four O 0 7.406854019009756e-10
mutations O 0 9.651771742946735e-11
are O 0 1.0394587968143298e-11
located O 0 2.3329826959184174e-10
within O 0 6.278255137992517e-10
the O 0 3.57399732031638e-09
PAX6 O 0 1.4253455447033048e-06
paired O 0 2.2175303371341215e-08
domain O 0 8.604261125810808e-08
and O 0 2.6093418536987656e-09
affect O 0 1.4682414395394972e-08
amino O 0 1.0265021721522771e-08
acids O 0 1.7222108184000717e-09
which O 0 1.5724470336930807e-11
are O 0 9.450738802652126e-13
highly O 0 1.743314347046887e-11
conserved O 0 1.7361909132596054e-10
in O 0 7.664784779093381e-11
all O 0 9.095406372505721e-11
known O 0 5.189204621558474e-10
paired O 0 3.74094044630624e-09
domain O 0 3.7153576215587236e-08
proteins O 0 1.9301877429711567e-08
. O 0 9.597135175454241e-08

Our O 0 6.510551884275628e-07
results O 0 2.675341903568551e-08
support O 0 6.414455189229784e-09
the O 0 5.516416656803358e-09
hypothesis O 0 1.2247012293187254e-09
that O 0 2.443744208727172e-12
the O 0 2.6751592260843005e-11
under O 0 6.044617584244349e-10
- O 0 1.5706494438383345e-10
representation O 0 9.575990000953993e-10
of O 0 1.6069964914322554e-08
missense O 0 6.203400744198007e-07
mutations O 0 5.724624330127881e-09
is O 0 1.4901842260162113e-10
caused O 0 1.6041323824822484e-09
by O 0 4.2467676597546244e-10
ascertainment O 0 0.0003300686657894403
bias O 0 3.4888691970991204e-06
and O 0 3.636530632178392e-09
suggest O 0 2.3555011274822846e-09
that O 0 1.0841346050061151e-11
a O 0 6.94239596366053e-11
substantial O 0 6.589689904856755e-10
burden O 0 5.724583473920575e-08
of O 0 6.258366056499653e-07
PAX6 B-Disease 1 0.7658669948577881
- I-Disease 0 1.6297217371175066e-05
related I-Disease 0 9.765104186953977e-05
disease I-Disease 0 0.0010231774067506194
remains O 0 9.436386960715026e-08
to O 0 1.786731040898104e-10
be O 0 1.607972921480183e-10
uncovered O 0 1.0538337313903412e-08
. O 0 1.8523158007432983e-10
. O 0 5.387375878740386e-09

The O 0 1.1830035617776957e-07
chromosomal O 0 3.570525223040022e-06
order O 0 3.849708463121715e-08
of O 0 2.4336748083442217e-07
genes O 0 7.596927531494657e-08
controlling O 0 1.2737291399389505e-05
the O 0 1.2057427056788583e-07
major O 0 1.7557090359332506e-06
histocompatibility O 0 0.004487080965191126
complex O 0 0.00016351115482393652
, O 0 4.505202877425063e-09
properdin O 0 1.3988407943088532e-07
factor O 0 2.2598701576725944e-08
B O 0 4.115461251785746e-07
, O 0 9.611874629555928e-10
and O 0 2.1879265066360176e-09
deficiency B-Disease 0 0.00018868892220780253
of I-Disease 0 5.080327537143603e-05
the I-Disease 0 1.0979769058394595e-06
second I-Disease 0 2.60161613141463e-07
component I-Disease 0 4.99653822316759e-07
of I-Disease 0 2.007373041124083e-07
complement I-Disease 0 2.9766354714411136e-07
. O 0 4.590134778936772e-07

The O 0 3.101611127931392e-07
relationship O 0 1.651966954341333e-07
of O 0 2.1228949265150732e-08
the O 0 9.898090125304293e-10
genes O 0 1.28611205019169e-10
coding O 0 9.415222379516308e-09
for O 0 7.500141063765398e-10
HLA O 0 1.3656544339823995e-08
to O 0 1.3029090306648783e-10
those O 0 5.7847893142337625e-11
coding O 0 8.37289082511461e-09
for O 0 7.038396532266233e-10
properdin O 0 1.2827428008677089e-07
Factor O 0 1.3878246107879022e-08
B O 0 1.24788599009662e-07
allotypes O 0 2.057504389085807e-07
and O 0 1.4636746259455435e-09
for O 0 2.9710969240426266e-09
deficiency B-Disease 0 0.0001701826840871945
of I-Disease 0 8.850945960148238e-06
the I-Disease 0 2.0386619326018263e-07
second I-Disease 0 6.461820589720446e-08
component I-Disease 0 2.5247541657336114e-07
of I-Disease 0 6.023860805726144e-07
complement I-Disease 0 9.247941790135883e-08
( O 0 1.4895170652451384e-09
C2 O 0 1.3856848113391607e-08
) O 0 2.1434709909784466e-11
was O 0 7.241708344096764e-10
studied O 0 2.9773259413445885e-09
in O 0 3.8236726285223455e-11
families O 0 2.3474872219708676e-12
of O 0 1.6686438342183862e-10
patients O 0 9.005904355596783e-10
with O 0 2.0684551849114996e-09
connective O 1 0.9998006224632263
tissue O 1 0.9999997615814209
disorders O 1 1.0
. O 0 6.541041511809453e-05

Patients O 0 2.0306208625697764e-07
were O 0 1.1560508106356338e-08
selected O 0 6.654192197252939e-10
because O 0 8.309657822946903e-11
they O 0 8.673613910437084e-12
were O 0 2.845102452242454e-11
heterozygous O 0 1.6162195193292206e-10
or O 0 4.792594793245897e-11
homozygous O 0 5.059947572050305e-09
for O 0 4.641420758844106e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 7.254395768541144e-06

12 O 0 1.0977382771670818e-06
families O 0 1.5117448404211586e-09
with O 0 8.3563261865649e-10
15 O 0 2.299853463227919e-08
matings O 0 5.81642950692185e-07
informative O 0 7.685818559366453e-08
for O 0 1.1378526210137352e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.5085896027121635e-07
found O 0 7.503951238163609e-09
. O 0 5.71310554420279e-09

Of O 0 1.899675407912582e-05
57 O 0 3.365833890711656e-06
informative O 0 6.551160254275601e-07
meioses O 0 1.2708153462881455e-06
, O 0 1.8165381421297866e-09
two O 0 1.449598913128014e-10
crossovers O 0 9.31549060112502e-10
were O 0 3.312992380433144e-10
noted O 0 2.925006459264523e-09
between O 0 9.546818802164125e-08
the O 0 7.8687044151593e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.1362300433859218e-08
and O 0 1.2410938943219207e-09
the O 0 3.318521457629231e-09
HLA O 0 2.688412337192858e-07
- O 0 7.236661758724949e-08
B O 0 1.0912816605923581e-07
gene O 0 1.9952395291511493e-10
, O 0 2.3494279438596166e-11
with O 0 6.390875675887919e-12
a O 0 1.0263151439815488e-10
recombinant O 0 1.739223626229247e-10
fraction O 0 1.4598577902091847e-09
of O 0 1.3036238755148588e-08
0 O 0 7.958931291796034e-08
. O 0 3.1830758473461174e-08

035 O 0 0.006161065772175789
. O 0 5.74014920857735e-05

A O 0 1.0915498933172785e-05
lod O 0 0.00011311890557408333
score O 0 3.6896244637318887e-07
of O 0 1.1302690694492412e-07
13 O 0 9.638535303224671e-09
was O 0 2.5539770298621534e-09
calculated O 0 2.486368222420765e-09
for O 0 5.520772172751265e-10
linkage O 0 5.043376859248383e-06
between O 0 0.3713153898715973
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.1441657338527875e-07
HLA O 0 2.2165336304169614e-06
- O 0 1.9476696877518407e-07
B O 0 4.833665911974094e-07
at O 0 1.9824197394768817e-08
a O 0 4.9482567349157236e-11
maximum O 0 9.640916537323463e-11
likelihood O 0 5.883007969664789e-11
value O 0 1.1540293720635475e-10
of O 0 2.3130000692539454e-10
the O 0 7.261732187791026e-11
recombinant O 0 2.492371933837667e-11
fraction O 0 1.9232146430958608e-10
of O 0 1.7114211159352521e-09
0 O 0 2.2094621243695656e-08
. O 0 2.3133820192811072e-08

04 O 0 0.004492080770432949
. O 0 7.305184408323839e-05

18 O 0 1.7267645944230026e-06
families O 0 1.9761974279219885e-09
with O 0 7.769485055320047e-10
21 O 0 2.9093728315388034e-08
informative O 0 5.1475868012573756e-09
matings O 0 3.3976601088170355e-08
for O 0 8.357697312000312e-10
both O 0 2.2586279513348018e-09
properdin O 0 1.4806299475367268e-07
Factor O 0 1.0221316237846167e-08
B O 0 8.628897063545082e-08
allotype O 0 8.811632312699658e-08
and O 0 1.4439289763856777e-09
HLA O 0 1.7231916160653782e-07
- O 0 9.752303498089532e-08
B O 0 5.344490432435123e-07
were O 0 4.017326471483784e-09
found O 0 1.2160934481642016e-09
. O 0 5.1639008624704275e-09

Of O 0 1.3459386536851525e-05
72 O 0 5.1811575758620165e-06
informative O 0 1.7980528355110437e-07
meioses O 0 1.6192115026569809e-06
, O 0 3.6743335041222736e-09
three O 0 1.228062651570383e-09
recombinants O 0 2.257509805758673e-07
were O 0 2.626889372692176e-09
found O 0 3.477752530400835e-10
, O 0 2.2763272169989968e-11
giving O 0 1.61169341761358e-11
a O 0 3.728151121151768e-11
recombinant O 0 5.451186377292139e-11
fraction O 0 1.1074304806513169e-09
of O 0 9.219178309649578e-09
0 O 0 5.455500939888225e-08
. O 0 4.260978414549754e-08

042 O 0 0.002005846006795764
. O 0 1.9926434106309898e-05

A O 0 4.8368242460128386e-06
lod O 0 4.85827295051422e-05
score O 0 4.3210351918787637e-07
of O 0 9.091499464375374e-08
16 O 0 7.704164772803779e-08
between O 0 4.099040751270877e-08
HLA O 0 2.331495636553882e-07
- O 0 4.165012867929363e-08
B O 0 3.4760713418791056e-08
and O 0 5.175975620330675e-11
Factor O 0 6.34124475151765e-10
B O 0 1.511866543069118e-08
allotypes O 0 3.3596780468769794e-08
was O 0 1.8929158684954928e-08
calculated O 0 1.0886036072577099e-08
at O 0 1.522440307155648e-08
a O 0 4.832314548508521e-10
maximum O 0 9.776450760057287e-10
likelihood O 0 3.9908992777171193e-10
value O 0 5.837351158000104e-10
of O 0 3.7263825358735403e-10
the O 0 1.3537906906613273e-10
recombinant O 0 8.608368878837425e-11
fraction O 0 5.590026774804358e-10
of O 0 1.239908398176226e-09
0 O 0 2.2737575378073416e-08
. O 0 2.211140071040063e-08

04 O 0 0.003034365363419056
. O 0 4.0496710425941274e-05

A O 0 1.3118095694153453e-06
crossover O 0 2.0412532819591434e-07
was O 0 1.7607179358947178e-07
shown O 0 3.1120916954563427e-09
to O 0 1.7378308514448548e-10
have O 0 2.3489663339426592e-11
occurred O 0 1.6165347949126385e-09
between O 0 3.610306498202931e-11
genes O 0 5.902753112685399e-12
for O 0 1.775946056881139e-11
Factor O 0 5.154894289205458e-10
B O 0 1.2998770948513538e-08
and O 0 7.578656591178401e-10
HLA O 0 8.702382103820128e-08
- O 0 1.2593235965141503e-07
D O 0 4.253634244832938e-07
, O 0 4.088276939206992e-10
in O 0 2.656667108524857e-10
which O 0 1.9281658214520547e-10
HLA O 0 1.6015948745007336e-07
- O 0 3.1288956847674854e-07
D O 0 2.4930543531809235e-06
segregared O 0 1.4508447065963992e-06
with O 0 1.0181254062047174e-08
HLA O 0 1.3203418347984552e-05
- O 0 9.975823331842548e-07
A O 0 1.9579647414502688e-07
and O 0 3.6111225121260304e-09
B O 0 2.692350335564697e-06
. O 0 3.1403867950530184e-08

These O 0 1.2168225538289335e-08
studies O 0 3.5897380623595154e-09
suggest O 0 3.179832785971115e-10
that O 0 1.1997020130799507e-12
the O 0 8.415835736630406e-12
genes O 0 3.1723115887644093e-12
for O 0 9.174766849029403e-12
Factor O 0 1.6010999193127873e-09
B O 0 1.4583829397452064e-06
and O 0 2.4076626914393273e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.169158044995072e-10
located O 0 1.0111386172795278e-09
outside O 0 7.054645756454647e-10
those O 0 4.493852859277503e-11
for O 0 4.768889727557735e-10
HLA O 0 1.6471530273065582e-07
, O 0 3.536631265621537e-10
that O 0 7.659417371186361e-12
the O 0 4.141850751260279e-11
order O 0 8.229358167133327e-11
of O 0 1.3301058032766377e-09
genese O 0 5.844542627642113e-08
is O 0 4.70668226615345e-10
HLA O 0 1.856756881579713e-08
- O 0 1.351578315933466e-08
A O 0 8.168755982751463e-08
, O 0 3.071536081034054e-10
- O 0 7.129979939790587e-10
B O 0 1.1275619549167004e-08
, O 0 1.2234376012276726e-10
- O 0 7.33428595633967e-10
D O 0 8.534922102398923e-09
, O 0 4.678361170684653e-11
Factor O 0 1.4274389448232228e-09
B O 0 6.788119435441331e-07
allotype O 0 4.815978536498733e-05
, O 0 3.2272002954414347e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.936052122594958e-10
that O 0 3.584074660320513e-12
the O 0 2.3136123225575567e-11
genes O 0 1.6796923574258216e-10
coding O 0 2.3136473714657768e-07
for O 0 1.491235508410682e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.363292032711797e-09
Factor O 0 5.5373106100375935e-09
B O 0 3.40540680099366e-08
allotypes O 0 3.241859758418286e-08
are O 0 2.6876329287106593e-11
approximately O 0 4.4261403570056146e-11
3 O 0 4.709447831707791e-10
- O 0 3.688993832628995e-10
- O 0 4.5814049776105037e-10
5 O 0 9.836941261553989e-10
centimorgans O 0 9.89447102028862e-09
from O 0 6.992367240776787e-10
the O 0 1.1865910476416275e-09
HLA O 0 2.797697895573492e-08
- O 0 9.062807393434014e-09
A O 0 1.8414221258922225e-08
and O 0 6.105682626156295e-10
HLA O 0 1.0421129559290421e-07
- O 0 4.171834433464028e-08
B O 0 5.405019365412045e-08
loci O 0 8.841810616999624e-10
, O 0 9.151055607725667e-11
and O 0 1.152300043577581e-11
that O 0 2.634406798610045e-12
the O 0 1.461143185610414e-11
apparent O 0 1.1251852782834249e-09
lack O 0 2.7181239481421926e-09
of O 0 2.835062185013726e-09
recombinants O 0 1.774178137736726e-08
between O 0 7.471043228512997e-10
the O 0 2.5639915191000284e-10
Factor O 0 1.5548139442600473e-09
B O 0 1.7684692465991247e-07
gene O 0 2.2900402996128832e-07
and O 0 3.276146344433073e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.175356818654109e-07
suggests O 0 1.1727451898480012e-08
that O 0 1.5907731729103425e-11
these O 0 1.4468580847304402e-11
two O 0 6.028713639416594e-11
genes O 0 6.085406623057565e-10
lie O 0 7.255983547338474e-08
in O 0 1.0022791485653215e-09
close O 0 6.959454879051918e-08
proximity O 0 7.34566043547602e-08
to O 0 4.320884539055214e-09
one O 0 8.074862556384232e-09
another O 0 2.1638982161675813e-08
. O 0 1.7618769732052897e-07

Distribution O 0 2.750853980160173e-07
of O 0 3.994925350525591e-07
emerin O 0 1.7180476788780652e-05
and O 0 2.7268910685052106e-08
lamins O 0 1.125865128415171e-05
in O 0 2.723474556987071e-09
the O 0 1.231476076668514e-08
heart O 0 1.5214525319606764e-06
and O 0 3.3941414123717095e-09
implications O 0 2.6392704910449538e-08
for O 0 7.055510398146225e-09
Emery B-Disease 1 0.8894942998886108
- I-Disease 1 0.997658371925354
Dreifuss I-Disease 1 0.9999984502792358
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.999998927116394
. O 0 1.8282782548340037e-05

Emerin O 0 0.000517456152010709
is O 0 3.615218417962751e-07
a O 0 1.621962724129844e-07
nuclear O 0 2.9940467811684357e-06
membrane O 0 4.070362535912864e-08
protein O 0 1.0858331123131393e-08
which O 0 6.478891728667335e-11
is O 0 6.299075150373312e-11
missing O 0 2.055617898122364e-09
or O 0 6.128106910807674e-10
defective O 0 2.1476787424035138e-06
in O 0 2.4377623475402288e-08
Emery B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.4830367263130029e-06
EDMD B-Disease 1 1.0
) O 0 2.9350786689974484e-08
. O 0 5.706856853748832e-08

It O 0 3.86338250280005e-08
is O 0 1.468344223987117e-09
one O 0 2.538870780277591e-10
member O 0 3.746381871394533e-09
of O 0 6.475774938508039e-08
a O 0 6.481051428863793e-08
family O 0 8.150636610082529e-09
of O 0 7.825054382237795e-08
lamina O 0 2.6949606763082556e-05
- O 0 1.4354452559928177e-07
associated O 0 1.8015983371810762e-08
proteins O 0 1.6882391318251422e-10
which O 0 2.7518827494521503e-11
includes O 0 4.0065402384659166e-11
LAP1 O 0 3.7355735571509285e-07
, O 0 1.4907506340477994e-09
LAP2 O 0 4.580536824505543e-06
and O 0 5.122643287336359e-08
lamin O 0 1.2836627320211846e-05
B O 0 3.5803968785330653e-06
receptor O 0 6.572323485443121e-08
( O 0 1.5363722738470642e-08
LBR O 0 2.238385832242784e-06
) O 0 4.518809326725659e-09
. O 0 1.3001577769955475e-07

A O 0 1.678480657574255e-06
panel O 0 9.222838457390026e-07
of O 0 1.1207718131345246e-07
16 O 0 1.93054496833156e-08
monoclonal O 0 1.291949547344018e-09
antibodies O 0 2.7096233590206964e-10
( O 0 2.5792359914511565e-10
mAbs O 0 1.088701218066035e-08
) O 0 1.3324412406756636e-10
has O 0 3.8505029026358883e-11
been O 0 6.847786920838317e-11
mapped O 0 3.7109273987034896e-10
to O 0 4.124916033743098e-11
six O 0 3.107628043785837e-11
specific O 0 1.768465582308032e-11
sites O 0 4.355010102541357e-11
throughout O 0 4.179721152519633e-11
the O 0 2.0064516714768388e-10
emerin O 0 8.843652921086687e-09
molecule O 0 3.1576272152555873e-10
using O 0 5.097666178066618e-10
phage O 0 6.055318024777989e-09
- O 0 5.804852709623276e-10
displayed O 0 1.46323353433786e-09
peptide O 0 6.560644805198024e-10
libraries O 0 4.1571041053956037e-10
and O 0 3.748257607072425e-11
has O 0 6.341915707863688e-12
been O 0 1.702680357817954e-11
used O 0 1.9026428002555384e-11
to O 0 3.766741085708958e-11
localize O 0 7.241548871661507e-08
emerin O 0 6.386532049873495e-07
in O 0 3.881002630379271e-09
human O 0 1.6781729783588162e-08
and O 0 1.1146529921290949e-08
rabbit O 0 5.2684953288917313e-08
heart O 0 4.895874099020148e-06
. O 0 6.90912315803871e-07

Several O 0 2.2207687777608953e-07
mAbs O 0 2.1226271655905293e-06
against O 0 7.291902903716618e-08
different O 0 8.90445139845042e-09
emerin O 0 5.499547341969446e-07
epitopes O 0 1.0329171118428349e-07
did O 0 6.102041982813944e-09
not O 0 2.6434443523015716e-10
recognize O 0 1.5102518124976427e-09
intercalated O 0 1.8412067959161504e-07
discs O 0 5.8547238950268365e-06
in O 0 2.77900920053753e-08
the O 0 6.057029366957067e-08
heart O 0 4.961342710885219e-06
, O 0 4.428304389847426e-10
though O 0 1.7797414930686983e-10
they O 0 8.169721843476196e-12
recognized O 0 1.1025570040290589e-10
cardiomyocyte O 0 2.1301143959817637e-08
nuclei O 0 7.165990023594304e-09
strongly O 0 1.3795606879085653e-09
, O 0 1.655847819970191e-10
both O 0 6.565037957706465e-10
at O 0 5.191070684418264e-08
the O 0 4.575800627293347e-09
rim O 0 4.9924704370596373e-08
and O 0 1.6724802098799785e-10
in O 0 7.956494907368494e-10
intranuclear O 0 7.585402528320628e-08
spots O 0 2.5617845622605273e-08
or O 0 3.009021920519217e-09
channels O 0 1.7593517043223983e-07
. O 0 1.3571172985393787e-07

A O 0 1.369457208966196e-06
polyclonal O 0 3.7925738638477924e-07
rabbit O 0 4.7987306572849775e-08
antiserum O 0 3.085031892169354e-07
against O 0 1.7589323419997527e-07
emerin O 0 5.82181201025378e-06
did O 0 2.0541294887266304e-08
recognize O 0 8.86914364173208e-09
both O 0 3.0577951282140248e-09
nuclear O 0 9.400547895666023e-08
membrane O 0 9.815500634502428e-10
and O 0 1.0934616406776954e-10
intercalated O 0 2.2536532640060614e-09
discs O 0 4.333704595183008e-08
but O 0 7.889635472713152e-11
, O 0 5.1321191220365936e-12
after O 0 3.869674719547689e-11
affinity O 0 1.8152902792056835e-10
purification O 0 4.104710793484401e-09
against O 0 1.3985140823180586e-09
a O 0 2.2972743707327936e-09
pure O 0 8.409321594626817e-08
- O 0 1.7946627517417824e-09
emerin O 0 4.881556847635693e-08
band O 0 1.7310309630147458e-08
on O 0 1.416358799133377e-07
a O 0 8.793831440812028e-09
western O 0 8.667987216881556e-09
blot O 0 1.1760562301788013e-07
, O 0 4.64287719381673e-10
it O 0 1.0238829228903512e-10
stained O 0 7.510468691407368e-08
only O 0 8.604597590000651e-10
the O 0 1.8519173972109115e-09
nuclear O 0 8.344802893134329e-08
membrane O 0 1.3842081258985672e-08
. O 0 4.700422273629101e-09

These O 0 1.1114875242412836e-08
results O 0 2.8846556254791267e-09
would O 0 5.375487277525792e-10
not O 0 2.831298216710021e-11
be O 0 2.4779100646354912e-11
expected O 0 1.394970111645577e-10
if O 0 1.4109452495247865e-10
immunostaining O 0 3.2968959118306884e-08
at O 0 3.461027375806225e-08
intercalated O 0 6.785078454640825e-08
discs O 0 7.36858908112481e-07
were O 0 4.8380073280895886e-09
due O 0 1.740821709006468e-08
to O 0 1.8186241401707548e-10
a O 0 2.3580892793972907e-10
product O 0 1.7170605215444112e-10
of O 0 1.355320855545017e-09
the O 0 1.8207249041779505e-09
emerin O 0 1.1266412514032709e-07
gene O 0 6.341740466098145e-10
and O 0 3.3724895098785623e-10
, O 0 1.0158665575410453e-10
therefore O 0 8.257318162563365e-10
, O 0 5.253405349625595e-11
cast O 0 1.994988341191828e-10
some O 0 8.911097554298308e-12
doubt O 0 5.05447628196265e-10
upon O 0 2.4508745033458013e-10
the O 0 2.2156887435897943e-10
hypothesis O 0 1.4841317064195891e-09
that O 0 5.059672472662591e-11
cardiac B-Disease 0 0.0002980482531711459
defects I-Disease 0 0.0007332718814723194
in O 0 2.0673182916652877e-06
EDMD B-Disease 1 1.0
are O 0 1.0863179689124536e-08
caused O 0 5.0162447529089604e-09
by O 0 7.407019442240426e-11
absence O 0 6.91953587761418e-08
of O 0 4.570037503981439e-08
emerin O 0 1.3923366850576713e-06
from O 0 1.785033099110933e-08
intercalated O 0 1.803794134502823e-06
discs O 0 4.674304000218399e-05
. O 0 3.903447520769987e-07

Although O 0 1.4483823917998961e-07
emerin O 0 9.374534784001298e-06
was O 0 1.5324219759804691e-07
abundant O 0 2.237369622903884e-09
in O 0 2.300733076276984e-10
the O 0 3.66535107820809e-10
membranes O 0 1.9367991654917205e-09
of O 0 1.7160276755134873e-08
cardiomyocyte O 0 1.6721666895591625e-07
nuclei O 0 5.899543076282043e-09
, O 0 7.826417292022825e-11
it O 0 8.338883403236075e-12
was O 0 1.3109937579969255e-09
absent O 0 9.28618404394399e-10
from O 0 6.96597918237174e-11
many O 0 8.211590261930635e-12
non O 0 6.211839931324903e-09
- O 0 4.491972127596e-09
myocyte O 0 1.0835702113354273e-07
cells O 0 1.559291584740663e-10
in O 0 1.0380512005525588e-09
the O 0 5.5168589696563686e-09
heart O 0 2.749592340478557e-06
. O 0 3.014745857399248e-07

This O 0 1.2615457123388296e-08
distribution O 0 7.729907736120367e-08
of O 0 1.0222275648175128e-07
emerin O 0 1.0743050324890646e-06
was O 0 6.59774457290041e-08
similar O 0 1.6492915366761451e-10
to O 0 3.1662138189059164e-11
that O 0 1.601147166241379e-11
of O 0 6.403416907829751e-09
lamin O 0 1.2564893268063315e-06
A O 0 5.2573227549146395e-08
, O 0 4.4489020800675405e-10
a O 0 5.913915468447328e-10
candidate O 0 3.500859324656602e-10
gene O 0 2.992285585978749e-10
for O 0 4.149530719033123e-10
an O 0 4.342023685044438e-10
autosomal O 0 1.4469798088612151e-06
form O 0 1.8821447156369686e-07
of O 0 0.0011989801423624158
EDMD B-Disease 1 1.0
. O 0 2.900168146879878e-05

In O 0 3.875945537856751e-07
contrast O 0 3.529162597715185e-07
, O 0 7.679400226834332e-08
lamin O 0 7.706603355472907e-05
B1 O 0 0.00011785714013967663
was O 0 5.658079771819757e-06
absent O 0 9.93495973489189e-07
from O 0 1.7402607355165856e-08
cardiomyocyte O 0 7.46493867609388e-07
nuclei O 0 2.394047982079428e-08
, O 0 5.931560798089208e-10
showing O 0 5.288174786954869e-09
that O 0 4.3967123275479025e-09
lamin O 0 1.3039370969636366e-05
B1 O 0 1.628983227419667e-06
is O 0 1.5057181890210103e-10
not O 0 1.3837968965146885e-11
essential O 0 4.759275751275993e-10
for O 0 4.563071101526539e-11
localization O 0 4.148569985318318e-07
of O 0 1.7175993960449887e-08
emerin O 0 5.601430643764616e-07
to O 0 1.910685609729512e-09
the O 0 1.017154982463353e-08
nuclear O 0 1.0717366194512579e-06
lamina O 0 3.2166396977117984e-06
. O 0 1.7077496750061982e-07

Lamin O 1 0.9834611415863037
B1 O 0 0.07096940279006958
is O 0 5.78929046923804e-08
also O 0 9.921339305662968e-10
almost O 0 1.5822534393805654e-09
completely O 0 1.9457642608244896e-08
absent O 0 1.2665803694744682e-07
from O 0 9.348138263476358e-09
skeletal O 0 0.000511840102262795
muscle O 0 1.927125958900433e-05
nuclei O 0 1.5670051652705297e-05
. O 0 6.719575935676403e-07

In O 0 5.961628176009981e-06
EDMD B-Disease 1 1.0
, O 0 4.097576944417369e-09
the O 0 2.7412916381308605e-10
additional O 0 1.3752854410853388e-10
absence O 0 2.379407426644775e-08
of O 0 9.109881915492224e-08
lamin O 0 5.9436122683109716e-05
B1 O 0 0.00072105647996068
from O 0 1.4958432075218298e-06
heart O 1 0.999567449092865
and O 0 4.985420673619956e-05
skeletal O 1 1.0
muscle O 1 0.999841570854187
nuclei O 0 0.29829928278923035
which O 0 1.1929051879633334e-07
already O 0 3.4283537786450324e-08
lack O 0 2.810861872148962e-07
emerin O 0 9.572617045705556e-07
may O 0 5.16766240910016e-10
offer O 0 2.5708310480432317e-11
an O 0 2.2731456474078815e-12
alternative O 0 2.714014846194601e-10
explanation O 0 6.35085595224183e-10
of O 0 1.4243195511909335e-09
why O 0 8.867447887084268e-10
these O 0 1.6311209327657394e-11
tissues O 0 2.2758334106143252e-10
are O 0 5.601334934074442e-12
particularly O 0 2.6137625050437485e-11
affected O 0 1.55149452313319e-11
. O 0 5.88871035267502e-11
. O 0 2.8463809087497793e-09

Genetic O 0 3.3593261150599574e-07
mapping O 0 1.0219172281722422e-06
of O 0 8.45799547732895e-07
the O 0 1.9722959621049085e-07
copper B-Disease 0 0.000385837338399142
toxicosis I-Disease 0 0.0006998282042331994
locus O 0 8.08576174904374e-08
in O 0 4.6036323197995443e-08
Bedlington O 0 6.461715383920819e-05
terriers O 0 8.140670615830459e-06
to O 0 1.3948198152036184e-08
dog O 0 1.2739067756228906e-07
chromosome O 0 7.668320733955625e-08
10 O 0 7.137249014022018e-09
, O 0 1.1857104187384948e-10
in O 0 3.3494756968011075e-10
a O 0 1.0939252836905666e-09
region O 0 8.254881223024313e-09
syntenic O 0 5.433890137851449e-08
to O 0 1.5025222732667487e-10
human O 0 6.294850196653101e-10
chromosome O 0 1.913523739460743e-08
region O 0 6.660341611564036e-09
2p13 O 0 2.3824735251309903e-07
- O 0 4.118539109754238e-08
p16 O 0 1.2243998526173527e-07
. O 0 5.0054186573333936e-08

Abnormal O 1 0.9999960660934448
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999833106994629
accumulation I-Disease 0 0.0062757316045463085
is O 0 1.1390589582660482e-09
recognized O 0 8.162036047032473e-10
as O 0 5.045335260689399e-10
an O 0 3.1146154544359206e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.00015077229181770235
man O 0 3.5960558761871653e-06
, O 0 2.0773541220542313e-10
mouse O 0 8.217712732516702e-09
, O 0 2.6382172002570314e-09
rat O 0 2.6078413384311716e-07
and O 0 1.371964675200843e-08
dog O 0 2.771770823528641e-06
. O 0 1.513607088554636e-07

The O 0 7.751359021312965e-07
major O 0 8.922439178604691e-07
cause O 0 4.58435670225299e-06
of O 0 5.3817413572687656e-05
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999998807907104
accumulation I-Disease 1 0.9999996423721313
in O 1 0.9909419417381287
man O 1 0.9948967099189758
is O 0 4.4277935984382566e-08
a O 0 6.797785800927159e-08
dysfunctional O 0 3.846798790618777e-05
ATP7B O 0 0.0003773561038542539
gene O 0 3.166472239968243e-08
, O 0 7.007012747806129e-10
causing O 0 1.518003855949246e-08
Wilson B-Disease 0 2.708443389565218e-07
disease I-Disease 0 5.18901686064055e-07
( O 0 1.4716386997903896e-09
WD B-Disease 0 1.7864366554931621e-06
) O 0 1.2922360070888317e-08
. O 0 1.3415264277227834e-07

Mutations O 0 2.0169292724858678e-07
in O 0 1.4439160089807501e-08
the O 0 2.3397364046218172e-08
ATP7B O 0 9.160118679574225e-06
genes O 0 1.5431321775949414e-09
have O 0 5.566828942260571e-11
also O 0 1.5648862414230358e-11
been O 0 1.1017072670815864e-11
demonstrated O 0 1.6465004359922375e-10
in O 0 1.3650748587057393e-10
mouse O 0 4.6896140304397704e-09
and O 0 6.745886516057453e-09
rat O 0 3.0797701811025036e-07
. O 0 4.441860568249467e-08

The O 0 6.613748610106995e-06
ATP7B O 0 0.0003336580120958388
gene O 0 1.984512465469379e-07
has O 0 3.966405426325537e-09
been O 0 5.310347717113473e-10
excluded O 0 9.048691795854324e-10
in O 0 1.1782280706640336e-10
the O 0 3.017699146123931e-10
much O 0 1.0191507637813402e-09
rarer O 0 4.972152822801945e-08
human O 0 1.960116335908424e-08
copper B-Disease 0 9.276849596062675e-05
overload I-Disease 0 0.0017527177697047591
disease O 0 0.0001470134302508086
non B-Disease 0 3.341630758768588e-07
- I-Disease 0 3.380426960575278e-08
Indian I-Disease 0 9.19515485975353e-09
childhood I-Disease 0 1.536381932965014e-05
cirrhosis I-Disease 1 0.8802043795585632
, O 0 3.763138134438293e-10
indicating O 0 8.057323697130414e-09
genetic O 0 1.978449759576506e-08
heterogeneity O 0 4.053264603953721e-07
. O 0 3.5975128298559866e-07

By O 0 2.4696082956410237e-09
investigating O 0 6.811218611346703e-08
the O 0 1.3057340098043824e-08
common O 0 2.3847155716794077e-06
autosomal O 1 0.9999676942825317
recessive O 1 0.9999721050262451
copper B-Disease 1 0.9999998807907104
toxicosis I-Disease 1 0.9999997615814209
( O 0 1.0907572800533671e-07
CT B-Disease 0 0.00019386327767279
) O 0 1.3963497025315519e-09
in O 0 1.5303475819905543e-08
Bedlington O 0 0.013611951842904091
terriers O 0 0.0005069850012660027
, O 0 1.9704424758515415e-09
we O 0 3.8538330859871905e-10
have O 0 4.01807883840255e-12
identified O 0 7.761627278390915e-12
a O 0 2.6687211468479077e-12
new O 0 1.6436560229191044e-12
locus O 0 2.5849771975727798e-11
involved O 0 1.6294302018771134e-10
in O 0 1.264573223913601e-09
progressive O 1 0.9999990463256836
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.5268016795744188e-05

We O 0 3.2478763500876084e-07
examined O 0 2.2058540594116494e-07
whether O 0 8.060982104041159e-09
the O 0 7.861118866969719e-09
WD B-Disease 0 1.980852857741411e-06
gene O 0 4.8389608764409786e-08
ATP7B O 0 1.9701446944964118e-05
was O 0 8.152535428962437e-07
also O 0 1.3353421701722823e-09
causative O 0 7.837868132298809e-09
for O 0 1.7006018815379775e-09
CT B-Disease 0 3.319958750580554e-06
by O 0 2.199926907309191e-10
investigating O 0 3.9278837959955126e-08
the O 0 2.6684046083857993e-09
chromosomal O 0 1.445823727408424e-05
co O 0 3.362561528774677e-06
- O 0 1.0460419730407011e-07
localization O 0 0.0005319006741046906
of O 0 1.7368968201481039e-06
ATP7B O 0 3.081547765759751e-05
and O 0 7.699940685057527e-10
C04107 O 0 9.223752428511034e-09
, O 0 8.69695548216809e-12
using O 0 5.398126390332436e-12
fluorescence O 0 3.936167225493392e-10
in O 0 3.4023908690450355e-10
situ O 0 8.390944117309118e-08
hybridization O 0 2.6269797448463805e-09
( O 0 9.543765083774858e-11
FISH O 0 1.1952021594652251e-09
) O 0 1.2322008691167952e-10
. O 0 7.1843699878115785e-09

C04107 O 0 1.9606830392149277e-05
is O 0 7.796150391925494e-09
an O 0 2.384066000171714e-10
anonymous O 0 6.079991177188049e-09
microsatellite O 0 2.626981654429983e-07
marker O 0 2.1030709262959135e-07
closely O 0 1.0227093127923581e-07
linked O 0 5.503917464011465e-07
to O 0 3.535724246717109e-08
CT B-Disease 1 0.9992990493774414
. O 0 2.9895045372541063e-06

However O 0 2.570715651017963e-06
, O 0 2.498621256563638e-07
BAC O 0 4.85946839035023e-05
clones O 0 3.320194252864894e-08
containing O 0 8.861399614090715e-09
ATP7B O 0 1.6996254998957738e-06
and O 0 7.613142116724703e-09
C04107 O 0 2.93496782433067e-07
mapped O 0 6.213608116922842e-08
to O 0 3.00665825569979e-09
the O 0 1.1204144279020056e-08
canine O 0 2.731160009261657e-07
chromosome O 0 1.8767174481126858e-07
regions O 0 6.359719861848134e-09
CFA22q11 O 0 5.909101332690625e-07
and O 0 2.6034459033041912e-09
CFA10q26 O 0 3.3311243896605447e-07
, O 0 1.6153166304544442e-10
respectively O 0 1.5625644111949555e-09
, O 0 4.632313282959544e-11
demonstrating O 0 1.3051979497191724e-09
that O 0 1.696253554284155e-10
WD B-Disease 0 7.902915655222387e-08
cannot O 0 2.013334166051095e-09
be O 0 2.9834637538250774e-10
homologous O 0 3.141745086310266e-09
to O 0 1.9950883167751954e-09
CT B-Disease 0 9.750820754561573e-05
. O 0 2.8032269483446726e-07

The O 0 1.6744277218094794e-06
copper O 0 2.2900343537912704e-05
transport O 0 4.248546190410707e-07
genes O 0 1.8009524538342703e-08
CTR1 O 0 2.9727141281910008e-06
and O 0 1.676358163393843e-09
CTR2 O 0 4.197770067548845e-06
were O 0 4.38028102678345e-09
also O 0 2.0700645364524206e-10
excluded O 0 9.947866974613362e-10
as O 0 2.1245331882635554e-10
candidate O 0 5.05200881129042e-10
genes O 0 3.0812646878430883e-10
for O 0 6.564763177507871e-10
CT B-Disease 0 3.8115949791972525e-06
since O 0 9.581639481837101e-09
they O 0 9.446638610244307e-11
both O 0 1.2230595702877878e-10
mapped O 0 2.036219859391508e-09
to O 0 5.290149429626467e-10
canine O 0 1.9110989057935512e-07
chromosome O 0 4.0346529317503155e-07
region O 0 2.357197246283249e-07
CFA11q22 O 0 1.9415516362641938e-05
. O 0 4.780204676535504e-07

2 O 0 0.00012958139996044338
- O 0 7.0417722781712655e-06
22 O 0 1.6471058188471943e-06
. O 0 3.6451649521040963e-07

5 O 0 8.753554720897228e-05
. O 0 5.04018453284516e-06

A O 0 7.957289085425145e-07
transcribed O 0 5.105465561427991e-08
sequence O 0 8.03035149488096e-09
identified O 0 3.3031446466935677e-09
from O 0 8.258184691634085e-10
the O 0 1.3207066551501612e-09
C04107 O 0 2.7794067491981878e-08
- O 0 1.5761149052551104e-09
containing O 0 6.768824389880024e-10
BAC O 0 5.238297944742953e-06
was O 0 5.001934866299962e-08
found O 0 2.7453833650881165e-10
to O 0 2.988645095292064e-11
be O 0 3.059261871607433e-11
homologous O 0 1.2337036947585034e-10
to O 0 1.0867810124048916e-10
a O 0 1.344978156625487e-10
gene O 0 2.037186114245415e-10
expressed O 0 3.8527528389842303e-10
from O 0 6.502726690449379e-10
human O 0 1.0432554820027917e-09
chromosome O 0 2.8918680783363016e-08
2p13 O 0 7.546569236183132e-08
- O 0 5.928023849577357e-09
p16 O 0 1.4052718100288075e-08
, O 0 1.6622334064742006e-10
a O 0 2.2767668306222788e-10
region O 0 1.1394348797821863e-09
devoid O 0 9.379646570550904e-08
of O 0 1.9219688063287776e-09
any O 0 7.411771751897334e-10
positional O 0 2.426619971629407e-07
candidate O 0 3.9822126041144656e-08
genes O 0 3.652506563867064e-08
. O 0 1.3841730606145575e-07

Molecular O 0 3.594506097215344e-06
analysis O 0 1.6663784663251135e-07
of O 0 1.1109580810853004e-07
the O 0 2.2106465991100777e-08
APC B-Disease 0 2.4622815786301544e-08
gene O 0 9.532544753554362e-10
in O 0 1.008301886429308e-09
205 O 0 3.1660358779106446e-09
families O 0 1.179432506520639e-11
: O 0 7.1237742267638016e-12
extended O 0 4.313841506231597e-10
genotype O 0 4.7460904539775584e-08
- O 0 1.0234679770348976e-08
phenotype O 0 2.924041453411519e-09
correlations O 0 4.383376150940421e-08
in O 0 9.258823707725128e-10
FAP B-Disease 0 2.2783537279025268e-09
and O 0 6.790247530918947e-11
evidence O 0 1.0529083854793342e-10
for O 0 4.138737096093248e-12
the O 0 3.5924877656023924e-11
role O 0 2.1748123302245403e-09
of O 0 2.5772617817665378e-08
APC B-Disease 0 7.700609927496771e-08
amino O 0 2.2461959403585752e-08
acid O 0 2.1296351349064935e-08
changes O 0 1.8946858304502712e-08
in O 0 6.442710855480982e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999645948410034
. O 0 1.898349728435278e-05

BACKGROUND O 0 4.465087113203481e-05
/ O 0 3.2636851301504066e-06
AIMS O 0 1.1769134289352223e-07
The O 0 1.50055257108761e-09
development O 0 7.277660785121043e-08
of O 0 0.002770103979855776
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5795305330357223e-07
a O 0 8.10139177964686e-10
variable O 0 3.52260998148779e-09
range O 0 2.8432609600059777e-09
of O 0 1.7242289818142353e-09
extracolonic O 0 3.8981127659099e-07
manifestations O 0 5.241070994088659e-06
in O 0 2.8853010007878765e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 1.2128283799484052e-07
FAP B-Disease 0 5.848322714996357e-08
) O 0 1.7735808655050533e-10
is O 0 1.9037936158095015e-11
the O 0 1.7037135591202457e-11
result O 0 9.46873690566008e-11
of O 0 4.680978937798841e-10
the O 0 4.923612073604033e-10
dominant O 0 7.867757290114241e-07
inheritance O 0 1.9939345747843618e-06
of O 0 1.66818754223641e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9998509883880615
coli I-Disease 1 0.9999433755874634
( O 0 1.013719064246743e-08
APC B-Disease 0 1.147194836903509e-07
) O 0 6.637945304532877e-09
gene O 0 7.794696443852445e-08
mutations O 0 5.302327394929307e-07
. O 0 4.378634059776232e-07

In O 0 1.0909670500325319e-08
this O 0 8.878206503304398e-11
study O 0 8.068325868526571e-11
, O 0 5.610016357709968e-12
direct O 0 3.935700029766842e-11
mutation O 0 1.4409040800800188e-11
analysis O 0 1.5126958019529013e-10
of O 0 3.434720508010969e-09
the O 0 1.5573702327742467e-08
APC B-Disease 0 8.453336164393477e-08
gene O 0 1.9623159985826533e-08
was O 0 1.2563714335556142e-07
performed O 0 1.168578567245504e-08
to O 0 5.407138070623319e-10
determine O 0 1.4929737446323088e-08
genotype O 0 5.6079205279502276e-08
- O 0 3.1782775522515294e-08
phenotype O 0 3.4258094139261175e-09
correlations O 0 8.012729324491374e-08
for O 0 1.9433896714105003e-09
nine O 0 1.0424883178927757e-08
extracolonic O 0 4.1332398836857465e-07
manifestations O 0 3.850854568554496e-07
and O 0 4.934536668166345e-10
to O 0 2.8687460393306274e-11
investigate O 0 6.062051971511551e-10
the O 0 1.1152111178969193e-10
incidence O 0 1.7052742862233572e-07
of O 0 1.6164925398243213e-08
APC B-Disease 0 4.4944680865910414e-08
mutations O 0 3.2415119477491317e-09
in O 0 4.161897493304423e-09
non O 0 0.16200128197669983
- O 1 0.9981131553649902
FAP O 1 0.9998776912689209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00038105915882624686

METHODS O 0 1.924176831380464e-05
The O 0 1.4546920112934458e-07
APC B-Disease 0 7.326868711743373e-08
gene O 0 4.1367465009045645e-09
was O 0 1.1675671096611495e-08
analysed O 0 4.033188005791999e-09
in O 0 3.1110988785165716e-10
190 O 0 4.883544679756824e-10
unrelated O 0 1.9508505921805863e-09
FAP B-Disease 0 5.71466096666029e-10
and O 0 7.246097472046742e-11
15 O 0 1.1274480016254529e-08
non O 0 3.204775930498727e-05
- O 1 0.686379075050354
FAP O 1 0.9948955178260803
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.033062393522414e-07
using O 0 1.029390261919616e-08
denaturing O 0 4.039668056066148e-06
gradient O 0 2.1116203186011262e-07
gel O 0 1.498706296843011e-07
electrophoresis O 0 4.549564280864615e-08
, O 0 5.458066221208924e-10
the O 0 1.4710690443564545e-09
protein O 0 1.5472346737155362e-09
truncation O 0 1.1207991867934197e-08
test O 0 3.774344448093103e-10
, O 0 9.670377346115977e-12
and O 0 5.954633921362307e-12
direct O 0 1.2612388911037442e-10
sequencing O 0 4.072845616320819e-09
. O 0 5.929044633035119e-08

RESULTS O 0 2.6782529403135413e-06
Chain O 0 1.500589746683545e-06
terminating O 0 4.250661902460706e-07
signals O 0 1.1677680333832541e-07
were O 0 1.0968523866949909e-09
only O 0 3.567952530647567e-11
identified O 0 8.894070896436901e-11
in O 0 1.2741674382255042e-10
patients O 0 4.790660090847609e-10
belonging O 0 3.548667359964952e-09
to O 0 3.121768954450488e-10
the O 0 6.834640853270457e-09
FAP B-Disease 0 6.863304236048862e-08
group O 0 6.223153992124253e-09
( O 0 3.8702230309439756e-10
105 O 0 3.9299223431044084e-08
patients O 0 4.799295627577749e-09
) O 0 1.439875219055864e-09
. O 0 5.270213776498167e-08

Amino O 0 2.3561910893477034e-06
acid O 0 1.1359162499502418e-07
changes O 0 2.07145967046074e-09
were O 0 3.989902574996762e-10
identified O 0 5.382627676908669e-10
in O 0 1.4856094132653652e-10
four O 0 3.187568820006703e-10
patients O 0 2.2811048883131235e-10
, O 0 2.643392622847518e-11
three O 0 1.999922033535384e-10
of O 0 5.294137395139842e-07
whom O 0 2.1252613180422486e-07
belonged O 0 1.4783296137466095e-05
to O 0 1.2843404118001445e-09
the O 0 2.128721376948306e-08
non O 0 4.638111931853928e-06
- O 0 7.034336846345468e-08
FAP O 0 8.452219368848546e-09
group O 0 3.692008698763516e-09
of O 0 0.016387423500418663
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9964511394500732
. O 0 3.008134171977872e-06

Genotype O 0 7.979199290275574e-05
- O 0 9.110660357691813e-06
phenotype O 0 2.567336991887714e-07
correlations O 0 6.914719392625557e-07
identified O 0 6.380094674796055e-09
significant O 0 1.0082485069062841e-08
differences O 0 2.745923950442375e-07
in O 0 2.0998989214149333e-09
the O 0 5.778418854518463e-10
nature O 0 1.1754048845347143e-09
of O 0 3.2118463444419376e-10
certain O 0 3.091890909967532e-10
extracolonic O 0 2.0324609550925743e-08
manifestations O 0 1.8199793672124542e-08
in O 0 2.7352536902114366e-10
FAP B-Disease 0 3.379632351752093e-09
patients O 0 8.109771187925219e-10
belonging O 0 1.9693415787003232e-09
to O 0 2.7796956403314255e-10
three O 0 1.288140594191134e-09
mutation O 0 1.2367771695664942e-08
subgroups O 0 4.720046149486734e-07
. O 0 4.7263975488931464e-07

CONCLUSIONS O 0 1.5276403928510263e-06
Extended O 0 1.291865743269227e-07
genotype O 0 1.791869550515912e-07
- O 0 3.643051371682304e-08
phenotype O 0 2.450328828729198e-09
correlations O 0 6.697401744304443e-08
made O 0 8.359323233619875e-10
in O 0 2.8230118243044444e-10
this O 0 4.073447135155561e-11
study O 0 1.7445127287185613e-10
may O 0 8.498801662426558e-11
have O 0 9.02913247641246e-12
the O 0 2.596456036285666e-11
potential O 0 4.870231301579153e-11
to O 0 9.984049177680365e-12
determine O 0 2.671280419086486e-10
the O 0 5.5942910026640646e-11
most O 0 3.6232596783980497e-12
appropriate O 0 6.483626135977971e-11
surveillance O 0 2.022613854180122e-09
and O 0 7.969552101583233e-11
prophylactic O 0 1.245971503749388e-07
treatment O 0 8.86055406823516e-09
regimens O 0 1.6532364810473155e-08
for O 0 5.5820546102092194e-11
those O 0 1.3259502870677231e-11
patients O 0 4.017889146390452e-11
with O 0 3.801267026842803e-12
mutations O 0 3.035525719674581e-10
associated O 0 1.852602848906315e-09
with O 0 3.088896638470118e-10
life O 0 1.8954811054072707e-08
threatening O 0 1.3467379211817843e-08
conditions O 0 3.9989427591535787e-07
. O 0 1.8148980984733498e-07

This O 0 1.1207991867934197e-08
study O 0 1.834525642507856e-09
also O 0 7.592151213264842e-11
provided O 0 6.422944814898912e-11
evidence O 0 2.128568987735946e-10
for O 0 7.707882943019939e-12
the O 0 1.3437680135286456e-10
pathological O 0 1.7105863662436604e-05
nature O 0 1.2151758710388094e-08
of O 0 9.768813313826286e-09
amino O 0 2.233813356511405e-09
acid O 0 1.131894689088142e-09
changes O 0 7.9460760193939e-10
in O 0 8.733001544136698e-10
APC O 0 1.1787483877867544e-08
associated O 0 1.2588007969327464e-08
with O 0 7.792901740577562e-11
both O 0 2.7934185520273047e-10
FAP B-Disease 0 6.1305889254015256e-09
and O 0 1.5029356648099679e-09
non O 1 0.9924512505531311
- O 1 0.9999990463256836
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.9535563953686506e-05
. O 0 1.0446459697277533e-08
. O 0 5.526182178527961e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999990463256836
and O 0 6.675862096017227e-06
cancer B-Disease 0 0.00988613162189722
risk O 0 6.237547154341883e-07
of O 0 5.493938033396262e-07
the O 0 3.7690469412154926e-07
APC O 0 2.776307837848435e-06
I1307K O 0 5.362267643249652e-07
polymorphism O 0 2.607169733437331e-07
. O 0 4.251699436963463e-08

Germ O 0 0.005341631826013327
- O 0 5.133861122885719e-06
line O 0 2.327288086689805e-07
and O 0 6.315305500770307e-10
somatic O 0 3.1001320621726336e-08
truncating O 0 1.9241599602537462e-07
mutations O 0 6.035231869816471e-09
of O 0 2.2228192619877518e-08
the O 0 1.1237553110277076e-08
APC B-Disease 0 1.78875552592217e-07
gene O 0 1.3891435557411569e-08
are O 0 4.5486925337456796e-10
thought O 0 2.111711250307735e-09
to O 0 1.4253759283988643e-10
initiate O 0 1.3512334362530964e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 5.50844697499997e-06
formation O 0 2.3707430955255404e-05
in O 0 0.0001828088134061545
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.204938255090383e-06
sporadic O 1 0.9999940395355225
colorectal O 1 1.0
carcinogenesis O 1 0.9999998807907104
, O 0 2.0909477882469218e-07
respectively O 0 3.1167528504738584e-06
. O 0 1.342905534329475e-06

Recently O 0 1.0227829534414923e-06
, O 0 2.842111435086281e-09
an O 0 5.681978776372887e-10
isoleucine O 0 6.329287884909718e-07
- O 0 4.375056903427321e-07
- O 0 2.7521556944520853e-07
> O 0 6.894886439567927e-08
lysine O 0 3.603301479415677e-08
polymorphism O 0 3.054513086908628e-09
at O 0 2.298073020767788e-08
codon O 0 4.8295070165238485e-09
1307 O 0 2.3759569955927873e-07
( O 0 4.0805100964824703e-10
I1307K O 0 1.4027063066635037e-08
) O 0 1.1531185034607816e-10
of O 0 3.124289937872504e-09
the O 0 3.752854027538888e-09
APC B-Disease 0 1.975162078338144e-08
gene O 0 1.7348807945793965e-09
has O 0 1.9700094333607865e-10
been O 0 3.888794147810515e-11
identified O 0 5.666347946409189e-11
in O 0 9.573336567925139e-11
6 O 0 1.784872138976823e-09
% O 0 1.0546188228266473e-10
- O 0 1.082676837071972e-09
7 O 0 4.8712305300568914e-09
% O 0 1.9127847916688978e-10
of O 0 1.1989443882143291e-09
the O 0 4.1382755555652295e-10
Ashkenazi O 0 7.461188888946424e-10
Jewish O 0 7.553081077249502e-11
population O 0 6.4336452831881275e-12
. O 0 3.834529582746882e-09

To O 0 5.7014172938352203e-08
assess O 0 4.927234158458305e-07
the O 0 9.15984799121361e-09
risk O 0 6.171946065336442e-09
of O 0 4.81372330884966e-10
this O 0 2.2971098981305893e-11
common O 0 3.1285879442677356e-10
APC B-Disease 0 3.2428602025902364e-09
allelic O 0 1.578329822393698e-08
variant O 0 2.1235169356259576e-07
in O 0 8.24781807295949e-08
colorectal O 1 1.0
carcinogenesis O 1 0.9999958276748657
, O 0 2.1471615241352993e-07
we O 0 1.112573499995051e-08
have O 0 7.995283601847092e-11
analyzed O 0 5.800613878115257e-10
a O 0 4.486573265682914e-11
large O 0 3.762289091380211e-11
cohort O 0 1.683230554938575e-09
of O 0 1.1957653756056175e-09
unselected O 0 5.65370010008337e-06
Ashkenazi O 0 4.232265027326321e-08
Jewish O 0 2.0619241869468397e-09
subjects O 0 6.504841820742513e-08
with O 0 8.59601834157786e-10
adenomatous B-Disease 0 7.603232461406151e-07
polyps I-Disease 0 3.315059871056292e-07
and O 0 3.168875384318426e-09
. O 0 5.6718252317011775e-09
or O 0 0.29549267888069153
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.2715763375581446e-07
for O 0 3.178657559388398e-09
the O 0 3.614177046529221e-08
APC O 0 9.801074156712275e-07
I1307K O 0 1.0523161790843005e-06
polymorphism O 0 4.391091295019578e-07
. O 0 6.423554310686086e-08

The O 0 1.5702996734034969e-06
APC O 0 3.6345775811241765e-07
I1307K O 0 1.4497697975457413e-07
allele O 0 4.772422457222092e-09
was O 0 1.0167514830072832e-08
identified O 0 9.080260987559541e-10
in O 0 5.178259487870207e-10
48 O 0 9.807739509426483e-09
( O 0 8.781821103642784e-11
10 O 0 2.229687545707293e-10
. O 0 1.648737049664284e-11
1 O 0 9.917517918012209e-10
% O 0 2.838359582091332e-11
) O 0 6.458493462258019e-12
of O 0 4.757060856341866e-10
476 O 0 5.536067249067855e-08
patients O 0 4.110675178026213e-08
. O 0 8.97905252372766e-08

Compared O 0 4.668420316988886e-08
with O 0 4.3648248904126774e-10
the O 0 7.895661346957183e-10
frequency O 0 4.770092321138009e-09
in O 0 6.145391834300185e-11
two O 0 2.769267671079434e-12
separate O 0 2.5729930339113416e-12
population O 0 3.1639933186465574e-14
control O 0 2.2736164340120268e-10
groups O 0 7.285688545521918e-12
, O 0 1.176915682965518e-11
the O 0 1.9505892734361652e-10
APC O 0 8.18878209685181e-09
I1307K O 0 5.186725715589091e-08
allele O 0 4.21880308465461e-09
is O 0 2.761537942763681e-10
associated O 0 5.480986220440798e-10
with O 0 1.6288451490376055e-11
an O 0 8.86610316414016e-12
estimated O 0 2.5909401360491024e-11
relative O 0 6.86623469192682e-09
risk O 0 1.0516089332668344e-08
of O 0 3.8462147244899825e-08
1 O 0 1.9081244317931123e-06
. O 0 1.6499232913247397e-07

5 O 0 1.9671970221679658e-05
- O 0 4.911133146379143e-06
1 O 0 6.01865167482174e-06
. O 0 2.2726524662175507e-07

7 O 0 3.529281821101904e-05
for O 0 2.336945499337162e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.966421902179718
( O 0 7.607861363112534e-08
both O 0 9.414616641834073e-08
P O 0 4.8221871111309156e-05
= O 0 3.164920414633343e-08
. O 0 3.9776992810658385e-10
01 O 0 6.864888746349607e-08
) O 0 1.1648416675669182e-09
. O 0 1.9926021721516918e-08

Furthermore O 0 1.093564947041159e-06
, O 0 6.662349338881768e-09
compared O 0 7.081787600782263e-09
with O 0 1.0111271819823742e-09
noncarriers O 0 2.053398930002004e-06
, O 0 1.9803969575349356e-09
APC O 0 2.7016065828888713e-08
I1307K O 0 5.8932815960588414e-08
carriers O 0 2.6636029493154467e-10
had O 0 4.541018255865836e-11
increased O 0 3.992448732725862e-12
numbers O 0 6.584720615987472e-12
of O 0 1.0170457809266509e-09
adenomas B-Disease 0 0.0001640000264160335
and O 0 4.727542182081379e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999957084655762
per O 0 9.130247235589195e-06
patient O 0 1.9416438590269536e-06
( O 0 3.2736595656501777e-09
P O 0 2.0502232018770883e-06
= O 0 8.930167716414417e-09
. O 0 2.0116863730379464e-10
03 O 0 8.88543283394938e-09
) O 0 4.522003257956264e-11
, O 0 4.061561850732254e-11
as O 0 7.873670465619043e-11
well O 0 1.686272788070653e-10
as O 0 2.979914925926863e-10
a O 0 1.36227173985759e-09
younger O 0 2.461378878493292e-09
age O 0 1.3022916967031506e-08
at O 0 3.283178955371113e-07
diagnosis O 0 1.3736740811509662e-06
. O 0 5.1242064813550314e-08

We O 0 4.01347648448791e-07
conclude O 0 4.030699187751452e-07
that O 0 4.3913800373829304e-10
the O 0 1.9893922065250536e-09
APC O 0 2.5171370765519896e-08
I1307K O 0 1.2423572570696706e-07
variant O 0 4.255901941974116e-08
leads O 0 3.4802092319097255e-09
to O 0 3.1001345934811297e-10
increased O 0 1.4163554773460874e-08
adenoma B-Disease 1 1.0
formation O 0 2.329961716895923e-05
and O 0 4.298225064758299e-08
directly O 0 1.442743258195378e-08
contributes O 0 1.2247877156923437e-09
to O 0 2.453507952360212e-10
3 O 0 1.0120980498129484e-08
% O 0 2.0722963622876733e-10
- O 0 5.020099336228157e-10
4 O 0 1.00730424001938e-09
% O 0 2.548675159808056e-11
of O 0 1.293430640370019e-10
all O 0 1.3017092959088927e-10
Ashkenazi O 0 9.760026387084508e-08
Jewish O 0 6.913281822562567e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.5885191209672485e-06

The O 0 5.915760326047348e-08
estimated O 0 3.5773868312105606e-09
relative O 0 6.837903043788174e-08
risk O 0 3.751444488386824e-09
for O 0 3.1128441491112824e-10
carriers O 0 7.566581805562578e-10
may O 0 2.8684685182689407e-10
justify O 0 2.0622929752800445e-10
specific O 0 2.368405818686803e-11
clinical O 0 1.5338877390469463e-10
screening O 0 6.771700561403193e-11
for O 0 1.769683705132863e-11
the O 0 1.6906656630233385e-10
360 O 0 3.976889484391677e-09
, O 0 7.811815777580833e-11
000 O 0 7.485078112878796e-10
Americans O 0 9.878791534800868e-11
expected O 0 2.1242940739796268e-10
to O 0 6.317001782774057e-11
harbor O 0 1.8195107642782204e-08
this O 0 1.3552625167945198e-11
allele O 0 1.7641071936580488e-10
, O 0 2.7098700020045108e-11
and O 0 8.826367588199435e-12
genetic O 0 1.050368472754748e-11
testing O 0 5.531287927684758e-11
in O 0 1.6281741579970976e-11
the O 0 1.1721289217003772e-10
setting O 0 3.645072021996043e-09
of O 0 6.970505506131985e-09
long O 0 2.631121764906652e-09
- O 0 4.439384859722395e-09
term O 0 5.933804558821976e-09
- O 0 1.551315520487151e-09
outcome O 0 1.5394985286576457e-09
studies O 0 2.525694930977096e-10
may O 0 1.653479957119952e-11
impact O 0 7.903281501464576e-11
significantly O 0 2.2404527122432683e-09
on O 0 2.4966991986730136e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.421319191460498e-06
in O 0 4.13134908228141e-11
this O 0 2.793980758558634e-12
population O 0 7.446930984193745e-13
. O 0 6.949871789174722e-10

Localization O 0 5.6885775848058984e-05
of O 0 1.962168198588188e-06
human O 0 6.518229866969705e-08
BRCA1 O 0 1.1891065909708232e-08
and O 0 4.1909473114110085e-10
its O 0 7.816168545726754e-11
loss O 0 6.270527208585008e-09
in O 0 1.4837100437148365e-09
high O 0 4.7316154905274743e-07
- O 0 7.882063002284667e-09
grade O 0 2.2931480714305508e-07
, O 0 5.689342885695226e-10
non B-Disease 0 8.810573490336537e-06
- I-Disease 0 0.010942405089735985
inherited I-Disease 1 0.9999960660934448
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.45056214928627014

Although O 0 5.6762001321430944e-08
the O 0 6.836661459175275e-09
link O 0 8.775404580774193e-08
between O 0 5.9322118772797694e-08
the O 0 3.877800835994094e-08
BRCA1 O 0 9.171179726763512e-08
tumour B-Disease 1 0.9999996423721313
- O 0 8.090711958175234e-07
suppressor O 0 3.080545525335765e-07
gene O 0 5.625468446623927e-08
and O 0 7.017116843144322e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 0.14454999566078186
established O 0 5.593985406449065e-06
, O 0 6.642513761256907e-10
the O 0 2.532859921799968e-09
role O 0 1.1599872351553131e-07
, O 0 2.0385541865675094e-10
if O 0 3.547817942206599e-11
any O 0 3.940567316895738e-11
, O 0 2.754050026226862e-12
of O 0 9.048842924963552e-11
BRCA1 O 0 2.101207818849815e-10
in O 0 8.886038016520104e-10
non B-Disease 0 0.2691364586353302
- I-Disease 0 0.27626585960388184
familial I-Disease 0 0.05201263353228569
cancers I-Disease 1 0.7305448055267334
is O 0 8.505685933357654e-09
unclear O 0 1.7177362110487593e-07
. O 0 5.6107342771838375e-08

BRCA1 O 0 1.4528118299494963e-05
mutations O 0 1.5408807030325988e-07
are O 0 1.75575887162438e-10
rare O 0 1.9580825849629946e-09
in O 0 1.8494888953668465e-09
sporadic B-Disease 0 2.3807162506273016e-05
cancers I-Disease 1 0.6770193576812744
, O 0 3.2634603908121562e-09
but O 0 7.636231647012437e-10
loss O 0 6.979434630238757e-08
of O 0 7.176017788879108e-07
BRCA1 O 0 1.8846083804646696e-08
resulting O 0 4.189207203353362e-09
from O 0 8.07710676120621e-10
reduced O 0 1.3957744959824936e-09
expression O 0 3.5581881885349276e-10
or O 0 2.018489264621337e-10
incorrect O 0 3.910725965283746e-09
subcellular O 0 1.7629997728363378e-07
localization O 0 8.362662242689112e-07
is O 0 7.073522323430836e-10
postulated O 0 4.160120248286603e-09
to O 0 2.8328377837949503e-11
be O 0 1.7365112819911488e-11
important O 0 6.320014650507133e-11
in O 0 6.473407226925687e-11
non B-Disease 0 5.062024683866184e-06
- I-Disease 0 0.023036619648337364
familial I-Disease 1 0.9999964237213135
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9997792840003967

Epigenetic O 0 0.04634245112538338
loss O 0 0.0007855427684262395
, O 0 1.0221808111054997e-07
however O 0 4.895263217008505e-08
, O 0 6.027831567223529e-10
has O 0 1.4264277259368185e-11
not O 0 1.9976973634344697e-12
received O 0 7.70110884784625e-12
general O 0 1.0264071537147146e-10
acceptance O 0 1.8671392210123372e-10
due O 0 2.3550608130307182e-09
to O 0 1.6403942093567991e-10
controversy O 0 2.1524483584389742e-10
regarding O 0 7.673491841941882e-10
the O 0 4.4822132116983937e-10
subcellular O 0 3.8849006500640826e-07
localization O 0 2.4021037461352535e-06
of O 0 2.5851815621535934e-07
BRCA1 O 0 1.4290741923161931e-08
proteins O 0 5.057330665358961e-10
, O 0 1.5115766971440792e-10
reports O 0 2.066793819421875e-10
of O 0 2.0328243532929946e-09
which O 0 1.468449944974637e-10
have O 0 5.388582635657002e-11
ranged O 0 1.2533719839780133e-08
from O 0 2.0819793111748197e-10
exclusively O 0 1.5878888204312602e-09
nuclear O 0 2.5832461503227933e-08
, O 0 9.350656533790858e-12
to O 0 2.6302961544932835e-11
conditionally O 0 1.0884915191411437e-08
nuclear O 0 1.1630511664861842e-07
, O 0 3.905809356496981e-11
to O 0 4.8207406816436205e-11
the O 0 2.3563955231509226e-09
ER O 0 1.063152808455925e-06
/ O 0 6.856998169268991e-08
golgi O 0 5.677250101143727e-07
, O 0 1.2918952574381137e-09
to O 0 7.10786096647098e-10
cytoplasmic O 0 3.487280864078457e-08
invaginations O 0 1.1717544339262531e-06
into O 0 6.529874863048235e-09
the O 0 1.5183079682401512e-08
nucleus O 0 5.835219596406205e-08
. O 0 7.266869062050318e-08

In O 0 5.767940365331015e-07
an O 0 1.7890620540583768e-08
attempt O 0 9.722160143610381e-08
to O 0 2.2380950426281743e-09
resolve O 0 4.0832085801412177e-07
this O 0 2.9072400042906565e-10
issue O 0 5.099010991216346e-09
, O 0 7.854216582670048e-11
we O 0 8.097711390320228e-11
have O 0 8.78096206857748e-12
comprehensively O 0 2.718590685901745e-09
characterized O 0 4.0831105163618986e-10
19 O 0 1.0479308087951722e-08
anti O 0 1.4553191363120277e-07
- O 0 7.322774564499923e-08
BRCA1 O 0 7.141470526050853e-09
antibodies O 0 1.2779796110251596e-09
. O 0 3.6126124314250774e-08

These O 0 2.5023691563319517e-08
reagents O 0 1.354199241632159e-07
detect O 0 1.1487099982332438e-07
a O 0 3.914264823379199e-08
220 O 0 5.474921138670652e-08
- O 0 4.4793889486527405e-08
kD O 0 2.4868489845175645e-07
protein O 0 1.886482259294553e-08
localized O 0 4.691145960578069e-08
in O 0 1.8442261051632158e-09
discrete O 0 2.91281111231001e-07
nuclear O 0 4.7121213242462545e-07
foci O 0 1.6676216318955994e-07
in O 0 2.3029983475808535e-10
all O 0 2.388594877444916e-10
epithelial O 0 3.3169474278338384e-08
cell O 0 4.3412913441898127e-07
lines O 0 5.245281098353871e-09
, O 0 1.244100135411319e-11
including O 0 2.235122677218815e-12
those O 0 4.4528282970579536e-12
derived O 0 1.4733371467290368e-10
from O 0 3.8260621337826706e-09
breast B-Disease 0 1.2574517995744827e-06
malignancies I-Disease 0 3.0767216685489984e-06
. O 0 1.0326840538255055e-06

Immunohistochemical O 0 3.094201019848697e-05
staining O 0 1.0019902219937649e-05
of O 0 7.023810667305952e-06
human O 0 3.4363480949650693e-07
breast O 0 5.459929752760218e-07
specimens O 0 6.958576381776993e-09
also O 0 1.1415624001642755e-09
revealed O 0 1.5492028637709154e-07
BRCA1 O 0 3.725988619862619e-07
nuclear O 0 1.699422909950954e-06
foci O 0 1.3787021089228801e-06
in O 0 3.881565291408151e-09
benign O 0 0.000521813053637743
breast O 0 0.06133890524506569
, O 0 1.3420562083865661e-07
invasive B-Disease 1 0.9999796152114868
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
and O 0 2.3782336938893422e-05
low B-Disease 1 0.9999961853027344
- I-Disease 1 0.999958872795105
grade I-Disease 1 0.9999990463256836
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.04958738014101982

Conversely O 0 1.2839846931456123e-05
, O 0 1.456632787721901e-07
BRCA1 O 0 5.453607698768792e-08
expression O 0 3.046909569093259e-08
was O 0 8.562269471212858e-08
reduced O 0 6.542990593771947e-09
or O 0 7.209070146396712e-11
undetectable O 0 6.263904506198514e-09
in O 0 3.023193848039618e-11
the O 0 6.028656046597192e-11
majority O 0 4.3362115981215865e-11
of O 0 4.241151430051104e-09
high O 0 6.475762575064437e-07
- O 0 1.1087057316672144e-07
grade O 0 2.1758980892627733e-06
, O 0 2.8437179722118344e-08
ductal B-Disease 1 0.9992337226867676
carcinomas I-Disease 1 1.0
, O 0 6.94774371368112e-07
suggesting O 0 1.0172232123295544e-07
that O 0 1.244785052811892e-09
absence O 0 1.076769876817707e-06
of O 0 3.539413000908098e-06
BRCA1 O 0 1.471575501454936e-07
may O 0 1.1271146682645394e-08
contribute O 0 5.183694029575747e-10
to O 0 6.042390199301195e-11
the O 0 6.551229003726178e-10
pathogenesis O 0 2.3263612547452794e-06
of O 0 1.0090026592024515e-08
a O 0 1.8368741250274212e-10
significant O 0 3.2377656111748365e-10
percentage O 0 2.3781541180767363e-09
of O 0 1.9405421269880208e-08
sporadic B-Disease 0 0.0063941590487957
breast I-Disease 0 0.2648695707321167
cancers I-Disease 0 0.08852632343769073
. O 0 1.621000933482719e-07
. O 0 9.956225994756096e-07

